



2nd CONGRESS OF THE EUROPEAN ACADEMY OF NEUROLOGY

COPENHAGEN, DENMARK, MAY 28 - 31, 2016



FINAL PROGRAMME

2016



www.eaneurology.org/copenhagen2016

EACCME EVENT CODE: 13595

GENERAL

Welcoming words	IV
About EAN	IV
Board and committees	V
EAN membership information	VI
Education information	VII
Resident and research section (EAN-RRFS)	VIII
Congress Grants	IX
Appreciation and Thanks	X
Continuing Medical Education (CME Information)	XI
Instructions for speakers and poster presenter	XII
Information from A-Z	XII
Floor plans	XVI
Business meetings	XVIII
Poster sessions overview	XXI
Official networking programme	XXV
Timetable	XXVIII

SCIENTIFIC PROGRAMME

Saturday, 28 May, 2016

Educational Sessions	37, 54
Focused Workshops	37
Special Sessions	39
Symposia	40
Teaching Courses	44
Oral Sessions	48
Poster Sessions	59

Sunday, 29 May, 2016

Educational Sessions	59, 66, 69
Focused Workshops	61
Special Sessions	62
Plenary Symposium	64
Teaching Courses	67
Tournament basic	72
Oral Sessions	72
Poster Sessions	108

Monday, 30 May, 2016

Educational Sessions	79, 82
Focused Workshops	80
Special Sessions	81, 82, 83
Plenary Symposium	82
Symposia	83
Teaching Courses	85
Tournament clinical	87
Oral Sessions	87
Poster Sessions	155

Tuesday, 31 May, 2016

Symposia	93
Educational Sessions	93
Special Sessions	94
Plenary Symposium	96
Teaching Courses	96

COMPANY SPONSORED PROGRAMMES

Exhibitors	104
Satellite Symposia	108
Forum Programmes	221
Speaker Index	129

DEAR COLLEAGUES,

On behalf of the European Academy of Neurology and the Danish Society of Neurology, we are pleased to invite you to the 2nd Congress of the European Academy of Neurology (EAN) taking place in Copenhagen from May 28 - 31, 2016. The first highly successful meeting of the EAN in Berlin left us with valuable experiences that have been used to optimize our second annual meeting. You will meet innovations in the teaching courses and the programme outline. EAN has instituted three named lectures (Romberg, Golgi and Brown-Séguard), which will be presented for the first time during the presidential symposium. The congress will certainly also cover all the well-established formats for scientific exchange. The Copenhagen Bella Congress Center has outstanding facilities for lectures, small group teaching courses, exhibition and for scientific exchange, but also enough space for meeting colleagues and making new friends.

Denmark is renowned for the Little Mermaid, Hans Christian Andersen, Niels Bohr and Danish design. Today however, the "New Nordic Cuisine" as well as TV series like "Borgen" and "The Bridge" have taken over as "Danish Trademarks". Landing at Copenhagen airport, you will have a wonderful view of "The Bridge" and on the ground again, you may visit "Borgen", the Danish Parliament. In between is the newly

modernised Bella Center, the venue of EAN 2016, with easy and fast transfer to both the city centre and the airport. The coastal area of southern Sweden - with the important cities of Malmö and Lund - is developing into one metropolitan area with Copenhagen, and thousands of citizens of both nationalities commute over the bridge every day. Copenhagen is one of the most vivid cities in northern Europe.

At the EAN congress 2016 you will interact with your European network, you will be absorbed in Academia, and you will be thrilled by Neurology.

Welcome to Copenhagen 2016!
Sincerely yours,



Günther Deuschl
PRESIDENT OF THE EUROPEAN
ACADEMY OF NEUROLOGY



Mads Ravnborg
PRESIDENT OF THE DANISH
NEUROLOGICAL SOCIETY

ABOUT EAN

The European Academy of Neurology (EAN) has been founded on the initiative of the European Neurological Society (ENS) and the European Federation of Neurological Societies (EFNS), who both consider it essential to have one joint professional and scientific Neurology organisation in Europe. EAN shall provide the essential infrastructure together with the organisational framework for the support and development of neurological education and research in Europe.

The Aim of EAN (European Academy of Neurology) is Excellence in Neurology in Europe

EAN is a non-profit organisation and identifies itself with the following five values:

- Professionalism. EAN will strive to reach the highest scientific standards and to deliver unbiased information in its research and educational activities.
- High ethical standards. EAN will apply high ethical standards in all its activities within science, education, liaison, and administration, complying with applicable regulations and codes of ethics.

- Involvement. EAN will strive to involve its members and collaborators in the organisation of research, education and liaison activities.
- Independence. EAN will operate as a professional and scientific organisation, independent from the political or commercial interests of external companies or organisations.
- Transparency. EAN will provide transparency in the organisation of all its scientific and administrative activities.

The EAN is an organisation of:

- 47 European national neurological societies
- 800 individual members
- 9 corresponding member societies

The EAN consists of:

- an Assembly of Delegates of institutional and individual delegates
- elected officers
- 4 committees (+ 2 sub-committees)
- 31 Scientific Panels

BOARD

PRESIDENT	Günther Deuschl, GERMANY
VICE PRESIDENT	Franz Fazekas, AUSTRIA
SECRETARY GENERAL	Didier Leys, FRANCE
TREASURER	Marianne de Visser, THE NETHERLANDS
CHAIR SCIENTIFIC COMMITTEE	Antonio Federico, ITALY
CHAIR LIAISON COMMITTEE	David Vodusek, SLOVENIA
CHAIR EDUCATION COMMITTEE	Hannah Cock, UK
CHAIR PROGRAMME COMMITTEE	Paul A.J.M. Boon, BELGIUM
MEMBER AT LARGE	Per Soelberg Sørensen, DENMARK

PROGRAMME COMMITTEE

CHAIR:	Paul A.J.M. Boon, BELGIUM
CO-CHAIR:	Mads Henrik Ravnborg, DENMARK
	Ljiljana Beslac-Bumbaširević, SERBIA
	Valeria Caso, ITALY
	Hannah Cock, UK (CHAIR EDUCATION COMMITTEE)
	Marianne Dieterich, GERMANY
	Antonio Federico, ITALY (CHAIR SCIENTIFIC COMMITTEE)
	Theodor Landis, SWITZERLAND (CHAIR TEACHING COURSE SUB-COMMITTEE)
	Philip Scheltens, THE NETHERLANDS
	Aksel Siva, TURKEY
	Riccardo Soffietti, ITALY
	Guido Stoll, GERMANY
	Joaquim Ferreira, PORTUGAL (MDS-ES REPRESENTATIVE)

LOCAL ORGANISING COMMITTEE

CHAIR:	Mads Henrik Ravnborg
	Karen Aegidius
	Lars Bendtsen
	Marie Bruun
	Jakob Christensen
	Jesper Erdal
	Daniel Kondziella
	Hanne Krarup Christensen
	Christina Rostrup Kruuse
	Per Soelberg Sørensen
	Gunhild Waldemar

TEACHING COURSE SUB-COMMITTEE

CHAIR:	Theodor Landis, SWITZERLAND
	Anish Bahra, UK
	Gilles Edan, FRANCE
	Oleg Levin, RUSSIAN FEDERATION
	Erich Schmutzhard, AUSTRIA
	Claudia Sommer, GERMANY
	Marie José D. Vidailhet, FRANCE
	Viktoria Papp, DENMARK (REPRESENTATIVE RRFs)

EAN MEMBERSHIP INFORMATION



Become an EAN individual member and benefit from the following:

- reduced membership fee at the annual congresses
- active and passive voting rights at the Assembly of Delegates of the EAN
- possibility to participate in EAN Committees and Scientific Panels
- free online access to the online learning platform eBrain
- free online access to the *European Journal of Neurology*
- free online access to the guidelines
- access to educational grants (if applicable)
- right to purchase the *European Journal of Neurology* (EJN) at a reduced rate
- a membership certificate
- monthly mailshots of the EAN electronic newsletter Neuroopenews
- one free Teaching Course at EAN annual congresses
- free access to VIP (catering) area at EAN annual congresses
- free access to selected congress webcasts on the website after the congress
- NEW: AAN shared Membership:

If you are an AAN Member, you are eligible of a 10% discount off your EAN Individual Membership fee. In reverse, all EAN members receive a 10% discount when applying for AAN membership



INDIVIDUAL MEMBERSHIP CATEGORIES:

Full Individual Member:

Neurologists who are nationals of any EAN member country; and/or neurologists practicing in any EAN member country including neurologists in training.

Resident and Research Fellow (RRF):

Physicians in training can become individual members of the EAN via the EAN Resident and Research Fellow Section at a reduced fee. Residency has to be proven annually by a signed confirmation of the physician in charge of the residency programme.



Corresponding Individual Member:

- Neurologists who are nationals of and practice in countries other than EAN member countries and/or Health Professionals
- and/or Scientists of other specialities or professions related to Neurology

Undergraduate Student:

Undergraduate medical students can become individual members. They need to explain their special interest in neurology and the purpose why they request membership.

Retired Member:

Neurologists who are retired from their professional work but like to keep in touch and benefit from the various EAN membership highlights.

FELLOW OF THE EAN (FEAN)

The title 'Fellow of the EAN' acknowledges a limited number of neurologists who are full individual members and who deserve a special recognition of the EAN because of

- a scientific achievement that places them within the European leaders in their field, or
- significant and continuing service in a leadership position for of a European or World society for neurology or neurological subspecialty society, or
- a service for neurological patients that is considered exceptional



Fellow of the EAN is a title honouring special service to neurology and the Society.

Please apply by sending your application form and CV (in English) to the EAN Head Office:
membership@ean.org

Forms can be downloaded online or be sent to upon request.

EDUCATION INFORMATION



CLINICAL FELLOWSHIP 2017

APPLICATION DEADLINE: OCTOBER 31, 2016

The purpose of this award is to provide a well-defined observational clinical practice, service structure or technical experience to support training. The grant is to support a visit of six weeks duration.

Each grant is amounting to € 1,500.-/month (plus travel expenses of up to € 300.-)

A list of approved hosting departments (and details for interested hosts of how to apply) is available on www.eaneurology.org

Candidates from all EAN member (and associate member) countries are eligible to apply. Applicants must be current residents with a minimum of 2 – 8 years training in neurology, or have obtained their board certificate/completed training within the last 3 years at the time of application; be fluent in English or the local language (host department).

Awardees from previous years (applies also to former D-D programme) are no more qualified.

All application documents must be submitted by October 31 2016 by email to Ms. Magda Dohnalová:

E-MAIL: dohnalova@ean.org

Application is open between 1 August and 31 October 2016.



EAN RESEARCH FELLOWSHIP 2017

APPLICATION DEADLINE: AUGUST 31, 2016

In 2017, the EAN will offer up to 8 research experience or training fellowships. The research work must be carried out at a European academic neurological department outside the country of residence. The purpose is to support training and experience for European

Neurologists in any area of basic or clinical or applied research in neuroscience. All applications should demonstrate experience/training of clear value to the home department/individual beyond that available in their own countries/institutions. Successful applicants will be awarded € 2,000.- per month. Research training fellowship: Expected to be of 12 months duration, to lead either to completion of a higher degree, a grant application or peer-reviewed publication. Research experience fellowship: Expected to be of at least 6 months duration for individuals who might otherwise not have the opportunity to gain high quality research experience; more experienced clinicians/researchers

requiring training in a specific research methodology or technique not currently available in their own country and of clear value to home department will also be considered. Candidates from EAN member countries and affiliated to a European academic neurological department with a minimum of 2 years neurology training, up to a maximum of 5 years beyond their final degree (PhD, MD, or equivalent) at the time of application are eligible to apply. Applicants and hosts are expected to have consulted and worked together on any application to maximise the likelihood of success. All application documents must be submitted by August 31 2016 by email to Ms. Julia Mayer: E-MAIL: fellowship@ean.org

EAN SPRING SCHOOL 2017

MAY 11-14, 2017

APPLICATION DEADLINE: JANUARY 31, 2017



Preliminary Programme:

1. Multiple sclerosis
2. Inflammatory neuropathies
3. Stroke

Participants can prepare their own cases for presentation and discussion, including video if appropriate and the patient has consented. Contributions

to the optimal organisation of neurological care, neurological services and postgraduate education throughout Europe will be presented.

Location:

Hotel Bezděz
Lazensky Vrch 216
471 63 Staré Splavy
Czech Republic

This site is situated in North Bohemia, about 90 km from Prague, on the shore of the romantic Macha Lake. A half-day trip to Prague is planned. All applicants must be neurologists in training (not yet completed residency/ clinical speciality training) who will have had at least 2 years of clinical experience by the time of the course, and who are able to attend the full course. Participants nominated for attendance by their national neurological societies will be prioritised, but individual applications are also welcome up to the full capacity. Where oversubscribed, the selection process will take into account geographical and gender balance, and unsuccessful applications in previous years. Awardees from previous years are no more qualified. Accommodation, tuition, board and programme are sponsored by the EAN. Participants pay only for their travel. All participants will receive a manuscript CD-ROM and a certificate after having finished the course. All application documents must be submitted by January 31 2017 by email to Ms. Magda Dohnalová E-MAIL: dohnalova@ean.org

Applications open between 1 October 2016 and 31 January 2017



CME ARTICLES

Each month a CME article is published in the European Journal of Neurology and on the EAN website. Answer 5 article-related questions correctly and receive a certificate recommending one hour of CME.

Please register on the EAN website for free-of-charge access to all e-learning features and the online version of the European Journal of Neurology



EBRAIN

ebrain represents the world's largest, most comprehensive web-based training resource in clinical neuroscience designed to support training and continuous professional development for clinical neuroscience trainees, consultants and non-specialists. It is free-of-charge for EAN members. For log-in data, please contact education@ean.org.

The multimedia-rich, engaging materials are designed to enhance traditional learning, support existing teaching methods and provide a valuable reference point that is accessible anytime, anywhere.

The online training content comprises approximately 20 modules of e-learning, with each of the 550+ individual lessons taking around 20 minutes to complete.

www.ebrainJNC.com

GUIDELINE PAPERS

Included in the EJoN, the Handbook as well as FREE OF CHARGE access for EAN members via the Guidetive Reference Center the EAN website.

EAN REGIONAL TEACHING COURSES (RTC)

EAN RTCs are specially designed for the purpose to bring neurological standards directly to those countries that are seeking EAN support in education and to avoid that our colleagues in training have to travel to expensive congresses. In the past, these courses were in the Eastern European Regions as well as in Sub-Saharan Africa.

RTCs provide basic teaching in neurology and thus also establish friendly relations with the colleagues still in training or wishing to expand their knowledge.

The 3-day courses are organised by the local host together with the EAN Teaching Course sub-committee. Plenary sessions in the morning are followed small tutorial groups in the afternoon. Each day is dedicated to one topic plus various themes on the third day. The exam quiz as well as certificates will be made available to all participants.

RESIDENT AND RESEARCH FELLOW SECTION

Residents and research fellows section of the European Academy of Neurology (EAN-RRFS) represents the junior generation of neurologists within EAN. Our members are physicians currently working as a resident in Neurology, research fellow, PhD student or neurologist with not more than 3 years of practice after completion of the residence training. Application for membership should be sent to rrfs@ean.org, further information is provided on the EAN homepage. The aims of RRFS are to support neurology trainees in their clinical training or research, to promote network between European junior neurologists and different generations of neurologists. Our program during the 2nd Congress of the European Academy of Neurology in Copenhagen 2016:

THE RRFS BOOTH will welcome you during the whole congress. Here, you can receive information on how to become an RRFS member and regarding the benefits of the membership.

RRFS HOSPITAL VISIT (max. 100 participants) on Sunday, 29 May 2016 will be organised in co-operation with the Danish Young Neurologist Society. We are going to meet 18.00-18.15 in front of the registration desk. We will visit the Rigshospital - University Hospital followed by a get-together. Registration is available via facebook or by contacting rrfs@ean.org or at the RRFS booth at the congress.

RRFS ASSEMBLY on Monday, 30 May 2016 in Room B4M2 at 16.45-18.15.

RRFS SPECIAL SESSION on Tuesday 31 May 2016, 8.30-10.00 in Hall B5.2. The discussed topic is "Prospects for young neurologists in 3 corners of Europe."
See Page XXVI

RRFS LOTTERY on Tuesday 31 May 2016, 10.00-10.30 at the RRFS Booth.

PHOTO CONTEST, upload your best picture of the congress to RRFS facebook profile until 01 July 2016.

EAN NETWORKING EVENT on Monday 30 May 2016, at 20.00 we meet in front of the conference center and will travel together to the networking event of the EAN at the renowned Paper Island Street Food market.



CONGRESS GRANTS

BURSARIES

The 2nd Congress of the EAN offered up to 320 bursaries consisting of free registration to the congress and up to four nights hotel accommodation. In addition, free admission to three half-day teaching courses was offered.

Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) who are working in Europe and whose abstract has been accepted.

It was also possible for colleagues in training from Algeria, Egypt, Jordan, Kyrgistan, Lebanon, Libya, Morocco, Palestine, Tunisia and Syria as well as from sub-Saharan countries belonging to the HINARI Group A list of countries as established by WHO (www.who.int/hinari/eligibility/en/) to apply for bursaries.

Bursary recipients were selected on the basis of abstract evaluation by the Programme Committee.

The prize is not transferable and will not be paid off in cash. The bursaries were co-sponsored by an educational grant from MDS-ES and Lundbeckfonden.

INVESTIGATOR AWARD

All free presentations (oral presentations, posters) selected for presentation at the 2nd EAN Congress 2016 will automatically take part in the selection of an Investigator Award. The award for the 20 best presentations will be a registration to the 3rd EAN Congress in Amsterdam, The Netherlands, a diploma and the winners will be announced in the European Journal of Neurology and the EAN newsletter. These presentations will also be filmed and displayed on the EAN website if the presenters agree. The award will be given to the first author who needs to be the person to present the work at the congress. The EAN Scientific Panels together with the Scientific Committee and the Programme Committee will be responsible for the evaluation process before as well as during the congress.

TOURNAMENT FOR NEUROLOGISTS IN TRAINING

A tournament for neurologists in training will take place. The tournament will be carried out in two groups, one on clinical related research, and one on basic neurological science.

Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) working in Europe and whose abstract has been accepted.

Selection of candidates: The EAN Programme Committee was selected 6 candidates for each tournament group on the basis of the contents of the abstracts submitted. The clinical subjects must be received from authors who work in Europe and thus carry out their projects in Europe. For the basic science session, clinical relevance will be weighted.

Financial support: Candidates selected for the tournament have received a bursary consisting of free registration to the Congress, up to four nights hotel accommodation, and a travel grant.

Presentation: Each selected candidate is allotted 10 minutes for presentation of his/her paper plus five minutes for discussion with the jury.

Jury: Members of the Programme, the Scientific and the Teaching Course Committees.

Evaluation: Candidates will be judged not only on the scientific value of the work presented, but also on the quality of the oral presentation and the way the candidate responds to the questions of the jury.

Prize: The winner of each group will receive a prize consisting of: Free registration at the 3rd EAN Congress in Amsterdam 2017, up to four nights hotel accommodation as well as a travel grant. The prize is not transferable and will not be paid off in cash.

Two runner-up prizes in each, the clinical and basic tournament will be awarded. They will consist of a certificate and a free registration to the 3rd EAN Congress in Amsterdam 2017.

APPRECIATION AND THANKS

2016

APPRECIATION AND THANKS

We would like to thank the reviewers of the submitted abstracts for their invaluable help and assistance:

A

Federica Agosta, ITALY
Corrado Angelini, ITALY
Heather Angus-Leppan, UK
Pasquale Annunziata, ITALY
Fabio Antonaci, ITALY
Isabelle Arnulf, FRANCE
Ethem Murat Arsava, TURKEY
Nadine Attal, FRANCE

B

Peter Balicza, HUNGARY
Frederik Barkhof, THE NETHERLANDS
Mads Barloese, DENMARK
Rui Barreto, PORTUGAL
Hansjörg Bänzner, GERMANY
Peter Berlit, GERMANY
Kailash Bhatia, UK
Michela Bisciglia, BELGIUM
Paul A. J. M. Boon, BELGIUM
Geir Brathen, NORWAY
Jean Marc Burgunder, SWITZERLAND

C

Stefano Cappa, ITALY
Valeria Caso, ITALY
Abhijit Chaudhuri, UK
Pawel Chochol, POLAND
Hanne Krarup Christensen, DENMARK
Pamela Correia, INDIA
Giorgio Cruccu, ITALY
Anna Czlonkowska, POLAND

D

Günther Deuschl, GERMANY
Marianne Dieterich, GERMANY
Volker Dietz, GERMANY
Raffaele Dubbioso, ITALY
Andriy Dubenko, UKRAINE
Francois Ducray, FRANCE
Karolina Dziezyc, POLAND

E

Edvard Ehler, CZECH REPUBLIC
Stefan Evers, GERMANY

F

Franz Fazekas, AUSTRIA
Antonio Federico, ITALY
Óscar Fernández, SPAIN
Joaquim Ferreira, PORTUGAL
Massimo Filippi, ITALY
Alessandro Filla, ITALY
Gereon Fink, GERMANY
Katharina Fink, SWEDEN
Ana Catarina Fonseca, PORTUGAL

G

Christopher Gardner-Thorpe, UK
Orsi Györfi, HUNGARY

H

Maija Haanpää, FINLAND
Orla Hardiman, IRLAND
Raimund Helbok, GERMANY
Max Hilz, GERMANY
Henry Houlden, UK
Helle Hvilsted Nielsen, DENMARK

I

Isabel Illa, SPAIN
Alejandro Iranzo, SPAIN

K

Ludwig Kappos, SWITZERLAND
Peter Kennedy, UK
Lisa Klingelhöfer, GERMANY
Matthias Koepp, UK
Anneli Kolk, ESTONIA
Daniel Kondziella, DENMARK
Christian Krarup, DENMARK
Nikola Kresojevic, SERBIA

L

Lieven Lagae, BELGIUM
Hans Lassmann, GERMANY
Pavel Leahu, MOLDOVA
Letizia Leocani, ITALY
Maurizio Leone, ITALY
Vitalie Lisnic, MOLDOVA
Albert Ludolph, GERMANY

M

Michelangelo Mancuso, ITALY
Monica Margoni, ITALY
Luca Massacesi, ITALY
Antonija Mišmaš, CROATIA
Monica Moarcas, UK
Tiziana Mongini, ITALY
Elena Moro, FRANCE
Kirsten Müller-Vahl, GERMANY
Lucia Muntean, GERMANY

N

Eduardo Nobile-Orazio, ITALY
Lino Nobili, ITALY

O

Stefan Oberndorfer, AUSTRIA
David Oliver, UK
Józef Opara, POLAND

P

Massimo Pandolfo, BELGIUM
Eleftherios Papathanasiou, CYPRUS
Viktoria Papp, UK
Giovanni Pellegrino, ITALY
Marija Perovska, FYRO MACEDONIA
Fabienne Perren, SWITZERLAND
Gordon Plant, UK
Werner Poewe, AUSTRIA
Maura Pugliatti, ITALY

R

Martin Rakusa, SLOVENIA
Dorota Religa, SWEDEN
Maria Assunta Rocca, ITALY
Andrea Rossetti, ITALY
Uros Rot, SLOVENIA
Philippe Ryvlin, SWITZERLAND

S

Anna Sauerbier, UK
Philip Scheltens, THE NETHERLANDS
Reinhold Schmidt, AUSTRIA
Erich Schmutzhard, AUSTRIA
Benedikt Schoser, GERMANY
Stefan Schwab, GERMANY
Barry Seemungal, UK
Johann Sellner, AUSTRIA
Vincenzo Silani, ITALY
Aksel Siva, TURKEY
Riccardo Soffietti, ITALY
Sandro Sorbi, ITALY
Israel Steiner, ISRAEL
Maria Stoyanova, BULGARIA
Dominik Straumann, SWITZERLAND
Walter Struhal, AUSTRIA

T

Pravin Thomas, UK
Maarten Titulaer, THE NETHERLANDS

U

Bjarne Udd, FINLAND

V

Josep Valls-Sole, SPAIN
Sanja Vodopić, CROATIA
David B. Vodušek, SLOVENIA

Z

Panagiotis Zis, UK

CONTINUING MEDICAL EDUCATION (CME INFORMATION)

PURPOSE

The purpose of the 2nd EAN Congress is to offer a forum for clinical and basic discussion on a variety of neurological topics including presentations of current research and available treatments.

LEARNING OBJECTIVES

Through Plenary Symposia, Main Symposia, Focused Workshops, Teaching Courses, Case-based facilitated workshops, Hands-on courses, controversy sessions, Interactive sessions and special sessions, participants will be better able to:

1. Describe the pathophysiology and neurobiology of neurological diseases
2. Discuss the diagnostic approaches and tool available for neurological diseases
3. Discuss the pharmacological and non-pharmacological treatment options available for neurological diseases

TARGET AUDIENCE

The target audience includes clinicians, researchers, post-doc fellows, medical residents, students and other healthcare professionals with an interest in the current research and diagnosis and treatment of neurological diseases. Kindly note that in the description of some courses the target audience is separately disclosed.

FINANCIAL DISCLOSURE INFORMATION

It is the policy of the European Academy of Neurology to ensure objectivity, independence and balance in all congress activities. All participants are required to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the activity. Financial disclosure information will be provided on the presentations and/or abstracts.

EACCME ACCREDITATION STATEMENT

EACCME Event code: 13595

The 2nd Congress of the European Academy of Neurology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): <http://www.uems.net>.

The Congress of the European Academy of Neurology (Saturday, Sunday, Monday, Tuesday) is designated for a maximum of 24 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. These points are accepted by several national societies, and thus may be claimed in these countries.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be in the Accredited Group

Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

The Danish Medical Association is accepting the EACCME CME accreditation.

EACCME CREDITS

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

EACCME credits are automatically accepted by the Austrian Chamber of Physicians.

ATTENDANCE TRACKING REPORT


If you need a report of your attendance in sessions, please approach the information desk located at the exhibition entrance area, in order to scan your badge and record your attendance. Only participants who have recorded their attendance receive a report, tracking their daily attendance at the congress, which will be sent from the secretariat on request.

INSTRUCTIONS FOR SPEAKERS AND POSTER PRESENTERS

SPEAKERS' SERVICE CENTRE

All speakers are requested to hand in their presentations (PowerPoint only) via a USB compatible memory stick at the Speakers' Service Centre (SSC) at least *three hours before the beginning of the session*. The SSC is located outside of the exhibition area close to the entrance.

Speakers will have the opportunity to check their presentations on PCs available in the SSC.

The Speakers' Service Centre is supported by  Bial Group.

POSTERS

All posters will be presented as e-posters only.

Within the Poster area (located in the exhibition area) there are poster screens (30 screens, 25 computer stations) available throughout the whole congress, where presenters and audience are invited to interact with each other. You will be able to contact poster presenters and meet with them at any time at one of the poster screens to discuss his/her work.

In addition there will be poster sessions, taking place Saturday to Monday from 12.30 - 13.15 and 13.30 - 14.15. Please see page XXIII or Interactive Programme Planner (IPP) for details and exact presentation times.

Poster with discussion

All poster sessions will be discussed with a chairperson. In such poster sessions (45 minutes) up to 15 presentations are scheduled at the dedicated poster screens. A chairperson will be present and discuss each presentation with the presenter and the audience. Each presenter will have 2 minutes presentation time and approximately 1 minutes of discussion. Please make sure that you are present at your poster screen during your session.

The poster stations are supported by  Bial Group.

POSTER DESK

Technicians will be available throughout the congress in the poster area.

INFORMATION FROM A TO Z

ABSTRACTS

All accepted abstracts will be published as a supplement to the European Journal of Neurology. There will be no printed book available, but a USB drive can be picked up at the Genzyme booth in the Exhibition Area. You will receive a voucher together with your badge.

The abstracts can also be found online on www.eaneurology.org/copenhagen2016 and www.europeanjournalofneurology.com.

You can create your personal abstract book by using the Interactive Programme Planner (IPP).

APP

The congress app "EAN 2016" is available for download free of charge on Google Play and iTunes.

The congress app is supported by



Hoffmann-La Roche AG.

ATM/CASH MACHINE

An ATM cash machine is located at the Bella Sky, Tower 1 close to the reception. VISA and MasterCard are accepted.

ATTENDANCE TRACKING REPORT

See page XI.

BADGES

Access to all scientific events will only be possible with your personal badge, which you will receive at the self-print stations if your registration is fully paid. Therefore, please print the page which contains the barcode and take it along with you to the conference. All participants are requested to wear their name badge throughout the congress.

Full and Corresponding Individual Members of the EAN will receive special badges providing them with exclusive access to the VIP member area.

For replacement of a lost badge EUR 30 will be charged.

BUSINESS CENTRE

There is a business centre located at the main entrance of the Bella Center (entrance west).

Opening times:

Saturday, 28 May 2016: 08.00 – 17.00 h

Sunday, 29 May 2016: 08.00 – 17.00 h

Monday, 30 May 2016: 08.00 – 17.00 h

Tuesday, 31 May 2016: 08.00 – 16.00 h

CARING FOR THE ENVIRONMENT

Green print - The print materials of this congress have been printed on paper that is PEFC approved. The PEFC is an organisation that certifies paper manufacturers who keep to sustainable forest management criteria.

Reducing print - The book of abstracts is published on a USB drive. The printed programme is available only for participants who ordered it in advance at the material Pick-up. The complete programme can also be found online in the Interactive Programme Planner (IPP).

Recycling - As part of our efforts we try to produce less waste. We will recycle plastic, glass, cans and paper.

Offset your Carbon Footprint - You can contribute to our ecological efforts by offsetting the Carbon Footprint of your travels to Copenhagen. A Carbon Offset represents a reduction in emissions somewhere else. You can learn more and offset your carbon foot print at: www.carbonfund.org. We are doing our best and there is still much to learn. We will be happy to hear your ideas; please do not hesitate to write to us at headoffice@ean.org.

CERTIFICATE OF ATTENDANCE

Certificates of attendance (not indicating CME credits) are available from Monday morning, 30 May 2016. They can be printed at the self-print stations in the registration area, using the barcode printed on your name badge. Changes of certificates due to incorrect submission of names and/or email addresses will be charged EUR 10.

CHILDREN AT EAN CONGRESS 2016

There is no childcare facility available at the congress. Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the pharma codex. Thank you for your understanding.

CLOAKROOM

A cloakroom is available at the main entrance of the Bella Center (Entrance West) and is open during the secretariat opening hours. The cloakroom service is free of charge.

CME CERTIFICATE

You will receive an email with your personal login details for the online evaluation form during the evening of the last day of the congress (Tuesday, 31 May 2016). After completing the congress evaluation form you can download the certificate indicating the CME credits at home. If you need a tracking report for your national body to receive accreditation, please see page XI.

CONGRESS SECRETARIAT AND REGISTRATION

The registration desk at the congress venue is open during the following hours:

Friday,	27 May 2016:	16.00 – 19.00 h (badge/congress bag pick-up for pre-registered delegates only)
Saturday	28 May 2016:	07.30 – 20.30 h
Sunday,	29 May 2016:	08.00 – 19.00 h
Monday,	30 May 2016:	08.00 – 19.00 h
Tuesday,	31 May 2016:	07.30 – 17.00 h

All documents included in the registration package (congress bag, personal name badge) will be handed over to the registered participants. Onsite registration will be accepted, but receipt of all congress documents cannot be guaranteed.

The secretariat can be reached at +45 91 608 588 (from Thursday, 26 May onwards)

CONGRESS VENUE

Bella Center Copenhagen
Bella Center A/S
Center Boulevard 5
2300 Copenhagen
Denmark
www.bellacenter.dk

The 2nd Congress of the European Academy of Neurology takes place at the Bella Center. The Bella Center is located in the heart of Ørestad with its own Metro station. Bella Center Copenhagen is just 6 kilometers away from Copenhagen Airport and 8 kilometers away from Copenhagen city centre.

CURRENCY

The official currency of the 2nd EAN Congress in Copenhagen is Euro (€). However, the local currency is Danish Krone (DKK). Please keep in mind that credit cards (Visa, Mastercard, American Express) will be charged only in Euro.

EAN BOOTH

Location: in front of the exhibition hall

Opening hours:

Saturday,	28 May 2016:	10.00 - 17.00 h
Sunday,	29 May 2016:	10.00 - 17.00 h
Monday,	30 May 2016:	10.00 - 17.00 h
Tuesday,	31 May 2016:	09.30 - 13.30 h

EXHIBITION

An extensive exhibition will be held concurrently with the congress.

Exhibition opening hours are:

Saturday,	28 May 2016:	10.00 - 17.00 h
Sunday,	29 May 2016:	10.00 - 17.00 h
Monday,	30 May 2016:	10.00 - 17.00 h
Tuesday,	31 May 2016:	09.30 - 13.30 h

GENERAL INFORMATION

2016

Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the Pharma Codex. Thank you for your understanding.

The exhibition floor plan can be found on page 105.

HOTEL AND TRAVEL

Official Housing/Travel Agency

Congrex Travel Ltd.

PHONE: +45 91 60 87 69

E-MAIL: hotel.ean@congrex.com

Congrex Travel is present at the Congress Secretariat. Staff can assist you with your hotel and flight bookings.

INSURANCE & LIABILITY

The Congress organisers and PCO cannot accept liability for personal accidents or loss of or damage to private property of participants, either during or indirectly arising from the 2nd Congress of the European Academy of Neurology.

It is recommended that all participants are covered by personal travel insurance for their trip.

INTERNET CORNER

An Internet Corner is located in the exhibition area and is available to all congress participants during the opening hours of the exhibition. In this area also Wi-Fi (see page XV) is available.


The Internet Corner is supported by  Bial Group.

INTERACTIVE PROGRAMME PLANNER (IPP)

Please use the IPP in order to create your personal programme and abstract book. All invited lectures, oral sessions and poster presentations will be available in the IPP. By logging in you will be able to save and edit your personal programme. It is available for desktop, laptop and as smartphone app. Contents are sorted by topic and prerequisites and can be searched through standard web search functions. Once you have created your personal programme, you can export it to different calendar formats, or download it as a book of abstracts.

The IPP will be available before and during the congress.

iPad Stations will be placed on different locations throughout the congress venue. The congress app including the IPP will be displayed on the iPads.

The iPad Stations are supported by  Bial Group.

LANGUAGE

The official language of the congress is English. No simultaneous translation will be provided.

LOST & FOUND

Please apply to the congress secretariat.

LUNCH AND COFFEE BREAKS

Light lunch and coffee is included in the registration fee and will be served in the exhibition area as per the times indicated in the timetable.

MAIL/MESSAGES

A message board is available close to the congress secretariat in the registration area.

MEDICAL ASSISTANCE

Please apply to the congress secretariat.

MINI-PROGRAMME

The mini-programme gives you an overview of the scientific programme at a glance.

MOBILE PHONES

Please note that mobile phones must be switched off during all sessions.

NETWORKING

Opening (See page XXV)

Challenges for women in neurology (see page XXVI)

Networking event on Monday "Meet the speakers" (see page XXVII)

Resident and Research Fellow Section Activities (see page VIII)

POSTER SESSIONS

Please see page XXI

PRESS CONFERENCE AND PRESS ROOM

A media room with wireless internet access is available to registered journalists. The Press Room is located in room B4 M5. The press conference will be held on Monday, 30 May 2016 from 10.30 to 11.30 in meeting room 5 (first floor, Bella Center).

QUALITY CONTROL/ EVALUATION

In order to guarantee the quality of the upcoming congresses, and to get CME certification, we have to carry out congress evaluations. Each teaching course participant should fill in an electronic TC evaluation directly after the TC.

The general evaluation of the congress will be done online. On Tuesday, 31 May all participants will receive a username and password per email during the evening. We kindly ask you to participate to receive your certificate.

Please take time to complete the electronic evaluation forms provided for each session you attend. The forms are available in the EAN Congress app and on the Congress website. Your input is essential for planning future EAN congresses.

SCIENTIFIC REPLAY LOUNGE

The Scientific Replay Lounge is located in the exhibition area and will be available for the comfort of participants, providing a place to see webcasts of selected previous sessions, relax and meet with colleagues.

The Scientific Replay Lounge is supported

by  SANOFI GENZYME  Europe B.V.

SESSIONS

Please make sure to be in session halls on time as all sessions will begin as per schedule.

SYMPOSIA:

Symposia are scheduled in the morning of each congress day and will last 2 hours each. Lecturers will give general information on the main topics of the congress.

Special insight will be covered in Teaching courses and Focused workshops.

TEACHING COURSES:

If you wish to participate, tickets may still be purchased at the Secretariat for a fee of € 40/ €25, availability permitting. TCs are held on each congress day in the afternoon and last for 3 hours (plus 1/2 hour coffee break). They are interactive with ample opportunity for participants to ask questions. All TCs are aimed primarily at a post-graduate audience.

There are 3 levels of TCs:

Level 1 (Introductory): Aimed primarily at neurologists in training, or those wishing to refresh/update their basic knowledge in the field. Level 1 may also be suitable for undergraduates or general trainees with a particular interest.

Level 2 (standard): Assumes familiarity with basic clinical knowledge and practice, aimed at specialist trainees or practitioners wishing to update and further develop their knowledge in the field.

Level 3 (advanced): Aimed at specialist trainees or practitioners with a particular interest in that field, covering the latest advances of particular interest to a specialist audience.

Participants will receive a manuscript/ summary of the lectures as well as a certificate of attendance.

TCs are not included in the registration fee, but have to be booked in addition.

HANDS-ON COURSES:

These Hands-on teaching courses (HoC) are for a limited number of participants only, with some built-in work in smaller groups who attend parallel by rotating to each presenter of the course. Live demonstrations with screening machines are the core of these courses.

For a limited number of participants only. Participation is not included in the registration fee.

CASE-BASED FACILITATED WORKSHOPS:

The case-based workshops are to support knowledge and practice in clinical diagnosis and management in a format, which requires the attendees to actively participate, with opportunities for direct discussion/contact with leading experts to discuss pre-prepared cases.

For a limited number of participants only. Participation is not included in the registration fee.

INTERACTIVE SESSIONS:

These sessions are open for all participants. Through an interactive voting system, the opinions of colleagues will be collected.

FOCUSED WORKSHOPS

Focused workshops (FWs) will be held in the late morning and last for 1,5 hours. They will cover narrow topics and will aim to promote discussion around new ideas, evidence or theories. Ample time for discussion will be provided.

SPECIAL SESSIONS:

Special Sessions (SPS) cover topics of special interest.

"HOW TO IMPROVE YOUR CHANCES":

This new format shall allow to share and improve knowledge on: "how to best write an academic paper"; "how to plan and organize a clinical or scientific study"; "how to apply for a grant", "how to get a paper accepted" etc... and shall thus "improve your chances".

These sessions are open for all participants and primarily aim at a post-graduate audience.

SMOKING POLICY

Smoking is prohibited at all times in the meeting halls, exhibit halls and restrooms. Your compliance is appreciated.

SPEAKERS' SERVICE CENTRE (SSC)

See page XII.

TRAVEL

see "Hotel and Travel"

VIP LOUNGE

EAN Full and Corresponding individual members and FEANs have the possibility to enjoy their lunch in a separated VIP Area. The VIP Area is located on the right side next to the exit of the exhibition area and is open during the exhibition opening hours.

Coffee and lunch will be available during the official coffee and lunch breaks.


WI-FI

Wi-Fi will be available free of charge in the session rooms and the exhibition area.


Network name: sanofigenzyme@EAN2016

Password: see the voucher in your bag or visit the Genzyme Booth #A10

The Wi-Fi is supported by **SANOI GENZYME** 



FIRST FLOOR



GROUND FLOOR

OVERVIEW OF BUSINESS MEETINGS

2016

(in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area.

GROUP/COMMITTEE	DAY, TIME	BELLY CENTER/SKY HOTEL
European Affairs Sub-committee	Saturday, 28 May 08.30 - 10.00	Room 18a
Education Committee	Sunday, 29 May 09.00 - 11.00	Room 21
Quality Assurance Sub-Committee	Sunday, 29 May 11.15 - 12.45	Room 21
Scientific Committee	Sunday, 29 May 12.45 - 14.45	Room B4 M7
TF Sub-saharan Africa	Sunday, 29 May 13.30 - 15.30	Room 21
European Journal of Neurology – Editorial Board	Sunday, 29 May 13.30 - 14.30	Room 16
EAN/WFN Meeting	Sunday, 29 May 15.00 - 16.00	Room 16
Meeting with Wiley	Sunday, 29 May 16.30 - 17.30	Room 21
Liaison Committee	Monday, 30 May 09.00 - 10.30	Room 16
E-communication Board	Monday, 30 May 10.30 - 12.00	Room 16
Panel Chairs Meeting	Monday, 30 May 12.30 - 14.30	Hall B4 M1
Industrial Relations Board	Monday, 30 May 15.00 - 16.30	Room 5
Corresponding Institutional Member Societies	Monday, 30 May 15.00 - 16.30	Room 16
Guideline Production Group	Tuesday, 31 May 09.00 - 10.30	Room 16
Teaching Course Committee	Tuesday, 31 May 10.30 - 12.00	Room 16
Programme Committee	Tuesday, 31 May 12.45 - 14.15	Room 16

(in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area.

SCIENTIFIC PANEL	DAY, TIME	ROOM #
Scientific Panel Higher cortical functions	Saturday, 28 May 10.30 - 12.00	Room 16
Scientific Panel Neuroimaging	Saturday, 28 May 16.00 - 17.00	Room 16
Scientific Panel Neuroimmunology	Sunday, 29 May 9.00 - 10.30	Room 69/70
Scientific Panel Neuro-ophthalmology and -otology	Sunday, 29 May 10.30 - 11.30	Room 60/61
Scientific Panel Neurorehabilitation	Sunday, 29 May 11.00 - 13.00	Room 69/70
Scientific Panel Autonomic nervous system disorders	Sunday, 29 May 11.30-12.30	Room 62/63
Scientific Panel Multiple sclerosis	Sunday, 29 May 12.00 - 13.00	Hall B5M2
Scientific Panel Clinical neurophysiology	Sunday, 29 May 12.00 - 13.00	Room 60/61
Scientific Panel Stroke	Sunday, 29 May 13.00 - 14.00	Room 62/63
Scientific Panel Coma and chronic disorders of consciousness	Sunday, 29 May 13.30 - 14.30	Room 69/70
Scientific Panel Neuroepidemiology	Sunday, 29 May 14.30 - 16.00	Room 60/61
Scientific Panel Neurogenetics	Sunday, 29 May 14.30 - 16.00	Room 62/63
Scientific Panel ALS and frontotemporal dementia	Sunday, 29 May 16.00 - 19.00	Room 69/70
Scientific Panel General neurology	Sunday, 29 May 17.00 - 18.30	Room 62/63
Scientific Panel Sleep-wake disorders	Sunday, 29 May 17.00 - 19.00	Room 60/61

(in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area.

GROUP/COMMITTEE	DAY, TIME	BELLY CENTER/SKY HOTEL
Scientific Panel Translational neurology	Sunday, 29 May 17.00 - 19.00	Room 5
Scientific Panel Palliative care	Monday, 30 May 08.00 - 09.00	Room 22
Scientific Panel Muscle disorders	Monday, 30 May 08.00 - 09.30	Room 69/70
Scientific Panel Neurosonology	Monday, 30 May 08.00 - 09.30	Room 21
Rare Neurological Diseases Task Force	Monday, 30 May 09.30 - 11.00	Room 22
Scientific Panel Child neurology	Monday, 30 May 09.30 - 10.30	Room 60
Scientific Panel Neuropathies	Monday, 30 May 10.30 - 12.00	Room 69/70
Scientific Panel Neuro-oncology	Monday, 30 May 11.00 - 12.00	Room 22
Scientific Panel Epilepsy	Monday, 30 May 11.30 - 12.30	Room 61
Scientific Panel Pain	Monday, 30 May 11.30 - 12.30	Room 60
Scientific Panel Dementia and cognitive disorders	Monday, 30 May 14.30 - 16.00	Room 69/70
Scientific Panel Neurotoxicology	Monday, 30 May 15.00 - 16.00	Room 22
Scientific Panel Neurotraumatology	Monday, 30 May 15.00 - 16.00	Room 21
Scientific Panel Infectious diseases	Monday, 30 May 15.00 - 16.30	Room 61
Scientific Panel Neurocritical care	Monday, 30 May 16.00 - 17.30	Room 69/70
YESNA Meeting	Monday, 30 May 16.30 - 18.30	Room 22
Scientific Panel Headache	Monday, 30 May 17.00 - 18.30	Room 16

Poster presenters are requested to be at their poster screen at the beginning of the sessions.

TOPIC (SCREEN NR)	POSTER NUMBERS	CHAIRS
SATURDAY, 28 MAY 2016		12.30-13.15
Ageing and dementia 1 (Screen A2)	P11001 - P11013	Pasquale Calabrese, ITALY
Autonomic nervous system 1 (Screen B1)	P11014 - P11022	Astrid Terkelsen, DENMARK
Cerebrovascular diseases 1 (Screen G1)	P11023 - P11036	Anna Czlonkowska, POLAND
Cerebrovascular diseases 2 (Screen G3)	P11037 - P11049	Adam Kobayashi, POLAND
Cerebrovascular diseases 3 (Screen G4)	P11050 - P11065	Zuzana Gdovinova, SLOVAKIA
Child neurology/developmental neurology (Screen H1)	P11066 - P11080	Vittoria Papp, DENMARK
Clinical neurophysiology 1 (Screen H2)	P11081 - P11092	Einar Wilder-Smith, SINGAPORE
Cognitive neurology/neuropsychology 1 (Screen A3)	P11093 - P11105	Rita Formisano, ITALY
Critical care (Screen F4)	P11106 - P11116	Raimund Helbok, AUSTRIA
Epilepsy 1 (Screen B2)	P11117 - P11128	Jakob Christensen, DENMARK
Epilepsy 2 (Screen B3)	P11129 - P11141	Alla Guekht, RUSSIAN FEDERATION
Headache and pain 1 (Screen C1)	P11142 - P11155	Henriette Klit, DENMARK
Movement disorders 1 (Screen E4)	P11156 - P11168	Kristian Winge, DENMARK
MS and related disorders 1 (Screen F1)	P11169 - P11181	Oluf Andersen, SWEDEN (TBC)
MS and related disorders 2 (Screen F2)	P11182 - P11194	Ludwig Kappos, SWITZERLAND
MS and related disorders 3 (Screen F3)	P11195 - P11208	Krzysztof Selmaj, POLAND
Muscle and neuromuscular junction disease 1 (Screen B4)	P11209 - P11220	Tiziana Mongini, ITALY
Neuro-oncology 1 (Screen C4)	P11221 - P11233	Stefan Oberndorfer, AUSTRIA
Neurorehabilitation 1 (Screen G2)	P11234 - P11245	Józef Opara, POLAND
Peripheral nerve disorders 1 (Screen D2)	P11246 - P11258	Michaela Auer-Grumbach, AUSTRIA
Sleep disorders 1 (Screen E1)	P11259 - P11273	Isabelle Arnulf, FRANCE
Spinal cord and root disorders (Screen E2)	P11274 - P11286	Josef Bednarik, CZECH REPUBLIC (TBC)
SATURDAY, 28 MAY 2016		13:30 - 14:15
Ageing and dementia 2 (Screen A2)	P12001 - P12013	Dorota Religa, SWEDEN
Autonomic nervous system 2 (Screen B1)	P12014 - P12023	Josef Zeitlhofer, AUSTRIA (TBC)
Cerebrovascular diseases 4 (Screen G1)	P12024 - P12037	Christine Kremer, SWEDEN
Cerebrovascular diseases 5 (Screen G3)	P12038 - P12051	Urs Fischer, SWITZERLAND
Clinical neurophysiology 2 (Screen H2)	P12052 - P12062	Martin Rakusa, SLOVENIA
Epilepsy 3 (Screen B2)	P12063 - P12075	Philippe Ryvlin, SWITZERLAND
Headache and pain 2 (Screen C1)	P12076 - P12089	Troels Staehlin Jensen, DENMARK (TBC)
Movement disorders 2 (Screen E4)	P12090 - P12102	Christer Nilsson, SWEDEN
Movement disorders 3 (Screen E3)	P12103 - P12113	Espen Dietrichs, NORWAY
MS and related disorders 4 (Screen F1)	P12114 - P12126	Gordon Plant, UNITED KINGDOM
MS and related disorders 5 (Screen F2)	P12127 - P12139	Hans Lassmann, AUSTRIA
Muscle and neuromuscular junction disease 2 (Screen B4)	P12140 - P12151	Abhijit Chaudhuri, UNITED KINGDOM
Neuroimaging 1 (Screen A3)	P12152 - P12165	Frederik Barkhof, THE NETHERLANDS
Neurological manifestations of systemic diseases 1 (Screen B3)	P12166 - P12175	Daniel Kondziella, DENMARK
Peripheral nerve disorders 2 (Screen D2)	P12176 - P12187	Jonathan Baets, BELGIUM

All posters will be available throughout the congress on the poster screens and poster stations in the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).

OVERVIEW OF POSTER SESSIONS

SUNDAY, 29 MAY

Poster presenters are requested to be at their poster screen at the beginning of the sessions.

TOPIC (SCREEN NR)	POSTER NUMBERS	CHAIRS
SUNDAY, 29 MAY 2016		12.30-13.15
Ageing and dementia 3 (Screen A2)	P21001 - P21013	Sandro Sorbi, ITALY
Cerebrovascular diseases 6 (Screen G4)	P21014 - P21027	Didier Leys, FRANCE
Cerebrovascular diseases 7 (Screen G3)	P21028 - P21042	Caroline Renner, GERMANY
Cognitive neurology/neuropsychology 2 (Screen A3)	P21043 - P21055	Thomas Bak, UNITED KINGDOM (TBC)
Epilepsy 4 (Screen B2)	P21056 - P21068	Leone Ridsdale, UNITED KINGDOM
Headache and pain 3 (Screen C1)	P21069 - P21082	Mads Barloese, DENMARK
Motor neurone diseases 1 (Screen C2)	P21083 - P21095	Vincenzo Donadio, ITALY (TBC)
Movement disorders 4 (Screen E4)	P21096 - P21108	Joaquim Ferreira, PORTUGAL
MS and related disorders 6 (Screen F1)	P21109 - P21121	Bruno Stankoff, AUSTRIA
MS and related disorders 7 (Screen F2)	P21122 - P21133	Xavier Montalban, SPAIN
MS and related disorders 8 (Screen F3)	P21134 - P21147	Tjalf Ziemssen, GERMANY
Muscle and neuromuscular junction disease 3 (Screen B4)	P21148 - P21159	Edina Varga, HUNGARY
Neuroepidemiology 1 (Screen C3)	P21160 - P21167	Maura Pugliatti, ITALY
Neurogenetics 1 (Screen F4)	P21168 - P21181	Péter Balicza, HUNGARY
Neuroimmunology 1 (Screen H2)	P21182 - P21196	Pasquale Annunziata, ITALY
Neuro-oncology 2 (Screen C4)	P21197 - P21209	Maria Mallia, MALTA (TBC)
Neuro-ophthalmology/ neuro-otology 1 (Screen H1)	P21210 - P21221	Katharina Feil, GERMANY (TBC)
Neurorehabilitation 2 (Screen G2)	P21222 - P21234	Michaela Bisciglia, BELGIUM
Neurotoxicology/occupational neurology (Screen G1)	P21235 - P21247	Maurizio Leone, ITALY
Peripheral nerve disorders 3 (Screen D2)	P21248 - P21260	Frouke Nijhuis, THE NETHERLANDS
Sleep disorders 2 (Screen E1)	P21261 - P21274	Ulf Kallweit, SWITZERLAND
SUNDAY, 29 MAY 2016		13:30 - 14:15
Ageing and dementia 4 (Screen A2)	P22001 - P22013	Jonathan Schott, UK
Cerebrovascular diseases 8 (Screen G4)	P22014 - P22027	Volker Dietz, SWITZERLAND
Cerebrovascular diseases 9 (Screen G3)	P22028 - P22042	Uta Meyding-Lamadé, GERMANY
Epilepsy 5 (Screen B2)	P22043 - P22055	Geir Braathen, NORWAY
Headache and pain 4 (Screen C1)	P22056 - P22069	Kathrin Doppler, GERMANY
Motor neurone diseases 2 (Screen C2)	P22070 - P22082	David Oliver, UNITED KINGDOM
Movement disorders 5 (Screen E4)	P22083 - P22095	Lisa Klingelhöfer, GERMANY
MS and related disorders 9 (Screen F1)	P22096 - P22108	Nicola De Stefano, ITALY
MS and related disorders 10 (Screen F2)	P22109 - P22121	Celia Oreja-Guevara, SPAIN
Muscle and neuromuscular junction disease 4 (Screen B4)	P22122 - P22134	Miguel Pinto, PORTUGAL (TBC)
Neuroepidemiology 2 (Screen C3)	P22135 - P22142	Alexander Tsiskaridze, GEORGIA
Neurogenetics 2 (Screen F4)	P22143 - P22156	Karolina Dziezyc, POLAND
Neuroimaging 2 (Screen A3)	P22157 - P22172	Luigi Ferini Strambi, ITALY
Neuroimmunology 2 (Screen H2)	P22173 - P22186	Maarten Titulaer, THE NETHERLANDS
Neurological manifestations of systemic diseases 2 (Screen B3)	P22187 - P22196	Peter Berlit, GERMANY
Neuro-ophthalmology/ neuro-otology 2 (Screen H1)	P22197 - P22208	Dominik Straumann, SWITZERLAND
Peripheral nerve disorders 4 (Screen D2)	P22209 - P22221	Davide Pareyson, ITALY

All posters will be available throughout the congress on the poster screens and poster stations in the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).

Poster presenters are requested to be at their poster screen at the beginning of the sessions.

TOPIC (SCREEN NR)	POSTER NUMBERS	CHAIRS
MONDAY, 30 MAY 2016		12.30-13.15
Ageing and dementia 5 (Screen A2)	P31001 - P31012	Stefano Cappa, ITALY
Cerebrovascular diseases 10 (Screen G4)	P31013 - P31026	Fabienne Perren, SWITZERLAND
Cerebrovascular diseases 11 (Screen G3)	P31027 - P31041	Ana Subic, SLOVENIA (TBC)
Cognitive neurology/neuropsychology 3 (Screen A3)	P31042 - P31054	Laszlo Csiba, HUNGARY
Epilepsy 6 (Screen B2)	P31055 - P31067	Hermann Stefan, GERMANY
Headache and pain 5 (Screen C1)	P31068 - P31081	Panagiotis Zis, UNITED KINGDOM
Infection and AIDS 1 (Screen F3)	P31082 - P31093	Leo Visser, THE NETHERLANDS
Motor neurone diseases 3 (Screen C2)	P31094 - P31106	Josef Finsterer, AUSTRIA
Movement disorders 6 (Screen E4)	P31107 - P31119	Antonella Macerollo, UNITED KINGDOM
Movement disorders 7 (Screen E3)	P31120 - P31132	Nabil Mohsen, LEBANON
MS and related disorders 11 (Screen F1)	P31133 - P31145	Ralf Gold, GERMANY
MS and related disorders 12 (Screen F2)	P31146 - P31159	Paolo Preziosa, ITALY
MS and related disorders 13 (Screen E2)	P31160 - P31172	Johann Sellner, AUSTRIA
Muscle and neuromuscular junction disease 5 (Screen B4)	P31173 - P31184	Benedikt Schoser, GERMANY
Neurogenetics 3 (Screen F4)	P31185 - P31197	David Lynch, UNITED KINGDOM
Neuroimmunology 3 (Screen H2)	P31198 - P31211	Frank Leypoldt, GERMANY
Neuro-oncology 3 (Screen C4)	P31212 - P31225	Anette Storstein, NORWAY
Neuro-ophthalmology/ neuro-otology 3 (Screen H1)	P31226 - P31236	Eleftherios Papatthanasiou, CYPRUS
Neurorehabilitation 3 (Screen G2)	P31237 - P31247	Stefan Golaszewski, AUSTRIA
Neurotraumatology (Screen G1)	P31248 - P31261	Edvard Ehler, CZECH REPUBLIC
Peripheral nerve disorders 5 (Screen D2)	P31262 - P31273	Henry Houlden, UNITED KINGDOM
Sleep disorders 3 (Screen E1)	P31274 - P32000	Maria Stamelou, GREECE

All posters will be available throughout the congress on the poster screens and poster stations in the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).

OVERVIEW OF POSTER SESSIONS

MONDAY, 20 MAY

Poster presenters are requested to be at their poster screen at the beginning of the sessions.

TOPIC (SCREEN NR)	POSTER NUMBERS	CHAIRS
MONDAY, 30 MAY 2016		13:30 - 14:15
Ageing and dementia 6 (Screen A2)	P32001 - P32011	Rik Ossenkopppele, THE NETHERLANDS
Cerebrovascular diseases 12 (Screen G4)	P32012 - P32025	Valeria Caso, ITALY
Cerebrovascular diseases 13 (Screen G3)	P32026 - P32040	Catarina Fonseca, PORTUGAL
Epilepsy 7 (Screen B2)	P32041 - P32053	Eugen Trinkka, AUSTRIA (TBC)
Headache and pain 6 (Screen C1)	P32054 - P32066	Jera Kruja, ALBANIA
Headache and pain 7 (Screen C4)	P32067 - P32081	Jes Olesen, DENMARK
Infection and AIDS 2 (Screen F3)	P32082 - P32093	Johann Sellner, AUSTRIA
Motor neurone diseases 4 (Screen C2)	P32094 - P32105	Vincenzo Silani, ITALY
Movement disorders 8 (Screen E4)	P32106 - P32118	Evzen Ruzicka, CZECH REPUBLIC
Movement disorders 9 (Screen E3)	P32119 - P32131	Anna Sauerbier, UNITED KINGDOM
MS and related disorders 14 (Screen F1)	P32132 - P32144	Nicholas Gutowski, UNITED KINGDOM
MS and related disorders 15 (Screen F2)	P32145 - P32158	Óscar Fernández, SPAIN
Muscle and neuromuscular junction disease 6 (Screen B4)	P32159 - P32171	Klaus Toyka, GERMANY (TBC)
Neurogenetics 4 (Screen F4)	P32172 - P32184	Jochen Schäfer, GERMANY
Neuroimaging 3 (Screen A3)	P32185 - P32198	Tim von Oertzen, AUSTRIA
Neuroimmunology 4 (Screen H2)	P32199 - P32211	Heinz Wiendl, GERMANY
Neurological manifestations of systemic diseases 3 (Screen B3)	P32212 - P32221	Eduardo Nobile-Orazio, ITALY
Neurology and arts; History of neurology; Ethics in neurology; Education in neurology (Screen E2)	P32222 - P32236	Jan Kuks, THE NETHERLANDS
Neuro-ophthalmology/ neuro-otology 4 (Screen H1)	P32237 - P33247	Christopher Kennard, UNITED KINGDOM
Peripheral nerve disorders 6 (Screen D2)	P33248 - P32259	Nazha Birouk, MOROCCO

All posters will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).

EFNA PUBLIC AWARENESS DAY FOR: PATIENTS, CARERS, FAMILIES AND HEALTH PROFESSIONALS

Together under the Umbrella for
Huntington's disease

10:30 - 17:00



Location: DGI-byen, Tietgensgade 65 1704 Copenhagen V, Denmark.

As part of the *Together Under the Umbrella* awareness campaign for brain disorders, the European Federation of Neurological Associations will organise an information day on Huntington's Disease. The event, which will be organised to coincide with the EAN Annual Congress, is open to those living with Huntington's disease, their families and friends, carers, health professionals or those with an interest in learning more. World-Leading, Huntington Disease Specialist, Prof. Bernhard Landwehrmeyer will be the keynote speaker on the day.

This free event will take place on Saturday, 28 May, 2016 from 10:30 - 17:00 (Registration and Breakfast from 09:30) at DGI-byen, Tietgensgade 65, 1704 Copenhagen V, Denmark.

Presentations will focus on:

- Current, best-practice approaches to treatment and management
- Latest research and studies in the field - hope for the future
- Patient and Carer personal stories
- National service and support structures
- Coping tips and strategies for Carers
- Mindfulness and Relaxation

A buffet breakfast and sandwich lunch will be provided on the day, and there will be time throughout to speak to other families, ask questions and pick up more information on HD.

OPENING

18:30 | HALL A

Welcoming addresses

Mads Ravnborg, Local Chairperson, President Danish Society of Neurology

Günther Deuschl, President of the European Academy of Neurology

Opening Lecture:

Pleasures of the Brain

Morten Kringelbach, OXFORD UNITED KINGDOM

Royal Ballet performing scenes from "Swan Lake"

All participants and exhibitors are invited to the Opening and the welcome reception afterwards. There will be food, drinks and music.

Please wear your badge.



CHALLENGES FOR WOMEN IN NEUROLOGY – EXPERIENCES FROM WESTERN AND EASTERN EUROPE

13:00-14:30 | HALL B4.M1

The aim of this event is to help identify and overcome the challenges that women may find during their academic and hospital career development in neurology. This event is mainly directed to female neurology residents and female neurologists at the beginning of their career.

You are invited to bring your lunch to this session.



Nazha Birouk,
RABAT, MOROCCO

Professor Nazha Birouk (MD, Prof), is President of the Moroccan Society of Neurology (2012-2016). She received her Professor's Degree in Neurology at the Faculty of Medicine of Rabat in November 1997. Her training for neuromuscular disorders and neurophysiology was at the Hôpital de la Salpêtrière, Paris, France from 1994 -1997. Her main fields of interest are Neuromuscular disorders - Hereditary neuropathies and myopathies; ENMG, Neurophysiology. She is involved in research projects in hereditary neuropathies, muscular dystrophies, and hereditary ataxia. She gave invited lectures in International and National Meetings: Themes: Peripheral nerve disorders: hereditary neuropathies, Inflammatory neuropathies; Muscle disorders; ENMG; Neuropathic Pain. She was Secretary General of the Moroccan Society of Neurology from 1998 to 2004; Secretary General of the Moroccan Association against Myopathy: Since 2005 and was a Delegate Member of the EFNS for the Moroccan Society of Neurology: 2007-2013.



Elena Lebedeva,
JEKATERINBURG, RUSSIA

Elena Lebedeva (MD, PhD, DocMedSci) is associate professor of neurology of the Urals State Medical University, director of International Headache Center "Europe-Asia" in Yekaterinburg and consultant neurologist. She works 70% clinically and 30% in

research. She has 5 PhD students. Her main areas of interest concern stroke, intracranial aneurysms and headache. She got Investigator Award from the EFNS in 2012. She is currently part of the EAN Scientific Panels on Stroke and Headache. She was organizer of two EFNS Regional Teaching courses in Yekaterinburg (2006, 2011), 9 annual conferences on actual topics of neurology and 15 Headache schools. She is married and has two sons.



Gunhild Waldemar,
COPENHAGEN, DENMARK

Gunhild Waldemar, MD DMSc, Honorary member of the EAN, is a professor of clinical neurology and coordinating professor at the Neuroscience Centre, Rigshospitalet, University of Copenhagen, Denmark. She established the multi-disciplinary memory clinic in

her department in 1995, and later extended the clinic with a dementia research lab. and in 2007 with a national info & education centre, funded by the Danish Ministry of Health. In 2010 the combined centre, now named, The Danish Dementia Research Centre, won the "Global Excellence in Health" award from the Capital Region of Denmark and University of Copenhagen. She has also chaired the Liaison Committee in the EFNS and was part of the task force merging the EFNS with the ENS, forming the EAN.

RRFS HOSPITAL VISIT

18:00 | REGISTRATION DESK

(max. 100 participants) on Sunday, 29 May 2016 will be organised in co-operation with the Danish Young Neurologist Society. We are going to meet at 18.00-18.15 in front of the registration desk. We will visit the Rigshospital - University Hospital followed by a get-together. Registration is available via facebook or by contacting rrfs@ean.org or at the RRFS booth at the congress.

NETWORKING RECEPTION AND "MEET THE SPEAKERS"

EAN will be happy to encourage speakers and participants likewise to come to the renowned Paper Island Street Food market and offer the possibility to mingle and encounter in a relaxed atmosphere.


Copenhagen Street Food offers 35 food and beverage counters/stalls that represent almost the entire globe in a culinary way.

Entry is free of charge, food and beverages have to be paid at one's own expense. Come to the EAN Booth and win vouchers for food+drink at Paper Island Streetfood.

Location: Christiansholm - Papirøen Trangravsvej 14, Warehouse 7/8, 1436 København.

More information can be found here:
<http://copenhagenstreetfood.dk/en/>

From 20.15-22.15 a shuttle boat Nyhavn-Paper Island-Nyhavn will be available every 15 minutes for all participants.



HALL A	HALL B	HALL C	MO	M1	M2	M3	M4	M5	B4.M1	B4.M2	B5.M1	B5.M2	EXHIBITION/ POSTER
SpS1 08:30-10:30 MDS-ES: European Basal Ganglia Club	FW1 08:30-10:00 Advanced imaging methods for the assessment of MS patho- genesis and treatment	SpS7 09:00-10:00 Neurology across continents: WFN/WHO	FW6 08:30-10:00 New concepts about speech and language processing in the brain	FW2 08:30-10:00 Genetic approaches in neuropathies	FW3 08:30-10:00 Addressing quality of care for neurological patients		FW5 08:30-10:00 Abnormal movements in sleep	IS1 08:30-10:00 Cost-effective investigations of CNS infections	CbFW1 08:30-10:00 EEG in patients with acute consciousness impairment SOLD OUT!	FW4 08:30-10:00 Frontier applications in Neurosonology	SpS2 08:30-10:00 Music and neurological dis- orders of famous composers		
10:00-10:30 Coffee break @ exhibition													
Sy1 10:30-12:30 MDS-ES/EAN: Update in Movement disorders	Sy2 10:30-12:30 Neuro- stimulation, what can be achieved in....	Sy3 10:30-12:30 The changing landscape of coma treatment		Sy4 10:30-12:30 Evolving concepts in the management of gliomas									10.00-17.00 Exhibition
12:30-14:45 Lunch break @ exhibition (lunch served from 12.30-13.30)													
	SaS1 13:00-14:30 Excemed Current and future treatments for MS introduction		SaS1 13:00-14:30 Cynapsus From "OFF" to "ON" - treating levodopa induced OFF periods in Par- kinson's disease	SaS1 13:00-14:30 Dr. Willmar Schwabbe EG6761@in pre-clinic to clinic									12.30-13.15 / 13.30-14.15 Poster Session 1
TC1 14.45-18.15 Acute manage- ment of stroke Level 2	OS 14.45-16.15 Multiple sclerosis and related disorders 1	OS 14.45-16.15 Movement disorders 1	OS 14.45-16.15 Epilepsy 1	TC4 14.45-18.15 Testing for auto-antibodies in neurological disorders Level 2	TC3 14.45-18.15 Neuro- ophthalmological emergentes Level 2		TC5 14.45-18.15 Pharmacological and non-phar- macological treatments in Alzheimer's disease Level 2	TC6 14.45-18.15 Experimental study designs in neurological disorders Level 2	OS 14.45-16.15 Neurogenetics	TC2 14.45-18.15 MDS-ES/EAN: Abnormal movement disorders in children Level 1	OS 14.45-16.15 Neuro- epidemiology	OS 14.45-16.15 Autonomic nervous system disorders & Clinical neuro- physiology	10.00-17.00 Exhibition
16:15-16:45 Coffee break @ exhibition													
(cont.)	OS 16.45-18.15 Multiple sclerosis and related disorders 2	OS 16.30-18.15 Cerebro vascular diseases 1	OS 16.45-18.15 Epilepsy 2	(cont.)	(cont.)	How to... 16.45-18.15 ...write and publish scientific papers (EJON Session)	(cont.)	(cont.)	OS 16.30-18.15 Motor neurone disease	(cont.)	OS 16.45-18.15 Neuro-oncology	OS 16.30-18.15 Sleep disorders	
18:30-19:30 Opening	19:30 - 21:00 Welcome Reception @ Centerhall												

HALL A	HALL B	HALL C	MO	M1	M2	M3	M4	M5	B4.M1	B4.M2	B5.M1	B5.M2	EXHIBITION/ POSTER
IS2 08:30-10:00 Pitfalls in neurological sleep medicine	SpS2 08:30-10:00 Zika infectious neurological system		FW12 08:30-10:00 Impaired hand function after stroke and peripheral nerve injury: consequences for treatment	FW8 08:30-10:00 MDS-ES/EAN: Tics and Tourette Syndrome – Consensus and Controversies	FW9 08:30-10:00 Focal Dementias	SpS3 08:30-10:00 New European neurological Guidelines	FW10 08:30-10:00 MDS-ES/EAN: Biomarkers for Parkinson's disease	FW7 08:30-10:00 Stem cell therapies for the treatment of neurological diseases	HoC6 08:30-10:00 Neuro-otology SOLD OUT!	CbfW2 08:30-10:00 Cluster headache – a clinical challenge?	HoC1 08:30-10:00 Neuro-oncology (vascular)	SpS4 08:30-10:00 EFNA: Open Dialogue: Let's Talk about Sex, Sleep and Stress	
10:00-10:30 Coffee break @ exhibition													
PS1 10:30-12:30 Presidential Symposium													
12:30-14:45 Lunch break @ exhibition (lunch served from 12:30-13:30)													
TC7 14:45-18:15 Iatrogenic lesions of the peripheral nervous system Level 2	TC8 14:45-18:15 MDS-ES/EAN: Motor refractory to L-DOPA in PD Level 1	OS 14:45-18:15 Multiple-sclerosis and related disorders 3	TC12 14:45-18:15 How to assess autonomic dysfunction in general-neurology Level 1	TC9 14:45-18:15 Optimising the management of acute, preventive and non-pharmacological aspects Level 2	TC10 14:45-18:15 Generalised epilepsies: genetics, diagnostics and treatment Level 3	TC11 14:45-18:15 Current treatments in neurology I Level 1	OS 14:45-18:15 Neuro-rehabilitation	OS 14:45-18:15 Child neurology	TI 14:45-18:15 Tournament Basic	CbfW3 14:45-18:15 MDS-ES/EAN: What to do with ataxia?	HoC2 14:45-18:15 Neuro-physiology I NeedleEMG and single fibre EMG	OS 14:45-18:15 Cognitive neuro-physiology 1	
16:15-16:45 Coffee break @ exhibition													
(cont.)	(cont.)	OS 16:45-18:15 Ageing and dementia	(cont.)	(cont.)	(cont.)	(cont.)	OS 16:45-18:15 Headache and pain 1	OS 16:45-18:15 Movement disorders 2	OS 16:45-18:15 Critical care	How to... Question writing workshop	HoC3 16:45-18:15 Neuro-physiology II Nerve conduction studies + nerve/muscle ultra-sound	OS 16:45-18:15 Neuroimaging & Neuro-immunology	
SpS1 18:30-20:00 F. Hoffmann La Roche New insights in MS: How are approaches to MS management changing?	SpS1 18:30-20:00 Eli Lilly Exploring the interaction Amyloid and Tau in Alzheimer's Disease: Implications for Diagnosis, Disease Progression, and Management	SpS1 18:30-20:00 Alexion The role of complement in neurological disorders	(cont.)	(cont.)	(cont.)	(cont.)	(cont.)	(cont.)	(cont.)	(cont.)	(cont.)	(cont.)	

KEY: FW | Focused Workshop | SpS | Special Session | HOC | Hands-on course
 IS | Interactive Session | Sy | Symposium | NE | Networking Events
 OS | Oral Session | TC | Teaching Course | PS | Plenary Symposium
 SaS | Satellite Symposium | T | Tournament | CbfW | Case-based facilitated Workshops

HALL A	HALL B	HALL C	M0	M1	M2	M3	M4	M5	B4.M2	B5.M1	EXHIBITION/ POSTER
	IS3 08:30 - 10:00 MDS-ES/EAN: Paroxysmal and acute movement disorders	FW13 08:30 - 10:00 Sleep and Cognition	Sp56 08:30 - 10:00 ILAE-CEA/EAN: Hot topics in Epilepsy	FW14 08:30 - 10:00 Gut microbiota, immunology and neurological diseases	Sp55 08:30 - 10:00 PAUNS/EAN: Neuro-mediterranean Session: Infectious diseases	FW15 08:30 - 10:00 Exome sequencing goes bedside: new genes in neurological disorders	FW16 08:30 - 10:00 Syndromes of central visual and vestibular disorders	FW17 08:30 - 10:00 ALS and FTD: two converging diseases?	CbFW4 08:30 - 10:00 Management of multiple sclerosis SOLD OUT!	HoC4 08:30 - 10:00 Neuro-physiology III Non-invasive brain stimulation	
10:00-10:30 Coffee break @ exhibition											
PS2 10:30-12:30 Neuro-imaging of dementia											10:00-17:00 Exhibition
12:30-14:45 Lunch break @ exhibition (lunch served from 12:30-13:30)											
Sa5 13:00 - 14:30 Ever Neuropharma Integrating acute and rehabilitation treatment strategies in stroke therapy	Sa5 13:00 - 14:30 Novartis The real MS: outcomes and evidence in the real-world			Sa5 13:00 - 14:30 Sanofi Genzyme Tales of the unexpected: elementary clues to diagnosing muscular diseases					How to... 13:00 - 14:30 ...prepare your abstract submission for presenting at an international congress		12:30 - 13:15 / 13:30 - 14:15 Poster Session 3
Sy6 14:45 - 16:45 ESO-EAN: Acute Stroke: New Opportunities and challenges for neurologists	Sy5 14:45 - 16:45 New perspectives in the treatment of neuromuscular diseases: therapies on the horizon	TC13 14:45-18:15 Diagnostic and therapeutic approach to muscle syndromes Level 1	Sp51 14:45 - 16:15 History of neurology	TC14 14:45 - 18:15 Pain in central neurological conditions Level 2	TC15 14:45 - 18:15 Clinical presentations of metabolic disorders Level 2	TC16 14:45 - 18:15 Interventions in neurocritical care Level 2	TC17 14:45 - 18:15 Update on epilepsy in children - new trends in diagnosis and treatment Level 1	14:45 - 16:15 EHF/EAN Topical Symposium CGRP antibodies. A new class of migraine specific preventative medication	CbFW5 14:45 - 16:15 Care of the person with ALS	T 14:45 - 16:15 Tournament Clinical	10:00-17:00 Exhibition
16:15-16:45 Coffee break @ exhibition											
OS 16:45 - 18:15 Cerebro-vascular diseases 2	OS 16:45 - 18:15 Muscle and neuromuscular junction disease	(cont.)	OS 16:45 - 18:15 Movement disorders 3	(cont.)	(cont.)	(cont.)	(cont.)	OS 16:45 - 18:15 Headache and pain 2	16:45-18:15 Resident and Research Fellow Assembly	OS 16:45 - 18:15 Cognitive neuro- psychology 2	
		Sa5 18:30-20:00 TEVA multiple sclerosis - multiple solutions - one choice: what's yours? Challenge the expert in 60 seconds									

HALL B1	HALL B2	HALL B3	HALL C	M1	M2	M3	M4	M5	B4.M2	B5.M1	B5.M2	EXHIBITION/ POSTER
				Sv7 08:00-10:00 Understanding functional connectivity using MRI	Sv8 08:00-10:00 New diagnostic developments in Epilepsy	Sv9 08:00-10:00 Untangling inflammatory and degenerative aspects of multiple sclerosis	SpS8 08:30-10:00 European reference network	SpS9 08:30-10:00 Shared decision making (SDM) in neurology	08:30 -10:00 CfRW 6: Neuropsychological testing in dementia for non-neuro-psychologists	HoCS 08:00 -10:00 Nerve and muscle imaging for clinicians	SpS10 08:30-10:00 EAN - RRFs: Prospects for young neurologists in training in three corners of Europe	
10:00-10:30 Coffee break @ exhibition												
				PS3 10:30 -12:30 Highlights and Breaking News	PS3 10:30 -12:30 Overflow							09:30-13:30 Exhibition
12:00-13:00 Lunch break @ exhibition												
TC18 13:00-16:30 Life after stroke Level 2	TC19 13:00-16:30 Challenges in newly diagnosed epilepsy Level 1	TC20 13:00-16:30 Controversies: The natural history of incidental neuroimaging findings Level 2	TC22 13:00-16:30 Current treatments in neurology II Level 1							TC21 13:00-16:30 Preventing delayed neurological deficits in neurocritical care - Old fees, new concepts Level 2-3	TC23 13:00-16:30 Developing an EAN guideline Level 1	
14:30-15:00 Coffee break @ exhibition												
(cont.)	(cont.)	(cont.)	(cont.)							(cont.)	(cont.)	

KEY: **FW** | Focused Workshop | **SpS** | Special Session | **HOC** | Hands-on course
IS | Interactive Session | **Sy** | Symposium | **NE** | Networking Events
OS | Oral Session | **TC** | Teaching Course | **PS** | Plenary Symposium
SaS | Satellite Symposium | **T** | Tournament | **CbFW** | Case-based facilitated Workshops

SAVE THE DATE

ESNCH >> 2017



22nd MEETING
of the
EUROPEAN SOCIETY
of **NEUROSONOLOGY** and
CEREBRAL HEMODYNAMICS

19–21 May 2017

www.neurosonology2017.de



THE CONFERENCE OF ULTRASOUND IN NEUROLOGY

- discover the latest technologies
- present and discuss your research
- talk to the specialists
- improve your practical skills
- take the ESNCH exam

SEE YOU IN BERLIN



conventus


CONGRESSMANAGEMENT

2ND EAN CONGRESS

SCIENTIFIC PROGRAMME



CONCISE, PEER-REVIEWED, OPEN-ACCESS,
OPINION based ARTICLES & VIDEOS
from KEY OPINION LEADERS,
ACCESS and DOWNLOAD FREE



Connect with us and
join the debate



www.touchNEUROLOGY.com



SATURDAY, 28 MAY

SESSIONS

**WCN
2017**



XXIII World Congress of Neurology

September 16–21 2017
Kyoto, Japan

www.wcn-neurology.com



SOCIETAS
NEUROLOGICA
JAPONICA
Founded in 1960



Defining the Future of Neurology

CASE-BASED FACILITATED WORKSHOP 1: EEG IN PATIENTS WITH ACUTE CONSCIOUSNESS IMPAIRMENT

08:30 - 10:00 | HALL B4.M1

CHAIRPERSON:

Andrea Rossetti, LAUSANNE, SWITZERLAND

Use of the new ACNS nomenclature

Erik Westhall, LUND, SWEDEN

Advanced EEG monitoring

Nicolas Gaspard, BRUSSELS, BELGIUM

Spiky EEG: to treat or not to treat?

Andrea Rossetti, LAUSANNE, SWITZERLAND

Dr Westhall will familiarise the audience with some examples of EEG patterns to be described with the ACNS nomenclature. Dr Gaspard will focus on indications and values of video-EEG monitoring. Dr Rossetti will highlight some differentials regarding sharply contoured EEG patterns and treatment implications. The audience will interactively work in 3 groups of about 20 persons on vignettes with clinical and EEG data. Each speaker will discuss 4-5 vignettes; speakers will rotate among groups every 30 minutes.

INTERACTIVE SESSION 1: COST EFFECTIVE INVESTIGATIONS OF CNS INFECTIONS

08:30 - 10:00 | HALL M5

CHAIRPERSON:

Israel Steiner, PETACH TIKVA, ISRAEL

Neuroimaging

Uta Meyding-Lamade, FRANKFURT A.M., GERMANY

Microbiology

Peter Kennedy, GLASGOW, UK

Molecular biology

Israel Steiner, PETACH TIKVA, ISRAEL

Biopsy/Histology

Hans Lassmann, VIENNA, AUSTRIA

CNS infections are an important clinical challenge. Early diagnosis enables to provide specific therapy that will reduce mortality, cut down neurological sequels and improve prognosis. Besides history and systemic and neurological examination, laboratory tests are an important tool that may enable to reduce differential diagnosis and establish correct diagnosis. This interactive session will cover a spectrum of challenging neurological cases and provide knowledge how

to cost-effectively employ laboratory tests (on fluids and CSF) and auxiliary examinations (imaging, tissue biopsy) to provide prompt diagnosis.

Participants are encouraged to actively engage with immediate feedback to support learning (voting system)

FOCUSED WORKSHOP 1: ADVANCED IMAGING METHODS FOR THE ASSESSMENT OF MS PATHOGENESIS AND TREATMENT

08:30 - 10:00 | HALL B

CHAIRPERSON:

Bruno Stankoff, PARIS, FRANCE

Insight into the pathogenesis of multiple sclerosis using metabolic imaging

Olga Ciccarelli, LONDON, UK

The promise of ultra high field MRI in multiple sclerosis

Frederik Barkhof, AMSTERDAM, NETHERLANDS

Assessing tissue damage and repair in multiple sclerosis by positron emission tomography

Bruno Stankoff, PARIS, FRANCE

Target Audience:

Clinical academicians, Students/Residents/Trainees

Scientific Content:

Lecture 1 will discuss insights gained from metabolic imaging studies in MS patients, including raised sodium concentrations in the brain, increased glutamate levels in acute lesions and normal-appearing white matter, reduced GABA levels in the grey matter, and neuronal mitochondrial dysfunction.

Lecture 2 will describe the (challenges and) opportunities of ultra-high field MRI (7T) for human in vivo imaging, including how improved spatial resolution can be used for better cortical lesion detection, and how new contrast mechanisms provide novel diagnostic and pathogenetic disease insights

Lecture 3 will describe how molecular imaging by PET and various radiotracers will contribute to the quantitative assessment of the major pathophysiological mechanisms of MS: demyelination and remyelination in the white matter; neuronal damage in the grey matter; microglial activation in the CNS. Methodological issues related to this technology will be presented.

SATURDAY, 28 MAY

08:30 - 10:00

FOCUSED WORKSHOP 2: GENETIC APPROACHES IN NEUROPATHIES

08:30 - 10:00 | HALL M1

CHAIRPERSON:

Davide Pareyson, MILAN, ITALY

Genotype-phenotype correlations in hereditary neuropathies

Michaela Auer-Grumbach, GRAZ, AUSTRIA

Whole-exome sequencing in patients with inherited neuropathies: outcome and challenges

Jonathan Baets, ANTWERP, BELGIUM

New opportunities of therapy in genetic neuropathies

Davide Pareyson, MILAN, ITALY

Target Audience: Clinical academicians, Practitioners,
Students/Residents/Trainees

Scientific Content: This workshop will give an update on genetic neuropathies. The audience will get up-to-date information about genotype-phenotype correlations in Charcot-Marie-Tooth disease, and about what we can learn from these about the pathophysiology of peripheral neuropathies. We will report on the chances and challenges that whole-exome sequencing gives us in the diagnosis of hereditary neuropathies. Finally, we will try to persuade the audience that a genetic neuropathy is a reason to treat, and not for therapeutic nihilism. Up-to-date information on completed and ongoing randomized controlled trials as well as on promising novel approaches for the most important genetic neuropathies will be presented.

FOCUSED WORKSHOP 3: ADDRESSING QUALITY OF CARE FOR NEUROLOGICAL PATIENTS

08:30 - 10:00 | HALL M2

CHAIRPERSON:

Abhijit Chaudhuri, ROMFORD, UK

Optimising quality of care in epilepsy

Elinor Ben-Menachem, GOTHENBORG, SWEDEN

Quality standards of multiple sclerosis service

Abhijit Chaudhuri, ROMFORD, UK

Health related quality of life in Parkinson's disease

Bastiaan R. Bloem, NIJMEGEN, THE NETHERLANDS

Marjam Faber, NIJMEGEN, THE NETHERLANDS

Target Audience: Clinical academicians, Practitioners,
Students/Residents/Trainees, Non-physician Health
Professionals

Scientific Content: The definition of quality is care that is effective, safe and that provides a positive experience for patients. Quality of health care is a key concern in patients with long term neurological disorders. In this workshop, using examples of three common and chronic neurological conditions, the speakers will discuss measures to optimise care standards and quality of life in patients with epilepsy, multiple sclerosis and Parkinson's disease. The presentations will aim to provide a standardised approach in assessing the performance and impact of clinical services in the care quality of these patients.

The learning objective of the workshop is to empower professionals to recognise the key elements of care pathways that can meet patients' needs better and to challenge poor practices.

FOCUSED WORKSHOP 4: FRONTIER APPLICATIONS IN NEUROSONOLOGY

08:30 - 10:00 | HALL B4.M2

CHAIRPERSON:

David Russell, OSLO, NORWAY

Magnetic resonance guided focused ultrasound for neurological disorders

Ilana Schlesinger, HAIFA, ISRAEL

Ultrasound on the earth and in the orbit

Zsolt Garami, HOUSTON, USA

The unstable carotid artery plaque

David Russell, OSLO, NORWAY

Target Audience: Basic Scientists, Clinical academicians,
Non-physician Health Professionals

Scientific Content: During the last years revolutionary developments could be experienced in the field of neurosonology. New imaging and hemodynamic methods enriched the treasure of neurosonology and opened new diagnostic avenues. Besides, the neurosonology became one of the efficient tool of therapy in the cerebrovascular and other neurological diseases. The focused workshop will discuss the advantages and problems of these new methods.

FOCUSED WORKSHOP 5: ABNORMAL MOVEMENTS IN SLEEP

08:30 - 10:00 | HALL M4

CHAIRPERSON:

Ramin Khatami, BARMELWEID, SWITZERLAND

Regulation of motor control during sleep

Pierre-Hervé Luppi, LYON, FRANCE

Simple motor movements

Alejandro Iranzo, BARCELONA, SPAIN

Complex motor movements

Ramin Khatami, BARMELWEID, SWITZERLAND

Target Audience: (Basic Scientists), Clinical academicians, Practitioners, Students/Residents/Trainees

Scientific Content: Patients with complex motor movements present with a spectrum of semi-purposeful or non-purposeful movements arising from NREM- or REM-sleep. These movements typically last for minutes, and occur at sleep stages transitions or consolidated sleep stages. Movements are involuntary and characterized by repetitive stereotyped simple movements or irregular, unpredictable complex behaviours that occur as single event or clusters of episodes. Movements may include violent behaviour leading to self-injuries or unwarranted physical harm on others. Apart from injuries these movements can cause daytime symptoms such as excessive daytime sleepiness by disrupting sleep continuity or sleep quality. Complex motor movement of the adult population can result from various etiologically different conditions, including parasomnias, epilepsy, and psychiatric diseases. They frequently share common triggers such as sleep deprivation, fever or certain medications. This workshop will introduce the most common complex movements arising from NREM and REM-sleep and related disorders including arousal disorders and rapid eye movement behavior disorders (RBD), nocturnal frontal lobe epilepsy (NFLE), or dissociative states and factitious disorders.

FOCUSED WORKSHOP 6: NEW CONCEPTS ABOUT LANGUAGE PROCESSING IN THE BRAIN

08:30 - 10:00 | HALL M0

CHAIRPERSON:

Cornelius Weiller, FREIBURG, GERMANY

The dual-loop model and aphasia

Cornelius Weiller, FREIBURG, GERMANY

The impact of bilingualism on cognitive functions across the lifespan and in brain diseases

Thomas Bak, EDINBURGH, UK

The writing brain

Jean-Francois Démonet, LAUSANNE, SWITZERLAND

Target Audience:

Basic Scientists, Clinical academicians, Practitioners, Students/Residents/Trainees, Non-physician Health Professionals

Scientific Content:

The dual loop model provides a domain general framework of brain organisation. Its application to stroke patients may help in better understanding the fuzzy link of aphasia syndromes and brain lesions as well as recovery from aphasia. Bilingualism is associated with better cognitive performance in younger and older adults, also in people who have acquired their second language later in life and without reaching a perfect command of it.

Writing offers an interesting framework between language and motor output. Many conditions, from Parkinson's disease to developmental dyslexia, are interesting models to understand more how abstract orthography representations are transformed into motor output.

SPECIAL SESSION 1: MDS-ES EUROPEAN BASAL GANGLIA CLUB

08:30 - 10:30 | HALL A



International Parkinson and
Movement Disorder Society
European Section

CHAIRPERSONS:

Kailash Bhatia, LONDON, UK

Angelo Antonini, PADUA, ITALY

Video Case Presentations

Various presenters

Consciousness, Emotions and Basal Ganglia

Yves Agid, PARIS, FRANCE

Scientific Content: Every year the European Basal Ganglia Club features a prominent speaker to present a C. David Marsden Award lecture. During the 2nd congress of the European Academy of Neurology, it is an honor to have Prof. Yves Agid give a lecture on "Consciousness, Emotions and Basal Ganglia". The lecture will be preceded by the presentation of video case studies. Presenters of the video case studies will have been chosen through an application and selection process in partnership with the European Editor of the Movement Disorders – Clinical Practice Journal, providing Young Neurologists presenting their cases with a chance to see their work become published.

SATURDAY, 28 MAY

08:30 - 12:30

SPECIAL SESSION 2: MUSIC AND NEUROLOGY – NEUROLOGICAL DISORDERS OF FAMOUS COMPOSERS

08:30 - 10:00 | HALL B5.M1

CHAIRPERSON:

Tomislav Breitenfeld, ZAGREB, CROATIA

Subarachnoid haemorrhage as a likely cause of Mendelssohn's death

Hansjörg Bänzner, STUTTGART, GERMANY

Mozart's possible neurological disorders

Christopher Gardner Thorpe, EXETER, UK

Stroke in famous composers

Tomislav Breitenfeld, ZAGREB, CROATIA

Wagner's migraine and Gershwin's uncinat seizures

Vlasta Vukovic-Cvetkovic, GLOSTRUP, DENMARK

Scientific Content: This special session will present a series of biopatho-graphies and short portraits of famous composers describing their biography, talent, creation and medical history. All presented famous composers suffered from different neurological disorders. Presentations will explain influence of those disorders on composer's creativity. Audience will be allowed (and animated) to comment and discuss the interaction between neurological disorders and composer's ability to create art. While trying to explain the complex relationship between neurological disorders and creativity through pathographies of famous composers, the organisers intend to present a new, really interesting and „something else from other topics" session. *"We believe that it will turn into a memorable gathering of people who share the same passion, genuine love and enthusiasm for both, neurology and music. After all, Copenhagen with its glorious musical, cultural and medical history seems to be an ideal site for a special session „Neurological disorders of famous composers"."*

SPECIAL SESSION 7: NEUROLOGY ACROSS CONTINENTS: WFN/WHO

09:00 - 10:00 | HALL C

CHAIRPERSON:

Raad Shakir, LONDON, UK

The new WHO Neurology Atlas

Raad Shakir, LONDON, UK

Education Programmes of the WFN

Steven Lewis, CHICAGO, USA

The WFN teaching centres.

Wolfgang Grisold, VIENNA, AUSTRIA

SYMPOSIUM 1: MDS-ES/EAN: UPDATE IN MOVEMENT DISORDERS

10:30 - 12:30 | HALL A

International Parkinson and
Movement Disorder Society
European Section

CHAIRPERSONS:

Joaquim Ferreira, LISBON, PORTUGAL

K. Ray Chaudhuri, LONDON, UK

Essential tremor

Günther Deuschl, KIEL, GERMANY

Non-motor symptoms in Parkinson's disease

K. Ray Chaudhuri, LONDON, UK

Dystonia

Espen Dietrichs, OSLO, NORWAY

PSP/MSA

Maria Stamelou, ATHENS, GREECE

Scientific content: This symposium is dedicated to major recent developments in the field of movement disorders. Essential tremor definition is currently revised. Non-motor symptoms are becoming continuously more important for early diagnosis of PD and treatment. Major progress of the genetics and diagnosis of dystonias have been made and exciting new insights into the course and the causes of progressive supranuclear palsy and multiple system atrophies have been made.

SYMPOSIUM 2: NEUROSTIMULATION, WHAT CAN BE ACHIEVED IN...

10:30 - 12:30 | HALL B

CHAIRPERSONS:

Paul Boon, GHENT, BELGIUM

Sandra Boccard, OXFORD, UK

...Movement disorders

Marie Vidailhet, PARIS, FRANCE

...Epilepsy

Paul Boon, GHENT, BELGIUM

...Chronic pain

Sandra Boccard, OXFORD, UK

Scientific content: This symposium will provide an overview of the current status of deep brain stimulation in the most prevalent neurological disorders in which it has been applied. Besides providing information on mechanism of action, indication, efficacy, safety, quality of life outcomes and practical procedures, a prospect for the future of these neuromodulation applications will be provided. The target audience is practicing neurologists who treat patients with difficult to treat Parkinson disease, epilepsy and pain.

SYMPOSIUM 3: THE CHANGING LANDSCAPE OF COMA TREATMENT

10:30 - 12:30 | HALL C

CHAIRPERSONS:

Steven Laureys, LIEGE, BELGIUM

Daniel Kondziella, COPENHAGEN, DENMARK

.....

**Amantadine, benefit-risk balance
in severe brain injury**

Joe Giacino, CHARLESTOWN, USA

**Deep brain stimulation in the minimally
conscious state: which targets?**

Jean Jacques Lemaire, CLERMONT-FERRAND, FRANCE

**Modulating the anterior forebrain mesocircuit in
disorders of consciousness**

Nicholas Schiff, NEW YORK, USA

**Transcranial direct current stimulation:
a promising new avenue**

Steven Laureys, LIÈGE, BELGIUM

Scientific content: The past years have provided an unprecedented collection of discoveries that bear upon our scientific understanding of recovery of consciousness following severe brain damage. Highlighted among these findings are unique demonstrations that patients with little or no behavioral evidence of conscious awareness (e.g., minimally conscious and unresponsive wakefulness/vegetative states) may retain critical cognitive capacities and the first scientific demonstrations that some patients, with severely injured brains and longstanding conditions of limited behavioral responsiveness, may nonetheless harbor latent capacities for recovery – either spontaneously or related to pharmacological interventions (e.g., amantadine) or electrical stimulation (e.g., deep brain stimulation and transcranial direct current stimulation).

SYMPOSIUM 4: EVOLVING CONCEPTS IN THE MANAGEMENT OF GLIOMAS

10:30 - 12:30 | HALL M1

CHAIRPERSONS:

Riccardo Soffietti, TURIN, ITALY

Michael Weller, ZÜRICH, SWITZERLAND

.....

**How to integrate molecular markers of prognostic
significance in the new WHO classification?**

Johan Kros, ROTTERDAM, THE NETHERLANDS

**Will new forms of immunotherapy improve the
outcome of glioblastomas?**

Michael Weller, ZÜRICH, SWITZERLAND

**From chemotherapy to targeted therapy in low
grade gliomas**

Riccardo Soffietti, TURIN, ITALY

**New developments in neuroimaging to monitor
response and toxicity following antiangiogenic agents**

Wolfgang Wick, HEIDELBERG, GERMANY

Scientific content: The aim of the symposium is to provide an update on the recent advances in terms of molecular diagnosis and treatment modalities of both high and low grade gliomas. Overall, these advances have led to new concepts of management of these tumors. The target audience is represented either by general neurologists, who are involved in the diagnostic and follow-up phases of management of brain tumors or more specifically neurologists with interest in the whole management of gliomas.



ISNI

**13th International Congress
of Neuroimmunology**

1st GSNI Course

**Global Schools of Neuroimmunology
ESNI - ASNI - APSNI**

26 - 29 SEPTEMBER 2016 JERUSALEM, ISRAEL





3rd European Stroke Organisation Conference

16-18 May, 2017 | Prague, Czech Republic



Mark Your Calendar



www.esoc2017.com



SATURDAY, 28 MAY

14:45 - 18:15

TEACHING COURSE 1: ACUTE MANAGEMENT OF STROKE- LEVEL 2

14:45 - 18:15 | HALL A

CHAIRPERSON:

Robert Mikulik, BRNO, CZECH REPUBLIC

Acute Ischemic Stroke - what you should do in the first 4.5 hours

Dejana Jovanovic, BELGRADE, SERBIA

What you should do in the first 6-12 hours

Urs Fischer, BERN, SWITZERLAND

What you should do in the first 24-48 hours

Bart van der Worp, UTRECHT, THE NETHERLAND

What you should do in the first days

Robert Mikulik, BRNO, CZECH REPUBLIC

Recanalisation strategies in acute stroke aim to establish revascularization. Endovascular techniques have shown benefit up to 8 h after stroke onset in the proximal anterior circulation, in addition to rtPA compared to rt-PA alone. In selected patients with malignant anterior circulation infarct, decompressive surgery reduces mortality. This teaching course is divided into four different time frames in order to cover the main decision-making processes in acute stroke, starting from the onset of stroke, how to decrease DNT to perform intravenous thrombolysis, provide an overview on thrombectomy, to the selection of patients for hemispherectomy and when to start early secondary prevention.

TEACHING COURSE 2: MDS-ES/EAN: ABNORMAL MOVEMENT DISORDERS IN CHILDREN (DIAGNOSIS AND MANAGEMENT) - LEVEL 1

14:45 - 18:15 | HALL B4.M2



CHAIRPERSON:

Emilio Fernandez-Alvarez, BARCELONA, SPAIN

Normal and abnormal cerebral movements in babies and young children

Emilio Fernandez-Alvarez, BARCELONA, SPAIN

Primary dystonias: from childhood to adulthood

Nardo Nardocci, MILAN, ITALY

Clinical features of genetic and metabolic disorders from childhood to adulthood

Emmanuel Roze, PARIS, FRANCE

Cerebral Palsy

Jean-Pierre Lin, LONDON, UK

Paediatric movement disorders is a relatively new and exciting field of Child Neurology. In this session, the faculty will provide clear descriptions of the diagnosis and management of various movement disorders in children, with emphasis on their clinical features. They will concentrate on selected important conditions chosen because of their clinical relevance, potential benefit of treatment or because they cover a relatively new or poorly understood area. The session is supplemented by videos.

TEACHING COURSE 3: NEURO-OPHTHALMOLOGICAL EMERGENCIES - LEVEL 2

14:45 - 18:15 | HALL M2

CHAIRPERSON:

Gordon Plant, LONDON, UK

Visual loss

Gordon Plant, LONDON, UK

Diplopia

Konrad Weber, ZURICH, SWITZERLAND

Spontaneous nystagmus

Michael Strupp, MUNICH, GERMANY

Pupillary deficits

Aki Kawasaki, LAUSANNE, SWITZERLAND

The course will review the diagnosis and management of common Neuro-Ophthalmological emergencies. The discussion will centre around three syndromic presentations, Acute Monocular Visual Loss, Acute Bilateral Visual Loss and Acute Ophthalmoplegia. Consideration will also be given to situations when the presence of nystagmus or pupillary abnormalities can give important clues in the acute setting. After attending the course the trainees can expect to have a clearer understanding of the how the Neuro-Ophthalmic aspects of history taking and examination can be employed in the emergency setting to better manage patients.

TEACHING COURSE 4: TESTING FOR AUTO-ANTIBODIES IN NEUROLOGICAL DISORDERS - LEVEL 2

14:45 - 18:15 | HALL M1

CHAIRPERSONS:

Johann Sellner, SALZBURG, AUSTRIA

Maarten J. Titulaer, ROTTERDAM, THE NETHERLANDS

Neuropathies and myasthenic syndromes

Jan J.G.M. Verschuuren, LEIDEN, THE NETHERLANDS

Myelopathic and rhombencephalitic syndromes

Johann Sellner, SALZBURG, AUSTRIA

Epilepsy and status epilepticus in autoimmune encephalitis

Maarten J. Titulaer, ROTTERDAM, THE NETHERLANDS

Psychosis, movement disorders or rapid progressive dementia and autoimmune encephalitis

Josep O. Dalmau, BARCELONA, SPAIN

This teaching course will provide practical guidance to the emerging field of auto-antibodies in different neurological disorders. In recent years the number of autoantibodies against targets in the central as well as the peripheral nervous system has expanded. The knowledge of the underlying pathogenesis helps to understand the clinical features and course of the disease, and defines the treatment options. The speakers will discuss which patients should be tested (and re-tested) for autoantibodies, which panel of antibodies to consider, which assay to use and whether antibody titers are relevant for treatment decisions. Furthermore, the current state of therapeutic options, as well as new treatments that are being developed, will be covered.

TEACHING COURSE 5: PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENTS IN ALZHEIMER'S DISEASE - LEVEL 2

14:45 - 18:15 | HALL M4

CHAIRPERSON:

Bruno Dubois, PARIS, FRANCE

Ethical limitations and considerations on prodromal Alzheimer's disease diagnosis and treatment

Giovanni Frisoni, BRESCIA, ITALY

Prevention strategies

Philip Scheltens, AMSTERDAM, NETHERLANDS

Development of novel pharmacological treatment in Alzheimer's disease: an update

Jakub Hort, PRAGUE, CZECH REPUBLIC

**The preclinical state of AD:
is it a new target for intervention?**

Bruno Dubois, PARIS, FRANCE

The course is dedicated to pharmacological and non-pharmacological treatment in Alzheimer's disease. Until now, none of the current therapies have shown a significant effect in modifying the disease course of patients with AD. This is important to address the issue of alternative therapeutic strategies including prevention strategies and

non-pharmacological intervention. The course provides an update on new approaches in the treatment of the patients with AD given the lack of efficacy of the current valuable therapies. The move to early phase of the disease, including the prodromal stage, is important to consider together with ethical considerations, which need to be addressed.

TEACHING COURSE 6: EXPERIMENTAL STUDY DESIGNS IN NEUROLOGICAL DISORDERS - LEVEL 2

14:45 - 18:15 | HALL M5

CHAIRPERSON:

Maura Pugliatti, FERRARA, ITALY

The methodological bases of clinical trial designs

Ettore Beghi, MILAN, ITALY

Clinical trials: practical examples - stroke

Georgios Tsivgoulis, ATHENS, GREECE

Meta-analysis in clinical trials

Tony Marson, LIVERPOOL, UK

Writing your protocol for clinical studies in Neurology

Maura Pugliatti, FERRARA, ITALY

This TC on Experimental Study Designs (ESD) is part of an educational programme on Neuroepidemiology aimed to improve knowledge about study methodology, as fundamental basis for good scientific research, and started in 2014 with an Introductory course on descriptive epidemiology. Analytical Study Designs (e.g. ESD) imply 'comparison' across groups differing for an 'exposure' assigned by the investigator: the highest hierarchical methodology to investigate association between exposures and outcomes. Among ESD are randomized clinical trials (RCTs). The TC will include lectures on clinical trials (methodological bases, examples with stroke, use of meta-analysis), and a practical session for developing a research protocol.



Save the date!

2017

ANNUAL MEETING OF THE
THE CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS



New Orleans Ernest N. Morial Convention Center

May 24 - 27

New Orleans, Louisiana

MSCARE.ORG/2017



THE CONSORTIUM OF
MULTIPLE SCLEROSIS CENTERS

JOIN US IN VIENNA



Mechanisms, Clinical Strategies,
and Promising Treatments of
Neurodegenerative Diseases

AD/PD™ 2017

The 13th International Conference on
Alzheimer's & Parkinson's Diseases

March 29 - April 2, 2017 | Vienna, Austria

ORGANIZING COMMITTEE

Abraham Fisher, Israel, President

Roger M. Nitsch, Switzerland, Executive Organizer

Manfred Windisch, Austria, Executive Organizer



kenesinternational
is Kenes Group's company

adpd2017.kenes.com

SATURDAY, 28 MAY

14:45 - 16:15

ORAL SESSION: AUTONOMIC NERVOUS SYSTEM DISORDERS AND CLINICAL NEUROPHYSIOLOGY

14:45-16:15 | HALL B5, M2

CHAIRPERSONS:

Max Hilz, ERLANGEN, GERMANY

Walter Struhal, LINZ, AUSTRIA

O 1101 14:45 Intravascular electroencephalography: a pilot study in patients undergoing neuro-interventional surgery

V. Keereman, P. van Mierlo, L. Defreyne, P.A. Boon | GHENT, BELGIUM

O 1102 15:00 Fatigue of forearm extensor muscles induced by repetitive peripheral magnetic stimulation in healthy subjects

C. Cabib¹, M. Garcia-Magaña², M. Morales¹, L. Izquierdo-Robert¹, P. Pereira³, P. Arias⁴, J. Valls-Sole¹
¹BARCELONA, SPAIN, ²GUADALAJARA, MEXICO, ³LISBON, PORTUGAL, ⁴CORUÑA, SPAIN

O 1103 15:15 De-synchronization does not contribute to intra-cortical inhibition and facilitation: a paired-pulse paradigm combined with triple stimulation study

L. Caranzano, M.A. Stephan, F. Herrmann, D. Benninger | LAUSANNE, SWITZERLAND

O 1104 15:30 Autonomic dysfunction in Wilson's disease: a comprehensive evaluation

K. Li, C. Lindauer, R. Haase, H. Reichmann, U. Reuner, T. Ziemssen | DRESDEN, GERMANY

O 1105 15:45 The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy

J. Castro, B. Miranda, I. Castro, M. Carvalho, I. Conceicao | LISBON, PORTUGAL

O 1106 16:00 Combined CV and sudomotor autonomic testing to differentiate multiple system atrophy from Parkinson's disease

A. Pavy-Le Traon¹, C. Brefel-Courbon¹, F. Ory-Magne¹, O. Rascol¹, J.-H. Calvet², J.-M. Senard¹ | ¹TOULOUSE, ²PARIS, FRANCE

ORAL SESSION: EPILEPSY 1

14:45-16:15 | HALL M0

CHAIRPERSONS:

Reetta Kälviäinen, KUOPIO, FINLAND

Tim von Oertzen, LINZ, AUSTRIA

O 1107 14:45 Localizing value of electrical source imaging as compared to SEEG: which patients are the best candidates?

C. Abdallah¹, L. Koessler¹, E. Rikir², J.P. Vignal¹, S. Colnat-Coulbois¹, M. Gavaret³, L. Maillard¹ | ¹NANCY, FRANCE, ²LIEGE, BELGIUM, ³MARSEILLES, FRANCE

O 1108 15:00 Long-term prognosis of epilepsy and drug-resistance

E. Beghi¹, G. Giussani¹, V. Canelli¹, E. Bianchi¹, G. Erba², C. Franchi¹, A. Nobili¹, L.J. Sander³ | ¹MILAN, ITALY, ²ROCHESTER, USA, ³LONDON, UK

O 1109 15:15 Cognitive problems among children exposed to antiepileptic drugs: preliminary data

L.S. Elkjaer, B.H. Bech, T.M. Laursen, J. Christensen | AARHUS, DENMARK

O 1110 15:30 MIR - 155: a biomarker with a dual role in epilepsy?

B. Leal, C. Carvalho, R. Ferreira, J.M.M. Chaves, A. Bettencourt, J. Freitas, J.M.C.F. Lopes, J.E.D.P. Ramalheira, A. Martins Da Silva, P.P. Costa, B. Martins Da Silva | PORTO, PORTUGAL

O 1111 15:45 Predicting outcome of epilepsy after meningioma resection

H.-G. Wirsching, C. Morel, C. Gmür, M.C. Neidert, C.R. Baumann, A. Valavanis, E.J. Rushing, N. Krayenbühl, M. Weller | ZURICH, SWITZERLAND

O 1112 16:00 Long-term, observational study evaluating the impact of VNS therapy on SUDEP in drug resistant epilepsy patients

P. Ryvlin¹, D. Hesdorffer², M. Sperling³, E. So⁴, O. Devinsky⁵, D. Friedman⁵, M. Bunker⁶, C. Gordon⁶, B. Olin⁶ | ¹LAUSANNE, SWITZERLAND, ²NEW-YORK, USA, ³PHILADELPHIA, ⁴ROCHESTER, ⁵NEW YORK, ⁶HOUSTON, USA

ORAL SESSION: MOVEMENT DISORDERS 1

14:45-15:45 | HALL C

CHAIRPERSONS:

Joaquim Ferreira, LISBON, PORTUGAL (TBC)

Kailash Bhatia, LONDON, UK

O 1113 Abstract cancelled

O 1114 Clinical and genetic heterogeneity of
14:45 paroxysmal dyskinesias

R. Erro, A. Gardiner, F. Jaffer, M. Stamelou, D.M. Kullmann, M.C. Walker, M.G. Hanna, H. Houlden, K. Bhatia | LONDON, UK

O 1115 Predicting incident impulse control disorder
15:00 behaviour in Parkinson's disease patients using a clinical-genetic model

J. Kraemmer¹, K. Smith², D. Weintraub², M. Nalls³, F. Cormier-Dequaire¹, V. Guillemot¹, I. Moszer¹, A. Brice¹, A. Singleton³, J.-C. Corvo¹ | ¹PARIS, FRANCE, ²PHILADELPHIA, ³BETHESDA, USA

O 1116 Long-term effect of Epoetin alfa on clinical
15:15 and biochemical markers in Friedreich Ataxia

F. Sacca¹, G. Puorro¹, A. Marsili¹, A. Antenora¹, C. Pane¹, C. Casali², C. Marcotulli², G. Defazio³, D. Liuzzi³, C. Tatillo¹, D.M. Cambriglia¹, G. Schiano Di Cola¹, L. Giuliani¹, V. Guardasole¹, A. Salzano¹, A. Ruvolo¹, A. de Rosa¹, A. Cittadini¹, G. de Michele¹, A. Filla¹ | ¹NAPLES, ²ROME, ³BARI, ITALY

O 1117 Guided focused ultrasound thalamotomy for
15:30 tremor

I. Schlesinger, A. Eran, A. Sinai, I. Erikh, M. Nassar, D. Goldsher, M. Zaaroor | HAIFA, ISRAEL

O 1118 Abstract cancelled

ORAL SESSION: MS AND RELATED DISORDERS 1

14:45-16:15 | HALL B

CHAIRPERSONS:

Mads Ravnborg, COPENHAGEN, DENMARK

Per Soelberg Sørensen, COPENHAGEN, DENMARK

O 1119 Dysregulation of energy metabolism in
14:45 multiple sclerosis measured in-vivo with diffusion-weighted spectroscopy

B. Bodini¹, F. Branzoli¹, E. Poirion¹, D. Garcia-Lorenzo¹, E. Maillart¹, J. Socha¹, G. Bera¹, C. Lubetzki¹, I. Ronen², S. Lehericy¹, B. Stankoff¹ | ¹PARIS, FRANCE, ²LEIDEN, NETHERLANDS

O 1120 Cross-modal plasticity among sensory
15:00 networks in neuromyelitis optica spectrum disorders

M.A. Rocca¹, F. Savoldi¹, P. Valsasina¹, A. D'ambrosio², M. Radaelli¹, P. Preziosa¹, G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ²NAPLES, ITALY

O 1121 Age and disability drive cognitive impairment
15:15 in multiple sclerosis independent of disease subtype: insights from an Italian multicentre study

L. Ruano¹, E. Portaccio², B. Goretti², C. Niccolai², F. Patti³, S. Cilia⁴, P. Gallo⁵, P. Grossi⁵, A. Ghezzi⁶, M. Roscio⁶, F. Mattioli⁷, C. Stampatori⁷, M. Trojano⁸, R.G. Viterbo⁸, M.P. Amato² | ¹PORTO, PORTUGAL, ²FLORENCE, ³CATANIA, ⁴CATANIA, ⁵PADUA, ⁶GALLARATE, ⁷BRESCIA, ⁸BARI, ITALY

O 1122 Longitudinal changes in structural cortical
15:30 networks after clinically isolated syndrome

C. Tur, A. Eshaghi, T.M. Jenkins, F. Prados, J.D. Clayden, S. Ourselin, D. Altmann, C. Wheeler-Kingshott, D.H. Miller, A. Thompson, O. Ciccarelli, A. Toosy | LONDON, UK

O 1123 Systematic review of ganglion cell layer
15:45 changes measured by optical coherence tomography in multiple sclerosis and optic neuritis

J. Britze¹, J.L. Frederiksen² | ¹COPENHAGEN, ²GLOSTRUP, DENMARK

O 1124 Cerebellar contribution to motor and cognitive
16:00 impairment in multiple sclerosis patients: an MRI sub-regional structural analysis

A. D'ambrosio, M.A. Rocca, E. Pagani, G.C. Riccitelli, B. Colombo, M. Rodegher, A. Falini, G. Comi, M. Filippi | ¹MILAN, ITALY

SATURDAY, 28 MAY

14:45 - 16:15

ORAL SESSION:
NEUROEPIDEMIOLOGY

14:45-16:15 | HALL B5.M1

CHAIRPERSONS:

David Gaist, ODENSE, DENMARK

Vitalie Lisnic, CHISINAU, MOLDAVIA

O 1125 14:45 **The burden of neurological diseases in Hungary. The initial database of the NEUROHUN-2004-2017 project**

D. Bereczki, A. Ajtay, F. Oberfrank | BUDAPEST, HUNGARY

O 1126 15:00 **Diagnosing hereditary neuropathies in the clinic with next-generation sequencing technology, the Norwegian experience**

H. Høyer¹, Ø.L. Busk¹, Ø.L. Holla¹, L. Strand¹, C.F. Skjeltved¹, M.B. Russell², G.J. Braathen¹ | ¹SKIEN, ²LØRENSKOG, NORWAY

O 1127 15:15 **Temporal trends in transthyretin familial amyloid polyneuropathy survival over the last 100 years**

M. Ines¹, T. Coelho², I. Conceicao¹, P. Saramago³, M. Carvalho¹, J. Costa¹ | ¹LISBON, ²PORTO, PORTUGAL, ³YORK, UK

O 1128 15:30 **Epidemiology of Listeria monocytogenes meningitis in the Netherlands, 1985-2014**

M. Koopmans, M. Bijlsma, M. Brouwer, A. van der Ende, D. van de Beek | AMSTERDAM, NETHERLANDS

O 1129 15:45 **Seasonal changes in the incidence of transient global amnesia**

N. Lev, O. Keret, I. Steiner | PETACH TIKVA, ISRAEL

O 1130 16:00 **Epidemiologic aspects of the Charcot-Marie-Tooth diagnosis in Denmark: a nationwide study**

S. Væth, M. Væth, H. Andersen, R. Christensen, U.B. Jensen | AARHUS, DENMARK

ORAL SESSION:
NEUROGENETICS

14:45-16:15 | HALL B4. M1

CHAIRPERSONS:

Jørgen Nielsen, COPENHAGEN, DENMARK

Jean-Marc Burgunder, BERN, SWITZERLAND

O 1131 14:45 **Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy: cross-sectional and preliminary longitudinal data in a cohort of 13 patients**

A. Castellano¹, N. Papinutto², G. Brugnara¹, G. Scigliuolo¹, A. Falini¹, R. Henry², D. Pareyson¹, L. Politi¹, E. Salsano¹ | ¹MILAN, ITALY, ²SAN FRANCISCO, USA

O 1132 15:00 **Variants in four genes on chromosome 12 is associated with intermediate Charcot-Marie-Tooth disease**

G.J. Braathen¹, H. Høyer¹, Ø.L. Busk¹, K. Tveten¹, C.F. Skjeltved¹, M.B. Russell² | ¹MILAN, ITALY, ²ROCHESTER, USA, ³LONDON, UK

O 1133 15:15 **Low cancer prevalence in polyglutamine expansion diseases**

G. Coarelli¹, A. Diallo¹, F. Calvas¹, P. Charles¹, C. Tosi Marelli², C. Ewencyk¹, C. Tranchant³, M. Tchikviladze¹, M.-L. Monin¹, B. Carlander², M. Anheim³, F. Moche¹, A. Brice¹, S. Tezenas Du Montcel¹, S. Humbert⁴, A. Dürr¹ | ¹PARIS, ²MONTPELLIER, ³STRASBOURG, ⁴GRENOBLE, FRANCE

O 1134 15:30 **An SPG2/PLP1 mutation mimicking multiple sclerosis in a family identified through targeted next generation sequencing**

A. Rubegni¹, A. Tessa¹, C. Battisti², E. Storti¹, A. Cerase², A. Malandrini², F.M. Santorelli¹, A. Federico² | ¹PISA, ²SIENNA, ITALY

O 1135 15:45 **Idebenone is effective and well tolerated in Leber's Hereditary Optic Neuropathy (LHON): results of a 3-year Expanded Access Program (EAP)**

T. Klopstock¹, G. Metz², C. Gallenmüller¹, B. Livonius-Freifrau von Eyb¹, F. Lob¹, T. Meier², C. Catarino¹ | ¹MUNICH, GERMANY, ²LIESTAL, SWITZERLAND

O 1136 16:00 **Patients carrying a loss-of-function mutation in ABCA7 exhibit a classical late-onset Alzheimer's disease phenotype**

T. van Den Bossche¹, K. Sleegers¹, S. Engelborghs¹, A. Sieben¹, A. de Roeck¹, M. Vandenbulcke², R. Vandenberghe², J.-J. Martin¹, P.P. de Deyn¹, P. Cras¹, C. van Broeckhoven¹ | ¹ANTWERP, ²LEUVEN, BELGIUM

ORAL SESSION: CEREBROVASCULAR DISEASES 1

16:30-18:15 | HALL C

CHAIRPERSONS:

Tove Henriksen, HELLERUP, DENMARK

Daniel Strbian, HELSINKI, FINLAND

O 1201 Physicians are more certain when prescribing thrombolysis to MRI-examined stroke patients

C.K. Hansen, A. Christensen, I. Havsteen, H.K. Christensen | COPENHAGEN, DENMARK

O 1202 Mortality and use of psychotropic medication in stroke patients: a population-wide register-based study

P.J. Jennum¹, A.O. Baandrup², H.K. Iversen³, R. Ibsen⁴, J. Kjellberg⁵ | ¹GLOSTRUP - COPENHAGEN, ²ROSKILDE, ³GLOSTRUP, ⁴AARHUS, ⁵COPENHAGEN, DENMARK

O 1203 Non-infectious complications of acute stroke and their impact on hospital mortality in an urban Polish stroke unit: changes from 1995 to 2013

M. Karlinski, J. Bembenek, A. Baranowska, I. Kurkowska-Jastrzebska, A. Członkowska | WARSAW, POLAND

O 1204 Does the proportion of single-chain rtPA influence outcomes in patients with cerebral ischemia?

D. Leys¹, I. Sibon², J.-L. Mas³, T. Moulin⁴, M. Giroud⁵, R. Bordet¹, D. Vivien⁶ | ¹LILLE, ²BORDEAUX, ³PARIS, ⁴BESANÇON, ⁵DIJON, ⁶CAEN, FRANCE

O 1205 Early start of NOAC after an acute cerebrovascular event: risk of intracranial hemorrhage and recurrent events

D. Seiffge, C. Traenka, A. Polymeris, L. Hert, R. Sutter, N. Peters, P. Lyrer, L. Bonati, S. Engelter, G.M. de Marchis | BASEL, SWITZERLAND

O 1206 The rs12041331G alleles are associated with aspirin response in ischemic stroke patients in China

Y. Xu, X. Zhang, Y. Shao | NANJING, CHINA

O 1207 Endovascular therapy versus medical care alone for ischemic stroke: a systematic review and meta-analysis of 10 RCTs

F. Rodrigues, J.B. Neves, D. Caldeira, J.M.M.C. Ferro, J. Ferreira, J. Costa | LISBON, PORTUGAL

ORAL SESSION: MOTOR NEURONE DISEASE

16:30-18:15 | HALL B4.M1

CHAIRPERSONS:

Federica Agosta, MILAN, ITALY

Orla Hardiman, DUBLIN, IRELAND

O 1208 Long-term survival of 3000 transthyretin familial amyloid polyneuropathy patients over 100 years

M. Ines¹, T. Coelho², I. Conceicao¹, P. Saramago³, M. Carvalho¹, J. Costa¹ | ¹LISBON, ²PORTO, PORTUGAL, ³YORK, UK

O 1209 GDAP1 mutations in Spain: a nationwide study

R. Sivera¹, M. Frasquet Carrera¹, T. Garcia Sobrino², J. Pardo³, R. Fernandez Torron⁴, A. Lopez de Munain Arregui⁵, C. Marquez Infante⁶, R. Rojas-Garcia⁷, S. Segovia⁷, A. Nascimento⁷, C. Cortez⁷, M. Garcia⁸, S.I. Pascual Pascual⁸, A. Guerrero Sola⁸, C. Casasnovas⁷, J. Esteban Pérez⁸, J. Vázquez-Costa¹, M. Barreiro¹, M.J. Chumillas¹, C. Diaz⁹, F. Palau¹, J.J. Vilchez¹, C. Espinos¹, T. Sevilla¹ | ¹VALENCIA, ²SANTIAGO DE COMPOSTELA, ³SANTIAGO, ⁴SAN SEBASTIAN, ⁵SAN SEBASTIÁN, ⁶SEVILLE, ⁷BARCELONA, ⁸MADRID, ⁹ALICANTE, SPAIN

O 1210 Structural and functional MRI signatures of ALS patients with C9orf72 hexanucleotide repeat expansion

F. Agosta¹, P.M. Ferraro¹, N. Riva¹, T. Domi¹, M. Copetti², C. Lunetta¹, M. Ferrari¹, G. Comi¹, P. Carrera¹, A. Falini¹, A. Quattrini¹, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ITALY

O 1211 The utility of multimodal imaging in the diagnosis of ALS

P.M. Ferraro¹, F. Agosta¹, N. Riva¹, M. Copetti², Y. Falzone¹, A. Chiò³, G. Soraru⁴, G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ³TURIN, ⁴PADUA, ITALY

O 1212 Deconstructing caregiver burden in amyotrophic lateral sclerosis – adding a qualitative perspective

M. Galvin, T. Burke, B. Corr, C. Madden, I. Mays, R. McQuillan, V. Timonen, A. Staines, O. Hardiman | DUBLIN, IRELAND

O 1213 The CANALS study: a randomized, double-blind, placebo-controlled, multicentre study to assess the safety and efficacy on spasticity symptoms of a cannabis sativa extract in motor neuron disease Patients

N. Riva¹, G. Mora¹, G. Soraru², C. Lunetta¹, M. Clerici¹, Y. Falzone¹, K. Marinou¹, E. Maestri¹, R. Fazio¹, M. Comola¹, G. Comi¹ | ¹MILAN, ²PADUA, ITALY

O 1214 Neurofilament light chain protein as a biomarker in ALS differential diagnoses

D. Primdahj, K. Svenstrup, K. Winge, N. Heegaard, K. Hansen | COPENHAGEN, DENMARK

SATURDAY, 28 MAY

16:30 - 18:15

ORAL SESSION: SLEEP DISORDERS

16:30-18:00 | HALL B5.M2

CHAIRPERSONS:

Poul Jennum, COPENHAGEN, DENMARK

Pierre Maquet, LIÈGE, BELGIUM (TBC)

O 1215 Sleep transitions in hypocretin deficient narcolepsy

16:30

M.H. Hansen¹, B. Kornum², P.J. Jennum³ | ¹GLOSTRUP, ²COPENHAGEN, ³GLOSTRUP - COPENHAGEN, DENMARK

O 1216 Hypocretin-reactive CD4+ T-cells in narcoleptic patients

16:45

D. Latorre¹, E. Armentani¹, U. Kallweit², M. Manconi³, R. Khatami⁴, C. Bassetti², F. Sallusto¹ | ¹BELLINZONA, ²BERNE, SWITZERLAND, ³LUGANO, ITALY, ⁴BARMELWEID, SWITZERLAND

O 1217 Alzheimer's disease cerebrospinal-fluid biomarkers are altered in untreated but normal in continuous positive airway pressure treated obstructive sleep apnea patients

17:00

C. Liguori, N.B. Mercuri, F. Izzi, G. Sancesario, A. Romigi, A. Cordella, F. Placidi | ROME, ITALY

O 1218 Abstract cancelled

O 1219 White matter lesion burden and sleep disordered breathing in acute stroke

17:15

A. Seiler¹, M. Camilo¹, S. Ott¹, S. Miano², R. Wiest¹, C. Bassetti¹ | ¹BERNE, ²LUGANO, SWITZERLAND

O 1220 The comparison of cerebral hemodynamics between patients with obstructive sleep apnea syndrome (OSA) and periodic limb movement disorder (PLMD) during sleep

17:30

Z. Zhang, M. Schneider, M. Laures, M. Qi, R. Khatami | BARMELWEID, SWITZERLAND

O 1221 Does vitamin D play a role in restless legs syndrome/Willis Ekbom disease?

17:45

A. Stefani, T. Mitterling, G. Weiss, B. Högl | INNSBRUCK, AUSTRIA

ORAL SESSION: EPILEPSY 2

16:45-18:15 | HALL MO

CHAIRPERSONS:

Jukka Peltola, TAMPERE, FINLAND

Elinor Ben-Menachem, GOTHENBURG, SWEDEN (TBC)

O 1222 Efficacy and tolerability of lacosamide monotherapy in patients with newly diagnosed epilepsy: A randomized double-blind trial versus controlled-release carbamazepine

16:45

M. Baulac¹, F. Rosenow², M. Toledo³, K. Terada⁴, T. Li⁵, M. de Backer⁶, K.J. Werhahn⁷, M. Brock⁵ | ¹PARIS, FRANCE, ²FRANKFURT AM MAIN, GERMANY, ³BARCELONA, SPAIN, ⁴SHIZUOKA, JAPAN, ⁵RALEIGH, USA, ⁶BRUSSELS, BELGIUM, ⁷MONHEIM AM RHEIN, GERMANY

O 1223 Abstract cancelled

O 1224 Verbal learning and memory outcome in selective amygdalohippocampectomy versus temporal lobe resection in 108 patients with hippocampal sclerosis

17:05

M.T. Foged¹, K. Vinter¹, L. Kristensen¹, M.H. Litman¹, N. Breinegaard¹, V. Olesen¹, T.W. Kjær², F.F. Madsen¹, The Danish Epilepsy Surgery Group¹, O.B. Paulson¹, L.H. Pinborg¹ | ¹COPENHAGEN, ²ROSKILDE, DENMARK

O 1225 Exposure-response analysis of adjunctive everolimus therapy in patients with refractory partial-onset seizures associated with tuberous sclerosis complex (TSC)

17:25

J. French¹, J. Lawson², Z. Yapici³, T. Polster⁴, R. Nababout⁵, P. Curatolo⁶, P. de Vries⁷, N. Berkowitz⁸, M. Voi⁹, S. Peyrard⁹, A. Vaury⁹, D.N. Franz¹⁰ | ¹NEW YORK, INDIA, ²RANDWICK, AUSTRALIA, ³ISTANBUL, TURKEY, ⁴BIELEFELD, GERMANY, ⁵PARIS, FRANCE, ⁶ROME, ITALY, ⁷CAPE TOWN, SOUTH AFRICA, ⁸NEW JERSEY, USA, ⁹RUEIL-MALMAISON, FRANCE, ¹⁰OHIO, USA

O 1226 Sleep-related hypermotor seizures arising outside the frontal lobe: a review of 44 surgically treated cases

17:45

S. Gibbs, P. Proserpio, A. Losurdo, A. Rubino, F. Cardinale, R. Mai, S. Francione, M. Cossu, G. Lo Russo, L. Tassi, L. Nobili | MILAN, ITALY

O 1227 Diagnostic accuracy of Salzburg criteria for nonconvulsive status epilepticus

18:00

M. Leitinger¹, E. Trinkl¹, E. Gardella², A. Rohracher¹, G. Kalss¹, E. Oerama³, J. Höfler¹, A.H. Lindberg-Larsen³, G. Zimmermann¹, G. Kuchukhidze¹, J. Dobesberger¹, P.B. Langthaler¹, S. Beniczky² | ¹SALZBURG, AUSTRIA, ²DIANALUND, ³AARHUS, DENMARK

ORAL SESSION: MS AND RELATED DISORDERS 2

16:45-18:15 | HALL B

CHAIRPERSONS:

Ludwig Kappos, BASEL, SWITZERLAND (TBC)

Xavier Montalban, BARCELONA, SPAIN

O 1228 Efficacy and Safety of Tocilizumab for the Treatment of Refractory Neuromyelitis Optica

16:45

L. Moiola¹, G. Dalla Costa¹, F. Sangalli¹, M. Romeo¹, M. Radaelli¹, M. Falcini², M. Capobianco³, S. Malucchi³, G. Comi¹, V. Martinelli¹ | ¹MILAN, ²PRATO ³ORBASSANO, ITALY

O 1229 Efficacy of ocrelizumab in patients with primary progressive MS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial

17:00

J. Wolinsky¹, D. Arnold², A. Bar-*or*², J. de Seze³, G. Giovannoni⁴, B. Hemmer⁵, K. Rammohan⁶, A. Sauter⁷, D. Masterman⁸, P. Fontoura⁷, H. Garren⁷, P. Chin⁸, X. Montalban⁹ | ¹HOUSTON, USA, ²MONTREAL, CANADA, ³STRASBOURG, FRANCE, ⁴LONDON, UK, ⁵MUNICH, GERMANY, ⁶MIAMI, USA, ⁷BASEL, SWITZERLAND, ⁸SOUTH SAN FRANCISCO, USA, ⁹BARCELONA, SPAIN

O 1230 Myelin lipids attenuate Th17-cell during autoimmune demyelination

17:15

M. Mycko¹, B. Sliwinski¹, M. Cichalewska¹, H. Cwiklinska¹, C.S. Raine², K.W. Selmaj¹ | ¹LODZ, POLAND, ²BRONX, USA

O 1231 Anoctamin 2 identified as an autoimmune target in multiple sclerosis

17:30

B. Ayoglu, N. Mitsios, I. Kockum, T. Olsson, P. Nilsson | STOCKHOLM, SWEDEN

O 1232 Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies

17:45

A. Traboulsee¹, D. Arnold², A. Bar-*or*², G. Comi³, H.-P. Hartung⁴, L. Kappos⁵, F. Lublin⁶, K. Selmaj⁷, G. Klingelschmitt⁵, D. Masterman⁸, P. Fontoura⁵, P. Chin⁸, H. Garren⁵, S. Hauser⁹ | ¹VANCOUVER, ²MONTREAL, CANADA, ³MILAN, ITALY, ⁴DÜSSELDORF, GERMANY, ⁵BASEL, SWITZERLAND, ⁶NEW YORK, USA, ⁷LODZ, POLAND, ⁸SOUTH SAN FRANCISCO, ⁹SAN FRANCISCO, USA

O 1233 Neural correlates of motor fatigue and fatigability in multiple sclerosis: a functional MRI study

18:00

O. Svolgaard, K.W. Andersen, C. Bauer, K. Madsen, M. Blinkenberg, F. Selleberg, H.R. Siebner | COPENHAGEN, DENMARK

ORAL SESSION: NEURO-ONCOLOGY

16:45-18:15 | HALL B5.M1

CHAIRPERSONS:

Michael Weller, ZURICH, SWITZERLAND

Riccardo Soffietti, MILAN, ITALY

O 1234 IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas

16:45

A. Darlix¹, J. Deverdun¹, C. Gozé¹, F. Castan¹, S. Zouaoui¹, V. Rigau¹, M. Fabbro¹, Y. Yordanova², E. Le Bars¹, L. Bauchet¹, N. Menjot de Champfleury¹, H. Duffau¹ | ¹MONTPELLIER, FRANCE, ²PARIS, FRANCE

O 1235 GLITRAD: A national multidisciplinary group dedicated to brainstem gliomas (BSG) in adults

17:00

A. Duran-Pena¹, L. Bauchet², S. Grand³, D. Frappaz⁴, V. Rigau², M.-H. Baron⁵, C. Pasteris⁶, O. Langlois⁷, F. Ducray⁴, E. Nader⁸, J.-S. Guillamo⁹, E. Vauleon¹⁰, J.-M. Constans¹¹, M. Barrie-Attarian¹², A. Assouline¹, J. Savatovsky¹, A. Idbaih¹, K. Mokhtari¹, N. Martin-Duverneuil¹, R. Guillevin¹³, D. Figarella Branger¹², S. Blond¹⁴, C. Ramirez¹⁴, H. Loiseau¹⁵, F. Laigle-Donadey¹ | ¹PARIS, ²MONTPELLIER, ³GRENOBLE, ⁴LYONS, ⁵BESANCON, ⁶GRENOBLE ⁷ROUEN, ⁸ANGERS, ⁹NIMES, ¹⁰RENNES, ¹¹AMIENS, ¹²MARSEILLES, ¹³POITIERS, ¹⁴LILLE, ¹⁵BORDEAUX, FRANCE

O 1236 Dural metastases in 14 patients with systemic cancer: an exploratory retrospective study

17:15

M. Ackerl, M. Loyoddin, B. Horvath-Mechtler, A. Grisold, B. Surboeck, W. Grisold | VIENNA, AUSTRIA

O 1237 Clinical characteristics and outcome of neurosarcoidosis: a meta-analysis

17:30

D. Fritz, D. van de Beek, M. Brouwer | AMSTERDAM, NETHERLANDS

O 1238 Risk for prescription of psychotropic drugs among partners of glioma patients: a nationwide registry study

17:45

M. Jansson, A.B. von Heymann-Horan, B. Krogh Rasmussen, V. Albieri, N. Suppli, S.O. Dalton, C. Johansen, P.E. Bidstrup | COPENHAGEN, DENMARK

O 1239 MEK inhibitor-related rhabdomyolysis

18:00

S. Koeppe, B. Schilling, L. Zimmer, D. Schadendorf | Essen, Germany

SATURDAY, 28 MAY

16:45 - 18:15

HOW TO IMPROVE YOUR CHANCES 1: EUROPEAN JOURNAL OF NEUROLOGY SESSION: "HOW TO WRITE AND PUBLISH ACADEMIC PAPERS?"

16:45-18:15 | HALL M3

CHAIRPERSON:

Anthony Schapira, LONDON, UK

Writing a paper and increasing its chances of publication

Anthony Schapira, LONDON, UK

Writing for publication - the publisher's perspective

Silvana Losito, OXFORD, UK


Authorship issues and fraud in scientific publishing

Pertti Saloheimo, ESPOO, FINLAND

In this course the speakers will address the following points:

1. How to set about planning a paper for publication
2. Maximizing your chances of success
3. What not to do when trying to publish
4. What is the publisher's perspective on the publication process?
5. How can you ensure that your paper has the greatest impact?
6. The ICMJE criteria for authorship and challenges in defining authorship
7. Plagiarism and other types of fraud in science publication

**WHEN DO I NEED TO
REQUEST AN MRI
FOR THIS MS PATIENT?**



**DO YOU AGREE WITH
THEIR DEFINITION OF
AGGRESSIVE MS?**

**PERMANENT
OR REVERSIBLE?**



Where experts are talking MS

JOIN US

www.neuro-compass.education

- HOT TOPICS
- PRACTICE POINTS
- DIAGNOSIS
- IMMUNOPATHOLOGY
- MS IMAGING
- MEASURING DISEASE ACTIVITY
- TREATMENT SAFETY MONITORING

*This educational resource has been developed independently with
educational funding support from Biogen International GmbH.
© Adelphi Communications Ltd 2016*



12TH EUROPEAN CONGRESS ON EPILEPTOLOGY

11TH-15TH
SEPT
2016



PRAGUE



12th European Congress on Epileptology

11-15 September 2016

INTERNATIONAL
LEAGUE
AGAINST
EPILEPSY **ILAE**
Established 1909



ILAE-CEA
COMMISSION ON EUROPEAN AFFAIRS

SATURDAY, 28 MAY

POSTERSESSIONS

POSTER SESSION AGEING AND DEMENTIA 1

12:30-13:15 | SCREEN A2

CHAIRPERSONS:

Pasquale Calabrese, BASEL, SWITZERLAND

P 11001 „I think I caught Alzheimer’s disease in the surgery”

P. Agüero, V. Mañanes-Barral, C. Estévez-Fraga, E. Monreal, P. Pérez Torre, J.F. Boan, J. Alvarez-Linera, G. Garcia Ribas
I MADRID, SPAIN

P 11002 Abstract cancelled

P 11003 Abstract cancelled

P 11004 The latent cognitive impairment - an unrecognized disorder

Y. Balash, A.D. Korczyn, T. Gurevich | TEL AVIV, ISRAEL

P 11005 Cases of posterior cortical atrophy with and without amyloid pathology: is there any difference?

P. Basilico, A. Arighi, G. Marotta, M. Longo, M. Mercurio, G.G. Fumagalli, A.M. Pietroboni, T. Carandini, M. Scarioni, A. Calvi, P. Corti, E. Rotondo, R. Vimercati, D. Galimberti, R. Benti, E. Scarpini | MILAN, ITALY

P 11006 Infectious dementias. Experience of the Memory center of Rabat.

M. Benabdeljilil, N. Essahli, M. Rahmani, S. Aïdi, M. El Alaoui Faris | RABAT, MOROCCO

P 11007 Heterogeneous clinical manifestation of familial Creutzfeldt-Jakob disease with D178N mutation

F. Caisberger, J. Kuchyňka, Z. Pavelek, R. Herzig, M. Valis | HRADEC KRALOVE, CZECH REPUBLIC

P 11008 Multimodal imaging to distinguish in-vivo early onset Alzheimer’s disease from behavioral variant of frontotemporal dementia

E. Canu¹, F. Agosta¹, G. Mandic-Stojmenovic³, T. Stojkovic³, E. Stefanova³, F. Imperiale¹, M. Copetti², V.S. Kostic³, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ITALY, ³BELGRADE, SERBIA

P 11009 Abstract cancelled

P 11010 Modelling trajectories of brain damage in progressive supranuclear palsy: a longitudinal multimodal MRI study

F. Caso¹, F. Agosta¹, M. Ječmenica Lukić³, I. Petrović³, P. Valsasina¹, P.M. Ferraro¹, A. Meani¹, M. Copetti², V.S. Kostic³, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ITALY, ³BELGRADE, SERBIA, ³

P 11011 Different profiles of emotion recognition in amnesic MCI patients: the utility of early screening in patients with focal medial temporal lobe dysfunction.

C. Cerami, A. Dodich, S. Torre, G. Lettieri, S. Iannaccone, D. Perani, S.F. Cappa | MILAN, ITALY

P 11012 The supportive role of FDG-PET imaging in the differential diagnosis of primary progressive aphasia: a voxel-based FDG-PET study at the single-subject level

C. Cerami, A. Dodich, L. Greco, S. Iannaccone, E. Pelagallo, G. Magnani, S.F. Cappa, D. Perani | MILAN, ITALY

P 11013 Anosognosia for memory impairment in Mild Cognitive Impairment is not predictive for dementia and Alzheimer’s disease

I. Cova, G. Grande, V. Cucumo, R. Ghiretti, L. Maggiore, D. Galimberti, E. Scarpini, S. Pomati, C. Mariani | MILAN, ITALY

POSTER SESSION AUTONOMIC NERVOUS SYSTEM DISORDERS 1

12:30-13:15 | SCREEN B1

CHAIRPERSON:

Astrid Terkelsen, AARHUS, DENMARK (TBC)

P 11014 Autonomic disturbances in carpal tunnel syndrome

N. Belova, N. Suponeva, M.A. Piradov, V.V. Gnezditsky, A. Shabalina, D. Yusupova, D. Lagoda | MOSCOW, RUSSIAN FEDERATION

P 11015 Iatrogenic Harlequin syndrome due to central venous catheterization

V. Carvalho, C. Cunha, J. Martins | MATOSINHOS, PORTUGAL

P 11016 Autonomic dysfunction in multiple sclerosis correlates with EDSS and disease duration

L. Crnošija, A. Junaković, M. Krbot Skoric, M. Lovrić, I. Adamec, M. Habek | ZAGREB, CROATIA

P 11017 Dysautonomia is widely present in clinically isolated syndrome and correlates with brainstem lesions

L. Crnošija¹, I. Adamec¹, A. Junaković¹, B. Malojčić¹, S. Butkovic Soldo², M. Habek¹ | ¹ZAGREB, ²OSIJEK, CROATIA

SATURDAY, 28 MAY

12:30 - 13:15

P 11018 Fingolimod-initiation reduces cardiovagal buffer capacity in response to baroreflex loading in multiple sclerosis patients

C. de Rojas Leal¹, R. Wang¹, M. Liu¹, F. Canavese¹, K. Hösl², D.-H. Lee¹, R.A. Linker¹, M. Hiltz¹ | ¹ERLANGEN, ²NUREMBERG, GERMANY

P 11019 Autonomic neuropathy associated with anti-Gad antibodies

E. Fileccia, R. Liguori, A. Incensi, R. Rinaldi, R. D'angelo, M.P. Giannoccaro, V. Donadio | BOLOGNA, ITALY

P 11020 Hemodynamic response to air-conducted sound stimulus is mediated via vestibulosympathetic reflex

L. Crnošija, A. Pavelić, M. Krbot Skoric, I. Adamec, M. Habek | ZAGREB, CROATIA

P 11021 Autonomic function tests for Dysreflexia in Spinal Cord Injuries

G. Ingle, V. Iodice, E. Vichayanrat, L. Mason, K. Bleasdale-Barr, I. Skeavington, J. Navarro-Otano, E.M. Hagen | LONDON, UK

P 11022 Abstract cancelled

POSTER SESSION CEREBROVASCULAR DISEASES 1

12:30-13:15 | SCREEN G1

CHAIRPERSON:

Anna Czlonkowska, WARSAW, POLAND

P 11023 Cardiac hemodynamic measurements and short-term outcome in patients with acute ischemic stroke

A. Acewicz¹, H. Dudek¹, J. Siebert², D. Ryglewicz¹ | ¹WARSAW, ²GDANSK, POLAND

P 11024 Right posterior portical watershed infarct in a right handed patient presenting with global aphasia: a case of crossed aphasia

H. Akgun, A. Çetiz, Z. Özkan, M. Yücel, Ü.H. Ulas, S. Demirkaya | ANKARA, TURKEY

P 11025 Gerstmann's syndrome with atypical MRI findings: a case report

A. Çetiz, H. Akgun, Z. Özkan, S. Tasdemir, S. Demirkaya | ANKARA, TURKEY

P 11026 Feasibility study of the implementation of a strokes Registry in Grande-Terre and Marie Galante in Guadeloupe, F.W.I.

C. Alecu, L. Place, F. Alecu, N. Deschamps, A. Lannuzel, J. Deloumeaux | POINTE À PITRE, FRANCE

P 11027 Stroke thrombolysis in a tertiary care teaching hospital in Saudi Arabia

I. Khatri, A. Al Khathaami, A. Abulaban, O. Alhamouieh, S. Scriven, M. Tarawneh, D. Alrasheed, S. Kojan, N. Alotaibi, A. Al-Khalaf, A. Alshehri, A. El-Metwally | RIYADH, SAUDI ARABIA

P 11028 Simultaneous ischemic stroke and acute myocardial infarct of cardioembolic etiology

P. Alves, J. Pires, M. Menezes, D. Silva, A.C.G. Fonseca | LISBON, PORTUGAL

P 11029 Lumbar puncture associated with corticotherapy as a predisposing factor of Cerebral Venous Thrombosis

I. Amorim, C. Silva, M. Santos, A.P. Antunes, F. Falcão, L. Albuquerque | LISBON, PORTUGAL

P 11030 Total cholesterol, high-density and low-density lipoprotein cholesterol in adult patients with acute ischemic or hemorrhagic stroke

D. Arabadzhieva, A. Kaprelyan, I. Dimitrov, A. Tzoukeva, M. Boyadzhieva | VARNNA, BULGARIA

P 11031 The significance of Holter ECG in cryptogenic ischemic stroke

Y. Arslan, B. Selbest Demirtaş, C. Ekmekçi, U. Sener, Y. Zorlu | IZMIR, TURKEY

P 11032 Severity of the ischemic stroke and rheological disturbances in the blood

M. Azhermacheva, V. Alifirova, N. Pugachenko, T. Valikova, P.D. Plotnikov Denis, O. Aliev, M.A. Nikitina, O. Izhboldina | TOMSK, RUSSIAN FEDERATION

P 11033 Stroke risk factors and survival of patients during 28 post-stroke days

M. Azhermacheva¹, V. Alifirova¹, N. Pugachenko¹, T. Valikova¹, M.A. Nikitina¹, O. Izhboldina¹, E. Stegmeier² | ¹TOMSK, RUSSIAN FEDERATION, ²BAAR-EBENHAUSEN, GERMANY

P 11034 Thrombolysis for acute ischaemic stroke in Malta; the first 5 years

D. Micallef, S. Azzopardi, A.P. Grima, J. Aquilina, M. Mallia | ANKARA, TURKEY

P 11035 Spontaneous vertebral artery dissection associated with Pai-1, MTHFR C677T gene mutations and positive anti-Ro52 antibodies in a young woman

R.S. Badea, I.C. Cernat, A. Craciunoiu | BUCHAREST, ROMANIA

P 11036 Cannabis and cerebrovascular diseases

S. Aïdi, M. Benabdelljil, M. El Khalifi, M. Rahmani, M. El Alaoui Faris | RIYADH, SAUDI ARABIA

POSTER SESSION CEREBROVASCULAR DISEASES 2

12:30-13:15 | SCREEN G3

CHAIRPERSON:

Adam Kobayashi, WARSAW, POLAND

P 11037 Risk profile in patients with ischemic stroke aged under 50

M. Cholaková | SOFIA, BULGARIA

P 11038 Posterior reversible encephalopathy syndrome and intracranial hypotension syndrome in puerperium

A. Costa, J. Meireles, M. Rodrigues, S. Fonseca, L. Fonseca, P. Abreu | PORTO, PORTUGAL

P 11039 Abstract cancelled

P 11040 The effect of prior antithrombotic therapy in acute stroke in patients with atrial fibrillation

P. Crnac, H. Budincevic, L. Friedrich | ZAGREB, CROATIA

P 11041 Risk of cancer after ischemic stroke

A. Ois Santiago, E. Cuadrado, A. Rodríguez-Campello, E. Giralte-Steinhauer, R.M. Vivanco-Hidalgo, J. Jiménez-Conde, A. Gomez, J. Roquer Gonzalez | BARCELONA, SPAIN

P 11042 Short-term outcome in symptomatic carotid occlusion

E. Cuadrado-Godía, A. Ois Santiago, A. Rodríguez-Campello, E. Giralte-Steinhauer, R.M. Vivanco-Hidalgo, A. Gomez, J. Jiménez-Conde, J. Roquer Gonzalez | BARCELONA, SPAIN

P 11043 Death and pneumonia incidence in relation to dysphagia severity

J. Zaborski, A. Czernuszenko | WARSAW, POLAND

P 11044 Does it matter whether saliva is aspirated or penetrates only?

J. Zaborski, A. Czernuszenko | WARSAW, POLAND

P 11045 Risk factors and primary stroke prevention in the population of Republic of Moldova

E. Daniela, N. Ciobanu, S. Groppa | CHISINAU, MOLDOVA

P 11046 Importance in diagnosis of troponin values in stroke

V. Delgado¹, E. Sánchez², J.A. Sánchez³, N. Segura¹ | ¹LA LÍNEA DE LA CONCEPCIÓN, ²ALGECIRAS, ³MÁLGA, SPAIN

P 11047 Expression of TRPM2 ion channels with histopathological alterations following brain ischemia-reperfusion injury in rats

F. Balgetir, C. Demir, T. Kuloğlu, M. Gönen, E. Aytac, S. Bulut | ELAZIG, TURKEY

P 11048 Ischemic stroke as an isolated manifestation of temporal arteritis

L. Di Meglio, M. Yger, S. Alamowitch | PARIS, FRANCE

P 11049 Prevention of stroke in Republic of Srpska

V. Djajic, S. Miljkovic, Z. Vujkovic, D. Racic | BANJALUKA, BOSNIA AND HERZEGOVINA

POSTER SESSION CEREBROVASCULAR DISEASES 3

12:30-13:15 | SCREEN G4

CHAIRPERSON:

Zuzana Gdovinova, KOSICE, SLOVAKIA

P 11050 Bilateral extracranial internal carotid artery dissection with haemodynamic symptoms treated by stenting

E. Doche, A. Reyre, P. Dory-Lautrec, N. Messaoudi, M. de Masi, C. Rey, E. Robinet, N. Laksiri, H. Brunel, J. Pelletier | MARSEILLES, FRANCE

P 11051 Dynamical changes of hematological parameters in ischemic stroke patients after IV thrombolysis

M. Gafarova, M. Domashenko, M. Loskutnikov, M. Maximova, V. Shandalin, R. Kononov, A. Shabalina | MOSCOW, RUSSIAN FEDERATION

P 11052 Did anything change in prevention of stroke in patients with atrial fibrillation (AF) after initiation therapy with direct oral anticoagulants?

Z. Gdovinova, N. Lesko, V. Han | KOSICE, SLOVAKIA

P 11053 Internal carotid artery pseudo-occlusion in acute stroke patients

P. Gelener, S.H. Akpınar | NICOSIA, CYPRUS

P 11054 Safety and outcome of rTPA use in acute ischemic stroke in patients with active cancer: a case-control study

T. Galdes, L. Pereira, C.S.S. Guarda, M.D. Grunho, A.C. Ribeiro, J.N.M. Coimbra, I. Mendes, M.M.R.S. Rodrigues | ALMADA, PORTUGAL

P 11055 Detection of paroxysmal atrial fibrillation by implantable loop recorder in cryptogenic stroke

D. Giobbe, A. Balducci, G. Paglia, M.L. Giobbe, C. Budano, G.L. Alunni, M. Giorgi | TURIN, ITALY

P 11056 Cryptogenic stroke, patent foramen ovale and high risk associated conditions: very low recurrence rate with percutaneous closure

D. Giobbe | TURIN, ITALY

P 11057 Abstract cancelled

SATURDAY, 28 MAY

12:30 - 13:15

P 11058 Malignant posterior reversible encephalopathy syndrome (PRES): a case report

N. Giraldo Restrepo¹, L.V. Delgado González², M. Torres², O.E. Hernández Ortiz², P. Uruña² | ¹CIUDAD REAL, SPAIN, ²MEDELLIN, COLOMBIA

P 11059 Correlation of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome (CADASIL) with retinal pathology

E. Giyazitdinova, B. Muinjonov, G. Rakhimbaeva, Y. Musaeva | TASHKENT, UZBEKISTAN

P 11060 Neuropsychological abnormalities link with sensorimotor plasticity in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) patients

E. Giyazitdinova, B. Muinjonov, G. Rakhimbaeva, Y. Musaeva | TASHKENT, UZBEKISTAN

P 11061 Platelet receptor to von Willebrand factor in patients with different variant of ischemic stroke

V. Goldobin, E. Klocheva, O. Sirotkina, T. Vavilova | ST. PETERSBURG, RUSSIAN FEDERATION

P 11062 Association of Posterior Reversible Encephalopathy Syndrome (PRES) and Transient apical ballooning syndrome (Tako-Tsubo): first case report of a man and review of literature

S. Grimaldi, E. Doche, C. Rey, E. Robinet, N. Laksiri, J. Pelletier | TASHKENT, UZBEKISTAN

P 11063 Door-needle-times for CT versus MRI-examined stroke patients: a clinical randomized trial

C.K. Hansen, A. Christensen, I. Havsteen, H.K. Christensen | COPENHAGEN, DENMARK

P 11064 Centralisation of acute stroke treatment is associated with improved quality of care and lower mortality

S. Hastrup, S.J. Paaske, P. von Weitzel-Mudersbach, C. Simonsen, N. Hjort, A.T. Møller, T. Harbo, M.L.S. Poulsen, N. Ruiz de Morales Ayudarte, D. Damgaard, G. Andersen | AARHUS, DENMARK

P 11065 Endothelial dysfunction in leukoaraiosis

M. Zupan, M. Šabović, M. Zatelet, K. Šurlan Popović, B. Zvan | LJUBLJANA, SLOVENIA

POSTER SESSION CHILD NEUROLOGY/ DEVELOPMENTAL NEUROLOGY

12:30-13:15 | SCREEN H1

CHAIRPERSON:

Viktoria Papp, AARHUS, DENMARK (TBC)

P 11066 Sex differences in affective disorders in adult rats after infantile immune stimulation

I. Berkiks, A. Mesfioui, A. El Hessni | KENITRA, MOROCCO

P 11067 Abstract cancelled**P 11068** Diagnosing neuronal ceroid lipofuscinosis with next-generation sequencing: a case report

G.J. Braathen, S. Slinde, Ø.L. Busk, K. Tveten, Ø.L. Holla, H.T. Hilmarsen, J.R. Helle | SKIEN, NORWAY

P 11069 Long-term follow-up of two patients with cerebellar ataxia and CoenzymeQ10 deficiency due to mutations in ADCK3 gene.

V. Emmanuele¹, C. Sobreira², E. Barca¹, S. Dimauro³, C.M. Quinzii³, M. Hirano³ | ¹MESSINA, ITALY, ²SAO PAOLO, BRAZIL, ³NEW YORK, USA

P 11070 Gross motor function of children with hereditary spastic paraplegia is related with knee flexion in swing: an instrumented gait analysis study

D. Gómez-Andrés¹, I. Pulido-Valdeolivas¹, I. Rodríguez-Andonaegui¹, J.A. Martín-Gonzalo¹, J. López-López², S.I. Pascual Pascual¹, E. Rausell¹ | ¹MADRID, ²SAN SEBASTIÁN DE LOS REYES, SPAIN

P 11071 Flexion movements during the gait cycle are less predictable in children with cerebral palsy: a new dimension in motor control

M. Zanin¹, D. Gómez-Andrés¹, I. Pulido-Valdeolivas¹, I. Rodríguez-Andonaegui¹, J.A. Martín-Gonzalo¹, J. López-López², S.I. Pascual Pascual¹, E. Rausell¹ | ¹MADRID, ²SAN SEBASTIÁN DE LOS REYES, SPAIN

P 11072 Abstract cancelled**P 11073** Abstract cancelled**P 11074** Focal-onset seizures in children: correlation between clinical presentation and EEG findings

M. Mazurkiewicz-Bełdzińska, M. Szmuda, M. Zawadzka | GDANSK, POLAND

P 11075 Experience of usage of antibodies to brain specific protein S100 (antiS100) and regular herbal medicines (based on *Valeriana officinalis* - Valeriana) in children with non-severe tics

O. Mukalova, A. Mukalau | MINSK, BELARUS

P 11076 Abstract cancelled

P 11077 Cerebral proliferative angiopathy in a 3-year-old

G. Paton, C. Mignone, A. Singhal, M. Demos | VANCOUVER, CANADA

P 11078 Phenotypic variability in 4H leukodystrophy caused by POLR3A mutations

A. Potic, S. Pekić | BELGRADE, SERBIA

P 11079 Prognostic factors in children with PRES and hematologic diseases

M. Romoli, N. Tambasco, E. Mastrodicasa, C. Salvatori, G. Mancini, M. Caniglia, P. Calabresi, A. Verrotti | PERUGIA, ITALY

P 11080 Case report: Ataxia-telangiectasia: cerebral abnormalities in a case of long survival

E. Zupanic, S. Sega Jazbec | LJUBLJANA, SLOVENIA

POSTER SESSION CLINICAL NEUROPHYSIOLOGY 1 12:30-13:15 | SCREEN H2

CHAIRPERSON:

Einar Wilder-Smith, SINGAPORE, SINGAPORE

P 11081 Neurophysiological stability at median and ulnar nerve entrapment sites after weekly paclitaxel chemotherapy

A. Bandla, S. Tan, R. Sundar, N. Thakor, E. Wilder-Smith | SINGAPORE, SINGAPORE

P 11082 The importance of dense array EEG in detection of interictal epileptiform discharges and localization of epileptogenic foci

D. Ciolac, V. Chiosa, C. Munteanu, L. Mişina, A. Vataman, N. Gorincioi, S. Groppa | CHISINAU, MOLDOVA

P 11083 How long should we record routine EEG to get relevant information?

H. Doudoux, L. Vercueil | GRENOBLE, FRANCE

P 11084 Abstract cancelled

P 11085 Abstract cancelled

P 11086 Goniometric measurement of joint angles: a simple tool for standardising muscular pre-contraction to elicit motor evoked potentials?

A. Giordano, M. Fichera, M. Pisa, F. Vitali, A. Nuara, G. Comi, L. Leocani | MILAN, ITALY

P 11087 Optical Coherence Tomography, full-field Visual Evoked Potentials and multifocal Visual Evoked Potentials combined use to assess the visual system in multiple sclerosis.

S. Guerrieri, G. Di Maggio, M. Pisa, M. Vabanesi, F. Vitali, R. Santangelo, S. Medagliani, L. Moiola, U. Del Carro, V. Martinelli, G. Comi, L. Leocani | MILAN, ITALY

P 11088 Neurophysiological correlates of upper limb function in multiple sclerosis

M. Krbot Skoric, T. Gabelic, B. Malojcic, D. Mahovic Lakusic, M. Lisak, B. Barun, L. Crnošija, M. Habek | ZAGREB, CROATIA

P 11089 The influence of brainstem and cognitive function on upper extremities function in early multiple sclerosis

M. Krbot Skoric, T. Gabelic, L. Crnošija, D. Petravić, B. Barun, I. Adamec, M. Habek | ZAGREB, CROATIA

P 11090 The level of coherence with the largest number of events in the EEG is significantly lower in dementia

J. Kuchynka¹, F. Caisberger¹, Z. Pavelek¹, O. Vysata¹, A. Procházka², M. Valis¹ | ¹HRADEC KRÁLOVÉ, ²PRAGUE, CZECH REPUBLIC

P 11091 Typical communication EEG frequency is significantly lower in dementia

J. Kuchynka¹, Z. Pavelek¹, F. Caisberger¹, O. Vysata¹, A. Procházka², M. Valis¹ | ¹HRADEC KRÁLOVÉ, ²PRAGUE, CZECH REPUBLIC

P 11092 The efficacy of vitamin D replacement on pain, quality of life and nerve conduction velocities in the patients with chronic widespread pain

G. Akyuz, C. Sanal, I. Yagci, E. Giray, P. Kuru | ISTANBUL, TURKEY

SATURDAY, 28 MAY

12:30 - 13:15

POSTER SESSION COGNITIVE NEUROLOGY/ NEUROPSYCHOLOGY 1

12:30-13:15 | SCREEN A3

CHAIRPERSON:

Rita Formisano, ROME, ITALY

P 11093 The functional side of neurology in an ER

P. Agüero, C. Estévez-Fraga, E. Viedma-Guiard, L. Crespo, E. Monreal, P. Pérez Torre, R. Alvarez-Velasco, M.J. López-Martínez, A. Alonso Cánovas | MADRID, SPAIN

P 11094 Limb apraxia: neuropsychological and imaging study of two cases

D. Aguiar de Sousa¹, S. Reimão¹, G. Leal¹, J. Almeida², I. Pavão Martins¹ | ¹LISBON, ²COIMBRA, PORTUGAL

P 11095 Loss of ownership feeling following a left hemisphere infarct

P. Alves, S. Reimão, C. Campos, C. Maruta, L. Rocha, G. Sá, A.C.G. Fonseca, I. Pavão Martins | LISBON, PORTUGAL

P 11096 Abstract cancelled

P 11097 Sex differences in cognitive behaviour and melatonin treatment in early neuroinflammation induced by LPS in Wistar rats

I. Berkiks, A. Mesfioui, Y. Bahbiti, A. El Hessni | KENITRA, MOROCCO

P 11098 Subjective spatial navigation complaints - a frequent symptom reported by patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease

J. Cerman¹, R. Andel³, J. Laczó¹, M. Vyhnálek¹, Z. Nedelska¹, I. Mokrisova¹, K. Sheardova², J. Hort¹ | ¹PRAGUE, ²BRNO, CZECH REPUBLIC, ³TAMPA, FLORIDA, USA

P 11099 Mild neurocognitive disorder related to epilepsy

I.D. Cuciureanu, T. Cuciureanu, A. Cuciureanu | IASI, ROMANIA

P 11100 Neuropsychological disorders in patients with obstructive sleep apnea

M. Dimitrova, K. Genov, A. Pavlov, K. Prinova, K. Kostov, L.D. Traykov | SOFIA, BULGARIA

P 11101 Abstract cancelled

P 11102 The role of pre-morbid intelligence in the Clock Drawing Test: studies with the Portuguese Irregular Word Reading Test

D. Duro, L. Alves, S. Freitas, M. Tábuas-Pereira, M.R. Simões, I. Santana | COIMBRA, PORTUGAL

P 11103 The Clock Drawing Test as a cognitive screening instrument: development of Portuguese normative data for the Mini-mental State Examination + clock drawing combination

D. Duro, S. Freitas, M. Tábuas-Pereira, M.R. Simões, I. Santana | COIMBRA, PORTUGAL

P 11104 Selectively impaired visual processing in insomnia disorder patients

E. Giora, A. Galbiati, S. Marelli, M. Zucconi, L. Ferini Strambi | MILAN, ITALY

P 11105 The Italian validation of the QOLIBRI - Proxy Version

R. Formisano, M. Giustini, M. D'ippolito, E. Azicnuda, D. Silvestro, E. Longo, C. Barba, U. Bivona | ROME, ITALY

POSTER SESSION CRITICAL CARE

12:30-13:15 | SCREEN F4

CHAIRPERSON:

Raimund Helbok, INNSBRUCK, AUSTRIA

P 11106 Reversible liver dysfunction associated with high dose ketamine in refractory status epilepticus

H.C. Chua | SINGAPORE, SINGAPORE

P 11107 Abstract cancelled

P 11108 Lesional Shapiro syndrome

P. Devic, F. Mauguière, A. Richard-Mornas, S. Ernesto, L. Peter-Derex, S. Rheims | LYONS, FRANCE

P 11109 Objective and reliable diagnosis of delirium by quantitative EEG analyses: results from a large retrospective case-control study

R. Fleischmann, S. Tränkner, S. Schmidt, S. Schreiber, S. Brandt | BERLIN, GERMANY

P 11110 Levetiracetam vs. Phenytoin for Status Epilepticus: a prospective study.

A. Gujjar, A. Al-Asmi, R. Nandhagopal, J. Pc, A. Obaidi, G. Ss, A. Al-Hashim, K. Al-Amrani | MUSCAT, OMAN

P 11111 Causes of admission, morbidity and mortality of multiple sclerosis patients at the ICU: a matched cohort study

A. Karamyan¹, M. Dünser¹, D. Wiebe², G. Pilz¹, P. Wipfler¹, V. Chroust¹, H.F. Novak¹, E. Trinka¹, J. Sellner¹ | ¹SALZBURG, AUSTRIA, ²PHILADELPHIA, USA

P 11112 Optic nerve sheath sonography is a promising tool for assessment of raised intracranial pressure in stroke patients

I. Kobasic, A. Lovrencic-Huzjan, M. Bosnar-Puretic, I. Husic, M. Roje-Bedekovic, T. Breitenfeld, V. Supanc, V. Vargek-Solter, V. Basic-Kes | ZAGREB, CROATIA

P 11113 CONsciousness in NEurocritical Care cohort study using fMRI and EEG (CONNECTME)

D. Kondziella, P. Fisher, C. Friberg, V. Frokjær, V.A. Larsen, J. Højgaard, K. Hansen, J. Hauerberg, M. Fabricius, G.M. Knudsen, K. Møller | COPENHAGEN, DENMARK

P 11114 Abstract cancelled

P 11115 Documentation of brain death diagnostics in Upper Austria 2011-2013 - an audit

G. Puttinger, G. Caravias, F. Gruber, M. Guger, S. Guggenberger, S. Haas, M. Hamberger, A. Kaindlstorfer, G. Ransmayr, C. Röper, G. Schwarz, W. Struhal, R. Topakian, M. Vosko, T.J. von Oertzen | LINZ, AUSTRIA

P 11116 Abstract cancelled

POSTER SESSION EPILEPSY 1

12:30-13:15 | SCREEN B2

CHAIRPERSON:

Jakob Christensen, AARHUS, DENMARK

P 11117 Abstract cancelled

P 11118 Drug resistant epilepsy in adult Sudanese epilepsy patients: prevalence, patterns & characteristics

T. A-Hakam¹, H.E.R. Mohamed² | ¹KHAMIS MUSHAYT, SAUDI ARABIA, ²KHARTOUM, SUDAN

P 11119 Mobile phone based micro-personalised support groups in people with epilepsy

H. Angus-Leppan, A. Hasan | LONDON, UK

P 11120 Seizure triggers in focal and generalised epilepsies

A.A. Arbune, O. Tarta-Arsene, D. Craiu | BUCHAREST, ROMANIA

P 11121 Investigation of epilepsy by array CGH

A. Babameto Laku, Z. Ylli, D. Ylli, M. Rakacolli, J. Kruja | TIRANA, ALBANIA

P 11122 Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety

F. Bellante, B. Legros, C. Depondt, J. Creteur, F. Taccone, N. Gaspard | BRUSSELS, BELGIUM

P 11123 Retrospective study on outcome of treatment of psychogenic non-epileptic seizures

S.A. Beniczky¹, K. Noergaard², N. Andersen Becser² | ¹ROSKILDE, ²GLOSTRUP, DENMARK

P 11124 Absence status epilepticus in adults: subtleness of its clinical features

F. Bernardo, R. Martins, A. Martins, A.N. Pinto | AMADORA, PORTUGAL

P 11125 First Seizure Clinic evaluation at University Hospital centre of Tours

J. Biberon, N. Limousin, B. de Toffol | TOURS, FRANCE

P 11126 Responsive VNS Therapy: Long term results from two long-term, prospective, multi-center studies

P. Boon¹, K. Eggleston², P. Raman², A. Jayewardene², R.S. Fisher³ | ¹GHENT, BELGIUM, ²TEXAS, ³STANFORD, USA

P 11127 Abstract cancelled

P 11128 Non-convulsive status epilepticus presenting with hiccups

C. Campos, A.D. Magalhães, R. Peralta, A.P. Antunes, F. Falcão, J. Pimentel, L. Albuquerque | LISBON, PORTUGAL

POSTER SESSION EPILEPSY 2

12:30-13:15 | SCREEN B3

CHAIRPERSON:

Alla Guekht, MOSCOW, RUSSIAN FEDERATION

P 11129 Polysomnographic (PSG) based study of sleep in juvenile myoclonic epilepsy (JME) patients

S. Ibrahim Mohamed Elbhrawy, M. Fouad, H. Omar, J. Mekky | ALEXANDRIA, EGYPT

P 11130 Vitamin K prophylaxis in pregnant women taking anticonvulsant drugs

M. Evers¹, G. Luef¹, M. Rauchenzauner², U. Kiechl-Kohlendorfer¹, S. Pletnev | ¹INNSBRUCK, AUSTRIA, ²KAUFBEUREN, GERMANY

SATURDAY, 28 MAY

12:30 - 13:15

P 11131 Unpredictable seizure-worsening induced by Levetiracetam monotherapy in a patient with focal cortical dysplasia type IIC. Fois, A.L. Rassa, E. Sechi, A. Addis, R. Piredda, R. Demurtas, D. Mandia, G. Sechi | SASSARI, ITALY**P 11132** Non-hyperammonaemic Valproate encephalopathy after 20 years of treatmentE. Galizia, J. Isaacs, H. Cock | LONDON, UK**P 11133** Nocturnal temporal lobe epilepsy: reappraisal of a rare syndromeS. Gibbs¹, P. Proserpio², L. Tassi², A. Rubino², S. Francione², M. Cossu², G. Lo Russo², L. Nobili² | ¹MONTREAL, CANADA, ²MILAN, ITALY**P 11134** Altered brain connectivity in patients with long QT syndrome – a link between heart and brain?A. Gonzalez¹, I.T. Dahl¹, P.G. Larsson¹, K.H. Haugaa¹, T. Edvardsen¹, D. Aurlen², E. Taubøll¹ | ¹OSLO, ²STAVANGER, NORWAY**P 11135** Attitude towards people with epilepsy in MoscowA. Guekht, O. Danilenko, A. Lebedeva, I. Kaimovskiy, M. Mizinova, M. Grishkina, A. Gersamiya, R. Akzhigitov | MOSCOW, RUSSIAN FEDERATION**P 11136** The Danish Epilepsy Surgery Programme aligns with international standardsE. Holm, M.T. Foged, J. Brennum, L.H. Pinborg, The Danish Epilepsy Surgery Group | COPENHAGEN, DENMARK**P 11137** De novo truncating mutation in SCN1A as a cause of epilepsy with febrile seizures plus (FS+)A. Jaimes, M. Machío, M. Oses, R. Guerrero-Lopez, B.G. Giraldez, J.M. Serratosa | MADRID, SPAIN**P 11138** Abstract cancelled**P 11139** Affective disorders in patients with epilepsyT. Kapustina, A. Kotsiubinskiy, N. Sivakova, L. Lipatova | ST. PETERSBURG, RUSSIAN FEDERATION**P 11140** Enalapril but not losartan protects development of pentylenetetrazole induced kindling in rats: role of BDNFJ. Katyal, H. Kumar, D. Joshi, Y.K. Gupta | NEW DELHI, INDIA**P 11141** The diagnostic accuracy of dynamic susceptibility contrast-enhanced perfusion MRI in temporal lobe epilepsy.G. Witkowski, H. Sienkiewicz-Jarosz, M. Restel, R. Rola, G. Makowicz, D. Ryglewicz | WARSAW, POLANDPOSTER SESSION
HEADACHE AND PAIN 1

12:30-13:15 | SCREEN C1

CHAIRPERSON:

Henriette Klit, AARHUS, DENMARK

P 11142 EMA401, a novel angiotensin II type 2 receptor antagonist for treatment of peripheral neuropathic pain: design of two phase II studiesS. Pandhi¹, F. von Raison¹, A. Shah², G. Flesch¹, F. Callegari¹ | ¹BASEL, SWITZERLAND, ²EAST HANOVER, USA**P 11143** A case of Stroke-Like Migraine Attacks after Radiation Therapy (SMART)-syndrome: a rare but important differential diagnosis of migraine and strokeV. Haller¹, D. Dashti², N. Peters¹ | ¹BASEL, ²LIESTAL, SWITZERLAND**P 11144** Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, semi-randomized, placebo-controlled crossover studyA.S. Petersen, M. Barloese, N. Lund, R. Jensen | Glostrup, Denmark**P 11145** Prolonged migraine attack: acute and preventive response to anaesthetic nerve blockade in 41 patientsM. Ruiz Piñero¹, J. Barón¹, E. Martínez Velasco¹, M.I. Pedraza¹, L. López², H. Avellón¹, A.L. Guerrero Peral¹ | ¹VALLADOLID, ²SALAMANCA, SPAIN**P 11146** Changes in topographical pressure pain sensitivity maps over the head after onabotulinumtoxin-A therapy in chronic migraineM. Ruiz Piñero¹, J. Barón¹, A. Juanatey¹, L. Blanco¹, A.L. Guerrero¹, M. Palacios-Ceña², P. Madeleine³, C. Fernández-de-Las-Peñas² | ¹VALLADOLID, ²MADRID, SPAIN, ³AALBORG, DENMARK**P 11147** Systematic literature review of health state utility values in patients with migraineP. Desai¹, A. Ahuja², G. Pietri³, S. Saproa¹ | ¹THOUSAND OAKS, USA, ²CHANDIGARH, INDIA, ³LONDON, UK**P 11148** TV publicity: one of the causes of medication-overuse headache?G. Socoliuc, G. Mihailescu, B. Alexandra-Doina, C. Baetu, I. Buraga | BUCHAREST, ROMANIA**P 11149** Headache characteristics in cerebral venous thrombosis: an analysis of 55 patientsT. Švabić Medjedović, N. Čovičković Šternić, L. Beslac-Bumbasirevic, J. Zidverc Trajković, P.D. Stanarcevic, M. Mijajlovic, A. Pavlovic, A. Radojicic, M. Stefanović Budimkić, D. Jovanovic | BELGRADE, SERBIA

P 11150 Remote limited headaches associated with
Varicella Zoster Virus

K. Takagi¹, K. Yamazaki², R. Hishida¹, S. Nojima¹, H. Kobayashi¹
¹INASHIKI-GUN, ²NAGOYA, JAPAN

P 11151 Abstract cancelled

P 11152 Abstract cancelled

P 11153 Prevalence of migraineous infarction

T.S. Tsypushkina¹, N.M. Gurary¹, M.G. Toporkova¹,
E.R. Lebedeva¹, J. Olesen² ¹YEKATERINBURG, RUSSIAN
 FEDERATION, ²GLOSTRUP, DENMARK

P 11154 CO₂ laser-evoked potentials: working population
normative values

D. Petravić, K.I. Tudor, M. Krbot Skoric, V. Ižgum | ZAGREB,
 CROATIA

P 11155 Acute post-traumatic headache

I. Vyshlova, S. Karpov, A. Starodubcev, I. Azoidis, A. Karpov |
 STAVROPOL, RUSSIAN FEDERATION

POSTER SESSION
MOVEMENT DISORDERS 1

12:30-13:15 | SCREEN E4

CHAIRPERSON:

Kristian Winge, COPENHAGEN, DENMARK

P 11156 Evaluation of impulse control disorders and
related behaviours in patients with Idiopathic
Parkinson's disease

A. Acarer, A. Bayramov, S. Ciftci, Z. Colakoglu | IZMIR, TURKEY

P 11157 White matter connectome in patients with
genetic dystonia

F. Agosta¹, S. Basaia¹, A. Tomic², E. Sarasso¹,
N.D. Kresojevic², S. Galantucci¹, M. Svetel³, V.S. Kostic³,
M. Filippi¹ | ¹MILAN, ITALY, ²BELGRADE, SERBIA

P 11158 Features of pain perception during periods of
motor fluctuations in Parkinson's disease

O. Alenicova, S. Likhachev | MINSK, BELARUS

P 11159 Constant-current stimulation in Parkinson's
disease patients

P. Amami¹, M. Mascia², L.M. Romito¹, A. Albanese¹ | ¹MILAN,
²CAGLIARI, ITALY

P 11160 Rest and postural parkinsonian tremors are
based on a common neural mechanism: an analysis of
motor unit firing synchrony and patterns

O. Agapaki¹, C. Christakos¹, D. Anastasopoulos² | ¹HERAKLION,
²IOANNINA, GREECE

P 11161 Ventilatory disturbance in early Parkinson's
disease: a prospective study

G. Baille, T. Peres, D. Devos, L. Defebvre, C. Moreau | LILLE,
 FRANCE

P 11162 Decreased coenzyme Q10 levels in multiple
system atrophy cerebellum

E. Barca¹, G. Kleiner², G. Tang², S. Tadesse², C.-Y. Lin²,
E. Masliah², S.-H. Kuo³, C.M. Quinzii² | ¹MESSINA, ITALY, ²NEW
 YORK, ³NEUROLOGY, USA

P 11163 Accuracy of deep brain stimulation electrodes
placement using frameless system - Nexframe®

J. Bardon, D. Krahulik, M. Nevrlý, P. Otruba, M. Vaverka,
P. Kanovsky | OLOMOUC, CZECH REPUBLIC

P 11164 The anatomical basis of genetic dystonia: a
multimodal MRI study

S. Basaia¹, F. Agosta¹, A. Tomic², E. Sarasso¹, N. Dragasevic³,
M. Svetel³, M. Copetti², V.S. Kostic³, M. Filippi¹ | ¹MILAN, ²SAN
 GIOVANNI ROTONDO, ITALY, ³BELGRADE, SERBIA

P 11165 Conjugal Parkinson's disease – real or chance?

B. Balint¹, R. Erro², K. Bhatia¹ | ¹LONDON, UK, ²VERONA, ITALY

P 11166 The role of transcranial sonography in
diagnosis of progressive supranuclear palsy and
multiple system atrophy

K. Blažina, V. Miletić, M. Relja | ZAGREB, CROATIA

P 11167 Neurophysiological features of balance control
in patients with Parkinson's disease by posturographic
analysis

R. Bogdanov, S. Borisova, P. Ratmanova, D. Napalkov |
 MOSCOW, RUSSIAN FEDERATION

P 11168 Progressive encephalomyelitis with rigidity
and myoclonus (PERM) associated with glycine receptor
antibodies as first manifestation of Hodgkin's
lymphoma: a case report

L. Borellini, S. Lanfranconi, I. Trezzi, G. Franco, A. Di Fonzo,
S. Bonato, N. Bresolin | MILAN, ITALY

SATURDAY, 28 MAY

12:30 - 13:15

POSTER SESSION
MS AND RELATED DISORDERS 1

12:30-13:15 | SCREEN F1

CHAIRPERSON:

Oluf Andersen, STOCKHOLM, SWEDEN (TBC)

P 11169 Longitudinal assessment of cervical cord atrophy across MS clinical phenotypes: a multicenter study

M. Aboulwafa¹, M.A. Rocca¹, P. Valsasina¹, F. Barkhof³, H. Vrenken³, A. Rovira⁴, X. Montalban⁴, H. Kearney⁵, O. Ciccarelli⁵, L. Matthews⁶, J.A. Palace⁶, A. Gallo², A. Bisecco², A. Gass⁷, P. Eisele⁷, C. Lukas⁸, B. Bellenberg⁸, P. Preziosa¹, G. Comi¹, M. Filippi¹ | ¹MILAN, ²NAPLES, ITALY, ³AMSTERDAM, NETHERLANDS, ⁴BARCELONA, SPAIN, ⁵LONDON, ⁶OXFORD, UK, ⁷MANNHEIM, ⁸BOCHUM, GERMANY

P 11170 Sudomotor dysfunction in clinically isolated syndrome

I. Adamec, L. Crnošija, M. Lovrić, A. Junaković, M. Krbot Skoric, M. Habek | ZAGREB, CROATIA

P 11171 Abstract cancelled

P 11172 Abstract cancelled

P 11173 Endocan, novel potential biomarker for multiple sclerosis?

E. Akil, R. Alp, H.H. Ozdemir, D. Arslan, M.U. Çevik | DIYARBAKIR, TURKEY

P 11174 Comparative evaluation of clinical and epidemiological characteristics of multiple sclerosis in Kazakhstan

K. Almakhanova¹, A. Siva², A. Zhusupova¹ | ¹ASTANA, KAZAKHSTAN, ²ISTANBUL, TURKEY

P 11175 CSF markers of inflammation and neurodegeneration in two Hereditary Diffuse Leukoencephalopathy with Spheroids (HDLS) families with diverging genotype and phenotype

O. Andersen¹, C. Sundal³, H. Zetterberg¹, V.D. Karrenbauer² | ¹GOTHENBURG, ²STOCKHOLM, SWEDEN, ³GOTHENBURG, NORWAY

P 11176 Fatigue, depression and memory impairment in multiple sclerosis

L. Ben Aljia, K. Anissa, D. Rabiaa, N. Salma, B.A. Sofian, B.A. Leila | SOUSSE, TUNISIA

P 11177 Real life efficacy and tolerability of Teriflunomide: a multicentre study

P. Annovazzi¹, G. Mallucci², M. Lo Re³, S. Miente⁴, R. Cavarretta⁵, L. Moiola⁵, R. Bergamaschi², A. Bertolotto³, P. Perini⁴, M. Rovaris⁵, G. Comi⁵, A. Ghezzi¹ | ¹GALLARATE (VA), ²PAVIA, ³ORBASSANO (TO), ⁴PADUA, ⁵MILAN, ITALY

P 11178 T2 and Gd+ lesion conversion to chronic T1 black holes is correlated with worse outcomes in patients with RRMS in the ADVANCE Study

D. Arnold¹, X. You², D. Gasparotto², C. Castrillo-Viguera², B. Werneburg², D. Fiore² | ¹MONTREAL, CANADA, ²CAMBRIDGE, USA

P 11179 Comparative study of neuromyelitis optica and multiple sclerosis patients by optical coherence tomography

A. Orviz, I. Suárez González, J. Matias-Guiu, C. Oreja-Guevara | MADRID, SPAIN

P 11180 Neuropsychological assessment of patients with neuromyelitis optica spectrum disorders (NMOSD)

A. Orviz, M. Valles Salgado, J. Matias-Guiu, I. González-Suárez, J. Matias-Guiu, C. Oreja-Guevara | MADRID, SPAIN

P 11181 How does fampridine change gait kinematics to improve walking speed in primary progressive multiple sclerosis?

I. González-Suárez, A. Montero-Atalaya, D. Gómez-Andrés, I. Pulido-Valdeolivas, A. Orviz, I. Rodríguez-Andonaegui, J.A. Martín-Gonzalo, E. Rausell, C. Oreja-Guevara | MADRID, SPAIN

POSTER SESSION
MS AND RELATED DISORDERS 2

12:30-13:15 | SCREEN F2

CHAIRPERSON:

Ludwig Kappos, BASEL, SWITZERLAND

P 11182 Antibodies to myelin lipids in multiple sclerosis

M. Ivanova, M. Zakharova | MOSCOW, RUSSIAN FEDERATION

P 11183 Is there a relation between development of disease disability and cervical spinal cord lesion load in the early disease course of Multiple Sclerosis?

N. Kale, B. Kara, R. Simsekoglu, M. Özerden, Z. Ozdemir, N. Karagoz Sakalli, A. Soysal | ISTANBUL, TURKEY

P 11184 Early treatment with teriflunomide reduces the risk of advancing to EDSS ≥6 and EDSS ≥7 over the long term

L. Kappos¹, M.S. Freedman², G. Comi³, A. Miller⁴, K. Thangavelu⁵, P. Truffinet⁶, F. Lublin⁴ | ¹BASEL, SWITZERLAND, ²OTTAWA, CANADA, ³MILAN, ITALY, ⁴NEW YORK, ⁵CAMBRIDGE, USA, ⁶CHILLY-MAZARIN, FRANCE

P 11185 Clinical outcomes in patients with faster advancing MS treated with teriflunomide in TEMSO and TOWER

L. Kappos¹, K. Thangavelu⁵, S. Cavalier⁵, P. Truffinet², G. Comi³, A. Miller⁴ | ¹BASEL, SWITZERLAND, ²CHILLY-MAZARIN, FRANCE, ³MILAN, ITALY, ⁴NEW YORK, ⁵CAMBRIDGE, USA

P 11186 Abstract cancelled

P 11187 Is active herpes simplex virus a predictor of interferon-beta flu-like syndrome occurrence?

D. Kasatkin, N. Spirin, M. Gris | YAROSLAVL, RUSSIAN FEDERATION

P 11188 Comparison of the efficacy and retention of Natalizumab vs. Fingolimod in Cypriot patients with Relapsing Remitting Multiple Sclerosis.

E. Kkolou, E. Leonidou, E. Gaglia, M. Pantzaris | NICOSIA, CYPRUS

P 11189 Abstract cancelled

P 11190 Similarities and Differences in Properties of Glatiramer Acetate (Copaxone®, Teva) versus Polimunol (Synthon) using Standard and Emerging Technologies

A. Komlos¹, T. Hasson¹, K. Wells-Knecht³, T. Wells-Knecht¹, R. Krispin¹, G. Papir¹, H. Cooperman¹, S. Bakshi¹, S. Kolitz⁴, B. Weiner⁴, B. Zeskind⁴, D. Ladkani², P. Loupe⁵, V. Weinstein¹, I. Grossman¹, M. Hayden¹ | ¹NETANYA, ²PETAH TIKVA, ISRAEL, ³WEST CHESTER PA, ⁴CAMBRIDGE MA, ⁵OVERLAND PARK KS, USA

P 11191 Helminths are not associated with increased Multiple Sclerosis risk

A. Koskderelioglu, M. Gedizlioglu, I. Afsar, B. Pektas | IZMIR, TURKEY

P 11192 Open-label Phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS

R. Kuhelj¹, G. Deol-Bhullar¹, M. Garas¹, P. Chin², S. Hauser³, X. Montalban⁴ | ¹BASEL, SWITZERLAND, ²SOUTH SAN FRANCISCO, ³SAN FRANCISCO, USA, ⁴BARCELONA, SPAIN

P 11193 Executive functions and complex attention deficits in patients with relapsing-remitting multiple sclerosis

T. Kunchey, M. Petrova, M. Raycheva, L.D. Traykov | SOFIA, BULGARIA

P 11194 Abstract cancelled

POSTER SESSION
MS AND RELATED DISORDERS 3

12:30-13:15 | SCREEN F3

CHAIRPERSON:

Krzysztof Selmaj, LODZ, POLAND (TBC)

P 11195 Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β -1a-controlled OPERA I and OPERA II studies

K. Selmaj¹, D. Arnold², A. Bar-or², G. Comi⁴, H.-P. Hartung⁵, S. Hauser⁸, F. Lublin⁹, A. Traboulsee³, N. Mairon⁶, P. Chin⁷, P. Fontoura⁶, H. Garren⁶, G. Klingelschmitt⁶, D. Masterman⁷, L. Kappos⁶ | ¹LODZ, POLAND, ²MONTREAL, ³VANCOUVER, CANADA, ⁴MILAN, ITALY, ⁵DÜSSELDORF, GERMANY, ⁶BASEL, SWITZERLAND, ⁷SOUTH SAN FRANCISCO, ⁸SAN FRANCISCO, ⁹NEW YORK, USA

P 11196 Integrated rehabilitation paradigm for managing some disabling multiple sclerosis-related impairments

N. Shalaby, H. Shehata, A. Elmazny | CAIRO, EGYPT

P 11197 Pharmacokinetics, pharmacodynamics, safety, and tolerability of a novel anti-IL-6 receptor recycling antibody SA237: first in-human phase 1 single- and multiple-dose studies

Y. Shimada¹, Y. Munakata², M. Inoo³, R. Hanada¹, A. Yamada¹, R. Takubo¹, M. Shiramoto⁴ | ¹TOKYO, ²SENDAI, ³UTAZU, ⁴FUKUOKA, JAPAN

P 11198 More rapid multiple sclerosis progression in North African second generation immigrants to France: comparison between French Caucasian, North Africans in Tunisia and immigrants to France

Y. Sidhom¹, E. Maillart², S. Tezenas Du Montcel², Y. Nadjar², I. Kacem¹, R. Gouider¹, C. Lubetzki², C. Papeix² | ¹TUNIS, TUNISIA, ²PARIS, FRANCE

P 11199 Abstract cancelled

P 11200 Demyelination after anti TNF α therapy: An emerging trend? Report of two cases from South East England

S. Harikrishnan, J. Sivagnanasundaram, N. Moran, I. Redmond | CANTERBURY, UK

P 11201 Demyelinating neurological disease after treatment with etanercept: description of 2 cases

S. Skalska, V. Sladkova, Z. Matejckova, J. Doláková, T. Svrcinova, J. Mares, P. Kanovsky | OLOMOUC, CZECH REPUBLIC

P 11202 Immunogenicity with repeated dosing of ocrelizumab in patients with relapsing MS

A. Song¹, R. Hendricks¹, S. Chung¹, Q. Wang², P. Chin¹, H. Garren² | ¹SOUTH SAN FRANCISCO, USA, ²BASEL, SWITZERLAND

SATURDAY, 28 MAY

12:30 - 13:15

P 11203 Persistent MRI lesion activity and brain volume loss as predictors of long term disability progression under treatment in relapsing–remitting multiple sclerosis

M.P. Sormani¹, L. Kappos², D. Piani-Meier², D. Häring², D. Tomic², N. de Stefano³ | ¹GENOA, ITALY, ²BASEL, SWITZERLAND, ³SIENNA, ITALY

P 11204 Attention and Processing Speed Performance in Multiple Sclerosis is mostly related to thalamic and cerebellar volume

S. Stamenova¹, A. Bisecco², G. Caiazzo², A. D'ambrosio², R. Sacco², S. Bonavita², R. Docimo², L. Lavorgna², M. Cirillo², P.F. Esposito², G. Tedeschi², A. Gallo² | ¹SOFIA, BULGARIA, ²NAPLES, ITALY

P 11205 Multiple Sclerosis (MS) in Iceland 1900–2000: Survival and mortality up to the Year 2011 in a total population

S. Sveinbjornsdottir¹, H. Magnusson², J. Benedict² | ¹LONDON, UK, ²REYKJAVIK, ICELAND

P 11206 Bone marrow mesenchymal stem cells intrathecal transplantation in patients with progressive multiple sclerosis – 1-year follow-up

M. Swiderek-Matysiak¹, J. Wojtkiewicz², A. Habich², I. Selmaj¹, W. Maksymowicz², K. Selmaj¹ | ¹ŁÓDŹ, ²OLSZTYN, POLAND

P 11207 Abstract cancelled

P 11208 Anti-MOG antibody positivity in a case of chronic relapsing inflammatory optic neuritis

D. Tzanetakos, E. Andreadou, M.E. Evangelopoulos, M. Anagnostouli, G. Koutsis, K. Kilidireas | ATHENS, GREECE

POSTER SESSION
MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 1

12:30-13:15 | SCREEN B4

CHAIRPERSON:

Tiziana Mongini, TURIN, ITALY (TBC)

P 11209 Abstract cancelled

P 11210 Study design of an assessment protocol for central and peripheral fatigue in myotonic dystrophy type 1 DM1

S. Baldanzi, M. Bottari, C. Simoncini, G. Ricci, G. Siciliano | PISA, ITALY

P 11211 Anosognosic vs. non-anosognosic behaviour in adult-onset myotonic dystrophy type 1: clinical and management relevance

S. Baldanzi¹, F. Bevilacqua², R. Lorio², C. Simoncini¹, A. Petrucci³, G. Massimetti¹, G. Ricci¹, C. Angelini², G. Siciliano¹ | ¹PISA, ²LIDO VENICE, ³ROME, ITALY

P 11212 Oculopharyngeal muscular dystrophy (OPMD): long-term follow-up in 19 patients

S. Bortolani, V. Ponzalino, N. Ragusa, L. Chiado Piat, E. Vittonatto, S. Boschi, L. Vercelli, L. Pinessi, T. Mongini | TURIN, ITALY

P 11213 Lymphoma-associated inflammatory myopathy: a case report

R. Brusa, E. Mauri, L. Villa, S. Brajkovic, I. Faravelli, F. Tiberio, A. Govoni, F. Magri, S. Corti, M. Sciacco, M.G. Moggio, G.P. Comi | MILAN, ITALY

P 11214 Visceral leishmaniasis in a myasthenia gravis patient: a diagnostic and therapeutic challenge.

A. Camacho, A. Hernandez, N. Giraldo, J.J. Bravo, A. Parralo, S. Carrasco García de León | CIUDAD REAL, SPAIN

P 11215 Evidence-based survival prediction in patients with sporadic inclusion body myositis (sIBM)

G. Capkun¹, S. Ghosh², T. Obadia³, H. Sharma², B. Amzal³ | ¹BASEL, SWITZERLAND, ²HYDERABAD, INDIA, ³PARIS, FRANCE

P 11216 Systematic review and meta-analyses of the prevalence of sporadic inclusion body myositis (sIBM)

A. Callan¹, G. Capkun², V. Vasanthaprasad³, S. Ghosh³, M. Needham⁴ | ¹DUBLIN, IRELAND, ²BASEL, SWITZERLAND, ³HYDERABAD, INDIA, ⁴PERTH, AUSTRALIA

P 11217 Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1

P. Cecchi¹, S. Baldanzi¹, S. Fabbri¹, I. Pesaresi¹, C. Simoncini¹, C. Angelini², U. Bonuccelli¹, M. Cosottini¹, G. Siciliano¹ | ¹PISA, ²LIDO VENICE, ITALY

P 11218 A case of dropped head syndrome caused by focal myositis

J. Cho | GYEONGGI-DO, GOYANG-SI, KOREA, REPUBLIC OF

P 11219 The significance of thymectomy: a retrospective study comparing thymectomy with conservative treatment for myasthenia gravis

I. Dejanović, D. Lavrnjic, S. Knezevic-Apostolski, S. Apostolski | BELGRADE, SERBIA

P 11220 Mutations causing myofibrillar myopathies in the Polish population

J.P. Fichna, A. Potulska-Chromik, A. Macias, A. Kaminska, C. Zekanowski, A. Maruszak | WARSAW, POLAND

POSTER SESSION NEURO-ONCOLOGY 1

12:30-13:15 | SCREEN C4

CHAIRPERSON:

Stefan Oberndorfer, ST. PÖLTEN, AUSTRIA

P 11221 Autoimmune encephalitis in a patient with benign pancreatic neoplasia

A. Addis, A.L. Rassu, E. Sechi, R. Piredda, L. Agrò, C. Fois, D.G. Corda, G. Sechi | SASSARI, ITALY

P 11222 Diffuse large B-cell Lymphoma of the central nervous system in mycophenolate mofetil treated patients with lupus nephritis

D. Aksoy¹, P. Gelener³, S. Usar Incirli² | ¹LEFKOSA, ²NICOSIA MERSIN ¹⁰, TURKE, ³NICOSIA, CYPRUS

P 11223 Neurological paraneoplastic syndromes with positive antineuronal antibodies: clinical and laboratory characterization

J.N. Alves | BRAGA, PORTUGAL

P 11224 Evaluation of intraoperative photodynamic therapy with Photolon in patients with glioblastoma

A. Barouski, A. Fedulov, I. Sakovich, T. Trukhachova, S. Shliakhtsin | MINSK, BELARUS

P 11225 Infiltrating melanotic schwannoma of the cervical spinal cord: case report, radiology and pathology

A.S. Bisgård¹, M.-L.M. Talman², C. Thomsen¹, M. Lindelof¹ | ¹HERLEV, ²COPENHAGEN, DENMARK

P 11226 Accuracy of magnetic resonance imaging in pre-operative diagnosis of brain tumours: concordance with histopathology and interobserver reliability

S. Caerels¹, A. Boogers¹, T. D'hoore¹, M.-A. van Caillie¹, K. Ramboer¹, N. Libbrecht¹, P. Vanacker² | ¹BRUGES, ²ANTWERP, BELGIUM

P 11227 Rare primary tumour of the neurohypophysis: pituitaryoma

E. Cengiz¹, S. Demir², C. Kafadar², E. Togrol² | ¹HIZMIR, ²ISTANBUL, TURKEY

P 11228 Lhermitte-Duclos disease: a clinical and neuroradiological diagnosis: a case report

T. Croese¹, R. Messina¹, S. Guerrieri¹, V. Martinelli², A. Castellano³, G. Comi¹, A. Falini¹, B. Colombo¹ | ¹MILAN, ²ALME, ³VENAFRO, ITALY

P 11229 Age-histopathology related patterns of primary Central Nervous System (CNS) tumours in Albania

P. Djamandi, G. Brace, G. Kaloshi | TIRANA, ALBANIA

P 11230 Medical risk factors in the development of brain tumours in Albania

P. Djamandi, G. Brace, G. Kaloshi | TIRANA, ALBANIA

P 11231 Incidence patterns of primary Central Nervous System Tumours (CNS) in Albania

P. Djamandi, G. Brace, G. Kaloshi | TIRANA, ALBANIA

P 11232 Treatment efficacy of patients with neuroepithelial brain tumours under local intraoperative chemotherapy

V. Dmitry, A. Fedulov | MINSK, BELARUS

P 11233 The spectrum of neurological presentations of intravascular lymphoma: from recurrent stroke to severe peripheral neuropathy

A. Escobar-Villalba, P. Pérez Torre, P.L. Martínez Ulloa, E. Monreal Laguillo, J.L. Calleja, C. Montalbán, H. Pian, Í. Corral Corral | MADRID, SPAIN

POSTER SESSION NEUROREHABILITATION 1

12:30-13:15 | SCREEN G2

CHAIRPERSON:

Jozef Opara, TARNOWSKIE, POLAND

P 11234 Behavioural therapy for enhancing physical activity in Parkinson's disease – preliminary results

J. Opara¹, D. Grzybowska-Ganszczyk², A. Małecki² | ¹TARNOWSKIE GÓRY, ²KATOWICE, POLAND

P 11235 Predictor for positive response to an implanted drop foot stimulator post stroke

M.M. Pinter¹, O. Schuhfried² | ¹KREMS, ²VIENNA, AUSTRIA

SATURDAY, 28 MAY

12:30 - 13:15

P 11236 A new liquid formulation of abobotulinumtoxinA (Dysport®) significantly improves disease-specific quality of life (CDIP-58) and pain in cervical dystonia: a double-blind and open-label study

M. Simonetta-Moreau¹, S. Vohanka³, J. Ilkowski⁴, M. Magalhães⁵, T. Kovács⁶, P. Picaut², M. Volteau², W. Poewe⁷ | ¹TOULOUSE CEDEX, ²PARIS, FRANCE, ³BRNO, CZECH REPUBLIC, ⁴POZNAN, POLAND, ⁵PORTO, PORTUGAL, ⁶BUDAPEST, HUNGARY, ⁷INNSBRUCK, AUSTRIA

P 11237 Abstract cancelled

P 11238 Abstract cancelled

P 11239 Enhancement of cortical excitability and motor function in stroke patients after combined repetitive transcranial and peripheral magnetic stimulation

S. Kuznetsova, V. Kuznetsov, N. Skachkova | KIEV, UKRAINE

P 11240 Efficacy of low-frequency rTMS on motor recovery after-stroke

O. Sorato Bezerra¹, C. Babis Magoulas¹, A.L. Schuh Teixeira Da Rosa², L. Primo de Carvalho Alves² | ¹LONDON, UK, ²PORTO ALEGRE, BRAZIL

P 11241 A study of lobar atrophy and white matter tract damage in pediatric patients with traumatic brain injury

L. Storelli¹, M.A. Rocca¹, E. Molteni², E. Pagani¹, G. Boffa¹, M. Copetti³, S. Galbiati², F. Arrigoni², M. Recla², A. Bardoni², S. Strazzer², M. Filippi¹ | ¹MILAN, ²BOSISIO PARINI, ³SAN GIOVANNI ROTONDO, ITALY

P 11242 Neurogenic lower urinary tract dysfunction in acute stroke

K.I. Tudor¹, D. Petravić¹, M. Botica², D. Mahovic Lakusic¹, B. Ribarić¹ | ¹ZAGREB, ²POPOVAČA, CROATIA

P 11243 Innovations in the rehabilitation of patients with spinal cord injury

S. Turuspekova, D. Mitrokhin, A. Ostapenko, E. Kudabaev, B. Gaziz, A. Seydanova, Z. Kalelov, L. Abdullayeva | ALMATY, KAZAKHSTAN

P 11244 Clinical assessment of dysphagia in neurodegeneration (CADN): reliability and validity

A. Vogel¹, N. Rommel², C. Sauer², M. Synofzik² | ¹MELBOURNE, AUSTRALIA, ²TÜBINGEN, GERMANY

P 11245 Video game-based speech rehabilitation for reducing dysarthria severity in adults with degenerative ataxia

A. Vogel¹, J. Skarrat¹, J. Castles¹, M. Synofzik² | ¹MELBOURNE, AUSTRALIA, ²TÜBINGEN, GERMANY

POSTER SESSION PERIPHERAL NERVE DISORDERS 1

12:30-13:15 | SCREEN D2

CHAIRPERSON:

Michaela Auer-Grumbach, GRAZ, AUSTRIA

P 11246 POEMS syndrome – case descriptions from a center of Neuromuscular disorders

J. Afonso Ribeiro, J. Parra, S.R.M. Batista, F.V. Moreira, C. Galdes, N. Silva, A. Gouveia, L. Almendra, A. Geraldo, L.J.M.P. Negrão, A. Matos | COIMBRA, PORTUGAL

P 11247 Ectopic Nav1.8 channels on motor axons aggravate the toxicity of prolonged repetitive activity in a mouse model of CMT1B

S. Alvarez Herrero¹, M.R. Rosberg¹, D. Klein², R. Martini², S.R. Levinson³, M. Moldovan¹, C. Krarup¹ | ¹COPENHAGEN, DENMARK, ²WÜRZBURG, GERMANY, ³DENVER, USA

P 11248 Dynamic science internationalization in the field of polyneuritis and polyradiculoneuritis

D. Arabadzhieva, A. Kaprelyan, I. Dimitrov, B. Ivanov | VARNA, BULGARIA

P 11249 Chronic immune sensory polyradiculopathy (CISP): two cases

R. Araújo, S. Batista, J. Parra, L.J.M.P. Negrão, A. Matos | COIMBRA, PORTUGAL

P 11250 Dopaminergic medicines are alternative drugs for medication-resistant facial nerve neuropathy: EMG study.

A. Azimov, R. Sadykov, G. Rakhimbaeva, O. Azizova, S. Dadajonov, R. Ismoilov | TASHKENT, UZBEKISTAN

P 11251 Immunological aspects of the nervous system in patients with postoperative hypothyroidism and autoimmune thyroiditis

S. Karpov, G. Balaeva, G. Saneeva, I. Azoidis, I. Prochorenko | STAVROPOL, RUSSIAN FEDERATION

P 11252 Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculopathy: Is it really effective? Our experience

C. Baetu¹, I. Buraga¹, G. Giurea Neacsu², V. Lungu¹, A.M. Enachi¹, G. Mihailescu¹ | ¹BUCHAREST, ²RM VALCEA, ROMANIA

P 11253 The evaluation of small fibers in asymptomatic patients with Val30Met mutation

C.E. Bekircan-Kurt, F.G. Yildiz, H.N. Günes, S. Erdem-Özdamar, E. Tan | ANKARA, TURKEY

P 11254 Guillain-Barré syndrome and comorbid disorders

B. Bjelica, I. Bozovic, S.Z. Peric, I. Berisavac, L. Beslac-Bumbasirevic, D. Lavrnic, Z. Stevic | BELGRADE, SERBIA

P 11255 Spastic paraplegia and mutilating sensory neuropathy caused by mutation in FAM134B gene

S. Majid, S. Bohlega, D. Monies, S. Hagos, A. Al Qahtani, B. Meyer | RIYADH, SAUDI ARABIA

P 11256 A tropical polyneuropathy in a European country

M. Branco¹, L. Ruano¹, R. Taipa², M. Melo Pires², V.T. Cruz¹, M. Lopes¹ | ¹SANTA MARIA DA FEIRA, ²PORTO, PORTUGAL

P 11257 Non-systemic vasculitic neuropathy manifested as transient multiple mononeuropathy

J. Castelo¹, R. Taipa², M. Melo Pires², C. Santos¹ | ¹SANTA MARIA DA FEIRA, ²PORTO, PORTUGAL

P 11258 Distal sensory polyneuropathy with orthostatic syncope: Transthyretin-related amyloid polyneuropathy

W. Heide, L. Langfeldt, M. Trauscheid | CELLE, GERMANY

POSTER SESSION SLEEP DISORDERS 1

12:30-13:15 | SCREEN E1

CHAIRPERSON:

Isabelle Arnulf, PARIS, FRANCE

P 11259 Evolution of sleep-disordered breathing following acute ischemic stroke and TIA and its impact on neurological outcome at 3 months (SAS Care Study)

S. Ott¹, F. Fanfulla², S. Miano², T. Horvath¹, A. Seiler¹, A.-K. Brill¹, C. Bernasconi¹, C. Cereda², P. Young³, L. Nobili⁴, M. Manconi², C. Bassetti¹ | ¹BERNE, ²LUGANO, SWITZERLAND, ³MÜNSTER, GERMANY, ⁴MILAN, ITALY

P 11260 Polysomnographic findings in craniopharyngioma patients: a controlled study

L. Pickering¹, M. Klose², U. Feldt-Rasmussen², P. Jennum¹ | ¹GLOSTRUP, ²COPENHAGEN, DENMARK

P 11261 Polysomnographic predictors of mortality in stroke patients

L. Ponsaing¹, H.K. Iversen², P. Jennum¹ | ¹COPENHAGEN, ²GLOSTRUP, DENMARK

P 11262 Abstract cancelled

P 11263 Abstract cancelled

P 11264 Vagus nerve stimulation-induced catathrenia

M. Santos, T. Teodoro, R. Peralta, C. Bentes | LISBON, PORTUGAL

P 11265 Driving simulation as a clinical tool to assess fitness-to-drive in sleepy patients

D. Schreier¹, C. Banks², J. Mathis¹ | ¹BERNE, SWITZERLAND, ²LONDON, UK

P 11266 Sleep education in neurology - a European survey

M. Sieminski¹, F. Pizza², M. Rakusa³, H. Hidalgo Pareja⁴, D. Schreier⁷, A. Pijpers⁸, A. Karamyan¹⁰, S. Khachatryan¹¹, R. Fronczek⁹, C. Falup-Pecurariu¹², S. Diaconu¹², L. Muntean⁵, V. Cochen de Cock¹³, S. Rupprecht⁶, U. Kallweit⁷ | ¹GDANSK, POLAND, ²BOLOGNA, ITALY, ³MARIBOR, SLOVENIA, ⁴BONN, ⁵GÖTTINGEN, ⁶JENA, GERMANY, ⁷BERNE, SWITZERLAND, ⁸HEEZE, ⁹LEIDEN, NETHERLANDS, ¹⁰SALZBURG, AUSTRIA, ¹¹YEREVAN, ARMENIA, ¹²BRASOV, ROMANIA, ¹³MONTPELLIER, FRANCE

P 11267 High prevalence of smoking in narcolepsy with cataplexy

K. Sonka¹, P. Perinova¹, E. Feketeova², M.P. Kovalska¹, M.V. Ibarburu¹, S. Nevsimalová¹, E. Králíková¹, M.D. Kemlink¹ | ¹PRAGUE, CZECH REPUBLIC, ²KOSICE, SLOVAKIA

P 11268 Influence of high altitude on periodic leg movements during sleep in individuals with restless legs syndrome and healthy controls: a pilot study

A. Stefani, A. Heidbreder, H. Hackner, M. Burtscher, B. Högl | INNSBRUCK, AUSTRIA

P 11269 Evaluating the effect of night-shift working on sleep and attention of nurse professionals

G.H. Tomasi¹, A.B. Tomasi¹, M.D. Soldatelli¹, J. Lin² | ¹PORTO ALEGRE, ²TUBARAO, BRAZIL

P 11270 Is HPV (human papilloma virus) vaccine associated with later onset of narcolepsy type 1?

E.W. Torstensen¹, L. Schoubo Brinth², J. Mehlsen², P.J. Jennum¹ | ¹GLOSTRUP, ²FREDERIKSBERG, DENMARK

P 11271 The degree of anxiety and depression in patients with insomnia versus patients with obstructive sleep apnea syndrome

V. Vovc, A. Lupusor, I. Moldovanu | CHISINAU, MOLDOVA

P 11272 Abstract cancelled

P 11273 REM sleep behaviour screening questionnaire (RBDSQ): validation study

B. Ziso, A. Larner | LIVERPOOL, UK

SATURDAY, 28 MAY

12:30 - 13:15

POSTER SESSION SPINAL CORD AND ROOT DISORDERS

12:30-13:15 | SCREEN E2

CHAIRPERSON:

Josef Bednarik, BRNO-BOHUNICE, CZECH REPUBLIC (TBC)

P 11274 Longitudinal extensive transverse myelitis: a rare complication of Varicella-Zoster virus reactivation in an immunocompetent individual

S. Abbas, J. El Helou, H. Hilal, G. Eid, G. Saliba | BEIRUT,

LEBANON

P 11275 Epidemiology and imaging characteristics of degenerative cervical cord compression

J. Bednarik¹, M. Kerkovsky², Z. Kadanka², Z. Kadanka Jr.²,I. Kovalova², B. Jurova² | ¹BRNO-BOHUNICE, ²BRNO, CZECH

REPUBLIC

P 11276 Acute inflammatory myelitis: 8-year retrospective study

L. Braz, C. Andrade, M.J. Sá, J. Guimaraes | PORTO, PORTUGAL

P 11277 Spinal dural arteriovenous Fistulas - diagnosis, endovascular treatment and outcome

A. Ciobotaru, O. Rusu, A.C. Mergeani, C. Coclitu, F. Antochi,

O. Bajenaru, B. Dorobat, A. Dimitriade | BUCHAREST, ROMANIA

P 11278 Abstract cancelled

P 11279 Longitudinally extensive transverse myelitis in neuromyelitis optica and Sjögren's syndrome: a case report

R. Gutiérrez-Zúñiga, J. Ruiz-Jimenez, L. Triguero-Cueva,

R.M. Vilchez-Carrillo | GRANADA, SPAIN

P 11280 Single vertebral manipulative therapy (Kitchener's Technique): a new technique for treatment of acute and subacute spinal root compression

N. Kitchener | CAIRO, EGYPT

P 11281 Use of electromyography to evaluate recovery in patients with chronic and complete spinal cord injury who received combined therapy: Neurorehabilitation and autologous neural stem cell implant

M.T. Moviglia Brandolino, G.A. Moviglia, G. Albanese,

S. Piccone | CIUDAD AUTONOMA DE BUENOS AIRES, ARGENTINA

P 11282 Bilateral involvement in three patients with Hirayama disease

K. Okamoto, M. Amari, M. Takatama | MAEBASHI, JAPAN

P 11283 Are patients receiving spinal surgery at higher risk for multiple-drug resistant urinary infections?

M. Ricco¹, S. Cattani², F. Pezzetti², D. Nicolotti³, C. Signorelli²| ¹TRENT, ²PARMA, ³PIACENZA, ITALY

P 11284 Hirayama disease: a not so rare neither so idiopathic non-progressive, juvenile spinal muscular atrophy of the upper limbs

M. Ricco¹, S. Cattani² | ¹TRENT, ²PARMA, ITALY

P 11285 Electromyography and muscle biopsy of paraspinal muscles in adolescent idiopathic scoliosis

I. Štětkářová, J. Zamecnik, V. Bocek, P. Vasko, K. Brabec,

M. Krbec | PRAGUE, CZECH REPUBLIC

P 11286 Going to the root of the problem: Horner syndrome caused by T1-T2 disc herniation

M. Tábuas-Pereira, J. Parra, C. Januário | COIMBRA, PORTUGAL

POSTER SESSION AGEING AND DEMENTIA 2

13:30-14:15 | SCREEN A2

CHAIRPERSON:

Dorota Religa, STOCKHOLM, SWEDEN

P 12001 Cognitive impairment as a predictor of functional decline after hospitalisation, DECOFIRH STUDY

A. de Albóniga-Chindurza, C. Anciones, F. Acebrón, C. Guirao, D. Ibáñez, P. Roiz, P. Pérez, G. García-Ribas | MADRID, SPAIN

P 12002 Pathological gambling: an uncommon onset of frontotemporal dementia

F. de Marchi, G. Tondo, M. Sacchetti, E. Terazzi, R. Cantello | NOVARA, ITALY

P 12003 Real-world Alzheimer's disease drug treatment – 18-month results from an observational study in three European countries (GERAS)

C. Reed¹, J. Lebrech², G. Dell'agnello³ | ¹WINDLESHAM, UK, ²BAD HOMBURG, GERMANY, ³SESTO FIORENTINO, ITALY

P 12004 Family C9ORF72 mutation revealed by a severe catatonia syndrome

A. Dormeuil, Y. Chen, S. Bombois | LILLE, FRANCE

P 12005 Alzheimer's disease with or without the co-occurrence of other neurodegenerative diseases: Distinct clinical and neuropathological phenotypes? A preliminary survey

B. Dufournet, A. Maues de Paula, M. Ceccaldi | MARSEILLES, FRANCE

P 12006 Deviant driving measures of healthy controls, MCI and AD patients in simulated driving

A. Economou, I. Beratis, D. Pavlou, N. Andronas, J. Papatriantafyllou, G. Yannis, S.G. Papageorgiou | ATHENS, GREECE

P 12007 Midlife coffee drinking and dementia-related brain changes on MRI up to 28 years later

M. Eskelinen¹, G. Spulber³, T. Ngandu², M. Kivipelto³, H. Soininen¹, A. Solomon¹ | ¹KUOPIO, ²HELSINKI, FINLAND, ³STOCKHOLM, SWEDEN

P 12008 Effect of moderate-high intensity aerobic exercise on cortical beta-amyloid accumulation measured with 11C-PIB-PET in patients with mild Alzheimer's disease

K.S. Frederiksen¹, K. Madsen¹, B.B. Andersen¹, N. Beyer¹, E. Garde¹, P. Høgh², G. Waldemar¹, S.G. Hasselbalch¹, I. Law¹ | ¹COPENHAGEN, ²ROSKILDE, DENMARK

P 12009 Effect of moderate-to-high intensity aerobic exercise on hippocampus and cortical regions in patients with mild Alzheimer's disease

K.S. Frederiksen¹, C.T. Larsen¹, A.N. Christensen¹, S. Hasselbalch¹, P. Høgh², L. Wermuth¹, A. Lolk¹, B.B. Andersen¹, H.R. Siebner¹, G. Waldemar¹, E. Garde¹ | ¹COPENHAGEN, ²ROSKILDE, DENMARK

P 12010 Appraisal of the utility of the AIT appropriate use criteria of the amyloid-PET

M. Boccardi¹, D. Altomare¹, U. Guerra¹, M. Pievani¹, E. Albanese⁴, C. Festari¹, L. Antelmi⁴, P. Pasqualetti², C. Muscio¹, F. Nobili³, A. Padovani¹, G. Frisoni⁴ | ¹BRESCIA, ²ROME, ³GENOA, ITALY, ⁴GENEVA, SWITZERLAND

P 12011 The incremental diagnostic value of 18F-Florbetapir imaging in naturalistic patients with cognitive impairment: final results from the INDIA-FBP study

D. Altomare¹, M. Boccardi¹, C. Ferrari¹, C. Festari¹, L. Antelmi³, A. Tarallo¹, P. Pasqualetti², C. Muscio¹, U. Guerra¹, B. Paghera¹, A. Padovani¹, G. Frisoni³ | ¹BRESCIA, ²ROME, ITALY, ³GENEVA, SWITZERLAND

P 12012 Primary progressive aphasia as presentation of frontotemporal lobar degeneration due to novel GRN g.1642_1645delTGAG mutation

D. Galimberti¹, S. Cioffi¹, C. Fenoglio¹, M. Serpente¹, M. Hagen², A. Oblak³, F. Rodriguez-Porcel², E. Oldoni¹, M. Arcaro¹, E. Scarpini¹, B. Ghetti³, A. Espay² | ¹MILAN, ITALY, ²CINCINNATI, ³INDIANAPOLIS, USA

P 12013 Abstract cancelled

POSTER SESSION AUTONOMIC NERVOUS SYSTEM 2

13:30-14:15 | SCREEN B1

CHAIRPERSON:

Josef Zeitlhofer, VIENNA, AUSTRIA (TBC)

P 12014 The correlation of response between the Valsalva maneuver and head-up tilt table test

J.-J. Lee | DAEGU, KOREA, REPUBLIC OF

P 12015 Jasmine stimulation mitigates sympathetic and augments parasympathetic cardiovascular modulation in patients with a history of moderate or severe traumatic brain injury

M. Liu¹, R. Wang¹, F. Canavese¹, C. de Rojas Leal¹, K. Hösl², T. Hummel³, M. Hilz¹ | ¹ERLANGEN, ²NUREMBERG, ³DRESDEN, GERMANY

P 12016 Abstract cancelled

SATURDAY, 28 MAY

13:30 - 14:15

P 12017 Cardiovascular autonomic involvement in Holmes-Adie-Ross spectrumJ. Navarro, G. Ingle, V. Iodice, E. Vichayanrat, L. Mason, K. Bleasdale-Barr, L. Watson, E.M. Hagen | LONDON, UK**P 12018** Abstract cancelled**P 12019** Fatigue in multiple sclerosis associates with autonomic dysfunctionO. Tolson, J. Guadagno, J. Newton | NEWCASTLE, UK**P 12020** Cardiac autonomic modulation changes within one hour after Fingolimod-initiationR. Wang¹, C. de Rojas Leal¹, M. Liu¹, F. Canavese¹, K. Hösl², D.-H. Lee¹, R. Linker¹, M. Hiltz¹ | ¹ERLANGEN, ²NUREMBERG, GERMANY**P 12021** Neurological manifestations revealing a cerebral lymphomaN. Yengui, I. Ben Abdelaziz, B. Ayadi, E. Farhat, M. Zouari, F. Hentati | TUNIS, TUNISIA**P 12022** The disparity of patient-reported symptoms of autonomic dysfunction and objective autonomic nervous system testing in multiple sclerosisI. Zadro¹, L. Crnošija¹, B. Barun¹, A. Junaković¹, I. Lušić², I. Adamec¹, M. Habek¹ | ¹ZAGREB, ²SPLIT, CROATIA**P 12023** The influence of arousals, periodic leg movements, detected by EMG and 3D-videosomnography and heart-rate variability on non-restorative sleepJ. Zeitlhofer, H. Garn, B. Kohn, P. Hauschild, R. Stepansky, A. Stefanic, M. Boeck, M. Kemethofer, D. Grossegger, S. Seidel, G. Kloesch | VIENNA, AUSTRIAPOSTER SESSION
CEREBROVASCULAR DISEASES 4

13:30-14:15 | SCREEN G1

CHAIRPERSON:

Christine Kremer, MALMÖ, SWEDEN

P 12024 Association between mycoplasma pneumonia and increased risk of ischemic stroke: a case reportS. Benganem, C. Rosso, A. Leger, J. Haroche, Y. Samson | PARIS, FRANCE**P 12025** Balint's syndrome after cardiac catheterisation: an unusual presentation of strokeF. Bernardo, Â. Timóteo, A.N. Pinto | AMADORA, PORTUGAL**P 12026** CADASIL frequency in patients with leukoencephalopathyJ. Buczek, B. Błażejewska-Hyżorek, K. Gramza, A. Cudna, I. Kurkowska-Jastrzebska | WARSAW, POLAND**P 12027** Football: passion, indifference or vascular risk?C. Borbinha, J.P. Marto, L. Conceição, L. Alves, S.L. Calado, M. Viana-Baptista | LISBON, PORTUGAL**P 12028** Abstract cancelled**P 12029** Syndrome of the trephined: a case report related to atmospheric pressure changesA. Parralo, J.J. Bravo, N. Giraldo, A. Camacho, M.J. Corrales Arroyo, A. Hernandez, M.J. Gallardo | CIUDAD REAL, SPAIN**P 12030** Ventricular myxoma as a cause of vertebrobasilar strokeJ.J. Bravo, M.J. Corrales Arroyo, N. Giraldo, A. Parralo, S. Carrasco García de León | CIUDAD REAL, SPAIN**P 12031** Uric acid in acute ischemic stroke prognosisF. H. Cabrera Naranjo¹, M. Sosa Henriquez², P. Saavedra Santana¹, A. Gonzalez Hernandez², Ó. Fabre Pi¹ | ¹LAS PALMAS DE GC, ²LAS PALMAS, SPAIN**P 12032** Syncope and neurological signs: double trouble?E. Campos Costa, E. Guevara, M. Rodrigues | ALMADA, PORTUGAL**P 12033** Headache associated with acute stroke is less frequent in patients treated with intravenous recombinant tissue-type plasminogen activator treatmentM. Carvalho Dias, T. Guerreiro Martins, G. Basílio, L. Neto, L. Caeiro, A.C.G. Fonseca, T. Pinho E Melo, P. Canhão, J.M.M.C. Ferro, A. Verdelho | LISBON, PORTUGAL**P 12034** Reversible posterior leukoencephalopathy syndrome (RPLS) associated to therapy with sunitinib: first Italian case report and review of the literatureM. Cavalli, L. Saraceno, G. Bosco, G. Meola | MILAN, ITALY**P 12035** Abstract cancelled**P 12036** Abstract cancelled**P 12037** Risk factors for stroke-related pain and its variants in acute period ischemic strokeT. Cherenko, O. Markulan L. Sokolova | KIEV, UKRAINE

POSTER SESSION CEREBROVASCULAR DISEASES 5

13:30-14:15 | SCREEN G3

CHAIRPERSON:

Urs Fischer, BERN, SWITZERLAND

P 12038 Ischaemic stroke as presenting manifestation of a paraneoplastic granulomatous vasculitis

A. Ekmen, C. Rosso, F. Baronnet Chauvet, S. Crozier, A. Léger, D. Leclercq, Y. Samson | PARIS, FRANCE

P 12039 Clinical and prognostic impact of radiological parenchymal abnormalities associated with cerebral venous thrombosis

H. El Otmani, M. Fatima, Z. Attar, A. Hazim, B. El Moutawakil, M. A. Rafai, I. Slassi | CASABLANCA, MOROCCO

P 12040 Brain vascular lesions, gait and balance

D. Pinter¹, S.J. Ritchie², F. Doubal², T. Gattringer¹, Z. Morris², M. Bastin², M. Del C. Valdés Hernández², N.A. Royle², J. Corley², S. Muñoz Maniega², A. Pattie², D.A. Dickie², A.J. Gow², J.E. Staals³, J.M. Starr², I.J. Deary², C. Enzinger¹, F. Fazekas¹, J. Wardlaw² | ¹GRAZ, AUSTRIA, ²EDINBURGH, UK, ³MAASTRICHT, NETHERLANDS

P 12041 Abstract cancelled

P 12042 Spinal epidural haematoma during apixaban treatment

C. Estévez-Fraga, R. Alvarez-Velasco, P. Agüero-Rabes, L. Crespo-Araico, E. Viedma-Guiard, V. Nedkova, B. Escribano-Paredes, F.J. Gonzalez-Gomez, J. Masjuan Vallejo | MADRID, SPAIN

P 12043 Transient ischemic attack mimics in older patients with convexity subarachnoid hemorrhage: an early feature of cerebral amyloid angiopathy

S. Evain, B. Guillon, S. de Gaalon, P. Derkinderen, M. Sevin | NANTES, FRANCE

P 12044 How good is primary prevention of patients with known atrial fibrillation and a first-ever stroke

Ó. Fabre Pi, A. Gonzalez Hernandez, F.H. Cabrera Naranjo, Y. Miranda Bacallado, M. Viana-Baptista | LAS PALMAS DE GRAN CANARIA, SPAIN

P 12045 HTRA1 expression in HTRA1 gene mutation carriers

P. Formichi, A. Fasano, S. Bianchi, M.T. Dotti, A. Federico | SIENNA, ITALY

P 12046 Cerebral venous sinus thrombosis complicated with venous infarction with hemorrhagic transformation, sub-arachnoid hemorrhage and subdural hematoma – are NOAC safe?

A. Félix, A. Andre, H. Nzwalo | FARO, PORTUGAL

P 12047 A case of posterior reversible encephalopathy syndrome with isolated pons involvement in a patient with Turner syndrome

M. Ferrara, M.P. Di Viesti, M.V. Inchingolo, M.R. Latino, M.T. Popolizio, M. Leone | SAN GIOVANNI ROTONDO (FG), ITALY

P 12048 Does antiplatelet therapy during bridging thrombolysis increase rates of intracerebral hemorrhage in stroke patients?

A. Broeg-Morvay, P. Mordasini, A. Slezak, K. Liesirova, J. Meisterernst, G. Schroth, M. Arnold, S. Jung, H.P. Mattle, J. Gralla, U. Fischer | BERNE, SWITZERLAND

P 12049 Simultaneous acute both sided major trunk pulmonary artery embolism and ischemic stroke of left hemisphere. Successful multidisciplinary therapeutic collaboration

A. Folyovich¹, K.A. Beres-Molnar¹, N. Al-Muhanna¹, R. Kazinczy¹, K. Vas¹, S. Nardai¹, M. Bakos¹, G. Fazekas¹, D. Biczó², G. Turcsányi¹ | ¹BUDAPEST, HUNGARY, ²NEUWIED, GERMANY

P 12050 Bilateral middle cerebellar peduncles ischemia due to large vessel arteritis

A. Franco, S. Reimão, L. Neto, J.M.M.C. Ferro, T. Pinho E Melo | LISBON, PORTUGAL

P 12051 Do patients with stroke and newly diagnosed atrial fibrillation have benefit from prior treatment with acetylsalicylic acid?

L. Friedrich, P. Crnac, H. Budincevic | ZAGREB, CROATIA

POSTER SESSION CLINICAL NEUROPHYSIOLOGY 2

13:30-14:15 | SCREEN H2

CHAIRPERSON:

Martin Rakusa, MARIBOR, SLOVENIA

P 12052 The N100 potential in pattern reversal VEP: incidence and consequences for P100 interpretation

W.H. Mess, N. Bauer, D. Hilkmann, J. Reulen | MAASTRICHT, NETHERLANDS

P 12053 The burst-suppression EEG pattern in comatose children is reactive to photic stimulation

D. Nita¹, M. Moldovan², R. Sharma¹, S. Avramescu¹, H. Otsubo¹, C. Hahn¹ | ¹TORONTO, CANADA, ²COPENHAGEN, DENMARK

SATURDAY, 28 MAY

13:30 - 14:15

P 12054 Corticospinal reserve and disability predict efficacy of repetitive transcranial stimulation on walking abilities in people with progressive multiple sclerosis undergoing rehabilitation

A. Nuara¹, R. Chieffo¹, M. Fichera¹, F. Esposito¹, F.G. Martinelli Boneschi¹, M. Radaelli¹, A. Zangen², M. Comola¹, G. Comi¹, L. Leocani¹ | ¹MILAN, ITALY, ²BEER-SHEVA, ISRAEL

P 12055 Motor Unit Number index (MUNIX) of six muscles: normal values and effects of age and gender
T.A. Omer, G. Mullins, O. Hardiman | DUBLIN, IRELAND

P 12056 The number of events in the EEG is significantly lower in dementia
Z. Pavelek¹, J. Kuchyňka¹, F. Caisberger¹, O. Vyšata¹, A. Procházka², M. Valis¹ | ¹HRADEC KRÁLOVÉ, ²PRAGUE, CZECH REPUBLIC

P 12057 Intraoperative neurophysiological monitoring in transpedicle fixation at lumbosacral level
M. Podgurskaia, V. Lebedev, D. Ivanova, O. Vinogradov, E. Plastunenko, A. Tishuk, D. Epifanov | MOSCOW, RUSSIAN FEDERATION

P 12058 Proposal for electrodiagnostic evaluation of patients with suspected ulnar neuropathy at the elbow
G. Omejec, S. Podnar | LJUBLJANA, SLOVENIA

P 12059 Wide prefrontal and sensory-motor network involvement in the preparation of the choice in comparison to the simple reaching
M. Rakusa¹, P. Busan³, P. P. Battaglini³, B. Koritnik², J. Zidar² | ¹MARIBOR, ²LJUBLJANA, SLOVENIA, ³TRIESTE, ITALY

P 12060 Repeater F-waves in ALS
D. Veltsista, C. Papapavlou, E. Chroni | PATRAS, GREECE

P 12061 Asymmetric sensory nerve action potential amplitudes as an early hint for diagnosing Lewis-Sumner Syndrome
M.I. Yon, H.N. Günes, B. Gökçe Çokal, C.S. Demircan, S. Keskin Güler, C. Ataç Uçar, T. Yoldas | ANKARA, TURKEY

P 12062 Searching for electroencephalographic markers for use in long-term brain monitoring
I. Zibrandtsen¹, P. Kidmose², M. Otto², J. Ibsen¹, T. Kjaer¹ | ¹ROSKILDE, ²AARHUS, DENMARK

POSTER SESSION EPILEPSY 3

13:30-14:15 | SCREEN B2

CHAIRPERSON:
Phillippe Ryvlin, LAUSANNE, SWITZERLAND

P 12063 The influence of antiepileptic drugs in the lipid profile in patients with vascular epilepsy
I.-R. Carcalici, A. Lazaroae, G. Cioca, C. Roman-Filip | SIBIU, ROMANIA

P 12064 Continuous thetaburst stimulation for the treatment of refractory epilepsy: a case report
S. Carrette¹, D. Klooster³, L. Nollet¹, R. Duprat¹, W. Staljanssens¹, P. van Mierlo¹, A. van Dycke², E. Carrette¹, R. Raedt¹, A. Meurs¹, C. Baeken¹, K. Vonck¹, P.A. Boon¹ | ¹GHEENT, ²BRUGES, BELGIUM, ³HEEZE, NETHERLANDS

P 12065 Abstract cancelled

P 12066 Prognostic factor of Status epilepticus patients in Korea
S.-H. Chae, J. Han, M.-K. Kim, J.W. Cho | YANGSAN, KOREA, REPUBLIC OF

P 12067 Serotonin receptors in genetic generalized epilepsies
J.M.M. Chaves, B. Leal, C. Carvalho, A. Bettencourt, C. Barreira, R. Ferreira, D. Boleixa, S. Brás, F. Monteiro, J. Freitas, J.M.C.F. Lopes, J.E.D.P. Ramalheira, P.P. Costa, A. Martins Da Silva, B. Martins Da Silva | PORTO, PORTUGAL

P 12068 Fear of the dentist, a new form of reflex epilepsy?
R. de Jong, T. Schreuder | HEERLEN, NETHERLANDS

P 12069 Perampanel in the clinical practice. Data after one year of treatment
M. de Toledo¹, I. Garamendi Ruiz², M.E. Garcia-Garcia¹, V. Bertol³, J.A. Mauri Llerda³, A.B. Gago-Veiga¹, A. Marinas Alejo², I. Garcia Morales¹, V. Garayoa Irigoyen³, V. Garcia Morales⁴, M.J. Garcia Gomara³, M. Agúndez Sarasola⁵, S. Santos Lasasosa³, C. Arcos Sánchez³, I. Escalza Cortina⁶, E. Rueda⁴, M. Gómez Eguílaz⁷, I. Aranzábal Alústiza⁸, J.A. Oliván Usieto⁹, L. Diaz de Cerio Julian¹⁰, J.C. Gómez Esteban¹⁰ | ¹MADRID, ²BARACALDO, ³SARAGOSSA, ⁴ARABA, ⁵BILBAO, ⁶GALDAKAO, ⁷LOGROÑO, ⁸BASURTO, ⁹ALCAÑIZ, ¹⁰BARBASTRO, SPAIN

P 12070 An epileptic patient presented with atypical perivascular space
S. Demir, E. Togrol, C. Kafadar, M.F. Özdag | ISTANBUL, TURKEY

P 12071 Differences between mesial and neocortical magnetic resonance imaging negative temporal lobe epilepsy
I. Doležalová | BRNO, CZECH REPUBLIC

P 12072 Adult onset continuous partial epilepsy and acute unilateral hemispheric involvement. What is the diagnosis?
C. Duwicquet, C. Mouthon Reigner, J. Biberon, B. de Toffol, N. Limousin | TOURS, FRANCE

P 12073 Abstract cancelled

P 12074 Transient amnesic syndromes. The challenge to explain forgetfulness
T. Liaño Sanchez, M.E. García García, B. Parejo Carbonell, B. Abarrategui, D. Toledo Alfocea, I. Garcia Morales | MADRID, SPAIN

P 12075 The relationship between frequency of seizures, number of antiepileptic medications with anxiety, depression and quality of life (QoL) issues
G. Zemgulyte, G. Jurkeviciene, K. Lauckaite | KAUNAS, LITHUANIA

POSTER SESSION HEADACHE AND PAIN 2

13:30-14:15 | SCREEN C1

CHAIRPERSON:

Troels Staehlin Jensen, AARHUS, DENMARK

P 12076 Interictal cortex excitability in transcranial magnetic stimulation of migraine and chronic tension type headache
J.H. Han¹, D.E. Kim¹, S.W. Han¹, J.J. Joo² | ¹SEOUL, KOREA, REPUBLIC OF, ²GUMI, KOREA, REPUBLIC OF

P 12077 Management of headaches and sleep disturbances in patients with consequences of traumatic brain injury
I. Iakubenko, T. Litovchenko, O. Zavalna, L. Shevchenko | KHARKIV, UKRAINE

P 12078 Paroxysmal hemicrania evolving to cluster headache: a resistant case
L.E. Inan, C. Ataç-Uçar, H.A. Ünal-Artık, S. Akin-Takmaz | ANKARA, TURKEY

P 12079 Treatment of status migrainosus with local anesthetics
L.E. Inan, H.A. Ünal-Artık, C. Ataç-Uçar, N. Inan | ANKARA, TURKEY

P 12080 Personality traits in fibromyalgia patients with paresthetic complaints
O. Balbaloglu¹, N. Tanik¹, M. Alpayci², H. Ak¹, E. Karaahmet³, L.E. Inan¹ | ¹YOZGAT, ²VAN, ³ÇANAKKALE, TURKEY

P 12081 Botulinum toxin in chronic refractory migraine: is the effect of IncobotulinumtoxinA (XEOMIN®) sustained?
I.M. Ion¹, A. Le Floch¹, M.M. de Verdal¹, M.A. Lozza², M.P.E. Thouvenot¹, G. Castelnovo¹ | ¹NÎMES, FRANCE, ²PAVIA, ITALY

P 12082 Depression and anxiety as comorbidities in migraine
J. Jesus Ribeiro, A.M. Novo, L. Sousa, S. Batista | COIMBRA, PORTUGAL

P 12083 Peripheral nerve blocks in the treatment of migraine in pregnancy and breastfeeding: experience in a series of 23 patients
A. Juanatey, M. Ruiz Piñero, L. Blanco, M. de Lera Alfonso, E. Martinez Velasco, M.I. Pedraza, J. Barón, A.L. Guerrero Peral | VALLADOLID, SPAIN

P 12084 Primary headache associated with sexual activity: clinical characteristics in a series of 17 cases
A. Juanatey, M. Ruiz Piñero, L. Blanco, J. Ontañón, E. Martinez Velasco, M.I. Pedraza, J. Barón, A.L. Guerrero Peral | VALLADOLID, SPAIN

P 12085 Fibromyalgia is more prevalent in migraine with aura: a cross-sectional study
F. Khorvash | ISFAHAN, IRAN, ISLAMIC REPUBLIC OF

P 12086 Migraine and irritable bowel syndrome: an epidemiological study
M. Ghasemi, F. Khorvash, S. Mirzaei, S. Memar Montazerin, M. Khazaeili | ISFAHAN, IRAN, ISLAMIC REPUBLIC OF

P 12087 Vertebrogenic cervicgia as a risk factor for pathological deformation of the main arteries of the brain and their neurological symptoms in young people
S. Khudayarova, G. Rakhmatullaeva, K. Khalimova | TASHKENT, UZBEKISTAN

P 12088 Microstructural and metabolic abnormalities on migraine
K. Sadokha, V. Kistsen, V. Evstigneev, R. Sakovich | MINSK, BELARUS

SATURDAY, 28 MAY

13:30 - 14:15

P 12089 Epidemiology of vertebrogenic pain syndromes

I. Vyshlova, I. Azoidis, S. Karpov | STAVROPOL, RUSSIAN FEDERATION

POSTER SESSION
MOVEMENT DISORDERS 2

13:30-14:15 | SCREEN E4

CHAIRPERSON:

Christer Nilsson, LUND, SWEDEN

P 12090 Validation of the University of Pennsylvania Smell Identification Test (UPSIT-40) in Greek Parkinson's disease patients and healthy controls

E. Boura, T. Gioltzoglou, D. Tsalikakis, D. Karakostas, N. Grigoriadis | THESSALONIKI, GREECE

P 12091 The effects of visual cues on gait in Parkinson's disease patients with DBS

H. Brozova, H. Brozova, E. Plananska, K. Peterova, J. Ruz, L. Brabcova, R. Jech, D. Urgosik, E. Ruzicka | PRAGUE, CZECH REPUBLIC

P 12092 Quality of life in Parkinson's disease: impact of non-motor symptoms

M. Calejo, A. Gonçalves, I. Moreira, N.M.D.S. Vila-Chã, J. Damasio, A. Bastos Lima, S. Cavaco, A. Mendes, J. Fernandes | PORTO, PORTUGAL

P 12093 Longitudinal clinical and brain MRI changes in multiple system atrophyE. Caso¹, F. Agosta¹, I. Nikolic², M. Ječmenica Lukić², I. Petrović², I. Stanković², P. Valsasina¹, V.S. Kostić², M. Filippi¹
1^{MILAN, ITALY}, 2^{BELGRADE, SERBIA}**P 12094** Efficacy of safinamide on motor and non-motor symptoms in fluctuating Parkinson's disease patientsC. Cattaneo¹, E. Bonizzoni², M. Sardina¹, N. Grigoriadis | 1^{BRESSO (MILAN)}, 2^{MILAN, ITALY}**P 12095** Abstract cancelled**P 12096** Tyrosine Hydroxylase variant associates with motor disability in de-novo Parkinson's patients

J. Kraemmer, F. Cormier-Dequaire, V. Guillemot, F. Danjou, A. Brice, J.-C. Corvol | PARIS, FRANCE

P 12097 Late onset ophthalmoplegia and parkinsonism due to a novel POLG mutation

A. de Pue, P. Santens | GHENT, BELGIUM

P 12098 Abstract cancelled**P 12099** Sleep in essential tremor patients: a polysomnographic study

O. Dogu, S. Ozal, H. Kaleagasi | MERSIN, TURKEY

P 12100 The frequency of copper deficiency due to overtreatment in Wilson's disease patients

K. Dziezyc, A. Sobańska, T. Litwin, M. Rakowicz, A. Członkowska | WARSAW, POLAND

P 12101 Deviant driving measures and variability of Parkinson's disease patients and healthy controls in simulated driving

A. Economou, D. Pavlou, I. Beratis, N. Andronas, M. Stamelou, L. Stefanis, G. Yannis, S.G. Papageorgiou | ATHENS, GREECE

P 12102 Prevalence and characteristics of impulse control disorders in Parkinson's disease

H. El Otmani, Z. Attar, F. Mouni, N. Camara, B. El Moutawakil, M.A. Rafai, I. Slassi | CASABLANCA, MOROCCO

POSTER SESSION
MOVEMENT DISORDERS 3

13:30-14:15 | SCREEN E3

CHAIRPERSON:

Espen Dietrichs, OSLO, NORWAY

P 12103 Glucocerebrosidase activity in a cohort of PD patients

L. Trezzi, V. Melzi, G. Franco, L. Borellini, E. Monfrini, A. Bordoni, N. Bresolin, G.P. Comi, A.B. Di Fonzo | MILAN, ITALY

P 12104 Frequency of the dopamine dysregulation syndrome and risk factors for its development in Slovenian Parkinson's disease patients

V. Šet, J. Šinkovec, Z. Pirtošek, M. Trošt | LJUBLJANA, SLOVENIA

P 12105 Abstract cancelled

P 12106 Hemichorea due to hyperosmolar nonketotic hyperglycemia

E. Viedma-Guiard, P. Agüero-Rabes, L. Crespo-Araico, C. Estévez-Fraga, E. Monreal Laguillo, J. Buisán Catevilla, J.L. Lopez-Sendon, J.C. Martinez Castrillo, Í. Corral Corral | MADRID, SPAIN

P 12107 Email in a Movement Disorders clinic: answers one click away

E. Viedma-Guiard, P. Agüero-Rabes, L. Crespo, C. Estévez-Fraga, J.L. Lopez-Sendon, G. Garcia Ribas, I. Avilés Olmo, J.C. Martinez Castrillo, A. Alonso Cánovas | MADRID, SPAIN

P 12108 Sleep problems in dystonia patients and influence of deep brain stimulation

V. Vuletic | ZAGREB, CROATIA

P 12109 Abstract cancelled**P 12110** The efficacy of combination 123I-FP-CIT and 123I-MIBG in Parkinson syndrome

K. Yoshida, Y. Suzuki, K. Sakashia, H. Kishi, K. Nomura, Y. Aburakawa, K. Kuroda, T. Kimura | ASAHIKAWA, JAPAN

P 12111 Correlation between duration of Parkinson's disease and development of non-motor symptoms in a Siberian region

I.A. Zhukova, M.A. Nikitina, V.M. Alifirova, N.G. Zhukova, O.P. Izhboldina, J.S. Mironova, M.A. Titova, A.V. Latypova, N.G. Brazovskaya, S.E. Sukhanov | TOMSK, RUSSIAN FEDERATION

P 12112 Sleep disturbances in Parkinson's disease patients

L. Zonic, O. Sinanovic | TUZLA, BOSNIA AND HERZEGOVINA

P 12113 A case of the levitating hand: rapid progression of neurodegenerative disorder?

E. Zupanic¹, M. Jozef¹, L. Savšek², G. Granda¹ | ¹LJUBLJANA, ²CELJE, SLOVENIA

POSTER SESSION
MS AND RELATED DISORDERS 4

13:30-14:15 | SCREEN F1

CHAIRPERSON:

Gordon Plant, LONDON, UK

P 12114 A case of neuromyelitis optica with optic neuritis, extensive cerebral and spinal cord lesions, associated with anti-Ku antibodies and complicated with toxocariasis

R.S. Badea, I.C. Cernat, A. Craciunoiu | BUCHAREST, ROMANIA

P 12115 Quality of life does not predict conversion from CIS to definite MS: a five-year prospective study

E. Baldin¹, T. Riise¹³, E. Baldi², R. Balugani¹, M.D. Benedetti³, L. Caniatti², M. Galeotti⁴, F. Granella⁵, M. Leone⁶, A. Lugaresi⁷, S. Malagù⁸, K. Mattarozzi¹, P. Milani², E. Montanari⁹, L. Motti¹⁰, W. Neri¹¹, E. Pietrolongo⁷, M. Santangelo¹², C. Scandellari¹, M.R. Tola², L. Vignatelli¹, R. D'alexandro¹, Geronimus Study Group¹ | ¹BOLOGNA, ²FERRARA, ³VERONA, ⁴RAVENNA, ⁵PARMA, ⁶SAN GIOVANNI ROTONDO, ⁷CHIETI, ⁸CESENA, ⁹FIDENZA (PR), ¹⁰REGGIO EMILIA, ¹¹FORLÌ, ¹²MODENA, ITALY, ¹³BERGEN, NORWAY

P 12116 Effect of organisational features on patient satisfaction with care in Italian Multiple Sclerosis centres

E. Baldin¹, K. Mattarozzi¹, C. Zenesini¹, G. Franchino¹, A. Solari², M.P. Amato³, M. Leone⁴, G.L. Mancardi⁵, V. Martinelli², G. Savettieri⁶, C. Solaro⁵, M.R. Tola⁷, R. D'alexandro¹, Agorà Study Group¹ | ¹BOLOGNA, ²MILAN, ³FLORENCE, ⁴SAN GIOVANNI ROTONDO, ⁵GENOA, ⁶PALERMO, ⁷FERRARA, ITALY

P 12117 Anti-KIR4.1 antibodies as a biomarker for Multiple Sclerosis: difficulties and preliminary data

A. Bertolotto, P. Valentino, M. Caldano, F. Marnetto | ORBASSANO, ITALY

P 12118 Abstract cancelled**P 12119** Clinical trial subjects with relapsing-remitting multiple sclerosis in Russia have more advanced disease and/or higher disease activity than those enrolled in broader international trials: demographic evaluation of the RUSTYS trial of natalizumab

A. Boyko¹, E. Evdoshenko², O. Vorobyeva¹, V. Pukaite³ | ¹MOSCOW, ²SAINT PETERSBURG, RUSSIAN FEDERATION, ³ZUG, SWITZERLAND

P 12120 Therapeutic plasma exchange treatment in an aggressive tumefactive multiple sclerosis patient

M. Yücel, A. Çetiz, Ö. Boyraz, O. Altay, S. Alay, S. Demirkaya | ANKARA, TURKEY

P 12121 Value of cerebrospinal fluid oligoclonal bands in current everyday practice: analysis of a CIS patients cohort

L. Braz, L. Carvalho, M.J. Sá, J. Guimaraes | PORTO, PORTUGAL

SATURDAY, 28 MAY

13:30 - 14:15

P 12122 Progression of idiopathic optic neuritis to multiple sclerosis in a population of 93 patients from the North of Portugal

L. Braz, J. Máximo, C. Andrade, M.J. Sá, J. Guimaraes | PORTO, PORTUGAL

P 12123 Repeated episodes of status epilepticus correspond with severity of multiple sclerosis and can also indicate double pathology

T. Brede, E. Kantorova, E. Kurca, K. Zeleňák, L. Plank | MARTIN, SLOVAKIA

P 12124 Zinc in multiple sclerosis - a systematic review and meta-analysis

M. Bredholt, J.L. Frederiksen | GLOSTRUP, DENMARK

P 12125 Clinical features of patients with relapsing inflammatory optic neuropathy

A. Çakar, H.I. Akçay, T. Gunduz, M. Kürtüncü, M. Eraksoy | ISTANBUL, TURKEY

P 12126 Abstract cancelled

POSTER SESSION MS AND RELATED DISORDERS 5

13:30-14:15 | ROOM: SCREEN F2

CHAIRPERSON:

Hans Lassmann, VIENNA, AUSTRIA

P 12127 The risk of multiple sclerosis: a possible role of an interaction of the age of infections and a specific dietary factor at young age

K. J. Lauer¹, A. Wahl², M. Geilenkeuser³ | ¹GRIESHEIM, ²DARMSTADT, ³OBER-RAMSTADT, GERMANY

P 12128 First dose effects of fingolimod: in depth electrocardiographic analysis confirms first dose observation is usually uneventful

V. Limmroth¹, W. Haverkamp², R. Dechend², M. Lang³, J. Haas², B. Wagner⁴, S. Richter⁴, H. Schieb⁵, G. Wendt⁵, T. Ziemssen⁶ | ¹COLOGNE, ²BERLIN, ³ULM, ⁴STUTT GART, ⁵NUREMBERG, ⁶DRESDEN, GERMANY

P 12129 Treatment-naïve patients who had highly active relapsing-remitting multiple sclerosis at baseline demonstrate persistent suppression of MRI activity and brain atrophy with alemtuzumab over 5 years

V. Limmroth¹, P. Vermersch², J. Lycke³, B. Singer⁴, S. Krieger⁵, D.H. Margolin⁶, K. Thangavelu⁶, A. Traboulee⁷, On Behalf Of The Care-Ms I Investigators⁹ | ¹COLOGNE, GERMANY, ²LILLE, FRANCE, ³GOTHENBURG, SWEDEN, ⁴ST LOUIS, ⁵NEW YORK, ⁶CAMBRIDGE, USA, ⁷VANCOUVER, CANADA, ⁸

P 12130 Are eyes with and without history of optic neuritis in multiple sclerosis aging differently?

J. Lizrova Preiningerova, L. Sobisek, P. Kuthan, P. Diblik, E. Havrdova | PRAGUE, CZECH REPUBLIC

P 12131 Nasal RNFL segment thickness correlates best with corpus callosum atrophy in multiple sclerosis

J. Lizrova Preiningerova, J. Krasensky, P. Diblik, L. Sobisek, J. Resler, K. Jandova, Z. Seidl, E. Havrdova | PRAGUE, CZECH REPUBLIC

P 12132 The plasma values of 8-OH-deoxyguanosine and neurofilaments correlate with clinical and radiological features of Initial and relapsed demyelinating attacks

S. Ljubisavljevic, I. Stojanovic, S. Vojinovic, D. Stojanov | NICE, SERBIA

P 12133 Improved probabilistic segmentation of white matter lesions in multiple sclerosis

E. Lommers, G. Delrue, G. Reuter, P. Calay, V. Delvaux, P. Maquet, C. Phillips | LIEGE, BELGIUM

P 12134 Effect of fampridine on cognitive performance in patients with multiple sclerosis

M. Fernandez-Fournier, P. López Ruiz, J. Perez Lucas, B. Chamorro, A. Tallon, I. Puertas Muñoz, G. Lubrini | MADRID, SPAIN

P 12135 Infusion-associated reactions decline from the first to the second course of alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated with SC IFNB-1a: CARE-MS extension study.

J. Lycke¹, B. Khatri⁴, B. Sharrack², V. Brinar³, T. Miller⁵, D.H. Margolin⁶, K. Thangavelu⁶, L. Mayer⁷ | ¹GOTHENBURG, SWEDEN, ²SHEFFIELD, UK, ³ZAGREB, CROATIA, ⁴MILWAUKEE, ⁵FORT COLLINS, ⁶CAMBRIDGE, ⁷ROUND ROCK, USA

P 12136 Month of birth effect on the risk of multiple sclerosis in Denmark

M. Magyari, N.J. Koch-Henriksen | COPENHAGEN, DENMARK

P 12137 The effects of smoking on clinical evolution of multiple sclerosis patients treated with first line DMTs

M.-S. Maier, Z. Bajko, A. Motataianu, L. Bărcuțean, S. Voidăzan, R. Bălașa | TÂRGU MUREȘ, ROMANIA

P 12138 Vitamin D metabolic pathway abnormalities and risk of multiple sclerosis in patients with clinically isolated syndromes

V. Martinelli¹, G. Dalla Costa¹, M.J. Messina¹, A. Farina¹, F. Sangalli¹, L. Moiola¹, B. Colombo¹, R. Furlan¹, A. Rubinacci¹, M.D. Luque de Castro², G. Comi¹ | ¹MILAN, ITALY, ²CORDOBA, SPAIN

P 12139 Autologous mesenchymal stem cells transplantation impacts on neurological deficiency development in patients with relapsing–remitting multiple sclerosis
Y. Maskouskikh, A. Fedulov, A. Borisov, M. Andreeva | MINSK, BELARUS

POSTER SESSION MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 2

13:30-14:15 | ROOM: SCREEN B4

CHAIRPERSON:

Abhijit Chaudhuri, ROMFORD, UK

P 12140 Stress from myasthenic crisis triggers Takotsubo (broken heart) syndrome
J. Finsterer, C. Stöllberger | VIENNA, AUSTRIA

P 12141 Affection of the respiratory muscles in combined complex I and IV deficiency
J. Finsterer, H. Rauschka, L. Segal, G. Kovacs | VIENNA, AUSTRIA

P 12142 Polymyositis in antisynthetase syndrome: a piece of the puzzle
T. Geraldes, I. Cordeiro, I. Cruz, M.D. Grunho, A.C. Ribeiro | ALMADA, PORTUGAL

P 12143 Symptomatic Duchenne Muscular Dystrophy (DMD) in a female carrier of mutated dystrophin gene
N. Giraldo Restrepo, A. Hernandez, J.J. Bravo, A. Parralo, A. Camacho, S. Carrasco García de León | CIUDAD REAL, SPAIN

P 12144 Statin-induced necrotizing autoimmune myopathy: a case report
E. Gozke, Z. Aktan, P. Doğan Ak, I. Kalyoncu Aslan, P. Oflazer | ISTANBUL, TURKEY

P 12145 Pregnancy in anti-MuSK myasthenia gravis
A.M. Grapperon, A. Verschueren, A. Finet-Monnier, P. Poullin, F. Sanderson, B. Chabrol, J. Pouget, S. Attarian, E. Salort-Campana | MARSEILLES, FRANCE

P 12146 Abstract cancelled

P 12147 Abstract cancelled

P 12148 Myasthenia Gravis: clinical and epidemiological approaches (cohort of 40 cases)
R. Douma, A. Hassine, L. Ben Aljia, A. Khefifi, S. Ben Amor, S. Benammou | SOUSSE, TUNISIA

P 12149 A prospective natural history study of inclusion body myositis: baseline characteristics
P. Houston¹, P. Machado², A. Genge³, I. Scholten¹, L. Lowes⁴, D. Laurent¹, D. Papanicolaou⁵, M. Hanna² | ¹BASEL, SWITZERLAND, ²LONDON, UK, ³QUEBEC, CANADA, ⁴COLUMBUS, ⁵EAST HANOVER, USA

P 12150 Worsening of Myasthenia Gravis after administration of injectable long-acting risperidone for treatment of schizophrenia: a first case report
I. Ismail | KUWAIT, KUWAIT

P 12151 A Case of Myasthenia Gravis Presenting With Bilateral Facial Weakness and Bulbar Signs Without Extraocular Muscle Involvement
K.D. Jo, W. Jang, M.K. Lee | GANGNEUNG, KOREA, REPUBLIC OF

POSTER SESSION NEUROIMAGING 1

13:30-14:15 | SCREEN A3

CHAIRPERSON:

Frederik Barkhof, AMSTERDAM, THE NETHERLANDS

P 12152 The combined use of 3D T1- and T2-weighted sequences improves cervical cord lesion detection in patients with multiple sclerosis: a multicenter study at 3T

M. Aboulwafa¹, M.A. Rocca¹, P. Valsasina¹, F. Camesasca¹, M. Copetti², A. Rovira⁴, X. Montalban⁴, H. Kearney⁵, O. Ciccarelli⁵, L. Matthews⁶, J.A. Palace⁶, A. Gallo³, A. Bisecco³, C. Lukas⁷, B. Bellenberg⁷, G. Comi¹, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ³NAPLES, ITALY, ⁴BARCELONA, SPAIN, ⁵LONDON, ⁶OXFORD, UK, ⁷BOCHUM, GERMANY

P 12153 3D-imaging applying in MRI for assessment of the pathological dynamics in patients with multiple sclerosis after autologous mesenchymal stem cells transplantation
M. Andreeva | MINSK, BELARUS

P 12154 Imaging of vertebral artery: differentiation of hypoplasia from stenosis.
A. Azimov, G. Rakhimbaeva | TASHKENT, UZBEKISTAN

P 12155 Functional connectome architecture of Alzheimer's disease, mild cognitive impairment and behavioral variant of frontotemporal dementia: a graph analysis study
E. Canu, F. Agosta, S. Basaia, A. Meani, S. Galantucci, F. Caso, G. Magnani, R. Santangelo, M. Falautano, G. Comi, A. Falini, M. Filippi | MILAN, ITALY

SATURDAY, 28 MAY

13:30 - 14:15

P 12156 Radiological findings in Behçet diseaseM. Chraa, N. Kissani | MARRAKECH, MOROCCO**P 12157** Abstract cancelled**P 12158** Significance of voxel-based morphometry in studying mild cognitive impairment.A. Damulina, R. Konovalov, A. Kadukov | MOSCOW, RUSSIAN FEDERATION**P 12159** Structural connectivity in multiple sclerosis and simulation of disconnectionE. de Meo, M.A. Rocca, E. Pagani, B. Colombo, M. Rodegher, P. Preziosa, G. Comi, A. Falini, M. Filippi | MILAN, ITALY**P 12160** A PRES case developing in a young patient with a diagnosis of nephrotic syndrome after using cyclosporineS. Demir, B. Öztürk, E. Togrol, H. Tekeli | ISTANBUL, TURKEY**P 12161** Reproducibility of resting state connectivity in patients with stable multiple sclerosisD. Pinter¹, C. Beckmann², M. Koini¹, E. Pirker¹, N. Filippini³, A. Pichler¹, S. Fuchs¹, F. Fazekas¹, C. Enzinger¹ | ¹GRAZ, AUSTRIA, ²NIJMEGEN, NETHERLANDS, ³OXFORD, UK**P 12162** Dynamics of cerebral blood flow in patients with non-ischemic heart failureC. Erkelens, V. van Deursen, B.M. de Jong, J.W. Elting, R. Renken, M. Gerritsen, P.J. van Laar, H. van der Wal, P. van der Meer, D.J. van Veldhuisen, A. Voors, G.J. Luijckx | GRONINGEN, NETHERLANDS**P 12163** Delayed leukoencephalopathy following acute methadone intoxicationS. Fastré¹, O. Rocrelle¹, M.-C. Duray², M. Gille¹ | ¹BRUSSELS, ²OTTIGNIES-LOUVAIN-LA-NEUVE, BELGIUM**P 12164** Longitudinal assessment of large-scale brain functional networks in patients with multiple sclerosis: relationship with clinical disability and cognitive impairmentM.A. Rocca, P. Valsasina, A. Colombi, F. Pirro, E. Pagani, E. de Meo, B. Colombo, P. Preziosa, M. Rodegher, G. Comi, A. Falini, M. Filippi | MILAN, ITALY**P 12165** Diffusional Kurtosis Imaging Study in bilateral Substantia Nigra and Red Nucleus of Parkinson's DiseaseX. Ma, J. Guan, R. Wu, Z. Cao | SHANTOU, CHINAPOSTER SESSION
NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC DISEASES 1

13:30-14:15 | SCREEN B3

CHAIRPERSON:

Daniel Kondziella, COPENHAGEN, DENMARK

P 12166 Limbic encephalitis with GABA receptor antibodiesA. Andre, M. Shamasna, C. Basilio, A. Félix, M. Milheiro, H. Nzwalo | FARO, PORTUGAL**P 12167** CNS involvement in familial amyloidotic polyneuropathy: what mechanisms?J. Araújo, J.N. Alves, C. Machado, V. Mendes, J. Pereira, J. Pinho | BRAGA, PORTUGAL**P 12168** Diagnosis of a new mutation for Ehlers Danlos Syndrome type IV in a patient with a spontaneous spinal subarachnoid haemorrhageA. Arbex Bassols, M. Villa López, M. Rosón González, A. Perez Rodriguez, J. Lopez La Fuente, M. Barxias Martin, P. Ruiz Garcia, D. Lopez Wolf, L. Borrega Canelo, C. Martin Llorente | MADRID, SPAIN**P 12169** Subacute tetraparesis mimicking Guillan-Barré syndrome in two cases of acute intermittent porphyriaA.A. Arbune, A.M. Cobzaru, L. Tatu, C. Tiu, O.A. Bajenaru | BUCHAREST, ROMANIA**P 12170** Cerebrospinal fluid osmolality: determinants and correlation with plasma osmolalityG. Bellomo, M.B. Bardone, A. Mora, V. Castellina, E. Beltrami, E. Mairate, I. Crespi | NOVARA, ITALY**P 12171** Potassium channel antibodies in a patient with Sjögren syndrome, Hashimoto encephalitis and lung adenocarcinomaR. Beyroufi, S. Mostoufizadeh, E. Penombre, A. Fickl, E. Schluck, A. La Porta, S. Courtois, E. Cohen | MULHOUSE, FRANCE**P 12172** Isolated myelitis in Behçet's disease: report of seven casesW. Bnouhanna, M. Rahmani, M. Benabdeljalil, S. Aïdi, M. El Alaoui Faris | RABAT, MOROCCO**P 12173** Neurosarcoidosis: sometimes, the essential is invisible to the eye...E. Campos Costa, A.P. Pereira, I.R. Marques, A.C. Ribeiro | ALMADA, PORTUGAL**P 12174** Bickerstaff's brainstem encephalitisH. Çavuş¹, S. Aydınlik¹, P. Işeri² | ¹KOCAELI, ²İZMİT, TURKEY

P 12175 Neurological involvement in adult hemophagocytic lymphohistiocytosis as presenting manifestation of systemic lupus erythematosus

A. de Sousa, P. Brás, I. Botelho, M. Almeida, M. Manita | LISBON, PORTUGAL

POSTER SESSION PERIPHERAL NERVE DISORDERS 2

13:30-14:15 | SCREEN D2

CHAIRPERSON:

Jonathan Baets, ANTWERP, BELGIUM

P 12176 Clinical significance of asymmetrical polyneuropathy on nerve conduction studies

S.D. Pandya, Y.-C. Chan | SINGAPORE, SINGAPORE

P 12177 Sustained muscle strength and quality of life in patients with CIDP and MMN switched from intravenous to subcutaneous immunoglobulin

I. Christiansen¹, L.H. Markvardsen² | ¹FREDERIKSBERG, ²AARHUS, DENMARK

P 12178 Improvement of hemoglobin level following switch from intravenous to subcutaneous administration of immunoglobulin in CIDP and MMN

I. Christiansen¹, L.H. Markvardsen² | ¹FREDERIKSBERG, ²AARHUS, DENMARK

P 12179 Efficacy of intravenous immunoglobulin for painful peripheral neuropathy in a patient with eosinophilic granulomatosis with polyangiitis and type II diabetes

E.M. D'adda, A. Cagnana, M. Gennuso, A. Prella | CREMA, ITALY

P 12180 Abstract cancelled

P 12181 Usefulness of skin biopsy for the etiological diagnosis of small fiber neuropathy

V. Davy, F. Pico | VERSAILLES, FRANCE

P 12182 Genotypic and phenotypic presentation of TTR-FAP in turkey

H. Durmuş¹, A. Çakar¹, M.M. Atmaca¹, Z. Matur¹, U. Altunoglu¹, M. Poda¹, Ü.H. Ulas², P. Oflazer¹, F. Deymeer¹, Y. Parman¹ | ¹ISTANBUL, ²ANKARA, TURKEY

P 12183 Chronic inflammatory demyelinating polyradiculoneuropathy associated with an inflammatory disease of the central nervous system: a case report

J. El Mesbahy, N. Louhab, N. Kissani | MARRAKECH, MOROCCO

P 12184 Functioning and quality of life in patients with peripheral neuropathy associated with anti-MAG antibodies

Y.M. Falzone¹, D. Martinelli¹, N. Riva¹, C. Briani², E. Nobile-Orazio¹, G. Lauria¹, F. Giannini³, L. Benedetti⁴, P. Dacci¹, A. Quattrini¹, G. Comi¹, R. Fazio¹, A. Schenone⁴ | ¹MILAN, ²PADUA, ³SIENNA, ⁴GENOA, ITALY

P 12185 Guillain-Barré syndrome following acute hepatitis E

D. Fitas, R. Lobato | VIANA DO CASTELO, PORTUGAL

P 12186 Epileptic seizures as a presentation of central nervous system involvement in TTR Val30Met-FAP

A. Franco, C. Bentes, M. de Carvalho, P. Pereira, J. Pimentel, I. Conceicao | LISBON, PORTUGAL

P 12187 Description of a family with autosomal dominant spastic paraparesis and peripheral neuropathy caused by a novel KIF1A mutation

M. Frasquet Carrera¹, M. Barreiro¹, R. Sivera², J.F. Vázquez Costa¹, C. Espinos¹, Á. Álamo Arenas¹, T. Sevilla¹ | ¹VALENCIA, ²GANDIA, SPAIN

SUNDAY, 29 MAY 2016

SESSIONS

HANDS-ON COURSE 1: NEUROSONOLOGY (VASCULAR)

08:30 - 10:00 | HALL B5.M1

CHAIRPERSONS:

Natan Bornstein, TEL AVIV, ISRAEL

Laszlo Csiba, DEBRECEN, HUNGARY

Doppler evaluation of the carotid arteries

Natan Bornstein, TEL AVIV, ISRAEL

Duplex ultrasound evaluation of intracranial arteries – anterior circulation

Stephan Schreiber, BERLIN, GERMANY

Extra and intracranial sonographic assessment of the posterior circulation

Edoardo Vicenzini, ROME, ITALY

Neurosonology methods used in pharmaceutical trials

Laszlo Csiba, LASZLO CSIBA

This course will start with 4 short lectures (10 minutes each) about different aspects of methods, evaluation and assessment of neurosonology. These will be followed by hands-on demonstrations where the audience will be divided into two working-groups:

- Insonation of the extracranial and intracranial anterior circulation by Stephan Schreiber.
- Insonation of the extracranial and intracranial posterior circulation by Edoardo Vicenzini.

HANDS-ON COURSE 6: NEURO-OTOLOGY

08:30 - 10:00 | HALL B4.M1

CHAIRPERSON:

Eleftherios Papathanasiou, NICOSIA, CYPRUS

Benign paroxysmal positional vertigo: provocation and liberation manoeuvres

Michael Leo Strupp, MUNICH, GERMANY

Vestibular evoked myogenic potentials

Eleftherios Papathanasiou, NICOSIA, CYPRUS

Dominik Straumann, ZURICH, SWITZERLAND

Video impulse test

Erich Schneider, SENFTENBERG, GERMANY

Konrad P. Weber, ZURICH, SWITZERLAND

Neuro-otological bedside tests

Adolfo Bronstein, LONDON, UK

Marianne Dieterich, MUNICH, GERMANY

This course encompasses the major bedside and auxiliary tests for evaluating patients with vestibular signs and symptoms. A room rotating scheme has been designed with four stations, spending twenty minutes at each, with practical demonstrations. The benign paroxysmal positional vertigo (BPPV) and neurootological bedside test stations will involve the neurootological clinical examination and the treatment of BPPV with the different manoeuvres for each separate canal BPPV. The vestibular evoked myogenic potential station will use a common evoked potential system available in all neurophysiological laboratories. The head impulse station will demonstrate head mounted video systems commercially available for eye movement documentation.

CASE-BASED FACILITATED WORKSHOP 2: CLUSTER HEADACHE – A CLINICAL CHALLENGE?

08:30 - 10:00 | HALL B4.M2

CHAIRPERSON:

Peter Goadsby, LONDON, UK

Diagnosis of cluster headache and other TACS

Peter Goadsby, LONDON, UK

Neurobiology of cluster headache

Mads Barløse, GLOSTRUP, DENMARK

Pharmacological treatment strategies in cluster headache

Arne May, HAMBURG, GERMANY

Use of neuromodulation of cluster headache

Tim Jürgens, ROSTOCK, GERMANY

Cluster headache is one of the most painful disorders, severe enough to lead patients to suicidal thoughts. This primary headache, belonging to the trigeminal autonomic cephalalgias (TACs), is underdiagnosed and under- or mistreated. The diagnosis of other TACs (hemicrania continua, SUNCT...) may also be challenging, the more that their respective clinical presentations can overlap. The first purpose of this course is to provide a clear update on diagnosis and pathophysiology of cluster headache and other TACs, based on the most recent publications. The treatment strategies as well as the new non-pharmacological options like neurostimulation, will then be discussed using illustrative cases. We expect the audience to actively take part in the debate, especially by sharing personal experiences or issues with patients and their management.

SUNDAY, 29 MAY

8:30 - 10:00

INTERACTIVE SESSION 2: PITFALLS IN NEUROLOGICAL SLEEP MEDICINE

08:30 - 10:00 | HALL A

CHAIRPERSON:

Isabelle Arnulf, PARIS, FRANCE

Pitfalls in diagnosis of hypersomnias

Isabelle Arnulf, PARIS, FRANCE

Pitfalls in diagnosis of parasomnias/epilepsy

Lino Nobili, MILANO, ITALY

Pitfalls in diagnosis of movement disorders asleep

Birgit Högl, INNSBRUCK, AUSTRIA

Patients referred to a neurologist may complain of falling abnormally asleep during daytime (10% of the population), as well as experiencing abnormal behaviours (4% of young adults, 8% of elderly), sensations or movements during the night (2-4%). Because the nocturnal world is invisible to the neurologist unless the patient is studied in a sleep lab, the interview of patients and their bed-sharers is essential to recognize restless leg syndrome from numerous sensory problems (including neuropathies), to differentiate apathy and fatigue from sleep apnoea, narcolepsy and idiopathic hypersomnia, and to differentiate sleepwalking and REM sleep behaviour disorder from epilepsy and psychiatric disorders. Clinical cases and video-clips will help clinicians to switch on lights when lost in the darkness of the night.

Participants are encouraged to actively engage with immediate feedback to support learning (voting system)

FOCUSED WORKSHOP 7: STEM CELL THERAPIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES

08:30 - 10:00 | HALL B

CHAIRPERSON:

Antonio Uccelli, GENOVA, ITALY

Adult stem cells for the treatment of multiple sclerosis

Antonio Uccelli, GENOVA, ITALY

Stem cells in muscle diseases

Yvan Torrente, MILANO, ITALY

Cell transplantation for stroke

Sean I. Savitz, HOUSTON, USA

Target Audience: Basic scientists, clinical academicians, practitioners

Scientific Content: The workshop will focus on the most recent achievements in the field of adult stem cells and neurological diseases (focusing on multiple sclerosis, muscle diseases and stroke) encompassing the biological rationale arising from preclinical studies and current clinical translation at the bed side.

FOCUSED WORKSHOP 8: MDS-ES/EAN: TICS AND TOURETTE SYNDROME – CONSENSUS AND CONTROVERSIES

08:30 - 10:00 | HALL M1

CHAIRPERSON:

Andrea Cavanna, BIRMINGHAM, UK

Challenges in diagnosing tics, Tourette's and comorbidities

Kerstin von Plessen, BERGEN, NORWAY

Tics and Tourette Syndrome – Movement disorders or behavioural conditions?

Andrea Cavanna, BIRMINGHAM, UK

Treatment of tics and Tourette syndrome – cannabis, deep brain stimulation and beyond

Kirsten Müller-Vahl, HANNOVER, GERMANY

Target Audience: Clinical academicians, practitioners, students/residents/trainees, non-physician health professionals

Scientific Content: Tics and Tourette Syndrome: Consensus and Controversies Educational Objectives Tourette syndrome and other tic disorders are amongst the most common hyperkinetic movement disorders, especially in school-age children, and pose significant challenges in terms of both diagnosis and treatment. This Focused Workshop provides a comprehensive educational package on the clinical assessment of motor and phonic tics, with particular attention to the differential diagnosis, which is often complicated by the presence of behavioural co-morbidities such as obsessive-compulsive disorder and attention-deficit/hyperactivity disorder. Therapeutic frontiers for tics include use of cannabinoids and deep brain stimulation for severe treatment-refractory cases and illustrate current and future pathways to improve patient's health-related quality of life.



International Parkinson and
Movement Disorder Society
European Section

FOCUSED WORKSHOP 9: FOCAL DEMENTIAS

08:30 - 10:00 | HALL M2

CHAIRPERSON:

Jonathan M. Schott, LONDON, UK

The parietal lobes

Jonathan M. Schott, LONDON, UK

The temporal lobes

Stefano Cappa, MILAN, ITALY

The frontal lobes

Rik Ossenkoppele, AMSTERDAM, THE NETHERLANDS

Target Audience: Clinical academicians, practitioners, students/residents/trainees, non-physician health professionals

Scientific Content: The classical cortical dementia syndromes have predilection for certain brain regions with attendant fairly predictable patterns of cognitive impairment. This not only allows for them to be distinguished from one another and from normal ageing, but also informs the deficits encountered by patients, and how best these might be addressed. Identifying patterns of regional brain impairment is therefore a critical step in the evaluation of the cognitively impaired individual. In this focused workshop, we will use dementia syndromes associated with particular focal involvement to illustrate this approach, focussing on disorders that predominantly affect the parietal lobes, the temporal lobes, and the frontal lobes. Each speaker will provide a clinical overview of focal dementias affecting each of these three brain regions. Based on case histories, this will include aspects of the history, examination, and neuropsychology – illustrated with videos where possible – associated with involvement of different cortical areas; as well as a discussion of relevant investigations and the underlying pathology.

FOCUSED WORKSHOP 10: MDS-ES/EAN: BIOMARKERS FOR PARKINSON'S DISEASE

08:30 - 10:00 | HALL M4

CHAIRPERSON:

Werner Poewe, INNSBRUCK, AUSTRIA

The need for better biological markers for PD

Werner Poewe, INNSBRUCK, AUSTRIA

Alpha-Synuclein: a new evidence?

Wassilios Meissner, BORDEAUX, FRANCE

Imaging markers: MRI

Umberto Sabatini, ROME, ITALY

Imaging markers: PET/SPECT

Philippe Remy, CRETEIL, FRANCE

Target Audience: Basic scientists, clinical academicians, practitioners, students/residents/trainees

Scientific Content: The diagnostic accuracy and early diagnosis are major needs in current PD research. The focussed workshop will review the performance of current criteria to diagnose PD and the concept of preclinical and prodromal disease stages as well as state of current knowledge regarding diagnostic biomarkers. The role of alpha-synuclein in body fluids (particularly CSF and tissues accessible to biopsy) for PD diagnosis will be reviewed as well as current developments in MRI-based techniques to diagnose Parkinson's disease and follow its progression.



International Parkinson and
Movement Disorder Society
European Section

SUNDAY, 29 MAY

8:30 - 10:00

FOCUSED WORKSHOP 12: IMPAIRED HAND FUNCTION AFTER STROKE AND PERIPHERAL NERVE INJURY: CONSEQUENCES FOR TREATMENT

08:30 - 10:00 | HALL M0

CHAIRPERSON:

Volker Dietz, ZURICH, SWITZERLAND

Treatment of hand function after peripheral nerve injury

Josep Valls-Solé, BARCELONA, SPAIN

Normal and impaired neural coupling of cooperative hand movements

Volker Dietz, ZURICH, SWITZERLAND

Bilateral hand movement training after stroke: what is the benefit?

Caroline Renner, LEIPZIG, GERMANY

Target Audience: Clinical academicians, practitioners, students/residents/trainees, occupational therapists, rehabilitation experts

Scientific Content: The process from lesion repair to recovery and to functional rehabilitation of hand function after traumatic neurotmesis of ulnar or median nerves will be presented. Role and effects of peripheral nerve grafts. Focused training of hand function to promote nerve regeneration. In stroke patients with a severe hemiparesis constraint induced movement therapy (CIMT) will be contrasted with bimanual arm training. Significance of bimanual movements in the recovery of hand function after stroke. Task-specific neural coupling during cooperative hand movements involves ipsi- and contralateral pathways in movement control. Influence of unaffected hemisphere in the neural control of the paretic arm/hand during cooperative hand movements.

SPECIAL SESSION 3: NEW EUROPEAN NEUROLOGICAL GUIDELINES

08:30 - 10:00 | HALL M3



CHAIRPERSON:

Antonio Federico, SIENA, ITALY

Neurostimulation in Neuropathic Pain

Giorgio Cruccu, ROME, ITALY

Diagnosis and management of tick borne encephalitis

Pille Taba, TARTU, ESTONIA

Pre-hospital stroke management

Adam Kobayashi, WARSAW, POLAND

Alcohol-withdrawal seizures

Geir Brathen, TRONDHEIM, NORWAY

Scientific Content: We will report the most relevant results of the European Neurologic Academy Guidelines produced during the past year:

Neurostimulation in Neuropathic Pain (G Cruccu, Roma, and N. Attal, Boulogne-Billancourt) reviewing the 2007 EFNS guideline. The new recommendation is that given the weak evidence available so far, for future trials the authors encourage large scale multicentre studies of non-invasive and invasive neurostimulation. They also recommend high quality studies of predictive factors of the efficacy of these techniques.

Diagnosis and Management of Tick Borne Encephalitis (P Taba, Tartu, Estonia), reporting data obtained by a large analysis of the literature from 1979 to 2015.

Prehospital stroke management (A Kobayashi, Warsaw, Poland)

Alcohol-withdrawal seizures (G Brathen, Trondheim, Norway) presenting the preliminary results. Although important, the dosing and frequency of Thiamine treatment is virtually undocumented. Benzodiazepines but no other anticonvulsants reduced the seizure risk significantly compared to placebo. In three randomized controlled studies, phenytoin failed to prevent recurrent seizures. No recent evidence supports advice to people with epilepsy regarding safe levels or frequency of alcohol consumption.

SPECIAL SESSION 4:
EFNA OPEN DIALOGUE: LET'S
TALK ABOUT SEX, SLEEP AND
STRESS



08:30 - 10:00 HALL B5, M2

CHAIRPERSONS:

Audrey Craven, EFNA PAST PRESIDENT

Viktoria Papp, RRFS PRESIDENT

**Sleep: raising awareness of sleep disorders in
neuroscientific and neurological communities**

Wolfgang Oertel, MARBURG, GERMANY

**Stress: addressing mental health in neurological
disorders: experiences and findings from clinical
practice in neuropsychiatry**

Christian Schmidt-Kraepelin, DÜSSELDORF, GERMANY

**Sex: communicating on sexual dysfunction as a
symptom of neurological disorders**

David B. Vodušek, LJUBLJANA, SLOVENIA

Scientific Content: This session will show that for many patients affected by neurological disorders, it is the 'secondary symptoms' which are often the most burdensome. Sleep Disorders, Mental Health Problems and Sexual Dysfunction are all common 'secondary symptoms' or co-morbidities for neurology patients. During this session, specialists in each area will impart:

- Knowledge of the science/latest research on the symptoms/co-morbidities of sexual dysfunction, sleep disorders and poor mental health/wellbeing in patients affected by neurological disorders
- Education on how sexual dysfunction, sleep disorders and poor mental health/wellbeing, as symptoms of a primary neurological disorder, can be managed and treated effectively
- Tools/skills to ensure that such symptoms/co-morbidities are included as part of the consultation and how patient concerns/preferences can be accurately elicited

SUNDAY, 29 MAY

10:30 - 12:30

PLENARY SYMPOSIUM 1:
PRESIDENTIAL SYMPOSIUM

10:30 - 12:30 | HALL A



CHAIRPERSONS:

Günther Deuschl, KIEL, GERMANY

Mads Ravnborg, COPENHAGEN, DENMARK

Moritz Romberg Lecture - The pre-diagnostic phase of Parkinson's disease

Eduardo Tolosa, BARCELONA, SPAIN

Camillo Golgi Lecture - The mirror mechanism: social and medical implications

Giacomo Rizzolatti, PARMA, ITALY

Charles-Édouard Brown-Séquard Lecture - 3-D spatial memory and navigation: functions and disorders

Thomas Brandt, MUNICH, GERMANY

The European Academy of Neurology has established three lectures named after outstanding founders of European Neurology. This will be their first presentation during the presidential symposium at the congress.


**Prof. Eduardo Tolosa,**

earned his MD degree from the University of Barcelona, Spain. His neurological training was obtained at the University of Minnesota Hospital in Minneapolis. He was visiting scientist at Brookhaven National Hospital, between 1974 and 1975, and, subsequently, he joined the

faculty of the Department of Neurology at the University of Minnesota. He was later appointed chief of neurology at the University Hospital in Barcelona in 1982. Prof. Tolosa was certified as a neurologist by the American Board of Neurology and Psychiatry in 1976 and became a fellow in 1997. He is a founding member of the Movement Disorder Society (MDS). He has been president of the MDS and president of the ENS. Prof. Tolosa is an honorary member of several neurological societies, including the British Neurological Association and the French Neurological Society.


Field of research: movement disorders and particularly in issues related to experimental therapeutics, etiology and pathophysiology of various parkinsonisms. His team has investigated the clinical and molecular genetics of Parkinson's disease and progressive supranuclear palsy. In the areas of experimental therapeutics, Prof. Tolosa was involved in pioneer studies defining mechanisms underlying levodopa-related motor fluctuations, both in patients and in pre-clinical models of parkinsonism. His team has been among the first

in Europe to evaluate efficacy of novel surgical strategies for Parkinson's disease such as subthalamic nucleus stimulation and its impact upon patients cognition and quality of life. In addition, during the last years, he has dedicated his investigations to the study of the asymptomatic individuals carrying PD-causative mutations in the LRRK2 gene.

**Prof. Giacomo Rizzolatti,**

was born in Kiev, in the former Soviet Union. He studied at University of Padua where he graduated in Medicine and obtained the specialization in Neurology. He spent three years at the University of Pisa at the Institute of Physiology, directed at that time by Prof. Giuseppe

Moruzzi. His subsequent academic carrier took place mostly at the University of Parma where he started as an Assistant in Human Physiology and became Professor of Human Physiology, which is still his present academic position. He spent one year in the Department of Psychology of the McMaster University, Hamilton, Ontario, Canada and one year, as a Visiting Professor, in the Department of Anatomy of the University of Pennsylvania, Philadelphia. Since the early nineties he has a close collaboration with the Department of Computer Science and Neuroscience of the University of Southern California, Los Angeles and with Ahmanson Lovelace Brain Mapping Center of UCLA, Los Angeles. He was President of the European Brain Behavior Society and Italian Society for Neuroscience. For several years he directed the European Training Program in Brain and Behaviour Research (ETP) sponsored by the European Science Foundation and for a short time he has been a member of the "European Medical Research Council". At present he is a member of Scientific Committee of "Fondation Fyssen" and Associate Member of the Neuroscience Program directed by Gerald Edelman, San Diego. Among his major awards are the "Golgi Prize for Physiology", "George Miller Award" of the Cognitive Neuroscience Society, the "Feltrinelli Prize for Medicine" of Accademia dei Lincei, and the Herlitzka Prize for Physiology, Accademia delle Scienze di Torino. He received Honorary Degrees from the University Claude Bernard of Lyon, from the University of St. Petersburg, St. Petersburg, the Grawemeyer Prize for Psychology from the University of Louisville (USA) and the Prix J.-L. Signoret in Neuropsychologie from the IPSEN Fondation.

**Prof. Thomas Brandt,**

studied medicine at the Universities of Cologne and Essen. His clinical training was under Richard Jung in Neurology and Clinical Neurophysiology in Freiburg. From 1976 to 1984 he was Director of the Neurological Clinic of the Alfried Krupp Hospital in Essen, and from 1984 to 2008

Chairman of Neurology and Director of the Department of Neurology of Munich University. He has held a Hertie Senior Research Professorship since 2008 and is also Chief Executive Director of the German Center for Vertigo and Balance Disorders of Munich University. Prof. Brandt was formerly President of the German Neurological Society, the German Society for Clinical Neurophysiology and Functional Imaging, the International Society for Posture and Gait Research, and the European Neurological Society. He is an honorary member of the German, British, and French Neurological Societies, a member of the Bavarian Academy of Sciences, and of the German Academy of Life Scientists, Leopoldina. Awards include the Srinivasan Gold Medal, the Betty and David Koetser Prize for Brain Research, the Bárány Gold Medal, the Doctor Robert Pflieger Award, the Hans Berger Prize, the Wilhelm Erb Medal, and the Federal Cross of Merit, Germany.

Major research fields: general neurology and management of dizzy patients, basic mechanisms of vertigo, balance and ocular motor disorders, locomotion, visual-vestibular interaction, motion perception, spatial orientation, and navigation. Applied methods are stance and gait analysis, eye movement recordings, other neurophysiological measures, as well as psychophysics, functional imaging with MRI and PET, and modeling sensorimotor control.

SUNDAY, 29 MAY

14:45 - 18:15

HANDS-ON COURSE 2: NEUROPHYSIOLOGY I - NEEDLE EMG AND SINGLE FIBRE EMG

14:45 - 16:15 | HALL B5.M1

CHAIRPERSON:

Christian Krarup, COPENHAGEN, DENMARK

Electromyography - conventional

Christian Krarup, COPENHAGEN, DENMARK

Electromyography - single fibre

Sanjeev Nandedkar, HOPEWELL JUNCTION, USA

Christian Krarup will give a brief introductory presentation of conventional EMG using concentric needle electrodes and subsequently a demonstration of motor unit potential recording and analysis. Sanjeev Nandedkar will discuss the carrying out and analysis of single fiber EMG.

Regarding concentric and single fiber needle recordings emphasis will be on the practical aspects of the methods. Attendants are encouraged to participate in the discussion.

This course is supported by NATUS MEDICAL Inc.

CASE-BASED FACILITATED WORKSHOP 3: MDS-ES/EAN: WHAT TO DO WITH ATAXIA?

14:45 - 16:15 | HALL B4.M2



CHAIRPERSON:

Alexandra Dürr, PARIS, FRANCE

Sporadic ataxias: MSA-C or what else?

Massimo Pandolfo, BRUSSELS, BELGIUM

Ataxia and white matter lesions

Alessandro Filla, NAPLES, ITALY

Autosomal dominant ataxias

Alexandra Dürr, PARIS, FRANCE

Autosomal recessive ataxias

Bart van de Warrenburg, NIJMEGEN, THE NETHERLANDS

This workshop will focus on cerebellar ataxias and their diagnosis, important for therapeutic actions and genetic counseling issues. We will present the strategies to initiate genetic analysis performed based on transmission, starting with cases of isolated or sporadic cases that could be multiple systemic atrophy of the cerebellar subtype C but also other late onset genetic ataxias. The

very important issues on imaging clues for diagnosis, in addition to the nearly always present cerebellar atrophy will be discussed and illustrated by clinical cases and their discussion. The diagnostic approach in dominant and recessive ataxias and genotype-phenotype correlations illustrated by cases in each group will be discussed. The learning objectives are

- becoming familiar with the growing genetic heterogeneity of cerebellar ataxias and
- apprehension of strategies to choose genetic analysis to be performed insisting on important issues for treatment and genetic counseling.

TEACHING COURSE 7: IATROGENIC LESIONS OF THE PERIPHERAL NERVOUS SYSTEM - LEVEL 2

14:45 - 18:15 | HALL A

CHAIRPERSON:

Peter Berlit, ESSEN, GERMANY

Drug-induced neuropathies

Hadi Manji, LONDON, UK

Radiation induced lesions of the peripheral nervous system

Peter Berlit, ESSEN, GERMANY

Perioperative neuropathies

Isabel Conceição, LISABON, PORTUGAL

Neuropathies caused by puncture, injection or tourniquets

Ivana Stetkarova, PRAGUE, CZECH REPUBLIC

Newer recognised drugs causing neuropathy include TNF alpha antagonists, bortezomib and linezolid. Radiation lesions of the peripheral nervous system may occur many years after radiotherapy for neoplastic disease. The main diagnostic difficulty is distinguishing radiation-induced nerve lesions from tumour recurrence. Perioperative neuropathies are mainly due to direct damage during surgery, i.e. sciatic nerve during hip surgery, accessory nerve at the posterior triangle of the neck. Nerve injuries may develop secondary to expanding hematomas and pseudoaneurysms after angiography or puncture. Other causes are brakes, blasts, tourniquets or the dislocation of cement during vertebroplasty.

Critical in all iatrogenic lesions of the peripheral nervous system is an early recognition and prompt diagnosis.

TEACHING COURSE 8: MDS-ES/EAN: MOTOR SYMPTOMS REFRACTORY TO L-DOPA IN PARKINSON'S DISEASE – LEVEL 1

14:45 - 18:15 | HALL B

CHAIRPERSON:

Evzen Ruzicka, PRAGUE, CZECH REPUBLIC

Dysarthria and Dysphagia

Evzen Ruzicka, PRAGUE, CZECH REPUBLIC

Postural instability

Bastiaan Bloem, NIJMEGEN, THE NETHERLANDS

Frozen gait

Joaquim Ferreira, LISBON, PORTUGAL

Non-motor symptoms/cognitive and behavioural symptoms

Jaime Kulisevsky, BARCELONA, SPAIN

A variety of motor and non-motor symptoms not related to the nigrostriatal dopaminergic deficit develop in the course of Parkinson's disease (PD). Those dopa-unresponsive disorders may seriously interfere with life activities of patients in advanced stages of the disease. Postural instability and freezing of gait limit the patients' ability to walk and increase the risk of falls. Cognitive and behavioral disorders do further decrease the quality of life of both patients and their families. In addition, the patients' communication ability is limited due to unintelligible speech. Four lectures included in this course will demonstrate the clinical picture, basic pathophysiology and treatment strategies in specific subgroups of dopa-unresponsive PD symptoms. Possible pharmacological and non-pharmacological treatment approaches will be discussed.

TEACHING COURSE 9: OPTIMISING THE MANAGEMENT OF HEADACHE: ACUTE, PREVENTIVE AND NON-PHARMACOLOGICAL ASPECTS – LEVEL 2

14:45 - 18:15 | HALL M1

CHAIRPERSON:

Till Sprenger, WIESBADEN, GERMANY

How can we optimise the acute migraine treatment?

Messoud Ashina, COPENHAGEN, DENMARK



International Parkinson and
Movement Disorder Society
European Section

Advances and challenges in the preventive treatment of headache

Till Sprenger, WIESBADEN, GERMANY

Non-pharmacological treatment approaches 1: Is there evidence in favour of using acupuncture and alternative medicine in headache management?

Lars Bendtsen, COPENHAGEN, DENMARK

Non-pharmacological treatment approaches 2: Emerging neurostimulation techniques for the treatment of headache.

Tim Jürgens, ROSTOCK, GERMANY

Headache is one of the most frequent reasons for neurological consultations and many patients seek improved acute and preventive treatment of their attacks. Both of these fundamental aspects of headache treatment will be covered in this teaching course using an evidence-based approach. We will discuss medical as well as non-medical and neuromodulation approaches with the participants. Migraine will be the focus, but other primary headache syndromes will be covered, too. There is an evolving landscape of novel headache treatment approaches and we will discuss pros and cons of such approaches.

TEACHING COURSE 10: GENERALISED EPILEPSIES: GENETICS, DIAGNOSTICS AND TREATMENT – LEVEL 3

14:45 - 18:15 | HALL M2

CHAIRPERSON:

Reetta Kälviäinen, KUOPIO, FINLAND

Pathophysiology of generalised epilepsies

Gilles van Lujtelaar, NIJMEGEN, THE NETHERLANDS

Absence epilepsies

Marina Nikanorova, DIANALUND, DENMARK

Juvenile myoclonus epilepsy

Matthias Koepp, LONDON, UK

Progressive myoclonus epilepsies

Reetta Kälviäinen, KUOPIO, FINLAND

The purpose of this teaching course is to review the pathophysiology of most common forms of generalized epilepsies. We will also provide an update in the clinical, electroencephalographic, imaging and genetic findings of the specific syndromes as well as an update of the current therapy.

SUNDAY, 29 MAY

14:45 - 18:15

TEACHING COURSE 11: CURRENT TREATMENTS IN NEUROLOGY I – LEVEL 1

14:45 - 18:15 | HALL M3

CHAIRPERSON:

Eugen Trinka, SALZBURG, AUSTRIA
.....

Therapeutics in Amyotrophic Lateral Sclerosis

Albert Ludolph, ULM, GERMANY

Stroke in women

Hanne Christensen, COPENHAGEN, DENMARK

New therapeutic options for treating MS: benefits, limits and safety

Ludwig Kappos, BASEL SWITZERLAND

Current treatment of status epilepticus in adults

Eugen Trinka, SALZBURG, AUSTRIA

This Teaching Course will focus on complex diseases and special situation of common diseases. Professor Albert Ludolph will talk on the therapeutics in Amyotrophic Lateral Sclerosis, Professor Hanne Krarup Christensen will cover a special issue in cerebrovascular disorders in Women. Professor Ludwig Kappos will present the latest therapeutic options for treating MS with the focus on risks and benefits. Professor Eugen Trinka will cover the current treatment options of Status Epilepticus in adults.

TEACHING COURSE 12: HOW TO ASSESS AUTONOMIC DYSFUNCTION IN GENERAL NEUROLOGY – LEVEL 1

14:45 - 18:15 | HALL M0

CHAIRPERSON:

Jean-Michel Senard, TOULOUSE, FRANCE
.....

Bedside testing of cardiovascular autonomic function made easy

Walter Struhal, LINZ, AUSTRIA

Neuro-urology – an important territory lost between specialties but readily assessed in neurology

David B. Vodušek, LJUBLJANA, SLOVENIA

Sexual function and dysfunction – central and peripheral aspects of most important but coarsely neglected topic in medical education

Max J. Hilz, ERLANGEN, GERMANY

Differentiating autonomic dysfunction in movement disorders made easy

Jean-Michel Senard, TOULOUSE, FRANCE

Autonomic nervous system (ANS) disorders are common and increasingly recognized as relevant subspecialty. However, there are currently only very few neurologists specialized in this field and therefore teaching and mentoring is lacking. This teaching introduces autonomic dysfunction in general neurology by presenting common syndromes in everyday clinical practice.

After the teaching course, you will be able to:

- Form a structured autonomic differential diagnosis in the most common autonomic syndromes based on a sound history and bedside tests.
- Address and manage autonomic uro-sexual dysfunction
- Establish a sound autonomic syndrome diagnosis in movement disorders

In addition, this teaching course should act as your door opener to the wide field of autonomic dysfunction in general neurology. Therefore, our lectures will also provide recommendations for additional training resources.

HANDS-ON COURSE 3: NEUROPHYSIOLOGY II - NERVE CONDUCTION STUDIES AND NERVE/ MUSCLE ULTRASOUND

16:45 - 18:15 | HALL B5.M1

CHAIRPERSON:

Josep Valls-Solé, BARCELONA, SPAIN
.....

Nerve conduction studies

Josep Valls-Solé, BARCELONA, SPAIN

Nerve echography

Luca Padua, ROME, ITALY

In this hands-on session, we will present methods and techniques on how to perform two paraclinical tests that help with the assessment of peripheral neuropathies. In the first part, Josep Valls-Solé will demonstrate motor and sensory nerve conduction studies, together with some cues on the use of them for the diagnosis of functional disorders in neuropathies. In the second part, Luca Padua will demonstrate the use of echography for nerve and muscle ultrasound to show the various structural alterations that may affect peripheral nerves or muscles. Both techniques are nowadays complementary to each other and useful for the neurologist with interest in the assessment of functional or structural disorders involving the peripheral nervous system.

This course is supported by NATUS MEDICAL Inc.

HOW TO IMPROVE YOUR CHANCES... QUESTION-WRITING WORKSHOP

16:45 - 18:15 | HALL B4.M2

CHAIRPERSONS:

Hannah Cock, LONDON, UK

Jan Kuks, GRONINGEN, THE NETHERLANDS
.....

Hannah Cock and Jan Kuks, members of the EAN Education Committee will guide you through the difficult task on preparing questionnaires and SBAs which are of imminent importance for teachers and educators.




10th Congress of the
**EUROPEAN
PAIN FEDERATION**
EFIC[®]



www.efic.org

September 6-9, 2017 | Copenhagen, Denmark



PAIN IN EUROPE X

Bringing Pain Relief to All Patients



ECTRIMS

EUROPEAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS



32ND CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS

AND

21ST ANNUAL CONFERENCE OF REHABILITATION IN MS

14–17 SEPTEMBER 2016
LONDON, UNITED KINGDOM

Follow us on     #ECTRIMS2016

WWW.ECTRIMS-CONGRESS.EU

 **RIMS** REHABILITATION IN
MULTIPLE SCLEROSIS
European network for best practice and research

ECTRIMS
EUROPEAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

SUNDAY, 29 MAY

14:45 - 16:15

TOURNAMENT BASIC

14:45 - 16:15 | HALL B4.M1

CHAIRPERSONS:

Hannah Cock, LONDON, UK

Wolfgang Oertel, MARBURG, GERMANY

Philip Scheltens, AMSTERDAM, THE NETHERLANDS


T 101 Cognitive correlates of the brain functional connectome abnormalities in pediatric patients with multiple sclerosis

14:45

E. de Meo¹, M.A. Rocca¹, L. Moiola¹, A. Ghezzi², P. Veggiotti³, R. Capra⁴, M.P. Amato⁵, L. Vacchi¹, A. Fiorino¹, L. Pippolo², M.C. Pera³, M. Copetti⁶, G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ²GALLARATE, ³PAVIA, ⁴BRESCIA, ⁵FLORENCE, ⁶SAN GIOVANNI ROTONDO, ITALY

T 102 Zinc release and action at excitatory Schaeffer collateral-CA1 pyramidal cell synapses

15:00

A. Ekmen, A. Vergnano, P. Paoletti | PARIS, FRANCE

T 103 Modifications of gray matter volume in migraine patients over four years: a tensor-based morphometry study

15:15

R. Messina, M.A. Rocca, B. Colombo, E. Pagani, A. Falini, G. Comi, M. Filippi | MILAN, ITALY

T 104 Role of REM sleep and melanin concentrating hormone in the neuroprotective effect of sleep deprivation pre-ischemia preconditioning

15:30

M. Pace, A. Adamantidis, C. Bassetti | BERNE, SWITZERLAND

T 105 Bevacizumab: is the lower the better for glioblastoma patients?

15:45

L. Sirven-Villaros, V. Bourg, L. Mondot, F. Burel-Vandenbos, D. Fontaine, M. Frenay, C. Lebrun-Frenay | NICE, FRANCE

T 106 Clinical characterisation of SORL1 mutation carriers in a European early-onset Alzheimer's disease cohort

16:00

T. van Den Bossche¹, J. Verheijen¹, J. van der Zee¹, S. Engelborghs¹, R. Sanchez-Valle², A. Lladó², C. Graff³, H. Thonberg³, P. Pastor⁴, S. Ortega-Cubero⁴, M.A. Pastor⁵, L. Benussi⁶, R. Ghidoni⁶, G. Binetti⁶, J. Clarimon⁵, A. Lleó⁵, J. Fortea⁵, A. de Mendonça⁷, M. Martins⁷, E. Gelpi², P.P. de Deyn¹, K. Sleegers¹, P. Cras¹, C. van Broeckhoven¹ | ¹ANTWERP, BELGIUM, ²BARCELONA, SPAIN, ³HUDDINGE, SWEDEN, ⁴PAMPLONA, ⁵MADRID, SPAIN, ⁶BRESCIA, ITALY, ⁷LISBON, PORTUGAL

ORAL SESSION:
CHILD NEUROLOGY

14:45-16:15 | HALL M5

CHAIRPERSONS:

Lieven Lagae, LEUVEN, BELGIUM

Morton Ingvar Lossius, BAERUM, NORWAY

O 2101 Tuberos sclerosis complex, Serbian referral centre experience

14:45

A. Kosac, N. Jovic, D. Karaklic | BELGRADE, SERBIA

O 2102 Repeated dramatic reversal of thiamine-responsive necrotising encephalopathy due to SLC19A3 mutations emphasises the importance of considering vitamin-responsive pathologies in acute neurology

15:00

D. Lewis-Smith¹, A. Basu¹, R. Hussain¹, B. Patil², V. Ramesh¹, P. Chinnery³ | ¹NEWCASTLE UPON TYNE, MIDDLESBROUGH, ²CAMBRIDGE, UK

O 2103 The genetic deficiency of folate cycle, and autistic spectrum: the relationship with immunodeficiency, demyelination and i/v immunoglobulin effectiveness

15:15

D. Maltsev | KIEV, UKRAINE

O 2104 Neurologic manifestations of congenital disorders of glycosylation: a clinical follow-up study of 18 patients

15:30

C. Melo¹, A. Bandeira², C. Garrido², A.M. Fortuna², M. Gonçalves-Rocha³, S. Figueiroa², I. Carrilho², M. Santos², D. Quelhas², E. Martins² | ¹VILA NOVA DE FAMALICÃO, ²PORTO, ³BRAGA, PORTUGAL

O 2105 Differential contribution of cerebellar resting state functional connectivity abnormalities to cognitive impairment in pediatric and adult patients with multiple sclerosis

15:45

M.A. Rocca¹, P. Valsasina¹, L. Vacchi¹, L. Moiola¹, A. Ghezzi², P. Veggiotti³, R. Capra⁴, M.P. Amato⁵, A. Fiorino¹, L. Pippolo², M.C. Pera³, G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ²GALLARATE, ³PAVIA, ⁴BRESCIA, ⁵FLORENCE, ITALY

O 2106 Neonatal seizures: a retrospective analysis (2009-2014)

16:00

M. Santos¹, R. Sousa², J. Coelho², F. Durão², R. Machado², S. Quintas², T. Moreno², A. Levy², T. Santos² | ¹AMADORA/LISBON, ²LISBON, PORTUGAL

ORAL SESSION: COGNITIVE NEUROLOGY/ NEUROPSYCHOLOGY 1

14:45-16:15 | HALL B5.M2

CHAIRPERSONS:

Theodor Landis, LAUSANNE, SWITZERLAND

Lüder Deecke, VIENNA, AUSTRIA

O 2107 Insensitivity to reward characterises apathy but not depression in Parkinson's disease

14:45

K. Muhammed¹, M. Ben Yehuda¹, D. Drew¹, S. Manohar¹, T. Chong², D.G. Tofaris¹, D.M. Bogdanovic¹, D.G. Lennox¹, M. Hu¹, M. Husain¹ | ¹OXFORD, UK, ²SYDNEY, AUSTRALIA

O 2108 Influence of cognitive impairment and depression on cortical thinning in patients with multiple sclerosis

15:00

P. Preziosa¹, M.A. Rocca¹, P. Valsasina¹, E. Pravata², G. Riccitelli¹, G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ITALY, ²LUGANO, SWITZERLAND

O 2109 Relevance of functional connectivity abnormalities to cognitive impairment in neuromyelitis optica spectrum disorder

15:15

M.A. Rocca, P. Valsasina, F. Savoldi, G.C. Riccitelli, M. Radaelli, P. Preziosa, G. Comi, A. Falini, M. Filippi | MILAN, ITALY

O 2110 The head turning sign in Alzheimer's disease: its relationship with cognitive impairment and CSF biomarkers

15:30

M. Tábuas-Pereira, J. Durães, R. Araújo, S. Bernardino, D. Duro, B. Santiago, I. Santana | COIMBRA, PORTUGAL

O 2111 Predictors and signatures of recovery from neglect in acute stroke

15:45

R. Umarova¹, C. Kaller¹, K. Nitschke¹, S. Klöppel¹, L. Beume², I. Mader¹, C. Weiller² | ¹FREIBURG, ²FRIEBURG, GERMANY

O 2112 Functional cognitive control load across multiple sclerosis phenotypes: a clinical-imaging evaluation

16:00

L. Vacchi, M.A. Rocca, A. Meani, M. Rodegher, V. Martinelli, G. Comi, A. Falini, M. Filippi | MILAN, ITALY

ORAL SESSION: MS AND RELATED DISORDERS 3

14:45-16:15 | HALL C

CHAIRPERSONS:

Finn Sellebjerg, COPENHAGEN, DENMARK (TBC)

Giancarlo Comi, MILAN, ITALY

O 2113 Bipolar disorder, schizophrenia and psychoses in multiple sclerosis: a population-based, nationwide study in Denmark

14:45

A. Thormann, M. Magyari, N.J. Koch-Henriksen, B. Laursen, P.S. Sørensen | COPENHAGEN, DENMARK

O 2114 Long-term effect of fingolimod on disability: a categorical trend analysis over 8 years

15:00

A. Reder¹, J. Cohen², D. Piani-Meier³, D. Tomic³, S. Ritter⁴, B. Cree⁵ | ¹CHICAGO, ²CLEVELAND, USA, ³BASEL, SWITZERLAND, ⁴EAST HANOVER, ⁵SAN FRANCISCO, USA

O 2115 High doses of biotin in progressive multiple sclerosis: extension phase results of the MS-SPI trial

15:15

A. Tourbah¹, C. Lebrun-Frenay², G. Edan³, M. Clanet⁴, A.-C. Papeix⁵, S. Vukusic⁶, J. de Seze⁷, M. Debouverie⁸, O. Gout⁵, P. Clavelou⁹, G.L. Defer¹⁰, D. Laplaud¹¹, T. Moreau¹², P. Labauge¹³, B. Brochet¹⁴, F. Sedel⁵, J. Pelletier¹⁵ | ¹RHEIMS, ²NICE, ³RENNES, ⁴TOULOUSE, ⁵PARIS, ⁶LYONS, ⁷STRASBOURG, ⁸NANCY, ⁹CLERMONT-FERRAND, ¹⁰CAEN, ¹¹NANTES, ¹²DIJOU, ¹³MONTPELLIER, ¹⁴BORDEAUX, ¹⁵MARSEILLES, FRANCE

O 2116 Spinal cord volume loss in multiple sclerosis patients: a 7-Year longitudinal study

15:30

C. Tsagkas¹, S. Magon¹, L. Gaetano¹, S. Pezold¹, Y. Naegelin¹, M. Amann¹, P. Cattin¹, J. Würfel¹, O. Bieri¹, T. Sprenger², L. Kappos¹, K. Weier¹ | DÜSSELDORF, GERMANY

O 2117 Human polyomavirus JC and BKV antibody response in patients with PML

15:45

O. Adams, M. Andrée, H.-P. Hartung, C. Warnke | DÜSSELDORF, GERMANY

O 2118 Menarche is not associated with MS onset or disease activity in a prospective cohort of CIS women

16:00

M.I. Zuluaga, S. Otero-Romero, B. Pujal, I. Galán, G. Arrambide, J. Rio, M. Comabella, C. Nos, M.J. Arévalo, A. Vidal-Jordana, J. Castelló, B. Rodríguez, L. Midaglia, P. Mulero, R. Mitjana, C. Auger, J. Sastre-Garriga, A. Rovira, X. Montalban, M. Tintoré | BARCELONA, SPAIN

SUNDAY, 29 MAY

14:45 - 18:15

ORAL SESSION: NEUROREHABILITATION

14:45-16:15 | HALL M4

CHAIRPERSONS:

Tiina Rekand, BERGEN, NORWAY

Dafin Muresanu, CLUJ-NAPOKA, ROMANIA

O 2119 Mechanisms of motor plasticity after stroke
14:45 A. Guggisberg, P. Nicolo, A. Schnider | GENEVA, SWITZERLAND

O 2120 Risk assessment within 4 days after whiplash injury identifies long-term painful and non-painful neurologic disability: a twelve-year prospective study
15:00 M.K. Rasmussen¹, T.S. Jensen¹, H. Kasch² | ¹AARHUS, ²VYBORG, DENMARK

O 2121 Vascular encephalopathy impairs behavioural compensation following acute unilateral vestibulopathy
15:15 A. Zwergal, F. Schöberl, M. Patzig, R. Forbrig, T. Brandt, M. Dieterich | MUNICH, GERMANY

O 2122 Transcranial direct current stimulation combined with constraint induced movement therapy facilitates motor function in chronic stroke patients
15:30 K. Figuelewski¹, J.U. Blicher¹, J.F. Nielsen², K. Severinsen¹, H. Andersen¹ | ¹AARHUS, ²HAMMEL, DENMARK

O 2123 Effects of action observation therapy on rehabilitation of motor deficits of the dominant right upper limb in patients with MS: an exploratory study with functional MRI
15:45 S. Fumagalli, M.A. Rocca, P. Preziosa, R. Gatti, R. Messina, F.G. Martinelli Boneschi, M. Comola, G. Comi, M. Filippi | MILAN, ITALY

O 2124 Whole-hand electrical stimulation in stroke patients in the subacute stage
16:00 K. Schwenker¹, M. Christova², B. Wutzl¹, C. Florea¹, H. Bartsch¹, A.B. Kunz¹, E. Gallasch², E. Trinka¹, F. Gerstenbrand³, S. Golaszewski¹ | ¹SALZBURG, ²GRAZ, ³VIENNA, AUSTRIA

ORAL SESSION: AGEING AND DEMENTIA

16:45-18:15 | HALL C

CHAIRPERSONS:

Gunhild Waldemar, COPENHAGEN, DENMARK

Sten Fredrikson, STOCKHOLM, SWEDEN

O 2201 Roadmap to the biomarker-based diagnosis of Alzheimer's disease
16:45 G. Frisoni¹, C. Jack², B. Winblad³, F.T. Geneva Biomarker Roadmap Task Force¹ | ¹GENEVA, SWITZERLAND, ²ROCHESTER, MINNESOTA, USA, ³HUDDINGE, SWEDEN

O 2202 Cognitive and neuroanatomical features of amyloid positivity in primary progressive aphasia (PPA)
17:00 M. Santos, N. Ayakta, A. Lazaris, Z. Miller, E.G. Spinelli, M.L. Mandelli, H. Hubbard, H. Rosen, W. Jagust, B.L. Miller, L. Grinberg, W.W. Seeley, G. Rabinovici, M.L. Gorno-Tempini | SAN FRANCISCO, USA

O 2203 In vivo correlates of pathological diagnosis in primary progressive aphasia
17:15 E.G. Spinelli¹, M.L. Mandelli², M. Santos², G. Vinceti³, C. Watson², F. Agosta¹, B.L. Miller², W.W. Seeley², M. Filippi¹, M.L. Gorno-Tempini² | ¹MILAN, ITALY, ²SAN FRANCISCO, USA, ³MODENA, ITALY

O 2204 Higher intake of fats and carbohydrates is associated with smaller cortical thickness, whereas higher intake of vitamins is associated with larger cortical thickness
17:30 S. Staubo¹, J. Aakre², J. Syrjanen², M. Mielke², P. Vemuri², Y. Geda³, W. Kremers², M. Machulda², D. Knopman², R. Petersen², C. Jack², R. Roberts² | ¹HRADEC KRÁLOVÉ, CZECH REPUBLIC, ²ROCHESTER, MINNESOTA, USA, ³SCOTTSDALE, ARIZONA, USA

O 2205 Skin nerve α -synuclein deposits as new biomarkers for dementia with Lewy bodies
17:45 V. Donadio¹, A. Incensi¹, S. Capellari¹, G. Rizzo¹, R. Pantieri¹, M. Stanzani-Maserati¹, G. Devigili², R. Eleopra², F. Montini¹, A. Baruzzi¹, R. Liguori¹ | ¹BOLOGNA, ²UDINE, ITALY

O 2206 Retinal examination in Alzheimer's disease
18:00 U.A. Kayabasi¹, R.C. Sergott² | ¹ISTANBUL, TURKEY, ²PHILADELPHIA, USA

ORAL SESSION: HEADACHE AND PAIN 1

16:45-18:15 | HALL M4

CHAIRPERSONS:

Dimos Mitsikistas, ATHENS, GREECE (TBC)

Rigmor Jensen, GLOSTRUP, DENMARK

O 2207 Neurophysiological evaluation of pain processing in progressive supranuclear palsy

16:45

C. Tassorelli, M. Avenali, R. de Icco, M. Berlangieri, E. Berra, R. Zangaglia, C. Pacchetti, G. Sandrini | PAVIA, ITALY

O 2208 Migraine with aura and risk of silent brain infarcts and white matter hyperintensities in women: a population-based MRI-study of Danish twins

17:00

D. Gaist¹, E. Garde², M. Blaabjerg¹, H. Hvilsted Nielsen¹, T. Krøigård¹, K. Østergaard¹, H. Settegren Møller¹, J. von Bornemann Hjelmberg¹, C. Gøbel Madsen², P. Iversen², K. Ohm Kyvik¹, H.R. Siebner², M. Ashina² | ¹ODENSE, ²COPENHAGEN, DENMARK

O 2209 Variability of clinical features in attacks of migraine with aura

17:15

J.M. Hansen¹, P.J. Goadsby², A. Charles³ | ¹COPENHAGEN, DENMARK, ²LONDON, UK, ³LOS ANGELES, USA

O 2210 Sensory migraine aura is not associated with structural grey matter abnormalities

17:30

A. Hougaard, F.M. Amin, N.B. Arngim, M. Vlachou, V.A. Larsen, H. Larsson, M. Ashina | COPENHAGEN, DENMARK

O 2211 Randomised, double-blind, phase 2 study and 52-week interim results of an open-label extension to evaluate AMG334 for the prevention of episodic migraine

17:45

H. Sun¹, D. Dodick², P.J. Goadsby³, S. Silberstein⁴, U. Reuter⁵, M. Ashina⁶, J. Saper⁷, R. Cady⁸, F. Zhang¹, M.-L. Trotman¹, J. Dietrich¹, R. Lenz¹ | ¹THOUSAND OAKS, ²SCOTTSDALE, ³LONDON, UK, ⁴PHILADELPHIA, USA, ⁵BERLIN, GERMANY, ⁶COPENHAGEN, DENMARK, ⁷ANN ARBOR, ⁸SPRINGFIELD, USA

O 2212 Cost-effectiveness and feasibility of telemedicine for primary headaches

18:00

K.I. Mueller¹, K.B. Alstadhaug², S.I. Bekkelund¹ | ¹TROMSØ, ²BODØ, NORWAY

ORAL SESSION: NEUROIMAGING AND NEUROIMMUNOLOGY

16:45-18:15 | HALL B5.M2

CHAIRPERSONS:

Gitte Moos Knudsen, COPENHAGEN, DENMARK

Nils Erik Gilhus, BERGEN, NORWAY

O 2213 Magnetic resonance diffusion tensor imaging for evaluation of diabetic polyneuropathy

16:45

M. Vaeggemose¹, M. Pham², S. Ringgaard¹, H. Tankisi¹, N. Ejskjaer³, P. Poulsen¹, H. Andersen¹ | ¹AARHUS C, DENMARK, ²HEIDELBERG, GERMANY, ³ODENSE, DENMARK

O 2214 The role of functional MRI in the diagnosis and prognosis of patients with severe chronic disorders of consciousness

17:00

B. Wutzl¹, C. Florea¹, M. Seidl¹, A.B. Kunz¹, K. Schwenker¹, R. Nardone¹, E. Trinkl¹, F. Gerstenbrand², S. Golaszewski¹ | ¹SALZBURG, ²VIENNA, AUSTRIA

O 2215 Cerebrospinal fluid anti-Caspr2 antibodies determine a subtype of autoimmune encephalitis with prominent limbic symptoms and seizures

17:15

B. Joubert¹, M. Saint Martin², N. Noraz², G. Picard², V. Rogemond², F. Ducray², V. Desestret¹, D. Psimaras³, J.-Y. Delattre³, J.-C. Antoine⁴, J. Honnorat¹ | ¹LYON BRON, ²LYONS, ³PARIS CEDEX 20, ⁴SAINT-ETIENNE, FRANCE

O 2216 Hippocampal subfield volume loss in mild cognitive impairment patients with AD pathology

17:30

M. Marizzoni¹, D. Orlandi¹, S. Galluzzi¹, E. Rolandi¹, F.M. Nobili², M. Didic³, D. Bartrés Fas⁴, U. Fiedler⁵, P. Schonknecht⁶, P. Payoux⁷, A. Beltramello⁸, A. Soricelli⁹, L. Parnetti¹⁰, M. Tsolaki¹¹, P.M. Rossini¹², P.J. Visser¹³, R. Bordet¹⁴, J. Jovicich¹⁵, O. Blin³, G. Frisoni¹⁶ | ¹BRESCIA, ²GENOA, ITALY, ³MARSEILLES, FRANCE, ⁴BARCELONA, SPAIN, ⁵ESSEN, ⁶LEIPZIG, GERMANY, ⁷TOULOUSE, FRANCE, ⁸VERONA, ⁹NAPLES, ¹⁰PERUGIA, ITALY, ¹¹THESSALONIKI, GREECE, ¹²ROME, ITALY, ¹³AMSTERDAM, THE NETHERLANDS, ¹⁴LILLE, FRANCE, ¹⁵TRENT, ITALY, ¹⁶GENEVA, SWITZERLAND

O 2217 Evaluation by brain MRI of white matter perivenular lesions in inflammatory micro-angiopathic ischemia and in demyelinating multiple sclerosis lesions

17:45

L. Massacesi | FLORENCE, ITALY

O 2218 Novel findings in 13 patients with autoimmune encephalitis and antibodies to the GABAA receptor

17:00

M. Spatola¹, M. Petit-Pedrol¹, M. Rosenfeld¹, F. Graus¹, J. Dalmau² | ¹BARCELONA, SPAIN, ²PHILADELPHIA, USA

SUNDAY, 29 MAY

16:45 - 18:15

ORAL SESSION:
CRITICAL CARE

16:45-18:15 | HALL B4.M1

CHAIRPERSONS:

Erich Schmutzhard, INNSBRUCK, AUSTRIA

Ljiljana Beslac-Bumbasirevic, BELGRADE, SERBIA

O 2219 Comparison of different practices of
16:45 therapeutic coma in status epilepticus
management

V. Alvarez¹, J.W. Lee², M.B. Westover², F.W. Drislane²,
J. Novy³, M. Faouzi³, N. Marchi⁴, B.A. Dworetzky²,
A. Rossetti³ | ¹SION, SWITZERLAND, ²BOSTON, USA, ³LAUSANNE,
⁴GENEVA, SWITZERLAND

O 2220 Brain death determination in Germany:
17:00 updated guidelines and the necessity to have
uniform criteria

S. Brandt | BERLIN, GERMANY

O 2221 Status epilepticus in the intensive care unit:
17:15 incidence and outcome in Australia and New
Zealand from 2000 to 2013

A. Hay¹, R. Bellomo¹, D. Pilcher¹, G. Jackson¹,
K.-M. Kaukonen², M. Bailey¹ | ¹MELBOURNE, AUSTRALIA, ²HELSINKI,
FINLAND

O 2222 Head computed tomographic measurement as
17:30 an early predictor of poor outcome after
cardiac arrest

M. Moseby Knappe¹, T. Pellis², I. Dragancea¹, H. Friberg¹,
J. Horn³, M.A. Kuiper⁴, N. Nielsen¹, A. Roncarati²,
T. Cronberg¹ | ¹LUND, SWEDEN, ²PORDENONE, ITALY, ³AMSTERDAM,
THE NETHERLANDS, ⁴LEEWARDEN, THE NETHERLANDS

O 2223 Quantitative EEG in phase-2 trial of SAGE-
17:45 547: lessons learned for international phase3,
randomised, controlled trial for super-refractory status
epilepticus (the STATUS trial)

M. Quirk¹, E. Rosenthal², F. Postma¹, H. Colquhoun¹ |
¹CAMBRIDGE, ²BOSTON, USA

O 2224 Intravenous epoprostenol for treatment-
18:00 refractory reversible cerebral vasoconstriction
syndrome (RCVS)

A.L. Thydén¹, A. Abdul-Alzahra Muhamad², A. Jacobsen²,
D. Kondziella² | ¹KØBENHAVN V, ²COPENHAGEN, DENMARK

ORAL SESSION:
MOVEMENT DISORDERS 2

16:45-18:15 | HALL M5

CHAIRPERSONS:

Elena Moro, GRENOBLE, FRANCE

Bernhard Uitdehaag, MAARSSSEN, THE NETHERLANDS (TBC)

O 2225 Identification of a ponto-cerebello-thalamo-
16:45 cortical circuit in orthostatic tremor during
lying and standing

A. Zwergal, F. Schöberl, K. Feil, G. Xiong, K. Jahn, T. Brandt,
M. Strupp, M. Dieterich | MUNICH, GERMANY

O 2226 Structural and functional brain network
17:00 alterations in psychogenic dystonia

F. Agosta¹, E. Sarasso¹, A. Tomic², S. Basaia¹, M. Svetel²,
G. Mandic-Stojmenovic², M. Copetti³, V.S. Kostic², M. Filippi¹ |
¹MILAN, ITALY, ²BELGRADE, SERBIA, ³SAN GIOVANNI ROTONDO, ITALY

O 2227 Structural organisation of the brain
17:15 connectome in patients with psychogenic
dystonia

S. Basaia¹, F. Agosta¹, A. Tomic², E. Sarasso¹, M. Svetel²,
S. Galantucci¹, V.S. Kostic², M. Filippi¹ | ¹MILAN, ITALY, ²BELGRADE,
SERBIA

O 2228 Relationship between freezing and
17:30 pedunculopontine nucleus' size in Parkinson's
disease: semi quantitative analysis based on MRI with
modified FGATIR sequence

S. Chen, M. Tir, P. Monet, J.-M. Constans, O. Godefroy,
M. Lefranc, P. Krystkowiak | AMIENS, FRANCE

O 2229 An ongoing phase-2, open-label, study of
17:45 WTX101 in Wilson disease patients – early
observations

A. Czlonkowska¹, K.H. Weiss², A. Ala³, F. Askari⁴, D. Nicholl⁵,
M. Schilsky⁶ | ¹WARSAW, POLAND, ²HEIDELBERG, GERMANY,
³GUILDFORD, UK, ⁴ANN ARBOR, USA, ⁵BIRMINGHAM, UK, ⁶NEW HAVEN,
USA

O 2230 Phosphorilated alpha-synuclein cutaneous
18:00 deposits and cardiac autonomic involvement
in α-Synucleinopathies

M.P. Giannoccaro, V. Donadio, A. Incensi, E. Cason, R. Liguori
| BOLOGNA, ITALY

SUNDAY, 29 MAY 2016

POSTER SESSIONS

POSTER SESSION AGEING AND DEMENTIA 3

12:30-13:15 | SCREEN A2

CHAIRPERSONS:

Sandro Sorbi, FLORENCE, ITALY

P 21001 Incidence of dementia in patients suffering from depression and bipolar disorder

E. Giyazitdinova, B. Muinjonov, G. Rakhimbaeva, Y. Musaeva, F. Shermukhamedova | TASHKENT, UZBEKISTAN

P 21002 The use of benzodiazepines in the REMIND cohort: a cross-sectional study in elderly people with cognitive complaints

G. Grande, I. Tramacere, S. Pomati, C. Mariani, G. Filippini | MILAN, ITALY

P 21003 Assessing genetic risk factors for Alzheimer's disease in a Hungarian cohort

Z. Grosz, R. Bencsik, V. Reményi, D. Csaban, B. Sztatmari, M. J. Molnár | BUDAPEST, HUNGARY

P 21004 Abstract cancelled

P 21005 Clinical features of adult-onset neuronal intranuclear inclusion disease

Y. Harigaya¹, Y. Nakano², H. Hatsuta², M. Sato¹, K. Mizushima¹, S. Murayama² | ¹MAEBASHI, ²ITABASHI, JAPAN

P 21006 Data-driven differential diagnostics of neurodegenerative diseases

A. Tolonen¹, H. Rhodius-Meester³, M. Bruun⁴, M. Baroni⁵, J. Koikkalainen¹, F. Barkhof³, B. Tijms³, A. Lemstra³, T. Tong⁶, R. Guerrero⁶, A. Schuh⁶, C. Ledig⁶, D. Rueckert⁶, H. Soininen², A. Remes², G. Waldemar⁴, S. Hasselbalch⁴, P. Mecocci⁵, W. van der Flier³, J. Lötjönen¹ | ¹TAMPERE, ²KUOPIO, FINLAND, ³AMSTERDAM, THE NETHERLANDS, ⁴COPENHAGEN, DENMARK, ⁵PERUGIA, ITALY, ⁶LONDON, UK

P 21007 Improved fitness after aerobic exercise in patients with mild Alzheimer's disease

N. Sobol¹, S.G. Hasselbalch¹, C.H. Dall¹, P. Høgh², K. Hoffmann¹, K.S. Frederiksen¹, A. Vogel¹, V. Siersma¹, G. Waldemar¹, N. Beyer¹ | ¹COPENHAGEN, ²ROSILDE, DENMARK

P 21008 Epilepsy in Alzheimer's disease: a long-term EEG study

A. Horvath, G. Barcs, A. Szucs, A. Kamondi | BUDAPEST, HUNGARY

P 21009 Functional and structural brain alterations in two independent samples of patients with posterior cortical atrophy

F. Imperiale¹, F. Agosta¹, E. Canu¹, G. Mandic-Stojmenovic², G. Magnani¹, T. Stojkovic², F. Caso¹, E. Stefanova², G. Comi¹, V.S. Kostic², A. Falini¹, M. Filippi¹ | ¹MILAN, ITALY, ²BELGRADE, SERBIA

P 21010 Two times assessments on tap test for diagnosis of idiopathic normal pressure hydrocephalus

M. Ishikawa | KYOTO, JAPAN

P 21011 Regional differences in opioid use in elderly patients with dementia: a nationwide study

C.E.-A. Jensen-Dahm¹, J.K. Zakarias¹, C. Gasse², G. Waldemar¹ | ¹COPENHAGEN, ²AARHUS, DENMARK

P 21012 Abstract cancelled

P 21013 A robot as a caregiver? Expectations of patients with early dementia stages, caregivers and medical staff

A. Korchut¹, S. Szklener¹, K. Rejdak¹, C. Abdelnour Ruiz², N. Tantinyà³, J. Hernández³, J. Ribes³ | ¹LUBLIN, POLAND, ²MADRID, ³BARCELONA, SPAIN

POSTER SESSIONS CEREBROVASCULAR DISEASES 6

12:30-13:15 | SCREEN G4

CHAIRPERSON:

Didier Leys, LILLE, FRANCE

P 21014 Masked Mastoiditis' leading to saggital sinus thrombosis and 6th nerve palsy in an 8-year-old girl- a case report

M. Hira, C. Ramesh | WATFORD, UK

P 21015 Syncope and transient ischemic attack due to severe orthostatic hypotension after carotid endarterectomy: a case report

C. Hirel, A. Le Roux, A. Girbovan, F. Pico | VERSAILLES, FRANCE

P 21016 Endovascular treatment of a patient with multiple, symptomatic, unruptured intracranial aneurysms of anterior and posterior cerebral circulation: a case report

I. Hustić, T. Breitenfeld, V. Kalousek, B. Culo, V. Supanc, M. Roje Bedekovic, V. Vargek Solter, V. Basic Kes | ZAGREB, CROATIA

SUNDAY, 29 MAY

12:30 - 13:15

P 21017 CRP as a predictor of the size of ischemic brain lesions among diabetic patients

D. Imamovic, E. Suljic, N. Subasic, A. Nakicevic, A. Mehicevic | SARAJEVO, BOSNIA AND HERZEGOVINA

P 21018 Does the proportion of single-chain rtPA influence the risk of epileptic seizures in patients treated by thrombolytic therapy for cerebral ischemia?

C. Jacquet¹, D. Leys¹, I. Sibon², J.-L. Mas³, T. Moulin⁴, M. Giroud⁵, R. Bordet¹, D. Vivien⁶ | ¹LILLE, ²BORDEAUX, ³PARIS, ⁴BESANÇON, ⁵DIJON, ⁶CAEN, FRANCE

P 21019 Translocator protein dynamics in recovering stroke patients: A longitudinal [123I]CLINDE-SPECT imaging study.

P. Jensen, L. Feng, G. Thomsen, L.V. Knudsen, P. Meden, H. Steglich-Arnholm, C. Thomsen, A. Dyssegaard, K. Møller, C. Svarer, V. Beliveau, J.D. Mikkelsen, G.M. Knudsen, L.H. Pinborg | COPENHAGEN, DENMARK

P 21020 CBV-ASPECTS score as a predictor of final infarct core in acute ischemic stroke

J. Jesus Ribeiro, I. Correia, A.I. Martins, O. Galego, M. Baptista, A. Gouveia, J. Sargento Freitas, F. Silva, B. Rodrigues, C. Machado, G. Cordeiro, L. Cunha | COIMBRA, PORTUGAL

P 21021 Giant cell arteritis with eye involvement - clinical and color doppler imaging of orbital vessels features

D.C. Jianu, S.N. Jianu, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21022 Clinical and ultrasonographic features in anterior ischemic optic neuropathies

D.C. Jianu, S.N. Jianu, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21023 Clinical and neuroimaging features in emissary vein thrombosis

D.C. Jianu, S.N. Jianu, D. Matcau, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21024 Indirect carotid-cavernous fistula of low-flow type: Color Doppler imaging of retrobulbar vessels feature

D.C. Jianu, S.N. Jianu, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21025 Cryptogenic stroke in atrial fibrillation: The Nordic Atrial Fibrillation and Stroke Study (NOR-FIB)

H. Johansen¹, A.H. Aamodt¹, B. Ratajczak-Tretel², D. Atar¹, B. Halvorsen¹, H. Næss³, H. Tobro⁴, W. Ghanima², T. Idicula⁵, K.L. Aegidius⁶, T. Truelsen⁷, D. Russell¹ | ¹OSLO, ²FREDRIKSTAD, ³BERGEN, ⁴SKIEN, ⁵TRONDHEIM, NORWAY, ⁶COPENHAGEN, DENMARK, ⁷GENEVA, SWITZERLAND

P 21026 Cardioembolic stroke long-term outcome in Latvia

K. Jurjans, E. Miglane, B. Lurina, A. Millers, O. Kalejs, Z. Priede | RIGA, LATVIA

P 21027 Cardioembolic stroke prevention and mortality for elderly patients in Latvia

K. Jurjans, E. Miglane, B. Lurina, O. Kalejs, A. Millers, Z. Priede | RIGA, LATVIA

POSTER SESSION
CEREBROVASCULAR DISEASES 7

12:30-13:15 | SCREEN G3

CHAIRPERSON:

Caroline Renner, LEIPZIG, GERMANY

P 21028 Eagle syndrome with bilateral internal carotid artery dissection

K. Krbot, C. Gaebel, J.M. Valdeza | BAD SEGEBERG, GERMANY

P 21029 Abstract cancelled

P 21030 Elaboration of new prognostic model for ultraearly predicting of spontaneous hemorrhagic transformation of cerebral infarct in patients with acute ischemic supratentorial stroke

O. Kozyolkin, A. Kuznietsov | ZAPOROZHYE, UKRAINE

P 21031 New multivariate prognostic model for predicting early lethal outcome after acute ischemic supratentorial stroke

O. Kozyolkin, A. Kuznietsov | ZAPOROZHYE, UKRAINE

P 21032 More severe cerebral white matter changes are associated with elevated blood pressure in acute ischemic stroke - preliminary results

M. Kwarciany, D. Gasecki, K. Kowalczyk, T. Nowicki, E. Szurowska, K. Narkiewicz, B. Karaszewski | GDAŃSK, POLAND

P 21033 Prevalence of high on-treatment platelet reactivity to acetylsalicylic acid used in the prevention of stroke in patients with chronic renal failure

B. Labuz-Roszak, M. Horyniecki, B. Lacka-Gazdzik, M. Snit, B. Mazur, K. Pierzchala | ZABRZE, POLAND

P 21034 Capsular warning syndrome: blood pressure matters

F. Ladeira, S. Calado, M. Viana-Baptista | LISBON, PORTUGAL

P 21035 Buddy wire technique: a simple technique for treatment tortuous cervical ICA during CAS

S.-W. Lee¹, S.-G. Baik², Y. Kim², G.-S. Song² | ¹YANGSAN-SI, ²YANGSAN, KOREA, REPUBLIC OF

P 21036 Urgent stent-assisted angioplasty for severe intracranial atherosclerosis in patients with transient ischemic attack or minor stroke

T. H. Lee, S.M. Sung, S.W. Lee | BUSAN, KOREA, REPUBLIC OF

P 21037 Validation of the French version of the Stroke Specific Quality of Life scale (SS-QOL)

N. Legris, A. Daumas, H. Devilliers, B. Daubail, B. Lucas, M. Giroud, Y. Béjot | DIJON, FRANCE

P 21038 Cerebral venous thrombosis: retrospective analysis of cases from tertiary hospitals in Hong Kong

T.C. Li, Y.F. Cheung, W.C. Fong | HKSAR, CHINA

P 21039 Different strokes in younger folks: defining the causes of stroke in people under 45 years

A. Lockhart, R. O'connor, I. Noone, N. Tubridy, S. O'riordan, C. Mc Guigan | DUBLIN, IRELAND

P 21040 Determinants of adherence to oral anticoagulants in patients with atrial fibrillation and stroke

A. Polymeris, C. Traenka, L. Hert, D.J. Seiffge, N. Peters, G.M. de Marchis, L. Bonati, P.A. Lyrer, S.T. Engelter | BASEL, SWITZERLAND

P 21041 Intracerebral hemorrhage in an adult with Down syndrome and MoyaMoya disease

J.P. Marto, C. Borbinha, S. Calado, M. Viana-Baptista | LISBON, PORTUGAL

P 21042 Auditory evoked potentials in patients with posterior circulation stroke and vertebral artery hypoplasia

B. Zivadinovic, J. Stamenovic, B. Bisevac | NICE, SERBIA

POSTER SESSION COGNITIVE NEUROLOGY/ NEUROPSYCHOLOGY 2

12:30-13:15 | SCREEN A3

CHAIRPERSONS:

Thomas Bak, EDINBURGH, UK (TBC)

P 21043 Long lasting neuropsychological deficits in patients with Transient Global Amnesia (TGA)

S. Fragkiadaki, D. Kontaxopoulou, I. Beratis, S. Triantafyllou, M. Ioakeimidis, G. Papadimitropoulos, A. Bonakis, K. Voumvourakis, L. Stefanis, G. Tsivgoulis, S.G. Papageorgiou | ATHENS, GREECE

P 21044 Could ambulatory blood pressure monitoring be a routine investigation for patients with mild cognitive impairment?

M. Hamdy | CAIRO, EGYPT

P 21045 Mortality and functional disability of post-stroke delirium

Z. Dostovic, E. Dostovic, D. Smajlovic, O.C. Ibrahimagic, E. Becirovic | TUZLA, BOSNIA AND HERZEGOVINA

P 21046 Incidental vs. intentional memory in patients with Parkinson's disease (PD)

D. Kontaxopoulou, S. Fragkiadaki, I. Beratis, D. Pavlou, N. Andronas, A. Economou, L. Stefanis, M. Stamelou, S.G. Papageorgiou | ATHENS, GREECE

P 21047 Scopolamine disrupts place navigation in rats and humans

J. Laczó¹, H. Marková², V. Lobellová², I. Gazova², M. Pařížková², J. Cerman², J. Harrison³, M. Windisch⁴, J. Hort¹, A. Stuchlík² | ¹BRNO, ²PRAGUE, CZECH REPUBLIC, ³LONDON, UK, ⁴ST. RADEGUND/GRAZ, AUSTRIA

P 21048 Short Montreal Cognitive Assessment (s-MOCA): diagnostic accuracy study

A.J. Larner | LIVERPOOL, UK

P 21049 Young-onset cognitive decline: not always variant Creutzfeldt-Jakob disease

J. Williamson, A.J. Larner | LIVERPOOL, UK

P 21050 Abstract cancelled

P 21051 Fatigue defined in the context of CNS thermoregulation

R. Mills¹, C. Young² | ¹PRESTON, ²LIVERPOOL, UK

SUNDAY, 29 MAY

12:30 - 13:15

P 21052 High prevalence of cognitive impairment in Slovenian patients with diabetes mellitus type 2 (DM2)
L. Mumelj, M. Rakusa, M. Cokolic, A. Zavrtnik, M. Rakusa | MARIBOR, SLOVENIA

P 21053 Relation of hypertension and depression-executive dysfunction syndrom in hypertensive stroke patients
L. Mumladze, N. Lobjanidze, N. Akiashvili | TBILISI, GEORGIA

P 21054 The assessment of cognitive and mood disturbances in patients with Parkinson's disease without dementia
M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, N.G. Brazovskaya, O.P. Izhboldina, J.S. Mironova, A.V. Latypova, M.A. Titova, S.E. Sukhanov | TOMSK, RUSSIAN FEDERATION

P 21055 Deep phenotyping of Frontotemporal Dementia (FTD) and FTD-MND in Ireland (A clinic-based cohort longitudinal study)
T.A. Omer, S. Hutchinson, C. Doherty, O. Hardiman | DUBLIN, IRELAND

POSTER SESSION EPILEPSY 4

12:30-13:15 | SCREEN B2

CHAIRPERSONS:

Leone Ridsdale, LONDON, UK

P 21056 Ictal whistling: a manifestation of frontal discharge
J. El Helou, S. Abbas, S. Koussa | BEIRUT, LEBANON

P 21057 West Syndrome in Latvia (2004-2014)
L. Liepina | RIGA, LATVIA

P 21058 Abstract cancelled

P 21059 Double therapy in partial epilepsy: lamotrigine and levetiracetam
Z. Luciano-García, V. Hernando-Requejo, N. Huertas-González | MADRID, SPAIN

P 21060 Abstract cancelled

P 21061 Olfactory auras in patients with temporal lobe epilepsy
R. Manso Calderón | SALAMANCA, SPAIN

P 21062 Emotional affective disorders in elderly patients with post-stroke epilepsy
A. Druzhinin, V. Mikhailov, M. Kissin | SANKT-PETERSBURG, RUSSIAN FEDERATION

P 21063 Neurophysiological features of the pathogenesis of epilepsy in the elderly
V. Mikhailov, A. Druzhinin, A.L. Gorelyk | SANKT-PETERSBURG, RUSSIAN FEDERATION

P 21064 Online epilepsy counseling in Croatia: what do the users want to know?
M. Milosevic, L. Friedrich, I. Bielen, S. Tomasović | ZAGREB, CROATIA

P 21065 Nocebo in epilepsy: meta-analysis of placebo-controlled clinical trials
P. Zis¹, F. Shafiq¹, D. Mitsikostas² | ¹SHEFFIELD, UK, ²ATHENS, GREECE

P 21066 Focal epilepsy with occipital calcifications as a late presentation of a silent coeliac disease: clinical, radiological and electroencephalographic findings of two patients

E. Monreal, A. Escobar-Villalba, C. Anciones-Martin, Í. Corral, L. Peña-Jaimes, C. Estevez-Fraga, A. Gil-Nagel, R. Toledano | MADRID, SPAIN

P 21067 First real-life experience with Perampanel in primary generalized epilepsies

J. Montoya, A. Arciniegas, J. Escriba, B. Hoyo | XATIVA, SPAIN

P 21068 I am not alone: epilepsy self-management education and support in groups

L. Ridsdale, S. Philpott, A.-M. Krooupa, M. Morgan | LONDON, UK

POSTER SESSION HEADACHE AND PAIN 3

12:30-13:15 | SCREEN C1

CHAIRPERSONS:

Mads Barløese, COPENHAGEN, DENMARK

P 21069 Recurrent state of confusion during presentation of HaNDL syndrome: report of two cases and review of the literature

T. Bourinaris, T. Kalantzakou, G. Xiromerisiou, K. Katsiardanis, P. Petrou, X. Fitsioris, G. Deretzi | THESSALONIKI, GREECE

P 21070 Interim analysis from the long-term study of the real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine (REPOSE Study)

F. Ahmed¹, J. Pascual³, H. Geevarghese², S. Brown² | ¹ELLOUGHTON, ²MARLOW, BUCKINGHAMSHIRE, UK, ³SANTANDER, SPAIN

P 21071 A rare case of bilateral cluster headache - initially left sided cluster headache changing to a right sided cluster headache and subsequently to bilateral cluster headache

A. Buture, R. Nimeri, M. Hussain, F. Ahmed | HULL, UK

P 21072 Pain paroxysms with coronal radiation: proposal of a new variant of epicrania fugax

J. Casas¹, M.L. Cuadrado¹, M. Ruiz Piñero², E. Martínez², Á. Gutiérrez-Viedma¹, C. Ordás-Bandera³, A.L. Guerrero² | ¹MADRID, ²VALLADOLID, ³MOSTOLES, SPAIN

P 21073 A novel ATP1A2 mutation in a familial hemiplegic migraine with cognitive impairment

C. Chagot¹, S. Frismand¹, F. Riant², E. Tournier-Lasserre², L. Tyvaert¹ | ¹NANCY, ²PARIS, FRANCE

P 21074 Abstract cancelled

P 21075 Internal jugular vein thrombosis in a patient with cranial venolymphatic malformation and ocular migraine

A. Ciobotaru, A.C. Mergeani, O. Rusu, F. Antochi, B. Dorobat, C. Coclitu, A. Dimitriade, O. Bajenaru | BUCHAREST, ROMANIA

P 21076 Headache as isolate symptom in a case of extensive cerebral veins thrombosis

L.-H. Cioriceanu¹, M.R. Mărceanu¹, C. Baetu², M.G. Giurea Neacsu² | ¹BRASOV, ²BUCHAREST, ROMANIA

P 21077 Case report of nummular headache attributed to Langerhans cells histiocytosis. Is there evidence of a peripheral mechanism?

B. Colombo¹, G. Magnani¹, S. Guerrieri¹, V. Martinelli², G. Comi | ¹MILAN, ²ALME, ITALY

P 21078 Validating the English version of the Comprehensive Headache-related Quality of Life Questionnaire (CHQQ): first results

E. Csepany, K. Haslum, M. Magyar, T. Gyüre, C. Ertsey | BUDAPEST, HUNGARY

P 21079 Post-dural puncture headache and other complications following intrathecal chemotherapy administration

P. de la Riva¹, N. Andrés¹, N. Gonzalo², M. Tainta-Cuevas¹, M.A. Urtasun¹, J.F. Martí-Massó¹ | ¹SAN SEBASTIAN, SPAIN, ²RANKWEIL, GERMANY

P 21080 Migraneous aura phenomenon is not subtended by microstructural changes in visual brain areas: a diffusion tensor tract-based spatial statistic (TBSS) study

A. de Mase, A. Russo, F. Conte, L. Marcuccio, D. Corbo, G. Caiazzo, A. Giordano, R. Conforti, F. Esposito, G. Tedeschi, A. Tessitore | NAPLES, ITALY

P 21081 „Neural-Focusing”: a hybrid supportive therapy in the treatment of chronic cluster migraine: a case report

G. Dore¹, M. D'onofrio² | ¹ITTIRI, ²SASSARI, ITALY

P 21082 Headache related behaviours in population groups at high risk in Slovenia

M. Zaletel, L. Zadravec-Zaletel, J. Pretnar-Oblak, L. Zaletel-Kragelj | LJUBLJANA, SLOVENIA

SUNDAY, 29 MAY

12:30 - 13:15

POSTER SESSION MOTOR NEURONE DISEASES 1

12:30-13:15 | SCREEN C2

CHAIRPERSON:

Vincenzo Donadio, BOLOGNA, ITALY

P 21083 Riboflavin transporter neuronopathy (RTN) is a rare but treatable adult onset motor neuron disease that may mimic ALS: report of two cases

C. Benoit¹, T. Lenglet¹, C. Acquaviva², A. Veauville Merlin², F. Salachas¹, M.D.M. Amador¹, Y. Nadjar¹ | ¹PARIS, ²BRON,

FRANCE

P 21084 Cognitive and behavioral disorders in patients with familial and sporadic amyotrophic lateral sclerosis: clinical, genetic and radiological features

E. Bersano, F. de Marchi, I. Viganò, M.F. Sarnelli, L. Corrado, F. Palermo, V. Solara, S. D'alfonso, R. Cantello, L. Mazzini |

NOVARA, ITALY

P 21085 Amyotrophic Lateral Sclerosis and oxidative stress: a double-blind trial after dietary curcumin supplement

C. Bisordi, M. Rossi, E. Caldarazzo Ienco, M. Fabbrini, F. Agricola, L. Chico, A. Lo Gerfo, G. Siciliano | PISA, ITALY

P 21086 Abstract cancelled

P 21087 Acute onset Hirayama disease with extensive myelopathy on spinal cord MRI in flexed posture, illustrating a mechanical pathophysiology

M. Brems¹, B. Willekens², J. Baets³, J. van Goethem³,

M. de Praeter³ | ¹MECHELEN, ²EDEGEM, ³ANTWERP, BELGIUM

P 21088 Investigating resilience in caregivers of patients with Amyotrophic Lateral sclerosis.

T. Burke¹, M. Elamin², M. Galvin¹, L. Gallagher¹, O. Hardiman¹, N. Pender¹ | ¹DUBLIN, IRELAND, ²EDINBURGH, UK

P 21089 Do hypermetabolic Amyotrophic Lateral Sclerosis (ALS) patients have different clinical and survivorship patterns as compared to non-hypermetabolic patients?

P. Jesus, B. Marin, P. Fayemendy, M. Nicol, P.-M. Preux, P. Couratier, J.-C. Desport | LIMOGES, FRANCE

P 21090 Obsessive Compulsive Disorder as the initial presentation of Motor Neuron Disease/Frontotemporal Dementia: a case report.

F. de Marchi, E. Bersano, M.F. Sarnelli, I. Viganò, V. Solara, R. Cantello, L. Mazzini | NOVARA, ITALY

P 21091 Magnetic resonance measures of subcortical and cortical gray matter in amyotrophic lateral sclerosis

E. Distaso, D.M. Mezzapesa, E. D'errico, R. Cortese, A. Scarafino, A. Introna, I. Tempesta, F. Federico,

F. Dicuonzo, I.L. Simone | BARI, ITALY

P 21092 Serum Adiponectin alterations in Amyotrophic Lateral Sclerosis and frontotemporal dementia

A. Doretto, P. Bossolasco, R. Canello, C. Morelli, V. Silani, L. Cova | MILAN, ITALY

P 21093 Permutation entropy helps to distinguish EMG curve in axonal polyneuropathy

O. Dostal¹, O. Vyšata¹, P. Kunc¹, M. Valis¹, A. Procházka², J. Kuchynka¹ | ¹HRADEC KRÁLOVÉ, ²PRAGUE, CZECH REPUBLIC

P 21094 Targeting SOD1 with Morpholino for Amyotrophic Lateral Sclerosis treatment

I. Faravelli, C. Simone, F. Rizzo, G. Ulzi, A. Ramirez, M. Bucchia, A. Bordoni, N. Bresolin, G.P. Comi, S. Corti, M. Nizzardo | MILAN, ITALY

P 21095 TDP-43 is cytoplasmically mislocalised and associated with impaired stress responses and survival of primary neurons from symptomatic amyotrophic lateral sclerosis (ALS) mice

L. Farrimond, D. Gordon, R. Mutihac, J. Alegre-Abarrategui, B. Davies, O. Ansorge, R. Wade-Martins, K. Talbot | OXFORD, UK

POSTER SESSION MOVEMENT DISORDERS 4

12:30-13:15 | SCREEN E4

CHAIRPERSON:

Joaquim Ferreira, LISBON, PORTUGAL

P 21096 Abstract cancelled

P 21097 Is head tremor a sub-group of essential tremor?

B. Emmanuelle, T. Witjas, R. Carron, J. Regis, J.-P. Azulay, E. Guedj, M. Vaugoyeau | MARSEILLES, FRANCE

P 21098 Phenomenology and therapeutic strategies in a series of patients with chorea-acanthocytosis

C. Estevez-Fraga¹, M. Matarazzo¹, A. Minguez², R. Rigual¹, P. Garcia-Ruiz¹, L. Vela¹, M.C. Rodriguez-Oroz³, R. Luquin², M. Carmona-Abellan², I. Posadas¹, M.M. Kurtis¹, J. García de Yébenes¹, J.C. Martínez-Castrillo¹,

J.L. Lopez-Sendon¹ | ¹MADRID, ²PAMPLONA, ³SAN SEBASTIÁN, SPAIN

P 21099 Amphetamine-induced dyskinesias

C. Estevez-Fraga, R. Alvarez-Velasco, E. Viedma-Guiard, P. Agüero-Rabes, L. Crespo-Araico, S. García-Madrona, J. Martínez, J. Buisan, J.C. Martínez-Castrillo, A. Alonso-Canovas | MADRID, SPAIN

P 21100 Switch of double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I

J. Ferreira¹, A. Lees³, E. Tolosa⁴, W. Poewe⁵, M. Banach⁶, A. Santos², N. Lopes², J.F. Rocha², P. Soares-Da-Silva²ⁱ
¹LISBON, ²CORONADO (S. ROMÃO E S. MAMEDE), PORTUGAL, ³LONDON, UK, ⁴BARCELONA, SPAIN, ⁵INNSBRUCK, AUSTRIA, ⁶CRACOW, POLAND

P 21101 Parkinsonism due to GPi-DBS for cervical dystonia

D. Flisar, M. Trost, N. Zupancic Kriznar, M. Kramberger Gregoric, B. Meglic, Z. Pirtosek | LJUBLJANA, SLOVENIA

P 21102 Accelerometric assessment of movements in Parkinson's disease fluctuators

D. Flisar, B. Pikš, R. Berlot, J. Dreo, M. Kramberger Gregoric, M. Trost, N. Zupancic Kriznar, B. Meglic, Z. Pirtosek | LJUBLJANA, SLOVENIA

P 21103 Pathological features of iPSC-derived midbrain dopaminergic neurons of familial Parkinson's disease

E. Frattini, G. Monzio Compagnoni, S. Salani, N. Bresolin, G.P. Comi, S. Corti, A. Di Fonzo | MILAN, ITALY

P 21104 Cortical thinning associated with mild cognitive impairment in Parkinson's disease

S. Galantucci¹, F. Agosta¹, T. Stojkovic³, I. Petrovic³, E. Stefanova³, E. Canu¹, M. Copetti², V.S. Kostic³, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ITALY, ³BELGRADE, SERBIA

P 21105 Functional connectome organisation is altered in PD patients with mild cognitive impairment

S. Galantucci¹, F. Agosta¹, T. Stojkovic², S. Basaia¹, I. Stankovic², E. Stefanova², V.S. Kostic², M. Filippi¹ | ¹MILAN, ITALY, ²BELGRADE, SERBIA

P 21106 Features of speech in neurodegenerative diseases revealed by cepstral analysis

I. Goursky, S. Likhachev, T. Charnukha, Y. Rushkevich | IMINSK, BELARUS

P 21107 Volumetric and DTI study of the Corpus Callosum in pure Hereditary Spastic Paraplegia

F.J. Navas-Sánchez¹, Y. Alemán-Gómez¹, J.A. Guzmán-de-Villoria¹, L. Lillo¹, I. Catalina¹, J.L. Muñoz Blanco¹, M.-J. Sobrido², M. Desco¹, F.J. Grandas Pérez¹ | ¹MADRID, ²SANTIAGO DE COMPOSTELA, SPAIN

P 21108 Turkish version Quality Of Life In Essential Tremor Questionnaire (Quest): Validity And Reliability study

S. Güler, F. N. Turan | ADRIANOPLE, TURKEY

POSTER SESSION
MS AND RELATED DISORDERS 6

12:30-13:15 | SCREEN F1

CHAIRPERSON:

Bruno Stankoff, PARIS, FRANCE

P 21109 Four-year longitudinal index stability data from the STRATIFY-2 study

D. Campagnolo, P.-R. Ho, R. Patel, I. Chang, M. Subramanyam, H. Koendgen, G. Kuesters, N. Campbell | CAMBRIDGE, USA

P 21110 Modelling Uhthoff's phenomenon: warmer outdoor temperatures might not be enough for causing a decay in cognitive functionality in Multiple Sclerosis patients

J.M. Cañete-Valdeón | SEVILLE, SPAIN

P 21111 Characterisation of microvesicles release and gene expression profile in monocytes of patients with relapsing-remitting multiple sclerosis: preliminary results of a longitudinal study

T. Carandini, A. Finardi, L. Garzetti, L. Moiola, G. Comi, V. Martinelli, R. Furlan | MILAN, ITALY

P 21112 The interplay of communicative and cognitive impairment in multiple sclerosis: look behind the door, not through the keyhole

A. Carotenuto¹, G. Orefice¹, I. Cerillo¹, V. Giannino¹, M. Rasulo¹, G. Arcara², V. Bambini², R. Iodice¹ | ¹NAPLES, ²PAVIA, ITALY

P 21113 Growth Hormone/IGF-I function in CIS patients is not associated MS conversion in Interferon beta-1b therapy.

R. Lanzillo, A. Carotenuto, C. Di Somma, M. Quarantelli, M. Moccia, A. Cianflone, A. Marsili, G. Puorro, G. Sasso, C. Pivonello, C.V. Russo, A. Colao, V. Brescia Morra | NAPLES, ITALY

P 21114 Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and glatiramer acetate in multiple sclerosis patients

A. Chan¹, G. Cutter², R. Fox³, A. Zhang⁴, J. Xiao⁴, J. Lewin⁴, M. Edwards⁴, J. Marantz⁴ | ¹BOCHUM, GERMANY, ²BIRMINGHAM, ALABAMA, ³CLEVELAND, OHIO, ⁴CAMBRIDGE, MASSACHUSETTS, USA

SUNDAY, 29 MAY

12:30 - 13:15

P 21115 Adherence to subcutaneous interferon beta-1a in patients participating in the RebiSTAR® patient service program: interim analysis of the non-interventional study RebiSTART

A. Chan¹, J. Faiss², S. Schmidt³, A.-K. Eser⁴, T. Wagner⁵, E. Schel⁵, I.-K. Penner⁶ | ¹BERNE, SWITZERLAND, ²TEUPITZ, ³BONN, ⁴DEGGENDORF, ⁵DARMSTADT, ⁶DÜSSELDORF, GERMANY

P 21116 Relationship between 25-hydroxyvitamin D levels and Multiple Sclerosis disability

J.R. Chaudhri, S. Alladi, K. Mridula, B. Balaraju, V.S. Bandaru | HYDERABAD, INDIA

P 21117 Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β -1a-controlled studies

F. Lublin¹, D. Arnold⁴, A. Bar-*or*⁴, G. Comi⁵, H.-P. Hartung⁶, S. Hauser², K. Selmaj⁷, A. Traboulsee⁸, P. Chin³, P. Fontoura⁹, H. Garren⁹, G. Klingelschmitt⁹, D. Masterman³, L. Kappos⁹ | ¹NEW YORK, ²SAN FRANCISCO, ³SOUTH SAN FRANCISCO, USA, ⁴MONTREAL, CANADA, ⁵MILAN, ITALY, ⁶DÜSSELDORF, GERMANY, ⁷LODZ, POLAND, ⁸VANCOUVER, CANADA, ⁹BASEL, SWITZERLAND

P 21118 Hospital admissions due to infections in a cohort of multiple sclerosis patients

A. Costa, A. Silva-Pinto, R. Serrão, A. Sarmento, M.J. Sá, P. Abreu | PORTO, PORTUGAL

P 21119 Real life experience with Tecfidera treatment in relapsing remitting multiple sclerosis

S. Vijayarangam Shanmugam, O. Cousins, J. Wilton, Y. Leung, A. Edwards, D. Wren, M. Craner | LONDON, UK

P 21120 Combined use of kappa free light chain index and isoelectrofocusing of cerebrospinal fluid in diagnosing Multiple Sclerosis: performances and costs

I. Crespi, M.G. Sulas, R. Mora, P. Naldi, D. Vecchio, C. Comi, R. Cantello, G. Bellomo | NOVARA, ITALY

P 21121 Pharmacokinetic and safety study of GNBAC1, a humanised monoclonal antibody for multiple sclerosis

H. Porchet, A. Lang, F. Curtin | GENEVA, SWITZERLAND

POSTER SESSION MS AND RELATED DISORDERS 7

12:30-13:15 | SCREEN F2

CHAIRPERSON:

Xavier Montalban, BARCELONA, SPAIN

P 21122 Comparison of azathioprine and of beta interferon efficacy on measures of brain damage evaluated by MRI in relapsing-remitting multiple sclerosis.

L. Massacesi¹, M. Grammatico¹, L. Vuolo¹, A. Barilaro¹, M.D. Benedetti², L. La Mantia³, C. Milanese³, A.M. Repice¹, A. Solari³, G. Tedeschi⁴, G. Filippini³ | ¹FLORENCE, ²VERONA, ³MILAN, ⁴NAPLES, ITALY

P 21123 CSF and serum levels of interleukin 8 and its correlation with other CSF markers

Z. Matejckova, J. Mares, V. Sladkova, T. Svrncinova, P. Kanovsky | OLOMOUC, CZECH REPUBLIC

P 21124 Using a multidimensional unfolding approach to assess patient preferences for disease modifying therapies in multiple sclerosis

V. Vera-Lopez¹, A.P. Sempere², E. Ruiz-Beato³, J. Gimenez-Martinez², J. Cuervo⁴, J. Maurino³ | ¹SALAMANCA, ²ALICANTE, ³MADRID, ⁴OVIEDO, SPAIN

P 21125 Abstract cancelled

P 21126 Persistent herpetic infection and multiple sclerosis activity. Is there an association?

V. Megeryan, Z. Goncharova | ROSTOV-ON-DON, RUSSIAN FEDERATION

P 21127 Fingolimod every-other-day in Multiple Sclerosis patients who presented severe adverse events during conventional Fingolimod treatment

A. Merlini¹, C. Zecca⁵, G. Disanto⁵, L. Panicari⁵, M. Rodegher¹, M. Romeo¹, M.J. Messina¹, L. Moiola¹, C. Stefanin², A. Ghezzi², P. Perrone³, F. Patti⁴, G. Comi¹, C. Gobbi⁵, V. Martinelli¹ | ¹MILAN, ²GALLARATE, ³LEGNANO, ⁴CATANIA, ITALY, ⁵LUGANO, SWITZERLAND

P 21128 A Phase III, open-label study to evaluate the effect of ocrelizumab on immune responses in patients with relapsing MS

L. Millar, C. Li, H. Bennett, H. Garren | BASEL, SWITZERLAND

P 21129 The 10-year economic burden for multiple sclerosis treatment

M. Moccia, R. Palladino, R. Lanzillo, M. Triassi,
V. Brescia Morra | NAPLES, ITALY

P 21130 Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis

M. Moccia, R. Palladino, A. Carotenuto, C.V. Russo, M. Triassi,
R. Lanzillo, V. Brescia Morra | NAPLES, ITALY

P 21131 Full recovery of retinal periphlebitis in a multiple sclerosis patient after Natalizumab

M. Molina Sanchez, M.B. Gorroño-Echebarria,
M.H. Torregrosa Martinez, P. Hernández Navarro,
L. Ayuso Peralta | MADRID, SPAIN

P 21132 Safety and tolerability of cladribine tablets added to IFN-beta therapy in patients with active relapsing multiple sclerosis: final results from the ONWARD study (amended protocol)

X. Montalban¹, B. Cohen², T. Leist³, H. Moses⁴, C. Hicking⁶,
F. Dangond⁵ | ¹BARCELONA, SPAIN, ²CHICAGO, ³PHILADELPHIA,
⁴NASHVILLE, ⁵BILLERICA, USA, ⁶DARMSTADT, GERMANY

P 21133 Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS)

X. Montalban¹, D. Arnold², A. Bar-or², J. de Seze³,
G. Giovannoni⁴, B. Hemmer⁵, K. Rammohan⁶, N. Mairon⁹,
P. Chin⁷, P. Fontoura⁹, H. Garren⁹, D. Masterman⁷,
A. Sauter⁹, J. Wolinsky⁸ | ¹BARCELONA, SPAIN, ²MONTREAL,
CANADA, ³STRASBOURG, FRANCE, ⁴LONDON, UK, ⁵MUNICH, GERMANY,
⁶MIAMI, ⁷SOUTH SAN FRANCISCO, ⁸HOUSTON, USA, ⁹BASEL,
SWITZERLAND

P 21133 Pulmonary eosinophilia associated to Natalizumab treatment

A. Moreira Villanueva, E. Munteis Oliva,
M. Domínguez Álvarez, A. Zabalza de Torres,
E. Curto Sánchez, J. Roquer González | BARCELONA, SPAIN

POSTER SESSION
MS AND RELATED DISORDERS 8

12:30-13:15 | SCREEN F3

CHAIRPERSON:

Tjaef Ziemssen, DRESDEN, GERMANY

P 21135 Long-term clinical outcome of multiple sclerosis patients with initial spinal cord involvement

B.I. Tiftikcioglu, I. Ilgezdi, Y. Zorlu, U. Sener, F. Tokucoglu |
IZMIR, TURKEY

P 21136 Epidemiology of familial cases of multiple sclerosis in Tomsk region, Russian Federation

M. Titova, I. Zhukova, M.A. Nikitina, V.M. Alifirova, E. Terskikh,
A. Siomkina, Y. Shevtsova, J. Mironova | TOMSK, RUSSIAN
FEDERATION

P 21137 Confirmed progressive multifocal Leucoencephalopathy associated to Natalizumab treatment despite negative CSF and clinical findings

C. Tiu, C. Gavan, L. Tatu, A. Marinescu, O. Bajenaru |
BUCHAREST, ROMANIA

P 21138 Repetitive transcranial magnetic stimulation in the treatment of multiple sclerosis

V. Todorov¹, V. Stoyanova¹, S. Ivanova¹, D. Bogdanova¹,
G. Radevski², D. Georgiev¹, K. Kmetska¹, E. Milushev¹,
I. Milanov¹ | ¹SOFIA, ²STARAZAGORA, BULGARIA

P 21139 MRI parameters as predictors of long-term disease outcome over 8 years in RRMS patients

D. Jeffery¹, D. Piani Meier³, D. Tomic³, D. Häring³, T. Vollmer² |
¹MOORESVILLE, NC, ²DENVER, CO, USA, ³BASEL, SWITZERLAND

P 21140 Fingolimod effects on PASAT scores in RRMS and relation of patient characteristics to PASAT

D. Langdon¹, I.-K. Penner², P. Calabrese³, G. Cutter⁴, D.
Häring³, F. Dahlke³, D. Tomic³, L. Kappos³ | ¹LONDON, UK,
²DÜSSELDORF, GERMANY, ³BASEL, SWITZERLAND, ⁴BIRMINGHAM,
ALABAMA, USA

P 21141 Morphological peculiarities of peripheral nervous system in multiple sclerosis

O. Markovska, A. Shapkin, O. Tovazhnyanska, N. Nekrasova |
KHARKIV, UKRAINE

P 21142 4 years PANGAEA: long-term data on effectiveness and safety from patients on natalizumab switching to fingolimod in real world

T. Ziemssen¹, H. Albrecht², J. Haas³, L. Klotz⁴, M. Lang⁵,
C. Lassek⁶, S. Schmidt⁷, B. Tackenberg⁸, C. Cornelissen⁹
| ¹DRESDEN, ²MUNICH, ³BERLIN, ⁴MÜNSTER, ⁵ULM, ⁶KASSEL, ⁷BONN,
⁸MARBURG, ⁹NUREMBERG, GERMANY

SUNDAY, 29 MAY

12:30 - 13:15

P 21143 4 years safety of fingolimod in real world: PANGAEA, a non-interventional study of safety, effectiveness and pharmaco-economic data for fingolimod patients in daily clinical practice

T. Ziemssen¹, H. Albrecht², J. Haas³, L. Klotz⁴, M. Lang⁵, C. Lassek⁶, S. Schmidt⁷, B. Tackenberg⁸, C. Cornelissen⁹
¹DRESDEN, ²MUNICH, ³BERLIN, ⁴MÜNSTER, ⁵ULM, ⁶KASSEL, ⁷BONN, ⁸MARBURG, ⁹NUREMBERG, GERMANY

P 21144 4 years PANGAEA: A 5-year non-interventional study of safety, effectiveness and pharmaco-economic data for fingolimod patients in daily clinical practice – effectiveness update

T. Ziemssen¹, H. Albrecht², J. Haas³, L. Klotz⁴, M. Lang⁵, C. Lassek⁶, S. Schmidt⁷, B. Tackenberg⁸, C. Cornelissen⁹
¹DRESDEN, ²MUNICH, ³BERLIN, ⁴MÜNSTER, ⁵ULM, ⁶KASSEL, ⁷BONN, ⁸MARBURG, ⁹NUREMBERG, GERMANY

P 21145 PANGAEA 2.0: State of the art multiple sclerosis patient management in daily clinical practice. A 3-year observational study of patients receiving fingolimod

T. Ziemssen¹, R. Kern¹, C. Cornelissen² | ¹DRESDEN, ²NUREMBERG, GERMANY

P 21146 COPAXONE® Active Registry – Documentation of efficacy, tolerability and quality of life in outpatients with relapsing remitting multiple sclerosis (RRMS) treated with glatiramer acetate

U. Faude¹, T. Ziemssen² | ¹BERLIN, ²DRESDEN, GERMANY

P 21147 Multicenter open-label non-interventional study (NIS) assessing the alteration of activity in ambulatory patients with relapsing forms of multiple sclerosis (RMS) under treatment with Glatiramer acetate

A. Müller-Schubert¹, T. Ziemssen², H. Reichmann², R. Kern², D. Fendji¹ | ¹BERLIN, ²DRESDEN, GERMANY

POSTER SESSION MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 3

12:30-13:15 | SCREEN B4

CHAIRPERSON:

Edina Varga, SZEGED, HUNGARY

P 21148 Statin induced autoimmune necrotizing myopathy

T. Kalantzakou, G. Xiromerisiou, A. Tichalas, T. Bourinaris, O. Sinani, J. Rudolf, G. Deretzi | THESSALONIKI, GREECE

P 21149 Immunological subtypes of myasthenia gravis among Ukrainian population (pilot study)

O. Kalbus | DNIPROPETROVSK, UKRAINE

P 21150 Epidemiology of myasthenia gravis in the Dnipropetrovsk region, Ukraine

O. Kalbus | DNIPROPETROVSK, UKRAINE

P 21151 Anxiety and depression among myasthenia gravis patients

O. Kalbus | DNIPROPETROVSK, UKRAINE

P 21152 B-cell activating factor is elevated in serum of patients with myasthenia gravis

S.-Y. Kang | JEJU, KOREA, REPUBLIC OF

P 21153 Remudy, Japanese national registry for neuromuscular diseases

E. Kimura¹, H. Nakamura¹, S. Mitsuhashi¹, M. Mori-Yoshimura¹, M. Takahashi², F. Takeuchi¹, S. Wu⁵, Y. Zheng⁶, T. Matsumura³, H. Komaki¹, I. Nishino¹, M. Kawai⁴, H. Dawkins⁷, C. Bérout⁸, H. Lochmüller⁹, S. Takeda¹ | ¹KODAIRA, ²SUITA, ³TOYONAKA, ⁴HASUDA, JAPAN, ⁵BEIJING, ⁶DONGYING, CHINA, ⁷PERTH, AUSTRALIA, ⁸MARSEILLES, FRANCE, ⁹NEWCASTLE UPON TYNE, UK

P 21154 Long exercise test in Andersen-Tawil syndrome

A. Kostera-Pruszczyk, A. Potulska-Chromik, P. Szczudlik, M. Lipowska | WARSAW, POLAND

P 21155 Paraneoplastic neuromuscular syndromes and Ion channels antibodies

D. Labunskiy | SANTA ROSA, USA

P 21156 Usefulness of MRI in cases of hyperCKemia

P. Martí¹, N. Muelas¹, J. Diaz-Manera², J.J. Vilchez¹ | ¹VALENCIA, ²BARCELONA, SPAIN

P 21157 TRPV2 inhibition therapy can be effective for cardiomyopathy of muscular dystrophy

T. Matsumura¹, M. Matsui¹, Y. Iwata², M. Asakura², T. Saito¹, H. Fujimura¹, S. Sakoda¹ | ¹TOYONAKA, ²SUITA, JAPAN

P 21158 Acute steroid-induced respiratory myopathy secondary to intravenous methylprednisolone for multiple sclerosis relapse

N. McNicholas, E. McKone, C. McGuigan | DUBLIN, IRELAND

P 21159 Sporadic late-onset nemaline myopathy with MGUS: a rare cause of dropped-head

A. Monteiro, C. Lopes, L.M.C.A. Castro, S. Carpenter, H. Costa | PORTO, PORTUGAL

POSTER SESSION NEUROEPIDEMIOLOGY 1

12:30-13:15 | SCREEN C3

CHAIRPERSON:

Maura Pugliatti, FERRARA, ITALY

P 21160 The prevalence of dementia in Sidi M'Hamed, a district of Algiers city

S. Belarbi, M.I. Kediha, F. Mostefaoui, S. Abroukk, M. Tazir | ALGIERS, ALGERIA

P 21161 Neurological service use around pregnancy

D. Berczki Jr., A. Ajtay, F. Oberfrank, I. Vastagh | BUDAPEST, HUNGARY

P 21162 Trends in incidence of TIA and ischemic strokes: comparing data from two community-based studies

R. Felgueiras, R. Magalhães, M.C. Silva, M. Correia | PORTO, PORTUGAL

P 21163 Hypoglossal nerve palsy. A review of a series of cases.

N. García Lax, J.Á. Motos García, A. Sanz Monllor, M. Palao Rico, I.M. Sanchez Ortuño, A.M. García Medina, L. Sanchez Alonso, J.M. Rodríguez García, M.L. Martínez Navarro, J. Marín Marín, M.P. Salmerón Ato, J.A. Iniesta Valera, A. Díaz Ortuño | MURCIA, SPAIN

P 21164 Use of neuroimaging in patients presenting with seizure: concordance between guidelines and clinical practice.

N. García Lax, A. Sanz Monllor, J.Á. Motos García, I.M. Sanchez Ortuño, L. García Alonso, C.P. Gómez Cárdenas, J.L. Bauset Navarro, M. Palao Rico, A.M. García Medina, J.M. Rodríguez García, M.L. Martínez Navarro, J. Marín Marín, M.P. Salmerón Ato, J.A. Iniesta Valera, A. Díaz Ortuño | MURCIA, SPAIN

P 21165 Anatomical variations circle Willis, aneurisms corelation, and relationship with subarachnoid haemorrhage

E. Harizi¹, A. Rroji² | ¹DURRES, ²TIRANA, ALBANIA

P 21166 Epidemiology of brain and spinal tumours in a sample eight years from a tertiary hospital in Guanajuato, Mexico

M. Maldonado-Vega, F. Farias Serratos, M.Á. Guerrero-Ramos, A. Tabares | LEÓN, MEXICO

P 21167 Descriptive analysis of ambulatory neurological care demand in Salamanca, Spain

R. Manso Calderón | SALAMANCA, SPAIN

POSTER SESSION NEUROGENETICS 1

12:30-13:15 | SCREEN F4

CHAIRPERSON:

Péter Balicza, BUDAPEST, HUNGARY

P 21168 Peripheral Nervous System involvement in spinocerebellar ataxia type 3 - clinical and neurophysiological evaluation

J. Afonso Ribeiro, A.M. Novo, L. Almendra, A. Matos, C. Januário, L.J.M.P. Negrão | COIMBRA, PORTUGAL

P 21169 Joubert's syndrome: clinical and radiological findings in 14 patients

L. Ali Pacha¹, S. Assami¹, S. Nouioua¹, T. Benhassine¹, E.M. Valente², M. Tazir¹ | ¹ALGIERS, ALGERIA, ²ROME, ITALY

P 21170 Gene-specific DNA methylation is related to drug treatment in Alzheimer's disease patients

M. Altuna¹, I. Rubio¹, A. Labarga¹, R. Larumbe Ilundain¹, M. Zelaya¹, J. Ruiz-Sánchez de Gordo¹, M. Roldán¹, C. Echavarri², M. Mendioroz¹ | ¹PAMPLONA, ²ALSASUA, SPAIN

P 21171 Infantile neuroaxonal dystrophy in two female Albanian siblings

A. Babameto Laku, Z. Ylli, D. Ylli, M. Rakacolli, J. Kruja | TIRANA, ALBANIA

P 21172 Differential diagnosis of hyperintense corticospinal tract lesions, detected in adult patients with spastic paraplegia

P. Balicza, Z. Grosz, G. Lovas, P. Barsi, G. Rudas, A. Lengyel, J. M. Molnar | BUDAPEST, HUNGARY

P 21173 LRRK2, MAPT and HTRA2 mutations in the pedigree of familial neurodegenerative parkinsonism with cognitive deterioration spanning five generations in a genetically isolated population of south-eastern Moravia, Czech Republic

T. Bartonikova, R. Vodicka, K. Mensikova, R. Vrtel, M. Godava, P. Kanovsky, P. Otruba, M. Kaiserova, M. Vašík, L. Mikulicova | OLOMOUC, CZECH REPUBLIC

P 21174 A post-translational modification in histone is a novel marker for nociceptive activation in primary sensory neurons

S. Beattie, J.V. Torres-Perez, I. Nagy | LONDON, UK

P 21175 Next generation sequencing of SORCS3 in multiple sclerosis patients and controls from the isolated Faroe Islands

S. Binzer¹, E. Stenager², M. Binzer², J. Hillert³, K. Imrell³ | ¹ODENSE, ²SØNDERBORG, DENMARK, ³STOCKHOLM, SWEDEN

SUNDAY, 29 MAY

12:30 - 13:15

P 21176 Hereditary Spastic Paraplegia: clinical and mutational spectrum in the unexplored Greek population

M. Breza¹, G. Koutsis¹, D. Lynch², G. Karadima¹, A. Polymeris¹, R. Pons¹, A. Tucci², F.M. Santorelli³, A. Tessa³, H. Houlden², M. Panas¹ | ¹ATHENS, GREECE, ²LONDON, UK, ³PISA, ITALY

P 21177 Orthotopic liver transplantation in an MNGIE patients as a successful measure to correct biochemical imbalance

C. Casali | ROME, ITALY

P 21178 Characterisation of a Leber's hereditary optic neuropathy family with multiple affecteds and two primary LHON mutations m.11778G>A and m.14484T>C

C. Catarino¹, U. Ahting¹, K. Peters², C. Wilhelm², K. Hörtnagel², S. Biskup², B. Livonius-Freifrau von Eyb¹, T. Meitinger¹, T. Klopstock¹ | ¹MUNICH, ²TÜBINGEN, GERMANY

P 21179 Cerebellar and motor pathways changes in diffusion tensor imaging and tractography in cerebrotendinous xanthomatosis can be partially reversed by treatment with chenodeoxycholic acid

C. Catarino¹, C. Vollmar¹, C. Küpper¹, C. Gallenmüller¹, S. Lechner², K. Hörtnagel², C. Wilhelm², S. Biskup², T. Klopstock¹ | ¹MUNICH, ²TÜBINGEN, GERMANY

P 21180 GNE myopathy in Roma patients homozygous for the p.I618T founder mutation

T. Chamova¹, M. Gospodinova¹, V. Guerguelcheva¹, S. Krause³, S. Cirak⁴, A. Kaprelyan², L. Angelova², V. Mihaylova¹, S. Bichev¹, D. Chandler⁶, E. Naydenov¹, M. Grudkova², P. Djukmedzhiev², D. Bogdanova¹, K. Kmetska¹, T. Voit⁹, O. Pogoryelova⁹, H. Lochmuller⁹, H. Goebel⁵, M. Bahlo⁷, L. Kalaydjieva⁶, I. Tournev¹ | ¹SOFIA, ²VARNA, BULGARIA, ³MUNICH, ⁴COLOGNE, ⁵BERLIN, GERMANY, ⁶PERTH, ⁷PARKVILLE, VICTORIA, AUSTRALIA, ⁸PARIS, FRANCE, ⁹NEWCASTLE, UK

P 21181 A case of late-onset Pompe disease diagnosed by Whole Exome Sequencing despite inconclusive initial muscle biopsy and biochemical studies

D. Kotzamani, H. Latsoudis, E. Vogiatzi, A. Plaitakis, I. Zaganas | HERAKLION, CRETE, GREECE

POSTER SESSION
NEUROIMMUNOLOGY 1

12:30-13:15 | SCREEN H2

CHAIRPERSON:

Pasquale Annunziata, SIENNA, ITALY

P 21182 Refractory status epilepticus caused by anti-NMDAR encephalitis: a case report

T. Al-Harbi, S. Abdulmanaa' | DAMMAM, SAUDI ARABIA

P 21183 Circulating anti-CD64 antibodies and clinical outcome in multiple sclerosis patients

P. Annunziata, G. Masi, C. Cioni | SIENNA, ITALY

P 21184 Diagnostic and clinical significance of antigen-specific anti-Helicobacter pylori antibodies in patients with multiple sclerosis

G. Efthymiou, E. Dardiotis, C. Liaskos, E. Marou, S. Arseniou, D. Rikos, V. Tsimourtou, W. Meyer, L. Sakkas, G. Hadjigeorgiou, D. Bogdanos | LARISSA, GREECE

P 21185 Autoimmune storm

S. Aslan, C.E. Bekircan-Kurt, A.T. Kurne, S. Erdem-Özdamar | ANKARA, TURKEY

P 21186 Association between neuromyelitis optica spectrum disorders and Behçet's disease in 2 Moroccan patients

A. Bennis, Z. Attar, F. Dany, M.A. Rafai, B. El Moutawakil, H. El Otmani, I. Slassi | CASABLANCA, MOROCCO

P 21187 The role of serotonin in regulating interactions of the immune and nervous system in multiple sclerosis.

A. Boyko, M. Melnikov, M. Pashenkov | MOSCOW, RUSSIAN FEDERATION

P 21188 Paraplegia following lumbar puncture: a rare complication of spinal dural arteriovenous fistula

A. Çakar, H. I. Akçay, T. Gunduz, M. Kürtüncü | ISTANBUL, TURKEY

P 21189 Adhesion molecule dynamics after Natalizumab withdrawal in T - lymphocytes subpopulations

A. Cobo¹, A. Figueras², L. Bau², E. Matas², M.A. Mañe³, L. Romero Pinel², S. Martinez Yelamos² | ¹LYONS, FRANCE, ²BARCELONA, ³TARRAGONA, SPAIN

P 21190 A rare case of longitudinally extensive transverse myelitis - never disregard tuberculosis

C.I. Coclitu, A.C. Mergeani, O. Rusu, A. Ciobotaru, T. Parvu, O. Bajenaru, F. Antochi | BUCHAREST, ROMANIA

P 21191 Spastic paraparesis as the initial manifestation of Sjögren's syndrome
 F. Correia¹, C. Cunha¹, L.M. Afonso², R. Alves¹ | ¹PORTO, ²MATOSINHOS, PORTUGAL

P 21192 Maternal CASPR2 antibodies in neurodevelopmental disorders: findings in human cohorts and in a rodent maternal transfer model.
 E.P. Coutinho¹, L. Jacobson¹, D. Menassa¹, J. Domingos¹, T. Moloney¹, M. Benros², M. Pederson³, B. Lang¹, P.J. Harrison¹, P.B. Mortensen³, D. Bannerman¹, B. Nørgaard-Pedersen², A. Vincent¹ | ¹OXFORD, UK, ²COPENHAGEN, ³AARHUS, DENMARK

P 21193 Microvesicles as a possible biomarker for microglia activation in - vivo during phases of disease activity in Multiple Sclerosis.
 T. Croese, G. Dalla Costa, M. Pisa, V. Martinelli, G. Comi, R. Furlan | MILAN, ITALY

P 21194 Hepatocellular carcinoma and anti-N-methyl-D-aspartate receptor encephalitis
 C. Cunha, M. Baptista, F. Correia, S. França | PORTO, PORTUGAL

P 21195 Peripheral regulatory T / Th17 cells contributes to Moya Moya disease
 Y. Xu, X. Cao, L. Weng, D. Guan | NANJING, CHINA

P 21196 Causes of sporadic cerebellar ataxia with sensory neuronopathy
 P. Zis, P. Sarigiannis, D.G. Rao, M. Hadjivassiliou | SHEFFIELD, UK

POSTER SESSION NEURO-ONCOLOGY 2

12:30-13:15 | SCREEN C4

CHAIRPERSON:
 Maria Mallia, MSIDA, MALTA (TBC)

P 21197 Functional rearrangement of language areas in an adult patient with a left frontal lobe Glioblastoma
 M. Fernandes, J. Passos, J.R.L.D.M. Marques, C. Reizinho, S. Pimenta, S. Reimão, M. Lauterbach, A.L. Azevedo | LISBON, PORTUGAL

P 21198 Abstract cancelled

P 21199 Abstract cancelled

P 21200 Ma2-associated paraneoplastic limbic encephalitis in a patient with adeno-carcinoma of the lung
 A. Grisold¹, R. Höftberger¹, B. Giometto², E. Auff¹, T. Sycha¹ | ¹VIENNA, AUSTRIA, ²PADUA, ITALY

P 21201 Tanycytic ependymoma of the brain stem - presentation of a rare cystic disease variant and review of literature
 F. Ippen, R. Pfannl, R. Rojas, A. Mahadevan, E. Kasper | BOSTON, USA

P 21202 Peripheral facial paralysis generated by meningeal carcinomatosis - a rare presentation of Ewing Sarcoma
 A. Lazarogae, I.-R. Carcalici, C. Roman Filip | SIBIU, ROMANIA

P 21203 Tongue myokymia as an unusual symptom of a meningioma of the craniospinal junction
 D. Leupold, O.C. Kim, C. Brugnolaro, T. Hundtberger | ST. GALLEN, SWITZERLAND

P 21204 Primary central nervous system lymphoma: a chameleon case
 M. Lopes¹, C. Santos¹, V. Mesquita², L. Regadas², J. Coutinho² | ¹SANTA MARIA DA FEIRA, ²PORTO, PORTUGAL

P 21205 Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme
 M. Lopes¹, B. Carvalho², P. Linhares², R. Vaz² | ¹SANTA MARIA DA FEIRA, ²PORTO, PORTUGAL

P 21206 Incomplete cavernous sinus syndrome as unusual presentation of metastatic prostate adenocarcinoma
 M. Machio Castello, M. Oses, A. Jaimés, D.A. Escobar Montatixe, B. Pfang, A. Martínez Pueyo, R. Saez Pinel, J. Villacampa Aubá, M.A. García-Torres, I. Zamarbide Capdepón | MADRID, SPAIN

P 21207 Incidence of brain tumours in the Maltese Islands: a population based study
 M. Mallia¹, R. Galea², M.-A. Mifsud¹, M. Gruppetta¹, M.-A. Zammit¹ | ¹BIRKIRKARA, ²MSIDA, MALTA

P 21208 Trousseau's quest - Ischemic stroke and solid cancer: a retrospective 10 year case-control study
 C. Marques-Matos, A. Costa, G. Moreira, E. Azevedo, M. Carvalho | PORTO, PORTUGAL

P 21209 Atypical neurologic presentation of diffuse large B-cell lymphoma
 J.P. Marto, F. Ladeira, C. Borbinha, T. Lampreia, M. Viana-Baptista | LISBON, PORTUGAL

SUNDAY, 29 MAY

12:30 - 13:15

POSTER SESSION NEURO-OPHTHALMOLOGY/ NEURO-OTOLOGY 1

12:30-13:15 | SCREEN H1

CHAIRPERSON:

Katharina Feil, MUNICH, GERMANY

P 21210 Features of contrast sensitivity in Parkinson's disease and its changes during motor fluctuations

O. Alenicova, S. Likhachev, I. Goursky | MINSK, BELARUS

P 21211 Optic neuropathy in pernicious anaemia

I. Alves, M.J. Silva, C. Fraga | PENAFIEL, PORTUGAL

P 21212 Abstract cancelled

P 21213 Interhemispheric asymmetry and its role in higher-order vestibular function

Q. Arshad, A. Bronstein | LONDON, UK

P 21214 Association of multiple sclerosis and sudden deafness

S. Atula, S. Sinkkonen, R. Saat, T. Sairanen, T. Atula | HELSINKI, FINLAND

P 21215 Acute bilateral mydriasis associated with anti-GQ1b antibodies

A. Barros, S. Dias, S. Vaz, R. Relvas | LISBON, PORTUGAL

P 21216 Brainstem decompression and unilateral cerebellar tonsil resection in patients with Chiari malformation: prospective examination of clinical outcome and cerebellar, vestibular, and oculomotor function

N. Böttcher, K. Feil, M.L. Strupp, A. Peraud | MUNICH, GERMANY

P 21217 Vestibular function in patients with Niemann-Pick type C disease

T. Bremova¹, S. Krafczyk¹, S. Bardins¹, E. Mengel², J. Reinke², M. Strupp¹ | ¹MUNICH, ²MAINZ, GERMANY

P 21218 Oculomotor findings and their correlation with clinical abnormalities in Gaucher disease type 3

T. Bremova¹, R. Schiffmann³, M. Patterson⁴, N. Belmatoug⁵, S. Bardins¹, V. Malinova⁶, E. Mengel², J. Reinke², M. Strupp¹ | ¹MUNICH, ²MAINZ, GERMANY, ³DALLAS, ⁴ROCHESTER, USA, ⁵CLICHY, FRANCE, ⁶PRAGUE, CZECH REPUBLIC

P 21219 Acetazolamide in vestibular migraine prophylaxis: a retrospective study

N. Celebisoy, F. Gokcay, C. Bilgen, T. Kirazli, H. Karapolat, T. Kose | IZMIR, TURKEY

P 21220 Eye movements at an early stage of essential tremor

N. Celebisoy, M. Çelebisoy, A. Süzen Ekinci, E. Akyuz, A. Acarer | IZMIR, TURKEY

P 21221 What's behind cerebellar dizziness?

K. Feil, A. Schindler, S. Krafczyk, A. Zwergal, F. Schöberl, M. Strupp | MUNICH, GERMANY

POSTER SESSION NEUROREHABILITATION 2

12:30-13:15 | SCREEN G2

CHAIRPERSON:

Michaela Bisciglia, BRUSSELS, BELGIUM

P 21222 Functional evaluation of stroke patients undergoing early physiotherapy in the Neurointensive care unit

A. Guclu-Gunduz, G. Yazici, C. Ozkul, C. Irkeç, T. Ozkan, Y. Aydin, B. Nazliel, H.-Z. Batur-Caglayan | ANKARA, TURKEY

P 21223 Activities of daily living with FampyraLR

J. Jansa | LJUBLJANA, SLOVENIA

P 21224 Study on clinical therapeutic effect of acupuncture on post-stroke depression

Y. Kim, C.F. Teo | SKUDAI, JOHOR, MALAYSIA

P 21225 Comparing the efficacy of different types of repetitive navigated transcranial magnetic stimulation in treatment of pharmacoresistant spasticity in patients with multiple sclerosis: 20Hz rTMS, iTBS or placebo

I. Korzhova, A. Poydasheva, A. Chervyakov, M. Zakharova | MOSCOW, RUSSIAN FEDERATION

P 21226 Abstract cancelled

P 21227 New possible marker of severity of vascular remodeling of the patients in early recovery period after cerebral ischemic hemispheric stroke

S. Medvedkova, O.A. Kozyolkina | ZAPORIZHYA, UKRAINE

P 21228 Action observation training modifies brain grey matter structure in healthy adult individuals

S. Fumagalli, M.A. Rocca, P. Preziosa, E. Pagani, R. Gatti, G.C. Riccitelli, G. Comi, A. Falini, M. Filippi | MILAN, ITALY

P 21229 NeuroMuscular Electrical Stimulation (NMES) in stroke to improve activity: a systematic review

M.G.H. Kristensen, H. Busk, T. Wienecke | MILAN, ITALY

P 21230 Early web-based tele-rehabilitation in stroke patients: a randomized controlled pilot study
M.B. Poulsen¹, J. Badawey¹, M. Anhøj¹, E. Rostrup², K. Ellemann³, B.W. Larsson², H. Larsson², T. Weineke³, H.K. Iversen⁴, J.B. Nielsen², C. Kruuse¹ | ¹HERLEV, ²COPENHAGEN, ³ROSKILDE, ⁴GLOSTRUP, DENMARK

P 21231 fMRI-navigated rTMS original protocol for disorders of consciousness treatment
L. Legostaeva, E. Zmeykina, E. Kremneva, A. Poydasheva, A. Chervyakov, D. Sergeev, J. Ryabinkina, E. Gnedovskaya, N. Suponeva, M.A. Piradov | MOSCOW, RUSSIAN FEDERATION

P 21232 Cursive eye-writing with eye on line device (EOL) is feasible in subjects with ALS: a pilot study
T. Lenglet, M. Veyrat-Masson, J. Mirault, A. Guignebert, M.D.M. Amador, G. Bruneteau, N. Leforestier, P.-F. Pradat, F. Salachas, L. Lacomblez, J. Lorenceau | PARIS, FRANCE

P 21233 Life quality scores of the patients in early recovery period after cerebral ischemic hemispheric stroke
S. Medvedkova, O.A. Kozyolkin | ZAPORIZHYA, UKRAINE

P 21234 The Yin and Yang of pharmacological therapy in brain protection and recovery
D. Muresanu¹, A. Guekht² | ¹CLUJ, ROMANIA, ²MOSCOW, RUSSIAN FEDERATION

POSTER SESSION NEUROTOXICOLOGY/OCCUPATIONAL NEUROLOGY

12:30-13:15 | SCREEN G1

CHAIRPERSON:

Maurizio Leone, SAN GIOVANNI ROTONDO, ITALY

P 21235 Silver intoxication induced polyneuropathy: a case report
M. Yücel, Z. Özkan, H. Akgun, B. Kurt, Ü.H. Ulas, S. Demirkaya | ANKARA, TURKEY

P 21236 The struggle in establishing the diagnosis of delayed postanoxic encephalopathy
R.S. Badea, I.C. Cernat, A. Craciunoiu | BUCHAREST, ROMANIA

P 21237 Reversible encephalopathy induced by high dose Trimethoprim-Sulfamethazole
H. Ben Abdeljelil | PORRENTUY, SWITZERLAND

P 21238 A case of cerebral manganism
A. Topkan, S. Bilen, E. Erucar, Y.S. Karadag, N. Öztekin, F. Ak | ANKARA, TURKEY

P 21239 Atrophy of the corpus callosum and bilateral reversible putamen lesions: an atypical case of Marchiafava-Bignami disease
J. Castelo, C. Santos | SANTA MARIA DA FEIRA, PORTUGAL

P 21240 Metronidazole encephalopathy
N. Segura, V. Delgado, E. Sánchez | LA LÍNEA DE LA CONCEPCIÓN, SPAIN

P 21241 Hyperammonemic encephalopathy induced by sodium valproate
L. Ortega, N. Segura, V. Delgado | LA LÍNEA DE LA CONCEPCIÓN, SPAIN

P 21242 Low back pain disorders as an occupational disease – development methodology
E. Ehler¹, M. Nakládalová², D. Pelcová³, A. Laštovková³, Z. Fenclová³, P. Gaďourek³, J. Hlávková³, T. Lebeda³, T. Tichý³, P. Urban³, A. Eichlerová¹, M. Richter³, P. Ridzoň³, L. Pešáková² | ¹PARDUBICE, ²OLOMOUC, ³PRAGUE, CZECH REPUBLIC

P 21243 Marchiafava-Bignami disease mimicking left middle cerebral artery stroke
D. Fitas, A. Stocker, R. Lobato | VIANA DO CASTELO, PORTUGAL

P 21244 A case of severe toxic encephalopathy secondary to methanol poisoning
P. Hernandez Navarro, M. Molina Sanchez, M.H. Torregrosa Martinez, M.Á. García Soldevilla | MADRID, SPAIN

P 21245 Delayed leukoencephalopathy after acute carbon monoxide intoxication
P.L. Martínez Ulloa, A. Escobar Villalba, P. Pérez Torre, E. Monreal Laguillo, C. Estévez Fraga, C. Anciones, J. Buisán Catevilla, Í. Corral Corral | MADRID, SPAIN

P 21246 Copper deficiency, a not so uncommon cause of posterior cord syndrome
A. Poujois¹, C. Dussaule², S. Janny³, J. Poupon¹, P. Chaine¹, F. Woimant¹, N. Djebrani-Oussedik¹ | ¹PARIS, ²LE KREMLIN-BICÊTRE, ³CLICHY, FRANCE

P 21247 Chorea as a result of chronic carbon monoxide intoxication: a case report
C. Thomsen, A.S. Bisgård, M. Lindelof | HERLEV, DENMARK

SUNDAY, 29 MAY

12:30 - 13:15

POSTER SESSION PERIPHERAL NERVE DISORDERS 3

12:30-13:15 | SCREEN D2

CHAIRPERSON:

Frouke Nijhuis, NIJMEGEN, THE NETHERLANDS

P 21248 Pyridoxine (Vitamin B6) toxicity related neuropathy: a case series

J.-P. Nicolo, A. Malhotra, A.R. Carne, D.S. Ayyappan |
GEELONG, AUSTRALIA

P 21249 Treatments options in HINT1 neuropathy

J. Nikodinović Glumac, V. Milic Rasic, V. Brankovic,
J. Mladenovic, S. Todorovic | BELGRADE, SERBIA

P 21250 A patient homozygous for MFN2 mutation c.2119C>T developed both severe CMT2A and lipomatosis

K. Ørstavik¹, M. Rasmussen², B. Karime¹, H. Vindenes¹,
T. Fagerheim³, M. van Ghelue³, C. Jonsrud³, O. Røsbjø¹ |¹OSLO,
²OSLO UNIVERSITY HOSPITAL, ³TROMSØ, NORWAY

P 21251 Hereditary sensory neuropathy and cough – description of two Portuguese families

J. Parra, A. Brás, P. Carvalho, J. Ribeiro, L. Almendra,
A.P. Geraldo, L.J.M.P. Negrão, A. Matos | COIMBRA, PORTUGAL

P 21252 Familial amyloid polyneuropathy with Ser97Tyr transthyretin mutation: two new cases

M.I. Pedraza¹, A.L. Guerrero¹, N. Fernández¹, J.J. Tellería¹,
M. Ruiz Piñero¹, L. Galán² |¹VALLADOLID, ²MADRID, SPAIN

P 21253 Guillain-Barré syndrome in elderly

S.Z. Perić¹, I. Berisavac¹, O. Stojiljković¹, S. Rajić², M. Babić³,
M. Cvijanović², A. Dominović-Kovacević³, I. Basta¹,
L. Beslač-Bumbaširević¹, D. Lavrnić¹ |¹BELGRADE, ²NOVI SAD,
SERBIA, ³BANJA LUKA, BOSNIA AND HERZEGOVINA

P 21254 The livedoid vasculopathy, a rare cause at multiplex polyneuropathy in men

V.R. Petre, I. Buraga, C. Baetu, A.M. Enachi, V. Lungu,
M. Amarandei | BUCHAREST, ROMANIA

P 21255 Can neurological examination predict pathophysiology of peripheral neuropathy?

G. Omejec, T. Zgur, S. Podnar | LJUBLJANA, SLOVENIA

P 21256 Pathophysiology of peripheral nerve damage in familial amyloidotic polyneuropathy (FAP)

S. Podnar¹, S. Sarafović², I. Tournev², G. Omejec¹, J. Zidar¹ |
¹LJUBLJANA, SLOVENIA, ²SOFIA, BULGARIA

P 21257 Prevalence and risk factors for carpal tunnel syndrome in meat processing industry

M. Ricco¹, S. Cattani², C. Signorelli² |¹TRENT, ²PARMA, ITALY

P 21258 Observational study on neurological complications of acute virus E infection (NeuroCAVE)

P. Ripellino¹, C. Staedler¹, G. Melli¹, G. Martinetti², E. Pasi²,
M. Tiberti¹, A. Kaelin¹, C. Gobbi¹ |¹LUGANO, ²BELLINZONA,
SWITZERLAND

P 21259 Acute and chronic Nav1.8 blocker treatment to improve motor function in mice deficient of myelin protein PO: proof-of-concept study

M. Romer Rosberg, S. Alvarez, C. Krarup, M. Moldovan |
COPENHAGEN, DENMARK

P 21260 Wernicke encephalopathy revealed by peripheral polyneuropathy

N. Yengui, I. Ben Abdelaziz, E. Farhat, A. Rachdi, M. Zouari,
F. Hentati | TUNIS, TUNISIA

POSTER SESSION SLEEP DISORDERS 2

12:30-13:15 | SCREEN E1

CHAIRPERSON:

Ulf Kallweit, BERN, SWITZERLAND

P 21261 Quantified motor activity in REM sleep compared in REM sleep behaviour disorder, parkinson's disease, multiple system atrophy and narcolepsy with and without hypocretin deficiency

R. Frandsen¹, P.J. Jennum² |¹GLOSTRUP, ²GLOSTRUP -
COPENHAGEN, DENMARK

P 21262 Vitamin D deficiency in narcolepsy with cataplexy

H. Hidalgo¹, X. Messmer¹, C. Bassetti², U. Kallweit² |
¹KATZENELNBOGEN, GERMANY, ²BERNE, SWITZERLAND

P 21263 Effects of theta burst stimulation over dorsolateral prefrontal cortex on vigilance and executive functions after sleep deprivation

T. Ilic, Z. Sundric, N. Komatina | BELGRADE, SERBIA

P 21264 Pitolisant as alternative therapeutic option for narcolepsy: results from the German compassionate use program 2015/16

H. Hidalgo Pareja¹, G. Mayer², P. Young³, P. Geisler⁴,
U. Kallweit⁵ |¹BONN, ²SCHWALMSTADT, ³MÜNSTER, ⁴REGENSBURG,
GERMANY, ⁵BERNE, SWITZERLAND

P 21265 Restless legs syndrome risk gene BTBD9 knockdown alters expression of ferritin and dopamine receptor genes in zebrafish

M.-K. Kim | GWANGJU, KOREA, REPUBLIC OF

P 21266 Periodic limb movements during sleep are more severe in narcolepsy with cataplexy than in narcolepsy without cataplexy

J. Krpesova, K. Sonka, M.V. Ibarburu, M.P. Kovalska, M.D. Kemlink, M.I. Prihodova | PRAGUE, CZECH REPUBLIC

P 21267 Restless leg syndrome in patients with epilepsy under levetiracetam monotherapy

G. Kutlu¹, F. Genç², Y. Ünal¹, D. Aslan Öztürk¹, A. Erdal², Y. Gömceli² | ¹MUGLA, ²ANTALYA, TURKEY

P 21268 The use of melatonin for the treatment of REM sleep behavior disorder in Parkinson's disease

E. Lyashenko, O. Levin, M. Poluektov | MOSCOW, RUSSIAN FEDERATION

P 21269 Abstract cancelled

P 21270 Abstract cancelled

P 21271 Obstructive sleep apnoea and sensomotor polyneuropathy

M. Mihajl, Z. Đogaš, L. Lušić, M. Titlić | SPLIT, CROATIA

P 21272 Restless legs syndrome/Willis-Ekbom disease in patients with Parkinson's disease

M. Minar, R. Tosecka, P. Valkovic | BRATISLAVA, SLOVAKIA

P 21273 Abstract cancelled

P 21274 The effect of sleep and wakefulness disorders on cognitive function in patients with Parkinson's disease (PwPD)

M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, N.G. Brazovskaya, O.P. Izhboldina, J.S. Mironova, M.A. Titova, A.V. Latypova, S.E. Sukhanov | TOMSK, RUSSIAN FEDERATION

POSTER SESSION AGEING AND DEMENTIA 4

13:30-14:15 | SCREEN A2

CHAIRPERSON:

Jonathan Schott, LONDON, UK

P 22001 Predeterminative role of early choroid plexus ageing on presenil neuronal atrophy in an animal model: a preliminary histopathological study

N. Aydin¹, D. Kotan², M.D. Aydin³, G. Ozdemir¹, P. Keles³, A. Kanat⁴, C. Yolas³, C. Gundogdu³ | ¹ISTANBUL, ²SAKARYA, ³ERZURUM, ⁴RIZE, TURKEY

P 22002 Lille apathy rating scale and MDS-UPDRS for screening apathy in Parkinson's disease

N. Kovacs, R. Weintraut, A. Makkos, M. Kovács, J. Janszky, K. Karádi | PÉCS, HUNGARY

P 22003 Associations between hypoperfusion in cerebral cortical segments and cognitive impairment in dementia with Lewy Bodies

Y. Kujuro, K. Ohta, T. Toguchi, Y. Shinohara | TOKYO, JAPAN

P 22004 Abstract cancelled

P 22005 Abstract cancelled

P 22006 Frequency and risk factors for aberrant motor behaviour in Alzheimer's disease and vascular dementia

R. Manso Calderón¹, P. Cacabelos Pérez², M.D. Sevillano García¹, M.E. Herrero Prieto³, R. González-Sarmiento¹ | ¹SALAMANCA, ²SANTIAGO DE COMPOSTELA, ³LEÓN, SPAIN

P 22007 Involvement of kv3.1 in 7-ketocholesterol-, 24(S)-hydroxycholesterol- and tetracosanoic acid-induced lipotoxicity on murine oligodendrocytes 158N: impact on cytosolic potassium level

B. Maryem¹, Z. Amira², M. Sonia¹, N. Thomas³, B. Rym¹, E.A. Mohamed¹, L. Gerard³ | ¹TUNIS, ²MONASTIR, TUNISIA, ³DIJON, FRANCE

P 22008 Quantitative EEG in Alzheimer's disease, MCI before and after standardized tests on fatigue

A. Medvedeva | MOSCOW, RUSSIAN FEDERATION

P 22009 Influence of APOE status on subjective spatial navigation complaints and real space performance

I. Mokrisova¹, J. Laczó¹, M. Pařízková², M. Vyhnálek², K. Sheardova¹, V. Kaplan², V. Matoska², R. Andel³, J. Hort² | ¹BRNO, ²PRAGUE, CZECH REPUBLIC, ³TAMPA, FLORIDA, USA

P 22010 Severe spatial navigation impairment in Lewy body dementia and its structural underpinnings

Z. Nedelska¹, J. Laczó¹, M. Uller², M. Vyhnálek², K. Vlcek¹, J. Hort¹ | ¹PRAGUE, ²BRNO, CZECH REPUBLIC

SUNDAY, 29 MAY

12:30 - 13:15

P 22011 Psychotropic polypharmacy in patients with dementiaA. Nørgaard¹, C. Jensen-Dahm¹, C. Gasse², G. Waldemar¹
¹COPENHAGEN, ²AARHUS, DENMARK**P 22012** Driving performance in the frontotemporal dementia spectrumI. Beratis¹, C. Koros², D. Kontaxopoulou¹, S. Fragkiadaki¹,
N. Andronas¹, D. Pavlou¹, M. Stamelou¹, A. Bonakis¹,
L. Stefanis¹, G. Yannis¹, S.G. Papageorgiou¹ II¹ATHENS,
²PIRAEUS, GREECE**P 22013** Abstract cancelledPOSTER SESSION
CEREBROVASCULAR DISEASES 8

13:30-14:15 | SCREEN G4

CHAIRPERSON:

Volker Dietz, ZURICH, SWITZERLAND

P 22014 Cerebral infarction and Parry-Romberg syndrome: a rare presentationN. Kale, A. Ozudogru, B. Kara, E. Çoban, Z. Ozdemir, Y. Kayki,
A. Soysal I ISTANBUL, TURKEY**P 22015** Cerebral venous thrombosis: common presentation across a spectrum of quantitative hemoglobin abnormalitiesM. Khan, H. Hashim, Z. Nisa, A. Almadani, S. Alrukn I DUBAI,
UNITED ARAB EMIRATES**P 22016** Abstract cancelled**P 22017** Rapidly progressive primary Moya-Moya disease - A rare yet malignant cause of recurrent strokes

Q. Kian Kheng I SINGAPORE, MALAYSIA

P 22018 An increase of plasma endotoxin activity during ischemic stroke predicts worse short-term outcome

E. Klimiec, J. Pera, A. Slowik, T. Dziedzic II CRACOW, POLAND

P 22019 Hypophonia in strokeG. Koc¹, S. Bek² I¹ANKARA, ²ADANA, TURKEY**P 22020** Non - aneurysmal perimesencephalic haemorrhage with verdenafilG. Koc¹, S. Bek² I¹ANKARA, ²ADANA, TURKEY**P 22021** Prognostic role of absolute lymphocyte count in acute spontaneous cerebellar hemorrhage

A. Son, K. Kondratiuk I ODESSA, UKRAINE

P 22022 Admission absolute neutrophil count in acute spontaneous cerebellar hemorrhage: prognostic implications

A. Son, K. Kondratiuk I ODESSA, UKRAINE

P 22023 Prognostic value of total white blood cell count in acute spontaneous cerebellar hemorrhage: early-term outcome

A. Son, K. Kondratiuk I ODESSA, UKRAINE

P 22024 Diagnostic challenge of a dural arteriovenous fistula - case presentation

Á. Kornfeld, O. Györfi, M. Bokor I BUDAPEST, HUNGARY

P 22025 Efficiency of the «Stroke risk assessment» to identify individuals at high risk of strokeS. Kotov, E. Sandu, E. Isakova, A. Kotov I MOSCOW, RUSSIAN
FEDERATION**P 22026** Subacute blood pressure index is independently associated with wake-up strokeK. Kowalczyk, D. Gasecki, M. Kwarciany, B. Karaszewski I
GDAŃSK, POLAND**P 22027** Abstract cancelledPOSTER SESSION
CEREBROVASCULAR DISEASES 9

13:30-14:15 | SCREEN G3

CHAIRPERSON:

Uta Meyding-Lamadé, FRANKFURT AM MAIN, GERMANY

P 22028 Neuroimaging features of diagnosis of constitutional venous insufficiency in patients with hypertensive dyscirculatory encephalopathyV. Mashin, L. Belova, N. Belova, M. Moiseev, I. Kazymova,
A. Urdina, R. Akhmetova I ULYANOVSK, RUSSIAN FEDERATION**P 22029** Hyperglycemia, an independent predictor of outcome in acute ischemic stroke

D. Matcau, D.C. Jianu, I.D. Catalin I TIMISOARA, ROMANIA

P 22030 Lower activity of plasminogen and protein C - predictors of 14 - day mortality of ischemic stroke patients

V. Melnyk, L. Sokolova, O. Savchuk I KIEV, UKRAINE

P 22031 Common carotid artery dissection in a young patient with hyperhomocysteinemia and hyperuricemia
A.C. Mergeani, A. Dimitriade, B. Dorobat, O. Rusu, A. Ciobotaru, C. Coclitu, T. Parvu, O.A. Bajenaru, F. Antochi | BUCHAREST, ROMANIA

P 22032 The Brunei Epidemiological Study in Stroke and Multiple Sclerosis (BEST) - a Door-to-door survey
U. Meyding-Lamadé¹, E.M. Craemer¹, B. Bassa¹, M. Luissin³, J. Hengelbrock², A. Lupat³, H. Becher² | ¹FRANKFURT AM MAIN, ²HAMBURG, GERMANY, ³NEGARA, BRUNEI DARUSSALAM

P 22033 To teach to treat - to treat to teach - setting up the Brunei Neuroscience Stroke and Rehabilitation Centre 12,000km away by the help of telemedicine
U. Meyding-Lamadé¹, E.M. Craemer¹, B. Bassa¹, C. Jacobi¹, C. Chan², A. Masri², N. Yassin², A. Aziz², I. Jafaar², Z. Hanafi², B. Kress¹ | ¹FRANKFURT AM MAIN, GERMANY, ²JERUDONG, BRUNEI DARUSSALAM

P 22034 Correlation of risk factors and hemodynamic changes using Transcranial-Doppler and Echocardiography in patients with high grade symptomatic internal carotid stenosis
M. Militaru, A.G. Militaru, D. Lighezan, S. Iurciuc, M. Simu | TIMISOARA, ROMANIA

P 22035 Combinations of cardiovascular risk factors in elderly patients with silent brain infarctions in Ukraine
T.S. Mishchenko, I.M. Nikishkova, V.M. Mishchenko, O. Kutikov | KHARKIV, UKRAINE

P 22036 Abstract cancelled

P 22037 Repetitive intracerebral lobar hematomas in a patient with hidden adrenal pheochromocytoma
E. Monreal, P. Pérez Torre, A. Escobar-Villalba, P. Martínez-Ulloa, R. Vera, J. Masjuan, A. Cruz | MADRID, SPAIN

P 22038 Symptomatic cerebral capillary telangiectasias: report of three cases and literature review
A. Monteiro¹, C. Lopes¹, D. Fitas², H. Costa¹, M. Pinto¹ | ¹PORTO, ²VIANA DO CASTELO, PORTUGAL

P 22039 Myelin repair- correlates with CARASIL-associated neurological deficits
B. Muinjonov, E. Giyazitdinova | TASHKENT, UZBEKISTAN

P 22040 First application of intravenous thrombolytic therapy in Republic of Kosovo
B. Myftiu, I. Jusufi | PRISHTINA, KOSOVO

P 22041 Orolingual angioedema during thrombolysis for cerebral ischemia
F. Myslimi¹, D. Leys² | ¹TIRANA, ALBANIA, ²LILLE, FRANCE

P 22042 Protein S deficiency and ischemic stroke in young patients
I. Zekja¹, I. Alimehmeti², D. Dobi¹, A. Kuqo¹, S. Xhaxho¹, M. Rakacolli¹, J. Kruja¹ | ¹TIRANA, ALBANIA, ²MAASTRICHT, THE NETHERLANDS

POSTER SESSION EPILEPSY 5

13:30-14:15 | SCREEN B2

CHAIRPERSON:
Geir Braathen, SKIEN, NORWAY

P 22043 Status epilepticus in intensive care unit: frequency, management and outcome impact: a retrospective study
C. Munteanu, S. Groppa | CHISINAU, MOLDOVA

P 22044 EEGraphic status epilepticus might not be associated with poor neurological prognosis in cooled cardiac arrest survivors
J. Nørregaard¹, M. Engsig², M. Lindelof¹ | ¹HERLEV, ²COPENHAGEN, DENMARK

P 22045 Resting fMRI connectivity between hippocampal sub-region and extra-temporal area in patients of mesial temporal lobe epilepsy
H.-M. Park, J. Yang, Y.-D. Son, S.-I. Hwang | INCHEON, KOREA, REPUBLIC OF

P 22046 Epilepsy in multiple sclerosis
V. R. Petre, I. Buraga, C. Baetu, A.M. Enachi, V. Lungu, M. Amarandei | BUCHAREST, ROMANIA

P 22047 Effect of UGT1A4 and UGT2B7 polymorphism on lamotrigine metabolism during pregnancy
V. Petrengate¹, I. Öhman², L. Ekström², L. Bertilsson², D. Saebye¹, T. Tomson², A. Sabers¹ | ¹COPENHAGEN, DENMARK, ²STOCKHOLM, SWEDEN

P 22048 CT perfusion (CTP) findings in stroke-mimics of epileptic origin
S. Quintas, R. López Ruiz, M. de Toledo, M.T. Carreras, A. Gago-Veiga, J. Vivancos | MADRID, SPAIN

P 22049 Seven years of Status Epilepticus in a central hospital
I. Rosário Marques, F. Antunes, C. Fernandes, M.D. Grunho | ALMADA, PORTUGAL

SUNDAY, 29 MAY

13:30 - 14:15

P 22050 Mesial temporal sclerosis in children

I. Rosário Marques, M.D. Grunho, J.P. Monteiro,
M.J. Fonseca II ALMADA, PORTUGAL

P 22051 Disparity in onset of Lafora disease within the same family and detection at early stages of the disease

M. Ruggiero, M. Machío, M. Oses, L. Olivie, E. Diaz,
R. Guerrero-Lopez, B.G. Giraldez, J.M. Serratosa I MADRID,
SPAIN

P 22052 Compared to total sleep deprivation with epileptic patients, the partial sleep deprivation is more efficient diagnostic method

D. Sahovic, A. Alajbegovic, J. Djelilovic-Vranic, A. Kucora I
SARAJEVO, BOSNIA AND HERZEGOVINA

P 22053 Tonic-clonic seizures triggering recurrent Tako-tsubo stress cardiomyopathy: a case report and literature review

L. Saraceno, M. Toffetti, G. Bosco, G. Meola I MILAN, ITALY

P 22054 Quantitative MRI assessment of the differences in lateralization of language-related brain activation in patients with temporal lobe epilepsy

A. Umarov, A.V. Prokhorova, G. Rakhimbaeva,
N. Tychibaeva I TASHKENT, UZBEKISTAN

P 22055 Seizure semiology in patients with bilateral temporal lobe epilepsy in Uzbekistan

A. Umarov, A.V. Prokhorova, N. Tychibaeva I TASHKENT,
UZBEKISTAN

POSTER SESSION
HEADACHE AND PAIN 4

13:30-14:15 | SCREEN C1

CHAIRPERSONS:

Kathrin Doppler, WÜRZBURG, GERMANY

P 22056 Reduction of aquaporin-4 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension

K. Doppler¹, M. Schütt², C. Sommer¹ I ¹WÜRZBURG, ²LÜBECK,
GERMANY

P 22057 Efficacy of biofeedback treatment for migraine and tension type headaches

L. Friedrich¹, I. Zobic¹, M. Milosevic¹, J. Koscak¹,
A. Soldo Koruga², T. Pucic², K. Bacic Baronica¹ I ¹ZAGREB,
²OSIJEK, CROATIA

P 22058 OnabotulinumtoxinA is an effective therapy for nummular headache: experience in a series of 17 cases

B. Garcia, M. Ruiz Piñero, A. Juanatey, M. Pedraza,
E. Martínez, J. Barón, L. López-Mesonero, A.L. Guerrero I
VALLADOLID, SPAIN

P 22059 Searching for symptomatic hypnic headache: ambulatory blood pressure monitoring in a series of 25 patients

B. Garcia, M. Ruiz, M. de Lera Alfonso, E. Martínez Velasco,
J. Barón, A. Juanatey, J.J. Navarrete, A.L. Guerrero Peral I
VALLADOLID, SPAIN

P 22060 Tension-type headache over-diagnosis in the emergency department setting

D. Garcia Azorin, M. Farid-Zahran Osuna,
J.A. Abelaira Freire, T. Liaño Sanchez, G. Ortega Suero,
F.J. Martín Sánchez, J. Porta Etessam I MADRID, SPAIN

P 22061 Episodic migraine and calcitonin gene-related peptide. Effect of treatment with topiramate or zonisamide on peptide plasma levels

D.A. García-Estévez¹, S. Silvarrey-Rodríguez¹,
M. Pardo Parrado¹, T. Sogo Lopez², A. Garcia Pellitero²,
L. Bouzas Lago², J.A. Bravo-Ricoy², P. Alonso Alonso² I
¹LOURENSE, ²LUGO, SPAIN

P 22062 New daily persistent headache (NDPH) with thunderclap headache (TH) onset (NDPH-TH): possible causal role of reversible cerebral vasoconstrictive syndrome (RCVS)

I. Garza, S. Berini, A. Bubolz, C. Robertson I ROCHESTER, USA

P 22063 Multidisciplinary integrated headache treatment program: results and identification of factors that influence treatment response

V. Golovacheva, V. Parfenov, G. Tabeeva, V. Osipova,
D. Pushkarev, A. Andruschenko I MOSCOW, RUSSIAN FEDERATION

P 22064 Biofeedback training method for patients with lower back pain

I. Goursky, S. Likhachev, V. Vashchylin I MINSK, BELARUS

P 22065 An investigation of the relationship between the eNOS gene polymorphism and diagnosed migraine

S. Güler, H. Gürkan, H. Tozkir, F.N. Turan, Y. Çelik I ADRIANOPLE,
TURKEY

P 22066 Pituitary adenylate cyclase-activating polypeptide-38 induced migraine attacks in patients with and without familial aggregation of migraine

S. Guo, A.L.H. Vollesen, R.D. Hansen, A.-L. Esserlind,
F.M. Amin, A.F. Christensen, J. Olesen, M. Ashina I
COPENHAGEN, DENMARK

P 22067 Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients

S. Guo, A.L.H. Vollesen, Y.B.L. Hansen, E. Frandsen,
M.R. Andersen, F.M. Amin, J. Fahrenkrug, J. Olesen,
M. Ashina I COPENHAGEN, DENMARK

P 22068 Premonitory and non-headache symptoms induced by CGRP- and PACAP38 in migraine patients
S. Guo, A.L.H. Vollesen, J. Olesen, M. Ashina | COPENHAGEN, DENMARK

P 22069 Quantitative sensory testing in classical trigeminal neuralgia – a blinded study in patients with and without concomitant persistent pain
S. Younis | GLOSTRUP, DENMARK

POSTER SESSION MOTOR NEURONE DISEASES 2

13:30-14:15 | SCREEN C2

CHAIRPERSONS:

David Oliver, ROCHESTER, UK

P 22070 Unusual case of progressive hemiparesis
A. Félix, A. Andre, H. Nzwalo | FARO, PORTUGAL

P 22071 Man in the barrel with drop neck: an unexpected presentation of motor neuron disease
A. Félix, A. Andre, H. Nzwalo | FARO, PORTUGAL

P 22072 Theory of mind in early clinical stages of amyotrophic lateral sclerosis
C. Femiano¹, F. Trojsi¹, G. Santangelo², M. Siciliano¹, T. Ferrantino¹, G. Piccirillo¹, P.F. Esposito³, M.P.A. Tessitore¹, M.P.G. Tedeschi¹ | ¹NAPLES, ²CASERTA, ³SALERNO, ITALY

P 22073 Proposal for a routine-designed standardised EMG setting in early diagnosis of Amyotrophic Lateral Sclerosis (ALS)
M. Ferrara, M.M. Zarrelli, M.F.P. Apollo, M. Leone | SAN GIOVANNI ROTONDO (FG), ITALY

P 22074 Structural brain MRI abnormalities in Kennedy's disease
P.M. Ferraro¹, F. Agosta¹, G. Querin², N. Riva¹, C. Bertolin², E. Da Re², M. Copetti³, G. Comi¹, A. Falini¹, G. Soraru², M. Filippi¹ | ¹MILAN, ²PADUA, ³SAN GIOVANNI ROTONDO, ITALY

P 22075 An ASAH1 variant causing an adult spinal muscular atrophy phenotype without myoclonic epilepsy: a clinical, genetic and biochemical study
M. Filosto¹, M. Aureli², D. Schiumarini², M. Valsecchi², B. Castellotti², A. Todeschini¹, S. Rota¹, F. Rinaldi¹, C. Gellera², A. Padovani¹, M. Filocamo³ | ¹BRESCIA, ²MILAN, ³GENOVA, ITALY

P 22076 Onset manifestations of spinal and bulbar muscular atrophy (Kennedy disease)
J. Finsterer¹, G. Soraru² | ¹VIENNA, AUSTRIA, ²PADUA, ITALY

P 22077 An anterior epidural cyst mimicking Hirayama disease
D. Fitas¹, M.D.C. Branco², F. Silveira³, P. Soares Pinto¹, R. Lobato¹ | ¹VIANA DO CASTELO, ²VILA REAL, ³PORTO, PORTUGAL

P 22078 The patient journey to a national ALS clinic: delayed diagnosis and economic cost
M. Galvin, P. Ryan, M. Heverin, C. Madden, S. Maguire, A. Vajda, O. Hardiman | DUBLIN, IRELAND

P 22079 Brain sodium MRI depicts upper motor neuron involvement in amyotrophic Lateral Sclerosis (ALS)
A.M. Grapperon, A. Maarouf, A. Verschuere, A. Sévy, E. Soulier, S. Confort-Gouny, P. Viout, J.-P. Ranjeva, M. Guye, S. Attarian, W. Zaaraoui | MARSEILLES, FRANCE

P 22080 Evoked potentials in patients with amyotrophic lateral sclerosis
V. Hleb, Y. Rushkevich, G. Zabrodzets, S.A. Likhachev | MINSK, BELARUS

P 22081 An autopsy case of familial ALS-dementia with R487H VCP gene mutation
K. Inoue¹, H. Fujimura¹, K. Toyooka¹, M. Hirano², S. Maekura², Y. Nakamura², S. Sakoda¹ | ¹TOYONAKA, ²SAKAI, JAPAN

P 22082 CSF level of chromogranin A in amyotrophic lateral sclerosis
M. Kaiserova¹, P. Otruba¹, K. Mensikova¹, Z. Grambalova¹, H. Prikrylova-Vranova¹, J. Mares¹, D. Stejskal², P. Kanovsky¹ | ¹OLOMOUC, ²PROSTEJOV, CZECH REPUBLIC

POSTER SESSION MOVEMENT DISORDERS 5

13:30-14:15 | SCREEN E4

CHAIRPERSON:

Lisa Klingelhöfer, DRESDEN, GERMANY

P 22083 Restless Legs Syndrome (RLS) and insomnia frequency in patients with psoriasis
S. Güler, A. Tekatas, A. Ozer, Ö. Sarı Kaplan, Y. Doğru | ADRIANOPLE, TURKEY

P 22084 Myoclonus dystonia: a novel epsilon-sarcoglycan gene mutation with variable clinical presentation in a large Turkish pedigree
M. Gültekin¹, C. Ganos², N.E. Mencacci², M. Mirza¹ | ¹KAYSERI, TURKEY, ²LONDON, UK

P 22085 Motor disorder in Huntington's disease may begin like tic disorder: atypical clinical presentation in a large Turkish pedigree
M. Gültekin, F.F. Erdoğan, F. Yetkin, R. Baydemir, M. Mirza | KAYSERI, TURKEY

SUNDAY, 29 MAY

13:30 - 14:15

P 22086 Conversion of advanced Parkinson's disease patients to IPX066, modified-release levodopa-carbidopa (NUMIENT™), from other levodopa-carbidopa formulations

S. Gupta, R. Rubens, N. Rustay, S. Khanna, S. Kell | HAYWARD, USA

P 22087 Efficacy of IPX066, modified-release levodopa-carbidopa (NUMIENT™) in patients with advanced Parkinson's disease: responder analyses

S. Gupta, S. Khanna, N. Rustay, R. Rubens, S. Kell | HAYWARD, USA

P 22088 Cognitive performance fluctuations in Parkinson's disease: a case report

O. Györfi, E. Rigó, M. Bokor | BUDAPEST, HUNGARY

P 22089 The study of the therapeutic effect of transcranial magnetic stimulation in patients with hand's dystonia

V. Hleb, S.A. Likhachev, G. Zabrodzets, T. Charnukha | MINSK, BELARUS

P 22090 Abstract cancelled

P 22091 Abstract cancelled

P 22092 Validation of the Portuguese version of the 39-item Parkinson's disease questionnaire

J. Jesus Ribeiro, E. Vieira, P. Ferreira, C. Januário, A. Freire-Gonçalves | COIMBRA, PORTUGAL

P 22093 Autonomic dysfunctions and sleep disturbances identify Parkinson's disease patients at risk for developing dementia

A. Jurcau, A. Simion | ORADEA, ROMANIA

P 22094 Clusterin CSF levels in differential diagnosis of neurodegenerative disorders

P. Kanovsky¹, H. Prikrylova Vranova¹, M. Kaiserova¹, D. Stejskal², K. Mensikova¹, J. Mares¹, E. Henykova¹, M. Strnad¹ | ¹OLOMOUC, ²PROSTEJOV, CZECH REPUBLIC

P 22095 First comparison of continuous movement data (Hauser-diary versus Parkinson's KinetiGraph) in patients with Parkinson's disease

L. Klingelhöfer¹, A. Rizo², M. Horne³, A. Sauerbier², S. McGregor³, R. de Micco², D. Trivedi², L. Perkins², H. Reichmann¹, K.R. Chaudhuri² | ¹DRESDEN, GERMANY, ²LONDON, UK, ³MELBOURNE, AUSTRALIA

POSTER SESSION MS AND RELATED DISORDERS 9

13:30-14:15 | SCREEN F1

CHAIRPERSONS:

Nicola De Stefano, SIENNA, ITALY

P 22096 Myeloid microvesicles and risk of multiple sclerosis in patients with clinically isolated syndromes.

G. Dalla Costa, V. Martinelli, T. Croese, A. Finardi, L. Moiola, B. Colombo, G. Comi, R. Furlan | MILAN, ITALY

P 22097 A multi-centre audit to describe the burden of bladder dysfunction in multiple sclerosis

A. Davis, B. Turner, M. Ramadhan, C. Albor, K. Schmierer, G. Giovannoni | LONDON, UK

P 22098 Effect of cladribine tablets on brain atrophy rates in patients with relapsing-remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study

N. de Stefano¹, A. Giorgio¹, M. Battaglini¹, G. Giovannoni³, C. Hicking⁴, F. Dangond⁵, M.P. Sormani² | ¹SIENNA, ²GENOVA, ITALY, ³LONDON, UK, ⁴DARMSTADT, GERMANY, ⁵BILLERICA, USA

P 22099 Treatment-naïve patients with active relapsing-remitting multiple sclerosis at baseline demonstrate continued disability improvement over 5 years with alemtuzumab: CARE-MSI extension study

R. Arroyo Gonzalez¹, D. Dive², E. Havrdova³, S. Hunter⁴, D. H. Margolin⁵, K. Thangavelu⁵, Ó. Fernández⁶

¹MADRID, SPAIN, ²LIEGE, BELGIUM, ³PRAGUE, CZECH REPUBLIC,

⁴FRANKLIN, USA, ⁵CAMBRIDGE, USA, ⁶MALAGA, SPAIN

P 22100 Pregnancy-related estrogen receptor-alpha expression in lymphocyte subsets of women with multiple sclerosis

G. Di Liberto, G. Salemi, P. Ragonese, M. Lo Pizzo, S. Realmuto, D. Di Liberto, F. Dieli | PALERMO, ITALY

P 22101 Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis: a cross-sectional multicentre study

S. Dias¹, A. Gouveia², T. Santos³, H. Rocha⁴, C. Rosado Coelho⁵, L. Ruano⁶, O. Galego², M. Diogo¹, D. Seixas³, M.J. Sá⁴, S. Batista² | ¹LISBON, ²COIMBRA, ³VILA NOVA DE GAIA, ⁴PORTO, ⁵SETÚBAL, ⁶SANTA MARIA DA FEIRA, PORTUGAL

P 22102 Visuospatial skills are more severely impaired in secondary than primary progressive multiple sclerosis

S. Dias¹, A. Gouveia², T. Santos³, H. Rocha⁴, C. Rosado Coelho⁵, L. Ruano⁶, O. Galego², M. Diogo¹, D. Seixas³, M.J. Sá⁴, S. Batista² | ¹LISBON, ²COIMBRA, ³VILA NOVA DE GAIA, ⁴PORTO, ⁵SETÚBAL, ⁶SANTA MARIA DA FEIRA, PORTUGAL

P 22103 Descriptive study and prognosis analysis of longitudinally extensive transverse myelitis

E.D. Diaz Pertuz | PAMPLONA, SPAIN

P 22104 Epilepsy and multiple sclerosis

J. Djelilovic-Vranic, M. Tiric-Campara, A. Alajbegovic,

E. Djozic | SARAJEVO, BOSNIA AND HERZEGOVINA

P 22105 Familial multiple sclerosis: clinical features and course

O. Ekmekci, A.N. Yuceyar | IZMIR - BORNOVA, TURKEY

P 22106 Familial mediterranean fever and multiple sclerosis

O. Ekmekci, A.N. Yuceyar | IZMIR - BORNOVA, TURKEY

P 22107 Clinical efficacy of fingolimod and identification of predictors of relapses in an Italian cohort of multiple sclerosis patients

F. Esposito, L. Ferre¹, M. Radaelli, F. Clarelli, G. Sferruzza, F. Sangalli, M. Rodegher, M.J. Messina, L. Moiola, B. Colombo, M.A. Rocca, M. Filippi, F.G. Martinelli Boneschi, G. Comi, V. Martinelli | MILAN, ITALY

P 22108 Investigation of the role of sphingosine pathway genes on response to fingolimod in a cohort of relapsing remitting multiple sclerosis patients

F. Esposito, F. Clarelli, L. Ferre¹, E. Mascia, G. Sferruzza, I. Keller Sarmiento, M. Radaelli, F. Sangalli, M. Rodegher, M.J. Messina, L. Moiola, B. Colombo, V. Martinelli, M.A. Rocca, M. Filippi, G. Comi, F.G. Martinelli Boneschi | MILAN, ITALY

POSTER SESSION
MS AND RELATED DISORDERS 10

13:30-14:15 | SCREEN F2

CHAIRPERSONS:

Celia Oreja-Guevara, MADRID, SPAIN

P 22109 Percutaneous balloon compression for trigeminal neuralgia in patients with multiple sclerosis

A. Moreira Villanueva, E. Munteis Oliva, A. Zabalza de Torres, P. de Ceballos Cerrajería, G. Villalba Martínez, J. Roquer González | BARCELONA, SPAIN

P 22110 Urinary disorders screening in multiple sclerosis patients. An undervalued problem

T. Muñoz Ruiz¹, V. Fernandez Sanchez¹, P. Sánchez Lozano², V. Reyes Garrido¹, P. Urbaneja Romero¹, M. Guerrero¹, A. Leon Martin¹, A. Gallardo Tur¹, Ó. Fernández¹ | ¹MÁLAGA, ²OVIEDO, SPAIN

P 22111 Familial multiple sclerosis: characteristics in algerian cohort

L. Nessah, S. Daoudi | TIZI-OUZOU, ALGERIA

P 22112 Low-dose Rituximab therapy for neuromyelitis optica spectrum disorders

A. Novo, I. Correia, I. Marques, S. Batista, L. Sousa | COIMBRA, PORTUGAL

P 22113 Decreased soluble IFN β receptor (sIFNAR2) in multiple sclerosis patients: a potential serum diagnostic biomarker

B. Oliver-Martos¹, M.J. Pinto-Medel¹, J. Pavia¹, I. Hurtado¹, J.L. Rodriguez-Bada¹, P. Urbaneja¹, M. Suardiaz¹, L.M. Villar², M. Comabella³, X. Montalban³, J.C. Alvarez-Cermeño², L. Leyva¹, O. Fernandez¹ | ¹MÁLAGA, ²MADRID, ³BARCELONA, SPAIN

P 22114 Multiple sclerosis relapse-related costs of oral disease-modifying therapies in denmark: an economic analysis comparing delayed-release dimethyl fumarate, fingolimod, and teriflunomide

P. O'malley¹, A. Lee¹, K. O'day², M. Friedman² | ¹ZUG, SWITZERLAND, ²PALM HARBOR, USA

P 22115 Efficacy, tolerability and safety of teriflunomide in multiple sclerosis in a real-world clinical setting

C. Oreja-Guevara, A. Orviz-García, E. Guerra-Schulz, V. López de Velasco, F. López-Pérez, M. Palacios, I. González-Suárez | MADRID, SPAIN

P 22116 Switching from first and second line therapy to novel oral MS treatments

C. Oreja-Guevara, G. Ortega-Suero, A. Orviz-García, F. López-Pérez, M. Palacios, J. Matias-Guiu, I. González-Suárez | MADRID, SPAIN

P 22117 Atypical presentation of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a case report with spinal cord involvement

M. Padroni, C. Calanca, V. Rispoli, V. Tugnoli, E. Baldi, E. Fainardi, E. Granieri, M. Pugliatti, L. Caniatti | FERRARA, ITALY

P 22118 Prevalence of depression and fatigue in the 11-year follow-up from the BENEFIT study

I.-K. Penner¹, F. Foley⁴, G. Edan⁷, M. Freedman⁸, X. Montalban⁹, H.-P. Hartung¹, E.J. Fox⁶, B. Hemmer², F. Barkhof¹⁰, S. Schippling¹¹, R. Koelbach³, D. Pleimes³, G. Suarez⁵, E.-M. Wicklein³, L. Kappos¹² | ¹DÜSSELDORF, ²MUNICH, ³BERLIN, GERMANY, ⁴NEW YORK, ⁵WHIPPANY, ⁶ROUND ROCK, USA, ⁷RENNES, FRANCE, ⁸OTTAWA, CANADA, ⁹BARCELONA, SPAIN, ¹⁰AMSTERDAM, THE NETHERLANDS, ¹¹ZURICH, ¹²BASEL, SWITZERLAND

SUNDAY, 29 MAY

13:30 - 14:15

P 22119 Incorporating the TEMSO SIENA analysis improves correlation of brain atrophy and disability progression

M. Pia Sormani¹, E.-W. Radue², T. Sprenger³, L. Gaetano², N. Mueller-Lenke², J. Wuerfel², K. Thangavelu⁴, S. Cavalier⁴, L. Kappos² | ¹GENOA, ITALY, ²BASEL, SWITZERLAND, ³WIESBADEN, GERMANY, ⁴CAMBRIDGE, USA

P 22120 Functional and structural MRI predictors of disability worsening in multiple sclerosis: a 4-year follow-up study

F. Pirro¹, M.A. Rocca¹, P. Valsasina¹, E. Pagani¹, A. Meani¹, M. Copetti², F.G. Martinelli Boneschi¹, M. Rodegher¹, G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ITALY

P 22121 Multimodal evoked potentials predict NEDA evolution in patients starting first-line treatment for multiple sclerosis

M. Pisa¹, M. Bianco, S. Guerrieri, G. Di Maggio, M. Romeo, L. Moiola, V. Martinelli, G. Comi, L. Leocani | MILAN, ITALY

POSTER SESSION MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 4

13:30-14:15 | SCREEN B4

CHAIRPERSON:

Markus Weber, LONDON, UK

P 22122 Myasthenia gravis induced by ipilimumab in a patient with advanced melanoma

V. Montes, S. Sousa, R. Guerreiro, C. Carmona, F. Pita | CASCAIS, PORTUGAL

P 22123 Pseudometabolic phenotype in patients with ANO5 mutations

O. Musumeci¹, M. Savarese², G. Di Fruscio², C. Rodolico¹, E. Barca¹, V. Nigro², A. Toscano¹ | ¹MESSINA, ²NAPLES, ITALY

P 22124 Late-onset Pompe disease in Iran: a clinical and genetic report

F. Nazari, S. Nafissi, Y. Nilipour, F. Sinaie | TEHRAN, IRAN, ISLAMIC REPUBLIC OF

P 22125 Myofascial trigger points creation in mice

N. Ortiz¹, R. Margalef¹, M. Sisquella¹, M. Bosque¹, C. Romeu¹, O. Mayoral², S. Monterde¹, M. Priego¹, J. Tomas¹, M.M. Santafe¹ | ¹REUS, ²TOLEDO, SPAIN

P 22126 Neutral lipid storage with myopathy: role of micro RNA and muscle imaging

V. Pegoraro, C. Angelini, E. Pinzan, E. Tasca | VENICE, ITALY

P 22127 Abstract cancelled**P 22128** Clusters of cognitive impairment among different forms of myotonic dystrophies

S.Z. Peric, G. Mandic-Stojmenovic, V. Ilic, M. Kovacevic, A. Parojcic, V. Dobricic, J. Pesovic, I. Novakovic, D. Savic-Pavicevic, V. Rakocevic-Stojanovic | BELGRADE, SERBIA

P 22129 Progressive Merosin deficiency associated with Lama2 new mutation in a patient deviating from the classical clinical and morphological phenotypes

L. Peverelli, I. Colombo, R. Del Bo, C. Cinnante, F. Magri, F. Fortunato, R. Tironi, A. L'Erario, E. Mauri, N. Grimoldi, G.P. Comi, M.G. Moggio, M. Sciacco | MILAN, ITALY

P 22130 Evolution of inflammatory and degenerative pathological profiles in inclusion body myositis

M. Pinto¹, R. Taipa², M. Pires² | ¹LISBON, ²PORTO, PORTUGAL

P 22131 Necrotizing myopathies: a single-centre experience

V. Ponzalino, S. Bortolani, L. Vercelli, S. Boschi, E. Vittonatto, L. Chiado Piat, N. Ragusa, L. Pinessi, T. Mongini | TURIN, ITALY

P 22132 Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy: case series and magnetic resonance imaging findings

A. Shah, J. Hershenson, M. Novak, A. Davis, M. Stevens, M. Espasandin, S. Vaidya, S. Marino, A. Radunovic | LONDON, UK

P 22133 Anti-musk antibody negative myasthenic crisis patients managed with Rituximab: report of two cases

P. Ranganathan | CHENNAI, INDIA

P 22134 Myasthenia gravis associated with scleroderma: the first case in Greece and systematic review of the literature

P. Zis, P. Kokotis, P. Sfikakis | ATHENS, GREECE

POSTER SESSION NEUROEPIDEMIOLOGY 2

13:30-14:15 | SCREEN C3

CHAIRPERSON:

Alexander Tsiskaridze, TBILISI, GEORGIA

P 22135 Association between ambient temperature and stroke hospitalisations in Minsk, Belarus

O. Mukalova, A. Mukalau, A. Pyko | MINSK, BELARUS

P 22136 First epidemiologic study of Wilson's disease in France

A. Poujois, P. Tuppin, S. Samson, P. Chaine, N. Girardot-Tinant, F. Woimant | PARIS, FRANCE

P 22137 Prevalence of ischemic stroke phenotypes according to ASCOD classification in a Romanian cohort of patients

E. Terecoasa, R. Radu, N. Grecu, S. Gheorghievici, C. Tiu | BUCHAREST, ROMANIA

P 22138 Pregnancies before or after multiple sclerosis onset modify disease course, relapse rate and severity in women affected by multiple sclerosis: a cohort study

P. Ragonese, S. Realmuto, G. Vazzoler, P. Aridon, E. Portera, A. Bianchi, G. Savettieri, G. Salemi | PALERMO, ITALY

P 22139 Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk for most of them?

A. Nicoletti¹, R. Vasta¹, G. Mostile¹, G. Nicoletti², G. Arabia², G. Illiceto³, P. Lamberti³, R. Marconi⁴, L. Morgante⁵, P. Barone⁶, A. Quattrone², M. Zappia¹ | ¹CATANIA, ²CATANZARO, ³BARI, ⁴GROSSETO, ⁵MESSINA, ⁶SALERNO, ITALY

P 22140 Enhanced CJD surveillance in the older population

B. Waddell, G. Logan, S. Pal, G. Holloway, S. Shenkin, M. Head, C. Smith, A. Molesworth | EDINBURGH, UK

P 22141 Organizational model of ischemic stroke management in Northern Lombardy

M. Zagaria¹, V. Sangalli¹, V.D. Scigliano¹, R. Bertè¹, M. Arnaboldi², G. Bezzi³, G. Bono⁴, G. Grampa⁵, M. Guidotti², L. Lodetti¹, M. Migliori¹, P. Perrone⁶, A. Salmaggi⁷, D. Zarcione⁸, E. Agostoni¹ | ¹MILAN, ²COMO, ³SONDRIO, ⁴VARESE, ⁵BUSTO ARSIZIO, ⁶LEGNANO, ⁷LECCO HOSPITAL, ⁸GALLARATE, ITALY

P 22142 Evaluation of pre-hospital and in-hospital times in ischemic stroke management in Northern Lombardy

M. Zagaria¹, V. Sangalli¹, V.D. Scigliano¹, R. Bertè¹, M. Arnaboldi², G. Bezzi³, G. Bono⁴, G. Grampa⁵, M. Guidotti², L. Lodetti¹, M. Migliori¹, P. Perrone⁶, A. Salmaggi⁷, D. Zarcione⁸, E. Agostoni¹ | ¹MILAN, ²COMO, ³SONDRIO, ⁴VARESE, ⁵BUSTO ARSIZIO, ⁶LEGNANO, ⁷LECCO, ITALY, ⁸GALLARATE, ITALY

POSTER SESSION NEUROGENETICS 2

13:30-14:15 | SCREEN F4

CHAIRPERSON:

Karolina Dziezyc, WARSAW, POLAND

P 22143 Analysis of SPAST patients in the UK cohort reveals high rate of psychiatric comorbidities

V. Chelban, A. Tucci, H. Houlden | LONDON, UK

P 22144 Functional outcomes in hereditary spastic paraplegia: a prospective cohort study

N. Chrestian¹, N. Dupré¹, J.-D. Brisson¹, Z. Gan-or², K. Boycott³, O. Suchowersky⁴, G. Rouleau², G. Yoon⁵ | ¹QUEBEC CITY, ²MONTREAL, ³OTTAWA, ⁴EDMONTON, ⁵TORONTO, CANADA

P 22145 Heterozygous mutation of HTRA1 gene in an Italian family with cerebral ischemic small vessel disease

I. Di Donato, S. Bianchi, G.N. Gallus, A. Cerase, A. Federico, M.T. Dotti | SIENNA, ITALY

P 22146 Late-onset Krabbe disease in an adult metabolic disorders consultation

J. Durães¹, J. Tomás¹, M. Tábuas-Pereira¹, C. Caseiro², L. Lacerda², M.C. Macário¹ | ¹COIMBRA, ²PORTO, PORTUGAL

P 22147 Clinical presentation and molecular genetic testing in spinocerebellar ataxia type 17

J. Durães, J. Tomás, I. Santana, J.M.G. Lemos, M.C. Macário | COIMBRA, PORTUGAL

P 22148 Screening for SLC25A46 mutations in familial and sporadic ataxic patients

S. Efthymiou, C. Bettencourt, H. Houlden | LONDON, UK

P 22149 New mutation in the ABCD1 gene associated with X-linked adrenoleukodistrophy

N. García Lax, A. Sanz Monllor, J.Á. Motos García, M. Palao Rico, I.M. Sanchez Ortuño, J. Marín Marín, P.A. Sánchez Ayaso, L. Alemán Romero, A.M. García Medina, J.M. Rodríguez García, M.P. Salmerón Ato, M.L. Martínez Navarro, J.A. Iniesta Valera, A. Díaz Ortuño | MURCIA, SPAIN

P 22150 Double troubles in families with ALS/FTD related to C9orf72 repeat expansion: casual or causal?

M.P. Giannoccaro¹, A. Bartoletti-Stella¹, S. Piras¹, P. de Massis², A. Pession¹, F. Oppi¹, M. Stanzani-Maserati¹, E. Pasini¹, S. Baiardi¹, P. Avoni¹, P. Parchi¹, R. Liguori¹, S. Capellari¹ | ¹BOLOGNA, ²IMOLA, ITALY

P 22151 A next-generation sequencing study in Italian multiple sclerosis multiplex families: looking for rare susceptibility variants

C. Guaschino¹, A. Zauli¹, F. Esposito¹, M. Sorosina¹, E. Mascia¹, S. Santoro¹, A.M. Osiceanu¹, S. Peroni¹, D. Biancolini¹, D. Lazarevic¹, V. Martinelli¹, S. D'alfonso², G. Comi¹, F.G. Martinelli Boneschi¹ | ¹MILAN, ²NOVARA, ITALY

P 22152 A novel TTBK2 de novo mutation in a Danish family with early childhood onset spinocerebellar ataxia type 11 (SCA11)

S.G. Lindquist¹, L.B. Møller¹, E.-J. Kamsteeg², C.I. Dalí¹, J.E. Nielsen¹, L.E. Hjermand¹ | ¹COPENHAGEN, DENMARK, ²NIJMEGEN, THE NETHERLANDS

SUNDAY, 29 MAY

13:30 - 14:15

P 22153 Fragile X-associated tremor/ataxia syndrome in two female patients

L. Hvizdosova, M. Kaiserova, M. Vecerkova, K. Mensikova, P. Kanovsky | OLOMOUC, CZECH REPUBLIC

P 22154 Next generation sequencing in the diagnosis of neurodegenerative diseases: Russian experience

N. Abramychyeva, E. Fedotova, S. Klyushnikov, S. Illarioshkin | MOSCOW, RUSSIAN FEDERATION

P 22155 Variability in the clinical course of congenital myasthenic syndrome type IaK. Kastreva¹, T. Chamova¹, V. Guergelcheva¹, V.M. Mihaylova², S. Cherninkova¹, I. Tournev¹ | ¹SOFIA, BULGARIA, ²ZURICH, SWITZERLAND**P 22156** Cerebrospinal fluid markers in premanifest and manifest Huntington's disease: evidence of sequential development of neurodegeneration and inflammation

T. Vinther-Jensen, L. Börnsen, E. Budtz-Jørgensen, C. Ammitzbøll, I.U. Larsen, L.E. Hjermand, F. Sellebjerg, J. Nielsen | COPENHAGEN, DENMARK

POSTER SESSION
NEUROIMAGING 2

13:30-14:15 | SCREEN A3

CHAIRPERSON:

Luigi Ferini Strambi, MILAN, ITALY

P 22157 PET study in dementia with Lewy bodies patients with and without REM sleep behavior disorder

L. Ferini Strambi, L. Iaccarino, S. Marelli, S. Iannaccone, G. Magnani, D. Perani | MILAN, ITALY

P 22158 Neural network of predictive motor timing in the context of gender differences

P. Filip, M. Bares | BRNO, CZECH REPUBLIC

P 22159 fMRI findings in the final stage of Creutzfeldt-Jakob-diseaseC. Florea¹, S.M. Golaszewski¹, A.F. Unterrainer¹, M. Kronbichler¹, M. Seidl¹, R. Nardone¹, S. Weis², F. Gerstenbrand³, E. Trinka¹ | ¹SALZBURG, ²LINZ, ³VIENNA, AUSTRIA**P 22160** Prevalence of venous sinus stenosis in Pseudotumor cerebri (PTC) using digital subtraction angiography (DSA)

M. Hamdy | CAIRO, EGYPT

P 22161 Asymmetric cortical and basal ganglia MRI alterations on FLAIR and DWI in a patient with Creutzfeldt-Jakob disease (CJD) carrying a V210I mutation

D. Ippolito, L. Lavorgna, R. Docimo, M.P.M. Cirillo, G. Tedeschi, S. Bonavita | NAPLES, ITALY

P 22162 Squeeze and Trace: evaluation of a novel functional magnetic resonance imaging motor-paradigm developed for stroke patients with impaired hand motor functionL.V. Knudsen¹, P. Jensen¹, C. Thomsen¹, A.O. Baandrup², P.M. Fisher¹, L.H. Pinborg¹ | ¹COPENHAGEN, ²ROSKILDE, DENMARK**P 22163** Time course of multiple sclerosis lesions visualized with MRI: insight into focal pathologyP. Maggi¹, F. Zellini², A. Barilaro², A. Passeri², L. Massacesi² | ¹BRUSSELS, BELGIUM, ²FLORENCE, ITALY**P 22164** Resting state functional connectivity in olfactory network in de novo Parkinson's disease

S. Marino, L. Bonanno, F. Caminiti, S. de Salvo, F. Corallo, V. Lo Buono, P. Bramanti, G. Di Lorenzo | MESSINA, ITALY

P 22165 CSF biomarkers to detect cognitive decline in IMI PharmaCog WP5 / European ADNI: a multicenter studyM. Marizzoni¹, C. Ferrari¹, S. Galluzzi¹, E. Rolandi¹, P.J. Visser², L. Parnetti², F. Nobili³, M. Didic⁴, D. Bartrés-Fas¹², U. Fiedler¹³, P. Schonknecht¹⁴, P. Payoux¹⁰, A. Beltramello⁴, A. Soricelli⁵, M. Tsolaki¹⁵, P.M. Rossini⁶, G.L. Forloni⁷, R. Bordet¹¹, O. Blin⁹, G. Frisoni¹⁶ | ¹BRESCIA, ²PERUGIA, ³GENOVA, ⁴VERONA, ⁵NAPLES, ⁶ROME, ⁷MILAN, ITALY, ⁸AMSTERDAM, THE NETHERLANDS, ⁹MARSEILLES, ¹⁰TOULOUSE, ¹¹LILLE, FRANCE, ¹²BARCELONA, SPAIN, ¹³ESSEN, ¹⁴LEIPZIG, GERMANY, ¹⁵THESSALONIKI, GREECE, ¹⁶GENEVA, SWITZERLAND**P 22166** Brain magnetic resonance imaging in cerebrotendinous xanthomatosis: a single-centre experience

A. Mignarri, L. Monti, P. Galluzzi, N. de Stefano, A. Federico, M.T. Dotti | SIENNA, ITALY

P 22167 Clinical application of diffusion tensor imaging in pathology of the spinal cord

M. Moldovanu, O. Gavriluc | CHISINAU, MOLDOVA

P 22168 Quantitative sparing of cortical metabolism in combination with striatal hypermetabolism on cerebral FDG PET scanning in voltage gated potassium channel mediated limbic encephalitis

P. Moloney, R. Boylan, M. Elamin, S. O'riordan, K. Ronan, C. McGuigan | DUBLIN, IRELAND

P 22169 The investigation between DAT SPECT and MIBG myocardial scintigraphy in diagnosis of PD and DLB

R. Ohtani, N. Murase, Y. Hirokawa, N. Enomoto, Y. Kuwata, M. Takata, M. Sainouchi, M. Goto, K. Yasuda, T. Ito, M. Nakamura | KYOTO, JAPAN

P 22170 Preliminary analysis of chemical exchange saturation transfer (CEST) images and z-spectrum of different metabolism models

Y. Yang¹, R. Wu² | ¹XIAMEN, ²SHANTOU, CHINA

P 22171 Study of chemical exchange saturation transfer MRI on brain metastases at 1.5 Tesla

Y. Yang¹, R. Wu² | ¹XIAMEN, ²SHANTOU, CHINA

P 22172 Study of chemical exchange saturation transfer MRI on cerebral infarction at 1.5 Tesla

Y. Yang¹, R. Wu² | ¹XIAMEN, ²SHANTOU, CHINA

POSTER SESSION NEUROIMMUNOLOGY 2

13:30-14:15 | SCREEN H2

CHAIRPERSON:

Maarten Titulaer, ROTTERDAM, THE NETHERLANDS

P 22173 Clinical characteristics, immunological accompaniments and treatment outcomes of autoimmune cerebellar ataxia

V. Damato, G. Silvestri, A. Evoli, R. Iorio | ROME, ITALY

P 22174 Long-term neuropsychological outcome of anti-NMDA receptor encephalitis in children

M. de Bruijn¹, F. Aarsen¹, A. Sonderen van², C. Catsman-Berrepoets¹, R. Neuteboom¹, M. Schreurs¹, P.A. Sillevs Smitt¹, M. Titulaer¹ | ¹ROTTERDAM, ²THE HAGUE, THE NETHERLANDS

P 22175 Tolerability of the intravenous immunoglobulin octagam® 10% in neurologic indications: a subgroup analysis of a non-interventional study in Germany

A. Debes, S. Tascou | LANGENFELD, GERMANY

P 22176 Therapeutic plasma exchange in patients with neurological diseases: experience of the neurology department, Mohammed VI University Hospital of Marrakech

H. Elmouden, N. Adali, N. Kissani | MARRAKECH, MOROCCO

P 22177 Overlapping demyelinating syndrome in an anti-NMDA encephalitis case

L. Fontao¹, I. Alves², C. Santos¹ | ¹SANTA MARIA DA FEIRA, ²PENAFIEL, PORTUGAL

P 22178 Comparison of antibody assays in anti-NMDAR encephalitis

M. Gastaldi¹, A. Thouin², E.P. Coutinho³, L. Jacobson³, S. Irani³, A.C. Vincent³ | ¹PAVIA, ITALY, ²NEWCASTLE, ³OXFORD, UK

P 22179 Rare comorbidity of multiple sclerosis and HIV infection in a patient. New drugs and new possibilities

C. Skarlis, M. Gontika, S. Katsavos, M. Anagnostouli | ATHENS, GREECE

P 22180 NMDA autoimmune encephalitis triggered by a herpes simplex virus encephalitis: a case report

R. Gutiérrez-Zúñiga, J. Ruiz-Jimenez, R.M. Vilchez-Carrillo, A. Romero-Villarrubia, V. Guillén-Martínez, L. Triguero-Cueva, C. Carnero-Pardo | GRANADA, SPAIN

P 22181 Autoimmune encephalitis at the neurological intensive care unit: etiologies, reasons for admission and survival

G. Harutyunyan, L. Hauer, M.W. Dünser, A. Karamyan, T. Moser, S. Pikiya, M. Leitinger, H.F. Novak, E. Trinko, J. Sellner | SALZBURG, AUSTRIA

P 22182 The possible role of sirtuin 1 in migraine pathogenesis

C. Irkeç, D. Yazicioğlu Cezayir, T. Altıparmak, R. Tural, N. Altan | ANKARA, TURKEY

P 22183 CXCL10 and CXCL13 chemokines in relapsing-remitting and primary progressive multiple sclerosis

P. Iwanowski, L. Kramer, M. Wójcicka, E. Kaufman, R. Kaźmierski, J. Losy | POZNAN, POLAND

P 22184 Abstract cancelled

P 22185 MOG positive seronegative NMO presenting with absence F-wave in an electrophysiological study

S. Nahrir, N. Kajtazi, J. Saeedi | RIYADH, SAUDI ARABIA

P 22186 Peripheral regulatory T-/ Th17-cells contributes to Moya-Moya disease

Y. Xu, X. Cao, L. Weng | NANJING, CHINA

POSTER SESSION NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC DISEASES 2

13:30-14:15 | SCREEN B3

CHAIRPERSON:

Peter D. Berlit, ESSEN, GERMANY

P 22187 Association of parenchymal and vascular damage (mixed pattern) in neurobehcet's disease: a case series study

H. El Otmani, K. Obondzo, T. Benhsain, M.A. Rafai, B. El Moutawakil, I. Slassi | CASABLANCA, MOROCCO

SUNDAY, 29 MAY

13:30 - 14:15

P 22188 Prognostic factors and long-term follow-up of 20 cases of Neuro-Behçet disease: a retrospective study

B. Houria | ALGIERS, ALGERIA

P 22189 A case of posterior reversible encephalopathy syndrome (PRES) in a patient with paraganglioma

L. Huachan | OUTRAM, SINGAPORE

P 22190 Moya-Moya syndrome in a patient with Takayasu's arteritis

K.D. Jo, W. Jang, M.K. Lee | GANGNEUNG, KOREA, REPUBLIC OF

P 22191 Impact of white matter lesions on processing speed deficits in systemic lupus erythematosus patients

M. Pawlak¹, A. Kalinowska-Lyszczarz¹, M. Forycka¹, M. Wilkosc², Z. Serafin², K. Pawlak-Buś¹, P. Leszczynski¹, E. Wiesik-Szewczyk³, R. Kaźmierski¹, W. Kozubski¹ | ¹POZNAN, ²BYDGOSZCZ, ³WARSAW, POLAND

P 22192 Abstract cancelled

P 22193 Tacrolimus-induced posterior reversible encephalopathy

G. Koc¹, S. Bek² | ¹ANKARA, ²ADANA, TURKEY

P 22194 Hypoparathyroidism with severe brain calcinosis presenting as non-convulsive status epilepticus

M. Spilioti, G. Konstantinidis, K. Notas, A. Theofilidis, E. Pimpilidou, M. Grammatiki, K. Kotsa, E. Koutsouraki, A. Orologas | THESSALONIKI, GREECE

P 22195 Autoimmune meningoencephalitis with two possible etiologic factors: HCV infection and anti-NMDA receptor antibodies

R. Loureiro, M.V. Dias, J. Becho, M. Santos, F. Carrilho, P. Costa, J. Cruz, C. Fidalgo, F. Roxo, A. Palos | SANTARÉM, PORTUGAL

P 22196 Acquired hepatocerebral degeneration and hepatic encephalopathy: an overlapping case

C. Machado, A.F. Santos, J.N. Alves, A.S. Costa, V. Mendes, F. Sousa | BRAGA, PORTUGAL

POSTER SESSION NEURO-OPHTHALMOLOGY/ NEURO-OTOLOGY 2

13:30-14:15 | SCREEN H1

CHAIRPERSON:

Dominik Straumann, ZURICH, SWITZERLAND

P 22197 Palinopsia: a strange visual phenomenon

S. Fernández, N. Fabregat, A. Donaire | BARCELONA, SPAIN

P 22198 The association between multiple sclerosis and uveitis

T. Gadegaard Olsen¹, J. Frederiksen² | ¹THISTED, ²GLOSTRUP, DENMARK

P 22199 Blurred vision in MS: is it always optic neuritis?

J. Gauci, C. Chircop, N. Vella | MSIDA, MALTA

P 22200 Upbeat nystagmus due to B1 deficiency: a case report

M.J. Ibanez, E. Pappa, B. Gaymard, D. Psimaras | PARIS, FRANCE

P 22201 Isolated vertigo in emergency room

B. Kim | SEOUL, KOREA, REPUBLIC OF

P 22202 Isolated vertigo with posterior circulation infarction

B. Kim | SEOUL, KOREA, REPUBLIC OF

P 22203 Benign paroxysmal positional vertigo: 20-year experience in treating 1195 patients with canalith repositioning procedure

N. Chatzakis¹, D. Kotzamani¹, A. Karatzanis¹, S. Velegrakis², E. Prokopakis¹ | ¹HERAKLION CRETE, GREECE, ²ERLANGEN, GERMANY

P 22204 Neuro-phthamological and clinical findings in Wolfram syndrome: indications of mitochondrial dysfunction

C. La Morgia¹, M. Carbonelli¹, L. Caporali¹, F. Sadun², C. Tonon¹, R. Lodi¹, M.L. Valentino¹, P. Barboni¹, R. Liguori¹, V. Carelli¹ | ¹BOLOGNA, ²ROME, ITALY

P 22205 Saccade kinematics in myotonic syndromes

E. Livitzis, G. Papadimas, I. Potiri, I. Evdokimidis, E. Kararizou, E. Anagnostou | ATHENS, GREECE

P 22206 Relationship between retinal nerve fiber layer and vitamin D levels in patients with multiple sclerosis

P. López Méndez, A. Ruano Hernández, Á. Ruiz Pérez, M. Sosa Henríquez, A. Gonzalez Hernandez, J.R. García Rodríguez | LAS PALMAS DE GRAN CANARIA, SPAIN

P 22207 Status of the extracranial segments of the vertebral arteries in the vestibular dysfunction caused by the neurovascular conflict

H. Lushchyk, I. Maryenko, S.A. Likhachev, A. Antonenko, D. Naumenko | MINSK, BELARUS

P 22208 Gradenigo's syndrome caused by odontogenic infection: an unusual aetiology

M. Machio Castello, M. Oses, L. Olivie Garcia, R. Rigual Bobillo, M. Ruggiero Garcia, M.T. Montojo Villasanta, J. Villacampa Aubá, M.A. Garcia Torres, I. Zamarbide Capdepón | MADRID, SPAIN

POSTER SESSION
PERIPHERAL NERVE DISORDERS 4

13:30-14:15 | SCREEN D2

CHAIRPERSON:

Davide Pareyson, MILAN, ITALY

P 22209 Utility of sensory nerve conduction and summed Z-scores in polyneuropathy

T. Sand¹, K.B. Nilsen², M. Engstrom¹, R. Michler¹, T. Wader¹, K. Todnem¹ | ¹TRONDHEIM, ²OSLO, NORWAY

P 22210 Sjögren's syndrome presenting as subacute sensory ataxic neuropathy and sensorineural hearing loss

M. Santos, R. Martins, R. Paquete Oliveira, A. Furtado, A.P.S.P. Lobo, R. Manso, B. Grima, L. Santos, M.C.M. Costa | AMADORA/LISBON, PORTUGAL

P 22211 Sensory ganglionopathy associated with gluten sensitivity: a case report

J. Sequeira, S. Dias, J. Morgado, C.M.C. Capela, A. Calado, R.M.G. Pedrosa | LISBON, PORTUGAL

P 22212 Rituximab in the treatment of anti-myelin-associated glycoprotein (anti-MAG) neuropathy resistant to conventional immune therapies: a 15-year experience

S. Simonetti | GENOA, ITALY

P 22213 Interest of anti-ganglioside antibodies for the diagnosis of neuropathies of unknown aetiology: a series of 47 patients

M. Stéphant, P. Chretien, C. Cauquil, G. Beaudonnet, A. Not, S. Hacein-Bey, D. Adams, C. Labeyrie | LE KREMLIN-BICÊTRE, FRANCE

P 22214 An unusual cause of transient diplopia

K. Szóke, Z. Aranyi, G. Bozsik, D. Bereczki | BUDAPEST, HUNGARY

P 22215 Acute polyneuropathy secondary to thiamine deficiency: one year of follow-up

H. Tibar, W. Regragui, E. Ait Ben Haddou, A. Benomar, M. Yahyaoui | RABAT, MOROCCO

P 22216 Abstract cancelled

P 22217 Lewis-Sumner syndrome (L-SS), a rare variant of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

M.H. Torregrosa Martinez, M. Molina Sánchez, P. Hernández Navarro, L.A. Lozano García-Caro | MADRID, SPAIN

P 22218 Motor unit number estimation in acute inflammatory demyelinating polyneuropathy

M. Vaeggemose, A. Fuglsang-Frederiksen, H. Andersen, B. Isak, T. Harbo, H. Tankisi | AARHUS, DENMARK

P 22219 Can a mobile phone be used to test vibration sensation?

H. van Den Tooren¹, E. McKee², D. McKee¹ | ¹MANCHESTER, ²EDINBURGH, UK

P 22220 Chronic demyelinating polyneuropathy – clinical-immunological correlation

L. Vieira, I. Correia, J. Ribeiro, A. Matos, A.P. Geraldo, L.J.M.P. Negrão | COIMBRA, PORTUGAL

P 22221 Self-reported questionnaires for patients with suspected neuropathies in outpatient settings

N. Yavorska, V. Smilevska | LVIV, UKRAINE

MONDAY, 30 MAY 2016

SESSIONS



International Parkinson and
Movement Disorder Society

21st International Congress of Parkinson's Disease and Movement Disorders



SAVE THE DATE

June 4–8, 2017

VANCOUVER

British Columbia, Canada

www.mdscongress2017.org

CASE-BASED FACILITATED WORKSHOP 4: MANAGEMENT OF MULTIPLE SCLEROSIS

08:30 - 10:00 | HALL B4. M2

CHAIRPERSON:

Aksel Siva, ISTANBUL, TURKEY

Management of MS attacks

Aksel Siva, ISTANBUL, TURKEY

Symptomatic management

Oscar Fernandez, MALAGA, SPAIN

Long-term management

Michel Clanet, TOULOUSE, FRANCE

Management of pediatric MS

Alexey Boyko, MOSCOW, RUSSIA

In this case-based facilitated workshop different aspects of multiple sclerosis management will be discussed through pre-prepared real-life four clinical case scenarios.

- The first case will address management of MS attacks and will include issues such as the differential of pseudo-attacks, how to work up a patient prior to attack treatment and attack treatment protocols, including steroid non-responders.
- The second case will cover symptomatic management in an MS patient who had developed some neurologic deficits as a part of her MS.
- The third case is on long-term management, when to start a DMD, which one to start and some of the safety issues as well as when to consider that a patient is a responder or non-responder, and when to switch?
- In the fourth case scenario a paediatric patient with MS will be presented and available options in the management of paediatric MS will be reviewed.

In the first part of the workshop each of the cases will be discussed by one of the four groups together with one of the faculty members who will act as a facilitator and then in the second part each case will be discussed by all participants.

HANDS-ON COURSE 4: NEUROPHYSIOLOGY III – NON-INVASIVE BRAIN STIMULATION

08:30 - 10:00 | HALL B5. M1

CHAIRPERSON:

Letizia Leocani, ROME, ITALY

Single transcranial magnetic stimulation (TMS)

Josep Classen, LEIPZIG, GERMANY

Repetitive TMS and transcranial direct current stimulation (rTMS and tDCS)

Letizia Leocani, ROME, ITALY

The practical course on magnetic and direct current stimulation will provide an opportunity for learning of the basic principles, standards of use, and potential applications of TMS and tDCS in clinical neurophysiology and neurology. Participants will have learned how to determine motor threshold, how to record motor evoked potentials, how to determine central motor latency, conduct silent period, and paired-pulse TMS studies, and how to safely apply repetitive TMS and tDCS. Participants will also learn how to interpret findings of TMS studies.

This course is supported by NATUS MEDICAL Inc. and Neuroelectronics SL

INTERACTIVE SESSION 3: MDS-ES/EAN: PAROXYSMAL AND ACUTE MOVEMENT DISORDERS

08:30 - 10:00 | HALL B

CHAIRPERSON:

Timothy Lynch, DUBLIN, IRELAND

Movement disorders in the intensive care unit

Timothy Lynch, DUBLIN, IRELAND

Paroxysmal dyskinesia or epilepsy?

Laurent Vercueil, GRENOBLE, FRANCE

Psychogenic movement disorders

Kailash Bhatia, LONDON, UK

Participants are encouraged to actively engage with immediate feedback to support learning via the congress App EAN 2016.



MONDAY, 30 MAY

8:30 - 10:00

FOCUSED WORKSHOP 13: SLEEP AND COGNITION

08:30 - 10:00 | HALL C

CHAIRPERSON:

Pierre Maquet, LIÈGE, BELGIUM

Sleep and cognition

Pierre Maquet, LIÈGE, BELGIUM

Sleep and emotion

Virginie Sterpenich, GENEVA, SWITZERLAND

Sleep and dementia

Sebastian Overeem, NIJMEGEN, THE NETHERLANDS

Target Audience: Basic scientists, clinical academicians, (practitioners), students/residents/trainees

Scientific Content: The workshop covers three different topics illustrating the importance of sleep in clinical neurology. Pierre MAQUET presents the mechanisms by which sleep and wakefulness mutually interact, and which constrain patients' performance and recovery. Professor Schwartz explores the structural and anatomical links between emotional processing and neurological diseases such as narcolepsy.

Professor Overeem reviews the mechanisms by which sleep, and lack of sleep, are involved in brain amyloid clearance and accumulation, respectively.

FOCUSED WORKSHOP 14: GUT MICROBIOTA, IMMUNOLOGY AND NEUROLOGICAL DISEASES

08:30 - 10:00 | HALL M1

CHAIRPERSON:

Gurumoorthy Krishnamoorthy, MARTINSRIED, GERMANY

Microbiota and the gut-brain axis

Patricia Lepage, JOUY-EN-JOSAS, FRANCE

Microbiota and CNS autoimmunity (multiple sclerosis)

Gurumoorthy Krishnamoorthy, MARTINSRIED, GERMANY

Gut microbiome: a key regulator of neurodevelopment and behaviour

John F. Cryan, CORK, IRELAND

Target Audience: Basic scientists, clinical academicians, students/residents/trainees

Scientific Content: The human intestinal microbiota, composed of approximately 100,000 billion microorganisms, can be considered as an organ within another, which co-evolved with its host to achieve a symbiotic relationship leading to physiological homeostasis. Dysbiosis of the intestinal microbiota (changes in bacterial composition) has been associated with local dysfunctions of the gastrointestinal tract, such as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS), but also, at distance, in obesity and metabolic diseases. The possible involvement of the 'microbiota-gut-brain' axis in the development of such disorders, will be further discussed, as well as the role of gut microbiome in central nervous system immune-mediated, neurodevelopmental and behavioural disorders.

FOCUSED WORKSHOP 15: EXOME SEQUENCING GOES BEDSIDE: NEW GENES IN NEUROLOGICAL DISORDERS

08:30 - 10:00 | HALL M3

CHAIRPERSON:

Matthis Synofzik, TÜBINGEN, GERMANY

Cerebellar ataxias: exome sequencing unravels novel genes, false friends and clinical hints for bedside

Matthis Synofzik, TÜBINGEN, GERMANY

Atypical parkinsonian syndromes: rapidly expanding genetic disease spectrum, yet distinct clinical and imaging signatures

Henry Houlden, LONDON, UK

Motor neuron disease and spastic paraplegias: large-scale exome sequencing reveals common pathogenetic hubs

Rebecca Schüle, TÜBINGEN, GERMANY

Target Audience: Basic scientists, clinical academicians, practitioners, students/residents/trainees

Scientific Content: Next generation genomics like whole exome sequencing (WES) has led to a quantum leap in clinical neurology and neurogenetics, providing unprecedented options to diagnose previously unsolved patients, to define the genetic basis of many rare and complex neurological disorders, and to gain first insights into underlying molecular pathways. Given this success, WES is now moving from academic research settings to clinical routine, and from few well-selected families to many individual patients with less unique phenotypes. This development is evidenced by the fact that the „Clinical Exome“ has now become readily available, allowing to use standardized WES with high coverage, quick turn-around times, clear reports requiring no genetic expert knowledge, at relatively low cost (<1500€). This focused workshop will

1. give an overview on the methodology of WES, its strengths and its pitfalls
2. provide an overview on novel genes and associated molecular pathways in three exemplary neurodegenerative disease groups where WES has allowed to identify several new genes within only few years: degenerative ataxias, parkinsonian syndromes, and motor neuron diseases
3. outline and discuss the power and the limitations of using WES „at the bedside“, i.e. in the daily practice of busy clinical routine with only one patient or family at a time and sometimes without additional expert knowledge for interpreting the particular WES variants at hand.

Target Audience: Basic Scientists, clinical academicians, practitioners, students/residents/trainees, non-physician health professionals

Scientific Content: ALS and FTD are since 2016 a single disease: the neuropathology first provided proof and genetics largely confirmed and contributed in defining the convergence. The clinical implications are so relevant both in the subgrouping of the patients and in the design of clinical trials that further clarifications are highly needed for a more accurate definition of the cognitive and motor involvement of both diseases.

FOCUSED WORKSHOP 16: SYNDROMES OF CENTRAL VISUAL AND VESTIBULAR DISORDERS

08:30 - 10:00 | HALL M4

CHAIRPERSON:

Christopher Kennard, OXFORD, UK

Cortical visual disorders and neglect

Christopher Kennard, OXFORD, UK

Peripheral vestibular disorders with essential bedside testing

Barry Seemungal, LONDON, UK

Central vestibular disorders (from brainstem to cortex)

Thomas Brandt, MUNICH, GERMANY

Target Audience: Clinical academicians, practitioners, students/residents/trainees

Scientific Content: Actual knowledge of syndromes and diagnostic procedures of peripheral vestibular and the different central visual and vestibular disorders depending on the lesion site

FOCUSED WORKSHOP 17: ALS AND FTD: TWO CONVERGING DISEASES?

08:30 - 10:00 | HALL M5

CHAIRPERSON:

Vincenzo Silani, MILAN, ITALY

Neuropathology of FTD and ALS – comparing the patterns of propagation

Johannes Brettschneider, PHILADELPHIA, USA

Assessment of neuropsychology in ALS and FTD

Thomas Bak, EDINBURGH, UK

ALS and FTD: genetics and phenotypes

Vincenzo Silani, MILAN, ITALY

SPECIAL SESSION 5: PAUNS/EAN NEUROMEDITERRANEAN SESSION: INFECTIOUS DISEASES

08:30 - 10:00 | HALL M2

CHAIRPERSON:

Franz Fazekas, GRAZ, AUSTRIA

Nabil Mohsen, BEIRUT, LEBANON

Life-threatening infections of the central nervous system: time matters for optimal antimicrobial and adjunctive therapies.

Erich Schmutzhard, INNSBRUCK, AUSTRIA

Infectious neuropathies

Nazha Birouk, RABAT, MOROCCO

Early neuropathological changes during septic shock

Fabrice Chrétien, PARIS, FRANCE

Post infectious encephalitis

Nabil Mohsen, TRIPOLIS, LEBANON

Scientific Content: Infectious diseases are still a leading cause of burden in Mediterranean countries. In this context, neurological complications are quite frequent and CNS and PNS may be concerned. In this session will be discussed a few of these neurological disorders and some mechanisms inducing infectious lesions of the nervous system. The management of these diseases benefits of recent techniques and drugs which will be also presented.

MONDAY, 30 MAY

8:30 - 14:30

SPECIAL SESSION 6: ILAE-CEA/EAN: HOT TOPICS IN EPILEPSY

08:30 - 10:00 | HALL M0

CHAIRPERSON:

Hermann Stefan, ERLANGEN, GERMANY

Reetta Kälviäinen, KUOPIO, FINLAND

Recent advances in structural brain imaging in epilepsies

Reetta Kälviäinen, KUOPIO, FINLAND

EEG and MEG monitoring in epilepsy

Sándor Beniczky, DIANALUND, DENMARK

Epilepsy and gender

Gerhard Luef, INNSBRUCK, AUSTRIA

Seizures and epilepsy in the aging population

Hermann Stefan, ERLANGEN, GERMANY

PLENARY SYMPOSIUM 2: NEUROIMAGING OF DEMENTIA

10:30 - 12:30 | HALL A

CHAIRPERSON:

Reinhold Schmidt, GRAZ, AUSTRIA

Massimo Filippi, MILAN, ITALY

Imaging of cerebral small vessel disease

Reinhold Schmidt, GRAZ, AUSTRIA

Imaging of Alzheimer's disease

Philip Scheltens, AMSTERDAM, THE NETHERLANDS

Imaging of frontotemporal dementia

Massimo Filippi, MILAN, ITALY

Monitoring treatment response in dementia trials

Nick Fox, LONDON, UK

HOW TO IMPROVE YOUR CHANCES... ABSTRACT, POSTER AND PRESENTATION TIPS FOR SUCCESS AT INTERNATIONAL MEETINGS

13:00 - 14:30 | HALL B4, M2

CHAIRPERSON:

Hannah Cock, LONDON, UK

How to Prepare & Submit your abstract

Hannah Cock, LONDON, UK

Preparing your poster or slides

Aksel Siva, ISTANBUL, TURKEY

Delivering your poster or oral presentation

Claudia Sommer, WÜRZBURG, GERMANY (TBC)

Target Audience: Neurologists at any level who are relatively inexperienced in submitting work for presentation at international congresses, or experienced in their native country, but may be less competitive/successful on an international stage.

Educational objective: Practical advice on every step from abstract preparation to delivering your poster or oral platform presentation will be provided by experts from the Education and Program committees of the EAN, with ample opportunity to ask questions and seek advice.

CASE-BASED FACILITATED WORKSHOP 5: CARE OF THE PERSON WITH ALS

14:45 - 16:15 | HALL B4, M2

CHAIRPERSON:

David Oliver, CANTERBURY, UK

Telling the diagnosis and initial care

Marianne de Visser, AMSTERDAM, THE NETHERLANDS

Interventions – gastrostomy and ventilation – and the palliative care needs of ALS patients and their families

Johanna Anneser, MUNICH, GERMANY

Care at the end of life

David Oliver, CANTERBURY, UK

Assisted suicide and euthanasia in ALS – experience across Europe

Markus Weber, ST. GALLEN, SWITZERLAND

The care of the person with ALS and their family is complex and involves the careful assessment and management of all aspects of care – physical, psycho-social and spiritual. This workshop considers the pathway of care from the telling of the diagnosis and initial management of symptoms and other issues, the complex decisions for patients and families with interventions, in particular gastrostomy and non-invasive ventilation, and the care as the condition deteriorates and the patient approaches end of life, including when a patient considers assisted dying.

Learning objectives: The workshop will aim to allow participants to look at the issues of caring for a person with ALS, particularly as the end of life approaches.

At the end of the workshop participants will be able to

- Describe the importance of good care in the initial stages following diagnosis and the importance of the telling of the diagnosis
- Discuss the use of gastrostomy and ventilator support in the care of a person with ALS
- Discuss the changes in the use of gastrostomy and ventilator support as the end of life approaches
- Show awareness of the recognition of the end of life phase in ALS and the support that may be provided for patients and families
- Show awareness of the issues of hastened death – by assisted suicide or euthanasia for people with ALS

SPECIAL SESSION 11: HISTORY OF NEUROLOGY

14:45 - 16:15 | HALL M0

CHAIRPERSON:

Mads Ravnborg, COPENHAGEN, DENMARK

A short introduction to the history of Scandinavian neurology: from the sagas to the Nobel prizes

Ragnar Stien, OSLO, NORWAY

Nicolaus Steno, Discourse on the Anatomy of the Brain, Paris 1665, with a new programme for brain research

Troels Kardel, COPENHAGEN, DENMARK

Functional mapping of the human brain using regional cerebral blood flow techniques – the early development

Lars Friberg, FREDRIKSBERG, DENMARK

The regional CBF changes during migraine attacks

Jes Olesen, COPENHAGEN, DENMARK

SYMPOSIUM 5: NEW PERSPECTIVES IN THE TREATMENT OF NEUROMUSCULAR DISEASES: THERAPIES ON THE HORIZON

14:45 - 16:45 | HALL B

CHAIRPERSONS:

Eduardo Nobile-Orazio, MILAN, ITALY

John Vissing, COPENHAGEN, DENMARK

Amyotrophic lateral sclerosis: still far from an effective therapy?

Vincenzo Silani, MILAN, ITALY

Myasthenia gravis: new therapies for new antibodies?

Nils-Erik Gilhus, BERGEN, NORWAY

Immune mediated neuropathies: monoclonal antibodies and what else?

Eduardo Nobile-Orazio, MILAN, ITALY

Genetic treatment in muscular dystrophies: hope or reality?

Francesco Muntoni, LONDON, UK

Scientific content: A number of novel therapies have been proposed in the recent years in different neuromuscular disease raising some expectations especially for diseases where current therapies are unsatisfactory. We will approach in this Symposium the new therapeutic approach and the new possible perspective in some neuromuscular disease. We decided to address two diseases in whom effective therapies are available although they are not always satisfactory leading to the continuous search for more effective and safer therapies, such as myasthenia gravis and CIDP, and two diseases where the consistent advances in the comprehension of their pathogenesis has not yet led to effective therapies such as muscular dystrophies and motor neuron diseases.

MONDAY, 30 MAY

14:45 - 16:45

SYMPOSIUM 6: ESO/EAN: ACUTE STROKE: NEW OPPORTUNITIES AND CHALLENGES FOR NEUROLOGISTS

14:45 - 16:45 | HALL A

CHAIRPERSONS:

Danilo Toni, ROME, ITALY

Christina Kruuse, COPENHAGEN, DENMARK

Intracranial large vessel occlusions: how to recognise them as fast as possible

Patrik Michel, LAUSANNE, SWITZERLAND

Anterior and posterior circulation: mind the differences

Daniel Strbian, ESPOO, FINLAND

Pathway of acute stroke: how to reduce the 'pit-stops' of acute stroke

Danilo Toni, ROME, ITALY

Who should treat acute large vessel occlusions: neurologists, radiologists or neuro-interventionists?

Christine Kremer, MALMÖ, SWEDEN

Scientific content: Acute stroke is an emergency that general neurologists face regularly. Regarding its treatment, recanalisation strategies, including the administration of intravenous (IV) recombinant tissue-type plasminogen activator (rt-PA) and intra-arterial approaches, aim to establish revascularisation by rescuing cells in the penumbra prior to any irreversible injury. Endovascular techniques have shown greater benefit up to 8 h after stroke onset in the proximal anterior circulation in addition to best medical therapy (IVT up to 4.5 h in most patients), compared to intravenous rt-PA alone. However, several issues remain concerning their use in posterior circulation, the applicability of RCT trials on anterior circulation for basilar occlusion. Moreover, it needs to be discussed who should perform these techniques: certified neurologists, interventional radiologists or radiologists.

EHF/EAN TOPICAL SYMPOSIUM: CGRP ANTIBODIES: A NEW CLASS OF MIGRAINE-SPECIFIC PREVENTIVE MEDICATION

14:45 - 16:45 | HALL M5

CHAIRPERSONS:

Messoud Ashina, FREDRIKSBERG, DENMARK

Dimos Mitsikostas, ATHENS, GREECE

Current treatment for migraine: efficacy and safety outcomes

Julio Pascual, SANTANDER, SPAIN

The role of CGRP in migraine: from molecule to man

Messoud Ashina, FREDRIKSBERG, DENMARK

CGRP antibodies in treatment of migraine: efficacy and mechanism of action

Peter Goadsby, LONDON, UK

Can acute and preventive migraine medication pass the blood brain barrier?

Gitte Moos Knudsen, COPENHAGEN, DENMARK

Target Audience: Basic scientists, clinical academicians, practitioners, students/residents/trainees

Scientific content: Calcitonin gene related peptide (CGRP), a peptide present in sensory trigeminal fibres, induces dilatation of extracerebral arteries. CGRP plays a key role in migraine pathophysiology. In migraine patients, intravenous infusion of CGRP causes a migraine attack. Randomized controlled trials (RCT) have demonstrated that CGRP monoclonal antibodies may prevent migraine attacks. This session will review the role of CGRP in migraine, the results of RCT in migraine sufferers and discuss possible site of action of CGRP antibodies in migraine.

Supported by an unrestricted educational grant from Novartis

TEACHING COURSE 13: DIAGNOSTIC AND THERAPEUTICAL APPROACH TO MUSCLE SYNDROMES – LEVEL 1

14:45 - 18:15 | HALL C

CHAIRPERSON:

Corrado Angelini, VENICE, ITALY

Dysphagia: differential diagnosis and treatment

Bruno Eymard, PARIS, FRANCE

How to diagnose proximal muscle weakness

Corrado Angelini, VENICE, ITALY

How to diagnose distal muscle weakness

Bjarne Udd, TAMPERE, FINLAND

How to diagnose muscle weakness in children

Francesco Muntoni, LONDON, UK

This teaching course is directed to diagnose muscle and end-plate disorders by clinical patterns such as proximal or distal weakness, muscle MRI imaging, EMG studies and a series of laboratory investigations such as serum CK and antibody screening, muscle biopsy study such as biochemistry, muscle histopathology, immunohistochemistry, electron microscopy and new molecular techniques on DNA and RNA, i.e. next generation sequencing analysis. At the end of the presentations, physicians and neurologists attending to the teaching course will receive a full-immersion and up-to-date access to current diagnosis and possible treatments in neuromuscular disorders, including both muscular dystrophies and myositis, acquired muscle disorders and metabolic disorders or myasthenic disorders.

TEACHING COURSE 14: PAIN IN CENTRAL NEUROLOGICAL CONDITIONS – LEVEL 2

14:45 - 18:15 | HALL M1

CHAIRPERSON:

Nadine Attal, BOULOGNE-BILLAN COURT, FRANCE

Pain in stroke

Troels S. Jensen, ARHUS, DENMARK

Pain in spinal cord injury patients

Maija Haanpää, HELSINKI, FINLAND

Pain in multiple sclerosis

Giorgio Cruccu, ROME, ITALY

Pain in syringomyelia

Nadine Attal, BOULOGNE-BILLAN COURT, FRANCE

Pain is common in central neurological conditions including stroke, multiple sclerosis or spinal cord injury. Although neuropathic pain is usually the most troublesome, many of these patients also suffer from nociceptive or visceral pain, that can also impair quality of life and complexifies the therapeutic management.

Educational objectives:

- learn about epidemiology and risk factors for neuropathic pain associated with stroke, multiple sclerosis and spinal cord injury.
- understand the mechanisms of pain related to these neurological conditions
- know the therapeutic management of pain particularly neuropathic pain including drug and non pharmacological treatment, and the current therapeutic recommendations.

TEACHING COURSE 15: CLINICAL PRESENTATIONS OF METABOLIC DISORDERS – LEVEL 2

14:45 - 18:15 | HALL M2

CHAIRPERSON:

Davide Pareyson, MILAN, ITALY

Metabolic disorders presenting with dementia or psychosis

Oliver Bonnot, NANTES, FRANCE

Metabolic disorders presenting with movement disorders

Antonio Federico, SIENA, ITALY

Metabolic disorders presenting with ataxia or spastic paraplegia

Jean-Marc Burgunder, BERN, SWITZERLAND

Metabolic disorders presenting with peripheral neuropathies

Davide Pareyson, MILAN, ITALY

Genetic metabolic disorders of the central and peripheral nervous system are important for several reasons. Although rare if considered individually, they are overall frequent. Early diagnosis is fundamental to provide correct therapy (as some of them are treatable), proper genetic counselling, and to avoid misdiagnosis with the more common disorders they often mimic. Four specialists in the field will discuss metabolic diseases presenting with different clinical pictures. Olivier Bonnot, Antonio Federico, Jean-Marc Burgunder and Davide Pareyson will discuss heritable metabolic disorders characterized by psychosis/dementia, movement disorders, ataxia/spasticity, and peripheral neuropathy, respectively. They will review the diagnostic algorithms, the most relevant diagnostic challenges as well as the clinical and instrumental key elements for a correct diagnosis.

MONDAY, 30 MAY

14:45 - 18:15

TEACHING COURSE 16: INTERVENTIONS IN NEUROCRITICAL CARE – LEVEL 2

14:45 - 18:15 | HALL M3

CHAIRPERSON:

Christina Panea, BUCHAREST, ROMANIA

Fluid and electrolyte management

Christina Panea, BUCHAREST, ROMANIA

Analgesia, sedation and relaxation

Ronny Beer, INNSBRUCK, AUSTRIA

Nutrition in the Neuro ICU

Murat Arsava, ANKARA, TURKEY

Emerging new roles for neurologists in the treatment of patients with subarachnoid haemorrhage and traumatic brain injury

Erich Schmutzhard, INNSBRUCK, AUSTRIA

In neurocritical care it becomes more and more accepted that a wide variety of seemingly non-neurological interventions may interact with a stressed or even failing brain, thereby preventing progression of failure and reversing functional impairment. Therefore, a broad critical care medicine basis is the prerequisite for the best possible management of neurocritical care patients. Christina Panea details the aspects of fluid and electrolyte management, any mismanagement in this respect may add to neurological deterioration, even permanent damage of brain tissue, e.g. brain edema, pontine myelinolysis aso. The same applies to best balanced nutrition, avoiding malnutrition, refeeding syndrome and over-nutrition in NICU patients, discussed by Murat Arsava. Similarly, the delicate measures in NICU patients, so essential for keeping the intracranial equilibrium and homeostasis, namely analgesia, sedation and relaxation are discussed in this course, Ronny Beer will point to all potential pitfalls and how to avoid possible life-threatening mistakes in this ICU-management aspect. Finally, Erich Schmutzhard will address the emerging new roles for neurologists in the treatment of patients with subarachnoid haemorrhage and traumatic brain injury. It is the thorough knowledge of brain metabolism, brain function and malfunction which qualifies the neurologist to be the key person in the emergency-, intensive care- and post intensive care management of these patients.

TEACHING COURSE 17: UPDATE ON EPILEPSY IN CHILDREN – NEW TRENDS IN DIAGNOSIS AND TREATMENT – LEVEL 1

14:45 - 18:15 | HALL M4

CHAIRPERSON:

Rima Nabbout, PARIS, FRANCE

Clinical pearls and pitfalls in the diagnosis of pediatric epilepsy

Daniela Pohl, OTTAWA, CANADA

New genes – when, why and what to test in children with epilepsy

Rima Nabbout, PARIS, FRANCE

New antiepileptic drugs – pros and cons in kids

Thomas Bast, KEHL-KORK, GERMANY

Nonpharmacological treatment approaches: Ketogenic diet and neurostimulation

Helen Cross, LONDON, UK

This session is dedicated to childhood epilepsies and will focus on 4 major aspects.

Dr Pohl will present clinical cases of difficult to diagnose and common pitfalls in the diagnosis of pediatric epilepsies. Her talk will include the new proposals for classification and terminology in epilepsy syndromes. She will emphasize the key role of EEG-video.

Dr. Nabbout will speak about conjoint efforts of clinicians and the spectacular advances of molecular biology tools have allowed the identification of causal genes in childhood epilepsy syndromes as Dravet syndrome or Epilepsy of infancy with migrating focal seizures and the description of new genetic syndromes as for patients with PCDH19 or CDKL5 mutations. This presentation will focus on some monogenic genetic epilepsy syndromes of interest for paediatric neurologists. It aims to discuss the impact of gene discovery on diagnosis, genetic counselling and our future vision of development of new targeted therapies that should aim beyond the treatment of seizures to cure a genetic disease.

Dr. Bast will address the current knowledge of AEDS in childhood epilepsies and will emphasize the level of evidence for the efficacy of these drugs the new AEDs. He will discuss also possible misuse of these drugs.

And Dr. Cross will discuss the use of non pharmacological treatments in childhood epilepsies. Her topic will address the syndromes where these treatments showed the best response and will focus on syndromes where these treatments should be introduced early in the course of the disease. She will show how to follow-up Ketogenic diet and to avoid adverse events.

TOURNAMENT CLINICAL

14:45 - 16:15 | HALL B5. M1



CHAIRPERSONS:

Claudio Bassetti, BERN, SWITZERLAND
 Marianne Dieterich, MUNICH, GERMANY
 Jesper Erdal, COPENHAGEN, DENMARK

T 201 Low maternal folic acid in women with epilepsy during pregnancy is linked to autistic traits in the child at 3 years of age

M.H. Bjørk, G. Veiby, O. Spigset, B. Riedel, E. Kolstad, A.K. Daltveit, N.E. Gilhus | BERGEN, NORWAY

T 202 Anti-LGI1 mediated autoimmune encephalitis in Denmark: a multicenter retrospective study

M. Celicanin¹, F. Somnier¹, C. Mærsk-Møller², M. Blaabjerg³, F. Winther Bach⁴, D. Kondziella¹, H. Andersen², Z. Illes³, L. Pinborg¹ | ¹COPENHAGEN, ²AARHUS, ³ODENSE, ⁴AALBORG, DENMARK

T 203 Clinical, biochemical, molecular and histological features of 65 Portuguese patients with genetically confirmed mitochondrial disorders

S. Cruz¹, R. Taipa², C. Nogueira², C. Pereira², L. Almeida², R. Neiva², T. Geraldes³, M. Melo Pires², L. Vilarinho² | ¹AMADORA, ²PORTO, ³ALMADA, PORTUGAL

T 204 Imaging nigrostriatal circuitry with 11C-PE2I PET and Neuromelanin-sensitive MR in Parkinson's disease

A. Martin Bastida¹, N. Lao-Kaim¹, A.-A. Roussakis¹, M. Politis¹, W. Li¹, N. Valle-Guzman², Z. Kefalopoulou¹, G. Paul³, H. Widner³, T. Foltynie¹, R. Barker², P. Piccini¹ | ¹LONDON, ²CAMBRIDGE, UK, ³LUND, SWEDEN

T 205 Identification of MS patients at highest risk of cognitive impairment using integrated brain MRI assessment approach

T. Uher¹, M. Vaneckova¹, M.P. Sormani², J. Krasensky¹, L. Sobisek¹, J. Blahova¹, Z. Seidl¹, E. Havrdova¹, T. Kalincik³, R.H. Benedict⁴, D. Horakova¹ | ¹PRAGUE, CZECH REPUBLIC, ²GENOA, ITALY, ³MELBOURNE, AUSTRALIA, ⁴BUFFALO, USA

T 206 Complete resection of contrast enhancing tumor volume is associated with improved survival in recurrent glioblastoma – results from the DIRECTOR trial

H.-G. Wirsching¹, J.C. Tonn², G. Tabatabai¹, C. Senft³, P. Hau⁴, M.C. Sabel⁵, U. Herrlinger⁶, R. Ketter⁷, U. Schlegel⁸, C. Marosi⁹, G. Reifenberger⁵, W. Wick¹⁰, M. Weller¹, B. Suchorska² | ¹ZÜRICH, SWITZERLAND, ²MUNICH, ³FRANKFURT AM MAIN, ⁴REGENSBURG, ⁵DÜSSELDORF, ⁶BONN, ⁷HOMBURG/SAAR, ⁸BOCHUM, GERMANY, ⁹VIENNA, AUSTRIA, ¹⁰HEIDELBERG, GERMANY

ORAL SESSION: CEREBROVASCULAR DISEASES 2

16:45-18:30 | HALL A

CHAIRPERSONS:

Franz Fazekas, GRAZ, AUSTRIA
 Christina Kruuse, HERLEV, DENMARK

O 3101 Hemorrhagic strokes in Caribbean

M. Agbetou¹, R. Dellis¹, F. Alecu¹, S. Mecharles², C. Dan¹, A. Lannuzel¹, C. Alecu² | ¹POINTE À PITRE, ²POINTE A PITRE, FRANCE

O 3102 Brain metabolic alterations in patients with hypertension: a 2D-1H proton magnetic resonance spectroscopy imaging study

Z. Cao, R.H. Wu, B.D. Ye, Z.W. Shen, Y.Y. Xiao | SHANTOU, CHINA

O 3103 No evidence for increased brain iron deposition in patients with ischemic white matter disease

T. Gattringer, M. Khalil, C. Langkammer, M. Jehna, M. Kneihsl, A. Pichler, D. Pinter, K. Petrovic, S. Ropele, F. Fazekas, C. Enzinger | GRAZ, AUSTRIA

O 3104 The prehospital Aarhus stroke severity scale for prediction of emergent large vessel occlusion: design, validation and comparison with other scales

S. Hastrup, D. Damgaard, S.J. Paaske, G. Andersen | AARHUS, DENMARK

O 3105 Vertebrobasilar occlusion stroke: does stent retrievers' thrombectomy modify the outcome?

F. Perren¹, V. Mendes Pereira² | ¹GENEVA, SWITZERLAND, ²TORONTO, CANADA

O 3106 Gender differences in thrombolysed stroke patients

M.R. Heldner, R. Kurmann, R. Balasubramaniam, M.-L. Mono, F. Pult, K. Hsieh, S. Jung, P. Mordasini, J. Gralla, M. Arnold, U. Fischer | ¹KØBENHAVN V, ²COPENHAGEN, DENMARK

O 3107 Carotid endarterectomy and endovascular treatment in the recanalisation therapy of acute internal carotid artery occlusion

R. Herzig¹, M. Roubec², D. Skoloudik², M. Kuliha², D. Sanak³, P. Sevcik⁴, D. Václavik², A. Tomek⁵, A. Krajina¹, V. Prochazka², M. Kocher³, F. Slau⁴, T. Hrbac², P. Bachleda³, D. Krajicková¹, J. Waishaupt¹, E. Vitkova¹, K. Blejcharova¹, J. Zapletalova³, M. Valis¹ | ¹HRADEC KRALOVE, ²OSTRAVA, ³OLOMOUC, ⁴PILSEN, ⁵PRAGUE, CZECH REPUBLIC

MONDAY, 30 MAY

16:45 - 18:15

ORAL SESSION: COGNITIVE NEUROLOGY/ NEUROPSYCHOLOGY 2

16:45-18:15 | HALL B5, M1

CHAIRPERSONS:

Steen Hasselbalch, COPENHAGEN, DENMARK

Wolfgang Heide, CELLE, GERMANY

O 3108 Influence of lateralised hemispheric asymmetries upon numerical cognition and its influence upon pro-social decision making in Parkinson's disease
16:45

Q. Arshad, A. Bonsu, P.A. Malhotra, N. Pavese, A. Bronstein | MUNICH, GERMANY

O 3109 Prevalence of post-stroke cognitive disorders: a meta-analysis
17:00

M. Barbay, O. Godefroy, M. Roussel, M. Diouf, S.G. Grecogvasc | AMIENS, FRANCE

O 3110 Different patterns of gray and white matter damage are associated to PASAT and SDMT performances in relapsing remitting multiple sclerosis patients
17:15

A. D'ambrosio, M.A. Rocca, G.C. Riccitelli, E. Pagani, L. Vacchi, B. Colombo, P. Preziosa, A. Falini, G. Comi, M. Filippi | MILAN, ITALY

O 3111 Anodal tDCS over left parietal cortex improves apraxic imitation deficits
17:30

J. Ant¹, E. Achilles¹, E. Niessen², J. Saliger³, H. Karbe³, P.H. Weiss-Blankenhorn², G.R. Fink¹ | ¹COLOGNE, ²JÜLICH, ³BONN, GERMANY

O 3112 Personality traits could influence permeability of transcranial direct current stimulation in depressed patients
17:45

S.E. Parhizgar, S.M. Rayegani, S. Seyedahmadian, S. Ghafoorfard | TEHRAN, IRAN

O 3113 Montreal cognitive Assessment in mild cognitive impairment: correlation with cerebral spinal fluid biomarkers and prediction of conversion to dementia
18:00

I. Santana, I. Baldeiras, D. Duro, M. Tábuas-Pereira, M.J. Leitão, R. Lemos, C. Oliveira, S. Freitas | COIMBRA, PORTUGAL

ORAL SESSION: HEADACHE AND PAIN 2

16:45-18:15 | HALL M5

CHAIRPERSONS:

Jes Olsen, COPENHAGEN, DENMARK

Peter Goadsby, LONDON, UK

O 3114 Effectiveness of Sphenopalatine Ganglion (SPG) stimulation for cluster headache: 24-month long-term follow-up results from the pathway CH-1 study
16:45

R. Jensen¹, M. Barloese², J.M. Lainez³, C. Gaul⁴, J. Schoenen⁵, A. Goodman⁶, A. Caparso⁶, A. May⁷, T. Jürgens⁸ | ¹GLOSTRUP, ²COPENHAGEN, DENMARK, ³VALENCIA, SPAIN, ⁴KOENIGSTEIN, GERMANY, ⁵LIEGE, BELGIUM, ⁶REDWOOD CITY, USA, ⁷HAMBURG, GERMANY, ⁸ROSTOCK, GERMANY

O 3115 Persistent idiopathic facial pain: a prospective systematic study of clinical characteristics and neuroanatomical findings at 3.0 Tesla MRI
17:00

S. Maarbjerg, F. Wolfram, T.B. Heinskou, P. Rochat, A. Gozalov, J. Brennum, J. Olesen, L. Bendtsen | COPENHAGEN, DENMARK

O 3116 Self-medication with over-the-counter analgesics: a survey of patient characteristics and attitudes about pain medication
17:15

E. Mehuys¹, K. Paemeleire¹, G. Crombez¹, T. van Hees², S. Demarche², T. Christiaens¹, L. van Bortel¹, I. van Tongelen¹, J.-P. Remon¹, K. Boussey¹ | ¹GHENT, ²LIEGE, BELGIUM

O 3117 Overlooked chronic pain in diabetic patients with cognitive impairment
17:30

M. Rakusa, S. Gak, M. Rakusa, M. Cokolic | MARIBOR, SLOVENIA

O 3118 Tolerability of antiepileptic drugs in migraine and epilepsy: who is at increased risk of adverse events?
17:45

M. Romoli, S. Siliquini, I. Corbelli, S. Caproni, C. Bedetti, P. Eusebi, C. Costa, P. Sarchielli, P. Calabresi | PERUGIA, ITALY

O 3119 PACAP38 dose-response study in migraine patients
18:00

A.L.H. Vollesen, S. Guo, M. Ashina | COPENHAGEN, DENMARK

ORAL SESSION: MOVEMENT DISORDERS 3

16:45-18:15 | HALL MO

CHAIRPERSONS:

Pille Taba, TARTU, ESTONIA

Timothy Lynch, DUBLIN, IRELAND

O 3120 Functional connectivity underpinnings of fatigue in "drug-naïve" patients with Parkinson's disease

A. Giordano¹, M.P.A. Tessitore¹, R. de Micco¹, P.G. Caiazzo¹, A. Russo¹, M.P.M. Cirillo¹, P.F. Esposito², M.P.G. Tedeschi¹ | ¹NAPLES, ²SALERNO, ITALY

O 3121 The cerebral structural and functional signatures of impulse control disorder in Parkinson's disease

F. Imperiale¹, F. Agosta¹, E. Canu¹, V. Spica², M. Ječmenica Lukić², M. Copetti³, V.S. Kostic², M. Filippi¹ | ¹MILAN, ITALY, ²BELGRADE, SERBIA, ³SAN GIOVANNI ROTONDO, ITALY

O 3122 Increased serotonin-to-dopamine transporter ratios in Parkinson's disease dyskinesias: a longitudinal study

A.-A. Roussakis¹, N. Lao-Kaim¹, A. Martin Bastida¹, N. Valle-Guzman², Z. Kefalopoulou¹, G. Paul³, H. Widner³, M. Politis¹, T. Foltyni¹, R.A. Barker², P. Piccini¹ | ¹LONDON, ²CAMBRIDGE, UK, ³LUND, SWEDEN

O 3123 Unilateral MR-guided high intensity focused ultrasound ablation of the cerebellothalamic tract in essential tremor

S. Schreglmann¹, S. Haegle-Link², R. Bauer², N. A. Wegener³, A. Lebeda², B. Werner³, E. Martin³, G. Kägi¹ | ¹LONDON, UK, ²ST. GALLEN, SWITZERLAND, ³ZURICH, SWITZERLAND

O 3124 Relationship between the MDS-UPDRS and quality of life in Parkinson's disease: a large international multicenter study (the QUALPD study)

M. Škorvánek¹, P. Martinez-Martin², N. Kovacs³, I. Zezula¹, M. Rodriguez-Violante⁴, J.-C. Corvol⁵, P. Taba⁶, K. Seppi⁷, O. Levin⁸, A. Schrag⁹, T. Foltyni⁹, Z. Gdovinova¹, C. Goetz¹⁰, G.T. Stebbins¹⁰, Qualpd Study Group¹ | ¹KOSICE, SLOVAKIA, ²MADRID, SPAIN, ³PÉCS, HUNGARY, ⁴MEXICO DF, MEXICO, ⁵PARIS, FRANCE, ⁶TARTU, ESTONIA, ⁷INNSBRUCK, AUSTRIA, ⁸MOSCOW, RUSSIAN FEDERATION, ⁹LONDON, UK, ¹⁰CHICAGO, USA

O 3125 Is awake intraoperative mapping still necessary for bilateral subthalamic stimulation for Parkinson's disease in a modern surgical environment?

Y. Zouiting, M. Lefranc, M.P.O. Godefroy, M. Roussel, M. Tir, P. Merle, P. Krystkowiak | AMIENS, FRANCE, USA

ORAL SESSION: MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE

16:45-18:15 | HALL B

CHAIRPERSONS:

Antonio Toscano, MESSINA, ITALY

Henning Andersen, AARHUS, DENMARK

O 3126 Peripheral neuropathy in patients with CPEO associated with single and multiple mtDNA deletions

D. Lehmann¹, M.E. Kornhuber¹, C. Clajus¹, C.L. Alston², A. Wienke¹, M. Deschauer¹, R.W. Taylor², S. Zierz¹ | ¹HALLE, GERMANY, ²NEWCASTLE, UK

O 3127 Targeted next generation sequencing to unravel undiagnosed limb girdle muscular dystrophies

E. Mauri¹, F. Magri¹, M. Savarese², G. Di Fruscio², A. Govoni¹, M. Moggio¹, R. Brusa¹, D. Piga¹, D. Ronchi¹, R. Del Bo¹, F. Fortunato¹, V. Nigro², G.P. Comi¹ | ¹MILAN, ²NAPLES, ITALY

O 3128 Insulin signalling and cytoskeleton abnormalities contribute to insulin resistance in myotonic dystrophies

G. Meola¹, L.V. Renna¹, S. Iachettini¹, B. Fossati¹, L. Saraceno¹, R. Colombo², R. Cardani¹ | ¹SAN DONATO MIL., ²MILAN, ITALY

O 3129 Central nervous system abnormalities in late onset Pompe disease (LOPD): evidences from neuropsychological, morphological and functional MRI studies

Q. Musumeci, S. Marino, F. Granata, E. Barca, F. Corallo, S. de Salvo, L. Bonanno, R. Morabito, M. Longo, P. Bramanti, A. Toscano | MESSINA, ITALY

O 3130 A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes

G. Ricci¹, L. Ruggiero², L. Vercelli³, F. Sera⁴, A. Nikolic¹, F. Mele¹, M. Govi¹, C. Angelini⁵, G. Antonini⁶, A. Berardinelli⁷, E. Bucci⁶, M. Cao⁸, G. D'angelo⁹, A. Di Muzio¹⁰, M. Filosto¹¹, L. Maggi¹², M. Moggio¹², T. Mongini¹³, E. Pegoraro⁸, C. Rodolico¹³, L. Santoro², G. Siciliano¹⁴, G. Tomelleri¹⁵, L. Villa¹², R. Tupler¹ | ¹MODENA, ²NAPLES, ³TURIN, ITALY, ⁴LONDON, UK, ⁵LIDO VENICE, ⁶ROME, ⁷PAVIA, ⁸PADUA, ⁹BOSISIO PARINI, ¹⁰CHIETI, ¹¹BRESCIA, ¹²MILAN, ¹³MESSINA, ¹⁴PISA, ¹⁵VERONA, ITALY

O 3131 A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy

J. Vissing¹, R. Barresi², N. Witting¹, M. van Ghelue³, L. Gammelgaard⁴, L. Bindoff⁵, V. Straub⁶, H. Lochmuller⁶, J. Hudson⁷, C.M. Wahl⁸, S. Arnardottir⁹, K. Dahlbom¹⁰, C. Jonsrud³, M. Dunø¹ | ¹COPENHAGEN, DENMARK, ²NEWCASTLE UPON TYNE, UK, ³TROMSØ, NORWAY, ⁴VYBORG, DENMARK, ⁵BERGEN, NORWAY, ⁶NEWCASTLE, UK, ⁷NEWCASTLE UPON THYNE, UK, ⁸DURACH, GERMANY, ⁹SOLNA, SWEDEN, ¹⁰ÖREBRO, SWEDEN

MONDAY, 30 MAY 2016

POSTERSESSIONS

POSTER SESSION AGEING AND DEMENTIA 5

12:30-13:15 | SCREEN A2

CHAIRPERSON:

Stefano Cappa, MILAN, ITALY

P 31001 Abstract cancelled

P 31002 Differences in prevalence and treatment of atrial fibrillation in dementia disorders. Data from the Swedish Dementia Registry

D. Religa¹, L. Bognandi, P. Čermáková, B. Winblad, M. Seyed-Fereshtehnejad, S. Garcia-Ptacek, M.E. Eriksson² | STOCKHOLM, SWEDEN

P 31003 Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

G. Rizzo¹, S. Arcuti², M. Copetti³, M. Alessandria², R. Savica⁵, A. Fontana³, R. Liguori¹, G. Logroscino⁴ | ¹BOLOGNA, ²TRICASE, ³SAN GIOVANNI ROTONDO, ⁴BARI, ITALY, ⁵ROCHESTER, USA

P 31004 High incidence of sporadic Creutzfeldt-Jakob disease in Slovenia in 2015

T. Rus, N. Čakš Jager, M. Popović, M. Blaško Markič, M. Kramberger Gregoric | LJUBLJANA, SLOVENIA

P 31005 Clinical variability in Gerstmann-Sträussler-Scheinker syndrome: a retrospective case study

R. Rusinga, S. Johanidesová, Z. Rohan, R. Matěj | PRAGUE, CZECH REPUBLIC

P 31006 Timed Up and Go Dual Task and 11C-PiB-PET as prognostic indicators of progression in mild cognitive impairment and mild AD

M. Schjonning Nielsen¹, A. Hviid Simonsen², I. Law², V. Siersma², S.G. Hasselbalch², P. Høgh¹ | ROSKILDE, ²COPENHAGEN, DENMARK

P 31007 Quantitative electroencephalography (qEEG) as a prognostic marker of progression in mild cognitive impairment (MCI) and mild Alzheimer's disease (AD)

M. Schjonning Nielsen¹, A. Hviid Simonsen², S.G. Hasselbalch², P. Høgh¹ | ROSKILDE, ²COPENHAGEN, DENMARK

P 31008 Czech Brain Aging Study (CBAS) – National longitudinal cohort study with AD biomarkers. Design and first data about progression rates in 3 year follow-up

K. Sheardova¹, M. Vyhnálek², Z. Nedelska², J. Laczó², R. Andel³, R. Marciniak¹, D. Hudecek¹, B. Dvorakova¹, O. Lerch², J. Hort² | ¹BRNO, ²PRAGUE, CZECH REPUBLIC, ³TAMPA, FLORIDA, USA

P 31009 Combination therapy of cholinesterase inhibitor plus memantine for behavioral and psychological symptoms in Alzheimer's disease patients
C. Shin | GWANG-JU, KOREA, REPUBLIC OF

P 31010 miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia: an exploratory study
S.S. Sørensen, A.-B. Nygaard, T. Christensen | HILLERØD, DENMARK

P 31011 Structural brain changes on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)
R. Stephen¹, Y. Liu¹, T. Ngandu², E. Levälähti², J. Rinne³, N. Kempainen³, R. Parkkola³, R. Antikainen⁴, T. Strandberg⁴, M. Kivipelto⁵, H. Soininen¹, A. Solomon¹ | ¹KUOPIO, ²HELSINKI, ³TURKU, ⁴OULU, FINLAND, ⁵STOCKHOLM, SWEDEN

P 31012 Abstract cancelled

POSTER SESSION CEREBROVASCULAR DISEASES 10

12:30-13:15 | SCREEN G4

CHAIRPERSON:

Fabienne Perren, LAUSANNE, SWITZERLAND

P 31013 Wake-Up Stroke and Thrombolytic Therapy
M. Nevsimalova¹, M. Reiser¹, L. Štěrba¹, J. Sova², K. Hes², J. Fiedler², S. Ostry¹ | ¹ČESKÉ BUDĚJOVICE - BUDWEIS, CZECH REPUBLIC, ²ČESKÉ BUDĚJOVICE, CZECH REPUBLIC

P 31014 A case report of a young patient with acute ischemic stroke and marijuana/ cannabis abuse
N. Neykov, I. Staikov, A. Simeonova | SOFIA, BULGARIA

P 31015 Abstract cancelled

P 31016 Primary angiitis of the CNS presenting as migraine-like headache with oculomotor nerve palsy: a case report
Z.U. Nissa, M. Khan, H. Hashim, S. Alrukn | DUBAI, UNITED ARAB EMIRATES

MONDAY, 30 MAY

12:30 - 13:15

P 31017 Non-dominant posterior variant alien hand syndrome after acute right thalamo-occipital infarction: a case report

F.D. Örken, E. Kivrak, Z. Cengiz, N. Gonderten | ISTANBUL, TURKEY ARAB EMIRATES

P 31018 Isolated unilateral and bilateral internuclear ophthalmoplegia due to ischemic stroke

P. Orosz, I. Szócs, G. Varallyay, G. Rudas, D. Bereczki, I. Vastagh | BUDAPEST, HUNGARY

P 31019 Cognitive and behavioral deficiency after bilateral thalamic infarct due to occlusion of the artery of Percheron

B. Özkara, H. Kaya, S. Mulayim, H. Efendi | KOCAELI, TURKEY

P 31020 Gamma aminobutyric acid receptor antagonist promotes functional neurological recovery after permanent distal middle cerebral artery occlusion in rats

M. Pace¹, L. Facchin¹, A. Adamantidis¹, P. Machado², D.M. Hermann³, C. Bassetti¹ | ¹BERNE, SWITZERLAND, ²FRANCE, ³ESSEN, GERMANY

P 31021 Abstract cancelled

P 31022 Incidence of stroke in young adults admitted to a stroke unit

P. Pérez Torre, F.J. González Gómez, A. Escobar Villalba, P. Martínez Ulloa, E. Monreal Laguillo, A. de Albóniga-Chindurza, A. de Felipe Mimblera, C. Matute Lozano, R. Vera, A. Cruz Culebras, J. Masjuan | MADRID, SPAIN

P 31023 Subclavian steal syndrome: a diagnostic challenge: case report

I. Karanfilovic, M. Perovska | SKOPJE, MACEDONIA

P 31024 Stent retrievers thrombectomy in acute middle cerebral artery occlusion: should it be performed in the elderly?

F. Perren¹, L. Puke¹, C. Kremer², V. Mendes Pereira³ | ¹GENEVA, SWITZERLAND, ²LUND, SWEDEN, ³TORONTO, CANADA

P 31025 TOAST vs. ASCOD: Agreement and comparison between etiologic and phenotypic classification of ischemic stroke in a Romanian cohort of patients

C. Tiu, R. Radu, E. Terecoasa, V. Tiu, O.A. Bajenaru | BUCHAREST, ROMANIA

P 31026 Antiphospholipid antibodies negative Sneddon's syndrome: study of 25 cases with cerebral MRI and angiography

M. Rahman¹, S. Aidi¹, M. Maamar¹, L. Semli¹, R. Elhassani¹, M. Jiddane¹, C. Hicham², M. Benabdeljil¹, M. El Alaoui Faris¹ | ¹RABAT, ²MARRAKECH, MOROCCO

POSTER SESSION
CEREBROVASCULAR DISEASES 11

12:30-13:15 | SCREEN G3

CHAIRPERSON:

Ana Subic, LJUBLJANA, SLOVENIA

P 31027 Emotional and cognitive changes in stroke patients

I. Severyn | KHARKOV, UKRAINE

P 31028 Abstract cancelled

P 31029 Association of lipoprotein subfractions with arterial stiffness in acute ischemic stroke

P. Šiarnik, Z. Čarnická, K. Klobucnikova, B. Kollár, I. Žitňanová, P. Turcani | BRATISLAVA, SLOVAKIA

P 31030 Improved post-ischaemic stroke recovery over 1 year with Escitalopram for 3 months

A. Jurcau, A. Simion | ORADEA, ROMANIA

P 31031 Admission glucose levels affect stroke outcome after mechanical thrombectomy

A. Slowik, A. Ferens, A. Golenia, J. Chrzanowska-Wasko, D. Wloch-Kopec, B. Lasocha, P. Brzegowy, T. Popiela | CRACOW, POLAND

P 31032 Feasibility and safety of thrombolysis triage by mobile off-site teleconsultation with iPad in Hong Kong

Y. Soo, V. Ip, K. Leung, F. Fan, A. Chan, S.H. Ma, V. Mok, L. Wong, T. Leung | HONG KONG, HONG KONG (SAR OF CHINA)

P 31033 Recanalisation after revascularisation therapy in acute cardioembolic ischemic stroke

S. Sousa¹, A. Sousa², G. Nunes², S. Galego², M. Mariano², A. Fior², C. Sousa², A. Paiva Nunes² | ¹CASCAIS, ²LISBON, PORTUGAL

P 31034 Predictors of functional outcome at 3 months after cardioembolic ischemic stroke

S. Sousa¹, A. Sousa², G. Nunes², S. Galego², M. Mariano², A. Fior², C. Sousa², A. Paiva Nunes² | ¹CASCAIS, ²LISBON, PORTUGAL

P 31035 Influence of intravenous thrombolysis on long-term excellent functional outcome in ischemic stroke patients

M. Stefanović Budimkić, T. Pekmezovic, L. Bumbaširević, M. Ercegovac, I. Berisavac, P.D. Stanarcevic, V. Padjen, A. Rajic, D. Jovanovic | BELGRADE, SERBIA

P 31036 Stroke, atrial fibrillation and anticoagulation - fights with the mortar

M.H. Strothjohann, F. Weber | BAD CAMBERG, GERMANY

P 31037 Treatment of atrial fibrillation in dementia patients

A. Subic¹, S. Garcia-Ptacek², P. Čermáková², M. Gregoric Kramberger¹, B. Winblad², M.E. Eriksdotter² | ¹LJUBLJANA, SLOVENIA, ²STOCKHOLM, SWEDEN

P 31038 Factor affecting functional outcome after endovascular recanalisation in wake-up stroke

S.M. Sung¹, T.H. Lee¹, S.W. Lee² | ¹BUSAN, ²YANGSAN, KOREA, REPUBLIC OF

P 31039 Neurosonology for the diagnosis of stroke in isolated acute vestibular syndromes

M. Tábuas-Pereira, J. Sargento-Freitas, L.D.A.M.M. Isidoro, F. Silva, O. Galego, C. Nunes, G. Cordeiro, L. Cunha | COIMBRA, PORTUGAL

P 31040 Emotional and behavioural impairment: think about stroke

L. Tesolin | TRIESTE, ITALY

P 31041 Thickening of liquids reduces aspiration risk in acute stroke patients

J. Zaborski, A. Czernuszenko | WARSAW, POLAND

POSTER SESSION
COGNITIVE NEUROLOGY/
NEUROPSYCHOLOGY 3

12:30-13:15 | SCREEN A3

CHAIRPERSON:

Laszlo Csiba, DEBRECEN, HUNGARY

P 31042 Abstract cancelled

P 31043 Location of the ischemic lesions and severity of the physical disability have influence on cognitive impairment after stroke

K. Ovcar, J. Potocnik, M. Menih, T. Seruga, M. Rakusa | MARIBOR, SLOVENIA

P 31044 Could CGRP expression be useful as a serum biomarker indicating the inverse incidence of Alzheimer's disease versus a specific subtype of breast cancer?

V. Papantoniou, P. Valsamaki, C. Skiadaresi, Z. Delichas, I. Papantoniou, M. Tsiouma, D. Papadimitriou, A. Papadimitriou, M.-A. Dimopoulos, I. Dimitroulis, S. Papageorgiou | ATHENS, GREECE

P 31045 Neuropsychological tests for multiple sclerosis: validation of a battery for the Portuguese population

M. J. Sá¹, M. Neves², C. Sousa¹, A.M. Passos², A. Ferreira² | ¹PORTO, ²LISBON, PORTUGAL

P 31046 Normalisation of timed neuropsychological tests with the use of dysarthria and upper limbs performance tests

T. Costabile, F. Abate, A. Liguori, F. Paciello, G. de Michele, A. Filla, F. Sacca¹ | NAPLES, ITALY

P 31047 Montreal Cognitive Assessment (MoCA) in the detection of cognitive dysfunction in multiple sclerosis

M.I.J. Santana, S. Batista, A.C. Afonso, M.R. Simões, L. Sousa, L. Cunha, S. Freitas | COIMBRA, PORTUGAL

P 31048 Assessment of the visuospatial gnosis: using computer method of 3D rotating object recognition

I. Shvetsova, S. Brakk, E. Mozheiko, S. Prokopenko | KRASNOYARSK, RUSSIAN FEDERATION

P 31049 Dementia rating scale in differentiating multiple system atrophy, progressive supranuclear palsy and dementia with Lewy bodies

S. Skelina, M. Petrova, R. Pavlova, S. Mehrabian, L.D. Traykov | SOFIA, BULGARIA

P 31050 Pathogenetic aspects of cognitive disorders in type 2 diabetes mellitus

O. Tovazhnyanska, I. Bezuglova, N. Nekrasova, O. Markovska | KHARKIV, UKRAINE

P 31051 The investigation of cognitive impairment in young adults with substance use disorders

T. Unal, D. Aykol Unal | IZMIR, TURKEY

P 31052 Gray and white matter damage differently correlated with cognition in adult multiple sclerosis patients with different age of disease onset

L. Vacchi¹, M.A. Rocca¹, B. Colombo¹, M. Rodegher¹, L. Moiola¹, A. Ghezzi², G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ²GALLARATE, ITALY

P 31053 Abstract cancelled

P 31054 Ceramide and neuropsychiatric symptoms in Parkinson's disease with cognitive impairment

Y. Xing | BEIJING, CHINA

MONDAY, 30 MAY

12:30 - 13:30

POSTER SESSION EPILEPSY 6

12:30-13:15 | SCREEN B2

CHAIRPERSON:

Hermann Stefan, ERLANGEN, GERMANY

P 31055 The relation between Ala16Val polymorphism (MnSOD gene) and oxidative stress in epilepsy

A. Kegler¹, R. Scalco², A. Cardoso¹, F. Haupenthal¹, E.T. Pascotini¹, J. Arend¹, P. Gabbi¹, I. Cruz¹, M.M. Duarte¹, L.F. Royes¹, M.R. Figuera¹ | ¹SANTA MARIA, BRAZIL, ²LONDON, UK

P 31056 Neurosarcoïdosis, a chameleon for low grade glioma: a case report and literature review

P. Shanmugarajah, M. Vinjam, D. Warren, E. Wright, P. Chumas, M. Maguire | LEEDS, UK

P 31057 Palinopsia as an atypical manifestation of LGI1 antibody-associated limbic encephalitis: a case report

E. Stach, J. Biberon, B. de Toffol | TOURS, FRANCE

P 31058 Visual field defects in epilepsy patients treated with temporal lobe resection

A.T. Steensberg¹, A.S. Olsen¹, M.H. Litman¹, E. Holm¹, T. Kjaer², B. Jespersen¹, M. Kolko¹, L.H. Pinborg¹ | ¹COPENHAGEN, ²ROSKILDE, DENMARK

P 31059 Seizures and epilepsy in the aging population

H. Stefan | ERLANGEN, GERMANY

P 31060 Abstract cancelled

P 31061 Analysis of predictive values of historical data in evaluation of patients with first transient loss of consciousness

A. Stojanov, M. Spasic, Z. Peric, S. Lukic | NIS, SERBIA

P 31062 Acute systemic inflammatory response syndrome in status epilepticus

S. Szklener, A. Korchut, M. Godek, K. Rejdak | LUBLIN, POLAND

P 31063 Forced normalisation: an overlooked entity in epileptic patients

A. Topkan, S. Bilen, A.P. Titiz, E. Eruyar, F. Ak | ANKARA, TURKEY

P 31064 Abstract cancelled

P 31065 Abstract cancelled

P 31066 Acute ischemic stroke in status epilepticus – underestimated? Results from an 8-year cohort study

C. Traenka, G.M. de Marchis, L. Hert, D.J. Seiffge, A. Polymeris, N. Peters, L. Bonati, S.T. Engelter, P.A. Lyrer, S. Ruegg, R. Sutter | BASEL, SWITZERLAND

P 31067 Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures

E. Trinka¹, P. Kowacs², E. Ben-Menachem³, C.E. Elger⁴, J. Moreira⁵, R. Pinto⁶, F. Ikedo⁵, A. Pereira⁵, J.F. Rocha⁵, P. Soares-Da-Silva⁵ | ¹SALZBURG, AUSTRIA, ²CURITIBA, BRAZIL, ³GOTHENBURG, SWEDEN, ⁴BONN, GERMANY, ⁵CORONADO, ⁶PORTO, PORTUGAL

POSTER SESSION HEADACHE AND PAIN 5

12:30-13:15 | SCREEN C1

CHAIRPERSON:

Panagiotis Zis, SHEFFIELD, UK

P 31068 Onabotulinumtoxin A in chronic migraine beyond first year. Real-life data in 115 patients

I. Aicua-Rapun¹, E. Martínez Velasco², A. Hernando¹, M. Ruiz Piñero², A. Carreres², E. Porqueres¹, S. Herrero², Á.L. Guerrero Peral², F. Iglesias¹ | ¹BURGOS, ²VALLADOLID, SPAIN

P 31069 Abstract cancelled

P 31070 Communication of results of the employment of onabotulinumtoxin A in chronic migraine

M. Altuna, M. Martín Bujanda, M.C. Navarro | PAMPLONA, SPAIN

P 31071 Angiotensin II Type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy: efficacy and nerve biomarkers in skin biopsies

P. Anand, R. Privitera, Y. Yiangou, P. Misra | LONDON, UK

P 31072 Primary nasal pain

A. Arbex Bassols, M. Villa López, A. Perez Rodriguez, M. Rosón González, P. Pire García, L. Vela Desojo, J. Pareja Grande | MADRID, SPAIN

P 31073 Reduced medication use with sphenopalatine ganglion (SPG) stimulation for cluster headache: 24-month long-term follow-up results from the Pathway CH-1 study

M. Barloese¹, R. Jensen², J.M. Lainez³, C. Gaul⁴, J. Schoenen⁷, A. Goodman⁸, A. Caparso⁸, A. May⁵, T. Jürgens⁶ | ¹COPENHAGEN, ²GLOSTRUP, DENMARK, ³VALENCIA, SPAIN, ⁴KOENIGSTEIN, ⁵HAMBURG, ⁶ROSTOCK, GERMANY, ⁷LIEGE, BELGIUM, ⁸REDWOOD CITY, USA

P 31074 Women with chronic and episodic migraine exhibit similar widespread pressure pain sensitivity

M. Palacios-Ceña¹, J. Baron Sanchez², L. Florencio⁴, G. Ferracini⁴, Á.L. Guerrero Peral², C. Ordás-Bandera³, C. Fernández-de-Las-Peñas¹ | ¹MADRID, ²VALLADOLID, ³MOSTOLES, SPAIN, ⁴SÃO PAULO, BRAZIL

P 31075 Epicrania fugax combining forward and backward paroxysms in the same patient: the first three cases

J. Baron Sanchez¹, A. Gutierrez², M. Ruiz Piñero¹, A. Perez², Á.L. Guerrero Peral¹, M.L. Cuadrado² | ¹VALLADOLID, ²MADRID, SPAIN

P 31076 Topographical pressure pain sensitivity maps over the head are different in migraine patients compared with health controls

J. Baron Sanchez¹, M. Palacios-Ceña², M. Ruiz Piñero¹, M. de Lera¹, Á.L. Guerrero Peral¹, P. Madeleine³, C. Fernández-de-Las-Peñas² | ¹VALLADOLID, ²MADRID, SPAIN, ³AALBORG, DENMARK

P 31077 Onabotulinumtoxin A in chronic refractory migraine: a pilot study

A. Bartkova, P. Otruba, V. Sladkova, J. Zapletalova, P. Hlustik, P. Kanovsky | OLOMOUC, CZECH REPUBLIC

P 31078 Abstract cancelled

P 31079 The prevalence of chronic headache in people with constitutional phlebopathy

L. Belova, V. Mashin, L. Saprygina, O. Vereshchagina, D. Belomestnova, E. Shukyurova, M. Solyannicova | ULYANOVSK, RUSSIAN FEDERATION

P 31080 The effectiveness of acupuncture in cluster headache: the first randomised patient/assessor blinded, controlled sham study

A. Bougea, N. Spantideas, M. Karavis, M. Fili, E. Anagnostou, L. Gkika, T. Thomaidis, E. Kararizou, I. Evdokimidis | ATHENS, GREECE

P 31081 Effectiveness and impact on life quality of capsaicin 8% patch in patients with lumbosacral pain: an open-label study

P. Zis¹, N. Bernali², E. Argira³, I. Sifaka³, A. Vadalouka³ | ¹SHEFFIELD, UK, ²THIVA, ³ATHENS, GREECE

POSTER SESSION
INFECTION AND AIDS 1

12:30-13:15 | SCREEN F3

CHAIRPERSON:

Leo Visser, TIEBURG, THE NETHERLANDS

P 31082 Abstract cancelled

P 31083 Progressive multifocal encephalopathy (PML) causing an isolated cerebellar syndrome

M. Bayat | ÅRHUS, DENMARK

P 31084 Isolated intracranial hypertension as the presenting sign of Lyme disease

R. Beyroufi, S. Mostoufizadeh, S. Courtois, E. Cohen | TOURS, FRANCE

P 31085 A rare cause of facial nerve palsy

M. Carvalho Dias, A.P. Antunes, A.C.G. Fonseca, T. Pinho E Melo | LISBON, PORTUGAL

P 31086 Thromboelastometry for investigation of coagulation profile in patients with neuroinfectious diseases

E. M. Craemer¹, B. Bassa¹, F. Idris², N.A. Rahman², S. Diah³, H. Muharram³, U. Meyding-Lamade¹ | ¹FRANKFURT AM MAIN, GERMANY, ²JALAN TUNGKU, ³NEGARA, BRUNEI DARUSSALAM

P 31087 Electroencephalographic findings in Mexican patients with and without viral herpetic encephalitis

J.I. Castro Macías, F. Farias Serratos, M. Maldonado-Vega, C.V. Farias Serratos, J.M. Muñoz Barrett | LEÓN, MEXICO

P 31088 Abstract cancelled

P 31089 Abstract cancelled

P 31090 Neurosarcoidosis presenting as an immune reconstitution syndrome in HIV

P. Holmes | LONDON, UK

P 31091 The association of brachial neuritis and acute Hepatitis E infection

P. Holmes, V. Williams | LONDON, UK

MONDAY, 30 MAY

12:30 - 13:15

P 31092 Validation of the Lancet Consensus score for the diagnosis of tuberculous meningitis in a population of meningitis in Qatar

Y.Z.B. Imam, P. Chandra, H. Ahmadullah, M. Almaslamani, A. Alkhal, D. Deleu | DOHA, QATAR

P 31093 Validation of Thwaite's diagnostic score for the diagnosis of tuberculous meningitis in a population of meningitis in Qatar

Y.Z.B. Imam, H. Ahmadullah, P. Chandra, M. Almaslamani, A. Alkhal, D. Deleu | DOHA, QATAR

POSTER SESSION MOTOR NEURONE DISEASES 3

12:30-13:15 | SCREEN C2

CHAIRPERSON:

Josef Finsterer, VIENNA, AUSTRIA

P 31094 Abstract cancelled

P 31095 Breast cancer susceptibility in patients with spinal bulbar muscular atrophy: a case report

I. Martinelli¹, E. Da Re¹, G. Querin¹, C. Bertolin¹, E. Pegoraro¹, M. Pennuto², V. Guarneri¹, G. Soraru¹ | ¹PADUA, ²TRENT, ITALY

P 31096 Stratokinetic stability in patients with ALS

V. Merkul, Y. Rushkevich, I. Maryenko, S. Likhachev | MINSK, BELARUS

P 31097 Comparing the functioning and well-being of people with motor neurone disease, multiple sclerosis and Parkinson's disease

D. Morley, L. Kelly, S. Dummett, J. Dawson, R. Fitzpatrick, C. Jenkinson | OXFORD, UK

P 31098 The relationship between regional cortical atrophy and cognitive impairment in DM1 patients: a voxel based morphometric study

B. Muinjonov, E. Giyazitdinova | TASHKENT, UZBEKISTAN

P 31099 The development of an evidence based guideline on the assessment and management of motor neurone disease/ amyotrophic lateral sclerosis

D. Oliver¹, A. Edwards², C. McDermott³, A. Radunovic⁴ |

¹ROCHESTER, ²LEEDS, ³SHEFFIELD, ⁴LONDON, UK

P 31100 Immunohistochemical study of progranulin in the skin of amyotrophic lateral sclerosis

S. Ono | ICHIHARA, JAPAN

P 31101 MicroRNAs as biomarkers of spinal and bulbar ALS

V. Pegoraro¹, E. Tasca¹, A. Merico¹, E. Pinzan¹, C. Angelini² |

¹VENICE, ²PADUA, ITALY

P 31102 Intravenous immunoglobulins efficacy in a case of ALS with myasthenic symptoms

G. Piccirillo, F. Trojsi, M.R. Monsurrò, F. Habetswallner, B.M. de Martino, G. Tedeschi | NAPLES, ITALY

P 31103 Cortical dysfunction in symptomatic and at risk ALS detected by MEG

M. Proudfoot¹, G. Rohenkohl¹, G.L. Colclough¹, J. Wu², P.M. Andersen³, K. Talbot¹, M.W. Woolrich¹, M. Benatar², A.C. Nobre¹, M.R. Turner¹ | ¹OXFORD, UK, ²MIAMI, USA, ³UMEA, SWEDEN

P 31104 Spinal and Bulbar Muscular Atrophy (SBMA) outcome measures: is creatinine a new reliable biomarker?

G. Querin¹, E. Da Re¹, I. Martinelli¹, L. Bello¹, C. Bertolin¹, D. Pareyson², E. Pegoraro¹, G. Soraru¹ | ¹PADUA, ²MILAN, ITALY

P 31105 Neuromyelitis optica spectrum disorder and amyotrophic lateral sclerosis in a 50-year-old male: a case report

M. Radaelli, S. Guerrieri, Y. Falzone, B. Colombo, F. Agosta, M. Filippi, V. Martinelli, D. Velardo, G. Comi, M. Comola, N. Riva | MILAN, ITALY

P 31106 Prognostic value of ALSFRS sub-scores

J. Rooney, T. Burke, O. Hardiman | DUBLIN, IRELAND

POSTER SESSION MOVEMENT DISORDERS 6

12:30-13:15 | SCREEN E4

CHAIRPERSON:

Antonella Macerollo, LONDON, UK

P 31107 Complex tremorometry, electro-oculography and neuropsychological assessment of fragile X premutation carriers

A. Kovács, Z. Farkas, S. Gulyás, J. Kárpáti, A. Kamondi | BUDAPEST, HUNGARY

P 31108 More frequent presence of non-motor symptoms among Hungarian Parkinson's disease patients

M. Kovács, G. Deli, Z. Aschermann, P. Ács, E. Bosnyák, J. Janszky, A. Makkos, S. Komoly, N. Kovacs | PÉCS, HUNGARY

P 31109 Efficacy of opicapone in Parkinson's disease patients with motor fluctuations: exploratory OFF- and ON-time responder analyses of pooled phase III studies

A. Lees¹, J. Ferreira², T. Müller⁴, F. Stocchi⁵, C. Oliveira³, A. Santos³, N. Lopes³, J.F. Rocha³, P. Soares-Da-Silva³

| ¹LONDON, UK, ²LISBON, ³CORONADO (S. ROMÃO E S. MAMEDE), PORTUGAL, ⁴BERLIN, GERMANY, ⁵ROME, ITALY

P 31110 Opicapone's onset and stabilisation of treatment effects in Parkinson's disease patients with motor fluctuations

A. Lees¹, J. Ferreira², H. Reichmann⁴, E. Tolosa⁵, A. Santos³, C. Oliveira³, I. Oliveira³, N. Lopes³, J.F. Rocha³, P. Soares-Da-Silva³ | ¹LONDON, UK, ²LISBON, ³CORONADO (S. ROMÃO E S. MAMEDE), PORTUGAL, ⁴DRESDEN, GERMANY, ⁵BARCELONA, SPAIN

P 31111 Neurological manifestations of Wilson disease in Belarus

I. Pliashko, S. Likhachev | MINSK, BELARUS

P 31112 Paroxysmal non-kinesigenic dyskinesia with dysphonia alleviated by carbamazepine

N. Løkken, L.E. Hjermand, J. Vissing | COPENHAGEN, DENMARK

P 31113 Efficacy of opicapone in Parkinson's disease patients with motor fluctuations at different stages of symptom progression

N. Lopes¹, J. Ferreira², A. Lees³, W. Poewe⁴, H. Reichmann⁵, A. Santos¹, C. Oliveira¹, J.F. Rocha¹, P. Soares-Da-Silva¹ | ¹CORONADO (S. ROMÃO E S. MAMEDE), ²LISBON, PORTUGAL, ³LONDON, UK, ⁴INNSBRUCK, AUSTRIA, ⁵DRESDEN, GERMANY

P 31114 Analysis of impulse control disorders in phase III studies of opicapone in Parkinson's disease patients with motor fluctuations

N. Lopes¹, J. Ferreira², A. Lees³, T. Müller⁴, H. Reichmann⁵, H. Gama¹, A. Santos¹, C. Oliveira¹, J.F. Rocha¹, P. Soares-Da-Silva¹ | ¹CORONADO (S. ROMÃO E S. MAMEDE), ²LISBON, PORTUGAL, ³LONDON, UK, ⁴BERLIN, GERMANY, ⁵DRESDEN, GERMANY

P 31115 Effect of vibration on motor performance: a new intervention to improve bradykinesia in Parkinson's disease?

A. Macerollo, C. Palmer, T. Foltynie, P. Korlipara, P. Limousin, M. Edwards, J. Kilner | LONDON, UK

P 31116 Myoclonus-dystonia syndrome, obsessive-compulsive disorder and epilepsy: another plus in a dystonia-plus syndrome?

C. Machado, J. Pinho, J.N. Alves, P. Morgado, J. Pereira, E. Lourenço | BRAGA, PORTUGAL

P 31117 Novel PLA2G6 c.1627C>T homozygous mutation and response to DBS-GPi

A.D. Magalhães¹, L. Guedes¹, M.V.S. Coelho¹, T. Teodoro¹, A.F. Valadas², H. Carvalho¹, B. Cattoni¹, J. Ferreira¹ | ¹LISBON, ²SETÚBAL, PORTUGAL

P 31118 Direct comparisons for botulinum neurotoxins in movement disorders

R. Maggio, S. Lalli, A. Albanese | MILAN, ITALY

P 31119 Dopamine receptor genes polymorphisms: a risk factor for developing dyskinesia in Parkinson's disease

L. Magistrelli¹, M. Ferrari², F. de Marchi¹, F. Marino², G.D. Oggioni¹, M. Carecchio¹, G. Riboldazzi², G. Bono², M. Cosentino², R. Cantello¹, C. Comi¹ | ¹NOVARA, ²VARESE, ITALY

POSTER SESSION
MOVEMENT DISORDERS 7

12:30-13:15 | SCREEN E3

CHAIRPERSON:

Nabil Mohsen, TRIPOLI, LEBANON

P 31120 The effect of improved nutritional status on psychiatric features and quality of life in Parkinson's disease patients

N. Ongun, C. Erdogan, E. Degirmenci, L.S. Bir | DENIZLI, TURKEY

P 31121 Treatment of OFF episodes in Parkinson's disease: an evaluation of patient and caregiver insights

E. Pappert¹, N. Degruyther², A. Agro² | ¹SAN ANTONIO, USA, ²TORONTO, CANADA

P 31122 Treatment of OFF episodes in Parkinson's disease: an evaluation of physician practices

E. Pappert¹, A. Agro², N. Degruyther² | ¹SAN ANTONIO, USA, ²TORONTO, CANADA

P 31123 Oral sublingual apomorphine film (APL-130277) produces no buccal mucosal irritation: results of a toxicological study

E. Pappert¹, B. Dzyngel², T. Bilbault², A. Agro² | ¹SAN ANTONIO, USA, ²TORONTO, CANADA

P 31124 Late onset atypical Pantothenate-Kinase associated neurodegeneration with homozygous PANK2 mutation in three Sardinian siblings

R. Piredda, E. Sechi, A. L. Rassu, A. Addis, D. Urso, C. Fois, R. Ortu, G. Sechi | SASSARI, ITALY

P 31125 Abstract cancelled

P 31126 Additional gait impairment by the presence of peripheral nerve disease in pediatric patients with hereditary spastic paraplegia

I. Pulido-Valdeolivas¹, D. Gómez Andrés¹, J.A. Martín-Gonzalo¹, I. Rodríguez-Andonaegui¹, J. López-López², S.I. Pascual Pascual¹, E. Rausell¹ | ¹MADRID, ²SAN SEBASTIÁN DE LOS REYES, SPAIN

P 31127 Is there a relationship between non-motor symptoms and main indicators of Parkinson's disease (stage, form, duration)?

E. Rabadanova, Z. Goncharova, M. Gelpy | ROSTOV-ON-DON, RUSSIAN FEDERATION

MONDAY, 30 MAY

12:30 - 13:15

P 31128 Segawa disease: a clinical study of eight Tunisian patients

A. Riahi, M. Messelmani, I. Bedoui, H. Derbali, M. Mansour, J. Zaouali, R. Mrissa | TUNIS, TUNISIA

P 31129 Wilson's disease associated with immotile cilia syndrome: a case report

M. Romoli, N. Tambasco, P. Prontera, E. Nardi, C. Clerici, P. Calabresi | PERUGIA, ITALY

P 31130 Abstract cancelled

P 31131 Providing PD treating doctors much better disease status data: our measurement of typing cadence provides great data and enables treating doctors to evaluate changes in disease management. We will show data on actual patients

J. Samzelius | SAN FRANCISCO, USA

P 31132 Opicapone's safety in Parkinson's disease patients with motor fluctuations: results of the 1-year extension of study BIPARK I

A. Santos¹, J. Ferreira², A. Lees³, F. Stocchi⁴, O. Rascol⁵, N. Lopes¹, H. Gama¹, J.F. Rocha¹, P. Soares-Da-Silva¹ | ¹CORONADO (S. ROMÃO E S. MAMEDE), ²LISBON, PORTUGAL, ³LONDON, UK, ⁴ROME, ITALY, ⁵TOULOUSE, FRANCE

POSTER SESSION
MS AND RELATED DISORDERS 11

12:30-13:15 | SCREEN F1

CHAIRPERSON:

Ralf Gold, BOCHUM, GERMANY

P 31133 Daclizumab HYP efficacy on disease outcome measures using an expanded definition of highly active relapsing-remitting multiple sclerosis: results from SELECT and DECIDE

G. Giovannoni¹, T. Ziemssen², W. Ma³, S. Fam³ | ¹LONDON, UK, ²DRESDEN, GERMANY, ³CAMBRIDGE, USA

P 31134 Liver Transaminase Elevations in the DECIDE study of daclizumab HYP versus intramuscular interferon beta-1a

S. Fam¹, P. McCroskey¹, W. Ma¹, L. Chiodo², G. Sabatella¹ | ¹CAMBRIDGE, ²NORTH CHICAGO, USA

P 31135 Assessment of 2015 neuromyelitis optica criteria in Rouen university hospital

L. Fechtenbaum¹, R. Marignier², R. Lefaucheur¹, F. Le Goff¹, J. Gueudry¹, D. Maltete¹, B. Bourre¹ | ¹ROUEN, ²LYONS, FRANCE

P 31136 Observational, retrospective study to characterise patients with RRMS and long-term treatment with sc interferon (IFN) beta 1-a

J.R. Ara¹, S. Martínez-Yélamos², A. Saiz², A. Escartin², E. Munteis², M.Á. Hernández³, L. Midaglia⁴, M. Arias⁵, Y. Aladro⁶, C. de Andrés⁶, J.A. García Merino⁶, X. Olascoaga⁷, B. Casanova⁸, A. Roque⁸, L. Brieva⁹, A. Rodriguez-Antiguedad¹⁰, D. Muñoz⁴, O. Fernandez¹¹ | ¹SARAGOSSA, ²BARCELONA, ³SANTA CRUZ DE TENERIFE, ⁴VIGO, ⁵SANTIAGO DE COMPOSTELA, ⁶MADRID, ⁷GIPUZKOA, ⁸VALENCIA, ⁹LÉRIDA, ¹⁰VIZCAYA, ¹¹MALAGA, SPAIN

P 31137 Neural cell adhesion molecules in acute optic neuritis: relation to clinical and paraclinical findings

J.L. Frederiksen¹, K. Farooq¹, S. Gnanapavan² | ¹COPENHAGEN, DENMARK, ²LONDON, UK

P 31138 Long-term efficacy of teriflunomide in patients recently diagnosed with relapsing forms of MS

M. Freedman¹, G. Comi³, A. Miller⁴, J. Wolinsky⁵, J. Oh², K. Thangavelu⁶, P. Truffinet⁷, L. Kappos⁸ | ¹OTTAWA, ²TORONTO, CANADA, ³MILAN, ITALY, ⁴NEW YORK, ⁵HOUSTON, ⁶CAMBRIDGE, USA, ⁷CHILLY-MAZARIN, FRANCE, ⁸BASEL, SWITZERLAND

P 31139 A retrospective analysis of efficacy in McDonald 2010 multiple sclerosis (MS) patients in the ORACLE-MS study

M. Freedman¹, T. Leist², G. Comi⁶, B.A.C. Cree³, P.K. Coyle⁴, H.-P. Hartung⁷, P. Vermersch⁸, D. Damian⁵, F. Dangond⁵ | ¹OTTAWA, CANADA, ²PHILADELPHIA, ³SAN FRANCISCO, ⁴STONY BROOK, ⁵BILLERICA, USA, ⁶MILAN, ITALY, ⁷DÜSSELDORF, GERMANY, ⁸LILLE, FRANCE

P 31140 Number needed to treat analysis comparing teriflunomide with injectable and oral disease-modifying therapies in relapsing multiple sclerosis

M.S. Freedman¹, A.E. Miller², K. Thangavelu³, S. Hass³, T.P. Leist⁴ | ¹OTTAWA, CANADA, ²NEW YORK, USA, ³CAMBRIDGE, USA, ⁴PHILADELPHIA, USA

P 31141 INSPIRATION-MRI: standardized acquisition and centralised quantitative reading of MRI scans of RRMS patients in German daily clinical practice

A. Gass¹, J. Gregori², S. Hoffmann², A. Fuchs³, C. Cornelissen³ | ¹MANNHEIM, ²HEIDELBERG, ³NUREMBERG, GERMANY

P 31142 Quality of life in carers of patients with relapsing-remitting multiple sclerosis: a pilot study

D. Gigineishvili, M. Kareli, A. Tevzadze, S. Karakov, M. Kiziria, A. Tsiskaridze, R. Shakarishvili | TBILISI, GEORGIA

P 31143 Brain health: time matters in multiple sclerosis – developmental process and objectives of international consensus policy recommendations

G. Giovannoni¹, H. Butzkueven⁴, K. Costello⁵, S. Dhib-Jalbut⁶, J. Hobart², G. Kobelt⁸, G. Pepper³, M.P. Sormani⁹, C. Thalheim¹⁰, A. Traboulsee¹¹, T. Vollmer⁷ | ¹LONDON, ²PLYMOUTH, ³LEEDS, UK, ⁴PARKVILLE, AUSTRALIA, ⁵NEW YORK, ⁶NEW BRUNSWICK, ⁷AURORA, USA, ⁸MULHOUSE, FRANCE, ⁹GENOA, ITALY, ¹⁰BRUSSELS, BELGIUM, ¹¹VANCOUVER, CANADA

P 31144 Improvements in patient-reported treatment satisfaction with teriflunomide: preliminary results from the European, Latin American, and Canadian cohorts enrolled in the Teri-PRO Phase 4 study

R. Gold¹, C. Laganke², B. Khatri³, K. Edwards⁴, S. Cavalier⁵, S. Brette⁷, P. Rufi⁸, P. Coyle⁶ | ¹BOCHUM, GERMANY, ²CULLMAN, ³MILWAUKEE, ⁴LATHAM, ⁵CAMBRIDGE, ⁶STONY BROOK, USA, ⁷BOULOGNE-BILLANCOURT, ⁸CHILLY-MAZARIN, FRANCE

P 31145 CONFIDENCE: Phase IV study to evaluate medication satisfaction with glatiramer acetate 40mg/ml three-times weekly versus once-daily glatiramer acetate 20mg/ml in patients with RRMS

A. Grinspan¹, S.K. Gandhi¹, G.R. Cutter², M. Copetti³, D. Kormann¹, A. Veneziano⁴ | ¹FRAZER, ²BIRMINGHAM, USA, ³SAN GIOVANNI ROTONDO, ⁴MILAN, ITALY

POSTER SESSION
MS AND RELATED DISORDERS 12
12:30-13:15 | SCREEN F2

CHAIRPERSON:
Paolo Preziosa, MILAN, ITALY

P 31146 Reversibility of Natalizumab effects on peripheral immune cell dynamics in patients with multiple sclerosis (MS)

T. Plavina¹, K.K. Muralidharan¹, G. Kuesters¹, D. Mikol¹, K. Evans¹, M. Subramanyam¹, I. Nestorov¹, Y. Chen¹, P.-R. Ho¹, D. Amarante¹, J. de Seze⁵, R. Fox², R. Gold⁶, D. Jeffery³, L. Kappos⁸, B. Weinstock-Guttman⁹, H.-P. Hartung⁷, B. Cree⁴ | ¹CAMBRIDGE, ²CLEVELAND, ³MOORESVILLE, ⁴SAN FRANCISCO, USA, ⁵STRASBOURG, FRANCE, ⁶BOCHUM, ⁷DÜSSELDORF, GERMANY, ⁸BASEL, SWITZERLAND, ⁹BARCELONA, SPAIN

P 31147 Working memory and its relationship with the mood level in patients with multiple sclerosis

E. Tyburski, A. Potemkowski, A. Sołtys, M. Cheć, A. Samochowiec | SZCZECIN, POLAND

P 31148 Executive dysfunctions differ between secondary progressive and primary progressive MS

E. Tyburski, A. Potemkowski, A. Sołtys, M. Cheć, A. Samochowiec | SZCZECIN, POLAND

P 31149 Comparison of MRI criteria for the diagnosis of multiple sclerosis: role of cortical lesions

P. Preziosa¹, M.A. Rocca¹, S. Mesaros⁴, M. Copetti², A. Rovira⁵, J. Sastre-Garriga⁵, J. Drulovic⁴, A. Droby⁶, F. Zipp⁶, M. Calabrese³, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ³VERONA, ITALY, ⁴BELGRADE, SERBIA, ⁵BARCELONA, SPAIN, ⁶MAINZ, GERMANY

P 31150 Anti-myelin antibodies in demyelinating disorders – a search for disease biomarkers

K. Prus, E. Belniak, K. Mitosek Szewczyk, K. Rejdak | LUBLIN, POLAND

P 31151 Gait performance gets closer to normalcy after a 15-day course of fampridine in patients with primary progressive multiple sclerosis

I. Pulido-Valdeolivas, I. González-Suárez, A. Montero Atalaya, D. GómezAndrés, J.A. Martín-Gonzalo, I. Rodríguez-Andonaegui, C. Oreja-Guevara, E. Rausell | MADRID, SPAIN

P 31152 Transcranial sonography of subcortical structures in patients with multiple sclerosis

P. Puz, A. Lasek-Bal | KATOWICE, POLAND

P 31153 Characterisation of NMO spectrum disorders in an Italian cohort of patients

M. Radaelli, F. Sangalli, F. Esposito, L. Moiola, B. Colombo, R. Fazio, V. Martinelli, M. Comola, G. Comi | MILAN, ITALY

P 31154 Clinical spectrum of multiple sclerosis and response to treatment in south Indian population

B. Rangappan Munirathinam, J. Marimuthu, U.M. Elumalai | CHENNAI, INDIA

P 31155 A case of very late onset neuromyelitis optica spectrum disease

M. Reis Costa, P. Alves, T. Teodoro, P. Antunes, L. Albuquerque | LISBON, PORTUGAL

P 31156 Whole brain and gray matter atrophy are correlated to long-term disability progression in multiple sclerosis patients

V. Reyes Garrido, T. Muñoz Ruiz, V. Fernandez Sanchez, J.A. Sánchez García, P. Urbaneja Romero, A. Gallardo Tur, A. Leon Martin, M. Guerrero Fernandez, M.J. Postigo, B. Asenjo Benitez, Ó. Fernández Fernández | MÁLAGA, SPAIN

P 31157 Interim analysis of the non-interventional study REBIFLECT: adherence to subcutaneous interferon β -1a in patients using RebiSmart®-logged data and their reflection in doctor-patient interviews

P. Rieckmann¹, T. Ziemssen², I.-K. Penner³, A. Raji⁴, T. Wagner⁵, U. Vogel⁵, U.K. Zettl⁶ | ¹BAMBERG, ²DRESDEN, ³DÜSSELDORF, ⁴HAMBURG, ⁵DARMSTADT, ⁶ROSTOCK, GERMANY

MONDAY, 30 MAY

12:30 - 13:15

P 31158 Evidence of favourable changing course of multiple sclerosis in the last 15 years: a real-world clinical study

M. Romeo, V. Martinelli, M. Rodegher, B. Colombo, G. Dalla Costa, D. de Feo, F. Esposito, L. Ferre, G. Liberatore, F. Martinelli Boneschi, A. Merlini, M.J. Messina, R. Messina, L. Moiola, A. Nuara, G. Pavan, P. Preziosa, M. Radaelli, M.A. Rocca, F. Sangalli, G. Comi | MILAN, ITALY

P 31159 Differentiating neuromyelitis optica from multiple sclerosis after optic neuritis: the axon-myelin index

M. Vabanesi, S. Medaglini, S. Guerrieri, G. Di Maggio, M. Pisa, L. Moiola, U. Del Carro, V. Martinelli, G. Comi, L. Leocani | MILAN, ITALY

POSTER SESSION MS AND RELATED DISORDERS 13

12:30-13:15 | SCREEN E2

CHAIRPERSON:

Johann Sellner, SALZBURG, AUSTRIA

P 31160 Age at disease onset influences gray matter and white matter damage in adult multiple sclerosis patients

L. Vacchi¹, M.A. Rocca¹, B. Colombo¹, M. Rodegher¹, L. Moiola¹, A. Ghezzi², G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ²GALLARATE, ITALY

P 31161 Gene HLA DRB1 alleles characterisation of MS patients in Latvian population

L. Vainsteine, G. Gulbe, L. Kovalchka, G. Karelis, J. Eglite, V. Kenina | RIGA, LATVIA

P 31162 Post-lumbar puncture headache: a frequent and unpredictable adverse event in multiple sclerosis work up

D. Vecchio¹, P. Naldi¹, C. Comi¹, V. Ferro¹, M. Leone², R. Cantello¹ | ¹NOVARA, ²SAN GIOVANNI ROTONDO, ITALY

P 31163 Treatment-Naïve patients with highly active relapsing-remitting multiple sclerosis at baseline demonstrate continued clinical improvement with alemtuzumab over 5 years: CARE-MS I extension study

P. Vermersch¹, J. Lycke², V. Limmroth³, B. Singer⁴, S. Krieger⁵, D.H. Margolin⁶, K. Thangavelu⁶, R. Berkovich⁷ | ¹LILLE, FRANCE, ²GOTHENBURG, SWEDEN, ³COLOGNE, GERMANY, ⁴ST LOUIS, ⁵NEW YORK, ⁶CAMBRIDGE, ⁷LOS ANGELES, USA

P 31164 Dutch online survey patient reported outcomes (PROs) in MS: Improvement medication adherence after switch of daily glatiramer acetate 20mg/ml to 3x per week 40mg/ml

K. Zuurbier¹, M. Reijs-Scheijgrond¹, L.H. Visser² | ¹HAARLEM, ²TILBURG, NETHERLANDS

P 31165 Dutch online survey patient reported outcomes (PROs) in MS: modified Morisky scale correlates with real life medication adherence of daily glatiramer acetate 20mg/ml

K. Zuurbier¹, M. Reijs-Scheijgrond¹, L.H. Visser² | ¹HAARLEM, ²TILBURG, NETHERLANDS

P 31166 Visual evoked potentials in the study of the visual system in patients with multiple sclerosis

S. Karpov, I. Vyshlova, I. Azoidis, A. Karpov | STAVROPOL, RUSSIAN FEDERATION

P 31167 Comorbid conditions and medication utilisation among paediatric and adult-onset multiple sclerosis patients in England

M. Wenten, N. Everage, N. Payas, T. Soman | CAMBRIDGE, USA

P 31168 Assessment of treatment satisfaction in multiple sclerosis: a review of the literature

Y. Wu¹, S.K. Gandhi¹, J. Hobart⁴, G. Cutter², A. Grinspan³ | ¹FRAZER, ²BIRMINGHAM, ³WESTON, USA, ⁴PLYMOUTH, UK

P 31169 Adherence to glatiramer acetate 40mg versus oral disease-modifying therapies for multiple sclerosis

R. Halpern¹, R. Wolbeck¹, C. Blauer-Peterson¹, Y. Wu², S.K. Gandhi² | ¹EDEEN PRAIRIE, ²FRAZER, USA

P 31170 In patients with RRMS, SC peginterferon beta-1a every 2 weeks demonstrated comparable clinical efficacy to SC interferon beta-1a TIW using a matching-adjusted method

P. Coyle¹, S. Shang², X. You², C. Castrillo-Viguera², D. Gasparotto², B. Werneburg², D. Fiore | ¹STONY BROOK, ²CAMBRIDGE, USA

P 31171 Intrathecal chitotriosidase as a prognostic marker in multiple sclerosis

I. Zadro, M. Trbojević-Čepe, M. Krbot-Skorić, I. Adamec, B. Barun, T. Gabelic, M. Habek | ZAGREB, CROATIA

P 31172 Evaluation of patient's treatment methods using of walking tests during relapse of multiple sclerosis (MS)

G. Zemgulyte, R. Balnyte, K. Petrikonis | KAUNAS, LITHUANIA

POSTER SESSION MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 5

12:30-13:15 | SCREEN B4

CHAIRPERSON:

Benedikt Schoser, BERLIN, GERMANY

P 31173 Cardiac safety of multiple doses of bimagrumab (BYM338) in healthy older adults: a randomised, double-blind, phase I study

D. Rooks¹, D. Yates¹, S. Neelakantham², J. Buchbjerg³, D. Laurent³, O. Petricoul³, E. Svensson¹ | ¹CAMBRIDGE, USA, ²HYDERABAD, INDIA, ³BASEL, SWITZERLAND

P 31174 Homozygosity of the sodium channel myotonia SCN4A gene and intra familial phenotypic variability

M. Schahrazede Linda, M. Samira | ALGIERS, ALGERIA

P 31175 Abstract cancelled

P 31176 Enzyme replacement therapy with alglucosidase alfa and pregnancy in late-onset Pompe disease

M. Santos, I. Conceicao | LISBON, PORTUGAL

P 31177 Limb-girdle muscular dystrophy type 2A carrying novel mutations in the human CAPN3 gene (c.559delA)

A. Sanz Monllor, P.A. Sánchez Ayaso, M.P. Salmerón Ato, I.M. Sanchez Ortuño, N. García Lax, J.A. García Motos, M. Palao Rico, M.L. Martínez Navarro, A.M. García Medina, J. Marin Marín, J.M. Rodríguez García, J.A. Iniesta Valera, A. Díaz Ortuño | MURCIA, SPAIN

P 31178 Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis

R. Scalco¹, N. Voermans², H. Jungbluth¹, R. Quinlivan¹ | ¹LONDON, UK, ²NIJMEGEN (GLD), NETHERLANDS

P 31179 Muscle b-enolase deficiency presenting with different kinetic profiles in muscle tissue

R. Wigley¹, R. Scalco¹, A. Gardiner¹, S. Booth¹, S. Chatfield¹, R. Godfrey¹, R. Kirk¹, D. Hilton-Jones², H. Houlden¹, R. Quinlivan¹ | ¹LONDON, ²OXFORD, UK

P 31180 Chronic inflammatory demyelinating polyneuropathy. The RareBOX.org project: where the patient meets himself

E. Schirinzì¹, C. Lucchesi¹, E. Giorli¹, D. Cocito², E. Nobile-Orazio³, G. Siciliano¹, M. Marra⁴ | ¹PISA, ²TURIN, ³MILAN, ⁴LECCE, ITALY

P 31181 Amifampridine phosphate in patients with Lambert-Eaton myasthenic syndrome (LEMS): a phase 3, multicenter, double-blind, placebo-controlled trial

B. Schoser¹, S. Oh³, N. Shcherbakova¹⁰, A. Kostera-Pruszczyk¹¹, M. Alsharabati⁴, M. Dimachkie⁵, J.M. Blanco¹², D. Lavrnić¹³, P. Shieh⁶, C. Vial¹⁴, A. Meisel², T. Brannagan⁷, S. Komoly¹⁵, K. Sivakumar⁸, Y. So⁹ | ¹MUNICH, ²BERLIN, GERMANY, ³BIRMINGHAM, ⁴BIRMINGHAM, ALABAMA, ⁵KANSAS CITY, ⁶LOS ANGELES, ⁷NEW YORK, ⁸PHOENIX, ⁹STANFORD, USA, ¹⁰MOSCOW, RUSSIAN FEDERATION, ¹¹WARSAW, POLAND, ¹²MADRID, SPAIN, ¹³BELGRADE, SERBIA, ¹⁴LYONS, FRANCE, ¹⁵PÉCS, HUNGARY

P 31182 Treating anti-MuSK myasthenia gravis

V. Serban | PHILADELPHIA, USA

P 31183 Potential role of BAFF and TNF α in the course of myasthenia gravis

E. Sobieszczuk, J. Kubiszewska, M. Lipowska, P. Szczudlik, B. Szyluk, M. Dutkiewicz, A. Kostera-Pruszczyk | WARSAW, POLAND

P 31184 The number of CTG repeat is correlated with the accumulation of visceral fat in myotonic dystrophy type 1

H. Takada, S. Kon, Y. Oyama, T. Kimura, F. Nagahata | AOMORI, JAPAN

POSTER SESSION NEUROGENETICS 3

12:30-13:15 | SCREEN F4

CHAIRPERSON:

David Lynch, LONDON, UK

P 31185 A novel mutation in the CISD2 gene causing Wolfram Syndrome with neurological impairment

C. Delorme¹, C. Rouzier², C. Azuar¹, A. Chaussenot², Y. Samson¹, G. Challe¹, K. Fragaki², D. Dormont¹, V. Serre¹, M. Catala¹ | ¹PARIS, ²NICE, FRANCE

P 31186 Cerebrovascular disease with and without deformations of the cerebrovascular vessels and gene - (rs 2010963) vascularendothelial growth factor - S634G VEGFA

S. Khudayarova, K. Khalimova, G. Rakhmatullaeva | TASHKENT, UZBEKISTAN

P 31187 Clinical and pathogenetic structure of gene-gene interactions of MMP3, MMP9 and C634G VEGFA genes in cephalgic patients with and without deformations of cerebrovascular vessels

S. Khudayarova, G. Rakhmatullaeva, K. Khalimova | TASHKENT, UZBEKISTAN

MONDAY, 30 MAY

12:30 - 13:15

P 31188 Gene delivery to oligodendrocytes re-establishes gap junctions and rescues a hypomyelinating leukodystrophy model

E. Georgiou¹, A. Kagiava¹, K. Sidiropoulou², J. Richter¹, I. Sargiannidou¹, C. Papanephytoulou¹, G. von Jonquieres³, C. Christodoulou¹, M. Klugmann³, K. Kleopa¹ | ¹NICOSIA, CYPRUS, ²HERAKLION, GREECE, ³SYDNEY, AUSTRALIA

P 31189 Abstract cancelled**P 31190** Report of a family with a benign phenotype of SPG11

F. Ladeira, P. Esperança, T. Lampreia | LISBON, PORTUGAL

P 31191 Late-onset cerebellar ataxia: don't forget SCA 17

A. Randall, A. J. Larner | LIVERPOOL, UK

P 31192 Exome sequencing reveals double pathology: MFN2 and COL7A1 gene mutations in the same patient

L. Leonardis, A. Maver, B. Peterlin | LJUBLJANA, SLOVENIA

P 31193 Whole exome sequencing reveals novel NOV and DCAF13 mutations in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy

H. Lin | BEIJING, CHINA

P 31194 Novel biallelic missense mutations in CTC1 gene identified in a Chinese family with cerebroretinal microangiopathy with calcification and cysts (CRMCC)

H. Lin | BEIJING, CHINA

P 31195 A novel EPM2a mutation affecting only the cytoplasmic isoform of laforin leads to late onset and slow progression of Lafora disease with prominent parkinsonism

D. Lynch, D. Hughes, A. Pittman, H. Houlden | LONDON, UK

P 31196 Further evidence that mutations in AARS2 cause an adult onset leukodystrophy

D. Lynch¹, W.J. Zhang¹, R. Lakshmanan¹, R. Phadke¹, I. Davagnanam¹, H.A. Hanağasi², A. Bhattacharjee¹, H. Wilson¹, N.C. Fox¹, H. Houlden¹ | ¹LONDON, UK, ²ISTANBUL, TURKEY

P 31197 C9ORF72 hexanucleotide repeat expansion in ALS patients from Russia

E. Lysogorskaia, N. Abramycheva, M. Stepanova, M. Zakharova, S. Illarioshkin | MOSCOW, RUSSIAN FEDERATION

POSTER SESSIONS
NEUROIMMUNOLOGY 3

12:30-13:15 | SCREEN H2

CHAIRPERSON:

Frank Leyboldt, HAMBURG, GERMANY

P 31198 Results of a multicentre, non-interventional study (NIS) on the long-term tolerability of octagam® 5% in neurologic indications in Germany

A. Debes, C. Lietz, S. Tascou | LANGENFELD, GERMANY

P 31199 First case of anti SOX-1 (AGNA) paraneoplastic antibodies positive, seronegative, neuromyelitis optica in an elderly woman

M. Turk¹, M. Klarendic², T. Rus², B. Meglic², U. Rot² | ¹NOVO MESTO, ²LJUBLJANA, SLOVENIA

P 31200 Faciobrachial dystonic seizures. The importance of thinking about autoimmunity

T. Liaño Sanchez, M.E. García García, B. Parejo Carbonell, B. Abarrategui, I. García Morales | MADRID, SPAIN

P 31201 Borreliosis and associated autoimmunity

I. Lisá, J. Ďurovská, J. Pancák, G. Timarova, L. Lisý | BRATISLAVA, SLOVAKIA

P 31202 Myasthenia gravis: diagnostic and therapeutic aspects in Ukraine

R. Lomako, V. Pashkovskyi | DNEPROPETROVSK, UKRAINE

P 31203 Coexistence of onconeural antibodies anti-Hu and anti-Yo in a patient with small-cell lung carcinoma

E. Monreal, L. Crespo-Araico, P. Agüero-Rabes, P. Martínez-Ulloa, F. Acebrón-Sánchez, R. Toledano, Á. Carrasco, J. Buisan, Í. Corral | MADRID, SPAIN

P 31204 Response to therapeutic plasma exchange in central nervous system inflammatory diseases: multiple sclerosis and autoimmune encephalitis

T. Moser, G. Harutyunyan, A. Karamyan, F. Otto, C. Bacher, V. Chroust, M. Leitinger, H.F. Novak, E. Trinkka, J. Sellner | SALZBURG, AUSTRIA

P 31205 Aseptic meningitis as a rare manifestation of neuro-Behçet's disease: long-term follow-up of six patients

A.N. Ozdag Acarli, T. Gunduz, S. Ala, G. Akman Demir, M. Kürtüncü | ISTANBUL, TURKEY

P 31206 Humoral response against myelin associated glycoprotein in Parkinson's disease reflect oligodendroglial degeneration

E. Papuc, K. Rejdak | LUBLIN, POLAND

P 31207 Sjogren Syndrome presenting as autoimmune non-vasculitic meningoencephalitis (NAIM) and sensory ganglionopathy

J.P.G.N.T. Peres¹, A.H. Valverde² | ¹ALCABIDECHÉ, ²AMADORA, PORTUGAL

P 31208 Oxysterols, memory lymphocytes and multiple sclerosis : a peculiar team

A. Clottu¹, A. Mathias¹, J. Seebach², D.P. Renaud¹, C. Pot¹ | ¹LAUSANNE, ²GENEVA, SWITZERLAND

P 31209 Epidemiological features of paraneoplastic polyneuropathies in cancer patients

Y. Raduta¹, V. Raduta², V.V. Ponomarev¹, V. Sushko² | ¹MINSK, ²BREST, BELARUS

P 31210 CLIPPPERS syndrome - a very rare case of brainstem inflammation

A. Rojek, R. Podemski, M. Waliszewska-Proszól, A. Pokryszko-Dragan, J. Bladowska, K. Obara | WROCLAW, POLAND

P 31211 Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis

S. Tamer¹, H.N. Günes², E. Gökçal¹, T. Yoldas² | ¹VAN, ²ANKARA, TURKEY

POSTER SESSION NEURO-ONCOLOGY 3

12:30-13:15 | SCREEN C4

CHAIRPERSON:

Anette Storstein, BERGEN, NORWAY

P 31212 Skull chloroma in a patient with myeloid leukemia and pancytopenia

A.C. Mergeani, O. Rusu, C. Coclitu, A. Ciobotaru, T. Parvu, O.A. Bajenaru, F. Antochi | BUCHAREST, ROMANIA

P 31213 Bilateral facial nerve palsy secondary to administration of nab-paclitaxel

D. Naoumis, I. Spanou, M. Antonopoulou, A. Isaakidou, N. Kentepozidis, E. Kouremenos | ATHENS, GREECE

P 31214 Primary dural involvement of multiple myeloma (MM): description of 2 cases

A. Olaskoaga, L. Martinez-Merino, L. Pulido, A. Gorosquieta, M.C. Viguria, E. Erro | PAMPLONA, SPAIN

P 31215 Solitary intraventricular metastasis from lung adenocarcinoma mimicking glioblastoma

I.A. Orban, L. Dumitrescu, I. Gobej, I. Olaru Popescu, C. Nechifor, B.O. Popescu, R. Tanasescu | BUCHAREST, ROMANIA

P 31216 Posterior reversible encephalopathy syndrome in pediatric oncology: a four clinical cases

J. Passos, M. Valente, S. Nunes, D. Salgado | LISBON, PORTUGAL

P 31217 Intramedullary pleomorphic xanthastrocytoma with anaplastic features: a triple rare entity

C. Rosado Coelho¹, J. Pimentel², P. Pereira², L. Roque², J.P. Farias² | ¹SETÚBAL, ²LISBON, PORTUGAL

P 31218 Dramatic response and prolonged survival after intensive chemotherapy with autologous stem cell transplantation in a case of lymphomatosis cerebri

L. Royer-Perron, C. Houillier, K. Mokhtari, D. Leclercq, S. Choquet, A. Alentorn, A. Duran-Pena, K. Hoang-Xuan, A. Gonzalez-Aguilar | PARIS, FRANCE

P 31219 Abstract cancelled

P 31220 A case report of primary central nervous system lymphoma

M. Scarioni, P. Basilico, A.M. Pietroboni, A. Arighi, G.G. Fumagalli, A. Calvi, D. Galimberti, E. Scarpini | MILAN, ITALY

P 31221 Headache in renal cell carcinoma; a possible paraneoplastic symptom?

S. Thissen | HEERLEN, NETHERLANDS

P 31222 Germinoma mimicking lesion of inflammatory etiology on MRI

T. Urbanic Purkart, M. Asslaber, E. Holl, T. Seifert-Held, F. Payer | GRAZ, AUSTRIA

P 31223 Basal ganglia germinoma in adult: a case report

C. Vialatte de Pémille, K. Mokhtari, F. Bielle, C. Alapetite, A. Idbaih | PARIS, FRANCE

P 31224 Frontal parafalcine meningioma presenting as parkinsonism

S. Vijayarangam Shanmugam, P. Hart, S. Stapleton, S. Omer | LONDON, UK

P 31225 Abstract cancelled

MONDAY, 30 MAY

12:30 - 13:15

POSTER SESSION NEURO-OPHTHALMOLOGY/ NEURO-OTOLOGY 3

12:30-13:15 | SCREEN H1

CHAIRPERSON:

Eleftherios Papathanasiou, NICOSIA, CYPRUS

P 31226 Assessing rotation and acting forces in vestibular patients during walking and balance tasks with combined motion capture and accelerometers

J. Decker¹, C. Pradhan¹, T. Brandt¹, K. Jahn², R. Schniepp¹¹MUNICH, ²BAD AIBLING, GERMANY

P 31227 Ophthalmologic presentation of CADASIL

J. Martins, J. Serino, V. Carvalho, C. Cunha, J. Martins

MATOSINHOS, PORTUGAL

P 31228 Regional patterns of brain gray and white matter abnormalities in patients with hereditary optic neuropathies: dominant optic atrophy vs. leber hereditary optic neuropathy

R. Messing, M.A. Rocca, S. Bianchi-Marzoli, M. Petrolini, J. Milesi, F. Darvizeh, F. Bandello, G. Comi, A. Falini, M. Filippi

MILAN, ITALY

P 31229 Disconjugate horizontal eye movements in spinocerebellar ataxia type 3 (SCA3)

A. Novo, C. Duque, J. Ribeiro, J. Castelhana, J.M.G. Lemos, C. Januário

COIMBRA, PORTUGAL

P 31230 Improvement of visual field with medicinal herbs in normal tension glaucoma: a small open pilot study

T. Okabe

TOKYO, JAPAN

P 31231 Why and when to refer patients for vestibular evoked myogenic potentials: a critical review

E. Papathanasiou¹, D. Straumann²¹NICOSIA, CYPRUS, ²ZURICH, SWITZERLAND

P 31232 Isolated opsoclonus: a case series

E. Pappa, A. Alentorn, M.J. Ibanez, A.-I. Grinea, G. Breton, B. Gaymard, D. Psimaras

PARIS, FRANCE

P 31233 Isolated unilateral ptosis due to neurovascular conflict

G. Piccirillo, F. Trojsi, R. Conforti, G. Tedeschi

NAPLES, ITALY

P 31234 Sensitive assessment of acute optic neuritis by a new digital flicker test

G. Pihl-Jensen¹, S. Trauzettel-Klosinski², J.L. Frederiksen¹¹GLOSTRUP, DENMARK, ²TÜBINGEN, GERMANY

P 31235 No gender difference on optic coherence tomography in acute optic neuritis

G. Pihl-Jensen, J.L. Frederiksen

GLOSTRUP, DENMARK

P 31236 Susac's syndrome - a multidisciplinary approach

M. Reis Costa, T. Teodoro, L.P. Faria de Abreu, P. Alves,

L. Albuquerque, P. Antunes

LISBON, PORTUGAL

POSTER SESSION NEUROREHABILITATION 3

12:30-13:15 | SCREEN G2

CHAIRPERSON:

Stefan Golaszewski, SALZBURG, AUSTRIA

P 31237 Computer use aspects in patients with motor disabilities

S. Bostantjopoulou¹, M. Plotnick³, G. Zeilig³, A. Gottlieb³,R. Kizony³, S. Chlomiou², A. Nichogiannopoulou²,Z. Katsarou¹¹THESSALONIKI, ²ATHENS, GREECE, ³TEL AVIV, ISRAEL

P 31238 Towards a new way for upper limb rehabilitation: a promising combined approach

R.S. Calabrò, A. Naro, M. Russo, A. Cacciola, A. Leo,

D. Milardi, P. Bramanti

MESSINA, ITALY

P 31239 Functional validation of an iPad delivered prism adaptation procedure in healthy young adults

A.S. Champod¹, G. Haidar¹, G. Eskes²¹WOLFVILLE, ²HALIFAX, CANADA

P 31240 Abstract cancelled

P 31241 Outcome prediction of consciousness disorders in the acute stage based on a complementary motor behavioural tool

K. Diserens

LAUSANNE, SWITZERLAND

P 31242 Understanding of typed text by patients after stroke and healthy volunteers: does typography matter?

R. Gizatullin¹, L. Akhmadeeva¹, L. Nurtadinova¹, B. Veytsman²¹UFA, RUSSIAN FEDERATION, ²FAIRFAX, USA

P 31243 Long-term coma-state and the bedrest-syndrome

S. Golaszewski¹, B. Wutzl¹, C. Florea¹, A.B. Kunz¹, M. Seidl¹,K. Schwenker¹, R. Nardone¹, E. Trinka¹, F. Gerstenbrand²¹SALZBURG, ²VIENNA, AUSTRIA

P 31244 The locked-in-plus-syndrome

S. Golaszewski¹, C. Florea¹, B. Wutzl¹, M. Seidl¹, A.B. Kunz¹,K. Schwenker¹, R. Nardone¹, E. Trinka¹, F. Gerstenbrand²¹SALZBURG, ²VIENNA, AUSTRIA

P 31245 The impact of proper handling of ARAT zero scores on the heterogeneity of data in rehabilitation studies

A. Guekht¹, E. Doppler², J.C. Vester³, D. Muresanu⁴ | ¹MOSCOW, RUSSIAN FEDERATION, ²UNTERACH, AUSTRIA, ³MUNICH, GERMANY, ⁴CLUJ, ROMANIA

P 31246 Effects of early intervention of swallowing therapy on recovery from dysphagia following stroke

M.H. Harirchian¹, J. Bakhtiyari¹, P. Sarraf¹, N. Nakhostin-Ansari¹, A. Tafakhori¹, J. Logemann³, S. Faghihzadeh² | ¹TEHRAN, ²ZANJAN, IRAN, ISLAMIC REPUBLIC OF, ³EVANSTON, USA

P 31247 SPAssticity in PractiCE (SPACE) – an international, observational study of botulinum toxin type A in spasticity

J. Harriss¹, J. Wissel², O. Simon³, K. Sternberg³, N. Roche⁴, C. Cantú-Brito⁵, S. Khatkova⁶, P. Säterö⁷ | ¹LONDON, UK, ²BERLIN, ³FRANKFURT AM MAIN, GERMANY, ⁴GARCHES, FRANCE, ⁵MEXICO CITY, MEXICO, ⁶MOSCOW, RUSSIAN FEDERATION, ⁷GOTHENBURG, SWEDEN

POSTER SESSION NEUROTRAUMATOLOGY

12:30-13:15 | SCREEN G1

CHAIRPERSON:

Edvard Ehler, PARDUBICE, CZECH REPUBLIC

P 31248 Neurophysiological aspects of combined craniofacial trauma

S. Karpov, K. Gandylyan, K. Karakov, I. Azoidis, E. Elisseeva | STAVROPOL, RUSSIAN FEDERATION

P 31249 Characteristics of the neuropsychiatric status of patients in the acute phase of combined trauma (CT)

S. Karpov, E. Nazarova, I. Azoidis, A. Apaguni | STAVROPOL, RUSSIAN FEDERATION

P 31250 Duration and clinical course of post-concussion syndrome in Albania (PCS)

E. Basha, T. Qalliu, B. Zllami, J. Kruja | TIRANA, ALBANIA

P 31251 Abstract cancelled

P 31252 What are the clinical manifestations of a disabling atlantoaxial subluxation? A descriptive study

H. Huhmar, L. Soenne | HELSINKI, FINLAND

P 31253 The clinical presentation of atlantoaxial subluxation in light of three cases undergoing stabilising surgery

H. Huhmar¹, V. Leinonen², L. Soenne³ | ¹HELSINKI, ²KUOPIO, FINLAND

P 31254 Can occipitoatlantal subluxation cause a spasmodic dysphonia? A case study

H. Huhmar, L. Soenne | HELSINKI, FINLAND

P 31255 Formation of vertebral artery syndrome in the late period of cervical spine injury

M. Suleymanova, E. Karpova, E. Omelchenko, S. Karpov, I. Azoidis | STAVROPOL, RUSSIAN FEDERATION

P 31256 FAQ of traumatic brain injury patients: do I really have a chance for a full recovery after TBI?

A. Korchut, S. Szklener, M. Majewski, K. Rejdak, T. Trojanowski | LUBLIN, POLAND

P 31257 Indicators of melatonin and brain-specific proteins in patients with mild consequences of traumatic brain injury

V. Korshnyak, O. Korshnyak | KHARKIV, UKRAINE

P 31258 The characteristics of an acute craniocerebral injury, which was caused by explosive wave, in participants of military operations in Eastern Ukraine

V. Korshnyak, V.I. Sukhorukov, Y. Bovt | KHARKIV, UKRAINE

P 31259 Secondary brain ischemia in the postoperative period in patients with traumatic acute subdural hematomas

J. Kuzibaev | TASHKENT, UZBEKISTAN

P 31260 KPT-350, a selective inhibitor of nuclear export (SINE) compound, reduces primary and secondary injury in core-impact and peri-impact TBI lesions

S. Tamir¹, N. Tajiri², S. Acosta², Y. Landesman¹, M. Lee¹, S. Shacham¹, C. Borlongan², C. Drolen | ¹NEWTON, ²TAMPA, USA

P 31261 Diagnosis and monitoring with Brainstem Auditory Evoked Potentials (BAEP) in patients with brain concussion

D. Tsakova, K. Genov, A. Shmarov, L.D. Traykov | SOFIA, BULGARIA

MONDAY, 30 MAY

12:30 - 13:15

POSTER SESSION PERIPHERAL NERVE DISORDERS 5

12:30-13:15 | SCREEN D2

CHAIRPERSON:

Henry Houlden, LONDON, UK

P 31262 Nerve ultrasound findings in a patient with Charcot-Marie-Tooth (CMT) disease type 4C

A. Felbecker, R. Stark, D. Leupold, T. Hundsberger | ST. GALLEN, SWITZERLAND

P 31263 Parsonage-Turner syndrome or herpes zoster neuritis?

D. Gabriel, P. Salgado, M.N. Cardoso, C. Ramos, A.P. Correia, G. Lopes | PORTO, PORTUGAL

P 31264 IgM MGUS anti-MAG neuropathy can rarely express as distal motor neuropathy

G. Galassi, M. Tondelli, A. Ariatti, P. Nichelli, F. Valzania | MODENA, ITALY

P 31265 The clinical, electrophysiological and morphological peculiarities of atypical chronic inflammatory demyelinating polyneuropathies

E. Gavriluc | CHISINAU, MOLDOVA

P 31266 CIDP - intravenous immunoglobulin or corticosteroids?

M.G. Giurea Neacsu¹, B. Ioan², M. Buraga², C. Baetu², I.-H. Cioriceanu³, A.M. Ghitoiu², A.M. Enachi² | ¹RM. VALCEA, ²BUCHAREST, ³BRASOV, ROMANIA

P 31267 Recurrent facial edema: two new cases of Melkersson-Rosenthal Syndrome

B. Palazon, S. Atienza, J.J. Hernandez | MURCIA, SPAIN

P 31268 Neuronal ganglia as a cause of peripheral nerve lesion - clinical and neurosonographic findings

T. Hundsberger | ST. GALLEN, SWITZERLAND

P 31269 Abstract cancelled

P 31270 High dose intravenous immunoglobulin is effective in painful diabetic polyneuropathy resistant to conventional treatments. Results of a double blind, randomised, placebo-controlled, multicenter trial.

S. Jann¹, R. Fazio¹, D. Cocito², A. Toscano³, A. Schenone⁴, G.A. Marfia⁵, G. Antonini⁵, L. de Toni Franceschini⁶, D. Velardo¹, M. Grandis⁴, A. Mazzeo³, G. Mataluni⁵, E. Peci² | ¹MILAN, ²TURIN, ³MESSINA, ⁴GENOA, ⁵ROME, ⁶LECCO, ITALY

P 31271 Abstract cancelled

P 31272 Subjective symptoms of Carpal Tunnel Syndrome correlate more with psychological factors than electrophysiological severity

F. Khan¹, R. Paul², K.S. Sandhya¹, A. Majeed¹, A. Radhakrishnan³ | ¹THRISUR, ²COCHIN, ³THIRUVANANTHAPURAM, INDIA

P 31273 The anodal action potential for the assessment of sensory nerve excitability

J. Leote¹, P. Pereira², J. Valls-Sole¹ | ¹BARCELONA, SPAIN, ²LISBON, PORTUGAL

POSTER SESSION SLEEP DISORDERS 3

12:30-13:15 | SCREEN E1

CHAIRPERSON:

Maria Stamelou, ATHENS, GREECE

P 31274 Abstract cancelled

P 31275 A high-density polysomnographic picture of a case of NREM parasomnia

N. Amato¹, M. Manconi¹, O. David², S. Miano¹, F. Zellini¹, M. Abbafati¹, L. Ratti¹ | ¹LUGANO, SWITZERLAND, ²GRENOBLE, FRANCE

P 31276 Sleep-wake functions in advanced Parkinson's disease: frequency, associations and evolution after deep brain stimulation

P. Bargiotas, M. Oberholzer, J. Mathis, C. Pollo, M. Schüpbach, C. Bassetti | BERNE, SWITZERLAND

P 31277 Health-related quality of life in patients with narcolepsy type 1 and type 2

J.W. Cho, S.-H. Chae, M.-K. Kim | YANGSAN, KOREA, REPUBLIC OF

P 31278 Altered distribution of nocturnal eye movements in narcolepsy type 1

J.A.E. Christensen, L. Kempfner, H. Leonthin, M.H. Hansen, M. Nikolic, P.J. Jennum | GLOSTRUP, DENMARK

P 31279 Seizure frequency during recent year but not month correlates with quality of sleep, depression, anxiety and quality of life in epilepsy

A. Darabyan, L. Ghahramanyan, T. Stepanyan, N. Yeghiazaryan, S. Khachatryan | YEREVAN, ARMENIA

P 31280 Poor quality of sleep is associated with lower quality of life scores in patients with epilepsy compared to healthy controls

A. Darabyan¹, H. Amroyan¹, L. Ghahramanyan¹, A. Karamyan², S. Khachatryan¹ | ¹YEREVAN, ARMENIA, ²SALZBURG, AUSTRIA

P 31281 Prolonged bed rest and hypoxic exposure affect breathing stability and sleep macrostructure

L. Dolenc Groselj¹, S. Morrison¹, D. Mirnik¹, S. Korsic¹,
O. Eiken², I. Mekjavić¹ | ¹LJUBLJANA, SLOVENIA, ²STOCKHOLM,
SWEDEN

P 31282 Clinico-biological characteristics in restless legs syndrome in a population of hemodialysis patients - Role of vitamin C deficiency

J. El Helou, E. Sarkis, E. Khneisser, H. Azar, D. Chelala | BEIRUT, LEBANON

P 31283 Sleep disturbance in patients with Huntington's Disease - polysomnography characteristics

E. Feketeova, M. Škorvánek, Z. Gdovinova | KOSICE, SLOVAKIA

P 31284 Automatic and visual scorings of REM sleep without atonia for the diagnosis of idiopathic REM sleep behavior disorder

R. Ferri¹, M. Zucconi², A. Galbiati², F. Rinaldi³,
L. Ferini Strambi² | ¹TROINA, ²MILAN, ³BRESCIA, ITALY

P 31285 Evaluation of worry and rumination in insomnia patients

S. Marelli, M. Linares, A. Galbiati, G.E. Lombardi,
V. Castronovo, L. Ferini Strambi | MILAN, ITALY

P 31286 Clinical and polysomnographic differences between idiopathic and symptomatic REM sleep behavior disorder

S. Marelli, A. Galbiati, F. Colli, M. Zucconi, A. Oldani,
L. Ferini Strambi | MILAN, ITALY

P 31287 Is dream enactment or motor activity the pathological finding in REM sleep behaviour disorder? Correlation to changes in the brain quantified with diffusion tensor imaging

R. Frandsen¹, P.J. Jennum² | ¹GLOSTRUP, ²GLOSTRUP - COPENHAGEN, DENMARK

POSTER SESSION AGEING AND DEMENTIA 6

13:30-14:15 | SCREEN A2

CHAIRPERSON:

Rik Ossenkoppele, AMSTERDAM, THE NETHERLANDS

P 32001 Laterality of the breath holding index assessment

A. Tomek, B. Urbanová, H. Magerová, H. Marková,
J. Paulasová Schwabová, P. Jansky, I. Mokrisova,
J. Laczó, M. Vyhnálek, J. Hort | PRAGUE, CZECH REPUBLIC

P 32002 Heterogeneity of dementia associated with Parkinson's disease

N. Trofimova¹, I. Preobragenskaya² | ¹PERESLAVL, ²MOSCOW,
RUSSIAN FEDERATION

P 32003 The relationship with silent lacunar infarctions in basal ganglia and clinical features in Alzheimer's disease

Y. Uchiyama, M. Iwata, H. Hashida, K. Kitagawa | TOKYO, JAPAN

P 32004 The effect of physical exercise on cerebral blood flow in Alzheimer's disease

L.A. van der Kleij¹, E.T. Petersen², H.R. Siebner²,
J. Hendrikse¹, K. Frederiksen², N. Sobol², S.G. Hasselbalch²,
E. Garde² | ¹UTRECHT, NETHERLANDS, ²COPENHAGEN, DENMARK

P 32005 Comparing longitudinal behaviour changes in the primary progressive aphasia

T. van Langenhove, C. Leyton, O. Piguet, J.R. Hodges | SYDNEY, AUSTRALIA

P 32006 Insulin-like growth factors in spinal fluids from patients with and without Alzheimer's dementia

A.S. Vinther, H. Gottrup, J. Frystyk, H. Andersen | AARHUS, DENMARK

P 32007 Objective monitoring of dysarthria in FTD-MND: a case series

M. Poole, A. Brodtmann, D. Darby, A. Vogel | MELBOURNE, AUSTRALIA

P 32008 Development of a specialised tool for the assessment of testamentary capacity (TC) in patients with dementia

P. Voskou, I. Beratis, A. Economou, A. Douzenis,
S.G. Papageorgiou | ATHENS, GREECE

P 32009 A sporadic case of early-onset Alzheimer's disease with spastic paraparesis, cognitive impairment and cerebral white matter lesions due to a PSEN1 mutation

B. Willekens¹, M.T. van Den Bossche², S. Engelborghs²,
C. van Broeckhoven², P. Cras¹ | ¹EDEGEM, ²ANTWERP, BELGIUM

MONDAY, 30 MAY

13:30 - 14:15

P 32010 Plasma ceramides and neuropsychiatric symptoms of Alzheimer's disease

Y. Xing | BEIJING, CHINA

P 32011 Regional differences in antipsychotic drug use in elderly patients with dementia: a nationwide study

J.K. Zakarias¹, C. Jensen-Dahm¹, C. Gasse², A. Nørgaard¹, L. Stevnsborg¹, T. Moos³, G. Waldemar¹ | COPENHAGEN,

²AARHUS, ³AALBORG, DENMARK

POSTER SESSION CEREBROVASCULAR DISEASES 12

13:30-14:15 | SCREEN G4

CHAIRPERSON:

Valeria Caso, PERUGIA, ITALY

P 32012 Sex differences in the care, and outcomes of transient ischemic attack in Tashkent

S. Rakhimberdiyev, Y. Musaeva, G. Rakhimbaeva | TASHKENT, UZBEKISTAN

P 32013 RISCLON – Risk of recurrent stroke in CLOpidogrel non-responders

C.L. Rath, T. Wienecke | ROSKILDE, DENMARK

P 32014 Ultrasonographic evaluation of a series of patients with Takayasu's arteritis in a tertiary center

M. Reis Costa, P. Viana, V. Oliveira | LISBON, PORTUGAL

P 32015 Cognitive impairment in cerebral small vessel disease

A. Riqhi, I. Bedoui, H. Derbali, M. Messelmani, M. Mansour, J. Zaouali, R. Mrissa | TUNIS, TUNISIA

P 32016 Implication of Caudeate nucleus lacunar infarcts in post-stroke depression

A. Riqhi, H. Derbali, I. Bedoui, M. Messelmani, M. Mansour, J. Zaouali, R. Mrissa | TUNIS, TUNISIA

P 32017 Reversible cerebral vasoconstriction syndrome diagnosis with perfusion MRI

P. Ripellino, E. Prodi, A. Cianfoni, C.W. Cereda | LUGANO, SWITZERLAND

P 32018 Cardioembolic stroke caused by cardiac metastatic melanoma – a case report

M. Rosón González¹, L. Castillo¹, M. Villa¹, M.E. Novillo¹, A. Perez¹, P. Pire¹, A. Arbox¹, A. Mendez¹, P. Bandres¹, L. Vela² | ¹ALCORCÓN, SPAIN, ²MADRID, SPAIN

P 32019 Recurrent in-stent stenosis of cervico-cerebral arteries

O. Rusu, C. Coclitu, T. Parvu, A. Ciobotaru, A.C. Mergeani, B. Dorobat, O. Bajenaru, F. Antochi | BUCHAREST, ROMANIA

P 32020 Cerebral reperfusion syndrome–complication of carotid artery endarterectomy: a case report

O. Rusu, C. Coclitu, A. Ciobotaru, T. Parvu, A.C. Mergeani, M.T. Vasile, B. Dorobat, F. Antochi | BUCHAREST, ROMANIA

P 32021 Abstract cancelled

P 32022 Abstract cancelled

P 32023 Prevalence of post-stroke spasticity in Poland and its impact on activities of daily living and quality of life in one-year follow-up

M. Schinwelski, E. Sitek, J. Sławek | GDAŃSK, POLAND

P 32024 The impact of seasonal changes on cerebrovascular diseases: a retrospective study in Northern Cyprus

S. Ertuğrul Mut, F. Selcuk, S. Usar Incirli | NICOSIA, TURKEY

P 32025 Leukocyte subtype counts in the acute phase of ischemic stroke as biomarker for haemorrhagic complications and outcome

A. Semerano, D. Strambo, G. Comi, L. Roveri, M. Bacigaluppi | MILAN, ITALY

POSTER SESSION CEREBROVASCULAR DISEASES 13

13:30-14:15 | SCREEN G3

CHAIRPERSON:

Catarina Fonseca, LISBON, PORTUGAL

P 32026 Risk factors for hemorrhagic transformation in patients with acute posterior circulation territory infarction

B.S. Demirtas, L. Öcek, B.I. Tiftikcioglu, O. Oztekin, Y. Zorlu | IZMIR, TURKEY

P 32027 Positive trend in door-to-needle time and stroke outcome after implementation and data analysis of Romanian stroke thrombolysis registry

C. Tiu, V. Tiu, E. Terecoasa, A. Neacsu, O.A. Bajenaru | BUCHAREST, ROMANIA

P 32028 Unusual aetiologies of cerebral venous sinus thrombosis

G. Tondo, A. Naldi, R. Cantello | NOVARA, ITALY

P 32029 Headache – a common symptom in acute cerebrovascular disease

L.A. Torop, L. Sabre, R. Vibo, J. Kõrv | TARTU, ESTONIA

P 32030 The studying of lipid metabolism and endothelium dysfunction in young patients with spondylogenic vertebrobasilar insufficiency (SVBI)

N. Nekrasova, O. Tovazhnyanska, O. Markovska | KHARKIV, UKRAINE

P 32031 Neuropsychological disorders in isolated cerebellar infarctions

O. Mialovitska, G. Trepet | KIEV, UKRAINE

P 32032 Low prevalence of internal jugular valve insufficiency in transient global amnesia: a pilot, single-center study

S. Triantafyllou¹, D. Kontaxopoulou¹, S. Fragkiadaki¹, C. Zompola¹, M. Chondrogianni¹, C. Liantinioti¹, G. Papadimitropoulos¹, A. Kleisoura¹, K. Tasios¹, A. Papa², A. Roussopoulou¹, M. Ioakeimidis¹, A. Bonakis¹, K. Voumvourakis¹, L. Stefanis¹, S.G. Papageorgiou¹, G. Tsvigoulis¹ | ¹ATHENS, ²LARISSA, GREECE

P 32033 Imaging presentation of intracerebral hemorrhage in an East European community (Grodno, Belarus)

S. Tsimenava, I. Shaporov, N. Filina, S. Kulesh | GRODNO, BELARUS

P 32034 Abstract cancelled

P 32035 Ratio between carotid artery stiffness and blood flow - a new ultrasound index of ischemic Leukoaraiosis

M. Turk¹, M. Zaletel², J. Pretnar Oblak² | ¹NOVO MESTO, ²LJUBLJANA, SLOVENIA

P 32036 Abstract cancelled

P 32037 MoCA vs. MMSE in post-stroke patients

S. Xhaxho, J. Xhaxho, J. Hankollari, B. Xhaxho, J. Kruja | TIRANA, ALBANIA

P 32038 Time of the day and the onset of stroke

S. Xhaxho, J. Xhaxho, R. Sanxhaku, B. Xhaxho, J. Kruja | TIRANA, ALBANIA

P 32039 DSA study of supratentorial venous sinus in cases with non-venous system disease

L. Yin, D. Li, C. Ma | DALIAN, CHINA

P 32040 Color anomia and quadrantanopia in a case of alexia without agraphia: a rare disconnection syndrome

T. Yoldas, A. Akyüz, B. Gökçe Çokal, M.I. Yon, H.N. Günes, G. Çakar | ANKARA, TURKEY

POSTER SESSION EPILEPSY 7

13:30-14:15 | SCREEN B2

CHAIRPERSON:

Eugen Trinka, SALZBURG, AUSTRIA (TBC)

P 32041 Current practices in long-term video-EEG monitoring services: a survey among partners of the E-PILEPSY pilot network of reference for refractory epilepsy and epilepsy surgery

T. Kobulashvili¹, J. Döbesberger¹, J. Höfler¹, F. Ernst¹, P. Ryvlin², H. Cross⁴, K. Braun⁵, P. Dimova⁶, S. Francione⁷, H. Hecimovic⁸, C. Helmstaedter⁹, V. Kimiskidis¹¹, M.I. Lossius¹², K. Malmgren¹³, P. Marusic¹⁴, B.J. Steinhoff¹⁰, P.A. Boon¹⁵, D. Craiu¹⁶, N. Delanty¹⁷, D. Fabo¹⁸, A. Gil-Nagel¹⁹, A. Guekht²⁰, E. Hirsch²¹, S. Rheims²², P. Krsek¹⁴, G. Rubboli²³, M. Seeck³, C. Özkara²⁴, R. Mameniski²⁵, R.K. Kälviäinen²⁶, E. Trinka¹ | ¹SALZBURG, AUSTRIA, ²LAUSANNE, ³GENEVA, SWITZERLAND, ⁴LONDON, UK, ⁵UTRECHT, NETHERLANDS, ⁶SOFIA, BULGARIA, ⁷MILAN, ITALY, ⁸ZAGREB, CROATIA, ⁹BONN, ¹⁰KEHL-KORK, GERMANY, ¹¹THESSALONIKI, GREECE, ¹²OSLO, NORWAY, ¹³GOTHENBURG, SWEDEN, ¹⁴PRAGUE, CZECH REPUBLIC, ¹⁵GHENT, BELGIUM, ¹⁶BUCHAREST, ROMANIA, ¹⁷DUBLIN, IRELAND, ¹⁸BUDAPEST, HUNGARY, ¹⁹MADRID, SPAIN, ²⁰MOSCOW, RUSSIAN FEDERATION, ²¹STRASBOURG, ²²LYONS, FRANCE, ²³DIANALUND, DENMARK, ²⁴ISTANBUL - CERRAHPASA, TURKEY, ²⁵VILNIUS, LITHUANIA, ²⁶KUOPIO, FINLAND

P 32042 Young people with epilepsy have an increased risk of eating disorder symptoms and poor quality diet

E. Kolstad¹, M.H. Bjørk¹, N.E. Gilhus¹, J. Clench-Aas², G. Veiby¹, M.I. Lossius³ | ¹BERGEN, ²OSLO, ³BAERUM, NORWAY

P 32043 The prospective role of orexin-a levels in epileptic seizure

H.I. Cıkrıklar¹, D. Kotan¹, M. Yuce¹, M. Ceylan², G. Gurol¹, O.F. Bayraktutan², I.H. Ciftci¹ | ¹SAKARYA, ²ERZURUM, TURKEY

P 32044 Gene expression for Schwannoma-derived growth factor using microarrays method in epilepsy (of the temporal lobes, frontal and generalised)

M. Grabek Gawłowicz, L. Kotula, A. Petniak, J. Karwat, P. Gil-Kulik, J. Kocki | LUBLIN, POLAND

P 32045 Safety and tolerability of eslicarbazepine acetate as monotherapy in patients with newly diagnosed partial-onset seizures

P. Kowacs¹, E. Trinka², E. Ben-Menachem³, C.E. Elger⁴, J. Moreira⁵, R. Pinto⁶, F. Ikedo⁵, A. Pereira⁵, J.F. Rocha⁵, P. Soares-Da-Silva⁵ | ¹CURITIBA, BRAZIL, ²SALZBURG, AUSTRIA, ³GOTHENBURG, SWEDEN, ⁴BONN, GERMANY, ⁵CORONADO, ⁶PORTO, PORTUGAL

P 32046 Abstract cancelled

MONDAY, 30 MAY

13:30 - 14:15

P 32047 Serum MMP-9 and TIMP-1 level increases after generalised tonic-clonic seizures

A. Cudna, A. Jopowicz, P. Mierzejewski, I. Kurkowska-Jastrzebska | WARSAW, POLAND

P 32048 Interictal heart rate in patients with epilepsy

I. Manka-Gaca, B. Labuz-Roszak, K. Pierzchala, A. Machowska-Majchrzak, Z. Kalarus, B. Sredniawa | ZABRZE, POLAND

P 32049 EEG and ECG changes in patients with epilepsy

I. Manka-Gaca, B. Labuz-Roszak, K. Pierzchala, Z. Kalarus, B. Sredniawa, S. Cebula, A. Sliwinska, E. Markowicz-Pawlus, A. Musialik-Lydka, A. Machowska-Majchrzak | ZABRZE, POLAND

P 32050 The level of apoptotic cells and antiepileptic drug (AEDs) pharmacotherapy in epilepsy patients

U. Lagan-Jedrzejczyk, A. Oczkowska, A. Florczak, J. Florczak-Wypianska, J. Karczewski, A. Swiejkowska, E. Przedpelska-Ober, W. Kozubski, J. Dorszewska | POZNAN, POLAND

P 32051 Expression of circulating miR-132 in mesial temporal lobe epilepsy: a preliminary study

B. Leal, C. Carvalho, A. Bettencourt, J.M.M. Chaves, J. Freitas, J.M.C.F. Lopes, J.E.D.P. Ramalheira, A. Martins Da Silva, P.P Costa, B. Martins Da Silva | PORTO, PORTUGAL

P 32052 Rasmussen's encephalitis: other „movements” besides epilepsy

L. Leitão¹, J. Peres¹, S. Reimão², R. Peralta², J. Pimentel² | ¹AMADORA, ²LISBON, PORTUGAL

P 32053 Eslicarbazepine acetate: update of post-marketing safety data

M. Vieira, H. Gama, J. Graça, R. Costa, R. Sousa, P. Soares-Da-Silva | CORONADO, PORTUGAL

POSTER SESSION
HEADACHE AND PAIN 6

13:30-14:15 | SCREEN C1

CHAIRPERSON:

Jera Kruja, TIRANA, ALBANIA

P 32054 Abstract cancelled

P 32055 Depression prevalence and severity among headache patients compared to the general population in Albania

I. Alimehmeti¹, M. Rakacolli², S. Grabova², E. Kurmaku², P. Jahja², E. Rraklli², J. Kruja² | ¹MAASTRICHT, NETHERLANDS, ²TIRANA, ALBANIA

P 32056 Possible risk factors for migraine and tension type headache

E.R. Lebedeva¹, N.R. Kobzeva¹, D.V. Gilev¹, J. Olesen² | ¹YEKATERINBURG, RUSSIAN FEDERATION, ²COPENHAGEN, DENMARK

P 32057 Idiopathic intracranial hypertension clinically manifested as bilateral sixth nerve palsy, combined with the enlargement of superior ophthalmic veins: a case report

J.E. Lee¹, Y.B. Kim¹, I.U. Kang¹, D.W. Bae¹, K.S. Kim² | ¹SEOUL, ²POHANG, KOREA, REPUBLIC OF

P 32058 Case study of repetitive transcranial magnetic stimulation of the motor cortex for thalamic pain

H. Lin | BEIJING, CHINA

P 32059 Gender differences in the lifestyle of cluster headache patients: results from the Danish cluster headache survey

N. Lund, M. Barloese, A.S. Petersen, A.H. Snoer, R. Jensen | COPENHAGEN, DENMARK

P 32060 Marked diagnostic delay in cluster headache – An analysis of the clinical features: results from the Danish cluster headache survey

N. Lund, M. Barloese, A.S. Petersen, A.H. Snoer, R. Jensen | COPENHAGEN, DENMARK

P 32061 Experimental provocation of “ice-cream headache” by ice cubes and ice water

S. Mages, O. Hensel, T. Kraya, S. Zierz | HALLE, GERMANY

P 32062 An atypical migraine: the key role of perfusion imaging

S. Magno¹, M. Ghosn², F. Baronnet Chauvet², S. Deltour², M. Ollivier², C. Rosso², Y. Samson² | ¹PARIS/MILAN, ²PARIS, FRANCE

P 32063 Headache in Hungarian neurology outpatient services

M. Magyar, E. Csepány, T. Gyüre, A. Ajtay, D. Bereczki, F. Oberfrank, C. Ertsey | BUDAPEST, HUNGARY

P 32064 Clinico-demographic features of trigeminal autonomic cephalias: an experience from a tertiary care center

Y. Malik, S. Siddiqi, J. Inshasi, M. Altashi, A. Almadani | DUBAI, UNITED ARAB EMIRATES

P 32065 Primary headache data series from a tertiary care hospital: a review of 12 years

Y. Malik, P. Sarathchandran, J. Dar, S. Siddiqi, A. Almadani | DUBAI, UNITED ARAB EMIRATES

P 32066 Follow-up study of 12-18 years on subtypes of headache in a population of children below 6 years old: preliminary results

F. Marchese, P. Marchese, V. Raieli, D. Puma, G. La Franca, F. Vanadia | PALERMO, ITALY

POSTER SESSION HEADACHE AND PAIN 7

13:30-14:15 | SCREEN C4

CHAIRPERSON:

Jes Olesen, GLOSTRUP, DENMARK

P 32067 No pain perception abnormalities in allodinic patients between attacks

L. Marcuccio, A. Russo, F. Conte, A. Giordano, A. Tessitore, G. Tedeschi | NAPLES, ITALY

P 32068 Cluster headache in Czech patients

J. Markova¹, A. Bartkova², R. Kotas³, J. Mastik⁴, I. Niedermayerova⁴ | ¹PRAGUE, ²OLOMOUC, ³PLZEN, ⁴BRNO, CZECH REPUBLIC

P 32069 DT-MRI reveals widespread white matter abnormalities in migraine patients compared to healthy controls

E. Martinez, M. Ruiz Piñero, M. Mateos, G. Barrio-Arranz, M. Rodriguez, Á.L. Guerrero Peral, S. Aja-Fernández, R. Luis-García | VALLADOLID, SPAIN

P 32070 Pituitary apoplexy: a challenging and emergent diagnosis

R. Martins, P. Pita Lobo | PALERMO, ITALY

P 32071 Ice cream headache in students and family history of headache: a cross-sectional questionnaire-based study

T. Mehl, A. Zierz, T. Kraya, S. Zierz | HALLE, GERMANY

P 32072 Capabilities of electromyography in the dysfunction temporomandibular joint

N. Safonova, V. Mikhailov, J. Kotsiubinskaya, I. Ashnokova, T. Lopushanskaya | SAINT-PETERSBURG, RUSSIAN FEDERATION

P 32073 Tension type headache - an osteopathic treatment

D. Milka, M. Jachacz-Lopata, W. Likus, G. Bajor | KATOWICE, POLAND

P 32074 Cervicogenic headache as a symptom of poor posture

M. Jachacz-Lopata, D. Milka, W. Likus, G. Bajor | KATOWICE, POLAND

P 32075 Telemedicine in diagnosis and management of non-acute headaches: an open-labeled noninferiority randomised controlled study

K.I. Mueller¹, K.B. Alstadhaug², S.I. Bekkelund¹ | ¹TROMSØ, ²BODØ, NORWAY

P 32076 Modulatory effect of nitroglycerin on the L-kynurenine hydrolase and kynurenine 3-monooxygenase expression in the rat cervical spinal cord

G. Nagy-Grócz, Z. Bohar, K.F. Laborc, A. Fejes-Szabó, L. Vécsei, Á. Párdutz | SZEGED, HUNGARY

P 32077 Occipital seizure with persistent homonymous hemianopia with T2 hypointensity on MRI in non-ketotic hyperglycemia

Z.U. Nissa, S. Siddiqi, S. Abdool | DUBAI, UNITED ARAB EMIRATES

P 32078 Clinical factors associated with migraine chronification

A. Novo, J. Jesus Ribeiro, L. Sousa, S. Batista | COIMBRA, PORTUGAL

P 32079 Towards a pragmatic migraine model for drug testing: Cilostazol and Isosorbide-5-mononitrate provocation in healthy subjects

E.K. Hansen, J. Olesen | GLOSTRUP, DENMARK

P 32080 The role of mental and behavioural disorders in the primary headaches management determination

G. Osmanova, A. Musayev | BAKU, AZERBAIJAN

P 32081 Headache in multiple sclerosis

M. Öztürk, M. Ozerden, S. Topaloglu Tuac, F. Basoglu, A. Soysal, S. Baybas | ISTANBUL, TURKEY

POSTER SESSION INFECTION AND AIDS 2

13:30-14:15 | SCREEN F3

CHAIRPERSON:

Johann Sellner, SALZBURG, AUSTRIA

P 32082 Genetic variants influencing susceptibility to pneumococcal meningitis identified by an exome array analysis

A. Kloek¹, B. Ferwerda¹, J. van Setten², A. van der Ende¹, M. Valls Seron¹, M. Brouwer¹, D. van de Beek¹ | ¹AMSTERDAM, ²UTRECHT, NETHERLANDS

P 32083 Nonidiopathic hypertrophic pachymeningitis

A.D. Magalhães, C. Campos, D. Simão, A.P. Antunes, F. Falcão, L. Albuquerque, J.G.D.B.C. Pimentel | LISBON, PORTUGAL

P 32084 Activation of dormant infections in the acute period of experimental hemorrhagic stroke (EHS)

O. Makarenko | KIEV, UKRAINE

P 32085 A difficult diagnosis: Tuberculosis with CNS and peritoneal involvement in an immunocompetent patient

R. Martins, D. Aparício, R. Tojal, V. Geraldés, R. Manso, J. Campillo | AMADORA, PORTUGAL

P 32086 Meningitis caused by streptococcus suis

J.Á. Motos García, J.M. Rodríguez García, N. García Lax, A. Sanz Monllor, M. Palao Rico, A.M. García Medina, M.L. Martínez Navarro, J. Marín Marín, M.P. Salmerón Ato, J.A. Iniesta Valera, I.M. Sanchez Ortuño, A. Díaz Ortuño | MURCIA, SPAIN

MONDAY, 30 MAY

13:30 - 14:15

P 32087 Herpes simplex 1 encephalitis due to reactivation by cutaneous herpes zoster in an immunocompetent adult

M. Oses, B. Pfang, M. Machío, M.A. García-Torres, A. Herranz, R. Fernández-Roblas, I. Zamarbide | MADRID, SPAIN

P 32088 Atypical ramsay hunt syndrome with oculomotor palsy

M. Oses, M. Machío, L. Oliví, R. Rigual, B. Sobrino, M. Ruggiero García, M.A. García-Torres, I. Zamarbide | MADRID, SPAIN

P 32089 Diagnostic approach to acute encephalitis in adults in a spanish tertiary hospital over a three-year period (2013-2015)

J. Perez Lucas, E. Miñano Guillamón, E.M. Alba Suarez, P. López Ruiz | MADRID, SPAIN

P 32090 MRI findings in tick-borne encephalitis

A. Pichler, H. Rock, F. Fazekas | GRAZ, AUSTRIA

P 32091 Recurrence of herpes simplex encephalitis after 16 years

A.L. Rassu, R. Piredda, A. Addis, E. Sechi, C. Fois, W. Boadu, E. Nako, G. Sechi | SASSARI, ITALY

P 32092 Anti-NMDAR encephalitis after herpetic encephalitis in an adult patient

P. Salgado, I. Moreira, L. Albuquerque, A. Martins Silva | PORTO, PORTUGAL

P 32093 HIV-PML: remember to test

R. Samoes¹, S. Rackstraw², M. Marta² | ¹PORTO, PORTUGAL, ²LONDON, UK

POSTER SESSION MOTOR NEURONE DISEASES 4

13:30-14:15 | SCREEN C2

CHAIRPERSON:

Vincenzo Silani, MILAN, ITALY

P 32094 SOD1: phenotypic variability, incidence and penetrance in a north-west tuscan cohort of patients

M. Rossi, C. Bisordi, E. Caldarazzo Ienco, M. Fabbrini, L. Chico, C. Carlesi, A. Lo Gerfo, A. Fogli, G. Siciliano | PISA, ITALY

P 32095 Outcome measures and natural history study in spinal and bulbar muscular atrophy (SBMA)

A. Sagnelli¹, I. Tramacere¹, A. Castaldo¹, M. Montesano¹, V. Scaioli¹, C. Gellera¹, E. Vitelli², F. Taroni¹, C. Mariotti¹, D. Pareyson¹ | ¹MILAN, ²LODI, ITALY

P 32096 Absence of wide-spread mis-splicing in the pre-clinical phase of a native promoter driven TDP-43 mouse model of ALS

J. Scaber, D. Gordon, R. Mutihac, J. Alegre-Abarrategui, J. Riancho, D. Sims, R. Wade-Martins, A. Heger, K. Talbot | OXFORD, UK

P 32097 Participation of protein kinase C in neurite-inhibitory effect in plasma of patients with spinal muscular atrophy type II

M. Sokolova, V. Penniyaynen, S. Lobzin | SAINT-PETERSBURG, RUSSIAN FEDERATION

P 32098 Matching genetic and clinical information – a new spastin mutation causing HSP4 and a new non-pathogenic epsilon sarcoglycan mutation in one patient

R. Stark, A. Felbecker | ST. GALLEN, SWITZERLAND

P 32099 Occurrence of multiple ALS-associated mutations in Italian patients

N. Ticozzi, C. Tiloca, V. Pensato, D. Calini, B. Castellotti, A. Ratti, C. Gellera, V. Silani | MILAN, ITALY

P 32100 Care preferences in amyotrophic lateral sclerosis (ALS) patients and carers using a discrete choice experiment

S. Maguire, K. Tobin, O. Hardiman, C. Normand, M. Galvin | DUBLIN, IRELAND

P 32101 Longitudinal analysis of a discrete choice experiment of preferences for care of amyotrophic lateral sclerosis patients and their carers

K. Tobin, S. Maguire, C. Normand, O. Hardiman, M. Galvin | DUBLIN, IRELAND

P 32102 Whole-brain microstructural abnormalities in amyotrophic lateral sclerosis (ALS): High-Angular Resolution Diffusion Imaging (HARDI) study in bulbar-onset versus spinal-onset ALS

F. Trojsi¹, G. Caiazzo¹, C. Femiano¹, F. Di Nardo¹, M. Fratello¹, G. Santangelo², M. Siciliano¹, G. Piccirillo¹, M.R. Monsurrò¹, M. Cirillo¹, A. Tessitore¹, F. Esposito¹, G. Tedeschi¹ | ¹NAPLES, ²CASERTA, ITALY

P 32103 Abstract cancelled

P 32104 Phenotype comparison between young- and elderly-onset motor neuron disease patients

F. Verde, N. Ticozzi, C. Morelli, S. Messina, A. Doretti, B. Poletti, C. Tiloca, L. Maderna, V. Silani | MILAN, ITALY

P 32105 Severe MRI-visible Virchow-Robin spaces in amyotrophic lateral sclerosis: clue to the pathogenesis?

A. Vogrig | VERONA, ITALY

POSTER SESSION MOVEMENT DISORDERS 8

13:30-14:15 | SCREEN E4

CHAIRPERSON:

Evzen Ruzicka, PRAG, CZECH REPUBLIC

P 32106 Independent validation of the quality of life in essential tremor questionnaire (QUEST)

A. Makkos, M. Kovács, J. Janszky, N. Kovacs | PÉCS, HUNGARY

P 32107 Gastrostomy and parkinsonism: a retrospective study of indication and outcomes

C. Marois, M.D.M. Amador, C. Payan, L. Lacomblez, V. Mesnage, D. Grabli | PARIS, FRANCE

P 32108 Patient satisfaction with botulinum toxin for the treatment of cervical dystonia – a survey among patients in Spain

M.J. Marti Domenech¹, M.J. Catalán² | ¹BARCELONA, ²MADRID, SPAIN

P 32109 Abstract cancelled

P 32110 Abstract cancelled

P 32111 Intrusive thoughts as non-motor off symptoms of Parkinson's disease: a case report

S. Medic, D. Kuljic Obradovic | BELGRADE, SERBIA

P 32112 Hereditary atypical parkinsonism with novel mutation of the VPS35 and FBX07 genes

K. Mensikova¹, T. Bartonikova¹, L. Mikulicova¹, R. Vodicka¹, R. Vrteš, M. Godava¹, I. Dolinova², M. Vastik¹, M. Kaiserova¹, P. Otruba¹, P. Kanovsky¹ | ¹OLMOUC, ²LIBEREC, CZECH REPUBLIC

P 32113 Delayed improvement after spinal tap test in normal pressure hydrocephalus – evidence from a serial gait analysis experiment

K. Möhwalder¹, M. Wuehr¹, C. Pradhan¹, A. Peraud¹, M. Dieterich¹, T. Brandt¹, K. Jahn², R. Schniepp¹ | ¹MUNICH, ²BAD AIBLING, GERMANY

P 32114 Evaluation of symptomatic efficacy and safety of RASAGILINE (Azilect®) in Parkinson's disease patients with wearing-off/end-of-dose akinesia using wearing-off-questionnaire-32 (WOQ-32) in daily routine

U. Faude¹, D. Fendji¹, B. Mollenhauer² | ¹BERLIN, ²KASSEL, GERMANY

P 32115 Comparison of posterior striatal cholinergic interneurons in progressive supranuclear palsy, Alzheimer's disease and Lewy body dementia

B. Muinjonov, E. Giyazitdinova, G. Rakhimbayeva | TASHKENT, UZBEKISTAN

P 32116 Comparison of prognostic factors in progressive supranuclear palsy and frontotemporal dementia (Uzbeki trial)

B. Muinjonov, E. Giyazitdinova, G. Rakhimbayeva | TASHKENT, UZBEKISTAN

P 32117 Prevalence, clinical features and MRI correlation of poststroke movement disorders

L. Mumladze, N. Lobjanidze, N. Akiashvili | TBILISI, GEORGIA

P 32118 The features and frequency of motor and non-motor symptoms in patient with Parkinson's disease in Siberian region, Russia

M.A. Nikitina, I.A. Zhukova, V.M. Alifirova, N.G. Zhukova, O.P. Izhboldina, J.S. Mironova, M.A. Titova, A.V. Latypova, N.G. Brazovskaya, S.E. Sukhanov | TOMSK, RUSSIAN FEDERATION

POSTER SESSION MOVEMENT DISORDERS 9

13:30-14:15 | SCREEN E3

CHAIRPERSON:

Anna Sauerbier, LONDON, UK

P 32119 Comparative cross-sectional survey of Parkinson's non-motor symptoms in UK white Caucasian and Malaysian Chinese patients

A. Sauerbier¹, A. Tan², S.-Y. Lim², P. Martinez-Martin³, A. Rizos¹, G. Harington¹, L. Perkins¹, T. Chiwera¹, D. Trivedi¹, A. Martin¹, M. Parry¹, L. Green¹, N. Dimitrov¹, R. Brown¹, K. Ray Chaudhuri¹ | ¹LONDON, UK, ²KUALA LUMPUR, MALAYSIA, ³MADRID, SPAIN

P 32120 The applause sign in frontotemporal lobar degeneration and related conditions

S. Schönecker¹, F. Hell¹, K. Bötzel¹, D. Ftdl-Konsortium², M. Otto², A. Danek¹ | ¹MUNICH, ²ULM, GERMANY

P 32121 Abstract cancelled

P 32122 Demography and clinical profile among Parkinson Disease patients in Egypt: data of 374 cases

H. Shehata, N. Shalaby, A. Abdelalim, A. Elmazny | CAIRO, EGYPT

MONDAY, 30 MAY

13:30-14:15

P 32123 Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration: results of a large international multicenter study of 3206 patients (the QUALPD study)

M. Škorvánek¹, P. Martínez-Martin², N. Kovacs³, I. Zezula¹, M. Rodríguez-Violante⁴, J.-C. Corvol⁵, P. Taba⁶, K. Seppi⁷, O. Levin⁸, A. Schrag⁹, T. Foltynie⁹, V. Han¹, C. Goetz¹⁰, G.T. Stebbins¹⁰, Qualpd Study Group¹ | ¹KOSICE, SLOVAKIA, ²MADRID, SPAIN, ³PECS, HUNGARY, ⁴MEXICO DF, MEXICO, ⁵PARIS, FRANCE, ⁶TARTU, ESTONIA, ⁷INNSBRUCK, AUSTRIA, ⁸MOSCOW, RUSSIAN FEDERATION, ⁹LONDON, UK, ¹⁰CHICAGO, USA

P 32124 Multiple system atrophy (MSA) phenotype associated with frontotemporal lobar degeneration (FTLD)-TDP pathology

A.L. Sousa, R. Taipa, M. Melo Pires, M. Magalhães | PORTO, PORTUGAL

P 32125 MicroRNA in CSF and plasma as diagnostic biomarkers in Parkinson's disease and multiple system atrophy
C. Starhof, A.-M. Hejl, N. Heegaard, K. Winge | COPENHAGEN, DENMARK

P 32126 Adherence to pharmacotherapy in Parkinson's disease patients who take 3 and more daily doses of dopaminergic medication

I. Straka¹, M. Škorvánek², P. Valkovic¹ | ¹BRATISLAVA, ²KOSICE, SLOVAKIA

P 32127 Determinants of disability and quality of life in mild to moderate Parkinson's disease

N. Subasic, E. Suljic, D. Imamovic, S. Hajric, Z. Ajanovic, A. Mehicevic | SARAJEVO, BOSNIA AND HERZEGOVINA

P 32128 Abstract cancelled

P 32129 Objective olfactory testing and self-assessment of olfactory function in patients with Parkinson's disease

M. Titova, O. Izhboldina, J.S. Mironova, I.A. Zhukova, N. Zhukova, M. Nikitina, V. Alifirova | TOMSK, RUSSIAN FEDERATION

P 32130 Abstract cancelled

P 32131 Prospective study of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN)

A. Tomic, I. Petrović, M. Svetel, V. Dobricic, N. Dragasevic Miskovic, V. Kostic | BELGRADE, SERBIA

POSTER SESSIONS MS AND RELATED DISORDERS 14

13:30-14:15 | SCREEN F1

CHAIRPERSON:

Nicholas Gutowski, EXETER, UK

P 32132 Coping styles as predictors of long-term employment in multiple sclerosis - a prospective 13 years follow-up

N. Grytten¹, A.B.R. Skar¹, T. Smedal¹, J.H. Aarseth¹, J. Assmus¹, K. Lode², H. Nyland¹, E. Farbu², K.-M. Myhr¹ | ¹BERGEN, ²STAVANGER, NORWAY

P 32133 Comparison of Nitoxantrone versus cyclophosphamide in patients with secondary progressive multiple sclerosis

T. Gunduz, G. Ozcan, A. Çakar, H.I. Akçay, A.N. Ozdag Acarli, M. Kürtüncü, M. Eraksoy | ISTANBUL, TURKEY

P 32134 Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population

S. Gustavsen, H. Søndergaard, D. Oturai, B. Laursen, J. Hejgaard Laursen, H. Ullum, M. Larsen, F. Sellebjerg, A.B. Oturai | COPENHAGEN, DENMARK

P 32135 Endoplasmic reticulum and oxygen stress alter unfolded protein response gene expression in human neural cells
N.J. Gutowski¹, D. Green², L. Harries¹, J. Holley¹, G. Smerdon³, P. Eggleton¹ | ¹EXETER, ²STAFFORD, ³PLYMOUTH, UK

P 32136 CNS-transmigration of distinct B-cell subsets through the choroid plexus in patients with multiple sclerosis

J. Haas¹, H. Rudolph², S. Faller¹, K. Tessmer¹, A. Schwarz¹, S. Jarius¹, T. Tenenbaum², C. Schwerk², C. Stump-Guthier², H. Schroten², B.-T. Wildemann¹, M. Korporal-Kuhnke¹ | ¹HEIDELBERG, ²MANNHEIM, GERMANY

P 32137 Efficacy, tolerability, quality of life and spasticity in outpatients with relapsing remitting multiple sclerosis (RRMS) treated with glatiramer acetate - results of an observational study

U. Faude¹, D. Fendji¹, M.R. Haupts² | ¹BERLIN, ²ISSELBURG, GERMANY

P 32138 Progressive MS: significant benefit of combined corticoid pulse and complex therapy

M. Haupts¹, S. Wichert¹, D. Seidel¹, H.-P. Hartung² | ¹ISSELBURG, ²DÜSSELDORF, GERMANY

P 32139 A cohort of CARE-MS I patients had no evidence of disease activity over 4 years following 2 courses of alemtuzumab and no further treatment

E. Havrdova¹, K. Baum², H.-P. Hartung³, G. Giovannoni⁵, D.H. Margolin⁶, K. Thangavelu⁶, H. Wiendl⁴ | ¹PRAGUE, CZECH REPUBLIC, ²HENNIGSDORF, ³DÜSSELDORF, ⁴MÜNSTER, GERMANY, ⁵LONDON, UK, ⁶CAMBRIDGE, USA

P 32140 Efficacy and safety outcomes in Vitamin D supplement users in Fingolimod FREEDOMS trials
 K. Hongell¹, D. Silva², S. Ritter³, D. Piani-Meier², M. Soilu-Hänninen¹ | ¹TURKU, FINLAND, ²BASEL, SWITZERLAND, ³EAST HANOVER, USA

P 32141 Abstract cancelled

P 32142 The healthcare utilisation and cost of prolonged-release fampridine without disease-modifying therapies in patients with multiple sclerosis throughout Germany during 2011–2013
 M.-Y. Huang¹, C. Prosser³, P. Landsman-Blumberg², J. Haas³, S. Braun³, E. Gleissner⁴, T. Ziemssen⁵ | ¹CAMBRIDGE, ²PALM HARBOR, USA, ³HANOVER, ⁴ISMANING, ⁵DRESDEN, GERMANY

P 32143 Optical coherence tomography reflectance as a novel biomarker of retinal axonal damage in a preclinical model of multiple sclerosis
 S.-C. Huang, V. Castoldi, R. Santangelo, S. Marenga, S. Maestroni, L. Chaabane, G. Zerbini, P. Rama, G. Comi, L. Leocani | MILAN, ITALY

P 32144 Treatment-naïve patients with active relapsing-remitting multiple sclerosis demonstrate improved quality of life over 5 years with alemtuzumab related to disability improvement: CARE-MS I extension study
 R.M. Hupperts¹, P. Vermersch², D.H. Margolin³, K. Thangavelu³, R. Arroyo Gonzalez⁴ | ¹SITTARD, NETHERLANDS, ²LILLE, FRANCE, ³CAMBRIDGE, USA, ⁴MADRID, SPAIN

POSTER SESSION MS AND RELATED DISORDERS 15 13:30-14:15 | SCREEN F2

CHAIRPERSON:

Oscar Fernandez, MALAGA, SPAIN

P 32145 Can the motor disability level related to multiple sclerosis be measured from the French health insurance database?
 J. Roux, O. Grimaud, E. Leray | RENNES, FRANCE

P 32146 Rebound of multiple sclerosis activity during pregnancy after fingolimod withdrawal
 A. Rua, N. Solà Valls, M. Sepulveda, Y. Blanco, S. Llufrui, A. Saiz | BARCELONA, SPAIN

P 32147 Tracing premotor-motor connectivity during the phase of motor preparation in MS patients
 E. Ruiu¹, R. Dubbioso², F. Sjelleberg³, M. Blinkenberg³, K. Madsen³, O. Svolgaard³, E. Raffin⁴, A.N. Karabanov³, H.R. Siebner³ | ¹CAGLIARI, ²NAPLES, ITALY, ³COPENHAGEN, DENMARK, ⁴GRENOBLE, FRANCE

P 32148 Relation between gender and depression in multiple sclerosis patients
 S. Sabanagic-Hajric, E. Suljic, N. Subasic | SARAJEVO, BOSNIA AND HERZEGOVINA

P 32149 Reasons for subcutaneous interferon beta-1a three times a week discontinuation among patients with multiple sclerosis: a real-world retrospective cohort study
 M. Sabido-Espin¹, R. Munschauer² | ¹DARMSTADT, GERMANY, ²ROCKLAND, USA

P 32150 The brief international cognitive assessment for multiple sclerosis (BICAMS) for the evaluation of the EDSS cerebral functional score
 F. Sacca¹, T. Costabile, A.M. Barbarulo, A. Carotenuto, S. Casertano, R. Lanzillo, M. Moccia, C. Pane, F. Rossi, C.V. Russo, E. Signoriello, G. Lus, V. Brescia Morra | NAPLES, ITALY

P 32151 Balo's concentric sclerosis with a benign course
 I. Sanchez Ortuño, A. Sanz Monllor, N. García Lax, J.Á. Motos García, M. Palao Rico, M.L. Martínez Navarro | MURCIA, SPAIN

P 32152 The long-term impact of natalizumab on multiple sclerosis: to continue or to stop?
 F. Sangalli, L. Moiola, M. Radaelli, L. Ferre, F. Esposito, B. Colombo, V. Martinelli, G. Comi | MILAN, ITALY

P 32153 Acute disseminated encephalomyelitis: a 14 years review
 A. Sanz Monllor, M. Alcaraz Saura, C. Martínez Fernández, R. Domingo Jimenez, H. Alarcón Martínez, E. Martínez Salcedo, A. Cárceles Álvarez, A. Puche Mira | MURCIA, SPAIN

P 32154 Uncommon side effects of glatiramer acetate
 A. Sanz Monllor, I.M. Sanchez Ortuño, N. García Lax, J.A. García Motos, M. Palao Rico, J. Marín Marín, M.L. Martínez Navarro, A.M. García Medina, J.M. Rodríguez García, J.A. Iniesta Valera, M.P. Salmerón Ato, A. Díaz Ortuño | MURCIA, SPAIN

P 32155 Treatment-naïve patients with active relapsing-remitting multiple sclerosis at baseline demonstrate slowing of brain volume loss with alemtuzumab: 5-year outcomes from the CARE-MS I extension study
 S. Schippling¹, A. Rovira², G. Giovannoni³, D.L. Arnold⁴, A. Traboulee⁵, D.H. Margolin⁶, K. Thangavelu⁶, M. Filippi⁷ | ¹ZURICH, SWITZERLAND, ²BARCELONA, SPAIN, ³LONDON, UK, ⁴MONTREAL, ⁵VANCOUVER, CANADA, ⁶CAMBRIDGE, USA, ⁷MILAN, ITALY

P 32156 Effect of lipoic acid on oxidative stress in multiple sclerosis patients: a double blind randomised clinical trial
 F. Seifar¹, M. Khalili¹, A. Azimi² | ¹TABRIZ, ²TEHRAN, IRAN, ISLAMIC REPUBLIC OF

MONDAY, 30 MAY

13:30 - 14:15

P 32157 Serum exosomal microRNA profiling reveals new biomarkers of MS

I. Selmaj, M. Namiecinska, M. Cichalewska, K. Selmaj, M. Mycko | LODZ, POLAND

P 32158 Cerebrospinal fluid neurofilament light chain protein correlates with magnetic resonance imaging markers of inflammation in patients with a first demyelinating episode

A. Ungureanu, J. Piepgras, S. Papazoglou, C. Pfuhl, J. Oechtering, J. Ruth Behrens, R. Gieß, L. Rasche, H. Prüb, J. Wuerfel, H.G. Zimmermann, A. Brandt, J. Bellmann-Strobl, F. Paul, K. Ruprecht | BERLIN, GERMANY

POSTER SESSION
MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 6

13:30-14:15 | SCREEN B4

CHAIRPERSON:

Klaus Toyka, WÜRZBURG, GERMANY

P 32159 Novel GYG1 mutation causing late-onset polyglucosan body myopathy with nemaline rods

G. Tasca¹, F. Fattori¹, M. Monforte¹, C. Hedberg-Oldfors², M. Sabatelli³, B. Udd³, E. Bertini¹, E. Ricci¹, A. Oldfors² | ¹ROME, ITALY, ²GOTHENBURG, SWEDEN, ³TAMPERE, FINLAND

P 32160 Myopathy following the treatment of mesalazine: a case report

A. Çetiz, H. Akgun, S. Tasdemir, O. Oz, Ü.H. Ulas, S. Demirkaya | ANKARA, TURKEY

P 32161 Abstract cancelled

P 32162 Rigid spine syndrome: a rare subtype of muscular dystrophy: a case reporty

A. Çetiz, Ü.H. Ulas, O. Oz, M. Yücel, S. Demirkaya | ANKARA, TURKEY

P 32163 Screening of Pompe disease in South Hungary

E.T. Varga, L. Vécsei | SZEGED, HUNGARY

P 32164 Stiff Person Syndrome: a female case report with focal onset and multiple limb involvement

S. Vaz, A. Barros, A. Calado, J. Sequeira, D. Melancia, A. Fernandes | LISBON, PORTUGAL

P 32165 Congenital myasthenic syndromes - our experience

L. Vieira, C. Duque, J. Ribeiro, A.P. Geraldo, A. Matos, L.J.M.P. Negrão | COIMBRA, PORTUGAL

P 32166 Motor weakness and functional disability in patients with myasthenia gravis: a population based study

L. Vinge, J. Jakobsen, H. Andersen | AARHUS, DENMARK

P 32167 Myotonic dystrophy type 2 significantly affects quality of life

M. Vujnic¹, S.Z. Peric², T. Paunic², J. Pesovic², M. Peric², D. Lavrnic², D. Savic-Pavicevic², V. Rakocevic Stojanovic² | ¹BANJA LUKA, ²BELGRADE, SERBIA

P 32168 Perifascicular distribution of glycogen in juvenile dermatomyositis

S. Xirou, G. Papadimas | ATHENS, GREECE

P 32169 Demographic, clinical, and electrophysiologic features in patients with myasthenia gravis: case series study

M. Yücel¹, O. Oz², S. Tasdemir², H. Akgun², Ü.H. Ulas², S. Demirkaya² | ¹ISTANBUL, ²ANKARA, TURKEY

P 32170 Hormonal response to bimagrumab: a randomised, placebo-controlled study in healthy older men and women

M. Zakaria¹, A. He¹, Y. Li¹, P. Pinot², O. Petricoul², D. Laurent², D. Rooks¹, R. Roubenoff² | ¹CAMBRIDGE, USA, ²BASEL, SWITZERLAND

P 32171 Immune-mediated necrotising myopathy - serious adverse effect of statin treatment

E. Zupanec, U. Rot, M. Meznaric, B. Koritnik | LJUBLJANA, SLOVENIA

POSTER SESSION
NEUROGENETICS 4

13:30-14:15 | SCREEN F4

CHAIRPERSON:

Jochen Schäfer, DRESDEN, GERMANY

P 32172 Abstract cancelled

P 32173 Hereditary coproporphria due to a new mutation in the CPOX gene

J.Á. Motos García, N. García Lax, M.L. Martínez Navarro, A. Sanz Monllor, M. Palao Rico, I.M. Sanchez Ortuño, A.M. García Medina, J.A. Iniesta Valera, J.M. Rodríguez García, M.P. Salmerón Ato, J. Marín Marín, A. Díaz Ortuño | MURCIA, SPAIN

P 32174 Progressive neuronal degeneration in a patient with photosensitivity: a case of Xeroderma Pigmentosum of group A

M.A. Obadia, P. Reach, B. Law, B. Rohaut, J. Lamoril, M. Catala | PARIS, FRANCE

P 32175 Are mutations in the GJB1 gene risk factor for multiple sclerosis?

B. Peterlin¹, T. Hojs Fabjan², M. Menih², G. Rudolf¹, A. Peterlin¹, A. Maver¹ | ¹LJUBLJANA, ²MARIBOR, SLOVENIA

P 32176 Six generations of Frontotemporal Dementia linked to chromosome 3 (FTD-3): demographics of the Danish CHMP2B family

P. Roos¹, P. Johannsen¹, J. Stokholm¹, G. Waldemar¹, A. Isaacs², J. Brown³, J. Nielsen¹ | ¹COPENHAGEN, DENMARK, ²LONDON, ³CAMBRIDGE, UK

P 32177 The role of ApoE gene polymorphism and vascular risk factors in the susceptibility to early and late Alzheimer's disease in an Iranian population

S. Samadzadeh¹, R. Abolfazli¹, A. Shakoori¹, T. Sabokbar² | ¹TEHRAN, ²QOM, IRAN, ISLAMIC REPUBLIC OF

P 32178 New mutation in hereditary spastic paraplegia in Murcia

I. Sanchez Ortuño, A. Sanz Monllor, N. García Lax, J.Á. Motos García, M. Palao Rico, J.A. Iniesta Valera | MURCIA, SPAIN

P 32179 Late-onset Alexander disease: a novel mutation

D. Sangalli¹, A. Ciammola¹, C. Morelli¹, A. Moroni¹, I. Ceccherini², F. Girotti¹, V. Silani¹ | ¹MILAN, ²GENOVA, ITALY

P 32180 Ataxia-neuropathy with cognitive decline due to a novel mutation in MTCOII, a subunit of mitochondrial complex IV

J. Schäfer, S. Jackson | DRESDEN, GERMANY

P 32181 Diagnostic accuracy of laboratory tests and muscle biopsy in patients with genetically confirmed mitochondrial disease

S. Schreglmann¹, J. Petersen², L. Hoffelner², V.M. Mihaylova², M. Auer², G. Kägi³, A. Schaller⁴, H. Jung² | ¹LONDON, UK, ²ZURICH, ³ST. GALLEN, ⁴BERNE, SWITZERLAND

P 32182 Phenotypic features of GDAP1 mutations in Tunisian Charcot-Marie-Tooth patients

I. Kacem¹, A. Gargouri Berrechid¹, Y. Sidhom¹, A. Nasri¹, M. Ben Djebara¹, E. Leguern², R. Gouider¹ | ¹TUNIS, TUNISIA, ²PARIS, FRANCE

P 32183 Expression changes of genes associated with apoptosis and survival processes in Parkinson's disease

E. Tüzün, N. Yalçinkaya, H. Haytural, R. Türkoglu, B. Bilgic, H.A. Hanağasi, H. Gürvit | ISTANBUL, TURKEY

P 32184 mtDNA alterations and autism associated nuclear gene variants in the background of autism spectrum disorder

N. A. Varga, K. Pentelényi, P. Balicza, V. Reményi, V. Hársfalvi, R. Bencsik, A. Illés, C. Prekop, M.J. Molnar | BUDAPEST, HUNGARY

POSTER SESSION
NEUROIMAGING 3

13:30-14:15 | SCREEN A3

CHAIRPERSON:

Tim von Oertzen, LINZ, AUSTRIA

P 32185 A comprehensive assessment of cervical cord lesions in patients with multiple sclerosis on T1-MPRAGE at 3T: relationship with cord atrophy and disability

M.A. Rocca¹, P. Valsasina¹, P. Preziosa¹, M. Aboulwafa¹, M. Horsfield², G. Comi¹, A. Falini¹, M. Filippi¹ | ¹MILAN, ITALY, ²LEICESTER, UK

P 32186 Superficial siderosis: a case report

F.D. Örken, E. Timer, S. Mumcu, M. Korkmaz, Z. Tanriverdi, B. Aydin Islamoglu | ISTANBUL, TURKEY

P 32187 A case of spontaneous bilateral dissecting aneurysms of the internal carotid arteries

T. Parvu, C.I. Coclitu, O. Rusu, A. Ciobotaru, A.C. Mergeani, O. Bajenaru, F. Antochi | BUCHAREST, ROMANIA

P 32188 Correlation between brain MRI and anosognosia

E. Pinzan¹, C. Angelini¹, F. Bevilacqua², E. Tasca¹, S. Baldanzi³, G. Siciliano³, V. Pegoraro¹ | ¹VENICE, ²LIDO VENICE, ³PISA, ITALY

P 32189 Patterns of regional gray matter and white matter atrophy progression contributing to clinical deterioration in MS: a 5-year tensor-based morphometry study

P. Preziosa¹, M.A. Rocca¹, E. Paganì¹, S. Mesaros², J. Drulovic², M. Filippi¹ | ¹MILAN, ITALY, ²BELGRADE, SERBIA

P 32190 Asymmetric reversible restricted diffusion in hyperammonemic encephalopathy: a case report

N. Randhawa, J. Chew, J. Shewchuk, H. Nygaard | VANCOUVER, CANADA

P 32191 Altered corticostriatal connectivity in Parkinson's disease is related to cognitive impairment

I. Rektorova, L. Anderkova, M. Barton | BRNO, CZECH REPUBLIC

P 32192 Cerebral aneurysm causing a rare condition: superficial siderosis of the central nervous system

I. Sanchez Ortuño, A. Sanz Monllor, N. García Lax, J.Á. Motos García, M. Palao Rico, M.L. Martínez Navarro | MURCIA, SPAIN

MONDAY, 30 MAY

13:30 - 14:15

P 32193 Imaging of nuclear Overhauser enhancement in human brain tumor at 3 Tesla

Y. Shen, G. Xiao, Z. Cao, Z. Shen, X. Zhang, X. Tang, W. Hu, Z. Zhang, R. Wu | SHANTOU, CHINA

P 32194 Transcranial sonography of the insula: digitised image analysis of fusion images with magnetic resonanceD. Skoloudik¹, P. Bartova¹, J. Maskova², P. Dusek², J. Blahuta³, K. Langova⁴, U. Walter⁶, R. Herzig⁵ | ¹OSTRAVA, ²PRAGUE, ³OPAVA, ⁴OLOMOUC, ⁵HRADEC KRÁLOVÉ, CZECH REPUBLIC, ⁶ROSTOCK, GERMANY**P 32195** A semi-automatic method for multiple sclerosis lesion segmentation on dual-echo magnetic resonance images: application in a multicenter contextL. Storelli¹, E. Pagani¹, M. A. Rocca¹, P. Preziosa¹, A. Gallo², G. Tedeschi², M. L. Stromillo³, N. de Stefano³, H. Vrenken⁴, D. Thomas⁵, L. Mancini⁵, C. Enzinger⁶, F. Fazekas⁶, M. Filippi¹ | ¹MILAN, ²NAPLES, ³SIENNA, ITALY, ⁴AMSTERDAM, NETHERLANDS, ⁵LONDON, UK, ⁶GRAZ, AUSTRIA**P 32196** Optic neuritis imaging: changes in size and signal of the optic nerve over time in multiple sclerosis patientsM. Trad¹, A. Abanou², L. Hughes³ | ¹LEVALLOIS-PERRET, ²PARIS, FRANCE, ³READING, UK**P 32197** Regional cerebral blood flow SPECT: comparison of 99Tc-ECD and 99Tc-HMPAO tracersT.J. von Oertzen¹, W. Schwinger¹, K. Böck¹, G. Puttinger¹, C.M. Quesada², F.C. Gaertner², G. Schwarz¹, A.M. Hengsberger¹, T. Grunwald³, C.E. Elger², M. Essler², R. Pichler¹ | ¹LINZ, AUSTRIA, ²BONN, GERMANY, ³ZURICH, SWITZERLAND**P 32198** Gray matter alterations related to nocturnal stridor in multiple system atrophy

S. Zanigni, C. Testa, G. Giannini, G. Calandra-Buonaura, D.N. Manners, R. Lodi, F. Provini, P. Cortelli, C. Tonon | BOLOGNA, ITALY

POSTER SESSION
NEUROIMMUNOLOGY 4

13:30-14:15 | SCREEN H2

CHAIRPERSON:

Heinz Wiendl, MÜNSTER, GERMANY

P 32199 Therapeutic target of memory b-cells depletion helps to tailor administration frequency of Rituximab in neuromyelitis optica spectrum disorders patients.G. Romero¹, J. Bas², M. Cohen¹, M. Ticchioni¹, J. Pelletier², B. Audoin², C. Lebrun-Frenay¹ | ¹NICE, ²MARSEILLES, FRANCE**P 32200** In-vitro catecholamines mimic stroke induced inhibition of neutrophil extracellular traps formation

J. Ruhнау, L. Blümke, C. Lange, A. Dressel, A. Vogelgesang | GREIFSWALD, GERMANY

P 32201 Are CSF protein levels and plasma neutrophil/lymphocyte ratio associated with prognosis of Guillain-Barré syndrome?

S. Sahin, N. Çınar, S. Karsidag | ISTANBUL, TURKEY

P 32202 New biomarkers in the diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

M. Sialitski, V. Ponomarev, H. Ivanchyk | MINSK, BELARUS

P 32203 European AIDS clinical society screening questions don't predict nor exclude HIV-associated neurocognitive disorders: a NAMACO study (Neurocognitive Assessment of the Metabolic and Aging COhort)M. Métral¹, S. Simioni¹, I. Locatelli¹, Y. Vallet¹, A. Cusin², K. Gutbrod², H. Kovari³, P. Brugger³, A. Calmy⁴, F. Assal⁴, P. Tarr⁵, A.U. Monsch⁵, E. Bernasconi⁶, R. Pignatti⁷, R. Du Pasquier¹, M. Cavassini¹ | ¹LAUSANNE, ²BERNE, ³ZURICH, ⁴GENEVA, ⁵BASEL, ⁶LUGANO, ⁷BELLINZONA, SWITZERLAND**P 32204** Paraneoplastic ataxia associated to anti CV2 antibodies in an alcoholic patient: a diagnostic challenge

T. Kalantzakou, O. Sinani, G. Xiromerisiou, V. Paraskevopoulou, K. Katsiardanis, T. Bourinaris, A. Tychalas, E. Koutlas, G. Deretzi | THESSALONIKI, GREECE

P 32205 Anti-LGI1 encephalitis: clinical syndrome and long-term follow-upA. Sonderen van¹, R. Thijs², E. Coenders¹, L. Jiskoot³, E. Sanchez⁴, M. Bruijn de³, M. Coevorden van-Hameete⁵, P. Wirtz¹, M. Schreurs³, P.A. Sillevius Smitt³, M. Titulaer³ | ¹THE HAGUE, ²LEIDEN, ³ROTTERDAM, ⁴AMSTERDAM, ⁵UTRECHT, NETHERLANDS**P 32206** Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and neuropsychiatric autoimmune encephalopathy

M. Suzuki, H. Kato, T. Ohashi | CHIBA, JAPAN

P 32207 Limbic Encephalitis Associated with Sjögrens Syndrome: report of three cases

R. Türkoglu, S. Ozyurt, E. Tüzün | ISTANBUL, TURKEY

P 32208 Presumed tuberculous meningitis relapsing after steroid reduction: a case of AMPA receptor antibody-associated encephalitis

H. van Den Tooren, M. Maskery, C. Kobylecki, N. Rathod, R. Siripurapu, D. McKee | MANCHESTER, UK

P 32209 Therapeutic challenges of stiff person syndrome: a case report

E.T. Varga¹, T. Györgyi Md², L. Vécsei¹ | ¹SZEGED, ²BUDAPEST, HUNGARY

P 32210 Abstract cancelled

P 32211 Characterising the impact of teriflunomide on the CD4+ T-Cell repertoire of patients with relapsing-remitting MS in the Teri-DYNAMIC study

H. Wiendl¹, C.C. Gross¹, M. Lindner¹, M. Eschborn¹, L. Weisser¹, A. Posevitz-Fejfar¹, A. Schulte-Mecklenbeck¹, B. van Wijmeersch², S. Brette³, T.J. Turner⁵, A. Jagerschmidt⁴, A. Bar-or⁶, R. Hupperts⁷, L. Klotz¹ | ¹MÜNSTER, GERMANY, ²HASSELT, BELGIUM, ³BOULOGNE-BILLANCOURT, ⁴CHILLY-MAZARIN, FRANCE, ⁵CAMBRIDGE, USA, ⁶MONTREAL, CANADA, ⁷MAASTRICHT, NETHERLANDS

POSTER SESSION NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC DISEASES 3

13:30-14:15 | SCREEN B3

CHAIRPERSON:

Eduardo Nobile-Orazio, MILAN, ITALY

P 32212 Rapidly progressive dementia and orofacial dyskinesia: neurosyphilis and "Candy Sign"?

J.P. Marto, C. Borbinha, T. Lampreia, L. Alves, M. Viana-Baptista | LISBON, PORTUGAL

P 32213 Health-related quality of life of nursing student's with or without premenstrual syndrome

A. Ozkan¹, G. Tanriverdi¹, Y. Ozenli², C. Bakar¹, H.I. Özisik Karaman¹ | ¹CANAKKALE, ²ADANA, TURKEY

P 32214 The importance of thermal threshold testing in detecting of small fiber neuropathy in Type 1 diabetes mellitus

V. Potockova, R. Mazanec, A. Tomek | PRAGUE, CZECH REPUBLIC

P 32215 Ophthalmoparesis and temporal arteritis: double trouble

I. Rosário Marques, F. Antunes, M.D. Grunho, A. Ribeiro | ALMADA, PORTUGAL

P 32216 Eosinophilic granulomatosis with polyangitis (Churg-Strauss syndrome) with extensive neurologic involvement and neutrophilia

E. Sechi, A. Addis, R. Piredda, A. L. Rassu, C. Fois, L. Batzu, G. Sechi | SASSARI, ITALY

P 32217 Isolated central nervous system vasculitis caused by Whipple's disease

D. Sisak¹, C. Hornyák¹, I. Balogh², A. Moter³, A.K. Iljicsov¹, G. Várallyay¹, I. Zsigmond¹, P. Lakatos¹, L. Sipos¹, E. Turányi¹, D. Bereczki¹, T. Kovács¹ | ¹BUDAPEST, ²DEBRECEN, HUNGARY, ³BERLIN, GERMANY

P 32218 Rare case of deep cerebral hemorrhage and atrial fibrillation in a patient with Fabry's disease

E.A. Solomon, D. Anghel, A. Gitman, M. Marian | BUCHAREST, ROMANIA

P 32219 ANCA positive vasculitis disguised as a recurrent stroke due to vertebral artery dissection

A. Toth, G. Rudas, E. Kiss, D. Bereczki, I. Sipos | BUDAPEST, HUNGARY

P 32220 The neurologist and the gastroenterologist – inpatient neurological consultation in the gastroenterology and hepatology department

P. Viana, P. Santos, L. Guedes, A.I. Verdelho, J.G.D.B.C. Pimentel, J.M.M.C. Ferro | LISBON, PORTUGAL

P 32221 Ataxia as a presentation feature of Neurosarcoïd

S. Vijayarangam Shanmugam, A. Al-Memar | LONDON, UK

POSTER SESSION NEUROLOGY AND ARTS; HISTORY OF NEUROLOGY; ETHICS IN NEUROLOGY; EDUCATION IN NEUROLOGY;

13:30-14:15 | ROOM: E2

CHAIRPERSON:

Jan Kuks, GRONINGEN, THE NETHERLANDS

P 32222 Hazardous effects of nonnatural life on visual pathways: a biophysical experimental study

A. Aydin¹, A. Aydin¹, N. Aydin¹, M.D. Aydin², D. Kotan³, N. Gursan² | ¹ISTANBUL, ²ERZURUM, ³SAKARYA, TURKEY

P 32223 Abstract cancelled

P 32224 Neurology: an introductory course for neurology residents

M.A.S.F. Gago¹, P. Barros², P. Abreu³, J.M.G. Lemos⁴, H.A.G. Morais⁵, F.M.F. Palavra⁴, J. Pinho⁶, J. Pinheiro⁷, R. Taipa⁸, P. Morgado⁶, J.J.F.C.A. Cerqueira⁶ | ¹GUIMARÃES, ²VILA NOVA DE GAIA, ³PORTO, ⁴COIMBRA, ⁵MADALENA GAIA, ⁶BRAGA, ⁷GAIA, ⁸FREAMUNDE, PORTUGAL

P 32225 The neuro-ethics of the logical speech and the ethics of reality in the psychoneuroanalytical model

G. Dore¹, M. D'onofrio² | ¹ITTIRI, ²SASSARI, ITALY

MONDAY, 30 MAY

13:30 - 14:15

P 32226 Neurological training for fellows in Germany – from a chief physician's point of viewC. Franke¹, H. Hellriegel², A.-S. Biesalski³, R. Kiefer⁴ | ¹BERLIN, ²KIEL, ³WUPPERTAL, ⁴ROTENBURG, GERMANY**P 32227** Mozart's plausible neurological disorders

C. Gardner-Thorpe | EXETER, UK

P 32228 Mapping the clinical translation of successful and unsuccessful neurological drugs

A. Hakala, J. Kimmelman | MONTREAL, CANADA

P 32229 Quality of stroke patient information – a systematic reviewA.C. Kruetzelmann¹, S. Koepke², A.C. Rahn¹, G. Thomalla¹, C. Heesen¹ | ¹HAMBURG, ²LÜBECK, GERMANY**P 32230** Possible descriptions of stroke and some other neurological disorders with sudden onset in Greek mythology and in the Bible and their presentation in art

M. Klarendic, B. Podlipnik | LJUBLJANA, SLOVENIA

P 32231 Neural trophic and Determinant Structures in CNS pathology. Alexey Speransky and Georgy Kryzhanovsky – Contribution to theoretical basis of modern neurology

D. Labunskiy | SANTA ROSA CA, USA

P 32232 Patient and student attitudes to clinical demonstrations – is it time we stopped 'protecting' our patients?

J. Mistry, F. Schon, H. Cock | LONDON, UK

P 32233 Knowledge gap about neurology in Uganda lags behind children with learning disabilities in education

J. Nakibirango | KAMPALA, UGANDA

P 32234 Do we agree on the content of the screening neurological exam?

E. Ruzicka, P. Marusic | PRAGUE, CZECH REPUBLIC

P 32235 Oliver Sacks, „Awakenings“ to neurology? A 2015 survey among french neurologists

H. Doudoux, L. Vercueil | GRENOBLE, FRANCE

P 32236 William Warrington (1869-1919): GBS before G, B, and S?

B. Ziso, A. Larner | LIVERPOOL, UK

POSTER SESSION
NEURO-OPHTHALMOLOGY/ NEURO-OTOLOGY 4

13:30-14:15 | SCREEN H1

CHAIRPERSON:

Christopher Kennard, OXFORD, UK

P 32237 Bilateral optic disc swelling: not always papilledema: a case report

J. Perez Lucas, M. Baez, M. Fernandez-Fournier Ferna | MADRID, SPAIN

P 32238 Anterior ischemic optic neuropathy and hematological malignancy: a systematic review of case-reports and case-series

F. Rodrigues, D. Sousa, G. Duarte, F. Campos, F. Pinto | LISBON, PORTUGAL

P 32239 Visual system involvement in cerebrotendinous xanthomatosis: the role of dentate nucleus on eye movement controlF. Rosini¹, E. Pretegianni², A. Mignarri¹, G. Tumminelli¹, A. Federico¹, L. Optican², M.T. Dotti¹, A. Rufa¹ | ¹SIENNA, ITALY, ²BETHESDA, USA**P 32240** Situational factors of fear of falling in vertigo and balance disorders

C. Schlick, R. Schniepp, K. Jahn | MUNICH, GERMANY

P 32241 Abstract cancelled**P 32242** Development of an algorithm for the differential diagnosis of oculomotor abnormalitiesM. Strupp¹, S.A. Kolb² | ¹MUNICH, GERMANY, ²ALLSCHWIL, SWITZERLAND**P 32243** The benefit of optical coherence tomography and visual evoked potentials in optic neuritis: a pilot study

T. Svrčinová, J. Mares, V. Sladkova, M. Šin, P. Kanovsky | OLOMOUC, CZECH REPUBLIC

P 32244 Tolosa-Hunt syndrome: the recurrence is not always on the same side

H. Tibar, W. Regragui, E. Ait Ben Haddou, A. Benomar, M. Yahyaoui | RABAT, MOROCCO

P 32245 The role of the cerebellum in the antisaccade performance: insights from Spinocerebellar Ataxia Type 2 (SCA2) and Late Onset Cerebellar Ataxia (LOCA)G. Tumminelli¹, F. Rosini¹, P. Piu¹, E. Pretegianni², A. Federico¹, A. Rufa¹ | ¹SIENNA, ITALY, ²BETHESDA, USA

P 32246 Stochastic resonance in the vestibular system
 M. Wuehr, J. Boerner, J. Decker, C. Pradhan, R. Schniepp |
 MUNICH, GERMANY

P 32247 Dopamine preserves visual motion perception despite noise interference of human V5/MT
 N. Yousif, R. Fu, B. Abou-El-Ela-Bourquin, V. Bhrugubanda, S. Schultz, B.M. Seemungal | LONDON, UK

POSTER SESSION PERIPHERAL NERVE DISORDERS 6 13:30-14:15 | SCREEN D2

CHAIRPERSON:

Nazha Birouk, RABAT, MOROCCO

P 32248 Chronic inflammatory demyelinating polyneuropathy - still a challenging diagnosis
 D. Leupold, L. Schilg, A. Felbecker, D. Zieglgänsberger, B. Tettenborn, T. Hundsberger | ST. GALLEN, SWITZERLAND

P 32249 Abstract cancelled

P 32250 Abstract cancelled

P 32251 Trauma and Guillain-Barré syndrome
 C. Machado, J.N. Alves, A.F. Santos, J. Pinho, R.J.P. Maré, C. Ferreira | BRAGA, PORTUGAL

P 32252 Subcutaneous versus intravenous immunoglobulin in drug-naïve patients with chronic inflammatory demyelinating polyneuropathy (CIDP) - a randomised, single-blind, cross-over trial
 L.H. Markvardsen¹, S.H. Sindrup², I. Christiansen³, J. Jakobsen³, H. Andersen¹ | ¹AARHUS, ²ODENSE, ³COPENHAGEN, DENMARK

P 32253 Aerobic capacity and muscle strength are improved following aerobic and resistance exercise in patients treated with subcutaneous immunoglobulin for CIDP
 L.H. Markvardsen¹, K. Overgaard¹, K. Heje², S.H. Sindrup³, I. Christiansen², J. Vissing², H. Andersen¹ | ¹AARHUS, ²COPENHAGEN, ³ODENSE, DENMARK

P 32254 Nerve lesions can be detected by diffusion tensor imaging in patients with CIDP treated with subcutaneous immunoglobulin
 L.H. Markvardsen, M. Vaeggemose, H. Andersen | AARHUS, DENMARK

P 32255 The de-novo mutation p.R190W in the MORC2 gene cause severe axonal Charcot-Marie-Tooth disease in Czech a patient
 R. Mazanec¹, P. Lassuthová¹, M. Šafka-Brožková¹, M. Krůtová¹, S. Züchner², M. Gonzales², V. Potocková¹, P. Seeman¹ | ¹PRAGUE, CZECH REPUBLIC, ²MIAMI, USA

P 32256 Genetic epidemiology analysis of Cx32 gene mutations in Hungary
 G.M. Milley¹, A. Gal¹, E. Varga², Z. Grosz¹, Z. Aranyi¹, J. Boczan³, B. Kalman⁴, M.J. Molnar¹ | ¹BUDAPEST, ²SEGED, ³DEBRECEN, ⁴PÉCS, HUNGARY

P 32257 An axonal membrane excitability gradient could contribute to the length-dependent susceptibility to neuropathy
 M. Moldovan¹, R. Arnold², M. Rosberg¹, S. Alvarez¹, R. Morris², C. Krarup¹ | ¹COPENHAGEN, DENMARK, ²SYDNEY, AUSTRALIA

P 32258 Uncommon cluster of Guillain-Barré cases in northern Portugal - an outbreak?
 S. Moreira, C. Santos, P. Grebe, J. Roriz | SANTA MARIA DA FEIRA, PORTUGAL



P 32259 Late onset transthyretin familial amyloid polyneuropathy in Valencia, a non-endemic area
 N. Muelas Gomez¹, T. Sevilla¹, M. Frasset Carrera¹, R. Sivera², F. Mayordomo¹, M.M. Cano Teuler¹, R. Sánchez-Roy¹, M.Á. Garcia-Quesada³, M. Garcés-Sánchez¹, P. Martí Martínez¹, I. Azorin¹, C. Gomis¹, L. Bataller¹, J.F. Vázquez Costa¹, M.R. Vilchez¹, J.J. Vilchez¹ | ¹VALENCIA, ²GANDIA, ³ELCHE, SPAIN

TUESDAY, 31 MAY 2016

SESSIONS

Nervenheilkunde

ZEITSCHRIFT FÜR INTERDISZIPLINÄRE FORTBILDUNG



Interdisziplinäre Fortbildung
seit über 30 Jahren

Die **Nervenheilkunde** ist eine der bekanntesten Fort- und Weiterbildungszeitschriften für Neurologen, Psychiater und Nervenärzte. Da bei psychischen Störungen Hausärzte fast immer die ersten Ansprechpartner sind und die Weichenstellung für eine kompetente fachärztliche Behandlung in ihren Händen liegt, wendet sich die **Nervenheilkunde** zugleich an Primärärzte.

Ziel ist neben der Weitergabe aktueller wissenschaftlicher Erkenntnisse, praxistaugliche Informationen zu vermitteln, die zur besseren Versorgung von Patienten mit neurologischen und psychiatrischen Störungen beitragen. Folgerichtig können Leser der **Nervenheilkunde** CME-Punkte sammeln. Regelmäßig werden Empfehlungen oder Leitlinien der Deutschen Migräne- und Kopfschmerzgesellschaft sowie der Deutschen Gesellschaft für Muskelkranke veröffentlicht.

* Unsere Abonnements sind Medien-Abonnements (Print + Digital), die Preise sind unverbindlich empfohlene Preise. Innerhalb Deutschlands inkl. der gesetzlich gültigen MwSt., im Ausland zzgl. der gesetzlich gültigen MwSt. | Deutschland und Europa inkl. Versandkosten | Versandkosten „Übersee“ auf Anfrage

Nervenheilkunde

Zeitschrift für
interdisziplinäre Fortbildung

2016. 35. Jahrgang. 12 Ausgaben.
ISSN 0722-1541

Verfügbar: Abstracts/Volltext

Jährliche Bezugspreise*

Institute: € 340,-
Privatpersonen: € 192,-
Studierende: € 96,-
Einzelheft: € 32,-

Bestellen Sie jetzt!

Schattauer GmbH | Aboservice
Heuriedweg 19a | 88131 Lindau
Tel.: 01805 012562
E-Mail: aboservice@schattauer.de

SYMPOSIUM 7: UNDERSTANDING FUNCTIONAL CONNECTIVITY USING MRI

08:00 - 10:00 | HALL M1

CHAIRPERSONS:

Massimo Filippi, MILAN, ITALY

Ludwig Kappos, BASEL, SWITZERLAND

Brain functional connectivity assessed using MRI: the basis

Bharat B. Biswal, NEWARK, USA

Clinical applications in MS

Maria A. Rocca, MILAN, ITALY

Implications for clinical trial design and monitoring of drug efficacy

Till Sprenger, WIESBADEN, GERMANY

Scientific content: Functional connectivity is a useful research tool, and reliable analysis and methods have been developed. New disease insights are emerging in a variety of neurologic and psychiatric disorders, including multiple sclerosis. Though the acquisition and analysis methods are still evolving, meaningful data are emerging on the potential application of fMRI in trial design and monitoring treatment efficacy.

SYMPOSIUM 8: NEW DIAGNOSTIC DEVELOPMENTS IN EPILEPSY

08:00 - 10:00 | HALL M2

CHAIRPERSONS:

Paul Boon, GHENT, BELGIUM

Eric Taubøll, OSLO, NORWAY

Definitions and classification of seizures

Jukka Peltola, TAMPERE, FINLAND

Neurophysiological assessment of epilepsies

Paul Boon, GHENT, BELGIUM

3D multimodal imaging for epilepsy surgery

John Duncan, LONDON, UK

Genetic screening

Jose Serratosa, MADRID, SPAIN

Scientific content: This symposium will provide recent information on diagnostic definitions and techniques in epilepsy patients. The recently changed definition of epilepsy will be extensively explained, followed by state-of-the-art lectures on EEG, structural and functional imaging and genetic diagnostic procedures. The target

audience is general neurologist who seek to expand their knowledge on up-to-date diagnostic procedures for epilepsy in daily practice.

SYMPOSIUM 9: UNTANGLING INFLAMMATORY AND DEGENERATIVE ASPECTS OF MULTIPLE SCLEROSIS

08:00 - 10:00 | HALL M3

CHAIRPERSONS:

Martin Kerschensteiner, MUNICH, GERMANY

Xavier Montalban, VALL D'HEBRON, SPAIN

Insights from MS pathology

Wolfgang Brück, GÖTTINGEN, GERMANY

Insights from experimental models

Martin Kerschensteiner, MUNICH, GERMANY

Insights from clinical imaging

Paul Matthews, LONDON, UK

Insights from therapeutic trials

Xavier Montalban, VALL D'HEBRON, SPAIN

Scientific content: In this symposium we want to highlight how inflammation and neurodegeneration contribute to the common neuroinflammatory disease multiple sclerosis (MS). In particular, we want to explore how inflammatory and degenerative disease mechanisms drive disease progression, how their inter-relation changes as the disease advances and how they can be best targeted therapeutically. For this purpose, we will summarize recent insights from the histopathological analysis of MS tissue, the in vivo analysis of experimental disease models, the advanced multi-modal imaging of MS patients and therapeutic trials in relapsing-remitting and progressive MS.

HANDS-ON COURSE 5: NERVE AND MUSCLE IMAGING FOR CLINICIANS

08:00 - 10:00 | HALL B5.M1

CHAIRPERSON:

Einar Wilder-Smith, SINGAPORE, SINGAPORE

Ultrasound in nerve entrapments

Einar Wilder-Smith, SINGAPORE, SINGAPORE

Ultrasound as a diagnostic tool to classify polyneuropathies

Leo Visser, TILBURG, THE NETHERLANDS

MRI imaging in myopathies

Bjarne Udd, TAMPERE, FINLAND

TUESDAY, 31 MAY

8:30 - 10:00

This course aims to introduce clinicians to understanding the role Nerve Ultrasound imaging plays in the diagnosis of entrapment neuropathies and polyneuropathies. Focus will be on the sonographic patterns (specific distribution of nerve enlargement) in different entrapments and polyneuropathies. A special focus will be how ultrasound can help to determine whether a polyneuropathy is demyelinating or axonal.

MRI imaging in myopathies will provide basic insight into typical patterns of muscle involvement in the different muscle diseases and address when to request muscle MRI to accelerate the diagnostic process, and optimize site for muscle biopsy.

This course is supported by Cadwell Industries, Inc.

CASE-BASED FACILITATED WORKSHOP 6: NEUROPSYCHOLOGICAL TESTING IN DEMENTIA FOR NON-NEUROPSYCHOLOGISTS

08:30 - 10:00 | HALL B4.M2

CHAIRPERSON:

Ana Verdelho, LISBON, PORTUGAL

Global measures of cognition

Ana Verdelho, LISBON, PORTUGAL

Neuropsychological evaluation in demented patients

Florence Pasquier, LILLE, FRANCE

How non-psychiatrists can do a "psychiatric" bed-side evaluation

Elizabeta Mukaetova-Ladinska, NEWCASTLE UPON TYNE, UK

With the progressive ageing of population cognitive decline and dementia is becoming one of the most frequent challenges of health and neurological care. Recent advances lead to several ancillary investigations available to clarify the etiology of cognitive decline. Correct diagnosis and correct use of those investigations depends on the initial clinical diagnosis.

This case-based facilitated workshop is designed to improve the skills to make a cognitive evaluation more precise in the first approach to the patient. Three experts of the field will approach, in a very practical way, not only the neuropsychological procedures but also how to deal with the interview of a patient with cognitive decline.

SPECIAL SESSION 8: EUROPEAN REFERENCE NETWORK

08:30 - 10:00 | HALL M4

CHAIRPERSON:

Philippe Ryvlin, LAUSANNE, SWITZERLAND

European Reference Network: an EU law

Enrique Terol, BRUSSELS, BELGIUM

E-PILEPSY, a pre-ERN pilot network of cooperation in epilepsy surgery

Philippe Ryvlin, LAUSANNE, SWITZERLAND

Merging rare and complex diseases in a neurologically driven ERN

Helen Cross, LONDON, UK

ERN and cross-border healthcare in Neurology:

The patient's point of view

Ann Little, DUBLIN, IRELAND

Scientific content: European Reference Networks (ERN) are defined by a European law and directive which went into force in 2014. ERN are meant to promote harmonisation and optimisation of healthcare for rare and complex diseases across Europe, including through cross-border care whenever appropriate. ERNs also offer opportunities to establish strong hospital-based clinical research consortia that will gain in competitiveness towards H2020 research calls. The first ERN will be labelled by the EU in 2016, through a complex process that is expected to lead to 20 to 30 ERNs, including two to five that might primarily tackle neurological disorders. Two pre-ERN pilot networks of cooperation have been funded by DG-SANCO in 2013 to provide bottom-up experience on the building of such network, including one in the field of clinical neuroscience (E-PILEPSY). The latter focuses on epilepsy surgery, and shall involve into a full ERN while incorporating rare epilepsies and possibly other disorders.

This session aims at providing comprehensive information on this important topic to Neurologists. Enrique Terol, who works at DG SANCO, is the person in charge of developing and implementing ERNs for the European Commission, and thus the most expert person to introduce this topic. Philippe Ryvlin coordinates the E-PILEPSY pre-ERN pilot network of cooperation, and will report on his experience in setting up this network. Helen Cross is currently setting up a full ERN application that will merge the E-PILEPSY networks with other neurological disorders relevant to ERN, including rare epilepsies. She will explain how an ERN application needs to be settled and stress the challenges and opportunities of developing such project. Ann Little is the current President of the European Federation of Neurological Associations, i.e. associations of neurological diseases patient's group. She will provide what we consider an essential voice when it comes to reformatting organization of neurological healthcare in Europe, especially for complex or rare diseases where patients and their family remain too often at lost.

SPECIAL SESSION 9: SHARED DECISION MAKING IN NEUROLOGY

08:30 - 10:00 | HALL M5

CHAIRPERSON:

Christoph Heesen, HAMBURG, GERMANY

SDM as the concept for medicine of the 21st century – chances and challenges

Norbert Donner-Banzhoff, MARBURG, GERMANY

SDM in multiple sclerosis treatment decision making

Christoph Heesen, HAMBURG, GERMANY

SDM in Parkinson treatment choices

Frouke Nijhuis, NIJMEGEN, THE NETHERLANDS

SDM in stroke acute care and secondary prevention

Christopher McKeivitt, LONDON, UK

Scientific content: Patient involvement in medical decision making is increasingly recognized especially in ageing societies with more chronic diseases with partially effective treatments. SDM is a concept based on exchange of information on different levels between a patient and a healthcare provider based on different competencies of both. As a prerequisite SDM needs evidence-based patient information for which defining a decision to be made and listing all options with their possible benefits and risks is necessary. Based on a SDM approach even a scientifically clear superior option might not be the right one for a given patient. Therefore, SDM realizes individualized, preference sensitive medicine. While many medical decisions lack substantial controlled study evidence on one hand and a relevant number of patients might explicitly refrain from getting involved in medical decisions on the other there are a number of paradigmatic decisional issues in clinical neurology which could possibly be improved by structured SDM approaches. Examples are: early treatment of multiple sclerosis, anticoagulation in stroke, escalation and deescalation of antiepileptic drugs, deep brain stimulation for Parkinson's disease but also everyday issues as PRT for radicular syndromes or medical treatment for tension type headache. While SDM study data show increased knowledge and enhanced self-efficacy, some data indicate also increased effectivity of health-care resources use. However, improved health outcomes have seldom been shown up to now.

Three aims will be pursued:

1. to give an overview of the current theoretical and methodological concepts in SDM such as the concept of complex interventions and evidence-based patient information, different study designs, interventions and outcomes.

2. to summarise the development stage in neurology focusing multiple sclerosis, Parkinson's disease and stroke.

3. to develop a working group SDM in neurology with an educational but also research need and exchange agenda.

SPECIAL SESSION 10: EAN RESIDENT AND RESEARCH FELLOW SECTION (RRFS): PROSPECTS FOR NEUROLOGISTS IN TRAINING IN THREE CORNERS OF EUROPE

08:30 - 10:00 | HALL B5.M2

CHAIRPERSON:

Peter Balicza, BUDAPEST, HUNGARY

Prospects for young neurologists in the Nordic countries

Daniel Kondziella, COPENHAGEN, DENMARK

Neurology education in Western Europe

Elena Moro, GRENOBLE, FRANCE

Neurology education in Central and Eastern Europe

Ildiko Szöcs, BUDAPEST, HUNGARY

Scientific content:

The special session intends to shed light on strengths and weaknesses of neurology education in different parts of Europe, and identify common strategies to improve. Speakers will focus on neurology education from medical school through residency to consultant neurologist, and highlight the positions, opportunities, career prospects for neurologist in training, as well as drivers for mobility in their area.

TUESDAY, 31 MAY

10:30 - 16:30

PLENARY SYMPOSIUM 3: HIGHLIGHTS AND LATE BREAKING NEWS

10:30 - 12:30 | HALL M1



CHAIRPERSON:

Mads Ravnborg, COPENHAGEN, DENMARK

Faculty:

Steen Hasselbalch, COPENHAGEN, DENMARK

Finn Sellebjerg, COPENHAGEN, DENMARK

Arne Lindgren, LUND, SWEDEN

Erik Taubøll, OSLO, NORWAY

After the presentation of the Congress Highlights the winners of the Tournament Prizes will be announced and receive their certificates.

Closing words by Günther Deuschl, EAN President

TEACHING COURSE 18: LIFE AFTER STROKE – LEVEL 2

13:00 - 16:30 | HALL B1



CHAIRPERSON:

Natan Bornstein, TEL-AVIV, ISRAEL

Women issues

Valeria Caso, PERUGIA, ITALY

Motor deficits – their consequences and rehabilitation

Natan Bornstein, TEL-AVIV, ISRAEL

Cognitive and higher cortical disorders – how to help?

Dafin Muresanu, CLUJ-NAPOCA, ROMANIA

Pharmacological and non-pharmacological support beyond secondary prevention

Anna Czlonkowska, WARSAW, POLAND

Recent advances in acute stroke management and prevention have allowed to reduce the burden of stroke and reduce the incidence. Nevertheless, a vast majority of patients still require special attention and management due to their disability and specific issues like gender.

This teaching course will focus on specific issues in the female patients like pregnancy and future administration of oral contraceptives and also hormone replacement therapy. Motor rehabilitation is crucial for reducing disability rates, although recently there is a lot of discussion due to the arrival of new RCTs questioning the intensity of rehabilitation and when to start.

Cognitive and higher cortical disorders are often underestimated in post-stroke patients, especially in those who otherwise recover in terms of motor function. Their assessment, screening and treatment is crucial for full recovery of patients. Recent data also show that patients may benefit from additional pharmacological and non-pharmacological support in rehabilitation. Because of many controversies on this topic an overview will be presented.

TEACHING COURSE 19: CHALLENGES IN NEWLY DIAGNOSED EPILEPSY – LEVEL 1

13:00 - 16:30 | HALL B2

CHAIRPERSON:

Antonio Gil-Nagel, MADRID, SPAIN

What is enough for the diagnosis for epilepsy?

Heather Angus-Leppan, LONDON, UK

How to estimate the prognosis and risks of newly diagnosed epilepsy?

Torbjörn Tomson, STOCKHOLM, SWEDEN

How to choose the first-line drug?

Antonio Gil-Nagel, MADRID, SPAIN

What to do, when the patient does not accept the diagnosis?

Bettina Schmitz, BERLIN, GERMANY

Patients with newly diagnosed epilepsy are entitled to a diagnosis, prognosis and management that are specific and precise. This TC updates knowledge of adequate diagnosis of epilepsies and epileptic syndromes and discusses about the prognoses and risks. The aim is also to give an overview of current treatment options and the decision-making process in selecting the optimal initial treatment for each patient. As in any other medical condition, acceptance of diagnosis is the first step in the therapeutic process. We will cover those challenging situations, when the patient needs the treatment, but is not able to accept the diagnosis or therapy.

TEACHING COURSE 20: CONTROVERSIES - THE NATURAL HISTORY OF INCIDENTAL NEUROIMAGING FINDINGS -LEVEL 2

13:00 - 16:30 | HALL B3

CHAIRPERSON:

Massimo Filippi, MILAN, ITALY

Radiologically isolated syndromes

clinician: Ludwig Kappos, BASEL, SWITZERLAND

neuroimaging: Massimo Filippi, MILAN, ITALY

Hippocampal atrophy

clinician: Martin Rossor, LONDON, UK

neuroimaging: Reinhold Schmidt, GRAZ, AUSTRIA

Extrapyramidal system alterations

clinician: Kailash Bhatia, LONDON, UK

neuroimaging: Stephane Lehericy, PARIS, FRANCE

Microembolus

clinician: David Russell, OSLO, NORWAY

neuroimaging: Christian Enzinger, GRAZ, AUSTRIA

The increasing use of MRI of the CNS by clinicians and researchers has raised the amount of incidental neuroimaging findings. The prevalence of incidental brain findings is higher when high resolution MRI sequences are used and, as expected, the chance of revealing pathologic findings is higher in old age individuals. The proportion of subjects who actually have neurological symptoms referable to apparently incidental brain findings is low. Many of the detected abnormalities are nonspecific in aetiology and are classified as unidentified bright objects. Vascular white matter hyperintensities, silent brain infarcts, inflammatory lesions, tumors and structural or vascular abnormalities are often identified incidentally. The course will offer practical skills to be applied in the interpretation of incidental neuroimaging findings, understanding their pathophysiology, and deciding whether further investigations and possible treatment are necessary.

TEACHING COURSE 21: PREVENTING DELAYED NEUROLOGICAL DEFICITS IN NEUROCRITICAL CARE - OLD FOES, NEW CONCEPTS - LEVEL 2-3

13:00 - 16:30 | HALL B5.M1

CHAIRPERSON:

Jens P. Dreier, BERLIN, GERMANY

Spreading depolarizations and spreading ischemia in stroke and subarachnoid haemorrhage

Jens P. Dreier, BERLIN, GERMANY

Continuous EEG monitoring in the Neurointensive Care Unit

Martin Fabricius, COPENHAGEN, DENMARK

Hypothermia for anoxic ischemic encephalopathy

Andrea Rossetti, LAUSANNE, SWITZERLAND

Multimodal neuromonitoring

Raimund Helbok, INNSBRUCK, AUSTRIA

Once acute injury has occurred, the foremost aim of neurocritical care is to prevent secondary brain tissue damage. Cortical spreading depolarisations and cortical spreading ischemia are increasingly recognized as markers of ongoing brain injury in humans. This discovery might very well be the start of a paradigm shift that takes neurocritical care to a superior level in the near future. In this teaching course, world-leading experts provide a comprehensive overview of the most exciting areas in the diagnostics and management of patients with acute brain injury.

TUESDAY, 31 MAY

13:00 - 16:30

TEACHING COURSE 22: CURRENT TREATMENTS IN NEUROLOGY II – LEVEL 1

13:00 - 16:30 | HALL C

CHAIRPERSON:

Patricia Limousin, LONDON, UK
.....

Update on thrombolysis

Peter E. Ringleb, HEIDELBERG, GERMANY

Advances in the management of primary CNS lymphoma

Khe Hoang-Xuan, PARIS, FRANCE

How to approach muscle pain

Tiziana Mongini, TORINO, ITALY

DBS (deep brain stimulation) and the future

Patricia Limousin, LONDON UK

Prof. Ringleb will discuss the value of iv-thrombolysis in the light of mechanical thrombectomy. Prof Hoang-Xuan will refer about advances in correct management when facing primary Central Nervous System lymphoma. Prof. Mongini will explain how to best approach muscle pain in a patient and Prof. Limousin will inform about the future of Deep Brain Stimulation (DBS).

EAN considers the production of neurological guidelines a major commitment, as this is a primary tool to improve clinical practice in neurology. This level 1 teaching course is the first within an EAN Congress and will overview the problems and challenges of developing guidelines. It is aimed both at clinicians who want to critically evaluate and use guidelines and at EAN members and specialist trainees who want to develop guidelines within the umbrella of our 31 Scientific Panels. A specific attention will be paid to the knowledge of the GRADE system (Grading of Recommendations, Assessment, Development and Evaluation) which aims to provide a homogeneous and transparent approach to the entire process of guideline creation.

TEACHING COURSE 23: DEVELOPING AN EAN GUIDELINE – LEVEL 1

13:00 - 16:30 | HALL B5.M2

CHAIRPERSON:

Antonio Federico, SIENA, ITALY
.....

Critical appraisal of clinical practice guidelines: the AGREE instrument

Luca Vignatelli, BOLOGNA, ITALY

Finding the evidence: an introduction to literature searching and how to search

Christopher Cooper, EXETER, UK

The methodology of GL production: the GRADE approach for moving from evidence to recommendations


Maurizio Leone, SAN GIOVANNI ROTONDO, ITALY

An introduction to the use of the GRADE software

João Costa, LISBON, PORTUGAL



Non-Motor Dysfunctions in
Parkinson's Disease &
Related Disorders



Parkinson

NMDPD 2016


11th International Congress on Non-Motor
Dysfunctions in **Parkinson's Disease** and
Related Disorders

Ljubljana, Slovenia | October 6-9, 2016


Submit Your Abstract

Abstract Submission Deadline: **May 10, 2016**

Early Registration Deadline: **June 21, 2016**



Congress organizer



Kenes International Organizers of Congresses S.A.
Rue François-Versonnex 7, 1207 Geneva, Switzerland
Tel: +41 22 908 0488 | Fax: +41 22 906 9140

nmdpd2016.kenes.com



COMPANY SPONSORED


PROGRAMME

We wish to express our gratitude to the following companies, who, through their generosity, have helped to make this congress possible.

PREMIUM SPONSOR



MAJOR SPONSOR



SPONSOR




CONTRIBUTOR




EXHIBITORS

2016

NAME/TITLE	BOOTH NUMBER		
AbbVie Inc.	D16	EVER Pharma	C42
Actelion Pharmaceuticals Ltd	B20	EXCEMED - Excellence in Medical Education	D33
Aequus Research	D34	F. Hoffmann-La Roche Ltd	A20
Alexion Pharmaceuticals, Inc.	D10	icomatrix	C16
Allergan ApS	C18	Interacoustics	A48
American Academy of Neurology	D22	International Niemann-Pick Disease Alliance (INPDA)	D41
Autonomic Technologies GmbH	D43	International Parkinson and Movement Disorder Society	C15
Bayer	C20	Karger Publishers	C35
Bial & Eisai Cooperation	D14	Lifelines iEEG	B30
Biogen	C01	MedDay pharmaceuticals	C44
BioMarin Europe Ltd.	C03	Medtronic Inc.	C12
Boston Scientific	C10	Merck	B10
Britannia Pharmaceuticals	C17	Natus Europe GmbH	B38
BMJ	C32	Netherlands Society of Neurology	D42
Cadwell Industries, Inc.	C13	Neuroelectronics	D32
CeGaT GmbH	A46	Neuronix	D44
Charité - Universitätsmedizin Berlin	C14	Novartis Pharma AG	A01
CorTechs Labs	D40	Octapharma AG	A40
DEYMED Diagnostic s.r.o.	C40	"RRFS - Residents and research fellows section of the European Academy of Neurology"	EAN Booth
Dystonia Europe	C30	Otometrics	D47
European Academy of Neurology	Registration Area	Sanofi Genzyme	A10
ebrain	EAN Booth	Shire International GmbH	D20
ECNP	C31	Teva Pharmaceuticals Europe BV	A30
ECTRIMS	C36	The Brain Prize	D28
Electrical Geodesics, Inc.	D30	The Lancet	B32
Epilog	D26	Turkish Neurological Society	D45
ESNCH (European Society of Neurosonology and Cerebral Hemodynamics)	C37	Wisepress Ltd.	E01
European Brain Council	D46	Wiley	A50
EFNA (European Federation of Neurological Associations)	D01	Wolters Kluwer	D24
European Medical Journal	C33	Zambon SpA	C08
European Pain Federation EFIC	C34		





Join us in Copenhagen to learn more about treating Parkinson's Disease!

From OFF to ON – New approaches to the treatment of OFF episodes in Parkinson's Disease

Saturday, May 28th 2016
1:00pm - 2:30pm | Hall M0

Chair – C Warren Olanow, MD

Levodopa Induced OFF Episodes – The Problem
Fabrizio Stocchi, MD

Current Approaches to the Treatment of OFF Episodes
Anthony Schapira, MD

Rescue Therapies - What's in the Pipeline
C Warren Olanow, MD

Panel Discussion

CYNAPSUS

Symposium Sponsored by Cynapsus Therapeutics Inc.

97 % of dementia patients develop BPSD*



Dr. Willmar Schwabe Satellite Symposium:

»EGb 761[®] in Dementia«

**Learn more
about the prevalence, clinical importance
and treatment of BPSD!**

EGb761[®]

SATURDAY, 28 MAY

13:00 - 14:30

DR. WILLMAR SCHWABE

13:00 - 14:30 | HALL M1

EGb 761® in Dementia – from pre-clinic to clinic”

CHAIRPERSON:

Amos D. Korczyn, TEL AVIV, ISRAEL

.....

"Neurotransmitters and EGb761 in cognitive dysfunction – recent findings"

Jan Kehr, UPPSALA, SWEDEN

"BPSD : prevalence, clinical importance and treatment options"

Armin von Gunten, LAUSANNE, SWITZERLAND

EXCEMED

13:00 - 14:30 | HALL B

Current and future treatments for MS

CHAIRPERSON:

Giancarlo Comi, MILAN, ITALY

Mark Freedman, OTTAWA, CANADA

Per Soelberg Sørensen, COPENHAGEN, DENMARK

.....

Immunology of MS: classical theories and new insights

Tjalf Ziemssen, DRESDEN, GERMANY

From immunology to treatment: current and future therapeutic strategies

Alexandre Prat, MONTREAL, CANADA

From treatments to side effects: preventing and managing risks

Celia Oreja-Guevara, MADRID, SPAIN

Concluding remarks

Giancarlo Comi, MILAN, ITALY

Mark Freedman, OTTAWA, CANADA

Per Soelberg Sørensen, COPENHAGEN, DENMARK

CYNAPSUS

13:00 - 14:30 | HALL M0

From OFF to ON – New approaches to the treatment of OFF episodes in Parkinson's disease

CHAIRPERSON:

C. Warren Olanow, NEW YORK, NY, USA

.....

Levodopa-induced OFF episodes – the problem

Fabrizio Stocchi, ROME, ITALY

Current approaches to the treatment of OFF episodes

Anthony Schapira, LONDON, UNITED KINGDOM

Rescue therapies – what's in the pipeline

C. Warren Olanow, NEW YORK, NY, USA

2nd Congress of European Academy of Neurology



BRAIN HEALTH:

Translating Scientific Evidence Into
Clinical Practice in MS

Chair: Professor Per Soelberg Sørensen, MD, PhD, Denmark

Join us at the Sanofi Genzyme Satellite Symposium
Sunday, May 29th, 13.00 - 14.30hrs
Bella Center, Hall B

SANOFI GENZYME 

Satellite Symposium at the 2nd EAN Congress 2016
Copenhagen, Denmark, 28-31 May 2016

What's New in the Management of Motor Symptoms and Motor Complications in PD?



**Find out at the
Zambon Satellite Symposium
Sunday May 29
13.00-14.30 Hall C**

Zambon is proud to invite you to meet our Experts,
and discover more about the innovative treatment, safinamide.
At this symposium you will learn exactly how this new therapy can prolong
the efficacy window of levodopa in Parkinson's disease, providing
a balanced control of motor symptoms and motor complications.

13:00 – 14:30, Sunday 29 May 2016
Room M0, Bella Center Copenhagen, Copenhagen, Denmark


SATELLITE SYMPOSIUM

Innovations in diagnosis and monitoring of inherited ataxias:
a spotlight on NP-C


Chaired by Mathieu Anheim (Strasbourg, France)

Satellite Symposium at the 2nd Congress
of the European Academy of Neurology (EAN)
Supported by an educational grant
provided by Actelion Pharmaceuticals Ltd

Plan of the Bella Center Copenhagen Ground Floor



16007024_EAN_2016_ADVERT_05.2016



*"I've just buttoned
my own shirt. People
say, 'Is that all?'.
I say, 'to me it's
not all, but it is
a great victory.'"*

Our aim is to make a big difference to the lives of people with Parkinson's disease.
Even if it's one small thing at a time

SANOFI GENZYME**13:00 - 14:30 | HALL B**

Brain Health: Translating Scientific Evidence into Clinical Practice in MS

CHAIRPERSON:

Per Soelberg Sørensen, COPENHAGEN, DENMARK

Welcome and Opening

Per Soelberg Sørensen, COPENHAGEN, DENMARK

Brain volume loss in MS: underlying pathophysiology

Heinz Wiendl, MÜNSTER, GERMANY

Lost in Translation? Brain Atrophy from Clinical Studies to Clinical Practice

Andreas Lysandropoulos, BRUSSELS BELGIUM

The Role of Brain Atrophy in Decision-making for Early Treatment

Andrew Chan, BERN, SWITZERLAND

Q & A

Per Soelberg Sørensen, COPENHAGEN, DENMARK

ZAMBON**13:00 - 14:30 | HALL C**

What's New in the Management of Motor Symptoms & Motor Complications in PD?

CHAIRPERSON:

Bas Bloem, NIJMEGEN, THE NETHERLANDS

Per Odin, BREMERHAVEN, GERMANY

Levodopa: The Mainstay for Managing Motor Symptoms

Per Odin, BREMERHAVEN, GERMANY

How to manage PD progression?

Paolo Barone, SALERNO, ITALY

Introducing Safinamide: A New Therapeutic Options to Address Motor Symptoms & Motor Complications in PD

Werner Poewe, INNSBRUCK, AUSTRIA

Panel discussion**ACTELION****13:00 - 14:30 | HALL M0**

Innovations in diagnosis and monitoring of inherited ataxias: a spotlight on NP-C

CHAIRPERSON:

Mathieu Anheim, STRASBOURG, FRANCE

Niemann-Pick disease Type C: blink and you'll miss it!

John Ealing, MANCHESTER, UK

An algorithm for ataxia: paving the way for differential diagnosis of rare neurological disorders

Mathieu Anheim, STRASBOURG, FRANCE

Detecting NP-C patients in clinical practice: successful screening approaches in patients with unexplained ataxia

Matthis Synofzik, TÜBINGEN, GERMANY

Monitoring movement disorders in the modern world

Elin Haf Davies, LONDON, UK

Question & Answers

All

Summary and close

Mathieu Anheim, STRASBOURG, FRANCE

SHIRE**13:00 - 14:30 | HALL M5**

THE RARE AND UNDETECTED – Lysosomal storage diseases in neurology

CHAIRPERSON:

Arndt Rolfs, ROSTOCK, GERMANY

Caring for rare neurologic diseases in the EU – challenges and prospects

Arndt Rolfs, ROSTOCK, GERMANY

Parkinson and Gaucher disease – linking the rare and the undetected

TBC

Stroke and fabry disease – common manifestation of a rare disease

Ricardo Reisin, BUENOS AIRES, ARGENTINA

Mucopolysaccharidosis – implications of the blood-brain barrier for treating a rare neurodegenerative disease


Maurizio Scarpa, WIESBADEN, GERMANY

Neuroimaging in diagnosing rare neurologic diseases

Christian Enzinger, INNSBRUCK, AUSTRIA



Disease activity in MS The B-cell connection



Visit the Roche Booth

Exploring the Interaction between Amyloid and Tau in Alzheimer's Disease: Implications for Diagnosis, Disease Progression, and Management

Sunday, 29 May 2016: 18.30-20.00

Bella Center, Copenhagen: Hall C

This Satellite Symposium is being held in conjunction with the 2nd Congress of the European Academy of Neurology 2016.

Agenda

- | | |
|-------------|--|
| 18.30-18.45 | Introductory Remarks
John Hardy, UK (Chair) |
| 18.45-19.05 | Amyloid and Tau Interactions: How Does Current Knowledge Affect Treatment Targets in AD?
Bengt Winblad, Sweden |
| 19.05-19.15 | Q&A |
| 19.15-19.35 | Amyloid and Tau Imaging: What Can They Tell Us, Independently and Together?
Mark Mintun, USA |
| 19.35-19.55 | Panel Discussion
All |
| 19.55-20.00 | Closing Remarks
John Hardy, UK |

Learning Objectives:

At the end of this session, participants will be able to:

- Discuss hypothetical models of the relationship between amyloid and tau
- Understand potential roles of amyloid and tau imaging in diagnosis and management
- Recognize how recent knowledge and developments may influence future drug development



John Hardy, PhD

Professor of Neuroscience, Institute of Neurology, University College London, London, UK



Mark Mintun, MD

President and Chief Medical Officer, Avid Radiopharmaceuticals, A wholly owned subsidiary of Eli Lilly, Philadelphia PA, USA



Bengt Winblad, MD, PhD

Professor, Director, Karolinska Institutet, Center for Alzheimer Research, Stockholm, Sweden

Light refreshments provided

DKSOL00001

A Satellite Symposium at the 2nd Congress of the
European Academy of Neurology 2016

The Role of Complement in Neurological Disorders

Bella Center Copenhagen | Hall M1
Copenhagen, Denmark

Sunday, 29 May | 18:30 - 20:00

A light reception will be provided at 18:15

Overview:

Complement plays a role in several neurological disorders, including NMO, MG, and neuropathies.

Join us to learn about the complement cascade, its role in tissue damage, and the heterogeneity of patients across complement-mediated neurological disorders. Our faculty panel will conclude with a live question-and-answer session

No CME/CNE credits are associated with this program.

Agenda:

18:30 – 18:40

Welcome and Introductions

Saiju Jacob, MBBS, MD, DPhil, FRCP (Lon)



18:40 – 19:00

Complement in Neurological Disorders

Saiju Jacob, MBBS, MD, DPhil, FRCP (Lon)

Edgbaston, Birmingham, United Kingdom



19:00 – 19:20

Role of Complement in Myasthenia Gravis

James F. Howard, Jr, MD

Chapel Hill, North Carolina, USA



19:20 – 19:40

Complement in Neuromyelitis Optica Spectrum Disorder

Dean M. Wingerchuk, MD, MSc, FRCP(C)

Scottsdale, Arizona, USA

19:40 – 19:55

Question-and-Answer Session Panel

20:00

Meeting Adjournment

ALEXION

Copyright © 2016, Alexion Pharmaceuticals, Inc.
All rights reserved. EMEA/UNB-gMG/16/0001 4/2016



Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress In Mind

All over the world psychiatric and neurological disorders are a growing burden, not only for individuals but for families and societies as well.

An estimated 700 million people worldwide are living with these disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences.

Lundbeck is a specialized pharmaceutical company focused on depression, schizophrenia, Parkinson's disease and Alzheimer's disease. For more than

70 years, we have been at the forefront of research within neuroscience and our development and distribution of pioneering treatments continues to make a difference to patients worldwide.

We are recognized for having helped hundreds of millions of people living with psychiatric and neurological disorders. However, there is still a massive need for further help.

Therefore, in the early stage research and development pipeline we are exploring different drug modalities and effects, of both small molecules and antibodies.

PROGRESS
IN MIND |



SUNDAY, 29 MAY

18:00 - 20:00

ROCHE

18:30 - 20:00 | HALL B

New insights in MS: How are approaches to MS management changing?

CHAIRPERSON:

Per Soelberg Sørensen, COPENHAGEN, DENMARK
.....

Setting sights on optimised MS patient care

Per Soelberg Sørensen, COPENHAGEN, DENMARK

Exploring the impact of the MS disease burden

Eva Havrdová, PRAGUE, CZECH REPUBLIC

Connecting disease activity and progression in MS

Patrick Vermersch, LILLE, FRANCE

Striving for balance in MS clinical practice

Giancarlo Comi, MILAN, ITALY

Tjalf Ziemssen, DRESDEN, GERMANY

The time to act: optimising patient care

Gavin Giovannoni, LONDON, UK

Panel discussion

All faculty and Per Soelberg Sørensen

Meeting close

ELI LILLY

18:30 - 20:00 | HALL C

Exploring the interaction between Amyloid and Tau in Alzheimer's disease: implications for diagnosis, disease progression, and management

CHAIRPERSON:

John Hardy, LONDON, UK
.....

Introductory Remarks

John Hardy, LONDON, UK

Amyloid and Tau Interactions: How does current knowledge affect treatment targets in AD?

Bengt Winblad, STOCKHOLM, SWEDEN

Q&A**Amyloid and Tau imaging: what can they tell us, independently and together?**

Mark Mintun, PHILADELPHIA, PA, USA

Panel discussion

All

Closing remarks

John Hardy, LONDON, UK

ALEXION

18:30 - 20:00 | HALL M1

The role of complement in neurological disorders

CHAIRPERSON:

Saiju Jacobs, BIRMINGHAM, UK
.....

Welcome and Introductions

Saiju Jacobs, BIRMINGHAM, UK

Complement in Neurological Disorders

Saiju Jacobs, BIRMINGHAM, UK

Role of complement in myasthenia gravis

James F. Howard, CHAPEL HILL, NC, USA

Complement in neuromyelitis optica spectrum disorder

Dean M. Wingerchuk, SCOTTSDALE, AZ, USA

Question-and-answer session

Panel

Meeting Adjournment

Your invitation to the

Novartis sponsored satellite symposium at the 2nd EAN Congress 2016

The real MS

Monday, 30 May 2016, 13:00–14:30
Hall B, Bella Center Copenhagen, Denmark



TALES OF THE UNEXPECTED: ELEMENTARY CLUES TO DIAGNOSING MUSCULAR DISEASES

MONDAY 30 MAY 2016, 13:00–14:30

HALL M1, BELLA CENTRE, COPENHAGEN

Satellite symposium at the 2nd EAN Congress
Copenhagen, May 28–31, 2016

NOVARTIS

13:00 - 14:30 | HALL B

The real MS: outcomes and evidence in the real-world

CHAIRPERSON:

Maria Trojano, BARI, ITALY

The bigger picture: striving for better long-term outcomes in MS

Tjalf Ziemssen, DRESDEN, GERMANY

Building the evidence: making the most of real-world data

Jan Hillert, STOCKHOLM, SWEDEN

Where can big data take us?: personalised medicine in MS

Sergio Baranzini, SAN FRANCISCO, LA, USA

SANOFI GENZYME

13:00 - 14:30 | HALL M1

Tales of the unexpected: elementary clues to diagnosing muscular diseases

CHAIRPERSON:

John Vissing, COPENHAGEN, DENMARK

Introduction

John Vissing, COPENHAGEN, DENMARK

Excess of glycogen: pinpointing the cause

John Vissing, COPENHAGEN, DENMARK

Myalgia and exertional dyspnoea: tracking down the cause

Tiziana Mongini, TURIN, ITALY

Limb girdle muscle weakness: the road to a correct diagnosis

Nicolai Preisler, COPENHAGEN, DENMARK

Exertional myalgia: the diagnostic hunt

Cornelia Kornblum, BONN, GERMANY

Summary & Closing remarks

John Vissing, COPENHAGEN, DENMARK

EVER NEUROPHARMA

13:00 - 14:30 | HALL A

Integrating acute and rehabilitation treatment strategies in stroke therapy

CHAIRPERSON:

Valeria Caso, PERUGIA, ITALY

Neurorecovery in acute stroke – updates & highlights

Milan Vosko, LINZ, AUSTRIA

Challenges & opportunities in motor recovery after stroke

Andreas Winkler, BAD PIRAWARTH, AUSTRIA

The role of Imaging in Stroke Rehabilitation

Jan Sobesky, COLOGNE, GERMANY

Pharmacological Support in Early Rehabilitation – The CARS (Cerebrolysin and Recovery After Stroke) Trial Results

Dafin Muresanu, CLUJ-NAPOCA, ROMANIA

MONDAY, 30 MAY

18:30 - 20:00

TEVA

18:30 - 20:00 | HALL C

Multiple Sclerosis – Multiple Solutions – one choice:
What's yours?

CHAIRMAN:

Patrick Vermersch, NEUROLOGIST, LILLE, FRANCE

MODERATOR:

Astrid Joosten, SYMPOSIUM HOST, ROTTERDAM,

THE NETHERLANDS
.....

Facing challenges together

Patrick Vermersch, NEUROLOGIST, LILLE, FRANCE

Astrid Joosten, SYMPOSIUM HOST, ROTTERDAM,

THE NETHERLANDS

Keynote lecture: building a family – a patient's journey

Kerstin Hellwig, NEUROLOGIST, BOCHUM, GERMANY

Stefan Verlohen, GYNAECOLOGIST, BERLIN, GERMANY

60 seconds | Interactive panel discussion

All

Interfering with the immune system

Markus Kleinewietfeld, IMMUNOLOGIST, DIEPENBEEK, BELGIUM

60 seconds | Interactive panel discussion

All

Closing remarks

Patrick Vermersch, NEUROLOGIST, LILLE, FRANCE

Additional panel members:

Heinz Wiendl, NEUROLOGIST, MÜNSTER, GERMANY

Joop Arends, INFECTIOUS DISEASES PHYSICIAN, UTRECHT,

THE NETHERLANDS



Bianca Weinstock-Guttman, NEUROLOGIST, BUFFALO, NY,

USA

FORUM

PROGRAMMES

1 in 3 Patients will not Respond Adequately to Anti-Epileptic Drugs



VNS Therapy® – is an implantable medical device for Drug-Resistant Epilepsy (DRE)

VNS Therapy is an easy to use treatment that controls seizures by sending mild pulses from the generator to the left vagus nerve at regular intervals all day, every day.

Can be safely used as an adjunctive treatment, offering proven therapeutic outcomes.

To discover how VNS Therapy could help your DRE Patients visit www.vnstherapy.com

VNS = Vagus Nerve Stimulation

AspireSR® is CE mark approved and commercial distribution may vary by country.

VNS THERAPY EUROPEAN INDICATION FOR USE

VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to seizure medications. The Model 106 AspireSR® (Seizure Response) features the Automatic Stimulation Mode, which is intended for patients who experience seizures that are associated with cardiac rhythm increases known as ictal tachycardia.

CONTRAINDICATIONS: The VNS Therapy system cannot be used in patients after a bilateral or left cervical vagotomy. Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy on patients implanted with the VNS Therapy system. Diagnostic ultrasound is not included in this contraindication. Cardiac arrhythmia (Model 106 only)—The AutoStim Mode feature should not be used in patients with clinically meaningful arrhythmias or who are using treatments that interfere with normal intrinsic heart rate responses.

WARNINGS: Physicians should inform patients about all potential risks and adverse events discussed in the VNS Therapy Physician Manuals, including information that VNS Therapy may not be a cure for epilepsy. Since seizures may occur unexpectedly, patients should consult with a physician before engaging in unsupervised activities, such as driving, swimming, and bathing, or in strenuous sports that could harm them or others. A malfunction of the VNS Therapy system could cause painful or direct current stimulation, which could result in nerve damage. Removal or replacement of the VNS Therapy system requires an additional surgical procedure. Patients who have pre-existing swallowing,

cardiac, or respiratory difficulties (including, but not limited to, obstructive sleep apnea and chronic pulmonary disease) should discuss with their physicians whether VNS Therapy is appropriate for them since there is the possibility that stimulation might worsen their condition. Postoperative bradycardia can occur among patients with certain underlying cardiac arrhythmias. MRI can be safely performed; however, special equipment and procedures must be used.

ADVERSE EVENTS: The most commonly reported side effects from stimulation include hoarseness (voice alteration), paresthesia (prickling feeling in the skin), dyspnea (shortness of breath), sore throat and increased coughing. The most commonly reported side effect from the implant procedure is infection.

*The information contained here represents partial excerpts of important prescribing information from the product labeling. Patients should discuss the risks and benefits of VNS Therapy with their healthcare provider. Visit www.VNSTherapy.com for more information.

OUSADBS15-11-1000-EEA

CYBERONICS EUROPE BVBA
WHOLLY-OWNED SUBSIDIARY OF LIVANOVA PLC
Airport Plaza
Kyoto Building
Leonardo Da Vincilaan 19
B-1831 Diegem, Belgium
Tel: +32.2.720.95.93
Fax: +32.2.720.60.53

100 Cyberonics Boulevard
Houston, Texas 77058
Tel: +1.800.332.1375
Fax: +1.281.218.9332

OVERVIEW OF FORUM PROGRAMMES ORGANISED WITHIN THE EXHIBITION AREA

Additional forum talks reserved after the date of printing
will be announced-on site.

SATURDAY, 28 MAY

12:45 - 13:00

MEDTRONIC FORUM TALK

How can visualization become a common language for
multidisciplinary DBS teams?

Mathieu Chastellain,

MEDTRONIC EUROPE

.....

SUNDAY, 29 MAY

10:00 - 10:30

BOSTON SCIENTIFIC FORUM TALK

Possibilities offered by a DBS Directional System:
clinical cases

Manuela Pilleri,

VICENZA, ITALY

.....

12:45 - 13:00

MEDTRONIC FORUM TALK

Medtronic DBS and non-motor symptoms

Karen Østergaard (TBC),

ARHUS, DENMARK

.....

MONDAY, 30 MAY

10:00 - 10:15

BAYER FORUM TALK

VITAMIN D and MS

Paul Friedemann

.....

12:45 - 13:00

MEDTRONIC FORUM TALK

Long-term clinical experience with Medtronic DBS for
Epilepsy

Jukka Peltola,

TAMPERE, FINLAND

.....

16:15 - 16:45

BOSTON SCIENTIFIC FORUM TALK

Clinical experience with Vercise PC, directional system

Michael Schüpbach,

BERN, SWITZERLAND

.....

TUESDAY, 31 MAY

10:00 - 10:30

BOSTON SCIENTIFIC FORUM TALK

Directional DBS of the subthalamic nucleus: a pilot
study - preliminary observations

Martin Reich,

WÜRZBURG, GERMANY

FINAL PROGRAMME

INDEX

SPEAKER INDEX

2016

Baranzini, S.	217	Bellante, F.	65	Bilen, S.	123, 158	Bovt, Y.	169
Barba, C.	64	Bellenberg, B.	68, 83	Bilgen, C.	122	Boyadzhieva, M.	60
Barbarulo, A.M.	179	Bellmann-Strobl, J.	180	Bindoff, L.	151	Boycott, K.	133
Barbay, M.	150	Bello, L.	160	Binetti, G.	102	Boyko, A.	81, 120, 141
Barboni, P.	136	Bellomo, G.	84, 116	Binzer, M.	119	Boylan, R.	134
Barca, E.	62, 67, 132, 151	Bellomo, R.	106	Binzer, S.	119	Boyras, Ö.	81
Barcs, G.	109	Belmatoug, N.	122	Bir, L.S.	161	Bozovic, I.	73
Bărcuțean, L.	82	Belniak, E.	163	Birouk, N.	143, 185	Bozsik, G.	137
Bardins, S.	122	Belomestnova, D.	159	Bisciglia, M.	122	Braathen, G.	50, 62, 127
Bardone, M.B.	84	Belova, L.	126, 159	Bisecco, A.	68, 70, 83	Brabcova, L.	80
Bardoni, A.	72	Belova, N.	59, 126	Bisevac, B.	111	Brace, G.	71
Bardon, J.	67	Beltramello, A.	105, 134	Bisgård, A.S.	71, 123	Brajkovic, S.	70
Bares, M.	134	Beltrami, E.	84	Biskup, S.	120	Brakk, S.	157
Bargiotas, P.	170	Bembek, J.	51	Bisordi, C.	114, 176	Bramanti, P.	134, 151, 168
Barilaro, A.	116, 134	Ben Abdelaziz, I.	76, 124	Biswal, B.B.	189	Branco, M.	73
Barker, R.	149	Ben Abdeljalil, M.	84	Bivona, U.	64	Branco, M.D.C.	129
Barker, R.A.	151	Ben Abdeljelil, H.	123	Bjelica, B.	73	Brandolino, M.T.M.	74
Barkhof, F.	37, 68, 83, 109, 131	Ben Abdeljelil, M.	59, 60, 156	Bjork, M.H.	149, 173	Brandt, A.	180
Barlœse, M.	66, 89, 113, 150, 158, 174	Ben Aljia, L.	68, 83	Blaabjerg, M.	105, 149	Brandt, S.	64, 106
Barone, P.	133, 209	Benammou, S.	83	Bladowska, J.	167	Brandt, T.	94, 104, 106, 143, 168, 177
Baroni, M.	109	Benatar, M.	160	Blahova, J.	149	Brankovic, V.	124
Barón, J.	66, 79, 128	Bencsik, R.	109	Blanco, J.M.	165	Brannagan, T.	165
Baron, M.-H.	53	Bendtsen, L.	97, 150	Blanco, L.	66, 79	Branzoll, F.	49
Baronnet Chauvet, F.	77, 174	Benedetti, L.	85	Blanco, Y.	179	Brás, A.	124
Baron Sanchez, J.	159	Benedetti, M.D.	81, 116	Blaško Markič, M.	155	Brás, P.	85
Bar-or, A.	53, 69, 116, 117, 183	Benedict, J.	70	Blauer-Peterson, C.	164	Brás, S.	78
Barouski, A.	71	Benedict, R.H.	149	Blažejewska-Hyzorek, B.	76	Brathen, G.	92
Barreira, C.	78	Benghanem, S.	76	Blažina, K.	67	Braun, K.	173
Barreiro, M.	51, 85	Benhassine, T.	119	Bleasdale-Barr, K.	60, 76	Braun, S.	179
Barresi, R.	151	Benhsain, T.	135	Blejcharova, K.	149	Bravo, J.J.	70, 76, 83
Barrie-Attarian, M.	53	Beniczky, S.	52, 65, 144	Blicher, J.U.	104	Bravo-Ricoy, J.A.	128
Barrio-Arraz, G.	175	Ben-Menachem, E.	38, 52, 158, 173	Blinkenberg, M.	53, 179	Braz, L.	74, 81, 82
Barros, A.	122, 180	Bennett, H.	116	Blin, O.	105, 134	Brazovskaya, N.G.	81, 112, 125, 177
Barros, P.	183	Benninger, D.	48	Bloem, B.	97, 209	Brede, T.	82
Barsi, P.	119	Bennis, A.	120	Bloem, B.R.	38	Bredholt, M.	82
Bartkova, A.	159	Benoit, C.	114	Blond, S.	53	Brefel-Courbon, C.	48
Bartoletti-Stella, A.	133	Benomar, A.	137, 184	Blümke, L.	182	Brinegaard, N.	52
Bartoniukova, T.	119, 177	Benros, M.	121	Bnoughanna, W.	84	Breitenfeld, T.	40, 65, 109
Bartrés Fas, D.	105, 134	Bentes, C.	73, 85	Boadu, W.	176	Bremova, T.	122
Bartsch, H.	104	Benti, R.	59	Boan, J.F.	59	Brems, M.	114
Barun, B.	63, 76, 164	Benussi, L.	102	Boccardi, M.	75	Brennum, J.	66, 150
Baruzzi, A.	104	Ben Yehuda, M.	103	Boccard, S.	40	Brescia Morra, V.	117, 179
Barxias Martin, M.	84	Bera, G.	49	Boczan, J.	185	Bresolin, N.	67, 80, 114, 115
Basaia, S.	67, 83, 106, 115	Berardinelli, A.	151	Bodini, B.	49	Breton, G.	168
Basha, E.	169	Beratis, I.	75, 80, 111, 126, 171	Boeck, M.	76	Brette, S.	163, 183
Basic Kes, V.	65, 109	Bereczki, D.	50, 137, 156, 174, 183	Boerner, J.	185	Brettschneider, J.	143
Basilico, P.	59, 167	Bereczki Jr., D.	119	Bogdanos, D.	120	Breza, M.	120
Basilio, C.	84	Beres-Molnar, K.A.	77	Bogdanov, R.	67	Briani, C.	85
Basilio, G.	76	Bergamaschi, R.	68	Bogdanova, D.	117, 120	Brice, A.	49, 50, 80
Bas, J.	182	Berini, S.	128	Bogdanovic, D.M.	103	Brieva, L.	162
Basoglu, F.	175	Berisavac, I.	73, 124, 156	Bognandi, L.	155	Brill, A.-K.	73
Bassa, B.	127, 159	Berkiks, I.	62, 64	Bohar, Z.	175	Brinar, V.	82
Bassetti, C.	52, 73, 102, 124, 149, 156	Berkovich, R.	164	Bohlega, S.	73	Brisson, J.-D.	133
Basta, I.	124	Berkowitz, N.	52	Bokor, M.	126, 130	Britze, J.	49
Bastin, M.	77	Berlangieri, M.	105	Boleixa, D.	78	Brochet, B.	103
Bastos Lima, A.	80	Berlit, P.	96, 135	Bombois, S.	75	Brock, M.	52
Bast, T.	148	Berlot, R.	115	Bonaki, A.	111	Brodtmann, A.	171
Basu, A.	102	Bernali, N.	159	Bonakis, A.	126, 173	Broeg-Morvay, A.	77
Bataller, L.	185	Bernardino, S.	103	Bonanno, L.	134, 151	Bronstein, A.	89, 122, 150
Bathia, K.	49	Bernardo, F.	65, 76	Bonati, L.	51, 111, 158	Brouwer, M.	50, 53, 175
Batista, S.	72, 79, 130, 131, 157, 175	Bernasconi, C.	73	Bonato, S.	67	Brown, J.	181
Batista, S.R.M.	72	Bernasconi, E.	182	Bonavita, S.	70, 134	Brown, R.	177
Battagliani, M.	130	Béroud, C.	118	Bonizzoni, E.	80	Brown, S.	113
Battagliani, P.P.	78	Berra, E.	105	Bonnot, O.	147	Brzozva, H.	80
Battisti, C.	50	Bersano, E.	114	Bono, G.	133, 161	Brück, W.	189
Batur-Caglayan, H.-Z.	122	Bertè, R.	133	Bonsu, A.	150	Brugger, P.	182
Batzu, L.	183	Bertilsson, L.	127	Bonuccelli, U.	70	Brugnara, A.	50
Bauchet, L.	53	Bertini, E.	180	Boogers, A.	71	Brugnolaro, C.	121
Bauer, C.	53	Bertoli, C.	129	Boon, P.	40, 65, 189	Bruijn de, M.	182
Bauer, N.	77	Bertolin, C.	160	Boon, P.A.	48, 78, 173	Brunel, H.	61
Bauer, R.	151	Bertolotto, A.	68, 81	Booth, S.	165	Brunet, G.	123
Bau, L.	120	Bertol, V.	78	Borbinha, C.	76, 111, 121, 183	Brusa, R.	70, 151
Baulac, M.	52	Beslac-Bumbaširević, L.	66, 73, 106, 124	Bordet, R.	51, 105, 110, 134	Bruun, M.	109
Baumann, C.R.	48	Bettencourt, A.	48, 78, 174	Bordoni, A.	80, 114	Brzegowy, P.	156
Baum, K.	178	Bettencourt, C.	133	Borellini, L.	67, 80	Bubolz, A.	128
Bauset Navarro, J.L.	119	Beume, L.	103	Borisov, A.	83	Bucchia, M.	114
Bayat, M.	159	Bevilacqua, F.	70	Borisova, S.	67	Bucci, E.	151
Baybas, S.	175	Beyer, N.	75, 109	Borlongan, C.	169	Buchbjerg, J.	165
Baydemir, R.	129	Beyrouti, R.	84, 159	Börnsten, L.	134	Buczek, J.	76
Bayraktutan, O.F.	173	Bezuglova, I.	157	Bornstein, N.	89, 192	Budano, C.	61
Bayramov, A.	67	Bezzi, G.	133	Borrega Canelo, L.	84	Budinevic, H.	61, 77
Bäzner, H.	40	Bhatta, K.	39, 49, 67, 141, 193	Bortolani, S.	70, 132	Budtz-Jørgensen, E.	134
Beattie, S.	119	Bhattacharjee, A.	166	Boschi, S.	70, 132	Buitán Catevilla, J.	81, 123
Beaudonnet, G.	137	Bhrugubanda, V.	185	Bosco, G.	76, 128	Buisan, J.	115, 166
Bech, B.H.	48	Bianchi, A.	133	Bosnar-Puretic, M.	65	Bulut, S.	61
Becher, H.	127	Bianchi, E.	48	Bosnyák, E.	160	Bumbaširević, L.	156
Becho, J.	136	Bianchi-Marzoli, S.	168	Bosque, M.	132	Bunker, M.	48
Becirovic, E.	111	Bianchi, S.	77, 133	Bossolasco, P.	114	Buraga, I.	66, 72, 124, 127
Beckmann, C.	84	Biancolini, D.	133	Bostantjopoulou, S.	168	Buraga, M.	170
Bedetti, C.	150	Bianco, M.	132	Botelho, I.	85	Burel-Vandenbos, F.	102
Bednarik, J.	74	Biberon, J.	65, 79, 158	Botica, M.	72	Burgunder, J.-M.	50, 147
Bedoui, I.	162, 172	Bichev, S.	120	Bottari, M.	70	Burke, T.	114, 160
Beer, R.	148	Biczó, D.	77	Böttcher, N.	122	Burtscher, M.	73
Beghi, E.	45, 48	Bidstrup, P.E.	53	Böttzel, K.	177	Busan, P.	78
Béjat, Y.	111	Bielen, I.	112	Bougea, A.	159	Busk, H.	122
Bek, S.	126, 136	Bielle, F.	167	Bourg, V.	102	Busk, Ø.L.	50, 62
Bekircan-Kurt, C.E.	72, 120	Bieri, O.	103	Bourinaris, T.	113, 118, 182	Butkovic Soldo, S.	59
Bekkelund, S.I.	105, 175	Biesalski, A.-S.	184	Bourre, B.	162	Buture, A.	113
Belarbi, S.	119	Bijlsma, M.	50	Boussery, K.	150	Butzkueven, H.	163
Beliveau, V.	110	Bilbault, T.	161	Bouzas Lago, L.	128		

SPEAKER INDEX

2016

Crnac, P.	61, 77	De Feo, D.	164	Di Muzio, A.	151	Duarte, G.	184
Crnošija, L.	59, 60, 63, 68, 76	De Gaalon, S.	77	Di Nardo, F.	176	Duarte, M.M.	158
Croese, T.	71, 121, 130	De Icco, R.	105	Di Somma, C.	115	Dubbioso, R.	179
Crombez, G.	150	De Jong, B.M.	84	Di Viesti, M.P.	77	Dubois, B.	45
Cronberg, T.	106	De Jong, R.	78	Diaconu, S.	73	Ducray, F.	53, 105
Cross, H.	148, 173, 190	De la Riva, P.	113	Diah, S.	159	Dudek, H.	60
Crozier, S.	77	De Lera, M.	159	Diallo, A.	50	Dufournet, B.	75
Cruccu, G.	92, 147	De Lera Alfonso, M.	79, 128	Dias, M.V.	136	Dumitrescu, L.	167
Cruz, A.	127	De Marchi, F.	75, 114, 161	Dias, S.	122, 130, 137	Dummett, S.	160
Cruz Culebras, A.	156	De Marchis, G.M.	51, 111, 158	Diaz, C.	51	Duncan, J.	189
Cruz, I.	83, 158	De Martino, B.M.	160	Diaz de Cerio Julian, L.	78	Dunø, M.	151
Cruz, J.	136	De Mase, A.	113	Diaz, E.	128	Dünser, M.	64, 135
Cruz, S.	149	De Masi, M.	61	Diaz-Manera, J.	118	Du Pasquier, R.	182
Cruz, V.T.	73	De Massis, P.	133	Diaz-Ortuño, A.	119, 133, 165, 175, 179, 180	Duprat, R.	78
Cryan, John F.	142	De Mendonça, A.	102	Diaz Pertuz, E.D.	131	Dupré, N.	133
Csaban, D.	109	De Meo, E.	84, 102	Diblik, P.	82	Duque, C.	168, 180
Csepany, E.	113, 174	De Micco, R.	130, 151	Dickie, D.A.	77	Durães, J.	103, 133
Csiba, L.	89	De Michele, G.	49, 157	Dicuonzo, F.	114	Duran-Pena, A.	53, 167
Csiba, Laszlo	157	De Praeter, M.	114	Didic, M.	105, 134	Durão, F.	102
Cuadrado, E.	61	De Pue, A.	80	Dieli, F.	130	Duray, M.-C.	84
Cuadrado-Godía, E.	61	De Roeck, A.	50	Dieterich, M.	89, 104, 106, 149, 177	Durmuş, H.	85
Cuadrado, M.L.	113, 159	De Rojas Leal, C.	60, 75, 76	Dietrich, J.	105	Duro, D.	64, 103, 150
Cuciureanu, A.	64	De Rosa, A.	49	Dietrichs, E.	40, 80	Đurovská, J.	166
Cuciureanu, I.D.	64	De Salvo, S.	134, 151	Dietz, V.	92, 126	Dürr, A.	50, 96
Cuciureanu, T.	64	De Seze, J.	53, 103, 117, 163	Dimachkie, M.	165	Dussaule, C.	123
Cucumo, V.	59	De Sousa, A.	85	Dimauro, S.	62	Dutkiewicz, M.	165
Cudna, A.	76, 174	De Stefano, N.	70, 130, 134	Dimitriade, A.	74, 113, 127	Duticquet, C.	79
Cuervo, J.	116	De Toffol, B.	65, 79, 158	Dimitroulis, I.	157	Dvorakova, B.	155
Culo, B.	109	De Toledo, M.	78, 127	Dimitrova, M.	64	Dworetzky, B.A.	106
Cunha, C.	59, 121, 168	De Toni Franceschini, L.	170	Dimitrov, I.	60, 72	Dyssegaard, A.	110
Cunha, L.	110, 157	De Verdal, M.M.	79	Dimitrov, N.	177	Dziedzic, T.	126
Curatolo, P.	52	De Vries, P.	52	Dimopoulos, M.-A.	157	Dziedzyc, K.	80, 133
Curtin, F.	116	Deary, I.J.	77	Dimova, P.	173	Dzyngel, B.	161
Curto Sánchez, E.	117	Debes, A.	135, 166	Diogo, M.	130		
Cusin, A.	182	Debouvier, M.	103	Diouf, M.	150	E	
Cutter, G.	115, 117, 164	Dechend, R.	82	D'ippolito, M.	64	Ealing, J.	209
Cutter, G.R.	163	Decker, J.	168, 185	Disanto, G.	116	Echavarri, C.	119
Cvijanovic, M.	124	Deecke, L.	103	Diserens, K.	168	Economou, A.	75, 80, 111, 171
Cwiklinska, H.	53	Defazio, G.	49	Distaso, E.	114	Edan, G.	103, 131
Czernuszenko, A.	61, 157	Defebvre, L.	67	Djajic, V.	61	Edvardsen, T.	66
Czlonkowska, A.	51, 60, 80, 106, 192	Defer, G.L.	103	Djамandi, P.	71	Edwards, A.	116, 160
		Defreyne, L.	48	Djebrani-Oussedik, N.	123	Edwards, K.	163
D		Degirmenci, E.	161	Djellovic-Vranic, J.	128, 131	Edwards, M.	115, 161
Dogaš, Z.	125	Degruyther, N.	161	Djozic, E.	131	Efendi, H.	156
Dacci, P.	85	Dejanović, I.	71	Djukmedzhiev, P.	120	Efthymiou, G.	120
Dadajonov, S.	72	Delanty, N.	173	Dmitry, V.	71	Efthymiou, S.	133
D'adda, E.M.	85	Delattre, J.-Y.	105	Dobesberger, J.	52, 173	Eggleston, K.	65
Dahlbom, K.	151	Del Bo, R.	132, 151	Dobi, D.	127	Eggleton, P.	178
Dahl, I.T.	66	Del Carro, U.	63, 164	Dobricic, V.	132, 178	Eglite, J.	164
Dahlke, F.	117	Del C. Valdés Hernández, M.	77	Doche, E.	61, 62	Ehler, E.	123, 169
D'alexandro, R.	81	Deleu, D.	160	Docimo, R.	70, 134	Eichlerová, A.	123
D'alfonso, S.	114, 133	Delgado González, L.V.	62	Dodich, A.	59	Eid, G.	74
Dali, C.I.	133	Delgado, V.	61, 123	Dodick, D.	105	Eiken, O.	171
Dall, C.H.	109	Delichas, Z.	157	Doğan Ak, P.	83	Eisele, P.	68
Dalla Costa, G.	53, 82, 121, 130, 164	Deli, G.	160	Doğru, Y.	129	Ejskjaer, N.	105
Dalmau, J.	105	Dell'agnello, G.	75	Dogu, O.	80	Ekmekçi, C.	60
Dalmau, J.O.	45	Dellis, R.	149	Doherty, J.	112	Ekmen, A.	131
Dalton, S.O.	53	Delorme, C.	165	Dolák, J.	69	Ekmen, A.	77, 102
Daltveit, A.K.	149	Deloumeaux, J.	60	Dolenc Groselj, L.	171	Ekström, L.	127
Damasio, J.	80	Delrue, G.	82	Doležalová, I.	79	El Alaoui Faris, M.	59, 60, 84, 156
Damato, V.	135	Deltour, S.	174	Dolina, I.	177	Elamin, M.	114, 134
D'ambrosio, A.	49, 70, 150	Delvaux, V.	82	Domashenko, M.	61	Eloupra, R.	104
Damgaard, D.	62, 149	Demarche, S.	150	Domingo Jimenez, R.	179	Elger, C.E.	158, 173
Damian, D.	162	Demir, C.	61	Domingos, J.	121	Elhassani, R.	156
Damulina, A.	84	Demircan, C.S.	78	Dominguez Alvarez, M.	117	El Helou, J.	74, 112, 171
Dan, C.	149	Demirkaya, S.	60, 81, 123, 180	Dominovic-Kovacevic, A.	124	El Hessni, A.	62, 64
Dan, F.	110	Demir, S.	71, 79, 84	Domi, T.	51	Elsiseeva, E.	169
Dane, A.	177	Demirtas, B.S.	172	Donadio, V.	60, 104, 106, 114	El Khalifi, M.	60
D'angelo, G.	151	Démonet, J.-F.	39	Donaire, A.	136	Elkjær, L.S.	48
D'angelo, R.	60	Demos, M.	63	Donner-Banzhoff, N.	191	Ellemann, K.	123
Dangond, F.	117, 130, 162	Demurtas, R.	66	D'onofrio, M.	113, 183	Elmazny, A.	69, 177
Daniela, E.	61	Deol-Bhullar, G.	69	Doppler, E.	169	El Mesbahy, J.	85
Danilenko, O.	66	Depondt, C.	65	Doppler, K.	128	El-Metwally, A.	60
Danjou, F.	80	Derbali, H.	162, 172	Dore, G.	113, 183	Elmouden, H.	135
Dany, F.	120	Deretzi, G.	113, 118, 182	Doretta, A.	114, 176	El Moutawakil, B.	77, 80, 120, 135
Daoudi, S.	131	Derkinderen, P.	77	Dormeuil, A.	75	El Otmani, H.	77, 80, 120, 135
Darabyan, A.	170	D'errico, E.	114	Dormont, D.	165	Eiting, J.W.	84
Darby, D.	171	Desoi, P.	66	Dorobab, B.	74, 113, 127, 172	Elumalai, U.M.	163
Dardiotti, E.	120	Deschamps, N.	60	Dorszewska, J.	174	Emmanuelle, V.	62
Da Re, E.	129, 160	Deschauer, M.	151	Dory-Lautrec, P.	61	Emmanuelle, B.	114
Dar, J.	174	Desco, M.	115	Dostalic, O.	114	Enachi, A.M.	72, 124, 127, 170
Darlix, A.	53	Desestret, V.	105	Dostovic, E.	111	Engelborghs, S.	50, 102, 171
Darvizeh, F.	168	Desport, J.-C.	114	Dostovic, Z.	111	Engelster, S.	51
Dashti, D.	66	Deuschl, G.	40, 94, 192	Dotti, M.T.	77, 133, 134, 184	Engelster, S.T.	111, 158
Dauball, B.	111	Deverdun, J.	53	Doubal, F.	77	Engsig, M.	127
Daumas, A.	111	Devic, P.	64	Doudoux, H.	63, 184	Engstrom, M.	137
Davagnanam, I.	166	Devigili, G.	104	Douma, R.	83	Enomoto, N.	134
David, O.	170	Devilliers, H.	111	Douzenis, A.	171	Enzinger, C.	77, 84, 149, 193, 209
Davies, B.	114	Devinsky, O.	48	Dragancea, I.	106	Epifanov, D.	78
Davis, A.	130, 132	Devos, D.	67	Dragasevic, N.	178	Eraksoy, M.	82, 178
Davy, V.	85	Deymeier, F.	85	Dragasevic, N.	67	Eran, A.	49
Dawkins, H.	118	Dhib-Jalbut, S.	163	Dreier, J.P.	193	Erba, G.	48
Dawson, J.	160	D'hoore, T.	71	Dreo, J.	115	Ercegovic, M.	156
De Albóniga-Chindurza, A.	75, 156	Di Donato, I.	133	Dressel, A.	182	Erdal, A.	125
De Andrés, C.	162	Di Fanzo, A.	67, 80, 115	Drew, D.	103	Erdal, Jesper	149
De Backer, M.	52	Di Fruscio, G.	132, 151	Drislane, F.W.	106	Erdem-Özdamar, S.	72, 120
De Bruijn, M.	135	Di Liberto, D.	130	Droby, A.	163	Erdogan, C.	161
De Carvalho, M.	85	Di Liberto, G.	130	Drolen, C.	169	Erdogan, F.F.	129
De Ceballos Cerrajería, P.	131	Di Lorenzo, G.	134	Druhinin, A.	163	Erik Gillhus, N.	105
De Deyn, P.P.	50, 102	Di Maggio, G.	63, 132, 164		112	Erikh, I.	49
De Felipe Mimbrera, A.	156	Di Meglio, L.	61			Eriksdotter, M.E.	155, 157

Erkelens, C.	84	Feil, Katharina	122	Fonseca, L.	61	Galizia, E.	66
Ernesto, S.	64	Fejes-Szabó, A.	175	Fonseca, M.J.	128	Gallagher, L.	114
Ernst, F.	173	Feketeova, E.	73, 171	Fonseca, S.	61	Gallardo, M.J.	76
Erro, E.	167	Felbecker, A.	170, 176, 185	Fontaine, D.	102	Gallardo Tur, A.	131, 163
Erro, R.	49, 67, 178	Feldt-Rasmussen, U.	73	Fontana, A.	155	Gallasch, E.	104
Ertsey, C.	113, 174	Felgueiras, R.	119	Fontao, L.	135	Gallenmüller, C.	120
Ertuğrul Mut, S.	172	Félix, A.	77, 84, 129	Fontoura, P.	53, 69, 116, 117	Gallenmüller, C.	50
Eruyar, E.	123, 158	Femiano, C.	129, 176	Forbrig, R.	104	Gallo, A.	68, 70, 83
Escalza Cortina, I.	78	Fenclová, Z.	123	Forloni, G.L.	134	Gallo, P.	49
Escartin, A.	162	Fendji, D.	118, 177, 178	Formichi, P.	77	Gallus, G.N.	133
Eschborn, M.	183	Feng, L.	110	Formisano, R.	64	Galluzzi, P.	134
Escobar Montatixe, D.A.	121	Fenoglio, C.	75	Fortea, J.	102	Galluzzi, S.	105, 134
Escobar-Villalba, A.	71, 113, 123, 127, 156	Ferens, A.	156	Fortuna, A.M.	102	Galvin, M.	114, 129, 176
Escriba, J.	113	Ferini Strambi, L.	64, 134, 171	Fortunato, F.	132, 151	Gama, H.	161, 162, 174
Escribano-Paredes, B.	77	Fernandes, A.	180	Forycka, M.	136	Gammelgaard, L.	151
Eser, A.-K.	116	Fernandes, C.	127	Fossati, B.	151	Gandhi, S.K.	163, 164
Eshaghi, A.	49	Fernandes, M.	121	Fouad, M.	65	Gandylyan, K.	169
Eskelinen, M.	75	Fernandez-Alvarez, E.	44	Fox, E.J.	131	Gan-or, Z.	133
Eskes, G.	168	Fernández-de-Las-Peñas, C.	66, 159	Fox, N.	144	Ganos, C.	129
Espasandin, M.	132	Fernández Fernández, Ó.	163	Fox, N.C.	166	Garamendi Ruiz, I.	78
Espay, A.	75	Fernandez-Fournier Ferna, M.	184	Fox, R.	115, 163	Garami, Z.	38
Esperança, P.	166	Fernandez-Fournier, KM.	82	Fraga, C.	122	Garas, M.	69
Espinos, C.	51, 85	Fernández, N.	124	Fragaki, K.	165	Garayoa Irigoyen, V.	78
Espósito, F.	78, 113, 131, 133, 163, 164, 176, 179	Fernandez, O.	131, 141, 162, 179	Fragkiadaki, S.	111, 126, 173	Garcés-Sánchez, M.	185
Esposito, P.F.	70, 129, 151	Fernández-Roblas, R.	176	França, S.	121	García Alonso, L.	119
Essahli, N.	59	Fernández, S.	136	Franchi, C.	48	García Azorin, D.	128
Esserlind, A.-L.	128	Fernandez Sanchez, V.	131, 163	Franchino, G.	81	García, B.	128
Esteban Pérez, J.	51	Fernandez Torron, R.	51	Francione, S.	52, 66, 173	García de Yébenes, J.	114
Estévez Fraga, C.	59, 64, 77, 81, 113, 114, 115, 123	Ferracini, G.	159	Franco, A.	77, 85	García-Estévez, D.A.	128
Eusebi, P.	150	Ferrantino, T.	129	Franco, G.	67, 80	García-García, M.E.	78
Evain, S.	77	Ferrara, M.	77, 129	Frandsen, E.	128	García García, M.E.	79, 166
Evangelopoulos, M.E.	70	Ferrari, C.	75, 134	Frandsen, R.	124, 171	García Gomara, M.J.	78
Evans, K.	163	Ferrari, M.	51, 161	Franke, C.	184	García Lax, N.	119, 133, 165, 175, 179, 180
Evdokimidis, I.	136, 159	Ferraro, P.M.	51, 59, 129	Franz, D.N.	52	García-Lorenzo, D.	49
Evdoshenko, E.	81	Ferreira, A.	157	Frappoz, D.	53	García, M.	51
Everage, N.	164	Ferreira, C.	185	Frasquet Carrera, M.	51, 85, 185	García-Madróna, S.	115
Evers, M.	65	Ferreira, J.	40, 49, 51, 97, 114, 115, 160, 161, 162	Fratello, M.	176	García-Magaña, M.	48
Evoli, A.	135	Ferreira, P.	130	Fredderiksen, J.	136	García Medina, A.M.	119, 133, 165, 175, 179, 180
Evtigneev, V.	79	Ferreira, R.	48, 78	Fredderiksen, J.L.	49, 82, 162, 168	García Merino, J.A.	162
Eweczyk, C.	50	Ferre, L.	131, 164, 179	Fredderiksen, K.S.	75, 109	García Morales, I.	78, 79, 166
Eymard, B.	147	Ferri, R.	171	Freddrikson, Sten	104	García Morales, V.	78
F		Ferro, J.M.M.C.	51, 76, 77, 183	Freedman, M.	131, 162, 204	García Motos, J.A.	165, 179
Fabbrini, M.	114, 176	Ferro, V.	164	Freedman, M.S.	68, 162	García Pellitero, A.	128
Fabbri, S.	70	Ferwerda, B.	175	Freire-Gonçalves, A.	130	García-Ptacek, S.	155, 157
Fabbro, M.	53	Festari, C.	75	Freitas, J.	48, 78, 174	García-Quesada, M.Á.	185
Faber, Marjam	38	Fichera, M.	63, 78	Freitas, S.	64, 150, 157	García Ribas, G.	59, 81
Fabo, D.	173	Fichna, J.P.	71	Frenay, M.	102	García-Ribas, G.	75
Fabregat, N.	136	Fickl, A.	84	French, J.	52	García Rodríguez, J.R.	136
Fabre Pi, Ó.	76, 77	Fidalgo, C.	136	Friberg, C.	65	García-Ruiz, P.	114
Fabricius, M.	65, 193	Fiedler, J.	155	Friberg, H.	106	García Sobrino, T.	51
Facchin, L.	156	Fiedler, U.	105, 134	Friberg, L.	145	García Soldevilla, M.Á.	123
Fagerheim, T.	124	Figarella Branger, D.	53	Friedemann, P.	221	García Torres, M.A.	137
Faghizadeh, S.	169	Figuera, M.R.	158	Friedman, D.	48	García-Torres, M.A.	121, 176
Fahrenkrug, J.	128	Figlewski, K.	104	Friedman, M.	131	Garde, E.	75, 105, 171
Fainardi, E.	131	Figueiroa, S.	102	Friedrich, L.	61, 77, 112, 128	Gardella, E.	52
Faiss, J.	116	Figuerras, A.	120	Frismann, S.	113	Gardiner, A.	49, 165
Falautano, M.	83	Filleccia, E.	60	Frisoni, G.	75, 104, 105, 134	Gardner, C.	40
Falcão, F.	60, 65, 175	Fili, M.	159	Fritz, D.	53	Gardner-Thorpe, C.	184
Falcini, M.	53	Filina, N.	173	Frojkær, V.	65	Garn, H.	76
Falini, A.	49, 50, 51, 71, 83, 102, 103, 109, 122, 129, 132, 150, 157, 164, 168	Filip, P.	134	Froneczek, R.	73	Garren, H.	53, 69, 116, 117
Faller, S.	178	Filippi, M.	49, 51, 59, 67, 68, 72, 80, 83, 84, 102, 103, 104, 106, 109, 115, 122, 129, 131, 132, 144, 150, 151, 157, 160, 163, 164, 168, 179, 189, 193	Frystyk, J.	171	Garrido, C.	102
Falup-Pecurariu, C.	73	Filippini, G.	109, 116	Ftld-Konsortium, D.	177	Garza, I.	128
Falzone, Y.	51, 160	Filippini, N.	84	Fuchs, A.	162	Garzetti, L.	115
Falzone, Y.M.	85	Filla, A.	49, 96, 157	Fuchs, S.	84	Gasecki, D.	110, 126
Fam, S.	162	Filocamo, M.	129	Fuglsang-Frederiksen, A.	137	Gaspard, N.	37, 65
Fan, F.	156	Filosto, M.	129, 151	Fujimura, H.	118, 129	Gasparotto, D.	68, 164
Fanfulla, F.	73	Finardi, A.	115, 130	Fumagalli, G.G.	59, 167	Gass, A.	68, 162
Faouzi, M.	106	Finet-Monnier, A.	83	Fumagalli, S.	104, 122	Gasse, C.	109, 126, 172
Faravelli, I.	70, 114	Fink, G.R.	150	Fu, R.	185	Gastaldi, M.	135
Farbu, E.	178	Finsterer, J.	83, 129, 160	Furlan, R.	82, 115, 121, 130	Gatti, R.	104, 122
Faria de Abreu, L.P.	168	Fior, A.	156	Furtado, A.	137	Gattringer, T.	77, 149
Farias, J.P.	167	Fiore, D.	68	G		Gauci, J.	136
Farias Serratos, C.V.	159	Fiorino, A.	102	Gabbi, P.	158	Gaul, C.	150, 158
Farias Serratos, F.	119, 159	Fischer, U.	44, 77, 149	Gabelic, T.	63, 164	Gavan, C.	117
Farid-Zahran Osuna, M.	128	Fisher, P.	65	Gabriel, D.	170	Gavaret, M.	48
Farina, A.	82	Fisher, P.M.	134	Gadegaard Olsen, T.	136	Gavriliuc, E.	170
Farkas, Z.	160	Fisher, R.S.	65	Gadourek, P.	123	Gavriliuc, M.	159
Farooq, K.	162	Fitas, D.	85, 123, 127, 129	Gaebel, C.	110	Gavriliuc, O.	134
Farrimond, L.	114	Fitsioris, X.	113	Gaetano, L.	103, 132	Gaynard, B.	136, 168
Fasano, A.	77	Fitzpatrick, R.	160	Gafarova, M.	61	Gaziz, B.	72
Fastré, S.	84	Fleischmann, R.	64	Gaglia, E.	69	Gazova, I.	111
Fatima, M.	77	Flesch, G.	66	Gago, M.A.S.F.	183	Gdovinova, Z.	61, 151, 171
Fattori, F.	180	Flisar, D.	115	Gago-Veiga, A.	127	Geda, Y.	104
Faude, U.	118, 177, 178	Florczak, A.	174	Gago-Veiga, A.B.	78	Gedizlioglu, M.	69
Fayemendy, P.	114	Florczak-Wypianska, J.	174	Gaist, D.	50, 105	Geevarghese, H.	113
Fazekas, F.	77, 84, 143, 149, 176	Florea, C.	104, 105, 134, 168	Gak, S.	150	Geilenkeuser, M.	82
Fazekas, G.	77	Florencio, L.	159	Gal, A.	185	Geisler, P.	124
Fazio, R.	51, 85, 163, 170	Foged, M.T.	52, 66	Galán, I.	103	Gelener, P.	61, 71
Fechtenbaum, L.	162	Fogli, A.	176	Galán, L.	124	Gellera, C.	129, 176
Federico, A.	50, 77, 92, 133, 134, 147, 184, 194	Fois, C.	66, 71, 161, 176, 183	Galantucci, S.	67, 83, 115	Gelpy, M.	161
Federico, F.	114	Foley, F.	131	Galantucc, S.	106	Genç, F.	125
Fedotova, E.	134	Folynie, T.	149, 151, 161, 178	Galassi, G.	170	Genge, A.	83
Fedulov, A.	71, 83	Folyovich, A.	77	Galbiati, A.	64, 171	Gennuso, M.	85
Feil, K.	106, 122	Fong, W.C.	111	Galbiati, S.	72	Genov, K.	64, 169
		Fonseca, A.C.G.	60, 64, 76, 159	Galea, R.	121	Georgiev, D.	117
		Fonseca, C.	172	Galego, O.	110, 130, 157	Georgiou, E.	166
				Galego, S.	156	Geraldes, C.	72
				Galeotti, M.	81	Geraldes, T.	61, 83, 149
				Galimberti, D.	59, 75, 167	Geraldes, V.	175

Geraldo, A.	72	Gonzalez-Aguilar, A.	167	Guerra, U.	75	Hardy, J.	129, 160, 176
Geraldo, A.P.	124, 137, 180	Gonzalez-Gomez, F.J.	77	Guerreiro Martins, T.	76	Harigaya, Y.	214
Gerard, L.	125	González Gómez, F.J.	156	Guerreiro, R.	132	Harikrishnan, S.	109
Gerritsen, M.	84	Gonzalez Hernandez, A.	76, 77, 136	Guerrero, A.L.	66, 113, 124, 128	Harington, G.	69
Gersamiya, A.	66	Gonzalez, J. Roquer	61	Guerrero Fernandez, M.	163	Harington, G.	70, 117
Gerstenbrand, F.	104, 105, 134, 168	González-Sarmiento, R.	125	Guerrero-Lopez, R.	66, 128	Harichian, M.H.	177
Ghafoorfard, S.	150	González-Suárez, I.	131	Guerrero, M.	131	Harizi, E.	169
Ghahramanyan, L.	170	González-Suárez, I.	68, 131, 163	Guerrero Peral, A.L.	66, 79, 128	Haroche, J.	119
Ghanima, W.	110	Gonzalo, N.	113	Guerrero Peral, A.L.	158, 159, 175	Harries, L.	76
Ghasemi, M.	79	Goodman, A.	150, 158	Guerrero, R.	109	Harrison, J.	178
Gheorghievici, S.	133	Gordon, C.	48	Guerrero-Ramos, M.Á.	119	Harrison, P.J.	111
Ghetti, B.	75	Gordon, D.	114, 176	Guerrero Sola, A.	51	Harriss, J.	121
Ghezzi, A.	49, 68, 102, 116, 157, 164	Gorelyk, A.L.	112	Guerreri, S.	63, 71, 113, 132, 160, 164	Hart, P.	169
Ghidoni, R.	102	Goretti, B.	49	Gueudry, J.	162	Hartung, H.-P.	167
Ghiretti, R.	59	Gorincioi, N.	63	Guevara, E.	76	Harutyunyan, G.	53, 69, 103, 116, 131, 162, 163, 178
Ghitou, A.M.	170	Gorno-Tempini, M.L.	104	Guger, M.	65	Hasan, A.	135, 166
Ghosh, S.	70	Gorosquieta, A.	167	Guggenberger, S.	65	Hashida, H.	65
Ghosn, M.	174	Gorroño-Echebarria, M.B.	117	Guggisberg, A.	104	Hashim, H.	171
Giacino, J.	41	Gospodinova, M.	120	Guidotti, M.	133	Hashim, H.	126, 155
Giannini, F.	85	Goto, M.	134	Guignebert, A.	123	Haslum, K.	113
Giannino, V.	115	Gottlieb, A.	168	Guillamo, J.-S.	53	Hasselbalch, S.	75, 109, 150, 192
Giannoccaro, M.P.	60, 106, 133	Gottrup, H.	171	Guillemot, V.	49, 80	Hasselbalch, S.G.	75, 109, 155, 171
Gibbs, S.	52, 66	Gouider, R.	69	Guillén-Martinez, V.	135	Hassine, A.	83
Gieß, R.	180	Goursky, I.	115, 122, 128	Guillemin, R.	53	Hasson, T.	69
Gigineishvili, D.	162	Gout, O.	103	Guillon, B.	77	Hass, S.	162
Gilev, D.V.	174	Gouveia, A.	72, 110, 130	Guimaraes, J.	74, 81, 82	Hastrup, S.	62, 149
Gilhus, N.E.	149, 173	Govi, M.	151	Guirao, C.	75	Hatsuta, H.	109
Gil-Kulik, P.	173	Govoni, A.	70, 151	Gujjar, A.	64	Hauerberg, J.	65
Gille, M.	84	Gow, A.J.	77	Gulbe, G.	164	Hauer, L.	135
Gil-Nagel, A.	113, 173, 192	Gozalov, A.	150	Güler, S.	115, 128, 129	Haugaa, K.H.	66
Gimenez-Martinez, J.	116	Gozé, C.	53	Gültekin, M.	129	Hau, P.	149
Giobbe, D.	61	Gozke, E.	83	Gulyás, S.	160	Hauptenthal, F.	158
Giobbe, M.L.	61	Grabek Gawlowicz, M.	173	Gundogdu, C.	125	Haupts, M.	178
Gjoltzoglou, T.	80	Grabli, D.	177	Gunduz, T.	82, 120, 166, 178	Haupts, M.R.	178
Giometto, B.	121	Grabova, S.	174	Günes, H.N.	72, 78, 167, 173	Hauschild, P.	76
Giora, E.	64	Graça, J.	174	Guo, S.	128, 129, 150	Hauser, S.	53, 69, 116
Giordano, A.	63, 113, 151, 175	Graff, C.	102	Gupta, S.	130	Haverkamp, W.	82
Giorgi, M.	61	Gralla, J.	77, 149	Gupta, Y.K.	66	Havrdova, E.	82, 149, 178
Giorgio, A.	130	Grambalova, Z.	129	Gurary, N.M.	67	Havrdová, E.	214
Giovannoni, G.	53, 117, 130, 162, 163, 178, 179, 214	Grammatico, M.	116	Gurevich, T.	59	Havsteen, I.	51, 62
Giraldez, B.G.	66, 128	Grammatiki, M.	136	Gürkan, H.	128	Hay, A.	106
Giraldo, N.	70, 76	Grampa, G.	133	Guro, G.	173	Hayden, M.	69
Giraldo Restrepo, N.	62, 83	Gramza, K.	76	Gursan, N.	183	Hazim, A.	77
Giralt-Steinhauer, E.	61	Granata, F.	151	Gustavsen, S.	178	He, A.	180
Girardot-Tinant, N.	132	Granda, G.	81	Gutbrod, K.	182	Head, M.	133
Giray, E.	63	Grandas Pérez, F.J.	115	Gutierrez, A.	159	Hecimovic, H.	173
Girbovan, A.	109	Grande, G.	59, 109	Gutiérrez-Viedma, Á.	113	Hedberg-Oldfors, C.	180
Giroud, M.	51, 110, 111	Grandis, M.	170	Gutiérrez-Zúñiga, R.	74, 135	Heegaard, N.	51, 178
Gitman, A.	183	Grand, S.	53	Gutowski, Nicholas	178	Heesen, C.	184, 191
Giuliani, L.	49	Granella, F.	81	Gutowski, N.J.	178	Heger, A.	176
Giurea Neacsu, G.	72	Granieri, E.	131	Guye, M.	129	Heidbreder, A.	73
Giurea Neacsu, M.G.	113, 170	Grapperon, A.M.	83, 129	Guzmán-de-Villoria, J.A.	115	Heide, W.	73
Giussani, G.	48	Grau, D.	121	Györfi, O.	126, 130	Heide, Wolfgang	150
Giustini, M.	64	Graus, F.	105	Györgyi Md. T.	183	Heinskou, T.B.	150
Giyyazidinova, E.	62, 109, 127, 160, 177	Grebe, P.	185	Gyüre, T.	113, 174	Heje, K.	185
Gizatullin, R.	168	Grecogvasc, S.G.	150			Hejgaard Laursen, J.	178
Gkika, L.	159	Greco, L.	59			Hejl, A.-M.	178
Gleissner, E.	179	Greco, N.	133	H		Helbok, R.	64, 193
Glmür, C.	48	Green, D.	178	Haanpaa, M.	147	Heldner, M.R.	149
Gnanapavan, S.	162	Green, L.	177	Haase, R.	48	Helle, J.R.	62
Gnedovskaya, E.	123	Gregoric Kramberger, M.	157	Haas, J.	82, 117, 118, 178, 179	Hell, F.	177
Gnezditsky, V.V.	59	Gregori, J.	162	Haas, S.	65	Hellriegel, H.	184
Goadsby, P.	89, 146, 150	Grigoriadis, N.	80	Habek, M.	59, 60, 63, 68, 76, 164	Hellwig, Kerstin	218
Goadsby, P.J.	105	Grima, A.P.	60	Habetswallner, F.	160	Helmstaedter, C.	173
Gobbi, C.	116, 124	Grima, B.	137	Habich, A.	70	Hemmer, B.	53, 117, 131
Gobej, I.	167	Grimaldi, S.	62	Hacein-Bey, S.	137	Hendricks, R.	69
Gøbel Madsen, C.	105	Grimaud, O.	179	Hackner, H.	73	Hendrikse, J.	171
Godava, M.	119, 177	Grimoldi, N.	132	Haajigeorgiou, G.	120	Hengelbrock, J.	127
Godefroy, M.P.O.	151	Grinberg, L.	104	Haajivassiliou, M.	121	Henriksen, T.	51
Godefroy, O.	106, 150	Grinea, A.-I.	168	Haegle-Link, S.	151	Henry, R.	50
Godek, M.	158	Grinspan, A.	163, 164	Haf Davies, E.	209	Hensel, O.	174
Godfrey, R.	165	Grishkina, M.	66	Hagen, E.M.	60, 76	Hentati, F.	76, 124
Goebel, H.	120	Gris, M.	69	Hagos, S.	73	Henykova, E.	130
Goetz, C.	151, 178	Grisold, A.	53, 121	Hahn, C.	77	Hermann, D.M.	156
Goff, F. Le	162	Grisold, W.	53	Haidar, G.	168	Hernandez, A.	70, 76, 83
Gökçal, E.	167	Grisold, Wolfgang	40	Hajric, S.	178	Hernández, J.	109
Gökçay, F.	122	Groppa, S.	61, 63, 127	Hakala, A.	184	Hernandez, J.J.	170
Gökçe Çokal, B.	78, 173	Gross, C.C.	183	Haller, V.	66	Hernández, M.Á.	162
Golaszewski, S.	104, 105, 168	Grossegger, D.	76	Halpern, R.	164	Hernandez Navarro, P.	123
Golaszewski, S.M.	134	Grossi, P.	49	Halvorsen, B.	110	Hernández Navarro, P.	117, 137
Goldobin, V.	62	Grossman, I.	109, 119, 185	Hamberger, M.	65	Hernández Ortiz, O.E.	62
Gold, R.	163	Grosz, Z.	65	Hamdy, M.	111, 134	Hernando, A.	158
Gold, Ralf	162	Gruber, F.	65	Hanada, R.	69	Hernando-Requejo, V.	112
Goldsher, D.	49	Grudkova, M.	120	Hanaf, Z.	127	Herranz, A.	176
Golenia, A.	156	Grunho, M.D.	61, 83, 127, 128, 183	Hanağasi, H.A.	166	Herrero Prieto, M.E.	125
Golovacheva, V.	128	Gruppetta, M.	121	Han, J.	78	Herrero, S.	158
Gömceli, Y.	125	Grytten, N.	178	Han, J.H.	79	Herrlinger, U.	149
Gomez, A.	61	Grzybowska-Ganszczyk, D.	71	Hankollari, J.	173	Herrmann, F.	48
Gómez-Andrés, D.	62, 68, 163	Guadagno, J.	76	Hanna, M.	83	Hershenson, J.	132
Gómez Cárdenas, C.P.	119	Guan, J.	84	Hanna, M.G.	49	Hert, L.	51, 111, 158
Gómez Eguilaz, M.	78	Guarda, C.S.S.	61	Hanna, M.G.	49	Herzig, R.	59, 149
Gómez Esteban, J.C.	78	Guardasole, V.	49	Hansen, C.K.	51, 62	Hesdorffer, D.	48
Gomis, C.	185	Guarneri, V.	160	Hansen, E.K.	175	Hes, K.	155
Gonçalves, A.	80	Guaschino, C.	133	Hansen, J.M.	105	Heverin, M.	129
Gonçalves-Rocha, M.	102	Guclu-Gunduz, A.	122	Hansen, K.	51, 65	Hicham, C.	156
Goncharova, Z.	116, 161	Guedes, L.	161, 183	Hansen, M.H.	52, 170	Hicking, C.	117, 130
Gonderten, N.	156	Guedj, E.	114	Hansen, R.D.	128	Hidalgo, H.	124
Gönen, M.	61	Guekht, A.	66, 123, 169, 173	Hansen, Y.B.L.	128	Hidalgo Pareja, H.	73, 124
Gontika, M.	135	Guekht, Alla	65	Han, S.W.	79	Hilal, H.	74
Gonzales, M.	185	Guergelcheva, V.	134	Han, V.	61, 178	Hilkman, D.	77
Gonzalez, A.	66	Guergeltcheva, V.	120	Harbo, T.	62, 137	Hillert, J.	119, 217
		Guerra-Schulz, E.	131	Hardiman, O.	51, 78, 112, 114,		

Hilmarsen, H.T.	62	Ilgezdi, I.	117	Jensen-Dahm, C.	170, 171	Karakostas, D.	80
Hilton-Jones, D.	165	Iliceto, G.	133	Jensen-Dahm, C.E.-A.	126, 172	Karakov, K.	169
Hilz, M.	48, 60, 75, 76	Ilic, T.	124	Jensen, P.	109	Karakov, S.	162
Hilz, Max J.	98	Ilic, V.	132	Jensen, P.	110, 134	Karamyan, A.	64, 73, 135, 166, 170
Hira, M.	109	Ilijicov, A.K.	183	Jensen, R.	66, 150, 158, 174	Karanfilovic, I.	156
Hirano, M.	62, 129	Ilkowsky, J.	72	Jensen, Rigmar	105	Karapolat, H.	122
Hirel, C.	109	Illarioshkin, S.	134, 166	Jensen, Troels S.	147	Kararizou, E.	136, 159
Hirokawa, Y.	134	Illes, Z.	149	Jensen, T.S.	104	Karaszewski, B.	110, 126
Hirsch, E.	173	Imamovic, D.	110, 178	Jensen, U.B.	50	Karatzanis, A.	136
Hishida, R.	67	Imam, Y.Z.B.	160	Jespersen, B.	158	Karavis, M.	159
Hjermind, L.E.	133, 134, 161	Imperiale, F.	59, 109, 151	Jesus, P.	114	Karcewski, J.	174
Hjort, N.	62	Imrell, K.	119	Jesus Ribeiro, J.	79, 110, 130, 175	Kardel, T.	145
Hlávková, J.	123	Inan, L.E.	79	Jianu, D.C.	110, 126	Kareli, M.	162
Hleb, V.	129, 130	Inan, N.	79	Jianu, S.N.	110	Karelis, G.	164
Hlustik, P.	159	Incensi, A.	60, 104, 106	Jiddane, M.	156	Karime, B.	124
Ho, P.-R.	115, 163	Inchingolo, M.V.	77	Jiménez-Conde, J.	61	Karliniski, M.	51
Hoang-Xuan, K.	167, 194	Ines, M.	50, 51	Jiskoot, L.	182	Kárpáti, J.	160
Hobart, J.	163, 164	Ingle, G.	60, 76	Johanidesová, S.	155	Karpov, A.	67
Hodges, J.R.	171	Ingvar Lossius, M.	102	Johannsen, P.	181	Karpova, E.	169
Hoffmann, K.	109	Niesta Valera, J.A.	119, 133, 165, 175, 179, 180	Johansen, C.	53	Karpov, S.	67, 72, 80, 169
Hoffmann, S.	162	Inoo, M.	69	Johansen, H.	110	Karrenbauer, V.D.	68
Höfler, J.	52, 173	Inoue, K.	129	Jo, K.D.	83, 136	Karsidag, S.	182
Höftberger, R.	121	Inshasi, J.	174	Jonsrud, C.	124, 151	Karwat, J.	173
Høgh, P.	75, 109, 155	Introna, A.	114	Joo, J.J.	79	Kasatkina, D.	69
Högl, B.	52, 73	Ioakeimidis, M.	111, 173	Joosten, A.	218	Kasch, H.	104
Högl, Birgit	90	Ioan, B.	170	Jopowicz, A.	174	Kasper, E.	121
Højgaard, J.	65	Iodice, R.	115	Joshi, D.	66	Kastreva, K.	134
Højs Fabjan, T.	181	Iodice, V.	60, 76	Joubert, B.	105	Kato, H.	182
Holla, Ø.L.	50, 62	Ion, I.M.	79	Jovanovic, D.	44, 66, 156	Katsavos, S.	135
Holl, E.	167	Ionova, O.	130	Jovicich, J.	105	Katsiardanis, K.	113, 182
Holley, J.	178	Iorio, R.	135	Jovic, N.	102	Katyal, J.	66
Holloway, G.	133	Ippen, F.	121	Jozef, M.	81	Kaufman, E.	135
Holm, E.	66, 158	Ippolito, D.	134	Juanatey, A.	66, 79, 128	Kaukonen, K.-M.	106
Holmes, P.	159	Ip, V.	156	Junaković, A.	59, 68, 76	Kawai, M.	118
Hongell, K.	179	Irani, S.	135	Jungbluth, H.	165	Kawasaki, A.	44
Honnorat, J.	105	Iranzo, A.	39	Jung, S.	77, 149	Kayabasi, U.A.	104
Horakova, D.	149	Irkeç, C.	122, 135	Jurcau, A.	130, 156	Kaya, H.	156
Horne, M.	130	Isaacs, A.	181	Jürgens, T.	89, 97, 150, 158	Kayki, Y.	126
Horn, J.	106	Isaacs, J.	66	Jurjans, K.	110	Kazinczy, R.	77
Hornýák, C.	183	Isaakidou, A.	167	Jurkeviciene, G.	79	Kazmierski, R.	135, 136
Hort, J.	45, 64, 111, 125, 155, 171	Isak, B.	137	Jurova, B.	74	Kazymova, I.	126
Hörtnagel, K.	120	Isakova, E.	126	Jusufo, I.	127	Kearney, H.	68, 83
Horvath, A.	109	Işeri, P.	84	K		Kediha, M.I.	119
Horvath-Mechtler, B.	53	Ishikawa, M.	109	Kacem, I.	69	Keereman, V.	48
Horvath, T.	73	Isidoro, L.D.A.M.M.	157	Kadanka Jr., Z.	74	Kefalopoulou, Z.	149, 151
Horvat Ledinek, A.	179	Ismail, I.	83	Kadanka, Z.	74	Kegler, A.	158
Horyniecki, M.	110	Ismoilov, R.	72	Kadukov, A.	84	Kele, P.	125
Hösl, K.	60, 75, 76	Ito, T.	134	Kaelin, A.	124	Keller Sarmiento, I.	131
Hougaard, A.	105	Iurciuc, S.	127	Kafadar, C.	71, 79	Kell, S.	130
Houillier, C.	167	Ivanchyk, H.	182	Kagiava, A.	166	Kelly, L.	160
Houlden, H.	49, 120, 133, 142, 165, 166, 170	Ivanova, D.	78	Kägi, G.	151	Kemthofer, M.	76
Houria, B.	136	Ivanova, M.	68	Kaimovskiy, I.	66	Kemlink, M.D.	73, 125
Houston, P.	83	Ivanova, S.	117	Kaindlstorfer, A.	65	Kempfner, L.	170
Howard, J.F.	214	Ivanov, B.	72	Kaiserova, M.	119, 129, 130, 134, 177	Kemppainen, N.	155
Høyer, H.	50	Iversen, H.K.	51, 73, 123	Kajtazi, N.	135	Kenina, V.	164
Hoyo, B.	113	Iversen, P.	105	Kalantzakou, T.	113, 118, 182	Kennard, C.	143, 184
Hrbac, T.	149	Iwanowski, P.	135	Kalarus, Z.	174	Kennedy, P.	37
Hsieh, K.	149	Iwata, M.	171	Kalaydjieva, L.	120	Kentepozidis, N.	167
Huachan, L.	136	Iwata, Y.	118	Kalbus, O.	118	Keret, O.	50
Huang, M.-Y.	179	Izğum, V.	67	Kaleagasi, H.	80	Kerkovsky, M.	74
Huang, S.-C.	179	Izboldina, O.	60, 178	Kalejs, O.	110	Kern, R.	118
Hubbard, H.	104	Izboldina, O.P.	81, 112, 125, 177	Kalelov, Z.	72	Kerschenssteiner, M.	189
Hudeček, D.	155	Izquierdo-Robert, L.	48	Kale, N.	68, 126	Keskin Güler, S.	78
Hudson, J.	151	Izzi, F.	52	Kalincik, T.	149	Ketter, R.	149
Huertas-González, N.	112	J		Kalinowska-Lyszczarz, A.	136	Khachatryan, S.	73, 170
Hughes, D.	166	Jachacz-Lopata, M.	175	Kaller, C.	103	Khalili, M.	179
Huhmar, H.	169	Jack, C.	104	Kallweit, U.	52, 73, 124	Khalil, M.	149
Hu, M.	103	Jackson, G.	106	Kallweit, Ulf	124	Khalimova, K.	79, 165
Humbert, S.	50	Jacobi, C.	127	Kalman, B.	185	Khan, F.	170
Hummel, T.	75	Jacobi, G.	106	Kaloshi, G.	71	Khan, M.	126, 155
Hundsberger, T.	121, 170, 185	Jacobsen, A.	106	Kalousek, V.	109	Khan, S.	130
Hupperts, R.	183	Jacobsen, L.	121, 135	Kalss, G.	52	Khatami, R.	39, 52
Hupperts, R.M.	179	Jacobs, S.	214	Kälviäinen, R.	48, 97, 144	Khatkova, S.	169
Hurtado, I.	131	Jacques Lemaire, J.	41	Kälviäinen, R.K.	173	Khatrri, B.	82, 163
Husain, M.	103	Jacquet, C.	110	Kalyoncu Aslan, I.	83	Khatrri, I.	60
Hussain, M.	113	Jafaar, I.	127	Kaminska, A.	71	Khazaeili, M.	79
Hussain, R.	102	Jaffer, F.	49	Kamondi, A.	109, 160	Khefffi, A.	83
Hustić, I.	65, 109	Jagerschmidt, A.	183	Kamsteeg, E.-J.	133	Khneisser, E.	171
Hutchinson, S.	112	Jagust, W.	104	Kanat, A.	125	Khorvash, F.	79
Hviid Simonsen, A.	155	Jahn, P.	174	Kang, I.U.	174	Khudayarova, S.	79, 165
Hvilsted Nielsen, H.	105	Jahn, K.	106, 168, 177, 184	Kang, S.-Y.	118	Kian Kheng, Q.	126
Hvizdosova, L.	134	Jaimes, A.	66, 121	Kanovsky, P.	67, 69, 116, 119, 129, 130, 134, 159, 177, 184	Kidmose, P.	78
Hwang, S.-I.	127	Jakobsen, J.	180, 185	Kantorova, E.	82	Kiechl-Kohlendorfer, U.	65
I		Jandova, K.	82	Kaplan, V.	125	Kiefer, R.	184
Iaccarino, L.	134	Jang, W.	83, 136	Kappo, L.	116	Kilidireas, K.	70
Iachettini, S.	151	Jann, S.	170	Kappos, L.	53, 68, 69, 70, 98, 103, 117, 131, 132, 162, 163, 189	Kilner, J.	161
Iakubenko, I.	79	Janny, S.	123	Kapustina, T.	66	Kilt, H.	66
Iannaccone, S.	59, 134	Jansa, J.	122	Karaahmet, E.	79	Kim, B.	136
Ibáñez, D.	75	Jansky, P.	171	Kara, B.	68, 126	Kim, D.E.	79
Ibanez, M.J.	136, 168	Jansson, M.	53	Karabanov, A.N.	179	Kim, K.S.	174
Ibarburu, M.V.	73, 125	Janszky, J.	125, 160, 177	Karadag, Y.S.	123	Kim, M.-K.	78, 124, 170
Ibrahimagic, O.C.	111	Januário, C.	74, 119, 130, 168	Karadima, G.	120	Kim, O.C.	121
Ibrahim Mohamed Elbrawy, S.	65	Jarius, S.	178	Karadi, K.	125	Kim, Y.	110, 122
Ibsen, J.	78	Jayewardene, A.	65	Karadima, G.	120	Kim, Y.B.	174
Ibsen, R.	51	Jech, R.	80	Karagoz Sakalli, N.	68	Kimiskidis, V.	173
Idbaih, A.	53, 167	Ječmenica Lukić, M.	59, 80, 151	Karaklic, D.	102	Kimmelman, J.	184
Idicula, T.	110	Jeffery, D.	117, 163			Kimura, E.	118
Idris, F.	159	Jehna, M.	149			Kimura, T.	81, 165
Iglesias, F.	158	Jenkinson, C.	160			Kirazli, T.	122
Ikedo, F.	158, 173	Jenkins, T.M.	49			Kirk, R.	165
		Jennum, P.	51, 52, 73, 124,			Kishi, H.	81

Kissani, N.	84, 85, 135	Kotas, R.	175	Kuthan, P.	82	Lebedev, V.	78
Kiss, E.	183	Kotov, A.	126	Kutikov, O.	127	Lebrech, J.	75
Kissin, M.	112	Kotov, S.	122, 126	Kutlu, G.	125	Lebrun-Frenay, C.	102, 103, 182
Kistsen, V.	79	Kotsa, K.	136	Kuwata, Y.	134	Lechner, S.	120
Kitagawa, K.	171	Kotsiubinskaya, J.	175	Kuzibaev, J.	169	Leclercq, D.	77, 167
Kitchener, N.	74	Kotsiubinskiy, A.	66	Kuznetsova, S.	72	Ledig, C.	109
Kivipelto, M.	75, 155	Kotula, L.	173	Kuznetsov, V.	72	Lee, A.	131
Kivrak, E.	156	Kotzamani, D.	120, 136	Kuznetsov, A.	110	Lee, D.-H.	60, 76
Kiziria, M.	162	Kouremenos, E.	167	Kwarciany, M.	110, 126	Lee, J.E.	174
Kjaer, T.	78, 158	Koussa, S.	112			Lee, J.-J.	75
Kjaer, T.W.	52	Koutlas, E.	182			Lee, J.W.	106
Kjellberg, J.	51	Koutsis, G.	70, 120	L		Lee, M.	169
Kkolou, E.	69	Koutsouraki, E.	136	Labarga, A.	119	Lee, M.K.	83, 136
Klarendic, M.	166, 184	Kovacevic, M.	132	Labauge, P.	103	Lees, A.	115, 160, 161, 162
Klein, D.	72	Kovács, A.	160	Labeyrie, C.	137	Lee, S.-W.	110
Kleiner, G.	67	Kovács, G.	83	Laborc, K.F.	175	Lee, S.W.	111, 157
Kleinewietfeld, M.	218	Kovács, M.	125, 160, 177	Labunskiy, D.	118, 184	Lee, T. H.	111
Kleisoura, A.	173	Kovacs, N.	125, 151, 160, 177, 178	Labuz-Roszak, B.	110, 174	Lee, T.H.	157
Kleopa, K.	166	Kovács, T.	72, 183	Lacerda, L.	133	Lefaucheur, R.	162
Klimiec, E.	126	Kovalchka, L.	164	Lacka-Gazdzik, B.	110	Le Floch, A.	79
Klingelhöfer, L.	129, 130	Kovalova, I.	74	Lacomblez, L.	123, 177	Leforestier, N.	123
Klingelschmitt, G.	53, 69, 116	Kovalska, M.P.	73, 125	Laczó, J.	64, 111, 125, 155, 171	Lefranc, M.	106, 151
Klobucnikova, K.	156	Kovari, H.	182	Ladeira, F.	110, 121, 166	Leger, A.	76
Klocheva, E.	62	Kowacs, P.	158, 173	Ladkani, D.	69	Légar, A.	77
Kloek, A.	175	Kowalczyk, K.	110, 126	La Franca, G.	174	Legostaeva, L.	123
Kloesch, G.	76	Kozubski, W.	136, 174	Lagae, Lieven	102	Legris, N.	111
Klooster, D.	78	Kozyolkina, O.	110	Lagan-Jedrzejczyk, U.	174	Legros, B.	65
Klöppel, S.	103	Kozyolkina, O.A.	122, 123	Laganke, C.	163	Lehericy, S.	49
Klopstock, T.	50, 120	Kraemmer, J.	49, 80	Lagoda, D.	59	Lehericy, Stephane	193
Klose, M.	73	Krafczyk, S.	122	Laigle-Donadey, F.	53	Lehmann, D.	151
Klotz, L.	117, 118, 183	Krahulik, D.	67	Lainez, J.M.	150, 158	Leila, B.A.	68
Klugmann, M.	166	Krajicková, D.	149	Lakatos, P.	183	Leinonen, V.	169
Klyushnikov, S.	134	Krajina, A.	149	Lakshmanan, R.	166	Leist, T.	117, 162
Kmetska, K.	117, 20	Králiková, E.	73	Laksiri, N.	61, 62	Leist, T.P.	162
Kneihs, M.	149	Kramberger Gregoric, M.	115, 155	Lalli, S.	161	Leitão, L.	174
Knezevic-Apostolski, S.	71	Kramer, L.	135	La Mantia, L.	116	Leitão, M.J.	150
Knopman, D.	104	Krarup, C.	72, 96, 124, 185	Lamberti, P.	133	Leitinger, M.	52, 135, 166
Knudsen, G.M.	65, 110	Krasensky, J.	82, 149	La Morgia, J.	136	Lemos, J.M.G.	133, 168, 183
Knudsen, L.V.	110, 134	Krause, S.	120	Lamoril, J.	181	Lemos, R.	150
Kobasic, I.	65	Kraya, T.	174, 175	Lampreia, T.	121, 166, 183	Lemstra, A.	109
Kobayashi, A.	61, 92	Krayenbühl, N.	48	Landesman, Y.	169	Langlet, T.	114, 123
Kobayashi, H.	67	Krbec, M.	74	Landis, Theodor	103	Lengyel, A.	119
Kobelt, G.	163	Krbot, K.	110	Landsman-Blumberg, P.	179	Lennox, D.G.	103
Kobulashvili, T.	173	Krbot, K.	59, 60, 63, 67, 68, 164	Lafranconi, S.	67	Lenz, R.	105
Kobylecki, C.	182	Kremer, C.	76, 146, 156	Lang, A.	116	Leo, A.	168
Kobzeva, N.R.	174	Kremers, W.	104	Lang, B.	121	Leocani, L.	63, 78, 132, 141, 164, 179
Koc, G.	126, 136	Kremneva, E.	123	Langdon, D.	117	Leonardis, L.	166
Kocher, M.	149	Kresojevic, N.D.	67	Lange, C.	182	Leone, M.	77, 81, 123, 129, 164, 194
Koch-Henriksen, N.J.	82, 103	Kress, B.	127	Langfeldt, L.	73	Leonidou, E.	69
Kocki, J.	173	Krieger, S.	82, 164	Langhammer, C.	149	Leon Martin, A.	131, 163
Kockum, I.	53	Krishnamoorthy, G.	142	Langlois, O.	53	Leonthin, H.	170
Koelbach, R.	131	Krispin, R.	69	Lang, M.	82, 117, 118	Leote, J.	170
Koendgen, H.	115	Kristensen, L.	52	Langthaler, P.B.	52	Lepage, P.	142
Koepke, S.	184	Kristensen, M.G.H.	122	Lannuzel, A.	60, 149	L'Erario, A.	132
Koeppe, M.	97	Krogh Rasmussen, B.	53	Lanzillo, R.	115, 117, 179	Leray, E.	179
Koessler, L.	48	Krølgård, T.	105	Lao-Kaim, N.	149, 151	Lech, O.	155
Kohn, B.	76	Kronbichler, M.	134	Laplaud, D.	103	Le Roux, A.	109
Koikkalainen, J.	109	Krooupa, A.-M.	113	La Porta, A.	84	Lesko, N.	61
Koini, M.	84	Kros, J.	41	Larner, A.	73, 184	Leszczynski, P.	136
Kojan, S.	60	Krpesova, J.	125	Larner, A. J.	166	Lettieri, G.	59
Kokotis, P.	132	Krsek, P.	173	Larner, A.J.	111	Leung, K.	156
Kolb, S.A.	184	Kruetzelmann, A.C.	184	Larsen, C.T.	75	Leung, T.	156
Kolitz, S.	69	Kruja, J.	65, 119, 127, 169, 173, 174	Larsen, I.U.	134	Leung, Y.	116
Kolko, M.	158	Krůtová, M.	185	Larsen, M.	178	Leupold, D.	121, 170, 185
Kollár, B.	156	Kruuse, C.	123, 146, 149	Larsen, V.A.	65, 105	Levähti, E.	155
Kolstad, E.	149, 173	Krystkowiak, P.	106, 151	Larsson, B.W.	123	Levin, O.	125, 151, 178
Komaki, H.	118	Kubiszewska, J.	165	Larsson, H.	105, 123	Levinson, S.R.	72
Komatina, N.	124	Kuchukhidze, G.	52	Larsson, P.G.	66	Lev, N.	50
Komlos, A.	69	Kuchynka, J.	63, 114	Larumbe Ilundain, R.	119	Levy, A.	102
Komoly, S.	160, 165	Kuchyňka, J.	59, 78	Lasek-Bal, A.	163	Lewin, J.	115
Kondratiuk, K.	126	Kucora, A.	128	Lasocha, B.	156	Lewis-Smith, D.	102
Kondziella, D.	65, 84, 106, 149, 191	Kudabaev, E.	72	Lassek, C.	117, 118	Lewis, S.	40
Konovalov, R.	61, 84	Kuesters, G.	115, 163	Lassmann, H.	37, 82	Leyboldt, F.	166
Kon, S.	165	Kuhelj, R.	69	Lassuthová, P.	185	Leys, D.	109, 110, 127
Konstantinidis, G.	136	Kuiper, M.A.	106	Laštovková, A.	123	Leyton, C.	171
Kontaxopoulou, D.	111, 126, 173	Kujuro, Y.	125	Latino, M.R.	77	Leyva, L.	131
Koopmans, M.	50	Kuks, Jan	99, 183	Latorre, D.	52	Li, C.	116
Korchut, A.	109, 158, 169	Kulesh, S.	173	Latsoudis, H.	120	Li, D.	173
Korczyński, A.D.	59, 204	Kuliha, M.	149	Latyпова, A.V.	81, 112, 125, 177	Li, K.	48
Koritnik, B.	78, 180	Kulisevsky, J.	97	Lauckaite, K.	79	Liaño Sanchez, T.	79, 128, 166
Korlipara, P.	161	Kuljic Obradovic, D.	177	Lauer, K. J.	82	Liantinioti, C.	173
Kormann, D.	163	Kullmann, D.M.	49	Laurent, D.	83, 165, 180	Liascos, C.	120
Kornblum, C.	217	Kuloğlu, T.	61	Laures, M.	52	Libbrecht, N.	71
Kornfeld, A.	126	Kumar, H.	66	Laureys, S.	41	Liberatore, G.	164
Kornhuber, M.E.	151	Kunchev, T.	69	Lauria, G.	85	Liepiņa, L.	112
Kornum, B.	52	Kunc, P.	114	Laurson, B.	103, 178	Liesirova, K.	77
Koros, C.	126	Kunz, A.B.	104, 105, 168	Laurson, T.M.	48	Lietz, C.	166
Korshnyak, O.	169	Kuo, S.-H.	67	Lauterbach, M.	121	Lighezan, D.	127
Korshnyak, V.	169	Küpper, C.	120	Lavorgna, L.	70, 134	Liguori, A.	157
Korsic, S.	171	Kuqo, A.	127	Lavrnic, D.	71, 73, 124, 165, 180	Liguori, C.	52
Körv, J.	172	Kurca, E.	82	Law, B.	181	Liguori, R.	60, 104, 106, 133, 136, 155, 185
Korzhova, I.	122	Kurkowska-Jastrzebska, I.	51, 76, 174	Law, I.	75, 155	Likhachev, S.	67, 115, 122, 128, 160, 161
Kosac, A.	102	Kurmaku, E.	174	Lawson, J.	52	Likhachev, S.A.	129, 130, 137
Koscak, J.	128	Kurmann, R.	149	Lazarevic, D.	133	Likus, W.	175
Kose, T.	122	Kurme, A.T.	120	Lazaris, A.	104	Lillo, L.	115
Koskderelioglu, A.	69	Kuroda, K.	81	Lazarooae, A.	78, 121	Limmroth, V.	82, 164
Kostera-Pruszczyk, A.	118, 165	Kurt, B.	123	Leal, B.	48, 78, 174	Limousin, N.	65, 79
Kostic, V.	178	Kurtis, M.M.	114	Leal, G.	64	Limousin, P.	161, 194
Kostic, V.S.	59, 67, 80, 106, 109, 115, 151	Kürtüncü, M.	82, 120, 166, 178	Le Bars, E.	53	Lim, S.-Y.	177
Kostov, K.	64	Kuru, P.	63	Lebeda, A.	151	Linares, M.	171
Kotan, D.	125, 173, 183			Lebeda, T.	123	Lin, C.-Y.	67
				Lebedeva, A.	66		
				Lebedeva, E.R.	67, 174		

Lindauer, C.	48	Lozano García-Caro, L.A.	137	Malandrini, A.	50	Martínez-Castrillo, J.C.	114, 115
Lindberg-Larsen, A.H.	52	Lozza, M.A.	79	Maldonado-Vega, M.	119, 159	Martínez, E.	113, 128, 175
Lindelof, M.	71, 123, 127	Lubetzki, C.	49, 69	Malecki, A.	71	Martínez, J.	115
Lindgren, A.	192	Lublin, F.	53, 68, 69, 116	Malhotra, A.	124	Martínez Fernández, C.	179
Lindner, M.	183	Lubrini, G.	82	Malhotra, P.A.	150	Martínez-Martin, P.	151, 177, 178
Lindquist, S.G.	133	Lucas, B.	111	Malik, Y.	174	Martínez-Merino, L.	167
Lin, H.	166, 174	Luciano-García, Z.	112	Malinova, V.	122	Martínez Navarro, M.L.	119, 133, 165, 175, 179, 180
Linhares, P.	121	Ludolph, A.	98	Mallia, M.	60, 121	Martínez Pueyo, A.	121
Lin, J.	73	Luef, G.	65, 144	Mallia, Maria	121	Martínez Salcedo, E.	179
Lin, J.P.	44	Lugaresi, A.	81	Mallucci, G.	68	Martínez-Ulloa, P.	71, 123, 127, 156, 166
Linker, R.	76	Luijckx, G.J.	84	Malmgren, K.	173	Martínez Velasco, E.	66, 79, 128, 158
Linker, R.A.	60	Luis-García, R.	175	Malojčić, B.	59, 63	Martínez Yelamos, S.	120, 162
Lipatova, L.	66	Luissin, M.	127	Maltete, D.	102	Martin-Gonzalo, J.A.	62, 68, 161, 163
Lipowska, M.	118, 165	Lukas, C.	68, 83	Maltse, S.	53	Martini, R.	72
Lisá, I.	166	Lukic, S.	158	Malucchi, S.	173	Martin, J.-J.	50
Lisak, M.	63	Lund, N.	66, 174	Mameniskiēne, R.	59	Martin Llorente, C.	84
Lisnic, V.	50	Lunetta, C.	51	Mañanes-Barral, V.	81	Martins, A.	65
Lisy, L.	166	Lungu, V.	72, 124, 127	Mancardi, G.L.	63	Martins, A.I.	110
Li, T.	52	Lupat, A.	127	Mancini, G.	52, 73, 170	Martin Sánchez, F.J.	128
Li, T.C.	111	Luppi, P.-H.	39	Manconi, M.	104	Martins Da Silva, A.	48, 78, 174
Litman, M.H.	52, 158	Lupusor, A.	73	Mandelli, M.L.	66	Martins Da Silva, B.	48, 78, 174
Litovchenko, T.	79	Luque de Castro, M.D.	114	Mandia, D.	59, 106, 109, 132	Martins, E.	102
Little, A.	190	Luquin, R.	110	Mandic-Stojmenovic, G.	120	Martins, J.	59, 168
Litwin, T.	80	Lurina, B.	110	Mañe, M.A.	85	Martins, M.	102
Liu, M.	60, 75, 76	Lus, G.	179	Manita, M.	96	Martins, R.	65, 137, 175
Liu, Y.	155	Lushchik, H.	137	Manji, H.	174	Martins Silva, A.	176
Liuzzi, D.	49	Lušić, I.	76	Manka-Gacca, I.	103	Marti, P.	118
Livitzis, E.	136	Lušić, L.	125	Manohar, S.	112, 119, 125	Marto, J.P.	76, 111, 121, 183
Livonius-Freifrau von Eyb, B.	50, 120	Lyashenko, E.	125	Manso Calderón, R.	137, 175	Marusic, P.	173, 184
Li, W.	149	Lycke, J.	82, 164	Manso, R.	162, 172	Maruszak, A.	71
Li, Y.	180	Lynch, D.	120, 166	Mansour, M.	82, 142	Maruta, C.	64
Lizrova Preiningerova, J.	82	Lynch, David	165	Maquet, P.	52	Maryem, B.	125
Ljubisavljevic, S.	82	Lynch, T.	141	Maquet, Pierre	115	Maryenko, I.	137, 160
Lladó, A.	102	Lynch, Timothy	151	Marantz, J.	113	Mascia, E.	131, 133
Lleó, A.	102	Lyrer, P.	51	Márceanu, M.R.	174	Mascia, M.	67
Llufriu, S.	179	Lyrer, P.A.	111, 158	Marchese, F.	174	Mashin, V.	126, 159
Lobato, R.	85, 123, 129	Lysandropoulos, A.	209	Marchese, P.	106	Masi, G.	120
Lobellová, V.	111	Lysogorskaia, E.	166	Marchi, N.	155	Mas, J.-L.	51, 110
Lob, F.	50			Marciniak, R.	133	Masjuan, J.	127, 156
Lobjanidze, N.	112, 177	M		Marcotulli, C.	49	Masjuan Vallejo, J.	77
Lobo, A.P.S.P.	137	Ma, C.	173	Marcuccio, L.	113, 175	Maskery, M.	182
Lo Buono, V.	134	Ma, S.H.	156	Marelli, S.	64, 134, 171	Maskousikh, Y.	83
Lobzin, S.	176	Ma, W.	162	Marenna, S.	179	Maslioh, E.	67
Locatelli, I.	182	Ma, X.	84	Maré, R.J.P.	185	Mason, L.	60, 76
Lochmüller, H.	120, 151	Maamar, M.	156	Mares, J.	69, 116, 129, 130, 184	Masri, A.	127
Lochmüller, H.	118	Maarbjerg, S.	150	Maria, G.A.	170	Massacesi, L.	105, 116, 134
Lockhart, A.	111	Maarouf, A.	129	Margalef, R.	132	Massimetti, G.	70
Lode, K.	178	Macário, M.C.	133	Margolin, D.H.	82, 164, 178, 179	Masterman, D.	53, 69, 116, 117
Lodetti, L.	133	Macerollo, A.	160, 161	Mariani, C.	59, 109	Mastik, J.	175
Lodi, R.	136	Machado, C.	84, 110, 136, 161, 185	Marian, M.	183	Mastrodicasa, E.	63
Loga Andrijić, N.	112	Machado, P.	83, 156	Mariano, M.	156	Masuda, T.	75
Logan, G.	133	Machado, R.	102	Marignier, R.	162	Mataluni, G.	170
Logemann, J.	169	Machio Castello, M.	121, 137	Marimuthu, J.	163	Matarazzo, M.	114
Lo Gerfo, A.	114, 176	Machio, M.	66, 128, 176	Marinas Alejo, A.	78	Matas, E.	120
Logroscino, G.	155	Machowska-Majchrzak, A.	174	Marin, B.	114	Matcau, D.	110, 126
Loiseau, H.	53	Machulda, M.	104	Marinescu, A.	117	Matejčikova, Z.	69, 116
Løkken, N.	161	Macias, A.	71	Marin Marin, J.	119, 133, 165, 175, 179, 180	Matej, R.	155
Lolk, A.	75	Madden, C.	129	Marino, F.	161	Mateos, M.	175
Lomako, R.	166	Madeleine, P.	66, 159	Marino, S.	132, 134, 151	Mathias, A.	167
Lombardi, G.E.	171	Mader, I.	103	Marinou, K.	51	Mathis, J.	73, 170
Lommers, E.	82	Maderna, L.	176	Mariotti, C.	176	Matias-Guiu Antem, J.	68
Longo, E.	64	Madsen, F.F.	52	Marizzoni, M.	105, 134	Matias-Guiu, J.	68, 131
Longo, M.	59, 151	Madsen, K.	53, 75, 179	Marková, H.	111, 171	Matos, A.	72, 119, 124, 137, 180
Lopes, C.	118, 127	Maekura, S.	129	Markova, J.	175	Matoska, V.	125
Lopes, G.	170	Mærsk-Møller, C.	149	Markovska, O.	117, 157, 173	Matsui, M.	118
Lopes, J.M.C.F.	48, 78, 174	Maestri, E.	51	Markovskova, O.	174	Matsumura, T.	118
Lopes, M.	73, 121	Maestroni, S.	179	Markowicz-Pawlus, E.	76	Mattarozzi, K.	81
Lopes, N.	115, 160, 161, 162	Magalhães, A.D.	65, 161, 175	Markulan, O.	85, 185	Matthews, L.	68, 83
Lopez de Munain Arregui, A.	51	Magalhães, M.	72, 178	Markvardsen, L.H.	81	Matthews, P.	189
López de Velasco, V.	131	Magalhães, R.	119	Marnetto, F.	177	Mattioli, F.	49
López, L.	66	Magerová, H.	171	Marois, C.	149	Mattie, H.P.	77
López La Fuente, J.J.	84	Mages, S.	174	Marosi, C.	59	Matur, Z.	85
López-López, J.	62, 161	Maggi, L.	151	Marotta, G.	120	Matute Lozano, C.	156
López-Martínez, M.J.	64	Maggio, R.	161	Marou, E.	131	Maués de Paula, A.	75
López Méndez, P.	136	Maggiore, L.	59	Marques, I.	84	Mauguière, F.	64
López-Mesonero, L.	128	Maggi, P.	134	Marques, I.R.	121	Mauri, E.	70, 132, 151
López-Pérez, F.	131	Magistrelli, L.	161	Marques, J.R.L.D.M.	121	Mauri Llerda, J.A.	78
López Ruiz, P.	82, 176	Magnani, G.	59, 83, 109, 113, 134	Marques-Matos, C.	121	Maurino, J.	116
López Ruiz, R.	127	Magno, S.	174	Marquez Infante, C.	51	Maver, A.	166, 181
Lopez-Sendon, J.L.	81, 114	Magnusson, H.	70	Marsili, A.	49, 115	Máximo, J.	82
Lopez Wolf, D.	84	Magon, S.	103	Marson, T.	45	Maximova, M.	61
Lo Pizzo, M.	130	Magri, F.	70, 132, 151	Marta, M.	176	May, A.	89, 150, 158
Lopushanskaya, T.	175	Maguire, M.	158	Marti Domenech, M.J.	177	Mayer, G.	124
Lo Re, M.	68	Maguire, S.	129, 176	Marti Martínez, P.	185	Mayer, L.	82
Lorenceau, J.	123	Magyar, M.	82, 103	Marti-Massó, J.F.	113	Mayoral, O.	132
Lorio, R.	70	Mahadevan, A.	113, 174	Martin, A.	177	Mayordomo, F.	185
Lo Russo, G.	52, 66	Mahovic Lakusic, D.	121	Martin Bastida, A.	149, 151	Mazanec, R.	183, 185
Losito, S.	54	Maier, M.-S.	63, 72	Martin Bujanda, M.	158	Mazur, B.	110
Loskutnikov, M.	61	Maillard, L.	82	Martin-Duverneuil, N.	53	Mazurkiewicz-Beldzińska, M.	62
Lossius, M.I.	173	Maillard, E.	48	Martin, E.	151	Mazzeo, A.	170
Losurdo, A.	52	Maillart, E.	49, 69	Martinelli Boneschi, F.	78, 104, 131, 132, 133, 164	Mazzini, L.	114
Losy, J.	135	Mai, R.	52	Martinelli, D.	85	McCroskery, P.	162
Lötjönen, J.	109	Mairate, E.	84	Martinelli, I.	160	McDermott, C.	160
Louhab, N.	85	Mairon, N.	69, 117	Martinelli, V.	53, 63, 71, 81, 82, 103, 113, 115, 116, 121, 130, 131, 132, 133, 160, 163, 164, 179	McGregor, S.	130
Loupe, P.	69	Majeed, A.	170	Martineti, G.	124	McGuigan, C.	111, 118, 134
Loureiro, R.	136	Majewski, M.	169	Martinez Castrillo, J.C.	81	McKee, D.	137, 182
Loureiro, E.	161	Majid, S.	73			McKee, E.	137
Lovas, G.	119	Makarenko, O.	175			McKevitt, C.	191
Lovrencic-Huzjan, A.	65	Makkos, A.	125, 160, 177			McKone, E.	118
Lovrić, M.	59, 68	Makowicz, G.	66			McNicholas, N.	118
Lowes, L.	83	Maksymowicz, W.	70				
Loyoddin, M.	53	Malagú, S.	81				

Meani, A.	59, 83, 103, 132	Milesi, J.	168	Montes, V.	132	Myslimi, F.	127
Mecharles, S.	149	Miletic, V.	67	Monti, L.	134		
Mecacci, P.	109	Milheiro, M.	84	Montini, F.	104		
Medagliani, S.	63, 164	Milic Rasic, V.	124	Montejo Villasanta, M.T.	137	N	
Meden, P.	110	Militaru, A.G.	127	Montoya, J.	113	Nabbout, R.	52, 148
Medic, S.	177	Militaru, M.	127	Monzio Compagnoni, G.	115	Nader, E.	53
Medvedeva, A.	125	Miljkovic, S.	61	Moos Knudsen, G.	105, 146	Nadjar, Y.	69, 114
Medvedkova, S.	122, 123	Milka, D.	175	Moos, T.	172	Naegelin, Y.	103
Megeryan, V.	116	Millar, L.	116	Mora, A.	84	Næss, H.	110
Meglic, B.	115, 166	Miller, A.	68, 69, 162	Morabito, R.	151	Nafissi, S.	132
Mehicevic, A.	110, 178	Miller, A.E.	162	Mora, G.	51	Nagahata, F.	165
Mehlsen, J.	73	Miller, B.L.	104	Morais, H.A.G.	183	Nagy-Grocz, G.	175
Mehl, T.	175	Miller, D.H.	49	Morales, M.	48	Nagy, I.	119
Mehrabian, S.	157	Millers, A.	110	Moran, N.	69	Nahrir, S.	135
Mehuys, E.	150	Miller, T.	82	Mora, R.	116	Nakamura, H.	118
Meier, T.	50	Miller, Z.	104	Mordasini, P.	77, 149	Nakamura, M.	134
Meireles, J.	61	Milley, G.M.	185	Moreau, C.	67	Nakamura, Y.	129
Meisel, A.	165	Mills, R.	111	Moreau, T.	103	Nakano, Y.	109
Meissner, W.	91	Milosevic, M.	112, 128	Moreira, F.V.	72	Nakhostin-Ansari, N.	169
Meisterernt, J.	77	Milushev, E.	117	Moreira, G.	121	Nakibirango, J.	184
Meitinger, T.	120	Miñano Guillamón, E.	176	Moreira, I.	80, 176	Nakicevic, A.	110
Mekjavic, I.	171	Minar, M.	125	Moreira, J.	158, 173	Nakladdalová, M.	123
Mekky, J.	65	Minguez, A.	114	Moreira, S.	185	Nako, E.	176
Melancia, D.	180	Mintun, M.	214	Moreira Villanueva, A.	117, 131	Naldi, A.	172
Mele, F.	151	Miranda, B.	48	Morel, C.	48	Naldi, P.	116, 164
Melli, G.	124	Miranda Bacallado, Y.	77	Morelli, C.	114, 176	Nalls, M.	49
Melnikov, M.	120	Mirault, J.	123	Moreno, T.	102	Namiecinska, M.	180
Melnik, V.	126	Mirnik, D.	171	Morgado, J.	137	Nandekar, S.	96
Melo, C.	102	Mironova, J.	117	Morgado, P.	161, 183	Nandhagopal, R.	64
Melo Pires, M.	73, 149, 178	Mironova, J.S.	81, 112, 125, 177, 178	Morgan, M.	113	Naoumis, D.	167
Melzi, V.	80	Mirzaei, S.	79	Morgante, L.	133	Napalkov, D.	67
Memar Montazerin, S.	79	Mirza, M.	129	Mori-Yoshimura, M.	118	Naranjo, F.H.C.	76
Menassa, D.	121	Mishchenko, T.S.	127	Morley, D.	160	Naradai, S.	77
Mencacci, N.E.	129	Mishchenko, V.M.	127	Moro, E.	191	Nardi, E.	162
Mendes, A.	80	Mijina, L.	63	Moro, Elena	106	Nardocci, N.	44
Mendes, I.	61	Misra, P.	158	Morrai, V. Brescia	115	Nardone, R.	105, 134, 168
Mendes Pereira, V.	149, 156	Mistry, J.	184	Morrison, S.	171	Narkiewicz, K.	110
Mendes, V.	84, 136	Mitjana, R.	103	Morris, R.	185	Naro, A.	168
Mendez, A.	172	Mitosek Szewczyk, K.	163	Morris, Z.	77	Nascimento, A.	51
Mendoroz, M.	119	Mitrokhin, D.	72	Mortensen, P.B.	121	Nassar, M.	49
Menezes, M.	60	Mitsikostas, D.	105	Moseby Knappe, M.	106	Naumenko, D.	137
Mengel, E.	122	Mitsikostas, D.	112, 146	Moser, T.	135, 166	Navarrete, J.J.	128
Menih, M.	157, 181	Mitsios, N.	53	Moses, H.	117	Navarro, J.	76
Menjot de Champfleury, N.	53	Mitsuhashi, S.	118	Mostefaoui, F.	119	Navarro, M.C.	158
Mensikova, K.	119, 129, 130, 134, 177	Mitterling, T.	52	Mostile, G.	133	Navarro-Otano, J.	60
		Mizanova, M.	66	Mostoufizadeh, S.	84, 159	Navas-Sánchez, F.J.	115
Meola, G.	76, 128, 151	Mizushima, K.	109	Moszer, I.	49	Naydenov, E.	120
Mercuri, N.B.	52	Mladenovic, J.	124	Motataianu, A.	82	Nazari, F.	132
Mercurio, M.	59	Moccia, M.	115, 117, 179	Moter, A.	183	Nazarova, E.	169
Mergeani, A.C.	74, 113, 120, 127, 167, 172	Mochel, F.	50	Motos Garcia, J.Á.	119, 133, 175, 179, 180	Nazliel, B.	122
		Moggio, M.	151			Neacsu, A.	172
Merico, A.	160	Moggio, M.G.	70, 132	Motti, L.	81	Nechifor, C.	167
Merkul, V.	160	Mohamed, E.A.	125	Moulin, T.	51, 110	Nedelska, Z.	64, 125, 155
Merle, P.	151	Mohamed, H.E.R.	65	Mouni, F.	80	Nedkova, V.	77
Merlini, A.	116, 164	Mohammad, Y.	127	Mouthon Reigner, C.	79	Needham, M.	70
Mesáros, S.	163	Mohsen, N.	143	Moviglia, G.A.	74	Neelakantham, S.	165
Mesfioui, A.	62, 64	Mohsen, Nabil	161	Mozheiko, E.	157	Negrão, L.J.M.P.	72, 119, 124, 137, 180
Mesnage, V.	177	Möhwald, K.	177	Mridula, K.	116	Neider, M.C.	48
Mesquita, V.	121	Moiola, L.	53, 63, 68, 82, 102, 115, 116, 130, 131, 132, 157, 163, 164, 179	Mueles Gomez, N.	162, 172	Neiva, R.	149
Messaoudi, N.	61			Mueles, N.	185	Nekrasova, N.	117, 157, 173
Messelmani, M.	162, 172	Moiseev, M.	126	Muelles, N.	118	Neri, W.	81
Messina, M.J.	82, 116, 131, 164	Mokhtari, K.	53, 167	Mueller, K.I.	105, 175	Nessah, L.	131
Messina, R.	71, 102, 104, 164, 168	Mokrisova, I.	64, 125, 171	Mueller-Lenke, N.	132	Nestorov, I.	163
Messina, S.	176	Mokthari, K.	167	Muhammed, K.	103	Neto, L.	76, 77
Messmer, X.	124	Mok, V.	156	Muharram, H.	159	Neuteboom, R.	135
Mess, W.H.	77	Moldovan, M.	72, 77, 124, 185	Muinjonov, B.	62, 109, 127, 160, 177	Neves, J.B.	51
Métral, M.	182	Moldovanu, I.	73	Mukaetova-Ladinska, E.	190	Neves, M.	157
Metz, G.	50	Moldovanu, M.	134	Mukalau, A.	63, 132	Nevriy, M.	67
Meurs, A.	78	Molesworth, A.	133	Mukalova, O.	63, 132	Nevsimalova, M.	155
Meyding-Lamade, U.	126, 127, 159	Molina Sánchez, M.	117, 123, 137	Mulayim, S.	156	Nevsimalová, S.	73
Meyer, B.	73	Mollenhauer, B.	177	Mulero, P.	103	Newton, J.	76
Meyer, W.	120	Møller, A.T.	62	Müller-Schubert, A.	118	Neykov, N.	155
Mezmaric, M.	180	Møller, K.	65, 110	Müller, T.	160, 161	Ngandu, T.	75, 155
Mezzapapa, D.M.	114	Møller, L.B.	133	Muller-Vahl, K.	90	Nicolai, C.	49
Mialovitska, O.	173	Molnar, J. M.	119	Mullins, G.	78	Nichelli, P.	170
Miano, S.	52, 73, 170	Molnar, M.J.	109, 185	Mumelj, L.	112	Nicholl, D.	106
Miante, S.	68	Moloney, P.	134	Mumladze, L.	112, 177	Nicoletti, A.	133
Micallef, D.	60	Moloney, T.	121	Munakata, Y.	69	Nicoletti, G.	133
Michel, P.	146	Molteni, E.	72	Muñoz Barrett, J.M.	159	Nicol, M.	114
Michler, R.	137	Mondot, L.	102	Muñoz Blanco, J.L.	115	Nicolo, J.-P.	124
Midaglia, L.	103, 162	Monet, P.	106	Muñoz, D.	162	Nicolo, P.	104
Mielke, M.	104	Monforte, M.	180	Muñoz Maniega, S.	77	Nicolotti, D.	74
Mierzewski, P.	174	Monfrini, E.	80	Muñoz Ruiz, T.	131, 163	Niedermyerova, I.	175
Mifsud, M.-A.	121	Mongini, T.	70, 132, 151, 194, 217	Munschauer, R.	179	Nielsen, J.	50, 134, 181
Miglani, E.	110	Monies, D.	73	Munteanu, L.	73, 125	Nielsen, J.B.	123
Migliori, M.	133	Monin, M.-L.	50	Munteanu, C.	63, 127	Nielsen, J.E.	133
Mignarri, A.	134, 184	Mono, M.-L.	149	Munteis, E.	162	Nielsen, J.F.	104
Mignone, C.	63	Monreal, E.	59, 64, 113, 127, 166	Munteis Oliva, E.	117, 131	Nielsen, N.	106
Mihailescu, G.	66, 72	Monreal Laguiño, E.	71, 81, 123, 156	Muntoni, F.	145, 147	Niessen, E.	150
Mihalj, M.	125	Monsch, A.U.	182	Muralidharan, K.K.	163	Nigro, V.	132, 151
Mihaylova, V.	120	Monsurró, M.R.	160, 176	Murase, N.	134	Nijhuis, F.	191
Mihaylova, V.M.	134	Montalbán, C.	71	Murayama, S.	109	Nikanorova, M.	97
Mijajlovic, M.	66	Montalban, X.	53, 68, 69, 83, 103, 116, 117, 131, 189	Musaeve, Y.	104, 123, 169, 192, 217	Nikishkova, I.M.	127
Mikhailov, V.	112, 175	Montanari, E.	81	Musayev, A.	62, 109, 172	Nikitina, M.	60, 81, 112, 117, 125, 177, 178
Mikkelsen, J.D.	110	Monteiro, A.	118, 127	Muscio, C.	175		
Mikal, D.	163	Monteiro, F.	78	Musialik-Lydka, A.	75	Nikodinovic Glumac, J.	124
Mikulicova, L.	119, 177	Monteiro, J.P.	128	Musumeci, O.	132, 151	Nikolic, A.	151
Mikulik, R.	44	Monterde, S.	132	Mutihac, R.	114, 176	Nikolic, I.	80
Milanese, C.	116	Montero Atalaya, A.	68, 163	Mycko, M.	53, 180	Nikolic, M.	170
Milani, P.	81	Montesano, M.	176	Myftiu, B.	127	Nilipour, Y.	132
Milanov, I.	117			Myhr, K.-M.	178	Nilsen, K.B.	137
Milardi, D.	168					Nilsson, C.	80
						Nilsson, P.	53

Nimeri, R.	113	Omer, S.	167	Pal, S.	133	Payoux, P.	105, 134
Nisa, Z.	126	Omer, T.A.	78, 112	Panas, M.	120	Pc, J.	64
Nishino, I.	118	Ongun, N.	161	Pancák, J.	166	Peci, E.	170
Nissa, Z.U.	155, 175	Ono, S.	160	Pandhi, S.	66	Pederson, M.	121
Nita, D.	77	Ontañón, J.	79	Pandolfo, M.	96	Pedraza, M.	128
Nitschke, K.	103	Opapa, J.	71	Pandya, S.D.	85	Pedraza, M.I.	66, 79, 124
Nizzardo, M.	114	Opera, J.	71	Panea, C.	148	Pedrosa, R.M.G.	137
Nobile-Orazio, E.	85, 145, 183	Oppl, F.	133	Pane, C.	49, 179	Pegoraro, E.	151, 160
Nobili, A.	48	Optican, L.	184	Panica, L.	116	Pegoraro, V.	132, 160
Nobili, F.	75, 134	Orban, I.A.	167	Pantieri, R.	104	Pekic, S.	63
Nobili, F.M.	105	Ordás-Bandera, C.	113, 159	Pantzaris, M.	69	Pekmezovic, T.	156
Nobili, L.	52, 66, 73, 90	Orefice, G.	115	Paoletti, P.	102	Pektas, B.	69
Nobre, A.C.	160	Oreja-Guevara, C.	68, 131, 163, 204	Papa, A.	173	Pelagallo, E.	59
Noergaard, K.	65	O'riordan, S.	111, 134	Papadimas, G.	136, 180	Pelcová, D.	123
Nogueira, C.	149	Örken, F.D.	156	Papadimitriou, A.	157	Pelletier, J.	61, 62, 103, 182
Nojima, S.	67	Oriandi, D.	105	Papadimitriou, D.	157	Pellis, T.	106
Nollet, L.	78	Orologas, A.	136	Papadimitropoulos, G.	111, 173	Peltola, J.	52, 189, 221
Nomura, K.	81	Orosz, P.	156	Papageorgiou, S.	157	Peña-Jaimes, L.	113
Noone, I.	111	Ørstavik, K.	124	Papageorgiou, S.G.	75, 80, 111, 126, 171, 173	Pender, N.	114
Noraz, N.	105	Ortega-Cubero, S.	102			Penner, I.-K.	116, 117, 131, 163
Nørgaard, A.	126, 172	Ortega, L.	123	Papaneophytou, C.	166	Penniaynen, V.	176
Nørgaard-Pedersen, B.	121	Ortega Suero, G.	128, 131	Papanicolaou, D.	83	Pennuto, M.	160
Normand, C.	176	Ortiz, N.	132	Papantoniou, I.	157	Penombre, E.	84
Nørregaard, J.	127	Ortu, R.	161	Papantoniou, V.	157	Pensato, V.	176
Nos, C.	103	Orviz, A.	68	Papapavlou, C.	78	Pepper, G.	163
Not, A.	137	Orviz-Garcia, A.	131	Papathanasiou, E.	89, 168	Pera, J.	126
Notas, K.	136	Ory-Magne, F.	48	Papatriantafyllou, J.	75	Peralta, R.	65, 73, 174
Nouioua, S.	119	Oses, M.	66, 121, 128, 137, 176	Papazoglou, S.	180	Pera, M.C.	102
Novak, H.F.	64, 135, 166	Osiceanu, A.M.	133	Papeix, A.-C.	103	Perani, D.	59, 134
Novak, M.	132	Ospova, V.	128	Papeix, C.	69	Peraud, A.	122, 177
Novakovic, I.	132	Osmanova, G.	175	Papinutto, N.	50	Pereira, A.	158, 173
Novillo, M.E.	172	Ossenkoppele, R.	91, 171	Papir, G.	69	Pereira, A.P.	84
Novo, A.	131, 168, 175	Ostapenko, A.	72	Pappa, E.	136, 168	Pereira, C.	149
Novo, A.M.	79, 119	Østergaard, K.	105, 221	Pappert, E.	161	Pereira, J.	84, 161
Novy, J.	106	Ostry, S.	155	Papp, V.	62	Pereira, L.	61
Nywicki, T.	110	Otero-Romero, S.	103	Papp, Viktoria	93	Pereira, P.	48, 85, 167, 170
Nuara, A.	63, 78, 164	Otruba, P.	67, 119, 129, 159, 177	Papuc, E.	166	Peres, J.	174
Nunes, C.	157	Otsubo, H.	77	Paquete Oliveira, R.	137	Peres, J.P.G.N.T.	167
Nunes, G.	156	Otto, F.	166	Paraskevopoulou, V.	182	Peres, T.	67
Nunes, S.	167	Otto, M.	78, 177	Parchi, P.	133	Perez, A.	159, 172
Nurtdinova, L.	168	Ott, S.	52, 73	Pardo, J.	51	Perez Lucas, J.	82, 176, 184
Nygaard, A.-B.	155	Oturai, A.B.	178	Pardo Parrado, M.	128	Pérez, P.	75
Nyland, H.	178	Oturai, D.	178	Párdut, Á.	175	Perez Rodriguez, A.	84, 158
Nzwalo, H.	77, 84, 129	Ouachikh, O.	157	Parejo Grande, J.	158	Pérez Torre, P.	59, 64, 71, 123, 127, 156
		Ourselin, S.	49	Parejo Carbonell, B.	79, 166		
		Ovcac, K.	157	Pareyon, D.	38, 50, 147, 160, 176	Perić, M.	180
		Overeem, S.	142	Parfenov, V.	128	Peric, S.Z.	73, 124, 132, 180
		Overgaard, K.	185	Parhizgar, S.E.	150	Peric, Z.	158
		Obadia, M.A.	181	Pařizková, M.	111, 125	Perini, P.	68
		Obadia, T.	70	Park, H.-M.	127	Perinova, P.	73
		Obaidi, A.	64	Parkkola, R.	155	Perkins, L.	130, 177
		Obara, K.	167	Parman, Y.	85	Peroni, S.	133
		Oberfrank, F.	50, 119, 174	Parnetti, L.	105, 134	Perren, F.	149, 155, 156
		Oberholzer, M.	170	Parojcic, A.	132	Perrone, P.	116, 133
		Oberndorfer, S.	71	Parra, J.	72, 74, 124	Pešáková, L.	123
		Obiak, A.	75	Parralo, A.	70, 76, 83	Pesaresi, I.	70
		Obondzo, K.	135	Parry, M.	177	Pesovic, J.	132, 180
		Öcek, L.	172	Parvu, T.	120, 127, 167, 172	Pession, A.	133
		O'connor, R.	111	Pascotini, E.T.	158	Peter-Derex, L.	64
		Oczkowska, A.	174	Pascual, J.	113, 146	Peterlin, A.	181
		O'day, K.	131	Pascual Pascual, S.I.	51, 62, 161	Peterlin, B.	166, 181
		Odin, P.	209	Pashenkov, M.	120	Peterova, K.	80
		Oechtering, J.	180	Pashkovskiy, V.	166	Petersen, A.S.	66, 174
		Oertel, W.	93	Pasi, E.	124	Petersen, E.T.	171
		Oflazer, P.	83, 85	Pasini, E.	133	Petersen, R.	104
		Oggioni, G.D.	161	Pasqualetti, P.	75	Peters, K.	120
		Oh, J.	162	Pasquier, F.	190	Peters, N.	66, 111, 158
		Oh, S.	165	Passeri, A.	134	Petit-Pedrol, M.	105
		Ohashi, T.	182	Passos, A.M.	157	Petriak, A.	173
		Ohman, I.	127	Passos, J.	121, 167	Petravić, D.	63, 67, 72
		Ohm Kyvik, K.	105	Pasteris, C.	53	Petrenaite, V.	127
		Ohta, K.	125	Pastor4, P.	102	Petre, V.R.	124, 127
		Ohtani, R.	134	Pastor, M.A.	102	Petrica, L.	110
		Ois Santiago, A.	61	Patel, R.	115	Petricoul, O.	165, 180
		Okabe, T.	168	Patil, B.	102	Petrikonis, K.	164
		Okamoto, K.	74	Paton, G.	63	Petrolini, M.	168
		Olaru Popescu, I.	167	Patterson, M.	122	Petrou, P.	113
		Olascoaga, X.	162	Pattie, A.	77	Petrova, M.	69, 157
		Olaskoaga, A.	167	Patti, F.	49, 116	Petrović, I.	59, 80, 115, 178
		Oldani, A.	171	Patzig, M.	104	Petrović, K.	149
		Oldfors, A.	180	Paulasová Schwabová, J.	171	Petrucchi, A.	70
		Oldoni, E.	75	Paul, F.	180	Peverelli, L.	132
		Olesen, J.	67, 128, 129, 150, 174, 175	Paul, G.	149, 151	Peyrard, S.	52
		Olesen, Jes	145, 175	Paul, R.	170	Pezold, S.	103
		Olesen, V.	52	Paulson, O.B.	52	Pezzetti, F.	74
		Olin, B.	48	Paunic, T.	180	Pfang, B.	121, 176
		Olivan Usieto, J.A.	78	Pavan, G.	164	Pfannl, R.	121
		Oliveira, C.	150, 160, 161	Pavão Martins, I.	64	Pfuhl, C.	180
		Oliveira, I.	161	Pavelek, Z.	59, 63, 78	Phadke, R.	166
		Oliveira, V.	172	Pavelić, A.	60	Pham, M.	105
		Oliver, D.	144, 160	Pavese, N.	150	Phillips, C.	82
		Oliver, David	129	Pavia, J.	131	Philpott, S.	113
		Oliver-Martos, B.	131	Pavlou, D.	75, 80, 111, 126	Pian, H.	71
		Olivia Garcia, L.	137	Pavlov, A.	64	Piani-Meier, D.	70, 103, 117, 179
		Olivie, L.	128, 176	Pavlova, R.	157	Pia Sormani, M.	132
		Ollivier, M.	174	Pavlovic, A.	66	Picard, G.	105
		Olsen, A.S.	158	Pavy-Le Traon, A.	48	Picaut, P.	72
		Olsen, J.	150	Pawlak-Bus, K.	136	Piccini, P.	149, 151
		Olsson, T.	53	Pawlak, M.	136	Piccirillo, G.	129, 160, 168, 176
		O'malley, P.	131	Payan, C.	177	Picccone, S.	74
		Omar, H.	65	Payas, N.	164	Pichler, A.	84, 149, 176
		Omejec, G.	78, 124	Payer, F.	167	Pickering, L.	73
		Omelchenko, E.	169				

Pico, F.	85, 109	Postigo, M.J.	163	Radunovic, A.	132, 160	Reuner, U.	48
Piepgas, J.	180	Postma, F.	106	Radu, R.	133, 156	Reuter, G.	82
Pierzchala, K.	110, 174	Pot, C.	167	Raduta, V.	167	Reuter, U.	105
Pietri, G.	66	Potemkowski, A.	163	Raduta, Y.	167	Rey, C.	61, 62
Pietroboni, A.M.	59, 167	Potic, A.	63	Raedt, R.	78	Reyes Garrido, V.	131, 163
Pietrolongo, E.	81	Potiri, I.	136	Rafai, M. A.	77	Reyre, A.	61
Pievani, M.	75	Potockova, V.	183, 185	Rafai, M.A.	80, 120, 135	Rheims, S.	64, 173
Piga, D.	151	Potocnik, J.	157	Raffin, E.	179	Rhadius-Meester, H.	109
Pignatti, R.	182	Potulska-Chromik, A.	71, 118	Ragonese, P.	130, 133	Riahi, A.	162, 172
Piguet, O.	171	Pouget, J.	83	Ragusa, N.	70, 132	Riancho, J.	176
Pihl-Jensen, G.	168	Poujois, A.	123, 132	Rahmani, M.	59, 60, 84, 156	Riant, F.	113
Pijpers, A.	73	Poullin, P.	83	Rahman, N.A.	159	Ribaric, B.	72
Pikija, S.	135	Poulsen, M.B.	123	Rahn, A.C.	184	Ribeiro, A.	183
Pikš, B.	115	Poulsen, M.L.S.	62	Raieli, V.	174	Ribeiro, A.C.	61, 83, 84
Pilcher, D.	106	Poulsen, P.	105	Raine, C.S.	53	Ribeiro, J.	124, 137, 168, 180
Pillari, Manuela	221	Poupon, J.	123	Raji, A.	163	Ribes, J.	109
Pliz, G.	64	Poydasheva, A.	122, 123	Rajic, A.	156	Riboldazzi, G.	161
Pimenta, S.	121	Pradat, P.-F.	123	Rajic, S.	124	Ricci, E.	180
Pimentel, J.	65, 85, 167, 174	Pradhan, C.	168, 177, 185	Rakacolli, M.	65, 119, 127, 174	Ricci, G.	70, 151
Pimentel, J.G.D.B.C.	175, 183	Prados, F.	49	Rakhimbaeva, G.	62, 72, 83, 109, 128, 172	Riccitelli, G.	103
Pimpilidou, E.	136	Prat, A.	204	Rakhimbayeva, G.	177	Riccitelli, G.C.	49, 103, 122, 150
Pinborg, L.	149	Pravatá, E.	103	Rakhimberdiyev, S.	172	Ricco', M.	74, 124
Pinborg, L.H.	52, 66, 110, 134, 158	Preisler, Nicolas	217	Rakhmatullaeva, G.	79, 165	Richard-Mornas, A.	64
Pinessi, L.	70, 132	Prelle, A.	85	Rakocevic Stojanovic, V.	180	Richter, J.	166
Pinheiro, J.	183	Preobragenskaya, I.	171	Rakocevic-Stojanovic, V.	132	Richter, M.	123
Pinho E Melo, T.	76, 77, 159	Pretegianni, E.	184	Rakowicz, M.	80	Richter, S.	82
Pinho, J.	84, 161, 183, 185	Pretnar-Obla, J.	113, 173	Rakuska, M.	73, 77, 78, 112, 150, 157	Ridsdale, L.	112, 113
Pinot, P.	180	Preux, P.-M.	114	Ramadhan, M.	130	Ridzoň, P.	123
Pinter, D.	77, 84, 149	Preziosa, P.	49, 68, 84, 103, 104, 122, 150, 163, 164	Ramalheira, J.E.D.P.	48, 78, 174	Rieckmann, P.	163
Pinter, M.M.	71	Prezios, P.	103	Raman, P.	65	Riedel, B.	149
Pinto, A.N.	65, 76	Priede, Z.	110	Rama, P.	179	Rigau, V.	53
Pinto, F.	184	Priego, M.	132	Ramboer, K.	71	Rigó, E.	130
Pinto, M.	127, 132	Prihodova, M.I.	125	Ramesh, C.	109	Rigual Bobillo, R.	137
Pinto-Medel, M.J.	131	Prikrylova Vranova, H.	130	Ramesh, V.	102	Rigual, R.	114, 176
Pinto, R.	158, 173	Prikrylova-Vranova, H.	129	Ramirez, A.	114	Rise, T.	81
Pinzan, E.	132, 160	Primdahl, D.	51	Ramirez, C.	53	Rikier, E.	48
Pippolo, L.	102	Primo de Carvalho Alves, L.	64	Rammohan, K.	53, 117	Rikos, D.	120
Piradov, M.A.	59, 123	Privitera, R.	158	Ramos, C.	170	Rinaldi, F.	129, 171
Piras, S.	133	Procházka, A.	63, 78, 114	Randall, A.	166	Rinaldi, R.	60
Piredda, R.	66, 71, 161, 176, 183	Prochazka, V.	149	Ranganathan, P.	132	Ringgaard, S.	105
Pire García, P.	158	Prochorenko, I.	72	Rangappan Munirathinam, B.	163	Ringleb, P.E.	194
Pire, P.	172	Prodi, E.	172	Ranjaya, J.-P.	129	Rinne, J.	155
Pires, J.	60	Prokhorova, A.V.	128	Ransmayr, G.	65	Rio, J.	103
Pires, M.	132	Prokhorov, A.V.	128	Rao, D.G.	121	Ripellino, P.	124, 172
Pirker, E.	84	Prokopakis, E.	136	Rasche, L.	180	Rispoli, V.	131
Pirro, F.	84, 132	Prokopenko, S.	157	Rascol, O.	48, 162	Ritchie, S.J.	77
Pirtošek, Z.	80, 115	Prontera, P.	162	Rasmussen, M.	124	Ritter, S.	103, 179
Pisa, M.	63, 121, 132, 164	Proserpio, P.	52, 66	Rasmussen, M.K.	104	Riva, N.	51, 85, 129, 160
Pita, F.	132	Prosser, C.	179	Rassu, A.L.	66, 71, 161, 176, 183	Rizos, A.	130, 177
Pita Lobo, P.	175	Proudfoot, M.	160	Rasulo, M.	115	Rizzo, F.	114
Pittman, A.	166	Prus, K.	163	Ratajczak-Tretel, B.	110	Rizzo, G.	104, 155
Piu, P.	184	Prüß, H.	180	Rath, C.L.	172	Rizzolatti, G.	94
Pivonello, C.	115	Przedpelska-Ober, E.	174	Rathod, N.	182	Robertson, C.	128
Pizza, F.	73	Psimaras, D.	105, 136, 168	Ratmanova, P.	67	Roberts, R.	104
Place, L.	60	Puche Mira, A.	179	Ratti, A.	176	Robinet, E.	61, 62
Placidi, F.	52	Pucic, T.	128	Ratti, L.	170	Rocca, M.A.	49, 68, 72, 83, 84, 102, 103, 104, 122, 131, 132, 150, 157, 163, 164, 168, 189
Platakis, A.	120	Puertas Muñoz, I.	82	Reichenzauner, M.	65	Rocha, H.	130
Plananska, E.	80	Pugachenko, N.	60	Rauschka, H.	83	Rocha, J.F.	115, 158, 160, 161, 162, 173
Plank, L.	82	Pugliatti, M.	45, 119, 131	Rausell, E.	62, 68, 161, 163	Rocha, L.	64
Plant, G.	44	Pujal, B.	103	Ravnborg, M.	49, 145, 192	Rochat, P.	150
Plastunen, E.	78	Pukaite, V.	81	Ray Chaudhuri, K.	40, 177	Roche, N.	169
Plavina, T.	163	Puke, L.	156	Raycheva, M.	69	Rock, H.	176
Pleimes, D.	131	Pulido, L.	167	Rayegani, S.M.	150	Rocelle, O.	84
Pliashko, I.	161	Pulido-Valdeolivas, I.	62, 68, 161, 163	Reach, P.	181	Rodegher, M.	49, 84, 103, 116, 131, 132, 157, 164
Plotnikov Denis, P.D.	60	Pult, F.	149	Realmutto, S.	130, 133	Rodoligo, C.	132, 151
Poda, M.	85	Puma, D.	174	Rea, M.	72	Rodrigues, B.	110
Podemski, R.	167	Puorro, G.	49, 115	Recl, M.	103	Rodrigues, F.	51, 184
Podgurskaia, M.	78	Pushkarev, D.	128	Reeder, A.	69	Rodrigues, M.	61, 76
Podlipnik, B.	184	Puttinger, G.	65	Redmond, I.	75	Rodrigues, M.M.R.S.	61
Podnar, S.	78, 124	Puz, P.	163	Reed, C.	121	Rodriguez-Andonaeigui, I.	62, 68, 161, 163
Poewe, W.	72, 91, 115, 161, 209	Pyko, A.	132	Regada, L.	114	Rodriguez-Antiguedad, A.	162
Pogoryelova, O.	120			Regis, J.	137, 184	Rodriguez, B.	103
Pohl, D.	148			Regragui, W.	48, 118, 130, 161, 221	Rodriguez-Bada, J.L.	131
Poirion, E.	49			Reichmann, H.	48, 118, 130, 161, 221	Rodriguez-Campello, A.	61
Pokryszko-Dragan, A.	167			Reich, M.	221	Rodriguez Garcia, J.M.	119, 133, 165, 175, 179, 180
Poletti, B.	176			Reifenberger, G.	149	Rodriguez, M.	175
Politi, L.	50			Reijs-Scheijgrond, M.	64, 77, 121, 174	Rodriguez-Oroz, M.C.	114
Politis, M.	149, 151			Reimão, S.	64, 77, 121, 174	Rodriguez-Porcel, F.	75
Pollo, C.	170			Reinke, J.	122	Rodriguez-Violante, M.	151, 178
Polster, T.	52			Reink, J.	122	Rogemond, V.	105
Poluektov, M.	125			Reis Costa, M.	163, 168, 172	Rohan, Z.	155
Polymeri, A.	120			Reiser, M.	155	Rohaut, B.	181
Polymeris, A.	51, 111, 158			Reisin, R.	209	Rohenkohl, G.	160
Pomati, S.	59, 109			Reizinho, C.	121	Rohracher, A.	52
Ponomarev, V.	167, 182			Rejzda, K.	109, 158, 163, 166, 169	Roiz, P.	75
Ponsaing, L.	73			Rekand, T.	104	Rojas-Garcia, R.	51
Pons, R.	120			Quirk, M.	75, 155	Rojas, R.	121
Ponzalino, V.	70, 132			Religa, D.	67	Roje Bedekovic, M.	65, 109
Poole, M.	171			Reija, M.	67	Rojek, A.	167
Popescu, B.O.	167			Relvas, R.	122	Rolandi, E.	105, 134
Popiela, T.	156			Reményi, V.	109	Rola, R.	66
Popolizio, M.T.	77			Remes, A.	109	Roldán, M.	119
Popović, K.S.	62			Remon, J.-P.	150	Rolfs, A.	209
Popović, M.	155			Remy, P.	91	Roman Filip, C.	78, 121
Porchet, H.	116			Renaud, D.P.	167	Romeo, M.	53, 116, 132, 164
Porqueres, E.	158			Renken, R.	84		
Portaccio, E.	49			Renna, L.V.	151		
Porta Etessam, J.	128			Renner, C.	92, 110		
Portera, E.	133			Repice, A.M.	116		
Posadas, I.	114			Resler, J.	82		
Posevitz-Fejfar, A.	183			Restel, M.	66		
				Reulen, J.	77		

Romero, G.	182	Russo, M.	168	Santana, I.	64, 133, 150	Schönecker, S.	177
Romero Pinel, L.	120	Rus, T.	155, 166	Santana, M.I.J.	157	Schon, F.	184
Romero-Villarrubia, A.	135	Rustay, N.	130	Santangelo, G.	129, 176	Schonknecht, P.	105, 134
Romer Rosberg, M.	124	Rusu, O.	74, 113, 120, 127, 167, 172	Santangelo, M.	81	Schoser, B.	165
Romeu, C.	132	Rusz, J.	80	Santangelo, R.	63, 83, 179	Schoser, Benedikt	165
Romigi, A.	52	Ruth Behrens, J.	180	Santens, P.	80	Schott, J.M.	91
Romito, L.M.	67	Ruvolo, A.	49	Santiago, B.	103	Schott, J.	125
Rommel, N.	72	Ruzicka, E.	80, 97, 184	Santorelli, F.M.	50, 120	Schoubo Brinth, L.	73
Romoli, M.	63, 150, 162	Ruzicka, Evzen	177	Santoro, L.	151	Schrag, A.	151, 178
Ronan, K.	134	Ryabinkina, J.	123	Santoro, S.	133	Schreglmann, S.	151
Roncarati, A.	106	Ryan, P.	129	Santos, A.	115, 160, 161, 162	Schreiber, S.	64, 89
Ronchi, D.	151	Ryglewicz, D.	60, 66	Santos, A.F.	136, 185	Schreier, D.	73
Ronen, I.	49	Rym, B.	125	Santos, C.	121, 123, 135, 185	Schreuder, T.	78
Rooks, D.	165, 180	Ryvlin, P.	48, 78, 173, 190	Santos, L.	137	Schreurs, M.	135, 182
Rooney, J.	160			Santos Lasaoosa, S.	78	Schroten, H.	178
Roos, P.	181	S		Santos, M.	60, 73, 102, 104, 136, 137, 165	Schroth, G.	77
Ropele, S.	149	Saat, R.	122	Santos, P.	183	Schuh, A.	109
Róper, C.	65	Saavedra Santana, P.	76	Santos, T.	102, 130	Schuhfried, O.	71
Roque, A.	162	Sabanagic-Hajric, S.	179	Sanxhaku, R.	173	Schuh Teixeira Da Rosa, A.L.	72
Roque, L.	167	Sabatella, G.	162	Sanz Monllor, A.	119, 133, 165, 175, 179, 180	Schüle, R.	142
Roaquer Gonzalez, J.	61, 117, 131	Sabatelli, M.	180			Schulte-Mecklenbeck, A.	183
Roriz, J.	185	Sabatini, U.	91	Saper, J.	105	Schultz, S.	185
Rosado Coelho, C.	130, 167	Sabel, M.C.	149	Sapra, S.	66	Schübach, M.	170
Rosário Marques, I.	127, 128, 183	Sabers, A.	127	Saprygina, L.	159	Schübach, Michael	221
Rosberg, M.	72, 185	Sabido-Espin, M.	179	Saraceno, L.	76, 128, 151	Schütt, M.	128
Rösby, Ö.	124	Sabirov, J.	167	Saravaf, S.	124	Schwarz, A.	178
Roscio, M.	49	Sabovic, M.	62	Saramago, P.	50, 51	Schwarz, G.	65
Rosenfeld, M.	105	Sabre, L.	172	Sarasso, E.	67, 106	Schwenker, K.	104, 105, 168
Rosen, H.	104	Sacca', F.	49, 157, 179	Sarathchandran, P.	174	Schwerk, C.	178
Rosenow, F.	52	Sacchetti, M.	75	Sarchielli, P.	150	Sciacco, M.	70, 132
Rosenthal, E.	106	Sacco, R.	70	Sardina, M.	80	Scigliano, V.D.	133
Rosini, F.	184	Sadokha, K.	79	Sargento Freitas, J.	110	Scigliuolo, G.	50
Rosón González, M.	84, 158, 172	Sadun, F.	136	Sargiannidou, I.	157	Sclesinger, I.	38
Rossetti, A.	37, 106, 193	Sadykov, R.	72	Sarigiannis, P.	166	Scriven, S.	60
Rossi, F.	179	Saebye, D.	127	Sari Kaplan, Ö.	121	Sechi, E.	66, 71, 161, 176, 183
Rossi, M.	114, 176	Saeedi, J.	135	Sarkis, E.	129	Sechi, G.	66, 71, 161, 176, 183
Rossini, P.M.	105, 134	Saez Pinel, R.	121	Sarmiento, A.	171	Sedel, F.	103
Rosso, C.	76, 77, 174	Šafka-Brožková, M.	185	Sarnelli, M.F.	116	Seebach, J.	167
Rossor, M.	193	Sá, G.	64	Sarraff, P.	169	Seeck, M.	173
Rostrup, E.	123	Sagnelli, A.	176	Sasso, G.	115	Seeley, W.W.	104
Rota, S.	129	Sahin, S.	182	Sastre-Garriga, J.	103, 163	Seeman, P.	185
Rotondo, E.	59	Sahovic, D.	128	Säterö, P.	169	Seemungal, B.	143
Rot, U.	166, 180	Sainouchi, M.	134	Sato, M.	109	Seemungal, B.M.	185
Roubec, M.	149	Saint Martin, M.	105	Sauerbier, A.	130, 177	Sega Jazbec, S.	63
Roubenoff, R.	180	Sairanen, T.	122	Sauerbier, Anna	177	Segal, L.	83
Rouleau, G.	133	Saito, T.	118	Sauer, C.	72	Segovia, S.	51
Roussakis, A.-A.	149, 151	Saiz, A.	162, 179	Sauter, A.	53, 117	Segura, N.	61, 123
Roussel, M.	150, 151	Sakoshia, K.	81	Savarese, M.	132, 151	Seidel, D.	178
Roussopoulou, A.	173	Sakka, S.	172	Savatovsky, J.	53	Seidel, S.	76
Roux, J.	179	Sakkas, L.	120	Savchuk, O.	126	Seidl, M.	105, 134, 168
Rouzier, C.	165	Sakoda, S.	118, 129	Savettieri, G.	81, 133	Seidl, Z.	82, 149
Rovaris, M.	68	Sakovich, I.	71	Savica, R.	155	Seif, F.	179
Roveri, L.	172	Sakovich, R.	79	Savic-Pavicevic, D.	132, 180	Seiffert-Held, T.	167
Rovira, A.	68, 83, 103, 163, 179	Salachas, F.	114, 123	Savitz, Sean I.	90	Seiffge, D.	51
Roxo, F.	136	Salani, S.	115	Savoldi, F.	49, 103	Seiffge, D.J.	111, 158
Royer-Perron, L.	167	Salemi, G.	130, 133	Savšek, L.	81	Seiler, A.	52, 73
Royes, L.F.	158	Salgado, D.	167	Scaber, J.	176	Seixas, D.	130
Royle, N.A.	77	Saliba, G.	170, 176	Scaioli, V.	176	Selbest Demirtaş, B.	60
Roze, E.	44	Saliger, J.	74	Scalco, R.	158, 165	Selcuk, F.	172
Rraklii, E.	174	Sallusto, F.	150	Scandellari, C.	81	Selleberg, F.	53
Rraji, A.	119	Salmaggi, A.	52	Scarafino, A.	114	Sellebjerg, F.	103, 134, 178, 192
Rua, A.	179	Salma, N.	133	Scarioni, M.	59, 167	Sellner, J.	45, 64, 135, 164, 166, 175
Ruano Hernández, A.	136	Salmerón At, M.P.	68	Scarpa, M.	209	Selmaj, I.	70, 180
Ruano, L.	49, 73, 130	Salmerón Ato, M.P.	119, 133, 165, 175, 179, 180	Scarpini, E.	59, 75, 167	Selmaj, K.W.	53, 69, 70, 116, 180
Rubboli, G.	173	Saloheimo, P.	54	Schadendorf, D.	53	Selmay, K.	69
Rubegni, A.	50	Salort-Campana, E.	83	Schäfer, J.	180	Semerano, A.	172
Rubens, R.	130	Salvatori, C.	63	Schahrazade Linda, M.	165	Semlil, L.	156
Rubinacci, A.	82	Salvatori, C.	63	Schopira, A.	54, 204	Sempere, A.P.	116
Rubino, A.	52, 66	Salzano, A.	49	Schel, E.	116	Senard, J.-M.	48, 98
Rubio, I.	119	Salzano, A.	49	Scheltens, P.	45, 144	Sener, U.	60, 117
Rudas, G.	119, 156, 183	Samira, M.	165	Schenone, A.	85, 170	Senft, C.	149
Rudolf, G.	181	Sá, M.J.	74, 81, 82, 116, 130, 157	Schiano Di Cola, G.	49	Seppi, K.	151, 178
Rudolph, H.	178	Samochowiec, A.	163	Schieb, H.	82	Sepulveda, M.	179
Rueckert, D.	109	Samoës, R.	176	Schiffmann, R.	122	Sequeira, J.	137, 180
Rueda, E.	78	Samson, S.	132	Schiff, N.	41	Sera, F.	151
Rüegg, S.	158	Samson, Y.	76, 77, 165, 174	Schilg, L.	185	Serafin, Z.	136
Rufa, A.	184	Samzelius, J.	162	Schilsky, M.	106	Serban, V.	165
Rufi, P.	163	Sanak, D.	149	Schindler, A.	122	Sergeev, D.	123
Ruggiero Garcia, M.	137, 176	Sanal, C.	63	Schinwelski, M.	172	Sergott, R.C.	104
Ruggiero, L.	151	Sanca, S.	52	Schippling, S.	131, 179	Serino, J.	168
Ruggiero, M.	128	Sanca, S.	52	Schiurari, D.	129	Serpente, M.	75
Ruhnau, J.	182	Sanchez Alonso, L.	119	Schjønning Nielsen, M.	155	Serrão, R.	116
Ruii, E.	179	Sánchez Ayaso, P.A.	133, 165	Schlegel, U.	149	Serratosa, J.	189
Ruiz-Beato, E.	116	Sánchez, E.	61, 123	Schlesinger, I.	49	Serratoso, J.M.	66, 128
Ruiz de Morales Ayudarte, N.	62	Sánchez, E.	61, 123	Schlick, C.	184	Serre, V.	165
Ruiz Garcia, J.	84	Sánchez García, J.A.	163	Schluck, E.	84	Seruga, T.	157
Ruiz-Jimenez, J.	74, 135	Sánchez, J.A.	61	Schmidt-Kraepelin, C.	93	Settergren Møller, H.	105
Ruiz, M.	128	Sánchez Lozano, P.	131	Schmidt, R.	144, 193	Set, V.	80
Ruiz Pérez, Á.	136	Sánchez Ortuño, I.	119, 133, 165, 175, 179, 180	Schmidt, S.	64, 116, 117, 118	Sevcik, P.	149
Ruiz Piñero, M.	66, 79, 113, 124, 128, 158, 159, 175	Sánchez-Roy, R.	185	Schmierer, K.	130	Severinsen, K.	104
Ruiz-Sánchez de Gordo, J.	119	Sanchez-Valle, R.	102	Schmitz, B.	192	Severyn, I.	156
Rupperecht, S.	73	Sander, L.J.	48	Schmutzhard, E.	143, 148	Sevillano Garcia, M.D.	125
Ruprecht, K.	180	Sanderson, F.	83	Schmutzhard, Erich	106	Sevilla, T.	51, 85, 185
Rushing, E.J.	48	Sandhya, K.S.	170	Schneider, Erich	89	Sevin, M.	77
Rushkevich, Y.	115, 129, 160	Sandrini, G.	105	Schneider, M.	52	Sévy, A.	129
Rusina, R.	155	Sand, T.	137	Schnider, A.	104	Seydanova, A.	72
Russell, D.	38, 110, 193	Sandu, E.	126	Schniepp, R.	168, 177, 184, 185	Seyedahmadian, S.	150
Russell, M.B.	50	Saneeva, G.	72	Schöberl, F.	104, 106, 122	Seyed-Fereshtehnejad, M.	155
Russo, A.	113, 151, 175	Sangalli, F.	53, 82, 131, 163, 164, 179	Schoenen, J.	150, 158	Sferruzza, G.	131
Russo, C.V.	115, 117, 179	Sangalli, V.	133	Scholten, I.	83	Sfikakis, P.	132
		Santafe, M.M.	132				

Shabalina, A.	59, 61	Sisquella, M.	132	Soysal, A.	68, 126, 175	Subramanyam, M.	115, 163
Shacham, S.	169	Sitek, E.	172	Spanou, I.	167	Suchorska, B.	149
Shafiq, F.	112	Siva, A.	68, 141, 144	Spantideas, N.	159	Suchowersky, O.	133
Shah, A.	66, 132	Sivagnanasundaram, J.	69	Spasic, M.	158	Sukhanov, S.E.	81, 112, 125, 177
Shakarishvili, R.	162	Sivakova, N.	66	Spatola, M.	105	Sukhorukov, V.I.	169
Shakir, Raadh	40	Sivakumar, K.	165	Sperling, M.	48	Sulas, M.G.	116
Shalaby, N.	69, 177	Sivera, R.	51, 85, 185	Spica, V.	151	Suleymanova, M.	169
Shamasna, M.	84	Sjelleberg, F.	179	Spigset, O.	149	Suljic, E.	110, 178, 179
Shandalin, V.	61	Skachkova, N.	72	Spilioti, M.	136	Sundal, C.	68
Shang, S.	164	Skalska, S.	69	Spinelli, E.G.	104	Sundar, R.	63
Shanmugarajah, P.	158	Skar, A.B.R.	178	Spirin, N.	69	Sundric, Z.	124
Shao, Y.	51	Skarlis, C.	135	Sprenger, T.	97, 103, 132, 189	Sung, S.M.	111, 157
Shapkin, A.	117	Skarrat, J.	72	Spulber, G.	75	Sun, H.	105
Shaporov, I.	173	Skeavington, I.	60	Sredniawa, B.	174	Supanc, V.	65, 109
Sharma, H.	70	Skelina, S.	157	Ss, G.	64	Suponeva, N.	59, 123
Sharma, N.	177	Skiadaresi, C.	157	Staals, J.E.	77	Suppli, N.	53
Sharma, R.	77	Skjelbred, C.F.	50	Stach, E.	158	Surboeck, B.	53
Sharrack, B.	82	Skoloudik, D.	149	Staedler, C.	124	Sushko, V.	167
Shcherbakova, N.	165	Škorvánek, M.	151, 171, 178	Staehein Jensen, T.	79	Sutter, R.	51, 158
Sheardova, K.	64, 125, 155	Sladkova, V.	69, 116, 159, 184	Staikov, I.	155	Süzen Ekinci, A.	122
Shehata, H.	69, 177	Slassi, I.	77, 80, 120, 135	Staljanssens, W.	78	Suzuki, M.	182
Shenkin, S.	133	Slauf, F.	149	Stamelou, M.	40, 49, 80, 111, 126	Suzuki, Y.	81
Shen, Z.W.	149	Slawek, J.	172	Stamelou, Maria	170	Švabić Medjedović, T.	66
Shermukhamedova, F.	109	Sleegers, K.	50, 102	Stamenova, S.	70	Svarer, C.	110
Shevchenko, L.	79	Slezak, A.	77	Stamenovic, J.	111	Sveinbjornsdottir, S.	70
Shevtsova, Y.	117	Slinde, S.	62	Stampatori, C.	49	Svensson, E.	165
Shieh, P.	165	Sliwinska, A.	174	Stanarcevic, P.D.	66, 156	Svenstrup, K.	51
Shimada, Y.	69	Sliwinska, B.	53	Stankoff, B.	37, 49	Svetel, M.	67, 106, 178
Shin, C.	155	Slowik, A.	126, 156	Stankoff, Bruno	115	Svolgaard, O.	53, 179
Shinohara, Y.	125	Smajlovic, D.	111	Stanković, I.	80, 115	Svrinova, T.	69, 116, 184
Shiramoto, M.	69	Smedal, T.	178	Stanzani-Maserati, M.	104, 133	Swiderek-Matysiak, M.	70
Shliakhtsin, S.	71	Smerdon, G.	178	Stapleton, S.	167	Swiejkowska, A.	174
Shmarov, A.	169	Smilevska, V.	137	Starhof, C.	178	Sycha, T.	121
Shukyurova, E.	159	Smith, C.	133	Stark, R.	170, 176	Synofzik, M.	72, 142, 209
Shvetsova, I.	157	Smith, K.	49	Starodubcev, A.	67	Syrjanen, J.	104
Siafaka, I.	159	Snit, M.	110	Starr, J.M.	77	Szatmar, B.	109
Sialitski, M.	182	Snoer, A.H.	174	Staubo, S.	104	Szczudlik, P.	118, 165
Sianko, K.	156	Soares-Da-Silva, P.	115, 158, 160, 161,	Stebbins, G.T.	151, 178	Szklenar, S.	109, 158, 169
Šiarnik, P.	156	162, 173, 174		Steensberg, A.T.	158	Szmuda, M.	62
Sibon, I.	110	Soares Pinto, P.	129	Stefan, H.	144, 158	Szőcs, I.	156
Siciliano, G.	70, 114, 151, 176	Sobańska, A.	80	Stefan, Hermann	158	Szőcs, I.	191
Siciliano, M.	129, 176	Sobesky, J.	217	Stefani, A.	52, 73	Szöke, K.	137
Siddiqi, S.	174, 175	Sobieszczuk, E.	165	Stefanic, A.	76	Szucs, A.	109
Sidhom, Y.	69	Sobisek, L.	82, 149	Stefanin, C.	116	Szurowska, E.	110
Sidiropoulou, K.	166	Sobol, N.	109, 171	Stefanis, L.	80, 111, 126, 173	Szyluk, B.	165
Sieben, A.	50	Sobreira, C.	62	Stefanova, E.	59, 109, 115		
Siebert, J.	60	Sobrido, M.-J.	115	Stefanović Budimkić, M.	66, 156		
Siebner, H.R.	53, 75, 105, 171, 179	Sobrinho, B.	176	Steglich-Arnholm, H.	110	T	
Sieminski, M.	73	Socha, J.	49	Stegmeier, E.	60	Taba, P.	151, 178
Sienkiewicz-Jarosz, H.	66	Socoliuc, G.	66	Steiner, I.	37, 50	Taba, Pille	92, 151
Siersma, V.	109, 155	So, E.	48	Steinhoff, B.J.	173	Tabares, A.	119
Signorelli, C.	74, 124	Soelberg Sørensen, P.	49, 204,	Stejskal, D.	129, 130	Tabatabai, G.	149
Signoriello, E.	179		209, 214	Stenager, E.	119	Tabeeva, G.	128
Silani, V.	114, 143, 145, 176	Soffietti, R.	41, 53	Stepanova, M.	166	Tábuas-Pereira, M.	64, 74, 103, 133,
Silani, Vincenzo	176	Sofian, B.A.	68	Stepansky, R.	76	150, 157	
Silberstein, S.	105	Sogo Lopez, T.	128	Stepanyan, T.	170	Taccone, F.	65
Siliqini, S.	150	Soilu-Hänninen, M.	179	Stephan, M.A.	48	Tackenberg, B.	117, 118
Sillevis Smitt, P.A.	135, 182	Soininen, H.	75, 109, 155	Stéphant, M.	137	Tadesse, S.	67
Silva, C.	60	Soinne, L.	169	Stéphen, R.	155	Tafakhori, A.	169
Silva, D.	60, 179	Sokolova, L.	126	Štěrba, L.	155	Tainta-Cuezva, M.	113
Silva, F.	110, 157	Sokolova, M.	176	Šternberg, K.	169	Taipa, R.	73, 132, 149, 178, 183
Silva, M.C.	119	Solari, V.	114	Sterpenich, V.	142	Tajiri, N.	169
Silva, M.J.	122	Solari, A.	81, 116	Stetkarova, I.	96	Takada, H.	165
Silva, N.	72	Solaro, C.	81	Stevens, M.	132	Takagi, K.	67
Silva-Pinto, A.	116	Solà Valls, N.	179	Stevic, Z.	73	Takahashi P, M.	118
Silvarrey-Rodriguez, S.	128	Soldatelli, M.D.	73	Stevensborg, L.	172	Takata, M.	134
Silveira, F.	129	Soldo Koruga, A.	128	Stien, R.	145	Takata, M.	74
Silvestri, G.	135	Solomon, A.	75, 155	Stocchi, F.	160, 162, 204	Takeda, S.	118
Silvestro, D.	64	Solomon, E.A.	183	Stocker, A.	123	Takeuchi, F.	118
Simão, D.	175	Sołtys, A.	163	Stojanov, A.	158	Takubo, R.	69
Simeonova, A.	155	Solyannicova, M.	159	Stojanov, D.	82	Talbot, K.	114, 160, 176
Simion, A.	130, 156	Soman, T.	164	Stojanovic, I.	82	Tallon, A.	82
Simioni, S.	182	Sommer, C.	128, 144	Stojjkovic, O.	124	Talman, M.-L.M.	71
Simões, M.R.	64, 157	Somnier, F.	149	Stojkovic, T.	59, 109, 115	Tambasco, N.	63, 162
Simoncini, C.	70	Son, A.	126	Stokholm, J.	181	Tamer, S.	167
Simone, C.	114	Sonderen van, A.	135, 182	Stöllberger, C.	83	Tamir, S.	169
Simonetta-Moreau, M.	72	Søndergaard, H.	178	Storelli, L.	72	Tan, A.	177
Simonetti, S.	137	Song, A.	69	Storstein, A.	167	Tanasescu, R.	167
Simon, I.L.	114	Song, G.-S.	110	Starti, E.	50	Tan, E.	72
Simon, O.	169	Sonia, M.	125	Stoyanova, V.	117	Tang, G.	67
Simonsen, C.	62	Sonka, K.	73, 125	Straka, I.	178	Tanik, N.	79
Sims, D.	176	Son, Y.-D.	127	Strambo, D.	172	Tankisi, H.	105, 137
Simsekoglu, R.	68	Soo, Y.	156	Strandberg, T.	155	Tanrıverdi, G.	183
Simu, M.	127	Sorarú, G.	51, 129, 160	Strand, L.	50	Tan, S.	63
Sinai, A.	49	Sorato Bezerra, O.	72	Straub, V.	151	Tantinyá, N.	109
Sinaie, F.	132	Sorbi, S.	109	Straumann, D.	89, 136, 168	Tarollo, A.	75
Sinani, O.	118, 182	Sørensen, P.S.	103	Strazzer, S.	72	Tarawneh, M.	60
Sinanovic, O.	81	Sørensen, S.S.	155	Strbian, D.	51, 146	Taroni, F.	176
Sindrup, S.H.	185	Soricelli, A.	105, 134	Strnad, M.	130	Tarr, P.	182
Singer, B.	82, 164	Sormani, M.P.	70, 130, 149, 163	Strothjohann, M.H.	157	Tarta-Arsene, O.	65
Singhal, A.	63	Sorosina, M.	133	Struhal, W.	48, 65	Tasca, E.	132, 160
Singleton, A.	49	Sosa Henriquez, M.	76, 136	Struhal, Walter	98	Tasca, G.	180
Sinkkonen, S.	122	Soulier, E.	129	Strupp, M.	44, 106, 122, 184	Tascou, S.	135, 166
Šinkovec, J.	80	Sousa, A.	156	Strupp, M.L.	89, 122	Tasdemir, S.	60, 180
Šin, M.	184	Sousa, A.L.	178	Stuchlik, A.	111	Tasios, K.	173
Siomkina, A.	117	Sousa, C.	156, 157	Stump-Guthier, C.	178	Tassi, L.	52, 66
Sipos, I.	183	Sousa, D.	184	Suardiaz, M.	131	Tassorelli, C.	105
Sipos, L.	183	Sousa, L.	79, 131, 157, 175	Suarez, G.	131	Tatillo, C.	49
Siripurapu, R.	182	Sousa, R.	102, 174	Suárez González, I.	68	Tatu, L.	84, 117
Sirotkina, O.	62	Sousa, S.	132, 156	Subasic, N.	110, 178, 179	Taubøll, E.	66, 192
Sirven-Villaros, L.	102	Sova, J.	155	Subic, A.	157	Taubøll, Eric	189
Sisak, D.	183	So, Y.	165	Subic, Ana	156	Taylor, R.W.	151
						Tazir, M.	119

Tchikviladzé, M.	50	Tonn, J.C.	149	Ulzi, G.	114	Vaury, A.	52
Tedeschi, G.	70, 113, 116, 134, 160, 168, 175, 176	Tonon, C.	136	Umarov, A.	128	Vaverka, M.	67
Tedeschi, M.P.G.	129, 151	Toosy, A.	49	Umarova, R.	103	Vavilova, T.	62
Tekatas, A.	129	Topakian, R.	65	Únal-Artik, H.A.	79	Vázquez-Costa, J.	51
Tekeli, H.	84	Topaloglu Tuac, S.	175	Unal, T.	157	Vázquez Costa, J.F.	85, 185
Telleria, J.J.	124	Topkan, A.	123, 158	Únal, Y.	125	Vaz, R.	121
Tempesta, I.	114	Toporkova, M.G.	67	Ungureanu, A.	180	Vaz, S.	122, 180
Tenenbaum, T.	178	Torop, L.A.	172	Unterrainer, A.F.	134	Vazzoler, G.	133
Teo, C.F.	122	Torregrosa Martinez, M.H.	117, 123, 137	Urbaneja, P.	131	Veauville Merlin, A.	114
Teodoro, T.	73, 161, 163, 168	Torrente, Yvan	90	Urbaneja Romero, P.	131, 163	Vecchio, D.	116, 164
Terada, K.	52	Torre, S.	59	Urbanic Purkart, T.	167	Vecerkova, M.	134
Terazzi, E.	75	Torres, M.	62	Urbanová, B.	171	Vécsesi, L.	175, 180, 183
Terecoasa, E.	133, 156, 172	Torres-Perez, J.V.	119	Urban, P.	123	Veggiotti, P.	102
Terkelsen, A.	59	Torstensen, E.W.	73	Urdina, A.	126	Veiby, G.	149, 173
Terol, E.	190	Toscana, Antonio	151	Urgosik, D.	80	Vela Desojo, L.	158
Terskik, E.	117	Toscano, A.	132, 151, 170	Urso, D.	161	Vela, L.	114, 172
Tesolin, L.	157	Tosecka, R.	125	Urtasun, M.A.	113	Velardo, D.	160, 170
Tessa, A.	50, 120	Tosi Marelli, C.	50	Urueña, P.	62	Velegrakis, S.	136
Tessitore, A.	113, 175, 176	Toth, A.	183	Usar Incirli, S.	71, 172	Vella, N.	136
Tessitore, M.P.A.	129, 151	Tourbah, A.	103			Veltsista, D.	78
Tessmer, K.	178	Tournev, I.	120, 124, 134	V		Vemuri, P.	104
Tettenborn, B.	185	Tournier-Lasserve, E.	113	Vabanesi, M.	63, 164	Veneziano, A.	163
Tevezadze, A.	162	Tovazhnyanska, O.	117, 157, 173	Vacchi, L.	102, 103, 150, 157, 164	Vera-Lopez, V.	116
Tezenas Du Montcel, S.	50, 69	Toyka, K.	180	Václavik, D.	149	Vera, R.	127, 156
Thakor, N.	63	Toyooka, K.	129	Vadalouka, A.	159	Vercelli, L.	70, 132, 151
Thalheim, C.	163	Tozkir, H.	128	Vaeggemose, M.	105, 137, 185	Vercueil, L.	63, 141, 184
Thangavelu, K.	68, 69, 82, 132, 162, 164, 178, 179	Traboulee, A.	53, 69, 82, 116, 163, 179	Vaeth, M.	50	Verde, F.	176
Theofilidis, A.	136	Traenka, C.	51, 111, 158	Vaeth, S.	50	Verdelho, A.	76, 190
Thijs, R.	182	Tramacere, I.	109, 176	Vaidya, S.	132	Verdelho, A.I.	183
Thissen, S.	167	Tranchant, C.	50	Vainsteine, L.	164	Vereshchagina, O.	159
Thomaidis, T.	159	Tränkner, S.	64	Vajda, A.	129	Vergnano, A.	102
Thomalla, G.	184	Trauscheid, M.	73	Valadas, A.F.	161	Verheijen, J.	102
Thomas, N.	125	Trauzettel-Klosinski, S.	168	Valavanis, A.	48	Verlohen, S.	218
Thompson, A.	49	Traykov, L.D.	64, 69, 157, 169	Valdaveza, J.M.	110	Vermersch, P.	82, 162, 164, 179, 214, 218
Thomsen, C.	71, 110, 123, 134	Trbojević-Cepe, M.	164	Valente, E.M.	119	Verrotti, A.	63
Thomsen, G.	110	Trepet, G.	173	Valente, M.	167	Verschueren, A.	83, 129
Thonberg, H.	102	Trezzi, I.	67, 80	Valentino, M.L.	136	Verschueren, J.J.G.M.	44
Thormann, A.	103	Triantafyllou, S.	111, 173	Valentino, P.	81	Vester, J.C.	169
Thouin, A.	135	Triassi, M.	117	Valikova, T.	60	Veyrat-Masson, M.	123
Thouvenot, M.P.E.	79	Triguero-Cueva, L.	74, 135	Valis, M.	59, 63, 78, 114, 149	Veytsman, B.	168
Thydén, A.L.	106	Trinka, E.	52, 64, 98, 104, 105, 134, 135, 158, 166, 168, 173	Valkovic, P.	125, 178	Vialatte de Pémile, C.	167
Tibar, H.	137, 184	Trivedi, D.	130, 177	Valle-Guzman, N.	149, 151	Vial, C.	165
Tiberio, F.	70	Trofimova, N.	171	Valles Salgado, M.	68	Viana-Baptista, M.	76, 77, 110, 111, 121, 183
Tiberti, M.	124	Trojanov, M.	49, 217	Vallet, Y.	182	Viana, P.	172, 183
Ticchioni, M.	182	Trojanowski, T.	169	Valls Seron, M.	175	Vibo, R.	172
Tichalas, A.	118	Trojsi, F.	129, 160, 168, 176	Valls-Sole, J.	48, 170	Vicenzini, E.	89
Tichý, T.	123	Trost, M.	115	Valls-Solé, J.	92, 99	Vichayanrat, E.	60, 76
Ticozzi, N.	176	Troštna, M.-L.	105	Valsamaki, P.	157	Vidaillhet, M.	40
Tiftikcioglu, B.I.	117, 172	Truelsen, T.	110	Valsasina, P.	49, 59, 68, 80, 83, 84, 102, 103, 132	Vidal-Jordana, A.	103
Tijms, B.	109	Truffinet, P.	68, 69, 162	Valsecchi, M.	129	Viedma-Guiard, E.	64, 77, 81
Tiloca, C.	176	Trukhachova, T.	71	Valverde, A.H.	167	Viedma-Guiar, E.	115
Timarova, G.	166	Tsagkas, C.	103	Valzania, F.	170	Vieira, E.	130
Timóteo, Á.	76	Tsakova, D.	169	Vanacker, P.	71	Vieira, L.	137, 180
Tintoré, M.	103	Tsalikakis, D.	80	Vanadia, F.	174	Vieira, M.	174
Tiric-Campara, M.	131	Tsimenava, S.	173	Van Bortel, L.	150	Viganò, I.	114
Tir, M.	106, 151	Tsimourtou, V.	120	Van Broeckhoven, C.	50, 102, 171	Vignal, J.P.	48
Tironi, R.	132	Tsiouma, M.	157	Van Caillie, M.-A.	71	Vignatelli, L.	81, 194
Tishuk, A.	78	Tsiskaridze, A.	132, 162	Van de Beek, D.	50, 53, 175	Viguria, M.C.	167
Titiz, A.P.	158	Tsivgoulis, G.	45, 111, 173	Vandenbergh, R.	50	Vijayarangam Shanmugam, S.	116, 167, 183
Titlić, M.	125	Tsolaki, M.	105, 134	Van Den Bossche, M.T.	171	Vila-Chá, N.M.D.S.	80
Titova, M.	117, 178	Tsypushkina, T.S.	67	Van Den Bosche, T.	50, 102	Vilarinho, L.	149
Titova, M.A.	81, 112, 125, 177	Tubridy, N.	111	Vandenbulcke, H.	50	Vilchez-Carrillo, R.M.	74, 135
Titulaer, M.	135, 182	Tucci, A.	120, 133	Van Den Tooren, M.	137, 182	Vilchez, J.J.	51, 118, 185
Titulaer, M.J.	44, 45	Tudor, K.I.	67, 72	Van der Ende, A.	50, 175	Vilchez, M.R.	185
Tiu, C.	84, 117, 133, 156, 172	Tugnoli, V.	131	Van der Flier, W.	109	Villacampa Aubá, J.	121, 137
Tiu, V.	156, 172	Tumminelli, G.	184	Van der Kleij, L.A.	171	Villa, L.	70, 151
Tobin, K.	176	Tupler, R.	151	Van der Meer, P.	84	Villalba Martínez, G.	131
Tobro, H.	110	Tuppin, P.	132	Van der Wal, H.	84	Villa López, M.	84, 158
Tocca, P.	178	Tural, R.	135	Van der Worp, B.	44	Villa, M.	172
Todeschini, A.	129	Turan, F. N.	115	Van der Zee, J.	102	Villar, L.M.	131
Todnem, K.	137	Turan, F.N.	128	Van Deursen, V.	84	Vimercati, R.	59
Todorovic, S.	124	Turányi, E.	183	Van de Warrenburg, B.	96	Vincent, A.	121
Todorov, V.	117	Tur, C.	49	Van Dycke, A.	78	Vincent, A.C.	135
Tofaris, D.G.	103	Turcani, P.	156	Vaneckova, M.	149	Vinceti, G.	104
Toffetti, M.	128	Turcsányi, G.	77	Van Ghelue, M.	124, 151	Vindenes, H.	124
Togrol, E.	71, 79, 84	Turgunkhujiev, O.	180	Van Goethem, J.	114	Vinge, L.	180
Toguchi, T.	125	Turk, M.	166, 173	Van Hees, T.	150	Vinjam, M.	158
Tojal, R.	175	Türkoglu, R.	182	Van Laar, P.J.	84	Vinogradov, O.	78
Tokucoglu, F.	117	Turner, B.	130	Van Langenhove, T.	171	Vinter, K.	52
Tola, M.R.	81	Turner, M.R.	160	Van Lujtelaar, G.	97	Vinther, A.S.	171
Toledano, R.	113, 166	Turner, T.J.	183	Van Mierlo, P.	48, 78	Vinther-Jensen, T.	134
Toledo Alfoceda, D.	79	Turuspekova, S.	72	Van Setten, J.	175	Viout, P.	129
Toledo, M.	52	Tuychibaeva, N.	128	Van Tongelen, I.	150	Visser, L.	189
Tolonen, A.	109	Tüzün, E.	182	Van Veldhuisen, D.J.	84	Visser, Leo	159
Tolosa, E.	94, 115, 161	Tveten, K.	50, 62	Van Wijmeersch, B.	156	Visser, L.H.	164
Tolson, O.	76	Tyburski, E.	163	Várallyay, G.	183	Visser, P.J.	105, 134
Tomasi, A.B.	73	Tychalas, A.	182	Varga, E.	185	Vissing, J.	145, 151, 161, 185, 217
Tomasi, G.H.	73	Tyaert, L.	113	Varga, Edina	118	Vitali, F.	63
Tomas, J.	132	Tzanetakos, D.	70	Varga, E.T.	180, 183	Vitelli, E.	176
Tomás, J.	133	Tzoukeva, A.	60	Vargek Solter, V.	65, 109	Viterbo, R.G.	49
Tomasović, S.	112			Vasanthaprasad, V.	70	Vitkova, E.	149
Tomek, A.	149, 171, 183	U		Vashchilin, V.	128	Vitonatto, E.	70, 132
Tomelleri, G.	151	Uccelli, Antonio	90	Vasile, M.T.	172	Vivanco-Hidalgo, R.M.	61
Tomic, A.	67, 106, 178	Uchiyama, Y.	171	Vas, K.	77	Vivancos, J.	127
Tomic, D.	70, 103, 117	Udd, B.	147, 180	Vastagh, I.	119, 156	Vivien, D.	51, 110
Tomson, T.	127, 192	Uher, T.	149	Vasta, R.	133	Vlachou, M.	105
Tondelli, M.	170	Uitdehaag, B.	106	Vaštik, M.	119, 177	Vlcek, K.	125
Tondo, G.	75, 172	Ulas, Ü.H.	60, 85, 123, 180	Vataman, A.	63	Vodicka, R.	119, 177
Tong, T.	109	Uller, M.	125	Vaugoyeau, M.	114	Vodušek, D.B.	93, 98
Toni, D.	146	Ullum, H.	178	Vauleon, E.	53		

Voermans, N. 165
 Vogel, A. 72, 109, 171
 Vogelgesang, A. 182
 Vogel, U. 163
 Vogiatzi, E. 120
 Vogrig, A. 176
 Vohanka, S. 72
 Voidázan, S. 82
 Voi, M. 52
 Voit, T. 120
 Vojinovic, S. 82
 Vollesen, A.L.H. 128, 129, 150
 Vollmar, C. 120
 Vollmer, T. 117, 163
 Volteau, M. 72
 Von Bornemann Hjelmberg, J. 105
 Vonck, K. 78
 Von Gunten, A. 204
 Von Heymann-Horan, A.B. 53
 Von Jonquieres, G. 166
 Von Oertzen, T. 48, 181
 Von Oertzen, T.J. 65
 Von Plessen, K. 90
 Von Reason, F. 66
 Von Weitzel-Mudersbach, P. 62
 Voors, A. 84
 Vorobyeva, O. 81
 Vosko, M. 65, 217
 Vaskou, P. 171
 Voumvourakis, K. 111, 173
 Vovc, V. 73
 Vrenken, H. 68
 Vrtel, R. 119, 177
 Vujkovic, Z. 61
 Vujnic, M. 180
 Vukovic-Cvetkovic, V. 40
 Vukusic, S. 103
 Vuletic, V. 81
 Vuol, L. 116
 Vyhňálek, M. 64, 125, 155, 171
 Vysata, O. 63
 Vyšata, O. 78, 114
 Vyshlova, I. 67, 80

W

Waddell, B. 133
 Wade-Martins, R. 114, 176
 Wader, T. 137
 Wagner, B. 82
 Wagner, T. 116, 163
 Wahl, A. 82
 Wahl, C.M. 151
 Waishaupt, J. 149
 Waldemar, G. 75, 104, 109, 126, 172, 181
 Waliszewska-Prosol, M. 167
 Walker, M.C. 49
 Wang, Q. 69
 Wang, R. 60, 75, 76
 Wardlaw, J. 77
 Warnke, C. 103
 Warren, D. 158
 Warren Olanow, C. 204
 Watson, C. 104
 Watson, L. 76
 Weber, F. 157
 Weber, K. 44
 Weber, K.P. 89
 Weber, M. 132, 144
 Wegener, N. A. 151
 Weier, K. 103
 Weiller, C. 39, 103
 Weineke, T. 123
 Weiner, B. 69
 Weinstein, V. 69
 Weinstock-Guttman, B. 163
 Weinstock-Guttman, B. 218
 Weintraub, D. 49
 Weintraut, R. 125
 Weis, S. 134
 Weiss-Blankenhorn, P.H. 150
 Weisser, L. 183
 Weiss, G. 52
 Weiss, K.H. 106
 Weller, M. 41, 48, 53, 149
 Wells-Knecht, K. 69
 Wells-Knecht, T. 69
 Wendt, G. 82
 Weng, L. 121, 135
 Wenten, M. 164
 Werhahn, K.J. 52
 Wermuth, L. 75
 Werneburg, B. 68, 164
 Werner, B. 151
 Westhall, E. 37
 Westover, M.B. 106
 Wheeler-Kingshott, C. 49
 Wichert, S. 178
 Wicklein, E.-M. 131
 Wick, W. 41, 149
 Widner, H. 149, 151
 Wiebe, D. 64

X

Xhaxho, B. 173
 Xhaxho, J. 173
 Xhaxho, S. 127, 173
 Xiao, J. 115
 Xiao, Y.Y. 149
 Xing, Y. 172
 Xiong, G. 106
 Xiromerisiou, G. 113, 118, 182
 Xirou, S. 180
 Xu, Y. 51, 121, 135

Y

Yagci, I. 63
 Yahyaoui, M. 137, 184
 Yamada, A. 69
 Yamazaki, K. 67
 Yang, J. 127
 Yang, Y. 135
 Yannis, G. 75, 80, 126
 Yapici, Z. 52
 Yassin, N. 127
 Yasuda, K. 134
 Yates, D. 165
 Yavorska, N. 137
 Yazici, G. 122
 Yazicioğlu Cezayir, D. 135
 Ye, B.D. 149
 Yeghiazaryan, N. 170
 Yengui, N. 76, 124
 Yetkin, F. 129
 Yger, M. 61
 Yangou, Y. 158
 Yildiz, F.G. 72
 Yin, L. 173
 Ylli, D. 65, 119
 Ylli, Z. 65, 119
 Yolac, C. 125
 Yoldas, T. 78, 167, 173
 Yon, M.I. 78, 173
 Yoon, G. 133
 Yordanova, Y. 53
 Yoshida, K. 81
 Young, C. 111
 Young, P. 73, 124
 Younis, S. 129
 Yousif, N. 185
 You, X. 68, 164
 Yuçel, M. 173
 Yuçel, M. 60, 81, 123, 180
 Yuçeyar, A.N. 131
 Yusupova, D. 59

Z

Zaaraoui, W. 129
 Zaaroor, M. 49
 Zabalza de Torres, A. 117, 131
 Zaborski, J. 61, 157
 Zabrodzets, G. 129, 130
 Zadravec-Zaletel, L. 113
 Zadro, I. 76, 164
 Zaganas, I. 120
 Zagaria, M. 133
 Zakaria, M. 180
 Zakarias, J.K. 109, 172
 Zakharova, M. 68, 122, 166
 Zaletel-Kragelj, L. 113
 Zaletel, M. 62, 113, 173
 Zamarbide Capdepón, I. 121, 137
 Zamarbide, I. 176
 Zammit, M.-A. 121
 Zangaglia, R. 105
 Zangen, A. 78
 Zanin, M. 62
 Zaouali, J. 162, 172
 Zapletalova, J. 149, 159
 Zappia, M. 133
 Zarccone, D. 133
 Zarrilli, M.M. 129
 Zauli, A. 133
 Zavalna, O. 79
 Zavratnik, A. 112
 Zawadzka, M. 62
 Zecca, C. 116
 Zeilig, G. 168
 Zeitlhofer, J. 75, 76
 Zekanowski, C. 71
 Zekja, I. 127
 Zelaja, M. 119
 Zelenák, K. 82
 Zellini, F. 134, 170
 Zemgulyte, G. 79, 164
 Zenesini, C. 81
 Zerbini, G. 179
 Zeskind, B. 69
 Zetterberg, H. 68
 Zettl, U.K. 163
 Zezula, I. 151, 178
 Zgur, T. 124
 Zhang, A. 115
 Zhang, F. 105
 Zhang, W.J. 166
 Zhang, X. 51
 Zhang, Z. 52
 Zheng, Y. 118
 Zhukova, I. 117
 Zhukova, I.A. 81, 112, 125, 177, 178
 Zhukova, N. 178
 Zhukova, N.G. 81, 112, 125, 177
 Zhusupova, A. 68
 Zibrandtsen, I. 78
 Zidar, J. 78, 124
 Zidverc Trajković, J. 66
 Ziegängsberger, D. 185
 Ziemssen, T. 48, 82, 117, 118, 162, 163, 179, 204, 214, 217
 Zierz, A. 175
 Zierz, S. 151, 174, 175
 Zimmermann, G. 52
 Zimmermann, H.G. 180
 Zipp, F. 163
 Ziso, B. 73, 184
 Zis, P. 112, 121, 132, 158, 159
 Žitňanová, I. 156
 Zivadinovic, B. 111
 Zllami, B. 169
 Zmeykina, E. 123
 Zobic, I. 128
 Zompola, C. 173
 Zonic, L. 81
 Zorlu, Y. 60, 117, 172
 Zouaoui, S. 53
 Zouari, M. 76, 124
 Zouitina, Y. 151
 Zsigmond, I. 183
 Zucconi, M. 64, 171
 Züchner, S. 185
 Zuluaga, M.I. 103
 Zupancic Kriznar, N. 115
 Zupanic, E. 63, 81, 180
 Zupan, M. 62
 Zuurbier, K. 164
 Zvan, B. 62
 Zwegal, A. 104, 106, 122